{"PMC7497735": [["IntroductionIt is not yet clear why children, and especially newborns, are less susceptible to COVID-19 than adults [1], despite viral infections being much more frequent from childhood onwards.", [["viral infections", "DISEASE", 129, 145], ["children", "ORGANISM", 36, 44], ["newborns", "ORGANISM", 61, 69], ["children", "SPECIES", 36, 44], ["COVID", "TEST", 95, 100], ["viral infections", "PROBLEM", 129, 145], ["viral", "OBSERVATION_MODIFIER", 129, 134], ["infections", "OBSERVATION", 135, 145]]], ["One hypothesis is related to vaccinations that are carried out in the first weeks of life and which would favor an increase of a non-specific immunity related to an increase in inteleukin-2 (IL-2) or other factors not yet known [2].", [["inteleukin-2", "GENE_OR_GENE_PRODUCT", 177, 189], ["IL-2", "GENE_OR_GENE_PRODUCT", 191, 195], ["inteleukin", "PROTEIN", 177, 187], ["vaccinations", "TREATMENT", 29, 41], ["a non-specific immunity", "PROBLEM", 127, 150], ["an increase in inteleukin", "PROBLEM", 162, 187], ["increase", "OBSERVATION_MODIFIER", 115, 123]]], ["Another hypothesis concerns angiotensin-converting enzyme 2 (ACE2), a membrane-bound aminopeptidase which is highly expressed in pulmonary alveolar epithelial cells and small intestine enterocytes.", [["membrane", "ANATOMY", 70, 78], ["pulmonary alveolar epithelial cells", "ANATOMY", 129, 164], ["small intestine enterocytes", "ANATOMY", 169, 196], ["angiotensin", "CHEMICAL", 28, 39], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 28, 59], ["ACE2", "GENE_OR_GENE_PRODUCT", 61, 65], ["membrane", "CELLULAR_COMPONENT", 70, 78], ["aminopeptidase", "GENE_OR_GENE_PRODUCT", 85, 99], ["pulmonary alveolar epithelial cells", "CELL", 129, 164], ["intestine enterocytes", "MULTI-TISSUE_STRUCTURE", 175, 196], ["angiotensin-converting enzyme 2", "PROTEIN", 28, 59], ["ACE2", "PROTEIN", 61, 65], ["membrane-bound aminopeptidase", "PROTEIN", 70, 99], ["pulmonary alveolar epithelial cells", "CELL_TYPE", 129, 164], ["small intestine enterocytes", "CELL_TYPE", 169, 196], ["angiotensin", "TEST", 28, 39], ["enzyme", "TEST", 51, 57], ["ACE2", "TEST", 61, 65], ["a membrane-bound aminopeptidase", "PROBLEM", 68, 99], ["small intestine enterocytes", "PROBLEM", 169, 196], ["pulmonary", "ANATOMY", 129, 138], ["alveolar", "ANATOMY_MODIFIER", 139, 147], ["epithelial cells", "OBSERVATION", 148, 164], ["small", "OBSERVATION_MODIFIER", 169, 174], ["intestine enterocytes", "ANATOMY", 175, 196]]], ["Although ACE2 has been identified as a receptor for Sars-CoV-2, it is plausible that ACE2 tissue distribution differs between adults and children or that ACE2 binding capacity in children is lower than in adults [4].IntroductionOne reason why infant do not develop severe forms of the disease could be due to the fact that the immune system of infants is not mature at all and therefore probably is not yet able to start the cytokine storm that occurs in COVID-19 infection of the adults [5].", [["tissue", "ANATOMY", 90, 96], ["immune system", "ANATOMY", 327, 340], ["infection", "DISEASE", 464, 473], ["ACE2", "GENE_OR_GENE_PRODUCT", 9, 13], ["Sars-CoV-2", "GENE_OR_GENE_PRODUCT", 52, 62], ["ACE2", "GENE_OR_GENE_PRODUCT", 85, 89], ["tissue", "TISSUE", 90, 96], ["children", "ORGANISM", 137, 145], ["ACE2", "GENE_OR_GENE_PRODUCT", 154, 158], ["children", "ORGANISM", 179, 187], ["infant", "ORGANISM", 243, 249], ["infants", "ORGANISM", 344, 351], ["COVID-19", "ORGANISM", 455, 463], ["ACE2", "PROTEIN", 9, 13], ["ACE2", "PROTEIN", 85, 89], ["ACE2", "PROTEIN", 154, 158], ["cytokine", "PROTEIN", 425, 433], ["children", "SPECIES", 137, 145], ["children", "SPECIES", 179, 187], ["infants", "SPECIES", 344, 351], ["ACE2", "PROBLEM", 9, 13], ["ACE2 binding capacity", "PROBLEM", 154, 175], ["the disease", "PROBLEM", 281, 292], ["the cytokine storm", "TREATMENT", 421, 439], ["COVID", "TEST", 455, 460], ["disease", "OBSERVATION", 285, 292]]], ["In fact, from a clinical point of view, COVID-19 generally occurs in children with moderate or low fever accompanied by mild and non-specific symptoms.", [["fever", "DISEASE", 99, 104], ["children", "ORGANISM", 69, 77], ["children", "SPECIES", 69, 77], ["COVID", "TEST", 40, 45], ["moderate or low fever", "PROBLEM", 83, 104], ["mild and non-specific symptoms", "PROBLEM", 120, 150], ["moderate", "OBSERVATION_MODIFIER", 83, 91], ["low", "OBSERVATION_MODIFIER", 95, 98], ["fever", "OBSERVATION", 99, 104], ["mild", "OBSERVATION_MODIFIER", 120, 124], ["non-specific", "OBSERVATION_MODIFIER", 129, 141]]], ["In some cases, gastrointestinal symptoms such as diarrhea, abdominal distension and aversion to food may occur in newborns [6].IntroductionHypoxia and increased respiratory rate were recorded only in a small subgroup of children, which in severe cases does not respond to standard oxygen therapy and requires nasal cannula or mask.", [["gastrointestinal", "ANATOMY", 15, 31], ["abdominal", "ANATOMY", 59, 68], ["respiratory", "ANATOMY", 161, 172], ["nasal", "ANATOMY", 309, 314], ["gastrointestinal symptoms", "DISEASE", 15, 40], ["diarrhea", "DISEASE", 49, 57], ["abdominal distension", "DISEASE", 59, 79], ["Hypoxia", "DISEASE", 139, 146], ["oxygen", "CHEMICAL", 281, 287], ["oxygen", "CHEMICAL", 281, 287], ["gastrointestinal", "ORGAN", 15, 31], ["abdominal", "ORGANISM_SUBDIVISION", 59, 68], ["children", "ORGANISM", 220, 228], ["oxygen", "SIMPLE_CHEMICAL", 281, 287], ["nasal cannula", "MULTI-TISSUE_STRUCTURE", 309, 322], ["children", "SPECIES", 220, 228], ["gastrointestinal symptoms", "PROBLEM", 15, 40], ["diarrhea", "PROBLEM", 49, 57], ["abdominal distension", "PROBLEM", 59, 79], ["aversion to food", "PROBLEM", 84, 100], ["IntroductionHypoxia", "PROBLEM", 127, 146], ["increased respiratory rate", "PROBLEM", 151, 177], ["standard oxygen therapy", "TREATMENT", 272, 295], ["nasal cannula", "TREATMENT", 309, 322], ["mask", "TREATMENT", 326, 330], ["gastrointestinal", "ANATOMY", 15, 31], ["abdominal", "ANATOMY", 59, 68], ["distension", "OBSERVATION", 69, 79], ["increased", "OBSERVATION_MODIFIER", 151, 160], ["respiratory rate", "OBSERVATION", 161, 177], ["oxygen therapy", "OBSERVATION", 281, 295], ["nasal", "ANATOMY", 309, 314]]], ["Based on the reported cases, most of these children have a benign course which resolves within 1-2 weeks after the onset of the disease.", [["children", "ORGANISM", 43, 51], ["children", "SPECIES", 43, 51], ["the disease", "PROBLEM", 124, 135], ["benign", "OBSERVATION_MODIFIER", 59, 65], ["disease", "OBSERVATION", 128, 135]]], ["Infants with COVID-19 need more careful and cautious observation because they are more likely to present with non-specific symptoms such as lethargy and dehydration [4,7,8].Case reportOn 09 August 2020, a 34-year-old pregnant woman was admitted to the \"Mater Dei\" hospital (Bari, Apulia region, Italy) and following the standard procedures before the entrance was subjected to the nasopharyngeal swab for Sars-CoV-2 detection, resulting negative despite manifesting cold symptoms, but without fever.", [["nasopharyngeal swab", "ANATOMY", 381, 400], ["lethargy", "DISEASE", 140, 148], ["dehydration", "DISEASE", 153, 164], ["fever", "DISEASE", 493, 498], ["woman", "ORGANISM", 226, 231], ["Infants", "SPECIES", 0, 7], ["woman", "SPECIES", 226, 231], ["Sars-CoV", "SPECIES", 405, 413], ["COVID", "TEST", 13, 18], ["cautious observation", "TEST", 44, 64], ["non-specific symptoms", "PROBLEM", 110, 131], ["lethargy", "PROBLEM", 140, 148], ["dehydration", "PROBLEM", 153, 164], ["the standard procedures", "TREATMENT", 316, 339], ["the nasopharyngeal swab", "TEST", 377, 400], ["Sars", "PROBLEM", 405, 409], ["cold symptoms", "PROBLEM", 466, 479], ["fever", "PROBLEM", 493, 498], ["nasopharyngeal", "ANATOMY", 381, 395]]], ["Also an internal reaction control was used in order to exclude a false negativity.", [["an internal reaction control", "TREATMENT", 5, 33], ["a false negativity", "PROBLEM", 63, 81], ["internal", "OBSERVATION_MODIFIER", 8, 16], ["reaction", "OBSERVATION", 17, 25], ["false negativity", "OBSERVATION", 65, 81]]], ["On the same day the woman gave birth to a child weighing 3.100 Kg.", [["woman", "ORGANISM", 20, 25], ["woman", "SPECIES", 20, 25]]], ["Three days later mother and son came back home and after 10 days from the birth, the newborn developed low-grade fever and mild respiratory symptoms.", [["respiratory", "ANATOMY", 128, 139], ["fever", "DISEASE", 113, 118], ["respiratory symptoms", "DISEASE", 128, 148], ["low-grade fever", "PROBLEM", 103, 118], ["mild respiratory symptoms", "PROBLEM", 123, 148], ["fever", "OBSERVATION", 113, 118], ["mild", "OBSERVATION_MODIFIER", 123, 127], ["respiratory symptoms", "OBSERVATION", 128, 148]]], ["On 20 August 2020 he was transferred to the neonatology department of \u201cMiulli\u201d hospital (Acquaviva delle Fonti, Apulia region, Italy) for suspected sepsis since he manifested fever with a temperature of 37.8 \u00b0C. Immediately he was subjected to the following tests: complete blood count, C reactive protein, film array for the detection of Adenovirus, Coronavirus 229E-HKQ1-NL63-OC43, Metapneumovirus human, Rhinovirus, Enterovirus, Influenza A-B, Parainfluenza 1-2-3-4, RSV, Pertussis, Chlamydia and Mycoplasma pneumonia.", [["blood", "ANATOMY", 274, 279], ["sepsis", "DISEASE", 148, 154], ["fever", "DISEASE", 175, 180], ["Enterovirus", "DISEASE", 419, 430], ["Influenza A-B", "DISEASE", 432, 445], ["Parainfluenza 1-2-3-4, RSV", "CHEMICAL", 447, 473], ["Pertussis", "DISEASE", 475, 484], ["Chlamydia", "DISEASE", 486, 495], ["Mycoplasma pneumonia", "DISEASE", 500, 520], ["blood", "ORGANISM_SUBSTANCE", 274, 279], ["C reactive protein", "GENE_OR_GENE_PRODUCT", 287, 305], ["Adenovirus", "ORGANISM", 339, 349], ["Coronavirus 229E", "ORGANISM", 351, 367], ["HKQ1", "GENE_OR_GENE_PRODUCT", 368, 372], ["NL63", "GENE_OR_GENE_PRODUCT", 373, 377], ["Metapneumovirus human", "ORGANISM", 384, 405], ["Influenza A-B", "ORGANISM", 432, 445], ["Parainfluenza 1-2-3-4", "ORGANISM", 447, 468], ["RSV", "ORGANISM", 470, 473], ["Pertussis", "ORGANISM", 475, 484], ["Chlamydia", "ORGANISM", 486, 495], ["Mycoplasma pneumonia", "ORGANISM", 500, 520], ["C reactive protein", "PROTEIN", 287, 305], ["human", "SPECIES", 400, 405], ["Influenza", "SPECIES", 432, 441], ["RSV", "SPECIES", 470, 473], ["Mycoplasma pneumonia", "SPECIES", 500, 520], ["Adenovirus", "SPECIES", 339, 349], ["human", "SPECIES", 400, 405], ["Influenza A-B", "SPECIES", 432, 445], ["RSV", "SPECIES", 470, 473], ["sepsis", "PROBLEM", 148, 154], ["fever", "PROBLEM", 175, 180], ["a temperature", "TEST", 186, 199], ["complete blood count", "TEST", 265, 285], ["C reactive protein", "TEST", 287, 305], ["film array", "TEST", 307, 317], ["the detection", "TEST", 322, 335], ["Adenovirus", "PROBLEM", 339, 349], ["Coronavirus", "TEST", 351, 362], ["HKQ1", "TEST", 368, 372], ["NL63", "TEST", 373, 377], ["OC43", "TEST", 378, 382], ["Metapneumovirus human", "TEST", 384, 405], ["Rhinovirus", "PROBLEM", 407, 417], ["Enterovirus", "PROBLEM", 419, 430], ["Influenza A", "TEST", 432, 443], ["Parainfluenza", "PROBLEM", 447, 460], ["RSV", "PROBLEM", 470, 473], ["Pertussis", "PROBLEM", 475, 484], ["Chlamydia", "PROBLEM", 486, 495], ["Mycoplasma pneumonia", "PROBLEM", 500, 520], ["sepsis", "OBSERVATION", 148, 154], ["Chlamydia", "OBSERVATION", 486, 495], ["Mycoplasma pneumonia", "OBSERVATION", 500, 520]]], ["No lombar puncture was performed at the beginning, because the newborn showed mild respiratory symptoms and therefore a respiratory infection was suspected at first instance.Case reportThe values of the complete blood count were normal e C reactive protein resulted negative.", [["lombar", "ANATOMY", 3, 9], ["respiratory", "ANATOMY", 83, 94], ["respiratory", "ANATOMY", 120, 131], ["blood", "ANATOMY", 212, 217], ["respiratory symptoms", "DISEASE", 83, 103], ["respiratory infection", "DISEASE", 120, 141], ["blood", "ORGANISM_SUBSTANCE", 212, 217], ["C reactive protein", "PROTEIN", 238, 256], ["lombar puncture", "TEST", 3, 18], ["mild respiratory symptoms", "PROBLEM", 78, 103], ["a respiratory infection", "PROBLEM", 118, 141], ["The values", "TEST", 185, 195], ["the complete blood count", "TEST", 199, 223], ["reactive protein", "TEST", 240, 256], ["puncture", "OBSERVATION", 10, 18], ["mild", "OBSERVATION_MODIFIER", 78, 82], ["respiratory symptoms", "OBSERVATION", 83, 103], ["respiratory", "ANATOMY", 120, 131], ["infection", "OBSERVATION", 132, 141]]], ["Moreover, was not revealed the presence of respiratory pathogens.", [["respiratory pathogens", "DISEASE", 43, 64], ["respiratory pathogens", "PROBLEM", 43, 64], ["respiratory", "ANATOMY", 43, 54], ["pathogens", "OBSERVATION", 55, 64]]], ["Finally, it was decided to perform also the canonical nasopharyngeal swab to verify an eventual Sars-CoV-2 infection.Case reportThe real time PCR specific for Sars-CoV-2 was performed by Allplex 2019-nCoV Assay Kit (Seegene, Seul, Korea) on the CFX96 Real Time System C1000 Thermal Cycler (Bio-Rad, Hercules, California-USA).", [["nasopharyngeal swab", "ANATOMY", 54, 73], ["infection", "DISEASE", 107, 116], ["Sars-CoV-2", "SPECIES", 96, 106], ["Sars-CoV", "SPECIES", 159, 167], ["the canonical nasopharyngeal swab", "TEST", 40, 73], ["an eventual Sars-CoV-2 infection", "PROBLEM", 84, 116], ["The real time PCR", "TEST", 128, 145], ["Sars-CoV", "TEST", 159, 167], ["Allplex", "TEST", 187, 194], ["Thermal Cycler", "TEST", 274, 288], ["nasopharyngeal", "ANATOMY", 54, 68], ["infection", "OBSERVATION", 107, 116]]], ["The test resulted positive showing the amplification of the E gene with CT 9.7; RdRp gene with CT 13.3; and N gene with CT 14.5.", [["E", "GENE_OR_GENE_PRODUCT", 60, 61], ["E gene", "DNA", 60, 66], ["CT 9.7", "DNA", 72, 78], ["RdRp gene", "DNA", 80, 89], ["CT 13.3", "DNA", 95, 102], ["N gene", "DNA", 108, 114], ["CT 14.5", "DNA", 120, 127], ["The test", "TEST", 0, 8], ["CT", "TEST", 72, 74], ["RdRp gene", "TEST", 80, 89], ["CT", "TEST", 95, 97], ["CT", "TEST", 120, 122]]], ["After the results, the newborn was transferred to the infectious disease department of the pediatric hospital \u201cGiovanni XXIII\u201d (Bari).", [["infectious disease", "DISEASE", 54, 72]]], ["The day after, on 21 August, all his four family members (mother, father and two young brothers) were also tested for Sars-CoV-2, because the father complained of headache and sore throat and one of the children had 37,5 \u00b0C fever.", [["headache", "DISEASE", 163, 171], ["sore throat", "DISEASE", 176, 187], ["fever", "DISEASE", 224, 229], ["throat", "ORGANISM_SUBDIVISION", 181, 187], ["children", "ORGANISM", 203, 211], ["children", "SPECIES", 203, 211], ["Sars-CoV", "SPECIES", 118, 126], ["headache", "PROBLEM", 163, 171], ["sore throat", "PROBLEM", 176, 187], ["fever", "PROBLEM", 224, 229], ["headache", "OBSERVATION", 163, 171], ["sore throat", "ANATOMY", 176, 187]]], ["It\u2019s important to underline that the paternal grandmother during the days following the birth of the child complained a strong headache and cold flu symptoms and she went to visit the family at their home.", [["headache", "DISEASE", 127, 135], ["flu symptoms", "DISEASE", 145, 157], ["a strong headache", "PROBLEM", 118, 135], ["cold flu symptoms", "PROBLEM", 140, 157]]], ["The old woman was subjected to Sars-CoV-2 swab in the same day of the other relatives and she resulted to be positive.", [["woman", "ORGANISM", 8, 13], ["woman", "SPECIES", 8, 13], ["Sars-CoV", "SPECIES", 31, 39], ["Sars-CoV", "TEST", 31, 39], ["positive", "OBSERVATION", 109, 117]]], ["Probably she was the person who infected the others.", [["person", "SPECIES", 21, 27]]], ["Since that time all the family members were subjected to mandatory quarantine under the direct responsibility of the local health authorities.Case reportThe nasopharyngeal swab of the newborn was sent to the BSL-3 laboratory of the Istituto Zooprofilattico Sperimentale della Puglia e della Basilicata (Foggia, Apulia region, Italy) for the isolation test.", [["nasopharyngeal swab", "ANATOMY", 157, 176], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 157, 176], ["newborn", "ORGANISM", 184, 191], ["The nasopharyngeal swab", "TEST", 153, 176], ["the isolation test", "TEST", 337, 355], ["nasopharyngeal", "ANATOMY", 157, 171], ["swab", "OBSERVATION", 172, 176]]], ["Briefly, 500 \u00b5l of the swab medium was incubated with 250 \u00b5l of an antibiotic solution for 1 hour at room temperature.", [["the swab medium", "TREATMENT", 19, 34], ["an antibiotic solution", "TREATMENT", 64, 86]]], ["The suspension was then inoculated in a T25 Cell Culture Flask containing a monolayer of VeroE6 cells.", [["Cell", "ANATOMY", 44, 48], ["monolayer", "ANATOMY", 76, 85], ["VeroE6 cells", "ANATOMY", 89, 101], ["monolayer", "CELL", 76, 85], ["VeroE6 cells", "CELL", 89, 101], ["T25 Cell Culture Flask", "CELL_LINE", 40, 62], ["VeroE6 cells", "CELL_LINE", 89, 101], ["The suspension", "TREATMENT", 0, 14], ["a T25 Cell Culture Flask", "TEST", 38, 62], ["a monolayer of VeroE6 cells", "TREATMENT", 74, 101], ["suspension", "OBSERVATION_MODIFIER", 4, 14], ["T25 Cell", "OBSERVATION", 40, 48], ["Culture Flask", "OBSERVATION", 49, 62], ["monolayer", "OBSERVATION_MODIFIER", 76, 85], ["VeroE6 cells", "OBSERVATION", 89, 101]]], ["The flask was incubated in a thermostat at 37 \u00b0C for 1 h.", [["a thermostat", "TREATMENT", 27, 39]]], ["After incubation, 5.5 ml of EMEM with 6% fetal bovine serum were added and incubated again at 37 \u00b0C. After 48 hours of incubation a quite good cytopathic effect was appreciable.", [["fetal bovine serum", "ANATOMY", 41, 59], ["EMEM", "CHEMICAL", 28, 32], ["bovine", "ORGANISM", 47, 53], ["serum", "ORGANISM_SUBSTANCE", 54, 59], ["bovine", "SPECIES", 47, 53], ["bovine", "SPECIES", 47, 53], ["EMEM", "TREATMENT", 28, 32], ["6% fetal bovine serum", "TREATMENT", 38, 59], ["incubation", "TREATMENT", 119, 129]]], ["After further 24 hours, an impressive cytopathic effect was highlighted consisting of rounding and detachment of most of the cells (Fig. 1).", [["cells", "ANATOMY", 125, 130], ["cells", "CELL", 125, 130], ["an impressive cytopathic effect", "PROBLEM", 24, 55], ["detachment", "PROBLEM", 99, 109], ["impressive", "OBSERVATION_MODIFIER", 27, 37], ["cytopathic", "OBSERVATION", 38, 48], ["detachment", "OBSERVATION", 99, 109]]], ["The replication of the virus was confirmed by the specific biomolecular test for Sars-CoV-2 carried out on 200 \u00b5l of the culture medium.Case reportThe newborn manifested fever for 3 days following the admission and then the heath conditions resulted stable.DiscussionThe newborn almost certainly contracted Sars-CoV-2 from one member of the family, presumably the paternal grandmother who, most likely, was infective in the days following the birth, when she went to visit the newborn at his home.", [["fever", "DISEASE", 170, 175], ["Sars-CoV", "SPECIES", 81, 89], ["Sars-CoV", "SPECIES", 307, 315], ["the virus", "PROBLEM", 19, 28], ["the specific biomolecular test", "TEST", 46, 76], ["Sars-CoV", "TEST", 81, 89], ["the culture medium", "TEST", 117, 135], ["fever", "PROBLEM", 170, 175], ["infective", "PROBLEM", 407, 416], ["virus", "OBSERVATION", 23, 28], ["stable", "OBSERVATION_MODIFIER", 250, 256], ["most likely", "UNCERTAINTY", 390, 401], ["infective", "OBSERVATION", 407, 416]]], ["We do not know if the newborn or another family member infected the others, but it\u2019s very interesting that the viral load of the newborn was very high as demonstrated either by PCR or by isolation of the virus.", [["newborn", "ORGANISM", 129, 136], ["the viral load", "TEST", 107, 121], ["PCR", "TEST", 177, 180], ["the virus", "PROBLEM", 200, 209]]], ["The cytopathic effect on the Vero E6 monolayer was already evident after 48 hours post inoculation and was much clearer after 72 hours (Fig. 1).", [["Vero E6 monolayer", "ANATOMY", 29, 46], ["Vero E6 monolayer", "CELL", 29, 46], ["Vero E6 monolayer", "CELL_LINE", 29, 46], ["The cytopathic effect", "PROBLEM", 0, 21], ["the Vero E6 monolayer", "TREATMENT", 25, 46], ["cytopathic", "OBSERVATION_MODIFIER", 4, 14], ["effect", "OBSERVATION_MODIFIER", 15, 21]]], ["Despite the high viral load, the newborn never showed serious symptoms except mild respiratory symptoms and a not high fever for 3 days following the admission to the pediatric hospital.", [["respiratory", "ANATOMY", 83, 94], ["respiratory symptoms", "DISEASE", 83, 103], ["fever", "DISEASE", 119, 124], ["the high viral load", "PROBLEM", 8, 27], ["serious symptoms", "PROBLEM", 54, 70], ["mild respiratory symptoms", "PROBLEM", 78, 103], ["high fever", "PROBLEM", 114, 124], ["viral load", "OBSERVATION", 17, 27], ["mild", "OBSERVATION_MODIFIER", 78, 82]]], ["This case confirms what has already been reported in other similar works, even in presence of high viral loads, newborns usually show relatively mild symptoms [9].DiscussionThis case requires a reflection on the potentiality of Sars-CoV-2 transmission from newborns and children that, maybe, often is underestimated.", [["Sars-CoV-2", "ORGANISM", 228, 238], ["newborns", "ORGANISM", 257, 265], ["children", "ORGANISM", 270, 278], ["children", "SPECIES", 270, 278], ["high viral loads", "PROBLEM", 94, 110], ["relatively mild symptoms", "PROBLEM", 134, 158], ["viral loads", "OBSERVATION", 99, 110], ["mild", "OBSERVATION_MODIFIER", 145, 149]]], ["Moreover, some traditional behaviors of the Italian population and in particular of Southern Italy, where it is customary to visit newborn children in the days immediately following the return home, can amplify the transmission of Sars-CoV-2 from unknown infected children.", [["children", "ORGANISM", 139, 147], ["Sars-CoV-2", "ORGANISM", 231, 241], ["children", "ORGANISM", 264, 272], ["children", "SPECIES", 139, 147], ["children", "SPECIES", 264, 272], ["Sars-CoV", "SPECIES", 231, 239], ["infected", "OBSERVATION", 255, 263]]], ["In fact, newborns living inside home environment can spreadlarge quantities of virus and lead to high levels of contamination, so as to be dangerous for anyone who comes into contact with them.", [["newborns", "ORGANISM", 9, 17], ["virus", "PROBLEM", 79, 84], ["high levels of contamination", "PROBLEM", 97, 125]]], ["It\u2019s unlikely that that infant would generate effective cough aerosols for infection, but however they can have infectious secretions such as stool or saliva as reported in literature [10,11].DiscussionTherefore, the aim of this paper is to report that also from Sars-CoV-2 positive newborns is possible to isolate alive virus even in presence of moderate symptoms, as showed by the isolation on cell culture of this study, indicating that they could be dangerous for the dissemination of the virus.Ethical considerationsWritten informed consent was obtained from the patient for the publication of this case report and accompanying images.", [["secretions", "ANATOMY", 123, 133], ["stool", "ANATOMY", 142, 147], ["cell", "ANATOMY", 396, 400], ["infection", "DISEASE", 75, 84], ["infectious secretions such as stool or saliva", "DISEASE", 112, 157], ["infant", "ORGANISM", 24, 30], ["stool", "ORGANISM_SUBSTANCE", 142, 147], ["saliva", "ORGANISM_SUBSTANCE", 151, 157], ["Sars-CoV-2", "ORGANISM", 263, 273], ["newborns", "ORGANISM", 283, 291], ["cell", "CELL", 396, 400], ["patient", "ORGANISM", 568, 575], ["infant", "SPECIES", 24, 30], ["patient", "SPECIES", 568, 575], ["Sars-CoV", "SPECIES", 263, 271], ["effective cough aerosols", "PROBLEM", 46, 70], ["infection", "PROBLEM", 75, 84], ["infectious secretions", "PROBLEM", 112, 133], ["stool or saliva", "PROBLEM", 142, 157], ["Sars-CoV", "TEST", 263, 271], ["isolate alive virus", "PROBLEM", 307, 326], ["moderate symptoms", "PROBLEM", 347, 364], ["cell culture", "TEST", 396, 408], ["this study", "TEST", 412, 422], ["the virus", "PROBLEM", 489, 498], ["accompanying images", "TEST", 620, 639], ["unlikely", "UNCERTAINTY", 5, 13], ["infection", "OBSERVATION", 75, 84], ["moderate", "OBSERVATION_MODIFIER", 347, 355], ["symptoms", "OBSERVATION", 356, 364]]], ["All authors have made substantial contributions to thefollowing: (1) the conception and design of the study, oracquisition of data, or analysis and interpretation of data, (2) drafting the article or revising it critically for important intellectualcontent, (3) final approval of the version to be submitted.Declaration of Competing InterestThe authors report no declaration of interests.", [["the study", "TEST", 98, 107], ["analysis", "TEST", 135, 143], ["the version", "TREATMENT", 280, 291]]]], "b858c3fad34771ddf43961b1f93f3ca82f38ae2b": [["SECTION VIIIIt is hard to believe that the first consistent reports of acquired immunodeficiency syndrome (AIDS) were only 25 years ago.", [["acquired immunodeficiency syndrome", "DISEASE", 71, 105], ["AIDS", "DISEASE", 107, 111], ["acquired immunodeficiency syndrome", "PROBLEM", 71, 105]]], ["Since then, respiratory and general physicians have become accustomed to dealing with an extraordinary range of esoteric and previously unheard of conditions.", [["respiratory", "ANATOMY", 12, 23]]], ["Pneumocystis carinii (now known as Pneumocystis jirovecii) pneumonia is frequently part of the differential diagnosis of treatment-nonresponsive pneumonic illness.", [["Pneumocystis carinii", "DISEASE", 0, 20], ["Pneumocystis jirovecii) pneumonia", "DISEASE", 35, 68], ["pneumonic illness", "DISEASE", 145, 162], ["Pneumocystis carinii", "ORGANISM", 0, 20], ["Pneumocystis jirovecii", "ORGANISM", 35, 57], ["Pneumocystis carinii", "SPECIES", 0, 20], ["Pneumocystis jirovecii", "SPECIES", 35, 57], ["Pneumocystis carinii", "SPECIES", 0, 20], ["Pneumocystis jirovecii", "SPECIES", 35, 57], ["Pneumocystis carinii", "PROBLEM", 0, 20], ["Pneumocystis jirovecii", "PROBLEM", 35, 57], ["pneumonia", "PROBLEM", 59, 68], ["nonresponsive pneumonic illness", "PROBLEM", 131, 162], ["carinii", "OBSERVATION", 13, 20], ["Pneumocystis", "OBSERVATION_MODIFIER", 35, 47], ["jirovecii", "OBSERVATION", 48, 57], ["pneumonia", "OBSERVATION", 59, 68], ["nonresponsive", "OBSERVATION_MODIFIER", 131, 144], ["pneumonic", "OBSERVATION", 145, 154]]], ["Human immunodeficiency virus (HIV) testing is almost routinely offered as a \"rule out\" test in clinical cases that defy simple diagnosis.", [["Human immunodeficiency virus (HIV)", "DISEASE", 0, 34], ["Human immunodeficiency virus", "ORGANISM", 0, 28], ["HIV", "ORGANISM", 30, 33], ["Human", "SPECIES", 0, 5], ["immunodeficiency virus", "SPECIES", 6, 28], ["Human immunodeficiency virus", "SPECIES", 0, 28], ["HIV", "SPECIES", 30, 33], ["Human immunodeficiency virus", "PROBLEM", 0, 28], ["HIV) testing", "TEST", 30, 42], ["immunodeficiency virus", "OBSERVATION", 6, 28]]], ["In many parts of the developing world, advanced HIV disease is unfortunately the likeliest reason for seeking medical care.", [["HIV disease", "DISEASE", 48, 59], ["HIV", "ORGANISM", 48, 51], ["HIV", "SPECIES", 48, 51], ["advanced HIV disease", "PROBLEM", 39, 59], ["HIV disease", "OBSERVATION", 48, 59]]], ["The change this has wrought on people, countries and their economies is huge and depressing.", [["people", "ORGANISM", 31, 37], ["people", "SPECIES", 31, 37], ["huge", "OBSERVATION_MODIFIER", 72, 76]]], ["The isolation of HIV from patients with AIDS in the mid 1980s paved the way for intensive research with the ultimate development of drugs directed against this chronic infection.", [["AIDS", "DISEASE", 40, 44], ["chronic infection", "DISEASE", 160, 177], ["HIV", "ORGANISM", 17, 20], ["patients", "ORGANISM", 26, 34], ["HIV", "SPECIES", 17, 20], ["patients", "SPECIES", 26, 34], ["HIV", "SPECIES", 17, 20], ["HIV", "PROBLEM", 17, 20], ["AIDS", "PROBLEM", 40, 44], ["intensive research", "TREATMENT", 80, 98], ["drugs", "TREATMENT", 132, 137], ["this chronic infection", "PROBLEM", 155, 177], ["chronic", "OBSERVATION_MODIFIER", 160, 167], ["infection", "OBSERVATION", 168, 177]]], ["However, despite such advances, the methods by which HIV infection leads to severe immune dysregulation and clinical disease are still not fully defined.SECTION VIIIThe introduction in 1996, in the developed world, of highly active antiretroviral therapy, also known as combination antiretroviral therapy (cART) hereto referred to as HAART, has altered the natural history of this extraordinary condition.", [["HIV infection", "DISEASE", 53, 66], ["HIV", "ORGANISM", 53, 56], ["HIV", "SPECIES", 53, 56], ["the methods", "TREATMENT", 32, 43], ["HIV infection", "PROBLEM", 53, 66], ["severe immune dysregulation", "PROBLEM", 76, 103], ["clinical disease", "PROBLEM", 108, 124], ["highly active antiretroviral therapy", "TREATMENT", 218, 254], ["antiretroviral therapy", "TREATMENT", 282, 304], ["HAART", "TREATMENT", 334, 339], ["this extraordinary condition", "PROBLEM", 376, 404], ["infection", "OBSERVATION", 57, 66], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["immune dysregulation", "OBSERVATION", 83, 103], ["active", "OBSERVATION_MODIFIER", 225, 231], ["antiretroviral therapy", "OBSERVATION", 232, 254]]], ["Before HAART, defined as a combination of medications that usually includes at least three potent anti-HIV agents, treatment largely consisted of specific opportunistic infection management and less effective antiretroviral therapy.", [["opportunistic infection", "DISEASE", 155, 178], ["HAART", "TREATMENT", 7, 12], ["medications", "TREATMENT", 42, 53], ["potent anti-HIV agents", "TREATMENT", 91, 113], ["treatment", "TREATMENT", 115, 124], ["specific opportunistic infection management", "TREATMENT", 146, 189], ["less effective antiretroviral therapy", "TREATMENT", 194, 231], ["opportunistic", "OBSERVATION_MODIFIER", 155, 168], ["infection", "OBSERVATION", 169, 178]]], ["The clinical consequences of this change are enormous.", [["this change", "PROBLEM", 29, 40], ["enormous", "OBSERVATION_MODIFIER", 45, 53]]], ["The relative hazard for development of Pneumocystis pneumonia (PCP) in an HIVinfected individual has fallen by more than 80%.", [["Pneumocystis pneumonia", "DISEASE", 39, 61], ["PCP", "DISEASE", 63, 66], ["Pneumocystis", "ORGANISM", 39, 51], ["Pneumocystis pneumonia", "PROBLEM", 39, 61], ["Pneumocystis", "OBSERVATION_MODIFIER", 39, 51], ["pneumonia", "OBSERVATION", 52, 61]]], ["Drug therapy does have a down side.", [["Drug therapy", "TREATMENT", 0, 12]]], ["It has significant unwanted effects, as well as major interactions with other medication (e.g., rifamycins used in treating tuberculosis).", [["rifamycins", "CHEMICAL", 96, 106], ["tuberculosis", "DISEASE", 124, 136], ["rifamycins", "CHEMICAL", 96, 106], ["rifamycins", "SIMPLE_CHEMICAL", 96, 106], ["other medication", "TREATMENT", 72, 88], ["rifamycins", "TREATMENT", 96, 106], ["tuberculosis", "PROBLEM", 124, 136], ["significant", "OBSERVATION_MODIFIER", 7, 18], ["unwanted effects", "OBSERVATION", 19, 35], ["tuberculosis", "OBSERVATION", 124, 136]]], ["The profound change in immunity induced by HAART may also lead to disease (the immune reconstitution inflammatory syndrome [IRIS] ).SECTION VIIINotwithstanding HAART, respiratory disease remains an important cause of morbidity and mortality.", [["respiratory", "ANATOMY", 167, 178], ["immune reconstitution inflammatory syndrome", "DISEASE", 79, 122], ["IRIS", "DISEASE", 124, 128], ["respiratory disease", "DISEASE", 167, 186], ["The profound change", "PROBLEM", 0, 19], ["HAART", "TREATMENT", 43, 48], ["disease", "PROBLEM", 66, 73], ["the immune reconstitution inflammatory syndrome", "PROBLEM", 75, 122], ["respiratory disease", "PROBLEM", 167, 186], ["morbidity", "PROBLEM", 217, 226], ["profound", "OBSERVATION_MODIFIER", 4, 12], ["change", "OBSERVATION_MODIFIER", 13, 19], ["inflammatory", "OBSERVATION_MODIFIER", 101, 113], ["respiratory disease", "OBSERVATION", 167, 186], ["morbidity", "OBSERVATION", 217, 226]]], ["Much of the world cannot afford such medication, and more than two thirds of HIV-infected individuals have at least one respiratory episode during the course of their illness.", [["HIV-infected", "DISEASE", 77, 89], ["HIV", "ORGANISM", 77, 80], ["individuals", "ORGANISM", 90, 101], ["HIV", "SPECIES", 77, 80], ["such medication", "TREATMENT", 32, 47], ["HIV", "PROBLEM", 77, 80], ["infected individuals", "PROBLEM", 81, 101], ["infected", "OBSERVATION", 81, 89]]], ["In the early stages of HIV infection, when patients have relatively preserved immune responses, individuals have the same infections found in the general population, although at a greater incidence.SECTION VIIIWith progressive HIV disease, subjects are at an increased risk of opportunistic disease.", [["HIV infection", "DISEASE", 23, 36], ["infections", "DISEASE", 122, 132], ["HIV disease", "DISEASE", 227, 238], ["opportunistic disease", "DISEASE", 277, 298], ["HIV", "ORGANISM", 23, 26], ["patients", "ORGANISM", 43, 51], ["HIV", "SPECIES", 23, 26], ["patients", "SPECIES", 43, 51], ["HIV", "SPECIES", 227, 230], ["HIV", "SPECIES", 23, 26], ["HIV", "SPECIES", 227, 230], ["HIV infection", "PROBLEM", 23, 36], ["the same infections", "PROBLEM", 113, 132], ["progressive HIV disease", "PROBLEM", 215, 238], ["opportunistic disease", "PROBLEM", 277, 298], ["early stages", "OBSERVATION_MODIFIER", 7, 19], ["HIV", "OBSERVATION_MODIFIER", 23, 26], ["infection", "OBSERVATION", 27, 36], ["progressive", "OBSERVATION_MODIFIER", 215, 226], ["HIV disease", "OBSERVATION", 227, 238], ["opportunistic disease", "OBSERVATION", 277, 298]]], ["For example, the North American Prospective Study of Pulmonary Complications of HIV Infection (PSPC), a multicenter cohort drawn from all HIV risk groups at various stages of immunosuppression, revealed over an 18-month study period that of approximately 1000 subjects who were not using HAART:SECTION VIII33% reported an upper respiratory tract infection 16% had an episode of acute bronchitis 5% had acute sinusitis 5% had bacterial pneumonia 4% had PCP developSECTION VIIIThe immune dysregulation that arises from HIV infection means that bacteria, mycobacteria, fungi, viruses, and protozoa can all cause disease in subjects with advanced infection.", [["Pulmonary", "ANATOMY", 53, 62], ["upper respiratory tract", "ANATOMY", 322, 345], ["HIV Infection", "DISEASE", 80, 93], ["respiratory tract infection", "DISEASE", 328, 355], ["bronchitis", "DISEASE", 384, 394], ["sinusitis", "DISEASE", 408, 417], ["pneumonia", "DISEASE", 435, 444], ["PCP", "DISEASE", 452, 455], ["HIV infection", "DISEASE", 517, 530], ["infection", "DISEASE", 643, 652], ["PCP", "CHEMICAL", 452, 455], ["Pulmonary", "ORGAN", 53, 62], ["upper", "ORGANISM_SUBDIVISION", 322, 327], ["respiratory tract", "ORGANISM_SUBDIVISION", 328, 345], ["HIV", "ORGANISM", 517, 520], ["HIV", "SPECIES", 80, 83], ["HIV", "SPECIES", 517, 520], ["HIV", "SPECIES", 80, 83], ["HIV", "SPECIES", 138, 141], ["HIV", "SPECIES", 517, 520], ["HIV Infection", "PROBLEM", 80, 93], ["a multicenter cohort", "TEST", 102, 122], ["immunosuppression", "TREATMENT", 175, 192], ["an upper respiratory tract infection", "PROBLEM", 319, 355], ["acute bronchitis", "PROBLEM", 378, 394], ["acute sinusitis", "PROBLEM", 402, 417], ["bacterial pneumonia", "PROBLEM", 425, 444], ["immune dysregulation", "PROBLEM", 479, 499], ["HIV infection", "PROBLEM", 517, 530], ["bacteria", "PROBLEM", 542, 550], ["mycobacteria", "PROBLEM", 552, 564], ["fungi", "PROBLEM", 566, 571], ["viruses", "PROBLEM", 573, 580], ["protozoa", "PROBLEM", 586, 594], ["disease", "PROBLEM", 609, 616], ["advanced infection", "PROBLEM", 634, 652], ["Pulmonary", "ANATOMY", 53, 62], ["Complications", "OBSERVATION", 63, 76], ["HIV", "OBSERVATION_MODIFIER", 80, 83], ["Infection", "OBSERVATION", 84, 93], ["upper", "ANATOMY_MODIFIER", 322, 327], ["respiratory tract", "ANATOMY", 328, 345], ["acute", "OBSERVATION_MODIFIER", 378, 383], ["bronchitis", "OBSERVATION", 384, 394], ["acute", "OBSERVATION_MODIFIER", 402, 407], ["sinusitis", "OBSERVATION", 408, 417], ["bacterial", "OBSERVATION_MODIFIER", 425, 434], ["pneumonia", "OBSERVATION", 435, 444], ["advanced", "OBSERVATION_MODIFIER", 634, 642], ["infection", "OBSERVATION", 643, 652]]], ["Table 34 -1 shows the organisms that typically infect the lung in HIV disease.", [["lung", "ANATOMY", 58, 62], ["HIV disease", "DISEASE", 66, 77], ["lung", "ORGAN", 58, 62], ["HIV", "SPECIES", 66, 69], ["HIV", "SPECIES", 66, 69], ["the organisms", "PROBLEM", 18, 31], ["HIV disease", "PROBLEM", 66, 77], ["lung", "ANATOMY", 58, 62], ["HIV disease", "OBSERVATION", 66, 77]]], ["Of these, bacterial infections, tuberculosis, and PCP are the most important.", [["bacterial infections", "DISEASE", 10, 30], ["tuberculosis", "DISEASE", 32, 44], ["PCP", "DISEASE", 50, 53], ["bacterial infections", "PROBLEM", 10, 30], ["tuberculosis", "PROBLEM", 32, 44], ["PCP", "PROBLEM", 50, 53], ["bacterial", "OBSERVATION_MODIFIER", 10, 19], ["infections", "OBSERVATION", 20, 30], ["tuberculosis", "OBSERVATION", 32, 44]]], ["In the West, 40% of AIDS diagnoses are due to PCP.", [["AIDS", "DISEASE", 20, 24], ["PCP", "DISEASE", 46, 49], ["PCP", "CHEMICAL", 46, 49], ["PCP", "PROBLEM", 46, 49]]], ["This chapter provides a brief general overview of the epidemiology and pathogenesis of HIV infection before concentrating on HIV and its infectious pulmonary complications.SECTION VIIIIt is reported that by the end of 2006, 39.5 million individuals worldwide had acquired HIV infection (Figure 34 -1).", [["pulmonary", "ANATOMY", 148, 157], ["HIV infection", "DISEASE", 87, 100], ["infectious pulmonary complications", "DISEASE", 137, 171], ["HIV infection", "DISEASE", 272, 285], ["HIV", "ORGANISM", 87, 90], ["HIV", "ORGANISM", 125, 128], ["pulmonary", "ORGAN", 148, 157], ["HIV", "SPECIES", 87, 90], ["HIV", "SPECIES", 125, 128], ["HIV", "SPECIES", 272, 275], ["HIV", "SPECIES", 87, 90], ["HIV", "SPECIES", 125, 128], ["HIV", "SPECIES", 272, 275], ["HIV infection", "PROBLEM", 87, 100], ["HIV", "PROBLEM", 125, 128], ["its infectious pulmonary complications", "PROBLEM", 133, 171], ["acquired HIV infection", "PROBLEM", 263, 285], ["HIV", "OBSERVATION_MODIFIER", 87, 90], ["infection", "OBSERVATION", 91, 100], ["infectious", "OBSERVATION_MODIFIER", 137, 147], ["pulmonary", "ANATOMY", 148, 157], ["complications", "OBSERVATION", 158, 171]]], ["Of these, more than 40% are thought to have had AIDS develop (for definition of AIDS, see Tables 34-2 and 34-3, and Box 34-1).", [["AIDS", "DISEASE", 48, 52], ["AIDS", "DISEASE", 80, 84], ["AIDS", "PROBLEM", 48, 52], ["AIDS", "PROBLEM", 80, 84], ["Box", "TEST", 116, 119]]], ["Globally, 4.3 million individuals acquired HIV infection in 2006, and over this time 2.9 million died of AIDS.", [["HIV infection", "DISEASE", 43, 56], ["AIDS", "DISEASE", 105, 109], ["HIV", "ORGANISM", 43, 46], ["HIV", "SPECIES", 43, 46], ["HIV", "SPECIES", 43, 46], ["HIV infection", "PROBLEM", 43, 56], ["AIDS", "PROBLEM", 105, 109], ["4.3 million", "OBSERVATION_MODIFIER", 10, 21], ["infection", "OBSERVATION", 47, 56]]], ["The developing world has been most affected.", [["most affected", "OBSERVATION_MODIFIER", 30, 43]]], ["Sub-Saharan Africa is the current epicenter of the pandemic (two thirds of all infections); here, one in five adults is HIV infected.", [["infections", "DISEASE", 79, 89], ["HIV infected", "DISEASE", 120, 132], ["adults", "ORGANISM", 110, 116], ["HIV", "ORGANISM", 120, 123], ["HIV", "SPECIES", 120, 123], ["HIV", "SPECIES", 120, 123], ["all infections", "PROBLEM", 75, 89], ["HIV infected", "PROBLEM", 120, 132], ["Saharan Africa", "OBSERVATION", 4, 18], ["pandemic", "OBSERVATION_MODIFIER", 51, 59], ["infections", "OBSERVATION", 79, 89], ["HIV", "OBSERVATION_MODIFIER", 120, 123], ["infected", "OBSERVATION", 124, 132]]], ["South and Southeast Asia are responsible for almost a fifth of the estimated HIV global burden.", [["HIV", "SPECIES", 77, 80], ["the estimated HIV global burden", "PROBLEM", 63, 94]]], ["In Central-Eastern Europe and Central Asia, there are currently 1.7 million HIVinfected individuals.", [["Central", "ANATOMY_MODIFIER", 3, 10], ["Central", "ANATOMY_MODIFIER", 30, 37]]], ["In the developed world, North America and Western Europe account for approximately 1.4 million and 740,000 infections, respectively.", [["infections", "DISEASE", 107, 117], ["740,000 infections", "PROBLEM", 99, 117]]], ["Most of these are spread through sexual contact, although vertical (mother-to-child) and bloodborne infections are also common.", [["bloodborne infections", "DISEASE", 89, 110], ["bloodborne infections", "PROBLEM", 89, 110], ["bloodborne", "ANATOMY", 89, 99], ["infections", "OBSERVATION", 100, 110]]], ["In the developing world, heterosexual transmission is the norm; however, in North America and Europe, homosexual and bisexual men constitute the largest group of infected individuals.Virology and Immunology of the Human Immunodeficiency VirusHIV was first isolated in 1983 from patients with symptoms and signs of immune dysfunction.", [["Human Immunodeficiency VirusHIV", "DISEASE", 214, 245], ["immune dysfunction", "DISEASE", 314, 332], ["men", "ORGANISM", 126, 129], ["individuals", "ORGANISM", 171, 182], ["Human", "ORGANISM", 214, 219], ["Immunodeficiency VirusHIV", "ORGANISM", 220, 245], ["patients", "ORGANISM", 278, 286], ["men", "SPECIES", 126, 129], ["Human", "SPECIES", 214, 219], ["patients", "SPECIES", 278, 286], ["Human Immunodeficiency VirusHIV", "SPECIES", 214, 245], ["infected individuals", "PROBLEM", 162, 182], ["the Human Immunodeficiency VirusHIV", "TEST", 210, 245], ["symptoms", "PROBLEM", 292, 300], ["immune dysfunction", "PROBLEM", 314, 332], ["largest", "OBSERVATION_MODIFIER", 145, 152], ["infected", "OBSERVATION", 162, 170], ["immune dysfunction", "OBSERVATION", 314, 332]]], ["Two subtypes (HIV-1 and HIV-2) have subsequently been identified.", [["HIV-1", "ORGANISM", 14, 19], ["HIV-2", "ORGANISM", 24, 29], ["HIV-1", "SPECIES", 14, 19], ["HIV-2", "SPECIES", 24, 29], ["HIV-1", "SPECIES", 14, 19], ["HIV-2", "SPECIES", 24, 29], ["HIV", "TEST", 14, 17], ["HIV", "TEST", 24, 27], ["subtypes", "OBSERVATION_MODIFIER", 4, 12]]], ["HIV-1 (hereafter referred to as HIV) is responsible for most infections, has a more aggressive clinical course, and is the focus of this chapter.Virology and Immunology of the Human Immunodeficiency VirusHIV is a human retrovirus belonging to the lentivirus family.", [["infections", "DISEASE", 61, 71], ["Human Immunodeficiency VirusHIV", "DISEASE", 176, 207], ["HIV-1", "ORGANISM", 0, 5], ["HIV", "ORGANISM", 32, 35], ["Human Immunodeficiency VirusHIV", "ORGANISM", 176, 207], ["human", "ORGANISM", 213, 218], ["lentivirus", "ORGANISM", 247, 257], ["HIV-1", "SPECIES", 0, 5], ["Human", "SPECIES", 176, 181], ["human", "SPECIES", 213, 218], ["HIV-1", "SPECIES", 0, 5], ["HIV", "SPECIES", 32, 35], ["Human Immunodeficiency VirusHIV", "SPECIES", 176, 207], ["human", "SPECIES", 213, 218], ["HIV", "PROBLEM", 0, 3], ["most infections", "PROBLEM", 56, 71], ["a human retrovirus", "TREATMENT", 211, 229]]], ["Cell-free or cell-associated HIV infects through attachment of its viral envelope protein (gp120) to the CD4 antigen complex on host cells.", [["Cell", "ANATOMY", 0, 4], ["cell", "ANATOMY", 13, 17], ["cells", "ANATOMY", 133, 138], ["Cell", "CELL", 0, 4], ["cell", "CELL", 13, 17], ["HIV", "ORGANISM", 29, 32], ["gp120", "GENE_OR_GENE_PRODUCT", 91, 96], ["CD4 antigen", "GENE_OR_GENE_PRODUCT", 105, 116], ["host cells", "CELL", 128, 138], ["viral envelope protein", "PROTEIN", 67, 89], ["gp120", "PROTEIN", 91, 96], ["CD4 antigen complex", "PROTEIN", 105, 124], ["host cells", "CELL_TYPE", 128, 138], ["HIV", "SPECIES", 29, 32], ["Cell", "TEST", 0, 4], ["HIV infects", "PROBLEM", 29, 40], ["its viral envelope protein", "TEST", 63, 89], ["free", "OBSERVATION_MODIFIER", 5, 9], ["cell", "OBSERVATION", 13, 17], ["HIV infects", "OBSERVATION", 29, 40], ["host cells", "OBSERVATION", 128, 138]]], ["The CD4 receptor is found on several cell types, although the T-helper lymphocyte is the main site of HIV infection in the body.", [["cell", "ANATOMY", 37, 41], ["T-helper lymphocyte", "ANATOMY", 62, 81], ["body", "ANATOMY", 123, 127], ["HIV infection", "DISEASE", 102, 115], ["CD4 receptor", "GENE_OR_GENE_PRODUCT", 4, 16], ["cell", "CELL", 37, 41], ["T-helper lymphocyte", "CELL", 62, 81], ["HIV", "ORGANISM", 102, 105], ["body", "ORGANISM_SUBDIVISION", 123, 127], ["CD4 receptor", "PROTEIN", 4, 16], ["T-helper lymphocyte", "CELL_TYPE", 62, 81], ["HIV", "SPECIES", 102, 105], ["The CD4 receptor", "TEST", 0, 16], ["HIV infection in the body", "PROBLEM", 102, 127], ["CD4", "OBSERVATION", 4, 7], ["several cell", "OBSERVATION_MODIFIER", 29, 41], ["types", "OBSERVATION_MODIFIER", 42, 47], ["main", "OBSERVATION_MODIFIER", 89, 93], ["HIV", "OBSERVATION_MODIFIER", 102, 105], ["infection", "OBSERVATION", 106, 115], ["body", "ANATOMY_MODIFIER", 123, 127]]], ["HIV gp120 must also bind to a cell surface protein coreceptor called chemokine receptor 5 (CCR5) or to other co-receptors, including CXCR4, depending on the host cell type.", [["cell surface", "ANATOMY", 30, 42], ["cell", "ANATOMY", 162, 166], ["HIV gp120", "ORGANISM", 0, 9], ["cell", "CELL", 30, 34], ["coreceptor called chemokine receptor 5", "GENE_OR_GENE_PRODUCT", 51, 89], ["CCR5", "GENE_OR_GENE_PRODUCT", 91, 95], ["CXCR4", "GENE_OR_GENE_PRODUCT", 133, 138], ["host cell type", "CELL", 157, 171], ["HIV gp120", "PROTEIN", 0, 9], ["cell surface protein coreceptor", "PROTEIN", 30, 61], ["chemokine receptor 5", "PROTEIN", 69, 89], ["CCR5", "PROTEIN", 91, 95], ["co-receptors", "PROTEIN", 109, 121], ["CXCR4", "PROTEIN", 133, 138], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV gp120", "PROBLEM", 0, 9], ["a cell surface protein coreceptor", "TREATMENT", 28, 61], ["chemokine receptor", "TREATMENT", 69, 87], ["CXCR4", "TEST", 133, 138], ["host cell type", "OBSERVATION", 157, 171]]], ["Polymorphisms in genes for CCR5 may affect disease progression by reducing the ability of HIV to enter and infect cells.", [["cells", "ANATOMY", 114, 119], ["CCR5", "GENE_OR_GENE_PRODUCT", 27, 31], ["HIV", "ORGANISM", 90, 93], ["cells", "CELL", 114, 119], ["CCR5", "PROTEIN", 27, 31], ["HIV", "SPECIES", 90, 93], ["Polymorphisms in genes", "PROBLEM", 0, 22], ["CCR5", "PROBLEM", 27, 31], ["disease progression", "PROBLEM", 43, 62], ["HIV", "PROBLEM", 90, 93], ["infect cells", "OBSERVATION", 107, 119]]], ["However, at a population level, this effect is small.Virology and Immunology of the Human Immunodeficiency VirusOnce HIV is inside the cell, it can, by use of the enzyme reverse transcriptase (RNA-dependent DNA polymerase), transcribe its HIV RNA into a DNA copy that can translocate to the nucleus and integrate with host cell DNA by use of its viral integrase.", [["cell", "ANATOMY", 135, 139], ["nucleus", "ANATOMY", 291, 298], ["cell", "ANATOMY", 323, 327], ["Human Immunodeficiency VirusOnce HIV", "DISEASE", 84, 120], ["Human Immunodeficiency VirusOnce HIV", "ORGANISM", 84, 120], ["cell", "CELL", 135, 139], ["enzyme reverse transcriptase", "GENE_OR_GENE_PRODUCT", 163, 191], ["DNA", "CELLULAR_COMPONENT", 207, 210], ["DNA", "CELLULAR_COMPONENT", 254, 257], ["nucleus", "CELLULAR_COMPONENT", 291, 298], ["cell DNA", "CELLULAR_COMPONENT", 323, 331], ["enzyme reverse transcriptase", "PROTEIN", 163, 191], ["RNA-dependent DNA polymerase", "PROTEIN", 193, 221], ["HIV RNA", "RNA", 239, 246], ["host cell DNA", "DNA", 318, 331], ["viral integrase", "DNA", 346, 361], ["Human", "SPECIES", 84, 89], ["HIV", "SPECIES", 117, 120], ["Human Immunodeficiency VirusOnce HIV", "SPECIES", 84, 120], ["HIV", "SPECIES", 239, 242], ["the Human Immunodeficiency VirusOnce HIV", "PROBLEM", 80, 120], ["the enzyme", "TEST", 159, 169], ["transcriptase (RNA-dependent DNA polymerase", "TREATMENT", 178, 221], ["host cell DNA", "TREATMENT", 318, 331], ["its viral integrase", "TREATMENT", 342, 361], ["small", "OBSERVATION_MODIFIER", 47, 52], ["nucleus", "ANATOMY", 291, 298], ["host cell DNA", "OBSERVATION", 318, 331], ["viral integrase", "OBSERVATION", 346, 361]]], ["The virus (as proviral DNA) remains latent in many cells until the cell itself becomes activated.", [["cells", "ANATOMY", 51, 56], ["cell", "ANATOMY", 67, 71], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["cells", "CELL", 51, 56], ["cell", "CELL", 67, 71], ["The virus (as proviral DNA)", "TREATMENT", 0, 27], ["virus", "OBSERVATION", 4, 9], ["many cells", "OBSERVATION", 46, 56]]], ["This may arise from cytokine or antigen stimulation.", [["antigen", "GENE_OR_GENE_PRODUCT", 32, 39], ["cytokine", "PROTEIN", 20, 28], ["cytokine or antigen stimulation", "TREATMENT", 20, 51]]], ["The viral genetic material is then transcribed into new RNA, which, in the form of a newly created virion, buds from the cell surface and is free to infect other CD4-bearing cells.Virology and Immunology of the Human Immunodeficiency VirusHIV infection directly attacks the immune system and in particular the T-helper cells that are central to a coordinated immune response.", [["virion", "ANATOMY", 99, 105], ["buds", "ANATOMY", 107, 111], ["cell surface", "ANATOMY", 121, 133], ["CD4-bearing cells", "ANATOMY", 162, 179], ["immune system", "ANATOMY", 274, 287], ["T-helper cells", "ANATOMY", 310, 324], ["Human Immunodeficiency VirusHIV infection", "DISEASE", 211, 252], ["buds", "TISSUE", 107, 111], ["cell surface", "CELLULAR_COMPONENT", 121, 133], ["CD4", "GENE_OR_GENE_PRODUCT", 162, 165], ["cells", "CELL", 174, 179], ["Human Immunodeficiency VirusHIV", "ORGANISM", 211, 242], ["T-helper cells", "CELL", 310, 324], ["CD4-bearing cells", "CELL_TYPE", 162, 179], ["T-helper cells", "CELL_TYPE", 310, 324], ["Human", "SPECIES", 211, 216], ["Human Immunodeficiency VirusHIV", "SPECIES", 211, 242], ["The viral genetic material", "PROBLEM", 0, 26], ["a newly created virion", "PROBLEM", 83, 105], ["the Human Immunodeficiency VirusHIV infection", "PROBLEM", 207, 252], ["viral genetic material", "OBSERVATION", 4, 26], ["new", "OBSERVATION_MODIFIER", 52, 55], ["RNA", "OBSERVATION_MODIFIER", 56, 59], ["virion", "OBSERVATION", 99, 105], ["cell", "OBSERVATION_MODIFIER", 121, 125], ["surface", "OBSERVATION_MODIFIER", 126, 133], ["free", "OBSERVATION_MODIFIER", 141, 145], ["bearing cells", "OBSERVATION", 166, 179], ["immune response", "OBSERVATION", 359, 374]]], ["This leads to progressive immune dysfunction and an inability to resist opportunistic disease.", [["immune dysfunction", "DISEASE", 26, 44], ["opportunistic disease", "DISEASE", 72, 93], ["progressive immune dysfunction", "PROBLEM", 14, 44], ["an inability to resist opportunistic disease", "PROBLEM", 49, 93], ["progressive", "OBSERVATION_MODIFIER", 14, 25], ["immune dysfunction", "OBSERVATION", 26, 44]]], ["The pathogenic process is not well defined, although it is thought that at the time of primary infection, HIV spreads to the lymph nodes, circulating immune cells, and thymus.", [["lymph nodes", "ANATOMY", 125, 136], ["immune cells", "ANATOMY", 150, 162], ["thymus", "ANATOMY", 168, 174], ["primary infection", "DISEASE", 87, 104], ["HIV", "ORGANISM", 106, 109], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 125, 136], ["circulating immune cells", "CELL", 138, 162], ["thymus", "ORGAN", 168, 174], ["circulating immune cells", "CELL_TYPE", 138, 162], ["HIV", "SPECIES", 106, 109], ["The pathogenic process", "PROBLEM", 0, 22], ["primary infection", "PROBLEM", 87, 104], ["HIV", "PROBLEM", 106, 109], ["the lymph nodes", "PROBLEM", 121, 136], ["circulating immune cells", "PROBLEM", 138, 162], ["thymus", "PROBLEM", 168, 174], ["pathogenic", "OBSERVATION_MODIFIER", 4, 14], ["process", "OBSERVATION", 15, 22], ["not", "UNCERTAINTY", 26, 29], ["well defined", "OBSERVATION_MODIFIER", 30, 42], ["primary", "OBSERVATION_MODIFIER", 87, 94], ["infection", "OBSERVATION", 95, 104], ["lymph nodes", "OBSERVATION", 125, 136], ["immune cells", "OBSERVATION", 150, 162], ["thymus", "ANATOMY", 168, 174]]], ["This is a massive viral infection of the human host; and although there seems to be a relatively potent immune response, in fact, this initial onslaught is so devastating (targeting as it does specific memory T cells responsible for sustaining long-term protective immunity) that the scene is set for progressive immune failure.", [["memory T cells", "ANATOMY", 202, 216], ["viral infection", "DISEASE", 18, 33], ["immune failure", "DISEASE", 313, 327], ["human", "ORGANISM", 41, 46], ["memory T cells", "CELL", 202, 216], ["memory T cells", "CELL_TYPE", 202, 216], ["human", "SPECIES", 41, 46], ["human", "SPECIES", 41, 46], ["a massive viral infection of the human host", "PROBLEM", 8, 51], ["sustaining long-term protective immunity", "TREATMENT", 233, 273], ["progressive immune failure", "PROBLEM", 301, 327], ["massive", "OBSERVATION_MODIFIER", 10, 17], ["viral", "OBSERVATION_MODIFIER", 18, 23], ["infection", "OBSERVATION", 24, 33], ["human host", "OBSERVATION_MODIFIER", 41, 51], ["seems to be", "UNCERTAINTY", 72, 83], ["potent", "OBSERVATION_MODIFIER", 97, 103], ["immune response", "OBSERVATION", 104, 119], ["progressive", "OBSERVATION_MODIFIER", 301, 312], ["immune failure", "OBSERVATION", 313, 327]]], ["This occurs through a combination of direct cell killing by HIV replicating within cells, as well as the negative effects of chronic immune activation.", [["cell", "ANATOMY", 44, 48], ["cells", "ANATOMY", 83, 88], ["cell", "CELL", 44, 48], ["HIV", "ORGANISM", 60, 63], ["cells", "CELL", 83, 88], ["HIV", "SPECIES", 60, 63], ["direct cell killing", "TREATMENT", 37, 56], ["HIV", "PROBLEM", 60, 63], ["chronic immune activation", "PROBLEM", 125, 150], ["chronic", "OBSERVATION_MODIFIER", 125, 132], ["immune activation", "OBSERVATION", 133, 150]]], ["Ultimately, these lead in most individuals to immune system destruction and dysfunction.", [["immune system", "ANATOMY", 46, 59], ["immune system destruction", "PROBLEM", 46, 71], ["dysfunction", "PROBLEM", 76, 87], ["destruction", "OBSERVATION", 60, 71]]], ["This is reflected not only by clinical disease indicating profound immunosuppression but also by a measurable reduction in the circulating absolute CD4 cell count, the percentage of T cells expressing CD4 markers, and in the progressive reduction in CD4/CD8 T-cell ratio.Natural History of Human Immunodeficiency Virus InfectionThe use of HAART, as well as preventative (prophylactic) therapies for opportunistic infections, has changed the clinical picture of HIV disease in countries where these interventions are available.", [["CD4 cell", "ANATOMY", 148, 156], ["T cells", "ANATOMY", 182, 189], ["CD4/CD8 T-cell", "ANATOMY", 250, 264], ["Human Immunodeficiency Virus Infection", "DISEASE", 290, 328], ["opportunistic infections", "DISEASE", 399, 423], ["HIV disease", "DISEASE", 461, 472], ["CD4 cell", "CELL", 148, 156], ["T cells", "CELL", 182, 189], ["CD4", "GENE_OR_GENE_PRODUCT", 201, 204], ["CD4", "GENE_OR_GENE_PRODUCT", 250, 253], ["CD8", "GENE_OR_GENE_PRODUCT", 254, 257], ["Human Immunodeficiency Virus", "ORGANISM", 290, 318], ["HIV", "ORGANISM", 461, 464], ["CD4", "PROTEIN", 148, 151], ["T cells", "CELL_TYPE", 182, 189], ["CD4 markers", "PROTEIN", 201, 212], ["CD4", "PROTEIN", 250, 253], ["CD8", "PROTEIN", 254, 257], ["Human", "SPECIES", 290, 295], ["Human Immunodeficiency Virus", "SPECIES", 290, 318], ["HIV", "SPECIES", 461, 464], ["clinical disease", "PROBLEM", 30, 46], ["profound immunosuppression", "PROBLEM", 58, 84], ["a measurable reduction", "PROBLEM", 97, 119], ["the circulating absolute CD4 cell count", "TEST", 123, 162], ["T cells", "PROBLEM", 182, 189], ["CD4 markers", "TEST", 201, 212], ["the progressive reduction", "PROBLEM", 221, 246], ["CD4", "TEST", 250, 253], ["Human Immunodeficiency Virus Infection", "PROBLEM", 290, 328], ["HAART", "TREATMENT", 339, 344], ["preventative (prophylactic) therapies", "TREATMENT", 357, 394], ["opportunistic infections", "PROBLEM", 399, 423], ["HIV disease", "PROBLEM", 461, 472], ["these interventions", "TREATMENT", 492, 511], ["not only", "UNCERTAINTY", 18, 26], ["profound", "OBSERVATION_MODIFIER", 58, 66], ["immunosuppression", "OBSERVATION", 67, 84], ["measurable", "OBSERVATION_MODIFIER", 99, 109], ["reduction", "OBSERVATION_MODIFIER", 110, 119], ["absolute CD4 cell count", "OBSERVATION", 139, 162], ["progressive", "OBSERVATION_MODIFIER", 225, 236], ["reduction", "OBSERVATION_MODIFIER", 237, 246], ["Human Immunodeficiency Virus", "OBSERVATION", 290, 318]]], ["Death rates have fallen to one sixth of their previous levels.", [["Death", "DISEASE", 0, 5], ["Death rates", "TEST", 0, 11]]], ["However, in the absence of such treatments, the median interval between HIV seroconversion and progression to AIDS in the developed world has been estimated to be 10 years, although rather less in resource-poor countries.", [["HIV seroconversion", "DISEASE", 72, 90], ["AIDS", "DISEASE", 110, 114], ["HIV", "ORGANISM", 72, 75], ["HIV", "SPECIES", 72, 75], ["such treatments", "TREATMENT", 27, 42], ["HIV seroconversion", "PROBLEM", 72, 90], ["AIDS", "PROBLEM", 110, 114]]], ["Almost all individuals have AIDS develop if untreated, and without HAART, 95% of these will die within 5 years.", [["AIDS", "DISEASE", 28, 32], ["individuals", "ORGANISM", 11, 22], ["AIDS", "PROBLEM", 28, 32], ["HAART", "TREATMENT", 67, 72]]], ["In many parts of the world, the main causes of death in patients with HIV infection include bacterial pneumonia, tuberculosis, and PCP.Natural History of Human Immunodeficiency Virus InfectionThe course of HIV infection can be divided clinically into several distinct periods: Acquisition of the virus Seroconversion, with or without a clinical illness (primary HIV infection) Clinically silent period, lasting several months to years Development of symptoms and signs indicating some degree of immunosuppression AIDS (where the subject has opportunistic disease implying profound immunosuppression [e.g., PCP])Acute Primary Human Immunodeficiency Virus InfectionThe time from acquisition of HIV infection to development of detectable antibodies (the \"window\" period) is usually approximately 6-8 weeks.", [["death", "DISEASE", 47, 52], ["HIV infection", "DISEASE", 70, 83], ["bacterial pneumonia", "DISEASE", 92, 111], ["tuberculosis", "DISEASE", 113, 125], ["PCP", "DISEASE", 131, 134], ["Human Immunodeficiency Virus Infection", "DISEASE", 154, 192], ["HIV infection", "DISEASE", 206, 219], ["primary HIV infection", "DISEASE", 354, 375], ["AIDS", "DISEASE", 513, 517], ["opportunistic disease", "DISEASE", 541, 562], ["PCP", "DISEASE", 606, 609], ["Human Immunodeficiency Virus Infection", "DISEASE", 625, 663], ["HIV infection", "DISEASE", 692, 705], ["PCP", "CHEMICAL", 606, 609], ["patients", "ORGANISM", 56, 64], ["Human Immunodeficiency Virus", "ORGANISM", 154, 182], ["HIV", "ORGANISM", 206, 209], ["Human Immunodeficiency Virus", "ORGANISM", 625, 653], ["HIV", "ORGANISM", 692, 695], ["antibodies", "PROTEIN", 735, 745], ["patients", "SPECIES", 56, 64], ["HIV", "SPECIES", 70, 73], ["Human", "SPECIES", 154, 159], ["HIV", "SPECIES", 206, 209], ["Human", "SPECIES", 625, 630], ["HIV", "SPECIES", 70, 73], ["Human Immunodeficiency Virus", "SPECIES", 154, 182], ["HIV", "SPECIES", 206, 209], ["HIV", "SPECIES", 362, 365], ["Human Immunodeficiency Virus Infection", "SPECIES", 625, 663], ["HIV", "SPECIES", 692, 695], ["death", "PROBLEM", 47, 52], ["HIV infection", "PROBLEM", 70, 83], ["bacterial pneumonia", "PROBLEM", 92, 111], ["tuberculosis", "PROBLEM", 113, 125], ["PCP", "PROBLEM", 131, 134], ["Human Immunodeficiency Virus Infection", "PROBLEM", 154, 192], ["HIV infection", "PROBLEM", 206, 219], ["the virus Seroconversion", "TREATMENT", 292, 316], ["a clinical illness", "PROBLEM", 334, 352], ["primary HIV infection", "PROBLEM", 354, 375], ["symptoms", "PROBLEM", 450, 458], ["signs", "PROBLEM", 463, 468], ["immunosuppression AIDS", "PROBLEM", 495, 517], ["opportunistic disease", "PROBLEM", 541, 562], ["profound immunosuppression", "TREATMENT", 572, 598], ["Acute Primary Human Immunodeficiency Virus Infection", "PROBLEM", 611, 663], ["HIV infection", "PROBLEM", 692, 705], ["detectable antibodies", "PROBLEM", 724, 745], ["main", "OBSERVATION_MODIFIER", 32, 36], ["bacterial", "OBSERVATION_MODIFIER", 92, 101], ["pneumonia", "OBSERVATION", 102, 111], ["tuberculosis", "OBSERVATION", 113, 125], ["Human Immunodeficiency Virus", "OBSERVATION", 154, 182], ["some degree", "OBSERVATION_MODIFIER", 480, 491], ["immunosuppression", "OBSERVATION", 495, 512], ["profound", "OBSERVATION_MODIFIER", 572, 580], ["immunosuppression", "OBSERVATION", 581, 598], ["Immunodeficiency Virus", "OBSERVATION", 631, 653], ["infection", "OBSERVATION", 696, 705]]], ["Between 30 and 70% of individuals who become infected will have a seroconversion illness.", [["individuals", "ORGANISM", 22, 33], ["a seroconversion illness", "PROBLEM", 64, 88], ["infected", "OBSERVATION", 45, 53]]], ["HIV antibody is normally present within 2-3 weeks of these symptoms, although this can take longer.", [["HIV", "ORGANISM", 0, 3], ["HIV antibody", "PROTEIN", 0, 12], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV antibody", "TEST", 0, 12], ["these symptoms", "PROBLEM", 53, 67]]], ["HIV RNA in peripheral blood is detectable before this and is often used to confirm infection.", [["peripheral blood", "ANATOMY", 11, 27], ["infection", "DISEASE", 83, 92], ["HIV", "ORGANISM", 0, 3], ["peripheral blood", "ORGANISM_SUBSTANCE", 11, 27], ["HIV RNA", "RNA", 0, 7], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 0, 3], ["HIV RNA in peripheral blood", "PROBLEM", 0, 27], ["infection", "PROBLEM", 83, 92], ["peripheral", "ANATOMY_MODIFIER", 11, 21], ["blood", "ANATOMY", 22, 27], ["infection", "OBSERVATION", 83, 92]]], ["The nonspecific features of primary HIV infection are almost always self-limiting, and typically seroconversion mimics a \"flulike\" illness or glandular fever.", [["glandular", "ANATOMY", 142, 151], ["primary HIV infection", "DISEASE", 28, 49], ["glandular fever", "DISEASE", 142, 157], ["HIV", "ORGANISM", 36, 39], ["glandular", "ORGAN", 142, 151], ["HIV", "SPECIES", 36, 39], ["HIV", "SPECIES", 36, 39], ["primary HIV infection", "PROBLEM", 28, 49], ["a \"flulike\" illness", "PROBLEM", 119, 138], ["glandular fever", "PROBLEM", 142, 157], ["nonspecific", "OBSERVATION_MODIFIER", 4, 15], ["primary", "OBSERVATION_MODIFIER", 28, 35], ["HIV", "OBSERVATION_MODIFIER", 36, 39], ["infection", "OBSERVATION", 40, 49], ["self-limiting", "OBSERVATION_MODIFIER", 68, 81], ["glandular", "ANATOMY", 142, 151], ["fever", "OBSERVATION", 152, 157]]], ["Most individuals with primary HIV infection recover from the acute symptoms within 4 weeks.", [["primary HIV infection", "DISEASE", 22, 43], ["HIV", "ORGANISM", 30, 33], ["HIV", "SPECIES", 30, 33], ["HIV", "SPECIES", 30, 33], ["primary HIV infection", "PROBLEM", 22, 43], ["the acute symptoms", "PROBLEM", 57, 75], ["infection", "OBSERVATION", 34, 43], ["acute", "OBSERVATION_MODIFIER", 61, 66]]], ["A proportion may have persistent symmetric generalized lymphadenopathy.", [["lymphadenopathy", "DISEASE", 55, 70], ["persistent symmetric generalized lymphadenopathy", "PROBLEM", 22, 70], ["persistent", "OBSERVATION_MODIFIER", 22, 32], ["symmetric", "OBSERVATION_MODIFIER", 33, 42], ["generalized", "OBSERVATION_MODIFIER", 43, 54], ["lymphadenopathy", "OBSERVATION", 55, 70]]], ["There is no difference in prognosis in this group compared with asymptomatic HIV-positive individuals.Chronic Human Immunodeficiency Virus InfectionAlthough a proportion of individuals remain completely well without any treatment for an extended period (approximately 20% after 10 years), many HIV-infected individuals have minor symptoms and signs suggesting immune dysfunction.", [["HIV-positive", "DISEASE", 77, 89], ["Human Immunodeficiency Virus InfectionAlthough", "DISEASE", 110, 156], ["HIV-infected", "DISEASE", 294, 306], ["immune dysfunction", "DISEASE", 360, 378], ["HIV", "ORGANISM", 77, 80], ["Human Immunodeficiency Virus", "ORGANISM", 110, 138], ["individuals", "ORGANISM", 173, 184], ["HIV", "ORGANISM", 294, 297], ["individuals", "ORGANISM", 307, 318], ["HIV", "SPECIES", 77, 80], ["Human", "SPECIES", 110, 115], ["HIV", "SPECIES", 294, 297], ["HIV", "SPECIES", 77, 80], ["Human Immunodeficiency Virus", "SPECIES", 110, 138], ["HIV", "SPECIES", 294, 297], ["Chronic Human Immunodeficiency Virus", "PROBLEM", 102, 138], ["infected individuals", "PROBLEM", 298, 318], ["minor symptoms", "PROBLEM", 324, 338], ["immune dysfunction", "PROBLEM", 360, 378], ["no", "UNCERTAINTY", 9, 11], ["difference", "OBSERVATION_MODIFIER", 12, 22], ["Human Immunodeficiency Virus", "OBSERVATION", 110, 138], ["suggesting", "UNCERTAINTY", 349, 359], ["immune dysfunction", "OBSERVATION", 360, 378]]], ["Examples of these include new or worsening rashes (including herpes simplex), tiredness, cough, and low-grade anemia.", [["rashes", "DISEASE", 43, 49], ["herpes simplex", "DISEASE", 61, 75], ["tiredness", "DISEASE", 78, 87], ["cough", "DISEASE", 89, 94], ["anemia", "DISEASE", 110, 116], ["herpes simplex", "ORGANISM", 61, 75], ["herpes simplex", "SPECIES", 61, 75], ["new or worsening rashes", "PROBLEM", 26, 49], ["herpes simplex)", "PROBLEM", 61, 76], ["tiredness", "PROBLEM", 78, 87], ["cough", "PROBLEM", 89, 94], ["low-grade anemia", "PROBLEM", 100, 116], ["new", "OBSERVATION_MODIFIER", 26, 29], ["worsening", "OBSERVATION_MODIFIER", 33, 42], ["rashes", "OBSERVATION", 43, 49], ["low-grade", "OBSERVATION_MODIFIER", 100, 109], ["anemia", "OBSERVATION", 110, 116]]], ["Certain clinical symptoms and signs provide important prognostic information.", [["Certain clinical symptoms", "PROBLEM", 0, 25]]], ["Most studies have shown that oral candidiasis and constitutional symptoms (e.g., malaise, idiopathic fever, night sweats, diarrhea, and weight loss) are the strongest clinical predictors of progression to AIDS.", [["oral", "ANATOMY", 29, 33], ["oral candidiasis", "DISEASE", 29, 45], ["idiopathic fever", "DISEASE", 90, 106], ["night sweats", "DISEASE", 108, 120], ["diarrhea", "DISEASE", 122, 130], ["weight loss", "DISEASE", 136, 147], ["AIDS", "DISEASE", 205, 209], ["oral", "ORGANISM_SUBDIVISION", 29, 33], ["Most studies", "TEST", 0, 12], ["oral candidiasis", "PROBLEM", 29, 45], ["constitutional symptoms", "PROBLEM", 50, 73], ["malaise", "PROBLEM", 81, 88], ["idiopathic fever", "PROBLEM", 90, 106], ["night sweats", "PROBLEM", 108, 120], ["diarrhea", "PROBLEM", 122, 130], ["weight loss", "PROBLEM", 136, 147], ["AIDS", "PROBLEM", 205, 209], ["candidiasis", "OBSERVATION", 34, 45]]], ["The term AIDS was created as an epidemiologic tool to capture those conditions that early in the HIV epidemic seemed to suggest significant immune destruction.", [["AIDS", "DISEASE", 9, 13], ["HIV", "SPECIES", 97, 100], ["The term AIDS", "PROBLEM", 0, 13], ["the HIV epidemic", "PROBLEM", 93, 109], ["significant immune destruction", "PROBLEM", 128, 158], ["significant", "OBSERVATION_MODIFIER", 128, 139], ["immune destruction", "OBSERVATION", 140, 158]]], ["Over time, it has been modified to incorporate the expanding spectrum of recognized diseases affecting immunosuppressed individuals, such as cervical carcinoma and recurrent bacterial pneumonia (see Box 34-1).", [["cervical carcinoma", "ANATOMY", 141, 159], ["cervical carcinoma", "DISEASE", 141, 159], ["bacterial pneumonia", "DISEASE", 174, 193], ["cervical carcinoma", "CANCER", 141, 159], ["recognized diseases", "PROBLEM", 73, 92], ["immunosuppressed individuals", "PROBLEM", 103, 131], ["cervical carcinoma", "PROBLEM", 141, 159], ["recurrent bacterial pneumonia", "PROBLEM", 164, 193], ["diseases", "OBSERVATION", 84, 92], ["cervical", "ANATOMY", 141, 149], ["carcinoma", "OBSERVATION", 150, 159], ["recurrent", "OBSERVATION_MODIFIER", 164, 173], ["bacterial", "OBSERVATION_MODIFIER", 174, 183], ["pneumonia", "OBSERVATION", 184, 193]]], ["The 1993 Centers for Disease Control and Prevention (CDC) classification included an immunologic criterion for AIDS (CD4 count <200 cells/mL or CD4 percentage <14% of total lymphocytes) regardless of clinical symptoms (see Table 34 -3).", [["cells", "ANATOMY", 132, 137], ["lymphocytes", "ANATOMY", 173, 184], ["AIDS", "DISEASE", 111, 115], ["lymphocytes", "CELL", 173, 184], ["CD4", "PROTEIN", 117, 120], ["CD4", "PROTEIN", 144, 147], ["lymphocytes", "CELL_TYPE", 173, 184], ["Disease Control", "TREATMENT", 21, 36], ["an immunologic criterion", "TEST", 82, 106], ["AIDS", "PROBLEM", 111, 115], ["CD4 count", "TEST", 117, 126], ["cells", "TEST", 132, 137], ["CD4 percentage", "TEST", 144, 158], ["total lymphocytes", "TEST", 167, 184], ["clinical symptoms", "PROBLEM", 200, 217]]], ["These data are used to define a point at which the risk of severe opportunistic infection rises dramatically.", [["opportunistic infection", "DISEASE", 66, 89], ["severe opportunistic infection", "PROBLEM", 59, 89], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["opportunistic", "OBSERVATION_MODIFIER", 66, 79], ["infection", "OBSERVATION", 80, 89]]], ["An example of this can be seen in the Multicenter AIDS Cohort Study (MACS) of homosexual and bisexual men without AIDS, which found that the incidence of PCP in subjects who did not use prophylaxis rose from 0.5% at 6 months in men with a baseline CD4 count >200 cells/mL to 8.4% in those with a CD4 count <200 cells/mL.", [["cells", "ANATOMY", 263, 268], ["cells", "ANATOMY", 311, 316], ["AIDS", "DISEASE", 50, 54], ["AIDS", "DISEASE", 114, 118], ["PCP", "DISEASE", 154, 157], ["PCP", "CHEMICAL", 154, 157], ["men", "ORGANISM", 102, 105], ["men", "ORGANISM", 228, 231], ["CD4", "PROTEIN", 248, 251], ["CD4", "PROTEIN", 296, 299], ["men", "SPECIES", 102, 105], ["men", "SPECIES", 228, 231], ["Cohort Study", "TEST", 55, 67], ["AIDS", "PROBLEM", 114, 118], ["prophylaxis", "TREATMENT", 186, 197], ["a baseline CD4 count", "TEST", 237, 257], ["cells/mL", "TEST", 263, 271], ["a CD4 count", "TEST", 294, 305]]], ["Apart from cervical carcinoma, AIDS indicator diseases differ little between men and women.", [["cervical carcinoma", "ANATOMY", 11, 29], ["cervical carcinoma", "DISEASE", 11, 29], ["AIDS", "DISEASE", 31, 35], ["cervical carcinoma", "CANCER", 11, 29], ["men", "ORGANISM", 77, 80], ["women", "ORGANISM", 85, 90], ["men", "SPECIES", 77, 80], ["women", "SPECIES", 85, 90], ["cervical carcinoma", "PROBLEM", 11, 29], ["AIDS indicator diseases", "PROBLEM", 31, 54], ["cervical", "ANATOMY", 11, 19], ["carcinoma", "OBSERVATION", 20, 29]]], ["Injecting drug users have a high incidence of wasting syndrome, recurrent bacterial pneumonia, and tuberculosis.", [["wasting syndrome", "DISEASE", 46, 62], ["bacterial pneumonia", "DISEASE", 74, 93], ["tuberculosis", "DISEASE", 99, 111], ["wasting syndrome", "PROBLEM", 46, 62], ["recurrent bacterial pneumonia", "PROBLEM", 64, 93], ["tuberculosis", "PROBLEM", 99, 111], ["wasting syndrome", "OBSERVATION", 46, 62], ["recurrent", "OBSERVATION_MODIFIER", 64, 73], ["bacterial", "OBSERVATION_MODIFIER", 74, 83], ["pneumonia", "OBSERVATION", 84, 93], ["tuberculosis", "OBSERVATION", 99, 111]]], ["Geographic differences in diseases occur that reflect the opportunistic pathogens present in the local environment (e.g., histoplasmosis or visceral leishmaniasis usually occur only in patients from endemic areas).", [["visceral leishmaniasis", "ANATOMY", 140, 162], ["histoplasmosis", "DISEASE", 122, 136], ["visceral leishmaniasis", "DISEASE", 140, 162], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 185, 193], ["Geographic differences in diseases", "PROBLEM", 0, 34], ["the opportunistic pathogens", "PROBLEM", 54, 81], ["histoplasmosis", "PROBLEM", 122, 136], ["visceral leishmaniasis", "PROBLEM", 140, 162], ["diseases", "OBSERVATION", 26, 34], ["opportunistic", "OBSERVATION_MODIFIER", 58, 71], ["pathogens", "OBSERVATION", 72, 81], ["visceral", "ANATOMY", 140, 148], ["leishmaniasis", "OBSERVATION", 149, 162]]], ["In the developed world, sexual, racial, and HIV risk factor survival differences after an AIDS diagnosis mainly arise from variation in ease of access to medical care.", [["AIDS", "DISEASE", 90, 94], ["HIV", "SPECIES", 44, 47], ["HIV risk factor survival differences", "PROBLEM", 44, 80], ["an AIDS diagnosis", "PROBLEM", 87, 104], ["medical care", "TREATMENT", 154, 166]]], ["It is certainly the case, however, that better treatment outcomes are associated with genuine specialist care provided by people with extensive experience in the field.Chronic Human Immunodeficiency Virus InfectionIn countries where HAART is available, the spectrum of HIV-related disease has changed.", [["Human Immunodeficiency Virus InfectionIn", "DISEASE", 176, 216], ["HIV-related disease", "DISEASE", 269, 288], ["people", "ORGANISM", 122, 128], ["Human Immunodeficiency Virus", "ORGANISM", 176, 204], ["HIV", "ORGANISM", 269, 272], ["people", "SPECIES", 122, 128], ["Human", "SPECIES", 176, 181], ["Human Immunodeficiency Virus", "SPECIES", 176, 204], ["HIV", "SPECIES", 269, 272], ["Chronic Human Immunodeficiency Virus", "PROBLEM", 168, 204], ["HAART", "TREATMENT", 233, 238], ["HIV-related disease", "PROBLEM", 269, 288], ["Immunodeficiency Virus", "OBSERVATION", 182, 204], ["HIV", "OBSERVATION", 269, 272], ["disease", "OBSERVATION", 281, 288]]], ["In the EuroSIDA cohort (a pan-European prospective study of HIV infection), between 1994 and 2002, opportunistic infections associated with very low CD4 counts (e.g., cytomegalovirus [CMV] retinitis and Mycobacterium avium-intracellulare complex [MAC] infection) were observed less frequently over time.", [["HIV infection", "DISEASE", 60, 73], ["opportunistic infections", "DISEASE", 99, 123], ["cytomegalovirus [CMV] retinitis", "DISEASE", 167, 198], ["infection", "DISEASE", 252, 261], ["HIV", "ORGANISM", 60, 63], ["CD4", "GENE_OR_GENE_PRODUCT", 149, 152], ["cytomegalovirus", "ORGANISM", 167, 182], ["CMV", "ORGANISM", 184, 187], ["Mycobacterium avium-intracellulare complex", "GENE_OR_GENE_PRODUCT", 203, 245], ["CD4", "PROTEIN", 149, 152], ["Mycobacterium avium", "SPECIES", 203, 222], ["-intracellulare", "SPECIES", 222, 237], ["HIV", "SPECIES", 60, 63], ["CMV", "SPECIES", 184, 187], ["Mycobacterium avium-intracellulare", "SPECIES", 203, 237], ["a pan-European prospective study", "TEST", 24, 56], ["HIV infection", "PROBLEM", 60, 73], ["opportunistic infections", "PROBLEM", 99, 123], ["very low CD4 counts", "PROBLEM", 140, 159], ["cytomegalovirus", "PROBLEM", 167, 182], ["CMV", "PROBLEM", 184, 187], ["retinitis", "PROBLEM", 189, 198], ["Mycobacterium avium", "PROBLEM", 203, 222], ["intracellulare complex", "PROBLEM", 223, 245], ["MAC] infection", "PROBLEM", 247, 261], ["infections", "OBSERVATION", 113, 123], ["cytomegalovirus", "OBSERVATION", 167, 182], ["Mycobacterium avium", "OBSERVATION", 203, 222], ["intracellulare", "OBSERVATION_MODIFIER", 223, 237], ["infection", "OBSERVATION", 252, 261]]], ["Malignant disease, such as non-Hodgkin lymphoma, increased as an AIDS-defining event between 1994 and 2004.Chronic Human Immunodeficiency Virus InfectionAlthough death rates have fallen in HAART-treated populations, there has been a rise in the proportion of non-AIDS deaths.", [["Malignant disease", "ANATOMY", 0, 17], ["non-Hodgkin lymphoma", "ANATOMY", 27, 47], ["Malignant disease", "DISEASE", 0, 17], ["non-Hodgkin lymphoma", "DISEASE", 27, 47], ["AIDS", "DISEASE", 65, 69], ["Human Immunodeficiency Virus InfectionAlthough death", "DISEASE", 115, 167], ["deaths", "DISEASE", 268, 274], ["Malignant disease", "CANCER", 0, 17], ["non-Hodgkin lymphoma", "CANCER", 27, 47], ["Human Immunodeficiency Virus", "ORGANISM", 115, 143], ["Human", "SPECIES", 115, 120], ["Human Immunodeficiency Virus", "SPECIES", 115, 143], ["Malignant disease", "PROBLEM", 0, 17], ["non-Hodgkin lymphoma", "PROBLEM", 27, 47], ["an AIDS", "PROBLEM", 62, 69], ["Chronic Human Immunodeficiency Virus", "PROBLEM", 107, 143], ["death rates", "PROBLEM", 162, 173], ["HAART", "TREATMENT", 189, 194], ["non-AIDS deaths", "PROBLEM", 259, 274], ["non-Hodgkin lymphoma", "OBSERVATION", 27, 47], ["increased", "OBSERVATION_MODIFIER", 49, 58], ["Human Immunodeficiency Virus", "OBSERVATION", 115, 143], ["rise", "OBSERVATION_MODIFIER", 233, 237], ["non-AIDS deaths", "OBSERVATION", 259, 274]]], ["In some series, this accounts for most events.", [["most events", "PROBLEM", 34, 45]]], ["Causes include liver disease (often caused by viral hepatitis) and cancer, as well as cardiovascular disease and drug-related toxicity.", [["liver", "ANATOMY", 15, 20], ["cancer", "ANATOMY", 67, 73], ["cardiovascular", "ANATOMY", 86, 100], ["liver disease", "DISEASE", 15, 28], ["viral hepatitis", "DISEASE", 46, 61], ["cancer", "DISEASE", 67, 73], ["cardiovascular disease", "DISEASE", 86, 108], ["toxicity", "DISEASE", 126, 134], ["liver", "ORGAN", 15, 20], ["cancer", "CANCER", 67, 73], ["cardiovascular", "ANATOMICAL_SYSTEM", 86, 100], ["liver disease", "PROBLEM", 15, 28], ["viral hepatitis)", "PROBLEM", 46, 62], ["cancer", "PROBLEM", 67, 73], ["cardiovascular disease", "PROBLEM", 86, 108], ["drug-related toxicity", "PROBLEM", 113, 134], ["liver", "ANATOMY", 15, 20], ["disease", "OBSERVATION", 21, 28], ["viral", "OBSERVATION_MODIFIER", 46, 51], ["hepatitis", "OBSERVATION", 52, 61], ["cancer", "OBSERVATION", 67, 73], ["cardiovascular", "ANATOMY", 86, 100], ["disease", "OBSERVATION", 101, 108]]], ["In such circumstances, AIDS deaths usually occur among patients who have not accessed medical care regularly and who are initially seen with advanced HIV disease.Chronic Human Immunodeficiency Virus InfectionA new manifestation of opportunistic infection has been described in patients commencing HAART.", [["AIDS", "DISEASE", 23, 27], ["deaths", "DISEASE", 28, 34], ["HIV disease", "DISEASE", 150, 161], ["Human Immunodeficiency Virus InfectionA", "DISEASE", 170, 209], ["opportunistic infection", "DISEASE", 231, 254], ["patients", "ORGANISM", 55, 63], ["Human Immunodeficiency Virus", "ORGANISM", 170, 198], ["patients", "ORGANISM", 277, 285], ["patients", "SPECIES", 55, 63], ["Human", "SPECIES", 170, 175], ["patients", "SPECIES", 277, 285], ["HIV", "SPECIES", 150, 153], ["Human Immunodeficiency Virus", "SPECIES", 170, 198], ["advanced HIV disease", "PROBLEM", 141, 161], ["Chronic Human Immunodeficiency Virus InfectionA", "PROBLEM", 162, 209], ["opportunistic infection", "PROBLEM", 231, 254], ["HAART", "TREATMENT", 297, 302], ["Human Immunodeficiency Virus", "OBSERVATION", 170, 198], ["opportunistic", "OBSERVATION_MODIFIER", 231, 244], ["infection", "OBSERVATION", 245, 254]]], ["The immune reconstitution disease, IRIS, may cause severe, if temporary, clinical illness as the individual's immunity recovers.", [["immune reconstitution disease", "DISEASE", 4, 33], ["IRIS", "DISEASE", 35, 39], ["The immune reconstitution disease", "PROBLEM", 0, 33], ["IRIS", "PROBLEM", 35, 39], ["temporary, clinical illness", "PROBLEM", 62, 89], ["immune reconstitution disease", "OBSERVATION", 4, 33], ["may cause", "UNCERTAINTY", 41, 50], ["severe", "OBSERVATION_MODIFIER", 51, 57]]], ["Patients will appear to develop a relapse of their original (and partially treated) disease.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["partially treated) disease", "PROBLEM", 65, 91], ["relapse", "OBSERVATION", 34, 41]]], ["This is often seen in MAC infection, tuberculosis, hepatitis B, CMV retinitis, and herpesviral infection.", [["infection", "DISEASE", 26, 35], ["tuberculosis", "DISEASE", 37, 49], ["hepatitis B", "DISEASE", 51, 62], ["CMV retinitis", "DISEASE", 64, 77], ["herpesviral infection", "DISEASE", 83, 104], ["hepatitis B", "ORGANISM", 51, 62], ["CMV", "ORGANISM", 64, 67], ["hepatitis B", "SPECIES", 51, 62], ["CMV", "SPECIES", 64, 67], ["MAC infection", "PROBLEM", 22, 35], ["tuberculosis", "PROBLEM", 37, 49], ["hepatitis B", "PROBLEM", 51, 62], ["CMV retinitis", "PROBLEM", 64, 77], ["herpesviral infection", "PROBLEM", 83, 104], ["often seen", "UNCERTAINTY", 8, 18], ["MAC", "OBSERVATION_MODIFIER", 22, 25], ["infection", "OBSERVATION", 26, 35], ["tuberculosis", "OBSERVATION", 37, 49], ["hepatitis", "OBSERVATION", 51, 60], ["CMV retinitis", "OBSERVATION", 64, 77], ["herpesviral", "OBSERVATION_MODIFIER", 83, 94], ["infection", "OBSERVATION", 95, 104]]], ["Metabolic complications of HAART, such as ischemic heart disease and diabetes, are a potential problem in HIV practice in the developed world.", [["heart", "ANATOMY", 51, 56], ["ischemic heart disease", "DISEASE", 42, 64], ["diabetes", "DISEASE", 69, 77], ["heart", "ORGAN", 51, 56], ["HIV", "SPECIES", 106, 109], ["Metabolic complications", "PROBLEM", 0, 23], ["HAART", "TREATMENT", 27, 32], ["ischemic heart disease", "PROBLEM", 42, 64], ["diabetes", "PROBLEM", 69, 77], ["complications", "OBSERVATION", 10, 23], ["HAART", "OBSERVATION", 27, 32], ["ischemic", "OBSERVATION_MODIFIER", 42, 50], ["heart", "ANATOMY", 51, 56], ["disease", "OBSERVATION", 57, 64], ["diabetes", "OBSERVATION", 69, 77]]], ["A significant number of individuals taking HAART also experience drug toxicity.", [["toxicity", "DISEASE", 70, 78], ["individuals", "ORGANISM", 24, 35], ["HAART", "TREATMENT", 43, 48], ["drug toxicity", "PROBLEM", 65, 78], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["number", "OBSERVATION_MODIFIER", 14, 20]]], ["An increasing number of patients are also surviving to manifest symptoms associated with chronic hepatitis B and C infection.", [["chronic hepatitis B", "DISEASE", 89, 108], ["infection", "DISEASE", 115, 124], ["patients", "ORGANISM", 24, 32], ["C", "CANCER", 113, 114], ["patients", "SPECIES", 24, 32], ["symptoms", "PROBLEM", 64, 72], ["chronic hepatitis B", "PROBLEM", 89, 108], ["C infection", "PROBLEM", 113, 124], ["increasing", "OBSERVATION_MODIFIER", 3, 13], ["number", "OBSERVATION_MODIFIER", 14, 20], ["chronic", "OBSERVATION_MODIFIER", 89, 96], ["hepatitis", "OBSERVATION", 97, 106], ["infection", "OBSERVATION", 115, 124]]], ["HIVassociated nephropathy (often with chronic kidney disease) is common in black Africans and is a significant cause of long-term morbidity.Prognostic MarkersLaboratory markers and clinical symptoms (e.g., oral thrush) can independently reflect the immune changes that lead to serious disease.", [["kidney", "ANATOMY", 46, 52], ["oral", "ANATOMY", 206, 210], ["HIVassociated nephropathy", "DISEASE", 0, 25], ["chronic kidney disease", "DISEASE", 38, 60], ["kidney", "ORGAN", 46, 52], ["oral", "ORGANISM_SUBDIVISION", 206, 210], ["HIVassociated nephropathy", "PROBLEM", 0, 25], ["chronic kidney disease", "PROBLEM", 38, 60], ["long-term morbidity", "PROBLEM", 120, 139], ["Prognostic MarkersLaboratory markers", "TEST", 140, 176], ["clinical symptoms", "PROBLEM", 181, 198], ["oral thrush", "PROBLEM", 206, 217], ["the immune changes", "PROBLEM", 245, 263], ["serious disease", "PROBLEM", 277, 292], ["nephropathy", "OBSERVATION", 14, 25], ["chronic", "OBSERVATION_MODIFIER", 38, 45], ["kidney", "ANATOMY", 46, 52], ["disease", "OBSERVATION", 53, 60], ["significant", "OBSERVATION_MODIFIER", 99, 110], ["long-term", "OBSERVATION_MODIFIER", 120, 129], ["morbidity", "OBSERVATION", 130, 139]]], ["Staging systems have been developed that can predict the risk of progression to severe opportunistic disease (AIDS).", [["opportunistic disease", "DISEASE", 87, 108], ["AIDS", "DISEASE", 110, 114], ["Staging systems", "TEST", 0, 15], ["severe opportunistic disease (AIDS)", "PROBLEM", 80, 115], ["progression", "OBSERVATION_MODIFIER", 65, 76], ["severe", "OBSERVATION_MODIFIER", 80, 86], ["opportunistic", "OBSERVATION_MODIFIER", 87, 100], ["disease", "OBSERVATION", 101, 108]]], ["The fall in absolute blood CD4 T-lymphocyte count is the most widely used prognostic marker, although CD4 counts may be affected by a number of factors apart from HIV, including intercurrent infection, cigarette smoking, exercise, time of day, and laboratory variation.", [["blood CD4 T-lymphocyte", "ANATOMY", 21, 43], ["intercurrent infection", "DISEASE", 178, 200], ["blood", "ORGANISM_SUBSTANCE", 21, 26], ["CD4", "GENE_OR_GENE_PRODUCT", 102, 105], ["HIV", "ORGANISM", 163, 166], ["CD4", "PROTEIN", 27, 30], ["CD4", "PROTEIN", 102, 105], ["HIV", "SPECIES", 163, 166], ["HIV", "SPECIES", 163, 166], ["The fall", "PROBLEM", 0, 8], ["absolute blood CD4 T", "TEST", 12, 32], ["lymphocyte count", "TEST", 33, 49], ["prognostic marker", "TEST", 74, 91], ["CD4 counts", "TEST", 102, 112], ["HIV", "PROBLEM", 163, 166], ["intercurrent infection", "PROBLEM", 178, 200], ["fall", "OBSERVATION", 4, 8], ["most widely", "OBSERVATION_MODIFIER", 57, 68], ["infection", "OBSERVATION", 191, 200]]], ["The percentage of CD4 cells and ratio of CD4/CD8 cells are more stable measures and may be used if the CD4 absolute counts seem to vary widely from visit to visit.", [["CD4 cells", "ANATOMY", 18, 27], ["CD4/CD8 cells", "ANATOMY", 41, 54], ["CD4 cells", "CELL", 18, 27], ["CD4", "GENE_OR_GENE_PRODUCT", 41, 44], ["CD8", "GENE_OR_GENE_PRODUCT", 45, 48], ["CD4", "GENE_OR_GENE_PRODUCT", 103, 106], ["CD4 cells", "CELL_TYPE", 18, 27], ["CD4/CD8 cells", "CELL_TYPE", 41, 54], ["CD4", "PROTEIN", 103, 106], ["CD4 cells", "PROBLEM", 18, 27], ["ratio", "TEST", 32, 37], ["CD4/CD8 cells", "PROBLEM", 41, 54], ["the CD4 absolute counts", "TEST", 99, 122], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["CD4 cells", "OBSERVATION", 18, 27], ["CD8 cells", "OBSERVATION", 45, 54], ["stable", "OBSERVATION_MODIFIER", 64, 70]]], ["Measurement of plasma HIV RNA \"viral load\" provides important prognostic information that can both guide therapy and suggest long-term outcome.", [["plasma", "ANATOMY", 15, 21], ["plasma", "ORGANISM_SUBSTANCE", 15, 21], ["HIV", "SPECIES", 22, 25], ["Measurement of plasma HIV RNA", "TEST", 0, 29], ["long-term", "OBSERVATION_MODIFIER", 125, 134]]], ["It has a particular value in subjects who are clinically well and have high CD4 counts, because it can give some indication of the expected speed of clinical progression.Pulmonary Immune Response During Human Immunodeficiency Virus InfectionIt is clear from the frequency with which HIV-related respiratory disease occurs that the pulmonary immune response is profoundly dysregulated.", [["Pulmonary", "ANATOMY", 170, 179], ["respiratory", "ANATOMY", 295, 306], ["pulmonary", "ANATOMY", 331, 340], ["Human Immunodeficiency Virus InfectionIt", "DISEASE", 203, 243], ["respiratory disease", "DISEASE", 295, 314], ["CD4", "GENE_OR_GENE_PRODUCT", 76, 79], ["Pulmonary", "ORGAN", 170, 179], ["Human Immunodeficiency Virus", "ORGANISM", 203, 231], ["HIV", "ORGANISM", 283, 286], ["pulmonary", "ORGAN", 331, 340], ["CD4", "PROTEIN", 76, 79], ["Human", "SPECIES", 203, 208], ["Human Immunodeficiency Virus", "SPECIES", 203, 231], ["HIV", "SPECIES", 283, 286], ["high CD4 counts", "PROBLEM", 71, 86], ["Human Immunodeficiency Virus InfectionIt", "PROBLEM", 203, 243], ["respiratory disease", "PROBLEM", 295, 314], ["profoundly dysregulated", "PROBLEM", 360, 383], ["Immune Response", "OBSERVATION", 180, 195], ["respiratory disease", "OBSERVATION", 295, 314], ["pulmonary", "ANATOMY", 331, 340], ["immune response", "OBSERVATION", 341, 356]]], ["In part, this is because the alterations that arise reflect the complex interplay between systemically derived HIV and other circulating antigens trafficking through the pulmonary vasculature, local immune cells, and airborne antigen.", [["pulmonary vasculature", "ANATOMY", 170, 191], ["immune cells", "ANATOMY", 199, 211], ["HIV", "ORGANISM", 111, 114], ["pulmonary vasculature", "MULTI-TISSUE_STRUCTURE", 170, 191], ["immune cells", "CELL", 199, 211], ["airborne antigen", "GENE_OR_GENE_PRODUCT", 217, 233], ["local immune cells", "CELL_TYPE", 193, 211], ["airborne antigen", "PROTEIN", 217, 233], ["HIV", "SPECIES", 111, 114], ["the alterations", "PROBLEM", 25, 40], ["HIV", "PROBLEM", 111, 114], ["local immune cells", "PROBLEM", 193, 211], ["airborne antigen", "TEST", 217, 233], ["pulmonary vasculature", "ANATOMY", 170, 191], ["immune cells", "OBSERVATION", 199, 211]]], ["Most studies investigating the pulmonary immune response have used in vitro cell culture systems that seek to mimic the pulmonary environment or in some cases bronchoscopy and bronchoalveolar lavage (BAL) to recover lung cells from infected individuals.", [["pulmonary", "ANATOMY", 31, 40], ["cell", "ANATOMY", 76, 80], ["pulmonary", "ANATOMY", 120, 129], ["bronchoalveolar lavage", "ANATOMY", 176, 198], ["BAL", "ANATOMY", 200, 203], ["lung cells", "ANATOMY", 216, 226], ["pulmonary", "ORGAN", 31, 40], ["cell", "CELL", 76, 80], ["pulmonary", "ORGAN", 120, 129], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 176, 198], ["lung cells", "CELL", 216, 226], ["lung cells", "CELL_TYPE", 216, 226], ["Most studies", "TEST", 0, 12], ["the pulmonary immune response", "PROBLEM", 27, 56], ["vitro cell culture systems", "TREATMENT", 70, 96], ["some cases bronchoscopy", "TEST", 148, 171], ["bronchoalveolar lavage", "TEST", 176, 198], ["lung cells", "PROBLEM", 216, 226], ["infected individuals", "PROBLEM", 232, 252], ["pulmonary", "ANATOMY", 31, 40], ["pulmonary", "ANATOMY", 120, 129], ["bronchoalveolar lavage", "OBSERVATION", 176, 198], ["lung", "ANATOMY", 216, 220], ["infected", "OBSERVATION_MODIFIER", 232, 240]]], ["Until recently, these have been performed on symptomatic patients who required bronchoscopy as a diagnostic procedure.", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["bronchoscopy", "TREATMENT", 79, 91], ["a diagnostic procedure", "TREATMENT", 95, 117]]], ["Such subjects generally have advanced HIV infection, are often taking a number of different drugs (including antiretrovirals), and may have any number of different pathogens causing their pulmonary disease-which by themselves can influence the immune findings.", [["pulmonary", "ANATOMY", 188, 197], ["HIV infection", "DISEASE", 38, 51], ["pulmonary disease", "DISEASE", 188, 205], ["HIV", "ORGANISM", 38, 41], ["pulmonary", "ORGAN", 188, 197], ["HIV", "SPECIES", 38, 41], ["HIV", "SPECIES", 38, 41], ["advanced HIV infection", "PROBLEM", 29, 51], ["different drugs", "TREATMENT", 82, 97], ["antiretrovirals", "TREATMENT", 109, 124], ["different pathogens", "PROBLEM", 154, 173], ["their pulmonary disease", "PROBLEM", 182, 205], ["advanced", "OBSERVATION_MODIFIER", 29, 37], ["HIV", "OBSERVATION_MODIFIER", 38, 41], ["infection", "OBSERVATION", 42, 51], ["pulmonary", "ANATOMY", 188, 197], ["disease", "OBSERVATION", 198, 205]]], ["Finally, the question of whether BAL fluid truly represents the site of the immune response (the lung parenchyma) remains unclear.", [["BAL fluid", "ANATOMY", 33, 42], ["lung parenchyma", "ANATOMY", 97, 112], ["lung parenchyma", "MULTI-TISSUE_STRUCTURE", 97, 112], ["BAL fluid", "PROBLEM", 33, 42], ["fluid", "OBSERVATION", 37, 42], ["immune response", "OBSERVATION", 76, 91], ["lung", "ANATOMY", 97, 101], ["parenchyma", "ANATOMY_MODIFIER", 102, 112]]], ["For all these reasons, reported data should be interpreted with some care.Risk Factors for Respiratory DiseaseAn individual's risk for respiratory disease is determined by his or her medical history (e.g., receipt of effective preventative or antiretroviral therapy), place of residence and travel history (e.g., the influence of geography on mycobacterial and fungal disease), and state of host immunity.", [["respiratory", "ANATOMY", 135, 146], ["respiratory disease", "DISEASE", 135, 154], ["mycobacterial and fungal disease", "DISEASE", 343, 375], ["Risk Factors", "PROBLEM", 74, 86], ["Respiratory DiseaseAn", "PROBLEM", 91, 112], ["respiratory disease", "PROBLEM", 135, 154], ["antiretroviral therapy", "TREATMENT", 243, 265], ["mycobacterial and fungal disease)", "PROBLEM", 343, 376], ["fungal disease", "OBSERVATION", 361, 375]]], ["Falling blood CD4 counts or high plasma RNA \"viral loads\" increase the chance of respiratory infection, with an increased spectrum of potential organisms responsible for infection in the more immunosuppressed individual.", [["blood", "ANATOMY", 8, 13], ["plasma", "ANATOMY", 33, 39], ["respiratory", "ANATOMY", 81, 92], ["respiratory infection", "DISEASE", 81, 102], ["infection", "DISEASE", 170, 179], ["blood", "ORGANISM_SUBSTANCE", 8, 13], ["CD4", "GENE_OR_GENE_PRODUCT", 14, 17], ["plasma", "ORGANISM_SUBSTANCE", 33, 39], ["CD4", "PROTEIN", 14, 17], ["Falling blood CD4 counts", "PROBLEM", 0, 24], ["high plasma RNA \"viral loads\"", "PROBLEM", 28, 57], ["respiratory infection", "PROBLEM", 81, 102], ["potential organisms", "PROBLEM", 134, 153], ["infection", "PROBLEM", 170, 179], ["respiratory", "ANATOMY", 81, 92], ["infection", "OBSERVATION", 93, 102], ["infection", "OBSERVATION", 170, 179]]], ["For example, HIV-infected individuals with a CD4 count <200 cells/mL are four times more likely to have one episode of bacterial pneumonia per year than those with higher CD4 cell counts.", [["cells", "ANATOMY", 60, 65], ["CD4 cell", "ANATOMY", 171, 179], ["HIV-infected", "DISEASE", 13, 25], ["pneumonia", "DISEASE", 129, 138], ["HIV", "ORGANISM", 13, 16], ["individuals", "ORGANISM", 26, 37], ["CD4", "GENE_OR_GENE_PRODUCT", 45, 48], ["CD4 cell", "CELL", 171, 179], ["CD4", "PROTEIN", 45, 48], ["CD4", "PROTEIN", 171, 174], ["HIV", "SPECIES", 13, 16], ["HIV", "SPECIES", 13, 16], ["HIV", "PROBLEM", 13, 16], ["infected individuals", "PROBLEM", 17, 37], ["a CD4 count", "TEST", 43, 54], ["bacterial pneumonia", "PROBLEM", 119, 138], ["higher CD4 cell counts", "PROBLEM", 164, 186], ["infected", "OBSERVATION_MODIFIER", 17, 25], ["bacterial", "OBSERVATION_MODIFIER", 119, 128], ["pneumonia", "OBSERVATION", 129, 138], ["CD4 cell counts", "OBSERVATION", 171, 186]]], ["More exotic organisms are found in subjects with very low CD4 counts.", [["CD4", "GENE_OR_GENE_PRODUCT", 58, 61], ["CD4", "PROTEIN", 58, 61], ["More exotic organisms", "PROBLEM", 0, 21], ["very low CD4 counts", "PROBLEM", 49, 68], ["exotic organisms", "OBSERVATION", 5, 21]]], ["These include bacteria such as Rhodococcus equi and Nocardia asteroides and fungi such as Aspergillus species and Penicillium marneffei.", [["Nocardia asteroides", "DISEASE", 52, 71], ["Rhodococcus equi", "ORGANISM", 31, 47], ["Nocardia asteroides", "ORGANISM", 52, 71], ["Aspergillus species", "ORGANISM", 90, 109], ["Penicillium marneffei", "ORGANISM", 114, 135], ["Rhodococcus equi", "SPECIES", 31, 47], ["Nocardia asteroides", "SPECIES", 52, 71], ["Penicillium marneffei", "SPECIES", 114, 135], ["Rhodococcus equi", "SPECIES", 31, 47], ["Nocardia asteroides", "SPECIES", 52, 71], ["Penicillium marneffei", "SPECIES", 114, 135], ["bacteria", "PROBLEM", 14, 22], ["Rhodococcus equi", "PROBLEM", 31, 47], ["Nocardia asteroides", "PROBLEM", 52, 71], ["fungi", "PROBLEM", 76, 81], ["Aspergillus species", "PROBLEM", 90, 109], ["Penicillium marneffei", "PROBLEM", 114, 135], ["bacteria", "OBSERVATION", 14, 22], ["Nocardia asteroides", "OBSERVATION", 52, 71], ["Aspergillus species", "OBSERVATION", 90, 109], ["Penicillium marneffei", "OBSERVATION", 114, 135]]], ["Just as with P. jirovecii, this reflects the importance of T-cell depletion and macrophage dysfunction in the loss of host immunity (a process that has been confirmed by animal experiments).Risk Factors for Respiratory DiseaseAmong HIV-infected patients, injecting drug users are at greatest risk for development of bacterial pneumonia and tuberculosis.", [["T-cell", "ANATOMY", 59, 65], ["macrophage", "ANATOMY", 80, 90], ["P. jirovecii", "DISEASE", 13, 25], ["Respiratory DiseaseAmong HIV-infected", "DISEASE", 207, 244], ["bacterial pneumonia", "DISEASE", 316, 335], ["tuberculosis", "DISEASE", 340, 352], ["P. jirovecii", "ORGANISM", 13, 25], ["T-cell", "CELL", 59, 65], ["macrophage", "CELL", 80, 90], ["Respiratory DiseaseAmong HIV", "ORGANISM", 207, 235], ["patients", "ORGANISM", 245, 253], ["P. jirovecii", "SPECIES", 13, 25], ["HIV", "SPECIES", 232, 235], ["patients", "SPECIES", 245, 253], ["P. jirovecii", "SPECIES", 13, 25], ["P. jirovecii", "PROBLEM", 13, 25], ["T-cell depletion", "TREATMENT", 59, 75], ["macrophage dysfunction", "PROBLEM", 80, 102], ["Risk Factors", "PROBLEM", 190, 202], ["Respiratory DiseaseAmong HIV", "PROBLEM", 207, 235], ["bacterial pneumonia", "PROBLEM", 316, 335], ["tuberculosis", "PROBLEM", 340, 352], ["jirovecii", "OBSERVATION", 16, 25], ["cell depletion", "OBSERVATION", 61, 75], ["macrophage dysfunction", "OBSERVATION", 80, 102], ["bacterial", "OBSERVATION_MODIFIER", 316, 325], ["pneumonia", "OBSERVATION", 326, 335], ["tuberculosis", "OBSERVATION", 340, 352]]], ["Individuals who have had previous respiratory episodes (PCP or bacterial pneumonia) seem to be at increased risk of further disease.", [["respiratory", "ANATOMY", 34, 45], ["respiratory episodes", "DISEASE", 34, 54], ["PCP", "DISEASE", 56, 59], ["bacterial pneumonia", "DISEASE", 63, 82], ["previous respiratory episodes", "PROBLEM", 25, 54], ["PCP", "PROBLEM", 56, 59], ["bacterial pneumonia", "PROBLEM", 63, 82], ["further disease", "PROBLEM", 116, 131], ["pneumonia", "OBSERVATION", 73, 82], ["disease", "OBSERVATION", 124, 131]]], ["Whether this relates to host or environmental factors is not certain, although it seems likely that structural lung damage and abnormal pulmonary physiology would, in part, contribute to this.", [["lung", "ANATOMY", 111, 115], ["pulmonary", "ANATOMY", 136, 145], ["lung damage", "DISEASE", 111, 122], ["lung", "ORGAN", 111, 115], ["pulmonary", "ORGAN", 136, 145], ["structural lung damage", "PROBLEM", 100, 122], ["abnormal pulmonary physiology", "PROBLEM", 127, 156], ["seems likely", "UNCERTAINTY", 82, 94], ["lung", "ANATOMY", 111, 115], ["damage", "OBSERVATION", 116, 122], ["abnormal", "OBSERVATION_MODIFIER", 127, 135], ["pulmonary", "ANATOMY", 136, 145]]], ["This argument is supported by the increased rates of pneumonia in HIV-infected smokers compared with nonsmokers.", [["pneumonia", "DISEASE", 53, 62], ["HIV-infected", "DISEASE", 66, 78], ["HIV", "ORGANISM", 66, 69], ["HIV-", "SPECIES", 66, 70], ["HIV", "SPECIES", 66, 69], ["pneumonia", "PROBLEM", 53, 62], ["increased", "OBSERVATION_MODIFIER", 34, 43], ["rates", "OBSERVATION_MODIFIER", 44, 49], ["pneumonia", "OBSERVATION", 53, 62]]], ["Recent work has shown chronic obstructive pulmonary disease (COPD) and lung cancer occur more frequently among HIV-infected individuals compared with the general population.", [["pulmonary", "ANATOMY", 42, 51], ["lung cancer", "ANATOMY", 71, 82], ["chronic obstructive pulmonary disease", "DISEASE", 22, 59], ["COPD", "DISEASE", 61, 65], ["lung cancer", "DISEASE", 71, 82], ["HIV-infected", "DISEASE", 111, 123], ["pulmonary", "ORGAN", 42, 51], ["lung cancer", "CANCER", 71, 82], ["individuals", "ORGANISM", 124, 135], ["HIV", "SPECIES", 111, 114], ["HIV", "SPECIES", 111, 114], ["chronic obstructive pulmonary disease", "PROBLEM", 22, 59], ["COPD)", "PROBLEM", 61, 66], ["lung cancer", "PROBLEM", 71, 82], ["infected individuals", "PROBLEM", 115, 135], ["chronic", "OBSERVATION_MODIFIER", 22, 29], ["obstructive", "OBSERVATION_MODIFIER", 30, 41], ["pulmonary", "ANATOMY", 42, 51], ["disease", "OBSERVATION", 52, 59], ["COPD", "OBSERVATION", 61, 65], ["lung", "ANATOMY", 71, 75], ["cancer", "OBSERVATION", 76, 82]]], ["Given that a large number of HIV-infected individuals smoke heavily, there is a pressing need to target this population for smoking cessation.", [["HIV-infected", "DISEASE", 29, 41], ["smoking", "CHEMICAL", 124, 131], ["HIV", "ORGANISM", 29, 32], ["individuals", "ORGANISM", 42, 53], ["HIV-", "SPECIES", 29, 33], ["HIV", "SPECIES", 29, 32], ["smoking cessation", "TREATMENT", 124, 141], ["large", "OBSERVATION_MODIFIER", 13, 18]]], ["This is reinforced by the association demonstrated in some (but not all) studies between smoking and a more rapid progression to first AIDS illness and death.BronchitisThe presentation mimics bacterial exacerbations of chronic obstructive lung disease; most patients have a productive cough and fever.", [["lung", "ANATOMY", 239, 243], ["smoking", "CHEMICAL", 89, 96], ["AIDS illness", "DISEASE", 135, 147], ["death", "DISEASE", 152, 157], ["Bronchitis", "DISEASE", 158, 168], ["chronic obstructive lung disease", "DISEASE", 219, 251], ["cough", "DISEASE", 285, 290], ["fever", "DISEASE", 295, 300], ["lung", "ORGAN", 239, 243], ["patients", "ORGANISM", 258, 266], ["patients", "SPECIES", 258, 266], ["first AIDS illness", "PROBLEM", 129, 147], ["death", "PROBLEM", 152, 157], ["Bronchitis", "PROBLEM", 158, 168], ["bacterial exacerbations", "PROBLEM", 192, 215], ["chronic obstructive lung disease", "PROBLEM", 219, 251], ["a productive cough", "PROBLEM", 272, 290], ["fever", "PROBLEM", 295, 300], ["bacterial", "OBSERVATION_MODIFIER", 192, 201], ["exacerbations", "OBSERVATION_MODIFIER", 202, 215], ["chronic", "OBSERVATION_MODIFIER", 219, 226], ["obstructive", "OBSERVATION_MODIFIER", 227, 238], ["lung", "ANATOMY", 239, 243], ["disease", "OBSERVATION", 244, 251], ["productive", "OBSERVATION_MODIFIER", 274, 284], ["cough", "OBSERVATION", 285, 290], ["fever", "OBSERVATION", 295, 300]]], ["The pathogens commonly identified are similar to those in the general population (i.e., Streptococcus pneumoniae and Haemophilus influenzae).", [["Streptococcus pneumoniae", "DISEASE", 88, 112], ["Haemophilus influenzae", "DISEASE", 117, 139], ["Streptococcus pneumoniae", "ORGANISM", 88, 112], ["Haemophilus influenzae", "ORGANISM", 117, 139], ["Streptococcus pneumoniae", "SPECIES", 88, 112], ["Haemophilus influenzae", "SPECIES", 117, 139], ["Streptococcus pneumoniae", "SPECIES", 88, 112], ["Haemophilus influenzae", "SPECIES", 117, 139], ["The pathogens", "PROBLEM", 0, 13], ["Streptococcus pneumoniae", "PROBLEM", 88, 112], ["Haemophilus influenzae", "PROBLEM", 117, 139], ["pathogens", "OBSERVATION", 4, 13]]], ["However, patients with advanced disease may be infected with Pseudomonas aeruginosa or Staphylococcus aureus.", [["Pseudomonas aeruginosa or Staphylococcus aureus", "DISEASE", 61, 108], ["patients", "ORGANISM", 9, 17], ["Pseudomonas aeruginosa", "ORGANISM", 61, 83], ["Staphylococcus aureus", "ORGANISM", 87, 108], ["patients", "SPECIES", 9, 17], ["Pseudomonas aeruginosa", "SPECIES", 61, 83], ["Staphylococcus aureus", "SPECIES", 87, 108], ["Pseudomonas aeruginosa", "SPECIES", 61, 83], ["Staphylococcus aureus", "SPECIES", 87, 108], ["advanced disease", "PROBLEM", 23, 39], ["Pseudomonas aeruginosa", "PROBLEM", 61, 83], ["Staphylococcus aureus", "PROBLEM", 87, 108], ["Staphylococcus aureus", "OBSERVATION", 87, 108]]], ["Response to appropriate antibiotic therapy in conventional doses is good, although relapses frequently occur.BronchiectasisBronchiectasis is increasingly recognized in HIV-infected patients with advanced HIV disease and low CD4 lymphocyte counts.", [["CD4 lymphocyte", "ANATOMY", 224, 238], ["Bronchiectasis", "DISEASE", 123, 137], ["HIV-infected", "DISEASE", 168, 180], ["HIV disease", "DISEASE", 204, 215], ["HIV", "ORGANISM", 168, 171], ["patients", "ORGANISM", 181, 189], ["HIV", "ORGANISM", 204, 207], ["CD4 lymphocyte", "CELL", 224, 238], ["CD4", "PROTEIN", 224, 227], ["HIV", "SPECIES", 168, 171], ["patients", "SPECIES", 181, 189], ["HIV", "SPECIES", 204, 207], ["HIV", "SPECIES", 168, 171], ["HIV", "SPECIES", 204, 207], ["appropriate antibiotic therapy", "TREATMENT", 12, 42], ["relapses", "PROBLEM", 83, 91], ["BronchiectasisBronchiectasis", "PROBLEM", 109, 137], ["advanced HIV disease", "PROBLEM", 195, 215], ["low CD4 lymphocyte counts", "PROBLEM", 220, 245], ["antibiotic therapy", "OBSERVATION", 24, 42], ["Bronchiectasis", "OBSERVATION", 123, 137], ["infected", "OBSERVATION_MODIFIER", 172, 180], ["advanced", "OBSERVATION_MODIFIER", 195, 203], ["HIV disease", "OBSERVATION", 204, 215], ["low CD4 lymphocyte counts", "OBSERVATION", 220, 245]]], ["It probably arises secondary to recurrent bacterial or P. jirovecii infections.", [["bacterial or P. jirovecii infections", "DISEASE", 42, 78], ["P. jirovecii", "ORGANISM", 55, 67], ["P. jirovecii", "SPECIES", 55, 67], ["P. jirovecii", "SPECIES", 55, 67], ["recurrent bacterial or P. jirovecii infections", "PROBLEM", 32, 78], ["probably arises secondary to", "UNCERTAINTY", 3, 31], ["recurrent", "OBSERVATION_MODIFIER", 32, 41], ["bacterial", "OBSERVATION_MODIFIER", 42, 51], ["P.", "OBSERVATION_MODIFIER", 55, 57], ["jirovecii infections", "OBSERVATION", 58, 78]]], ["The diagnosis is most often made by high-resolution/fine-cut computed tomography (CT) scanning.", [["CT) scanning", "TEST", 82, 94]]], ["Its prevalence has not been accurately determined, although with improved survival from both opportunistic infections and HIV disease, it is likely that it will be increasingly common in clinical practice.", [["opportunistic infections", "DISEASE", 93, 117], ["HIV disease", "DISEASE", 122, 133], ["HIV", "SPECIES", 122, 125], ["HIV", "SPECIES", 122, 125], ["both opportunistic infections", "PROBLEM", 88, 117], ["HIV disease", "PROBLEM", 122, 133], ["opportunistic", "OBSERVATION_MODIFIER", 93, 106], ["infections", "OBSERVATION", 107, 117], ["HIV disease", "OBSERVATION", 122, 133]]], ["The pathogens isolated in patients with bronchiectasis are those seen in bronchitis.", [["bronchiectasis", "DISEASE", 40, 54], ["bronchitis", "DISEASE", 73, 83], ["patients", "ORGANISM", 26, 34], ["patients", "SPECIES", 26, 34], ["The pathogens", "PROBLEM", 0, 13], ["bronchiectasis", "PROBLEM", 40, 54], ["bronchitis", "PROBLEM", 73, 83], ["pathogens", "OBSERVATION_MODIFIER", 4, 13], ["bronchiectasis", "OBSERVATION", 40, 54], ["bronchitis", "OBSERVATION", 73, 83]]], ["In addition, Pseudomonas cepacia and Moraxella catarrhalis have been described.PneumoniaCommunity-acquired bacterial pneumonia occurs more frequently in HIV-infected patients than in the general population.", [["bacterial pneumonia", "DISEASE", 107, 126], ["HIV-infected", "DISEASE", 153, 165], ["Pseudomonas cepacia", "ORGANISM", 13, 32], ["Moraxella catarrhalis", "ORGANISM", 37, 58], ["patients", "ORGANISM", 166, 174], ["Pseudomonas cepacia", "SPECIES", 13, 32], ["Moraxella catarrhalis", "SPECIES", 37, 58], ["HIV", "SPECIES", 153, 156], ["patients", "SPECIES", 166, 174], ["Pseudomonas cepacia", "SPECIES", 13, 32], ["Moraxella catarrhalis", "SPECIES", 37, 58], ["HIV", "SPECIES", 153, 156], ["Pseudomonas cepacia", "PROBLEM", 13, 32], ["Moraxella catarrhalis", "PROBLEM", 37, 58], ["PneumoniaCommunity", "PROBLEM", 79, 97], ["acquired bacterial pneumonia", "PROBLEM", 98, 126], ["HIV", "PROBLEM", 153, 156], ["Pseudomonas", "OBSERVATION_MODIFIER", 13, 24], ["cepacia", "OBSERVATION", 25, 32], ["Moraxella catarrhalis", "OBSERVATION", 37, 58], ["bacterial", "OBSERVATION_MODIFIER", 107, 116], ["pneumonia", "OBSERVATION", 117, 126], ["more frequently", "OBSERVATION_MODIFIER", 134, 149], ["infected", "OBSERVATION_MODIFIER", 157, 165]]], ["It is especially common in HIV-infected injecting drug users.", [["HIV-infected", "DISEASE", 27, 39], ["HIV", "ORGANISM", 27, 30], ["HIV", "SPECIES", 27, 30], ["HIV", "SPECIES", 27, 30], ["infected", "OBSERVATION_MODIFIER", 31, 39]]], ["The spectrum of bacterial pathogens is similar to that in non-HIV-infected individuals (see Table 34 -1).", [["non-HIV-infected", "DISEASE", 58, 74], ["bacterial pathogens", "PROBLEM", 16, 35], ["bacterial", "OBSERVATION_MODIFIER", 16, 25], ["pathogens", "OBSERVATION", 26, 35]]], ["S. pneumoniae is the most common cause, followed by H. influenzae.PneumoniaHIV-infected individuals with S. pneumoniae pneumonia are frequently bacteremic.", [["S. pneumoniae", "DISEASE", 0, 13], ["PneumoniaHIV-infected", "DISEASE", 66, 87], ["S. pneumoniae pneumonia", "DISEASE", 105, 128], ["S. pneumoniae", "ORGANISM", 0, 13], ["H. influenzae", "ORGANISM", 52, 65], ["individuals", "ORGANISM", 88, 99], ["S. pneumoniae", "ORGANISM", 105, 118], ["S. pneumoniae", "SPECIES", 0, 13], ["H. influenzae", "SPECIES", 52, 65], ["S. pneumoniae", "SPECIES", 105, 118], ["S. pneumoniae", "SPECIES", 0, 13], ["H. influenzae", "SPECIES", 52, 65], ["S. pneumoniae", "SPECIES", 105, 118], ["S. pneumoniae", "PROBLEM", 0, 13], ["H. influenzae", "PROBLEM", 52, 65], ["PneumoniaHIV", "PROBLEM", 66, 78], ["infected individuals", "PROBLEM", 79, 99], ["S. pneumoniae pneumonia", "PROBLEM", 105, 128], ["bacteremic", "PROBLEM", 144, 154], ["pneumoniae", "OBSERVATION", 3, 13], ["most common", "OBSERVATION_MODIFIER", 21, 32], ["infected", "OBSERVATION", 79, 87], ["pneumoniae", "OBSERVATION_MODIFIER", 108, 118], ["pneumonia", "OBSERVATION", 119, 128], ["frequently", "OBSERVATION_MODIFIER", 133, 143], ["bacteremic", "OBSERVATION_MODIFIER", 144, 154]]], ["In one study, the rate of pneumococcal bacteremia in HIV-infected individuals was 100 times that of an HIV-negative population.", [["bacteremia", "DISEASE", 39, 49], ["HIV-infected", "DISEASE", 53, 65], ["pneumococcal", "ORGANISM", 26, 38], ["HIV", "ORGANISM", 53, 56], ["individuals", "ORGANISM", 66, 77], ["HIV", "SPECIES", 53, 56], ["pneumococcal", "SPECIES", 26, 38], ["HIV", "SPECIES", 53, 56], ["HIV", "SPECIES", 103, 106], ["one study", "TEST", 3, 12], ["pneumococcal bacteremia", "PROBLEM", 26, 49], ["HIV", "PROBLEM", 53, 56], ["infected individuals", "PROBLEM", 57, 77], ["an HIV", "TEST", 100, 106], ["pneumococcal", "OBSERVATION_MODIFIER", 26, 38], ["bacteremia", "OBSERVATION", 39, 49], ["negative population", "OBSERVATION", 107, 126]]], ["More recent work has confirmed this to be the case for all causes of HIV-related bacterial pneumonia.", [["pneumonia", "DISEASE", 91, 100], ["HIV", "ORGANISM", 69, 72], ["HIV", "SPECIES", 69, 72], ["HIV", "SPECIES", 69, 72], ["HIV", "PROBLEM", 69, 72], ["bacterial pneumonia", "PROBLEM", 81, 100], ["HIV", "OBSERVATION", 69, 72], ["bacterial", "OBSERVATION_MODIFIER", 81, 90], ["pneumonia", "OBSERVATION", 91, 100]]], ["Typically, blood cultures have a 40-fold increased pickup rate in HIV-positive patients.", [["blood cultures", "ANATOMY", 11, 25], ["HIV-positive", "DISEASE", 66, 78], ["blood", "ORGANISM_SUBSTANCE", 11, 16], ["cultures", "CELL", 17, 25], ["HIV", "ORGANISM", 66, 69], ["patients", "ORGANISM", 79, 87], ["HIV", "SPECIES", 66, 69], ["patients", "SPECIES", 79, 87], ["HIV", "SPECIES", 66, 69], ["blood cultures", "TEST", 11, 25], ["HIV", "TEST", 66, 69]]], ["The widespread use of HAART has led to some decrease in rates of bacterial pneumonia and bacteremia, although they are still considerably higher than those seen in a non-HIV-infected population.PneumoniaBacterial pneumonia has a similar presentation in HIVinfected and uninfected individuals.", [["pneumonia", "DISEASE", 75, 84], ["bacteremia", "DISEASE", 89, 99], ["non-HIV-infected", "DISEASE", 166, 182], ["pneumonia", "DISEASE", 213, 222], ["HAART", "TREATMENT", 22, 27], ["bacterial pneumonia", "PROBLEM", 65, 84], ["bacteremia", "PROBLEM", 89, 99], ["a non-HIV-infected population", "PROBLEM", 164, 193], ["PneumoniaBacterial pneumonia", "PROBLEM", 194, 222], ["HIVinfected and uninfected individuals", "PROBLEM", 253, 291], ["widespread", "OBSERVATION_MODIFIER", 4, 14], ["some", "OBSERVATION_MODIFIER", 39, 43], ["decrease", "OBSERVATION_MODIFIER", 44, 52], ["bacterial", "OBSERVATION_MODIFIER", 65, 74], ["pneumonia", "OBSERVATION", 75, 84], ["bacteremia", "OBSERVATION", 89, 99], ["considerably", "OBSERVATION_MODIFIER", 125, 137], ["higher", "OBSERVATION_MODIFIER", 138, 144], ["infected", "OBSERVATION_MODIFIER", 174, 182], ["population", "OBSERVATION", 183, 193], ["pneumonia", "OBSERVATION", 213, 222], ["similar", "OBSERVATION_MODIFIER", 229, 236], ["uninfected individuals", "OBSERVATION", 269, 291]]], ["Chest radiographs are frequently atypical, mimicking PCP in up to 50% of cases ( Figure 34 -2).", [["PCP", "DISEASE", 53, 56], ["Chest radiographs", "TEST", 0, 17], ["mimicking PCP", "PROBLEM", 43, 56]]], ["By contrast, radiographic lobar or segmental consolidation may also be seen in a wide range of bacterial organisms (Figure 34 -3); these include S. pneumoniae, P. aeruginosa, H. influenzae, and Mycobacterium tuberculosis.", [["lobar", "ANATOMY", 26, 31], ["P. aeruginosa, H. influenzae", "DISEASE", 160, 188], ["Mycobacterium tuberculosis", "DISEASE", 194, 220], ["S. pneumoniae", "ORGANISM", 145, 158], ["P. aeruginosa", "ORGANISM", 160, 173], ["H. influenzae", "ORGANISM", 175, 188], ["Mycobacterium tuberculosis", "ORGANISM", 194, 220], ["S. pneumoniae", "SPECIES", 145, 158], ["P. aeruginosa", "SPECIES", 160, 173], ["H. influenzae", "SPECIES", 175, 188], ["Mycobacterium tuberculosis", "SPECIES", 194, 220], ["S. pneumoniae", "SPECIES", 145, 158], ["P. aeruginosa", "SPECIES", 160, 173], ["H. influenzae", "SPECIES", 175, 188], ["Mycobacterium tuberculosis", "SPECIES", 194, 220], ["radiographic lobar or segmental consolidation", "PROBLEM", 13, 58], ["bacterial organisms", "PROBLEM", 95, 114], ["Figure", "TEST", 116, 122], ["S. pneumoniae", "PROBLEM", 145, 158], ["P. aeruginosa", "PROBLEM", 160, 173], ["H. influenzae", "PROBLEM", 175, 188], ["Mycobacterium tuberculosis", "PROBLEM", 194, 220], ["lobar", "OBSERVATION_MODIFIER", 26, 31], ["segmental", "OBSERVATION_MODIFIER", 35, 44], ["consolidation", "OBSERVATION", 45, 58], ["may also be seen", "UNCERTAINTY", 59, 75], ["wide", "OBSERVATION_MODIFIER", 81, 85], ["bacterial organisms", "OBSERVATION", 95, 114], ["pneumoniae", "OBSERVATION", 148, 158], ["Mycobacterium tuberculosis", "OBSERVATION", 194, 220]]], ["PCP may also present with lobar or segmental consolidation.PneumoniaIn subjects with more advanced HIV disease and low CD4 lymphocyte counts, P. aeruginosa and S. aureus also cause pneumonia.PneumoniaComplications of bacterial pneumonia frequently occur, and pleural effusions are twice as likely in HIV infection (often occurring with S. aureus infection); empyema and intrapulmonary abscess formation are present in up to 10% of patients.", [["lobar", "ANATOMY", 26, 31], ["CD4 lymphocyte", "ANATOMY", 119, 133], ["pleural effusions", "ANATOMY", 259, 276], ["intrapulmonary abscess", "ANATOMY", 370, 392], ["PCP", "DISEASE", 0, 3], ["HIV disease", "DISEASE", 99, 110], ["pneumonia", "DISEASE", 181, 190], ["bacterial pneumonia", "DISEASE", 217, 236], ["pleural effusions", "DISEASE", 259, 276], ["HIV infection", "DISEASE", 300, 313], ["S. aureus infection", "DISEASE", 336, 355], ["empyema", "DISEASE", 358, 365], ["intrapulmonary abscess", "DISEASE", 370, 392], ["PCP", "CHEMICAL", 0, 3], ["CD4 lymphocyte", "CELL", 119, 133], ["P. aeruginosa", "ORGANISM", 142, 155], ["S. aureus", "ORGANISM", 160, 169], ["pleural effusions", "PATHOLOGICAL_FORMATION", 259, 276], ["HIV", "ORGANISM", 300, 303], ["S. aureus", "ORGANISM", 336, 345], ["intrapulmonary abscess", "PATHOLOGICAL_FORMATION", 370, 392], ["patients", "ORGANISM", 431, 439], ["CD4 lymphocyte", "CELL_TYPE", 119, 133], ["HIV", "SPECIES", 99, 102], ["P. aeruginosa", "SPECIES", 142, 155], ["S. aureus", "SPECIES", 160, 169], ["HIV", "SPECIES", 300, 303], ["S. aureus", "SPECIES", 336, 345], ["patients", "SPECIES", 431, 439], ["HIV", "SPECIES", 99, 102], ["P. aeruginosa", "SPECIES", 142, 155], ["S. aureus", "SPECIES", 160, 169], ["HIV", "SPECIES", 300, 303], ["S. aureus", "SPECIES", 336, 345], ["lobar or segmental consolidation", "PROBLEM", 26, 58], ["PneumoniaIn subjects", "PROBLEM", 59, 79], ["more advanced HIV disease", "PROBLEM", 85, 110], ["low CD4 lymphocyte counts", "PROBLEM", 115, 140], ["P. aeruginosa", "PROBLEM", 142, 155], ["S. aureus", "PROBLEM", 160, 169], ["pneumonia", "PROBLEM", 181, 190], ["bacterial pneumonia", "PROBLEM", 217, 236], ["pleural effusions", "PROBLEM", 259, 276], ["HIV infection", "PROBLEM", 300, 313], ["S. aureus infection", "PROBLEM", 336, 355], ["empyema", "PROBLEM", 358, 365], ["intrapulmonary abscess formation", "PROBLEM", 370, 402], ["may also present with", "UNCERTAINTY", 4, 25], ["lobar", "ANATOMY_MODIFIER", 26, 31], ["segmental", "ANATOMY_MODIFIER", 35, 44], ["consolidation", "OBSERVATION", 45, 58], ["advanced", "OBSERVATION_MODIFIER", 90, 98], ["HIV disease", "OBSERVATION", 99, 110], ["low CD4 lymphocyte counts", "OBSERVATION", 115, 140], ["aureus", "OBSERVATION", 163, 169], ["pneumonia", "OBSERVATION", 181, 190], ["bacterial", "OBSERVATION_MODIFIER", 217, 226], ["pneumonia", "OBSERVATION", 227, 236], ["pleural", "ANATOMY", 259, 266], ["effusions", "OBSERVATION", 267, 276], ["HIV", "OBSERVATION_MODIFIER", 300, 303], ["infection", "OBSERVATION", 304, 313], ["aureus", "OBSERVATION_MODIFIER", 339, 345], ["infection", "OBSERVATION", 346, 355], ["empyema", "OBSERVATION", 358, 365], ["intrapulmonary", "ANATOMY", 370, 384], ["abscess", "OBSERVATION", 385, 392], ["up to 10", "OBSERVATION_MODIFIER", 418, 426]]], ["Inevitably, the mortality rate is high (approximately 10%).Other BacteriaNocardia Asteroides Infection.", [["BacteriaNocardia Asteroides", "ORGANISM", 65, 92], ["the mortality rate", "TEST", 12, 30], ["Other BacteriaNocardia Asteroides Infection", "PROBLEM", 59, 102], ["high", "OBSERVATION_MODIFIER", 34, 38], ["Asteroides", "OBSERVATION_MODIFIER", 82, 92], ["Infection", "OBSERVATION", 93, 102]]], ["This has been reported in patients with advanced HIV disease and low CD4 lymphocyte counts.", [["CD4 lymphocyte", "ANATOMY", 69, 83], ["HIV disease", "DISEASE", 49, 60], ["patients", "ORGANISM", 26, 34], ["CD4 lymphocyte", "CELL", 69, 83], ["CD4", "PROTEIN", 69, 72], ["patients", "SPECIES", 26, 34], ["HIV", "SPECIES", 49, 52], ["HIV", "SPECIES", 49, 52], ["advanced HIV disease", "PROBLEM", 40, 60], ["low CD4 lymphocyte counts", "PROBLEM", 65, 90], ["low CD4 lymphocyte counts", "OBSERVATION", 65, 90]]], ["The widespread use of trimethoprim/sulfamethoxazole (TMP/SMX) for prophylaxis of PCP may have reduced the incidence of infection.", [["trimethoprim/sulfamethoxazole", "CHEMICAL", 22, 51], ["TMP", "CHEMICAL", 53, 56], ["SMX", "CHEMICAL", 57, 60], ["PCP", "DISEASE", 81, 84], ["infection", "DISEASE", 119, 128], ["trimethoprim", "CHEMICAL", 22, 34], ["sulfamethoxazole", "CHEMICAL", 35, 51], ["TMP", "CHEMICAL", 53, 56], ["SMX", "CHEMICAL", 57, 60], ["PCP", "CHEMICAL", 81, 84], ["trimethoprim/sulfamethoxazole", "SIMPLE_CHEMICAL", 22, 51], ["TMP", "SIMPLE_CHEMICAL", 53, 56], ["SMX", "SIMPLE_CHEMICAL", 57, 60], ["trimethoprim", "TREATMENT", 22, 34], ["sulfamethoxazole", "TREATMENT", 35, 51], ["TMP/SMX)", "TREATMENT", 53, 61], ["prophylaxis", "TREATMENT", 66, 77], ["PCP", "PROBLEM", 81, 84], ["infection", "PROBLEM", 119, 128], ["infection", "OBSERVATION", 119, 128]]], ["The clinical presentation is often indistinguishable from that of other bacterial infections.", [["bacterial infections", "DISEASE", 72, 92], ["other bacterial infections", "PROBLEM", 66, 92], ["bacterial", "OBSERVATION_MODIFIER", 72, 81], ["infections", "OBSERVATION", 82, 92]]], ["Chest radiographic appearances may mimic tuberculosis (see later), with upper lobe consolidation, cavitation, interstitial infiltrates, pleural effusion, and hilar lymphadenopathy.", [["upper lobe", "ANATOMY", 72, 82], ["interstitial infiltrates", "ANATOMY", 110, 134], ["pleural", "ANATOMY", 136, 143], ["hilar lymphadenopathy", "ANATOMY", 158, 179], ["tuberculosis", "DISEASE", 41, 53], ["upper lobe consolidation", "DISEASE", 72, 96], ["cavitation", "DISEASE", 98, 108], ["pleural effusion", "DISEASE", 136, 152], ["lymphadenopathy", "DISEASE", 164, 179], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 72, 82], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 110, 134], ["hilar lymphadenopathy", "CANCER", 158, 179], ["Chest radiographic", "TEST", 0, 18], ["tuberculosis", "PROBLEM", 41, 53], ["upper lobe consolidation", "PROBLEM", 72, 96], ["cavitation", "PROBLEM", 98, 108], ["interstitial infiltrates", "PROBLEM", 110, 134], ["pleural effusion", "PROBLEM", 136, 152], ["hilar lymphadenopathy", "PROBLEM", 158, 179], ["tuberculosis", "OBSERVATION", 41, 53], ["upper lobe", "ANATOMY", 72, 82], ["consolidation", "OBSERVATION", 83, 96], ["cavitation", "OBSERVATION_MODIFIER", 98, 108], ["interstitial", "ANATOMY_MODIFIER", 110, 122], ["infiltrates", "OBSERVATION", 123, 134], ["pleural", "ANATOMY", 136, 143], ["effusion", "OBSERVATION", 144, 152], ["hilar", "ANATOMY", 158, 163], ["lymphadenopathy", "OBSERVATION", 164, 179]]], ["The diagnosis is made by identification of the organism in sputum/BAL fluid or lung tissue.Other BacteriaRhodococcus equi.", [["sputum", "ANATOMY", 59, 65], ["BAL fluid", "ANATOMY", 66, 75], ["lung tissue", "ANATOMY", 79, 90], ["sputum", "ORGANISM_SUBSTANCE", 59, 65], ["BAL fluid", "ORGANISM_SUBSTANCE", 66, 75], ["lung tissue", "TISSUE", 79, 90], ["BacteriaRhodococcus equi.", "SPECIES", 97, 122], ["the organism in sputum/BAL fluid or lung tissue", "PROBLEM", 43, 90], ["Other BacteriaRhodococcus", "TEST", 91, 116], ["BAL", "ANATOMY", 66, 69], ["fluid", "OBSERVATION", 70, 75], ["lung", "ANATOMY", 79, 83], ["tissue", "OBSERVATION", 84, 90]]], ["R. equi usually produces pneumonia in patients who have advanced HIV infection and have been in contact with farm animals or with soil from fields or barns where animals are housed.", [["pneumonia", "DISEASE", 25, 34], ["HIV infection", "DISEASE", 65, 78], ["R. equi", "ORGANISM", 0, 7], ["patients", "ORGANISM", 38, 46], ["HIV", "ORGANISM", 65, 68], ["R. equi", "SPECIES", 0, 7], ["patients", "SPECIES", 38, 46], ["HIV", "SPECIES", 65, 68], ["R. equi", "SPECIES", 0, 7], ["HIV", "SPECIES", 65, 68], ["pneumonia", "PROBLEM", 25, 34], ["advanced HIV infection", "PROBLEM", 56, 78], ["equi", "OBSERVATION", 3, 7], ["pneumonia", "OBSERVATION", 25, 34], ["advanced", "OBSERVATION_MODIFIER", 56, 64], ["HIV", "OBSERVATION_MODIFIER", 65, 68], ["infection", "OBSERVATION", 69, 78]]], ["The presentation is subacute, with 2-3 weeks of cough, dyspnea, fever, and pleuritic chest pain.", [["chest", "ANATOMY", 85, 90], ["cough", "DISEASE", 48, 53], ["dyspnea", "DISEASE", 55, 62], ["fever", "DISEASE", 64, 69], ["chest pain", "DISEASE", 85, 95], ["chest", "ORGANISM_SUBDIVISION", 85, 90], ["cough", "PROBLEM", 48, 53], ["dyspnea", "PROBLEM", 55, 62], ["fever", "PROBLEM", 64, 69], ["pleuritic chest pain", "PROBLEM", 75, 95], ["subacute", "OBSERVATION_MODIFIER", 20, 28], ["cough", "OBSERVATION", 48, 53], ["dyspnea", "OBSERVATION", 55, 62], ["fever", "OBSERVATION", 64, 69], ["pleuritic", "OBSERVATION_MODIFIER", 75, 84], ["chest", "ANATOMY", 85, 90], ["pain", "OBSERVATION", 91, 95]]], ["The chest radiograph typically shows consolidation with cavitation.Other BacteriaPleural effusions are common.", [["chest", "ANATOMY", 4, 9], ["BacteriaPleural effusions", "ANATOMY", 73, 98], ["effusions", "DISEASE", 89, 98], ["chest", "ORGAN", 4, 9], ["BacteriaPleural effusions", "CANCER", 73, 98], ["The chest radiograph", "TEST", 0, 20], ["consolidation", "PROBLEM", 37, 50], ["cavitation", "PROBLEM", 56, 66], ["Other BacteriaPleural effusions", "PROBLEM", 67, 98], ["chest", "ANATOMY", 4, 9], ["consolidation", "OBSERVATION", 37, 50], ["cavitation", "OBSERVATION", 56, 66], ["BacteriaPleural", "ANATOMY", 73, 88], ["effusions", "OBSERVATION", 89, 98]]], ["The diagnosis is usually made by culture of sputum or blood; bronchoscopy with BAL or pleural aspiration may be necessary in some cases.Other BacteriaBartonella henselae.", [["sputum", "ANATOMY", 44, 50], ["blood", "ANATOMY", 54, 59], ["BAL", "ANATOMY", 79, 82], ["pleural", "ANATOMY", 86, 93], ["BacteriaBartonella henselae", "DISEASE", 142, 169], ["sputum", "ORGANISM_SUBSTANCE", 44, 50], ["blood", "ORGANISM_SUBSTANCE", 54, 59], ["BAL", "ORGANISM_SUBSTANCE", 79, 82], ["pleural", "ORGAN", 86, 93], ["BacteriaBartonella henselae", "ORGANISM", 142, 169], ["BacteriaBartonella henselae", "SPECIES", 142, 169], ["BacteriaBartonella henselae", "SPECIES", 142, 169], ["sputum or blood", "PROBLEM", 44, 59], ["bronchoscopy", "TEST", 61, 73], ["BAL", "TREATMENT", 79, 82], ["pleural aspiration", "PROBLEM", 86, 104], ["Other BacteriaBartonella henselae", "PROBLEM", 136, 169], ["pleural", "ANATOMY", 86, 93], ["aspiration", "OBSERVATION", 94, 104], ["henselae", "OBSERVATION", 161, 169]]], ["B. henselae is a gram-negative bacillus that causes bacillary angiomatosis in HIV-infected patients.", [["B. henselae", "DISEASE", 0, 11], ["bacillary angiomatosis", "DISEASE", 52, 74], ["HIV-infected", "DISEASE", 78, 90], ["B. henselae", "ORGANISM", 0, 11], ["bacillary angiomatosis", "PATHOLOGICAL_FORMATION", 52, 74], ["HIV", "ORGANISM", 78, 81], ["patients", "ORGANISM", 91, 99], ["B. henselae", "SPECIES", 0, 11], ["HIV", "SPECIES", 78, 81], ["patients", "SPECIES", 91, 99], ["B. henselae", "SPECIES", 0, 11], ["HIV", "SPECIES", 78, 81], ["a gram", "TEST", 15, 21], ["bacillary angiomatosis", "PROBLEM", 52, 74], ["HIV", "PROBLEM", 78, 81], ["henselae", "OBSERVATION", 3, 11], ["negative bacillus", "OBSERVATION_MODIFIER", 22, 39], ["bacillary angiomatosis", "OBSERVATION", 52, 74], ["infected", "OBSERVATION_MODIFIER", 82, 90]]], ["Clinically, the cutaneous lesions may mimic Kaposi sarcoma, from which they may be distinguished by demonstration of organisms in tissue with Warthin-Starry silver stain.", [["cutaneous lesions", "ANATOMY", 16, 33], ["Kaposi sarcoma", "ANATOMY", 44, 58], ["tissue", "ANATOMY", 130, 136], ["Kaposi sarcoma", "DISEASE", 44, 58], ["silver", "CHEMICAL", 157, 163], ["cutaneous lesions", "PATHOLOGICAL_FORMATION", 16, 33], ["Kaposi sarcoma", "CANCER", 44, 58], ["tissue", "TISSUE", 130, 136], ["the cutaneous lesions", "PROBLEM", 12, 33], ["Kaposi sarcoma", "PROBLEM", 44, 58], ["organisms in tissue", "PROBLEM", 117, 136], ["cutaneous", "ANATOMY", 16, 25], ["lesions", "OBSERVATION", 26, 33], ["may mimic", "UNCERTAINTY", 34, 43], ["Kaposi sarcoma", "OBSERVATION", 44, 58], ["organisms", "OBSERVATION", 117, 126]]], ["Bacillary angiomatosis may also infect the lungs, where it produces endobronchial red or violet polypoid angiomatous lesions, which may resemble Kaposi sarcoma.", [["lungs", "ANATOMY", 43, 48], ["endobronchial red", "ANATOMY", 68, 85], ["polypoid angiomatous lesions", "ANATOMY", 96, 124], ["Kaposi sarcoma", "ANATOMY", 145, 159], ["angiomatosis", "DISEASE", 10, 22], ["Kaposi sarcoma", "DISEASE", 145, 159], ["violet", "CHEMICAL", 89, 95], ["lungs", "ORGAN", 43, 48], ["violet polypoid angiomatous lesions", "PATHOLOGICAL_FORMATION", 89, 124], ["Kaposi sarcoma", "CANCER", 145, 159], ["Bacillary angiomatosis", "PROBLEM", 0, 22], ["endobronchial red or violet polypoid angiomatous lesions", "PROBLEM", 68, 124], ["Kaposi sarcoma", "PROBLEM", 145, 159], ["angiomatosis", "OBSERVATION", 10, 22], ["lungs", "ANATOMY", 43, 48], ["endobronchial", "ANATOMY", 68, 81], ["violet", "OBSERVATION_MODIFIER", 89, 95], ["polypoid", "OBSERVATION_MODIFIER", 96, 104], ["angiomatous", "OBSERVATION_MODIFIER", 105, 116], ["lesions", "OBSERVATION", 117, 124], ["may resemble", "UNCERTAINTY", 132, 144], ["Kaposi sarcoma", "OBSERVATION", 145, 159]]], ["Biopsy is necessary to confirm a diagnosis.Mycobacterial InfectionsTuberculosis HIV infection is associated with at least a 40-fold increased risk of an individual having active tuberculosis develop compared with noninfected subjects.", [["Tuberculosis HIV infection", "DISEASE", 67, 93], ["tuberculosis", "DISEASE", 178, 190], ["Mycobacterial InfectionsTuberculosis HIV", "ORGANISM", 43, 83], ["HIV", "SPECIES", 80, 83], ["HIV", "SPECIES", 80, 83], ["Biopsy", "TEST", 0, 6], ["Mycobacterial InfectionsTuberculosis HIV infection", "PROBLEM", 43, 93], ["active tuberculosis", "PROBLEM", 171, 190], ["Infections", "OBSERVATION", 57, 67], ["infection", "OBSERVATION", 84, 93], ["at least", "OBSERVATION_MODIFIER", 113, 121], ["40-fold", "OBSERVATION_MODIFIER", 124, 131], ["increased", "OBSERVATION_MODIFIER", 132, 141], ["active", "OBSERVATION_MODIFIER", 171, 177], ["tuberculosis", "OBSERVATION", 178, 190]]], ["Taken together with its ability to infect both the immunosuppressed and immunocompetent, tuberculosis is perhaps, therefore, the single most important disease associated with HIV infection.", [["tuberculosis", "DISEASE", 89, 101], ["HIV infection", "DISEASE", 175, 188], ["HIV", "ORGANISM", 175, 178], ["HIV", "SPECIES", 175, 178], ["HIV", "SPECIES", 175, 178], ["immunocompetent", "PROBLEM", 72, 87], ["tuberculosis", "PROBLEM", 89, 101], ["HIV infection", "PROBLEM", 175, 188], ["immunosuppressed", "OBSERVATION", 51, 67], ["tuberculosis", "OBSERVATION", 89, 101], ["HIV", "OBSERVATION_MODIFIER", 175, 178], ["infection", "OBSERVATION", 179, 188]]], ["It is estimated that there are at least 13 million individuals with HIV-tuberculosis coinfection.", [["HIV-tuberculosis coinfection", "DISEASE", 68, 96], ["HIV-tuberculosis", "ORGANISM", 68, 84], ["HIV-tuberculosis", "SPECIES", 68, 84], ["HIV-tuberculosis", "SPECIES", 68, 84], ["HIV-tuberculosis coinfection", "PROBLEM", 68, 96], ["tuberculosis coinfection", "OBSERVATION", 72, 96]]], ["As such, tuberculosis is a major cause of HIV-related morbidity and mortality.", [["tuberculosis", "DISEASE", 9, 21], ["HIV", "ORGANISM", 42, 45], ["HIV", "SPECIES", 42, 45], ["tuberculosis", "PROBLEM", 9, 21], ["HIV", "PROBLEM", 42, 45], ["related morbidity", "PROBLEM", 46, 63], ["tuberculosis", "OBSERVATION", 9, 21]]], ["It is also a major driver in both resource-rich and resource-poor countries for the current overall increase in tuberculosis rates.", [["tuberculosis", "DISEASE", 112, 124], ["tuberculosis rates", "PROBLEM", 112, 130], ["increase", "OBSERVATION_MODIFIER", 100, 108], ["tuberculosis", "OBSERVATION", 112, 124]]], ["Where HIV infection is endemic, tuberculosis control at a population level is almost impossible if treatment for both infections is not available.Mycobacterial InfectionsIn the United Kingdom, many centers routinely offer HIV antibody testing to all patients with tuberculosis, regardless of risk factors for HIV infection.", [["HIV infection", "DISEASE", 6, 19], ["tuberculosis", "DISEASE", 32, 44], ["infections", "DISEASE", 118, 128], ["tuberculosis", "DISEASE", 264, 276], ["HIV infection", "DISEASE", 309, 322], ["HIV", "ORGANISM", 6, 9], ["HIV", "ORGANISM", 222, 225], ["patients", "ORGANISM", 250, 258], ["HIV", "ORGANISM", 309, 312], ["HIV", "SPECIES", 6, 9], ["patients", "SPECIES", 250, 258], ["HIV", "SPECIES", 309, 312], ["HIV", "SPECIES", 6, 9], ["HIV", "SPECIES", 222, 225], ["HIV", "SPECIES", 309, 312], ["HIV infection", "PROBLEM", 6, 19], ["endemic", "PROBLEM", 23, 30], ["tuberculosis control", "TREATMENT", 32, 52], ["treatment", "TREATMENT", 99, 108], ["both infections", "PROBLEM", 113, 128], ["HIV antibody testing", "TEST", 222, 242], ["tuberculosis", "PROBLEM", 264, 276], ["HIV infection", "PROBLEM", 309, 322], ["HIV", "OBSERVATION_MODIFIER", 6, 9], ["infection", "OBSERVATION", 10, 19], ["endemic", "OBSERVATION_MODIFIER", 23, 30], ["tuberculosis", "OBSERVATION", 32, 44], ["infections", "OBSERVATION", 118, 128], ["tuberculosis", "OBSERVATION", 264, 276], ["infection", "OBSERVATION", 313, 322]]], ["In the United States, the CDC now recommends HIV testing as a routine part of health care for all patients aged 13-64 accessing medical services.", [["HIV", "ORGANISM", 45, 48], ["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106], ["HIV", "SPECIES", 45, 48], ["HIV testing", "TEST", 45, 56]]], ["The advantage of this is that individuals who are found to be HIV infected can be given HAART.", [["HIV infected", "DISEASE", 62, 74], ["individuals", "ORGANISM", 30, 41], ["HIV", "ORGANISM", 62, 65], ["HIV", "SPECIES", 62, 65], ["HIV", "SPECIES", 62, 65], ["HIV infected", "PROBLEM", 62, 74], ["HAART", "TREATMENT", 88, 93]]], ["Furthermore, strategies to modify high-risk behavior and reduce ongoing HIV transmission may be offered.Mycobacterial InfectionsActive tuberculosis can occur at any stage of HIV infection, and unlike almost every other HIV-related infection, may do so despite effective antiretroviral therapy.", [["InfectionsActive tuberculosis", "DISEASE", 118, 147], ["HIV infection", "DISEASE", 174, 187], ["infection", "DISEASE", 231, 240], ["HIV", "ORGANISM", 72, 75], ["HIV", "ORGANISM", 174, 177], ["HIV", "SPECIES", 174, 177], ["HIV", "SPECIES", 219, 222], ["HIV", "SPECIES", 72, 75], ["HIV", "SPECIES", 174, 177], ["HIV", "SPECIES", 219, 222], ["high-risk behavior", "PROBLEM", 34, 52], ["ongoing HIV transmission", "TREATMENT", 64, 88], ["Mycobacterial InfectionsActive tuberculosis", "PROBLEM", 104, 147], ["HIV infection", "PROBLEM", 174, 187], ["related infection", "PROBLEM", 223, 240], ["effective antiretroviral therapy", "TREATMENT", 260, 292], ["tuberculosis", "OBSERVATION", 135, 147], ["HIV", "OBSERVATION_MODIFIER", 174, 177], ["infection", "OBSERVATION", 178, 187], ["infection", "OBSERVATION", 231, 240]]], ["In the United States, United Kingdom, and most European countries, reporting of tuberculosis in both HIV-infected and non-HIV-infected individuals is mandatory.Mycobacterial InfectionsClinical disease in HIV-infected patients may arise in several different ways: by reactivation of latent tuberculosis, by rapid progression of pulmonary infection, and by reinfection from an exogenous source.Mycobacterial InfectionsPulmonary disease is the most common presentation; and clinical manifestations are related to the level of an individual's cell-mediated immunity.", [["pulmonary", "ANATOMY", 327, 336], ["Pulmonary", "ANATOMY", 416, 425], ["cell", "ANATOMY", 539, 543], ["tuberculosis", "DISEASE", 80, 92], ["HIV-infected and non-HIV-infected", "DISEASE", 101, 134], ["Mycobacterial Infections", "DISEASE", 160, 184], ["Clinical disease", "DISEASE", 184, 200], ["HIV-infected", "DISEASE", 204, 216], ["tuberculosis", "DISEASE", 289, 301], ["pulmonary infection", "DISEASE", 327, 346], ["InfectionsPulmonary disease", "DISEASE", 406, 433], ["HIV", "ORGANISM", 101, 104], ["individuals", "ORGANISM", 135, 146], ["HIV", "ORGANISM", 204, 207], ["patients", "ORGANISM", 217, 225], ["pulmonary", "ORGAN", 327, 336], ["Pulmonary", "ORGAN", 416, 425], ["cell", "CELL", 539, 543], ["HIV-", "SPECIES", 101, 105], ["HIV", "SPECIES", 204, 207], ["patients", "SPECIES", 217, 225], ["HIV", "SPECIES", 101, 104], ["HIV", "SPECIES", 204, 207], ["tuberculosis", "PROBLEM", 80, 92], ["both HIV", "PROBLEM", 96, 104], ["Mycobacterial Infections", "PROBLEM", 160, 184], ["Clinical disease", "PROBLEM", 184, 200], ["HIV", "PROBLEM", 204, 207], ["latent tuberculosis", "PROBLEM", 282, 301], ["pulmonary infection", "PROBLEM", 327, 346], ["an exogenous source", "PROBLEM", 372, 391], ["Mycobacterial InfectionsPulmonary disease", "PROBLEM", 392, 433], ["clinical manifestations", "PROBLEM", 471, 494], ["tuberculosis", "OBSERVATION", 80, 92], ["infected", "OBSERVATION_MODIFIER", 105, 113], ["infected", "OBSERVATION", 126, 134], ["Infections", "OBSERVATION", 174, 184], ["latent", "OBSERVATION_MODIFIER", 282, 288], ["tuberculosis", "OBSERVATION", 289, 301], ["rapid", "OBSERVATION_MODIFIER", 306, 311], ["progression", "OBSERVATION_MODIFIER", 312, 323], ["pulmonary", "ANATOMY", 327, 336], ["infection", "OBSERVATION", 337, 346], ["exogenous source", "OBSERVATION", 375, 391], ["Infections", "OBSERVATION", 406, 416], ["Pulmonary", "ANATOMY", 416, 425], ["disease", "OBSERVATION", 426, 433], ["most common", "OBSERVATION_MODIFIER", 441, 452]]], ["For example, subjects with early HIV disease have clinical features similar to \"normal\" adult postprimary disease (Table 34 -4).", [["HIV disease", "DISEASE", 33, 44], ["postprimary disease", "DISEASE", 94, 113], ["HIV", "SPECIES", 33, 36], ["HIV", "SPECIES", 33, 36], ["early HIV disease", "PROBLEM", 27, 44], ["clinical features", "PROBLEM", 50, 67], ["normal\" adult postprimary disease", "PROBLEM", 80, 113], ["early", "OBSERVATION_MODIFIER", 27, 32], ["HIV disease", "OBSERVATION", 33, 44]]], ["Symptoms typically include weight loss, fever with sweats, cough, sputum, dyspnea, hemoptysis, and chest pain.", [["sputum", "ANATOMY", 66, 72], ["chest", "ANATOMY", 99, 104], ["weight loss", "DISEASE", 27, 38], ["fever", "DISEASE", 40, 45], ["sweats", "DISEASE", 51, 57], ["cough", "DISEASE", 59, 64], ["dyspnea", "DISEASE", 74, 81], ["hemoptysis", "DISEASE", 83, 93], ["chest pain", "DISEASE", 99, 109], ["chest", "ORGANISM_SUBDIVISION", 99, 104], ["Symptoms", "PROBLEM", 0, 8], ["weight loss", "PROBLEM", 27, 38], ["fever", "PROBLEM", 40, 45], ["sweats", "PROBLEM", 51, 57], ["cough", "PROBLEM", 59, 64], ["sputum", "PROBLEM", 66, 72], ["dyspnea", "PROBLEM", 74, 81], ["hemoptysis", "PROBLEM", 83, 93], ["chest pain", "PROBLEM", 99, 109], ["dyspnea", "OBSERVATION", 74, 81], ["hemoptysis", "OBSERVATION", 83, 93], ["chest", "ANATOMY", 99, 104]]], ["These patients may have no clinical features to suggest associated HIV infection.", [["HIV infection", "DISEASE", 67, 80], ["patients", "ORGANISM", 6, 14], ["HIV", "ORGANISM", 67, 70], ["patients", "SPECIES", 6, 14], ["HIV", "SPECIES", 67, 70], ["clinical features", "PROBLEM", 27, 44], ["associated HIV infection", "PROBLEM", 56, 80], ["HIV", "OBSERVATION_MODIFIER", 67, 70], ["infection", "OBSERVATION", 71, 80]]], ["The chest radiograph frequently shows upper lobe consolidation, and cavitary change is common (Figure 34-4) .", [["chest", "ANATOMY", 4, 9], ["upper lobe", "ANATOMY", 38, 48], ["cavitary", "ANATOMY", 68, 76], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 38, 48], ["The chest radiograph", "TEST", 0, 20], ["upper lobe consolidation", "PROBLEM", 38, 62], ["cavitary change", "PROBLEM", 68, 83], ["chest", "ANATOMY", 4, 9], ["upper lobe", "ANATOMY", 38, 48], ["consolidation", "OBSERVATION", 49, 62], ["cavitary", "OBSERVATION_MODIFIER", 68, 76]]], ["The tuberculin skin test (purified protein derivative [PPD] ) is usually positive, and the likelihood of spontaneously expectorated sputum or BAL fluid being smear positive for acid-fast bacilli is high.Mycobacterial InfectionsIn individuals with advanced HIV disease (i.e., low CD4 lymphocyte counts and clinically apparent immunosuppression), it may be difficult to diagnose tuberculosis.", [["skin", "ANATOMY", 15, 19], ["sputum", "ANATOMY", 132, 138], ["BAL fluid", "ANATOMY", 142, 151], ["CD4 lymphocyte", "ANATOMY", 279, 293], ["HIV disease", "DISEASE", 256, 267], ["tuberculosis", "DISEASE", 377, 389], ["skin", "ORGAN", 15, 19], ["sputum", "ORGANISM_SUBSTANCE", 132, 138], ["BAL fluid", "ORGANISM_SUBSTANCE", 142, 151], ["HIV", "ORGANISM", 256, 259], ["CD4 lymphocyte", "CELL_TYPE", 279, 293], ["HIV", "SPECIES", 256, 259], ["HIV", "SPECIES", 256, 259], ["The tuberculin skin test", "TEST", 0, 24], ["spontaneously expectorated sputum", "PROBLEM", 105, 138], ["BAL fluid", "TEST", 142, 151], ["smear", "TEST", 158, 163], ["acid-fast bacilli", "TEST", 177, 194], ["Mycobacterial InfectionsIn individuals", "PROBLEM", 203, 241], ["advanced HIV disease", "PROBLEM", 247, 267], ["low CD4 lymphocyte counts", "PROBLEM", 275, 300], ["immunosuppression", "TREATMENT", 325, 342], ["tuberculosis", "PROBLEM", 377, 389], ["skin", "ANATOMY", 15, 19], ["bacilli", "OBSERVATION", 187, 194], ["high", "OBSERVATION_MODIFIER", 198, 202], ["advanced", "OBSERVATION_MODIFIER", 247, 255], ["HIV disease", "OBSERVATION", 256, 267]]], ["The clinical presentation here is often with nonspecific symptoms.", [["nonspecific symptoms", "PROBLEM", 45, 65]]], ["Fever, weight loss, fatigue, and malaise may be mistakenly ascribed to HIV infection itself.", [["Fever", "DISEASE", 0, 5], ["weight loss", "DISEASE", 7, 18], ["fatigue", "DISEASE", 20, 27], ["HIV infection", "DISEASE", 71, 84], ["HIV", "ORGANISM", 71, 74], ["HIV", "SPECIES", 71, 74], ["HIV", "SPECIES", 71, 74], ["Fever", "PROBLEM", 0, 5], ["weight loss", "PROBLEM", 7, 18], ["fatigue", "PROBLEM", 20, 27], ["malaise", "PROBLEM", 33, 40], ["HIV infection itself", "PROBLEM", 71, 91], ["weight loss", "OBSERVATION_MODIFIER", 7, 18], ["infection", "OBSERVATION", 75, 84]]], ["In this context, pulmonary tuberculosis is often similar to primary infection, with the chest radiograph showing diffuse or military-type shadowing ( Figure 34 -5), hilar or mediastinal lymphadenopathy, or pleural effusion; cavitation is unusual.", [["pulmonary", "ANATOMY", 17, 26], ["chest", "ANATOMY", 88, 93], ["hilar", "ANATOMY", 165, 170], ["mediastinal lymphadenopathy", "ANATOMY", 174, 201], ["pleural effusion", "ANATOMY", 206, 222], ["pulmonary tuberculosis", "DISEASE", 17, 39], ["primary infection", "DISEASE", 60, 77], ["mediastinal lymphadenopathy", "DISEASE", 174, 201], ["pleural effusion", "DISEASE", 206, 222], ["pulmonary", "ORGAN", 17, 26], ["hilar", "CANCER", 165, 170], ["pleural", "ORGAN", 206, 213], ["pulmonary tuberculosis", "PROBLEM", 17, 39], ["primary infection", "PROBLEM", 60, 77], ["the chest radiograph", "TEST", 84, 104], ["diffuse or military-type shadowing", "PROBLEM", 113, 147], ["hilar or mediastinal lymphadenopathy", "PROBLEM", 165, 201], ["pleural effusion", "PROBLEM", 206, 222], ["cavitation", "PROBLEM", 224, 234], ["pulmonary", "ANATOMY", 17, 26], ["tuberculosis", "OBSERVATION", 27, 39], ["primary", "OBSERVATION_MODIFIER", 60, 67], ["infection", "OBSERVATION", 68, 77], ["chest", "ANATOMY", 88, 93], ["diffuse", "OBSERVATION_MODIFIER", 113, 120], ["military", "OBSERVATION_MODIFIER", 124, 132], ["type", "OBSERVATION_MODIFIER", 133, 137], ["shadowing", "OBSERVATION_MODIFIER", 138, 147], ["hilar", "ANATOMY", 165, 170], ["mediastinal", "ANATOMY", 174, 185], ["lymphadenopathy", "OBSERVATION", 186, 201], ["pleural", "ANATOMY", 206, 213], ["effusion", "OBSERVATION", 214, 222], ["cavitation", "OBSERVATION", 224, 234]]], ["In up to 10% of patients the chest radiograph may appear normal; in others, the pulmonary infiltrate can be bilateral, diffuse, and interstitial in pattern, thus mimicking PCP.", [["chest", "ANATOMY", 29, 34], ["pulmonary infiltrate", "ANATOMY", 80, 100], ["interstitial", "ANATOMY", 132, 144], ["PCP", "DISEASE", 172, 175], ["PCP", "CHEMICAL", 172, 175], ["patients", "ORGANISM", 16, 24], ["chest", "ORGAN", 29, 34], ["pulmonary", "ORGAN", 80, 89], ["patients", "SPECIES", 16, 24], ["patients the chest radiograph", "TEST", 16, 45], ["the pulmonary infiltrate", "PROBLEM", 76, 100], ["diffuse, and interstitial in pattern", "PROBLEM", 119, 155], ["mimicking PCP", "PROBLEM", 162, 175], ["chest", "ANATOMY", 29, 34], ["normal", "OBSERVATION", 57, 63], ["pulmonary", "ANATOMY", 80, 89], ["infiltrate", "OBSERVATION", 90, 100], ["bilateral", "ANATOMY_MODIFIER", 108, 117], ["diffuse", "OBSERVATION_MODIFIER", 119, 126], ["interstitial", "ANATOMY_MODIFIER", 132, 144]]], ["Hilar lymphadenopathy and pleural effusion may also be produced by pulmonary Kaposi sarcoma or lymphoma, with which M. tuberculosis may coexist.", [["Hilar", "ANATOMY", 0, 5], ["pleural effusion", "ANATOMY", 26, 42], ["pulmonary Kaposi sarcoma", "ANATOMY", 67, 91], ["lymphoma", "ANATOMY", 95, 103], ["lymphadenopathy", "DISEASE", 6, 21], ["pleural effusion", "DISEASE", 26, 42], ["pulmonary Kaposi sarcoma", "DISEASE", 67, 91], ["lymphoma", "DISEASE", 95, 103], ["tuberculosis", "DISEASE", 119, 131], ["pleural effusion", "CANCER", 26, 42], ["pulmonary Kaposi sarcoma", "CANCER", 67, 91], ["lymphoma", "CANCER", 95, 103], ["M. tuberculosis", "ORGANISM", 116, 131], ["M. tuberculosis", "SPECIES", 116, 131], ["M. tuberculosis", "SPECIES", 116, 131], ["Hilar lymphadenopathy", "PROBLEM", 0, 21], ["pleural effusion", "PROBLEM", 26, 42], ["pulmonary Kaposi sarcoma", "PROBLEM", 67, 91], ["lymphoma", "PROBLEM", 95, 103], ["lymphadenopathy", "OBSERVATION", 6, 21], ["pleural", "ANATOMY", 26, 33], ["effusion", "OBSERVATION", 34, 42], ["may also be", "UNCERTAINTY", 43, 54], ["pulmonary", "ANATOMY", 67, 76], ["Kaposi sarcoma", "OBSERVATION", 77, 91], ["lymphoma", "OBSERVATION", 95, 103], ["tuberculosis", "OBSERVATION", 119, 131]]], ["The tuberculin skin test is usually negative, and spontaneously expectorated sputum and BAL fluid are often smear negative (but culture positive).Mycobacterial InfectionsIn addition to pulmonary tuberculosis, extrapulmonary disease occurs in a high proportion of HIV-infected individuals with low CD4 lymphocyte counts (<150 cells/mL).", [["skin", "ANATOMY", 15, 19], ["sputum", "ANATOMY", 77, 83], ["BAL fluid", "ANATOMY", 88, 97], ["pulmonary", "ANATOMY", 185, 194], ["extrapulmonary", "ANATOMY", 209, 223], ["CD4 lymphocyte", "ANATOMY", 297, 311], ["cells", "ANATOMY", 325, 330], ["Mycobacterial Infections", "DISEASE", 146, 170], ["pulmonary tuberculosis", "DISEASE", 185, 207], ["extrapulmonary disease", "DISEASE", 209, 231], ["HIV-infected", "DISEASE", 263, 275], ["skin", "ORGAN", 15, 19], ["sputum", "ORGANISM_SUBSTANCE", 77, 83], ["BAL fluid", "ORGANISM_SUBSTANCE", 88, 97], ["pulmonary", "ORGAN", 185, 194], ["HIV", "ORGANISM", 263, 266], ["individuals", "ORGANISM", 276, 287], ["CD4 lymphocyte", "CELL", 297, 311], ["CD4", "PROTEIN", 297, 300], ["HIV", "SPECIES", 263, 266], ["The tuberculin skin test", "TEST", 0, 24], ["spontaneously expectorated sputum", "TEST", 50, 83], ["BAL fluid", "TEST", 88, 97], ["smear", "TEST", 108, 113], ["culture", "TEST", 128, 135], ["Mycobacterial Infections", "PROBLEM", 146, 170], ["pulmonary tuberculosis", "PROBLEM", 185, 207], ["extrapulmonary disease", "PROBLEM", 209, 231], ["HIV", "PROBLEM", 263, 266], ["infected individuals", "PROBLEM", 267, 287], ["low CD4 lymphocyte counts", "PROBLEM", 293, 318], ["skin", "ANATOMY", 15, 19], ["Infections", "OBSERVATION", 160, 170], ["pulmonary", "ANATOMY", 185, 194], ["tuberculosis", "OBSERVATION", 195, 207], ["extrapulmonary", "ANATOMY", 209, 223], ["disease", "OBSERVATION", 224, 231], ["infected", "OBSERVATION_MODIFIER", 267, 275], ["low CD4 lymphocyte counts", "OBSERVATION", 293, 318]]], ["Mycobacteremia and lymph node infection ( Figure 34 -6) are common, but involvement of bone marrow, liver, pericardium, meninges, and brain also occurs.Mycobacterial InfectionsEvidence of extrapulmonary tuberculosis should be sought in any HIV-infected patient with suspected or confirmed pulmonary tuberculosis, by culture of stool, urine, and blood or bone marrow.", [["lymph node", "ANATOMY", 19, 29], ["bone marrow", "ANATOMY", 87, 98], ["liver", "ANATOMY", 100, 105], ["pericardium", "ANATOMY", 107, 118], ["meninges", "ANATOMY", 120, 128], ["brain", "ANATOMY", 134, 139], ["pulmonary", "ANATOMY", 289, 298], ["stool", "ANATOMY", 327, 332], ["urine", "ANATOMY", 334, 339], ["blood", "ANATOMY", 345, 350], ["bone marrow", "ANATOMY", 354, 365], ["Mycobacteremia", "DISEASE", 0, 14], ["lymph node infection", "DISEASE", 19, 39], ["Mycobacterial Infections", "DISEASE", 152, 176], ["extrapulmonary tuberculosis", "DISEASE", 188, 215], ["HIV-infected", "DISEASE", 240, 252], ["pulmonary tuberculosis", "DISEASE", 289, 311], ["lymph node", "MULTI-TISSUE_STRUCTURE", 19, 29], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 87, 98], ["liver", "ORGAN", 100, 105], ["pericardium", "MULTI-TISSUE_STRUCTURE", 107, 118], ["meninges", "MULTI-TISSUE_STRUCTURE", 120, 128], ["brain", "ORGAN", 134, 139], ["HIV", "ORGANISM", 240, 243], ["patient", "ORGANISM", 253, 260], ["pulmonary", "ORGAN", 289, 298], ["stool", "ORGANISM_SUBSTANCE", 327, 332], ["urine", "ORGANISM_SUBSTANCE", 334, 339], ["blood", "ORGANISM_SUBSTANCE", 345, 350], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 354, 365], ["HIV", "SPECIES", 240, 243], ["patient", "SPECIES", 253, 260], ["HIV", "SPECIES", 240, 243], ["Mycobacteremia", "PROBLEM", 0, 14], ["lymph node infection", "PROBLEM", 19, 39], ["bone marrow, liver, pericardium, meninges, and brain", "PROBLEM", 87, 139], ["Mycobacterial Infections", "PROBLEM", 152, 176], ["extrapulmonary tuberculosis", "PROBLEM", 188, 215], ["pulmonary tuberculosis", "PROBLEM", 289, 311], ["culture of stool, urine", "TEST", 316, 339], [", and blood or bone marrow", "PROBLEM", 339, 365], ["lymph node infection", "OBSERVATION", 19, 39], ["bone marrow", "ANATOMY", 87, 98], ["liver", "ANATOMY", 100, 105], ["pericardium", "ANATOMY", 107, 118], ["meninges", "ANATOMY", 120, 128], ["brain", "ANATOMY", 134, 139], ["Infections", "OBSERVATION", 166, 176], ["extrapulmonary", "ANATOMY", 188, 202], ["tuberculosis", "OBSERVATION", 203, 215], ["infected", "OBSERVATION", 244, 252], ["pulmonary", "ANATOMY", 289, 298], ["tuberculosis", "OBSERVATION", 299, 311], ["blood", "ANATOMY", 345, 350], ["bone marrow", "ANATOMY", 354, 365]]], ["Traditional solid phase culture and speciation techniques may take 6-10 weeks.", [["Traditional solid phase culture", "TEST", 0, 31], ["speciation techniques", "TREATMENT", 36, 57]]], ["Liquid culture methods (e.g., BACTEC, Becton Dickinson) that detect early growth may provide a diagnosis in only 2-3 weeks.", [["Liquid culture methods", "TEST", 0, 22], ["BACTEC", "TEST", 30, 36]]], ["Molecular diagnostic tests that use M. tuberculosis genome detection (e.g., by polymerase chain reaction [PCR] ) offer the possibility of yet more rapid diagnosis (within hours), but are not yet in routine clinical use.", [["M. tuberculosis", "ORGANISM", 36, 51], ["M. tuberculosis", "SPECIES", 36, 51], ["M. tuberculosis", "SPECIES", 36, 51], ["Molecular diagnostic tests", "TEST", 0, 26], ["polymerase chain reaction", "PROBLEM", 79, 104]]], ["They are also less useful in primary samples with low bacterial load (e.g., smear negative sputum)-which is often when they will be most needed in HIV-coinfected patients.", [["primary samples", "ANATOMY", 29, 44], ["sputum", "ANATOMY", 91, 97], ["HIV-coinfected", "DISEASE", 147, 161], ["samples", "CANCER", 37, 44], ["HIV", "ORGANISM", 147, 150], ["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170], ["HIV", "SPECIES", 147, 150], ["low bacterial load", "PROBLEM", 50, 68], ["smear", "TEST", 76, 81], ["sputum", "TEST", 91, 97]]], ["The recent description of simple, but highly sensitive and specific, methods that use the inoculation of large quantities of, for example, sputum onto microscopic plates with subsequent rapid detection (in days) of both mycobacterial growth and resistance patterns (MODS) is of great potential significance.Mycobacterial InfectionsUntil the results of culture and speciation are known, acidfast bacilli identified in respiratory samples, biopsy tissue, an aspirate, or blood in an HIV-infected individual, regardless of the CD4 lymphocyte count, should be regarded as being M. tuberculosis, and conventional antituberculosis therapy should be commenced.", [["sputum", "ANATOMY", 139, 145], ["respiratory samples", "ANATOMY", 417, 436], ["biopsy tissue", "ANATOMY", 438, 451], ["aspirate", "ANATOMY", 456, 464], ["blood", "ANATOMY", 469, 474], ["CD4 lymphocyte", "ANATOMY", 524, 538], ["MODS", "DISEASE", 266, 270], ["Mycobacterial Infections", "DISEASE", 307, 331], ["HIV-infected", "DISEASE", 481, 493], ["tuberculosis", "DISEASE", 577, 589], ["respiratory samples", "CANCER", 417, 436], ["biopsy tissue", "TISSUE", 438, 451], ["blood", "ORGANISM_SUBSTANCE", 469, 474], ["CD4 lymphocyte", "CELL", 524, 538], ["M. tuberculosis", "ORGANISM", 574, 589], ["CD4 lymphocyte", "CELL_TYPE", 524, 538], ["HIV", "SPECIES", 481, 484], ["M. tuberculosis", "SPECIES", 574, 589], ["HIV", "SPECIES", 481, 484], ["M. tuberculosis", "SPECIES", 574, 589], ["microscopic plates", "TEST", 151, 169], ["subsequent rapid detection", "TEST", 175, 201], ["both mycobacterial growth", "PROBLEM", 215, 240], ["MODS", "PROBLEM", 266, 270], ["Mycobacterial Infections", "PROBLEM", 307, 331], ["culture", "TEST", 352, 359], ["acidfast bacilli", "PROBLEM", 386, 402], ["respiratory samples", "TEST", 417, 436], ["biopsy tissue", "TEST", 438, 451], ["an aspirate", "TEST", 453, 464], ["blood", "PROBLEM", 469, 474], ["an HIV", "PROBLEM", 478, 484], ["infected individual", "PROBLEM", 485, 504], ["the CD4 lymphocyte count", "TEST", 520, 544], ["M. tuberculosis", "PROBLEM", 574, 589], ["conventional antituberculosis therapy", "TREATMENT", 595, 632], ["mycobacterial growth", "OBSERVATION", 220, 240], ["great potential", "OBSERVATION_MODIFIER", 278, 293], ["Infections", "OBSERVATION", 321, 331], ["respiratory", "ANATOMY", 417, 428], ["CD4 lymphocyte count", "OBSERVATION", 524, 544], ["tuberculosis", "OBSERVATION", 577, 589]]], ["If culture fails to demonstrate M. tuberculosis and instead another mycobacterium (see later) is identified, treatment can be modified.Drug-Resistant TuberculosisMultiple drug-resistant (MDR) tuberculosis-that is, M. tuberculosis that is resistant to isoniazid and rifampicin (rifampin), with or without other drugs, is now an important clinical problem in HIV-infected individuals in the United States, where it is responsible for approximately 3% of all tuberculosis in HIV-infected patients.", [["tuberculosis", "DISEASE", 35, 47], ["TuberculosisMultiple drug-resistant (MDR) tuberculosis", "DISEASE", 150, 204], ["M. tuberculosis", "DISEASE", 214, 229], ["isoniazid", "CHEMICAL", 251, 260], ["rifampicin", "CHEMICAL", 265, 275], ["rifampin", "CHEMICAL", 277, 285], ["HIV-infected", "DISEASE", 357, 369], ["tuberculosis", "DISEASE", 456, 468], ["HIV-infected", "DISEASE", 472, 484], ["isoniazid", "CHEMICAL", 251, 260], ["rifampicin", "CHEMICAL", 265, 275], ["rifampin", "CHEMICAL", 277, 285], ["M. tuberculosis", "ORGANISM", 32, 47], ["M. tuberculosis", "ORGANISM", 214, 229], ["isoniazid", "SIMPLE_CHEMICAL", 251, 260], ["rifampicin", "SIMPLE_CHEMICAL", 265, 275], ["rifampin", "SIMPLE_CHEMICAL", 277, 285], ["HIV", "ORGANISM", 357, 360], ["individuals", "ORGANISM", 370, 381], ["HIV", "ORGANISM", 472, 475], ["patients", "ORGANISM", 485, 493], ["M. tuberculosis", "SPECIES", 32, 47], ["M. tuberculosis", "SPECIES", 214, 229], ["HIV", "SPECIES", 357, 360], ["HIV", "SPECIES", 472, 475], ["patients", "SPECIES", 485, 493], ["M. tuberculosis", "SPECIES", 32, 47], ["M. tuberculosis", "SPECIES", 214, 229], ["HIV", "SPECIES", 357, 360], ["HIV", "SPECIES", 472, 475], ["culture", "TEST", 3, 10], ["M. tuberculosis", "PROBLEM", 32, 47], ["another mycobacterium", "PROBLEM", 60, 81], ["treatment", "TREATMENT", 109, 118], ["Drug", "TEST", 135, 139], ["Resistant TuberculosisMultiple drug-resistant (MDR) tuberculosis", "PROBLEM", 140, 204], ["M. tuberculosis", "PROBLEM", 214, 229], ["isoniazid", "TREATMENT", 251, 260], ["rifampicin", "TREATMENT", 265, 275], ["rifampin", "TREATMENT", 277, 285], ["all tuberculosis", "PROBLEM", 452, 468], ["tuberculosis", "OBSERVATION", 35, 47], ["Resistant TuberculosisMultiple", "OBSERVATION_MODIFIER", 140, 170], ["drug-resistant", "OBSERVATION_MODIFIER", 171, 185], ["tuberculosis", "OBSERVATION", 192, 204], ["tuberculosis", "OBSERVATION", 217, 229], ["resistant", "OBSERVATION_MODIFIER", 238, 247], ["tuberculosis", "OBSERVATION", 456, 468]]], ["Outbreaks of MDR tuberculosis have occurred in both HIV-infected and non-HIV-infected individuals in the United States in prison facilities, hostels, and hospitals.", [["tuberculosis", "DISEASE", 17, 29], ["HIV-infected and non-HIV-infected", "DISEASE", 52, 85], ["HIV", "ORGANISM", 52, 55], ["non-HIV", "ORGANISM", 69, 76], ["HIV-", "SPECIES", 52, 56], ["HIV", "SPECIES", 52, 55], ["non-HIV", "SPECIES", 69, 76], ["MDR tuberculosis", "PROBLEM", 13, 29], ["MDR tuberculosis", "OBSERVATION", 13, 29], ["infected", "OBSERVATION_MODIFIER", 56, 64]]], ["Similar outbreaks have also been documented among HIV-infected patients in Europe.", [["HIV-infected", "DISEASE", 50, 62], ["HIV", "ORGANISM", 50, 53], ["patients", "ORGANISM", 63, 71], ["HIV", "SPECIES", 50, 53], ["patients", "SPECIES", 63, 71], ["HIV", "SPECIES", 50, 53], ["infected", "OBSERVATION_MODIFIER", 54, 62]]], ["Inadequate treatment (including case management and supervision of medication) of tuberculosis and poor patient compliance with antituberculosis therapy are the most important risk factors for development of MDR tuberculosis.", [["tuberculosis", "DISEASE", 82, 94], ["tuberculosis", "DISEASE", 212, 224], ["patient", "ORGANISM", 104, 111], ["patient", "SPECIES", 104, 111], ["Inadequate treatment", "TREATMENT", 0, 20], ["case management", "TREATMENT", 32, 47], ["medication", "TREATMENT", 67, 77], ["tuberculosis", "PROBLEM", 82, 94], ["antituberculosis therapy", "TREATMENT", 128, 152], ["MDR tuberculosis", "PROBLEM", 208, 224], ["tuberculosis", "OBSERVATION", 82, 94], ["MDR", "OBSERVATION_MODIFIER", 208, 211], ["tuberculosis", "OBSERVATION", 212, 224]]], ["Other cases have arisen because of exogenous reinfection of profoundly immunosuppressed HIV-infected patients who are already receiving treatment for drug-sensitive disease.Drug-Resistant TuberculosisDespite antituberculosis therapy, the median survival in HIV-infected individuals with MDR-tuberculosis was initially only 2-3 months.", [["HIV-infected", "DISEASE", 88, 100], ["drug-sensitive disease", "DISEASE", 150, 172], ["HIV-infected", "DISEASE", 257, 269], ["MDR-tuberculosis", "DISEASE", 287, 303], ["HIV", "ORGANISM", 88, 91], ["patients", "ORGANISM", 101, 109], ["HIV", "ORGANISM", 257, 260], ["individuals", "ORGANISM", 270, 281], ["HIV-", "SPECIES", 88, 92], ["patients", "SPECIES", 101, 109], ["HIV-", "SPECIES", 257, 261], ["HIV", "SPECIES", 88, 91], ["HIV", "SPECIES", 257, 260], ["treatment", "TREATMENT", 136, 145], ["drug-sensitive disease", "PROBLEM", 150, 172], ["Drug", "TREATMENT", 173, 177], ["Resistant TuberculosisDespite antituberculosis therapy", "TREATMENT", 178, 232], ["HIV", "PROBLEM", 257, 260], ["MDR", "PROBLEM", 287, 290], ["tuberculosis", "PROBLEM", 291, 303], ["sensitive disease", "OBSERVATION", 155, 172], ["Resistant TuberculosisDespite", "OBSERVATION", 178, 207], ["antituberculosis therapy", "OBSERVATION", 208, 232], ["tuberculosis", "OBSERVATION", 291, 303]]], ["Recently this has improved, largely because of an increased awareness of the condition with early initiation of suitable therapy as determined by drug sensitivity testing.Extensively Drug-Resistant TuberculosisExtensively drug-resistant (XDR) tuberculosis-that is, M. tuberculosis resistant to isoniazid and rifampicin (rifampin), plus any fluoroquinolone and one or more of the three injectable second-line drugs (capreomycin, kanamycin and amikacin)-is an increasingly important clinical problem.", [["TuberculosisExtensively drug-resistant (XDR) tuberculosis", "DISEASE", 198, 255], ["tuberculosis", "DISEASE", 268, 280], ["isoniazid", "CHEMICAL", 294, 303], ["rifampicin", "CHEMICAL", 308, 318], ["rifampin", "CHEMICAL", 320, 328], ["fluoroquinolone", "CHEMICAL", 340, 355], ["capreomycin", "CHEMICAL", 415, 426], ["kanamycin", "CHEMICAL", 428, 437], ["amikacin", "CHEMICAL", 442, 450], ["isoniazid", "CHEMICAL", 294, 303], ["rifampicin", "CHEMICAL", 308, 318], ["rifampin", "CHEMICAL", 320, 328], ["fluoroquinolone", "CHEMICAL", 340, 355], ["capreomycin", "CHEMICAL", 415, 426], ["kanamycin", "CHEMICAL", 428, 437], ["amikacin", "CHEMICAL", 442, 450], ["M. tuberculosis", "ORGANISM", 265, 280], ["isoniazid", "SIMPLE_CHEMICAL", 294, 303], ["rifampicin", "SIMPLE_CHEMICAL", 308, 318], ["rifampin", "SIMPLE_CHEMICAL", 320, 328], ["fluoroquinolone", "SIMPLE_CHEMICAL", 340, 355], ["capreomycin", "SIMPLE_CHEMICAL", 415, 426], ["kanamycin", "SIMPLE_CHEMICAL", 428, 437], ["amikacin", "SIMPLE_CHEMICAL", 442, 450], ["M. tuberculosis", "SPECIES", 265, 280], ["M. tuberculosis", "SPECIES", 265, 280], ["an increased awareness of the condition", "PROBLEM", 47, 86], ["suitable therapy", "TREATMENT", 112, 128], ["drug sensitivity testing", "TEST", 146, 170], ["Extensively Drug-Resistant Tuberculosis", "PROBLEM", 171, 210], ["Extensively drug-resistant (XDR) tuberculosis", "PROBLEM", 210, 255], ["M. tuberculosis", "PROBLEM", 265, 280], ["isoniazid", "TREATMENT", 294, 303], ["rifampicin", "TREATMENT", 308, 318], ["rifampin", "TREATMENT", 320, 328], ["any fluoroquinolone", "TREATMENT", 336, 355], ["the three injectable second-line drugs", "TREATMENT", 375, 413], ["capreomycin", "TREATMENT", 415, 426], ["kanamycin", "TREATMENT", 428, 437], ["amikacin", "TREATMENT", 442, 450], ["improved", "OBSERVATION_MODIFIER", 18, 26], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["Drug-", "OBSERVATION_MODIFIER", 183, 188], ["Resistant", "OBSERVATION_MODIFIER", 188, 197], ["Tuberculosis", "OBSERVATION", 198, 210], ["drug-resistant", "OBSERVATION_MODIFIER", 222, 236], ["XDR", "OBSERVATION_MODIFIER", 238, 241], ["tuberculosis", "OBSERVATION", 243, 255], ["tuberculosis", "OBSERVATION", 268, 280]]], ["Originally described in South Africa in association with HIV infection, XDR tuberculosis has also been identified in most parts of the world.", [["HIV infection", "DISEASE", 57, 70], ["XDR tuberculosis", "DISEASE", 72, 88], ["HIV", "ORGANISM", 57, 60], ["XDR tuberculosis", "ORGANISM", 72, 88], ["HIV", "SPECIES", 57, 60], ["HIV", "SPECIES", 57, 60], ["XDR tuberculosis", "SPECIES", 72, 88], ["HIV infection", "PROBLEM", 57, 70], ["XDR tuberculosis", "PROBLEM", 72, 88], ["HIV", "OBSERVATION_MODIFIER", 57, 60], ["infection", "OBSERVATION", 61, 70], ["XDR tuberculosis", "OBSERVATION", 72, 88]]], ["As of March 2007, 35 countries had reported at least one case; although in many places, testing for fluoroquinolone sensitivity is not standard practice; this number may be, in fact, a huge underestimate.", [["fluoroquinolone", "CHEMICAL", 100, 115], ["fluoroquinolone", "CHEMICAL", 100, 115], ["fluoroquinolone", "SIMPLE_CHEMICAL", 100, 115], ["fluoroquinolone sensitivity", "TEST", 100, 127], ["huge", "OBSERVATION_MODIFIER", 185, 189], ["underestimate", "OBSERVATION", 190, 203]]], ["What is of concern about XDR tuberculosis is that, despite specific therapy, mortality is high among HIV-infected individuals.", [["tuberculosis", "DISEASE", 29, 41], ["HIV-infected", "DISEASE", 101, 113], ["HIV", "ORGANISM", 101, 104], ["individuals", "ORGANISM", 114, 125], ["HIV", "SPECIES", 101, 104], ["HIV", "SPECIES", 101, 104], ["XDR tuberculosis", "PROBLEM", 25, 41], ["specific therapy", "TREATMENT", 59, 75], ["infected individuals", "PROBLEM", 105, 125]]], ["The current picture seems to mirror early reports of MDR tuberculosis in HIV infection: in the original South African study from KwaZulu Natal, survival was less than 3 weeks from the time of receipt of the first sputum sample.Mycobacteria Other Than TuberculosisMycobacterium avium-intracellulare Complex.", [["sputum sample", "ANATOMY", 213, 226], ["tuberculosis", "DISEASE", 57, 69], ["HIV infection", "DISEASE", 73, 86], ["Tuberculosis", "DISEASE", 251, 263], ["HIV", "ORGANISM", 73, 76], ["Mycobacterium avium", "ORGANISM", 263, 282], ["HIV", "SPECIES", 73, 76], ["Mycobacterium avium", "SPECIES", 263, 282], ["-intracellulare", "SPECIES", 282, 297], ["HIV", "SPECIES", 73, 76], ["Mycobacterium avium", "SPECIES", 263, 282], ["MDR tuberculosis", "PROBLEM", 53, 69], ["HIV infection", "PROBLEM", 73, 86], ["the first sputum sample", "TEST", 203, 226], ["Mycobacteria", "PROBLEM", 227, 239], ["Tuberculosis", "PROBLEM", 251, 263], ["Mycobacterium avium", "PROBLEM", 263, 282], ["MDR", "OBSERVATION_MODIFIER", 53, 56], ["tuberculosis", "OBSERVATION", 57, 69], ["HIV infection", "OBSERVATION", 73, 86], ["Tuberculosis", "OBSERVATION", 251, 263], ["intracellulare Complex", "OBSERVATION", 283, 305]]], ["Before the widespread availability of HAART, disseminated MAC infection developed in up to 50% of HIV-infected patients.", [["MAC infection", "DISEASE", 58, 71], ["HIV-infected", "DISEASE", 98, 110], ["HIV", "ORGANISM", 98, 101], ["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["HIV", "SPECIES", 98, 101], ["HAART", "TREATMENT", 38, 43], ["disseminated MAC infection", "PROBLEM", 45, 71], ["HIV", "PROBLEM", 98, 101], ["disseminated", "OBSERVATION_MODIFIER", 45, 57], ["MAC", "OBSERVATION_MODIFIER", 58, 61], ["infection", "OBSERVATION", 62, 71], ["infected", "OBSERVATION", 102, 110]]], ["It remains a problem in patients with advanced HIV disease not receiving antiretroviral therapy and who have CD4 lymphocyte counts <50 cells/mL.", [["CD4 lymphocyte", "ANATOMY", 109, 123], ["cells", "ANATOMY", 135, 140], ["HIV disease", "DISEASE", 47, 58], ["patients", "ORGANISM", 24, 32], ["CD4 lymphocyte", "CELL", 109, 123], ["CD4", "PROTEIN", 109, 112], ["patients", "SPECIES", 24, 32], ["HIV", "SPECIES", 47, 50], ["advanced HIV disease", "PROBLEM", 38, 58], ["antiretroviral therapy", "TREATMENT", 73, 95], ["CD4 lymphocyte counts", "TEST", 109, 130]]], ["Clinical presentation is nonspecific and may be confused with the effects of HIV itself.", [["HIV", "ORGANISM", 77, 80], ["HIV", "SPECIES", 77, 80], ["HIV itself", "PROBLEM", 77, 87], ["nonspecific", "OBSERVATION_MODIFIER", 25, 36]]], ["Fever, night sweats, weight loss, anorexia, and malaise are common.", [["Fever", "DISEASE", 0, 5], ["night sweats", "DISEASE", 7, 19], ["weight loss", "DISEASE", 21, 32], ["anorexia", "DISEASE", 34, 42], ["Fever", "PROBLEM", 0, 5], ["night sweats", "PROBLEM", 7, 19], ["weight loss", "PROBLEM", 21, 32], ["anorexia", "PROBLEM", 34, 42], ["malaise", "PROBLEM", 48, 55], ["anorexia", "OBSERVATION", 34, 42]]], ["Anemia, hepatosplenomegaly, abdominal pain, and chronic diarrhea are frequent findings.", [["abdominal", "ANATOMY", 28, 37], ["Anemia", "DISEASE", 0, 6], ["hepatosplenomegaly", "DISEASE", 8, 26], ["abdominal pain", "DISEASE", 28, 42], ["diarrhea", "DISEASE", 56, 64], ["abdominal", "ORGANISM_SUBDIVISION", 28, 37], ["Anemia", "PROBLEM", 0, 6], ["hepatosplenomegaly", "PROBLEM", 8, 26], ["abdominal pain", "PROBLEM", 28, 42], ["chronic diarrhea", "PROBLEM", 48, 64], ["hepatosplenomegaly", "OBSERVATION", 8, 26], ["abdominal", "ANATOMY", 28, 37], ["pain", "OBSERVATION", 38, 42], ["chronic", "OBSERVATION_MODIFIER", 48, 55], ["diarrhea", "OBSERVATION", 56, 64]]], ["The diagnosis of disseminated MAC infection is based on culture of the organism from blood, bone marrow, lymph node, or liver biopsy specimens.", [["blood", "ANATOMY", 85, 90], ["bone marrow", "ANATOMY", 92, 103], ["lymph node", "ANATOMY", 105, 115], ["liver biopsy specimens", "ANATOMY", 120, 142], ["MAC infection", "DISEASE", 30, 43], ["blood", "ORGANISM_SUBSTANCE", 85, 90], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 92, 103], ["lymph node", "MULTI-TISSUE_STRUCTURE", 105, 115], ["liver biopsy specimens", "MULTI-TISSUE_STRUCTURE", 120, 142], ["disseminated MAC infection", "PROBLEM", 17, 43], ["culture", "TEST", 56, 63], ["the organism", "PROBLEM", 67, 79], ["blood, bone marrow", "TEST", 85, 103], ["lymph node", "TEST", 105, 115], ["liver biopsy specimens", "TEST", 120, 142], ["disseminated", "OBSERVATION_MODIFIER", 17, 29], ["MAC", "OBSERVATION_MODIFIER", 30, 33], ["infection", "OBSERVATION", 34, 43], ["blood", "ANATOMY", 85, 90], ["bone marrow", "ANATOMY", 92, 103], ["lymph node", "OBSERVATION", 105, 115], ["liver", "ANATOMY", 120, 125], ["biopsy", "OBSERVATION", 126, 132]]], ["Also, MAC is frequently identified in BAL fluid, sputum, stool, and urine, but detection of the organism at these sites is not diagnostic of disseminated infection.", [["BAL fluid", "ANATOMY", 38, 47], ["sputum", "ANATOMY", 49, 55], ["stool", "ANATOMY", 57, 62], ["urine", "ANATOMY", 68, 73], ["infection", "DISEASE", 154, 163], ["BAL fluid", "ORGANISM_SUBSTANCE", 38, 47], ["sputum", "ORGANISM_SUBSTANCE", 49, 55], ["stool", "ORGANISM_SUBSTANCE", 57, 62], ["urine", "ORGANISM_SUBSTANCE", 68, 73], ["BAL fluid, sputum, stool, and urine", "TEST", 38, 73], ["the organism at these sites", "PROBLEM", 92, 119], ["disseminated infection", "PROBLEM", 141, 163], ["MAC", "OBSERVATION", 6, 9], ["BAL", "ANATOMY", 38, 41], ["fluid", "OBSERVATION", 42, 47], ["stool", "OBSERVATION", 57, 62], ["not diagnostic of", "UNCERTAINTY", 123, 140], ["disseminated", "OBSERVATION_MODIFIER", 141, 153], ["infection", "OBSERVATION", 154, 163]]], ["Evidence of pulmonary MAC infection is not usually obtained from a chest radiograph, which may be negative or show nonspecific infiltrates.", [["pulmonary", "ANATOMY", 12, 21], ["chest", "ANATOMY", 67, 72], ["pulmonary MAC infection", "DISEASE", 12, 35], ["pulmonary MAC", "MULTI-TISSUE_STRUCTURE", 12, 25], ["chest", "ORGANISM_SUBDIVISION", 67, 72], ["pulmonary MAC infection", "PROBLEM", 12, 35], ["a chest radiograph", "TEST", 65, 83], ["nonspecific infiltrates", "PROBLEM", 115, 138], ["pulmonary", "ANATOMY", 12, 21], ["MAC", "OBSERVATION", 22, 25], ["infection", "OBSERVATION", 26, 35], ["nonspecific", "OBSERVATION_MODIFIER", 115, 126], ["infiltrates", "OBSERVATION", 127, 138]]], ["Rarely, focal consolidation, nodular infiltrates, and apical cavitation (resembling M. tuberculosis) have been reported.Mycobacteria Other Than TuberculosisMycobacterium kansasii.", [["nodular infiltrates", "ANATOMY", 29, 48], ["M. tuberculosis", "DISEASE", 84, 99], ["TuberculosisMycobacterium kansasii", "DISEASE", 144, 178], ["nodular infiltrates", "PATHOLOGICAL_FORMATION", 29, 48], ["TuberculosisMycobacterium kansasii", "ORGANISM", 144, 178], ["M. tuberculosis", "SPECIES", 84, 99], ["TuberculosisMycobacterium kansasii", "SPECIES", 144, 178], ["M. tuberculosis", "SPECIES", 84, 99], ["TuberculosisMycobacterium kansasii", "SPECIES", 144, 178], ["focal consolidation", "PROBLEM", 8, 27], ["nodular infiltrates", "PROBLEM", 29, 48], ["apical cavitation", "PROBLEM", 54, 71], ["M. tuberculosis", "PROBLEM", 84, 99], ["Mycobacteria", "PROBLEM", 120, 132], ["TuberculosisMycobacterium kansasii", "PROBLEM", 144, 178], ["focal", "OBSERVATION_MODIFIER", 8, 13], ["consolidation", "OBSERVATION", 14, 27], ["nodular", "OBSERVATION_MODIFIER", 29, 36], ["infiltrates", "OBSERVATION", 37, 48], ["apical", "ANATOMY_MODIFIER", 54, 60], ["cavitation", "OBSERVATION_MODIFIER", 61, 71], ["M.", "OBSERVATION_MODIFIER", 84, 86], ["tuberculosis", "OBSERVATION", 87, 99], ["kansasii", "OBSERVATION", 170, 178]]], ["Mycobacterium kansasii is the second most common nontuberculous opportunistic mycobacterial infection in HIV-infected individuals and usually appears late in the course of HIV infection in patients with CD4 lymphocyte counts <100 cells/mL.", [["CD4 lymphocyte", "ANATOMY", 203, 217], ["cells", "ANATOMY", 230, 235], ["Mycobacterium kansasii", "DISEASE", 0, 22], ["mycobacterial infection", "DISEASE", 78, 101], ["HIV-infected", "DISEASE", 105, 117], ["HIV infection", "DISEASE", 172, 185], ["Mycobacterium kansasii", "ORGANISM", 0, 22], ["HIV", "ORGANISM", 105, 108], ["individuals", "ORGANISM", 118, 129], ["HIV", "ORGANISM", 172, 175], ["patients", "ORGANISM", 189, 197], ["CD4 lymphocyte", "CELL", 203, 217], ["CD4", "PROTEIN", 203, 206], ["Mycobacterium kansasii", "SPECIES", 0, 22], ["HIV", "SPECIES", 105, 108], ["patients", "SPECIES", 189, 197], ["Mycobacterium kansasii", "SPECIES", 0, 22], ["HIV", "SPECIES", 105, 108], ["HIV", "SPECIES", 172, 175], ["Mycobacterium kansasii", "PROBLEM", 0, 22], ["common nontuberculous opportunistic mycobacterial infection", "PROBLEM", 42, 101], ["HIV", "PROBLEM", 105, 108], ["infected individuals", "PROBLEM", 109, 129], ["HIV infection", "PROBLEM", 172, 185], ["CD4 lymphocyte counts", "TEST", 203, 224], ["kansasii", "OBSERVATION", 14, 22], ["second most", "OBSERVATION_MODIFIER", 30, 41], ["common", "OBSERVATION_MODIFIER", 42, 48], ["nontuberculous", "OBSERVATION_MODIFIER", 49, 63], ["opportunistic", "OBSERVATION_MODIFIER", 64, 77], ["mycobacterial", "OBSERVATION_MODIFIER", 78, 91], ["infection", "OBSERVATION", 92, 101], ["infected individuals", "OBSERVATION_MODIFIER", 109, 129], ["late", "OBSERVATION_MODIFIER", 150, 154], ["infection", "OBSERVATION", 176, 185]]], ["The most frequent presentation is with fever, cough, and dyspnea.", [["fever", "DISEASE", 39, 44], ["cough", "DISEASE", 46, 51], ["dyspnea", "DISEASE", 57, 64], ["fever", "PROBLEM", 39, 44], ["cough", "PROBLEM", 46, 51], ["dyspnea", "PROBLEM", 57, 64], ["most frequent", "OBSERVATION_MODIFIER", 4, 17], ["fever", "OBSERVATION", 39, 44], ["cough", "OBSERVATION", 46, 51], ["dyspnea", "OBSERVATION", 57, 64]]], ["In approximately two thirds of those who have M. kansasii infection, the disease is localized to the lungs; the remainder have disseminated disease that affects bone marrow, lymph node, skin, and lungs.", [["lungs", "ANATOMY", 101, 106], ["bone marrow", "ANATOMY", 161, 172], ["lymph node", "ANATOMY", 174, 184], ["skin", "ANATOMY", 186, 190], ["lungs", "ANATOMY", 196, 201], ["kansasii infection", "DISEASE", 49, 67], ["M. kansasii", "ORGANISM", 46, 57], ["lungs", "ORGAN", 101, 106], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 161, 172], ["lymph node", "MULTI-TISSUE_STRUCTURE", 174, 184], ["skin", "ORGAN", 186, 190], ["lungs", "ORGAN", 196, 201], ["M. kansasii", "SPECIES", 46, 57], ["M. kansasii", "SPECIES", 46, 57], ["M. kansasii infection", "PROBLEM", 46, 67], ["the disease", "PROBLEM", 69, 80], ["disseminated disease", "PROBLEM", 127, 147], ["bone marrow", "PROBLEM", 161, 172], ["lymph node, skin, and lungs", "PROBLEM", 174, 201], ["kansasii infection", "OBSERVATION", 49, 67], ["disease", "OBSERVATION", 73, 80], ["lungs", "ANATOMY", 101, 106], ["disseminated", "OBSERVATION_MODIFIER", 127, 139], ["disease", "OBSERVATION", 140, 147], ["bone", "ANATOMY", 161, 165], ["marrow", "OBSERVATION", 166, 172], ["lymph node", "OBSERVATION", 174, 184], ["skin", "ANATOMY", 186, 190], ["lungs", "ANATOMY", 196, 201]]], ["The diagnosis is made by culture of the organism from respiratory secretions or from bone marrow, lymph node aspirate, or skin biopsy.", [["respiratory secretions", "ANATOMY", 54, 76], ["bone marrow", "ANATOMY", 85, 96], ["lymph node aspirate", "ANATOMY", 98, 117], ["skin", "ANATOMY", 122, 126], ["secretions", "ORGANISM_SUBSTANCE", 66, 76], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 85, 96], ["lymph node", "MULTI-TISSUE_STRUCTURE", 98, 108], ["aspirate", "MULTI-TISSUE_STRUCTURE", 109, 117], ["skin biopsy", "MULTI-TISSUE_STRUCTURE", 122, 133], ["culture", "TEST", 25, 32], ["the organism", "PROBLEM", 36, 48], ["respiratory secretions", "PROBLEM", 54, 76], ["bone marrow", "TEST", 85, 96], ["lymph node aspirate", "TEST", 98, 117], ["skin biopsy", "TEST", 122, 133], ["bone marrow", "ANATOMY", 85, 96], ["lymph node", "OBSERVATION", 98, 108], ["skin", "ANATOMY", 122, 126], ["biopsy", "OBSERVATION", 127, 133]]], ["Focal upper lobe infiltrates with diffuse interstitial infiltrates are the most common radiographic abnormalities; thin-walled cavitary lesions and hilar adenopathy have also been reported.Mycobacteria Other Than TuberculosisMycobacterium xenopi.", [["Focal upper lobe infiltrates", "ANATOMY", 0, 28], ["diffuse interstitial infiltrates", "ANATOMY", 34, 66], ["thin-walled cavitary lesions", "ANATOMY", 115, 143], ["hilar adenopathy", "ANATOMY", 148, 164], ["adenopathy", "DISEASE", 154, 164], ["upper lobe", "PATHOLOGICAL_FORMATION", 6, 16], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 42, 66], ["-walled cavitary lesions", "PATHOLOGICAL_FORMATION", 119, 143], ["hilar adenopathy", "CANCER", 148, 164], ["TuberculosisMycobacterium xenopi.", "SPECIES", 213, 246], ["Focal upper lobe infiltrates", "PROBLEM", 0, 28], ["diffuse interstitial infiltrates", "PROBLEM", 34, 66], ["the most common radiographic abnormalities", "PROBLEM", 71, 113], ["thin-walled cavitary lesions", "PROBLEM", 115, 143], ["hilar adenopathy", "PROBLEM", 148, 164], ["Mycobacteria", "TEST", 189, 201], ["upper lobe", "ANATOMY", 6, 16], ["infiltrates", "OBSERVATION", 17, 28], ["diffuse", "OBSERVATION_MODIFIER", 34, 41], ["interstitial", "ANATOMY_MODIFIER", 42, 54], ["infiltrates", "OBSERVATION", 55, 66], ["thin", "OBSERVATION_MODIFIER", 115, 119], ["walled", "OBSERVATION_MODIFIER", 120, 126], ["cavitary", "OBSERVATION_MODIFIER", 127, 135], ["lesions", "OBSERVATION", 136, 143], ["hilar", "ANATOMY", 148, 153], ["adenopathy", "OBSERVATION", 154, 164]]], ["Mycobacterium xenopi may occasionally be isolated from sputum or BAL fluid samples, but its significance is uncertain.", [["sputum", "ANATOMY", 55, 61], ["BAL fluid samples", "ANATOMY", 65, 82], ["Mycobacterium xenopi", "ORGANISM", 0, 20], ["sputum", "ORGANISM_SUBSTANCE", 55, 61], ["BAL fluid samples", "ORGANISM_SUBSTANCE", 65, 82], ["Mycobacterium xenopi", "SPECIES", 0, 20], ["Mycobacterium xenopi", "SPECIES", 0, 20], ["Mycobacterium xenopi", "PROBLEM", 0, 20], ["sputum or BAL fluid samples", "TEST", 55, 82], ["xenopi", "OBSERVATION", 14, 20], ["sputum", "OBSERVATION", 55, 61]]], ["Patients have low CD4 counts, and M. xenopi is usually accompanied by isolation of a copathogen, such as P. jirovecii.", [["P. jirovecii", "DISEASE", 105, 117], ["Patients", "ORGANISM", 0, 8], ["CD4", "GENE_OR_GENE_PRODUCT", 18, 21], ["M. xenopi", "ORGANISM", 34, 43], ["P. jirovecii", "ORGANISM", 105, 117], ["CD4", "PROTEIN", 18, 21], ["Patients", "SPECIES", 0, 8], ["M. xenopi", "SPECIES", 34, 43], ["P. jirovecii", "SPECIES", 105, 117], ["M. xenopi", "SPECIES", 34, 43], ["P. jirovecii", "SPECIES", 105, 117], ["low CD4 counts", "PROBLEM", 14, 28], ["M. xenopi", "PROBLEM", 34, 43], ["a copathogen", "PROBLEM", 83, 95], ["P. jirovecii", "PROBLEM", 105, 117], ["low", "OBSERVATION_MODIFIER", 14, 17], ["CD4 counts", "OBSERVATION", 18, 28], ["xenopi", "OBSERVATION", 37, 43], ["jirovecii", "OBSERVATION", 108, 117]]], ["Treatment of the latter condition is associated in most cases with resolution of symptoms.", [["the latter condition", "PROBLEM", 13, 33], ["symptoms", "PROBLEM", 81, 89]]], ["There is some evidence that starting HAART prevents disease recurrence, provided there is an adequate immune response.Mycobacteria Other Than TuberculosisPneumocystis jirovecii Pneumonia.", [["TuberculosisPneumocystis jirovecii Pneumonia", "DISEASE", 142, 186], ["TuberculosisPneumocystis jirovecii", "ORGANISM", 142, 176], ["TuberculosisPneumocystis jirovecii", "SPECIES", 142, 176], ["TuberculosisPneumocystis jirovecii", "SPECIES", 142, 176], ["HAART", "TREATMENT", 37, 42], ["disease recurrence", "PROBLEM", 52, 70], ["Mycobacteria", "PROBLEM", 118, 130], ["TuberculosisPneumocystis jirovecii Pneumonia", "PROBLEM", 142, 186], ["jirovecii", "OBSERVATION", 167, 176]]], ["The development of PCP is largely related to underlying states of immunosuppression induced by malignancy or treatment thereof, organ transplantation, or HIV infection.", [["organ", "ANATOMY", 128, 133], ["PCP", "DISEASE", 19, 22], ["malignancy", "DISEASE", 95, 105], ["HIV infection", "DISEASE", 154, 167], ["PCP", "CHEMICAL", 19, 22], ["organ", "ORGAN", 128, 133], ["HIV", "ORGANISM", 154, 157], ["HIV", "SPECIES", 154, 157], ["HIV", "SPECIES", 154, 157], ["PCP", "PROBLEM", 19, 22], ["immunosuppression", "TREATMENT", 66, 83], ["malignancy", "PROBLEM", 95, 105], ["treatment thereof", "TREATMENT", 109, 126], ["organ transplantation", "TREATMENT", 128, 149], ["HIV infection", "PROBLEM", 154, 167], ["PCP", "OBSERVATION", 19, 22], ["immunosuppression", "OBSERVATION", 66, 83], ["malignancy", "OBSERVATION", 95, 105], ["HIV", "OBSERVATION_MODIFIER", 154, 157], ["infection", "OBSERVATION", 158, 167]]], ["In 2007 in the United States, United Kingdom, Europe, and Australasia, PCP is largely seen only in HIV-infected individuals unaware of their serostatus or in those who are intolerant of, or noncompliant with, anti-P. jirovecii prophylaxis and HAART.Mycobacteria Other Than TuberculosisUntil recently, P. jirovecii was regarded taxonomically as a protozoan, on the basis of its morphology and the lack of response to antifungal agents such as amphotericin B. The organism has now been ascribed to the fungal kingdom.", [["PCP", "DISEASE", 71, 74], ["HIV-infected", "DISEASE", 99, 111], ["anti-P. jirovecii", "DISEASE", 209, 226], ["Tuberculosis", "DISEASE", 273, 285], ["P. jirovecii", "DISEASE", 301, 313], ["amphotericin B.", "CHEMICAL", 442, 457], ["amphotericin", "CHEMICAL", 442, 454], ["HIV", "ORGANISM", 99, 102], ["individuals", "ORGANISM", 112, 123], ["anti-P. jirovecii", "ORGANISM", 209, 226], ["P. jirovecii", "ORGANISM", 301, 313], ["amphotericin B.", "SIMPLE_CHEMICAL", 442, 457], ["P. jirovecii", "SPECIES", 301, 313], ["HIV", "SPECIES", 99, 102], ["anti-P. jirovecii", "SPECIES", 209, 226], ["P. jirovecii", "SPECIES", 301, 313], ["anti-P. jirovecii prophylaxis", "TREATMENT", 209, 238], ["HAART", "TREATMENT", 243, 248], ["Mycobacteria", "PROBLEM", 249, 261], ["Tuberculosis", "PROBLEM", 273, 285], ["P. jirovecii", "PROBLEM", 301, 313], ["a protozoan", "PROBLEM", 344, 355], ["antifungal agents", "TREATMENT", 416, 433], ["amphotericin B.", "TREATMENT", 442, 457], ["Tuberculosis", "OBSERVATION", 273, 285], ["jirovecii", "OBSERVATION", 304, 313], ["fungal kingdom", "OBSERVATION", 500, 514]]], ["The demonstration of antibodies against P. jirovecii in most healthy children/adults suggests that organisms are acquired in childhood and persist in the lungs in a dormant phase.", [["lungs", "ANATOMY", 154, 159], ["P. jirovecii", "DISEASE", 40, 52], ["P. jirovecii", "ORGANISM", 40, 52], ["children", "ORGANISM", 69, 77], ["lungs", "ORGAN", 154, 159], ["antibodies", "PROTEIN", 21, 31], ["P. jirovecii", "SPECIES", 40, 52], ["children", "SPECIES", 69, 77], ["P. jirovecii", "SPECIES", 40, 52], ["antibodies", "TREATMENT", 21, 31], ["P. jirovecii", "PROBLEM", 40, 52], ["organisms", "PROBLEM", 99, 108], ["lungs", "ANATOMY", 154, 159]]], ["Subsequent immunosuppression (e.g., as a result of HIV infection) allows the fungus to propagate in the lung and cause clinical disease.", [["lung", "ANATOMY", 104, 108], ["HIV infection", "DISEASE", 51, 64], ["HIV", "ORGANISM", 51, 54], ["lung", "ORGAN", 104, 108], ["HIV", "SPECIES", 51, 54], ["Subsequent immunosuppression", "TREATMENT", 0, 28], ["HIV infection", "PROBLEM", 51, 64], ["the fungus", "PROBLEM", 73, 83], ["clinical disease", "PROBLEM", 119, 135], ["immunosuppression", "OBSERVATION", 11, 28], ["lung", "ANATOMY", 104, 108]]], ["However, this \"latency\" hypothesis is challenged by several observations:Mycobacteria Other Than TuberculosisP. jirovecii cannot be identified in the lungs of immunocompetent individuals.", [["lungs", "ANATOMY", 150, 155], ["TuberculosisP. jirovecii", "ORGANISM", 97, 121], ["lungs", "ORGAN", 150, 155], ["individuals", "ORGANISM", 175, 186], ["TuberculosisP. jirovecii", "SPECIES", 97, 121], ["TuberculosisP. jirovecii", "SPECIES", 97, 121], ["Mycobacteria", "PROBLEM", 73, 85], ["jirovecii", "PROBLEM", 112, 121], ["immunocompetent individuals", "PROBLEM", 159, 186], ["jirovecii", "OBSERVATION", 112, 121], ["lungs", "ANATOMY", 150, 155], ["immunocompetent", "OBSERVATION", 159, 174]]], ["\"Case clusters\" of PCP in health care facilities suggest recent transmission.Mycobacteria Other Than TuberculosisDifferent genotypes of P. jirovecii are identified in each episode in HIV-infected patients who have recurrent PCP.", [["PCP", "DISEASE", 19, 22], ["P. jirovecii", "DISEASE", 136, 148], ["HIV-infected", "DISEASE", 183, 195], ["PCP", "DISEASE", 224, 227], ["PCP", "CHEMICAL", 19, 22], ["PCP", "CHEMICAL", 224, 227], ["P. jirovecii", "ORGANISM", 136, 148], ["HIV", "ORGANISM", 183, 186], ["patients", "ORGANISM", 196, 204], ["P. jirovecii", "SPECIES", 136, 148], ["HIV", "SPECIES", 183, 186], ["patients", "SPECIES", 196, 204], ["P. jirovecii", "SPECIES", 136, 148], ["HIV", "SPECIES", 183, 186], ["Mycobacteria", "PROBLEM", 77, 89], ["P. jirovecii", "PROBLEM", 136, 148], ["recurrent PCP", "PROBLEM", 214, 227], ["jirovecii", "OBSERVATION", 139, 148]]], ["Genotypes of P. jirovecii in patients who have PCP correlate with place of diagnosis and not with their place of birthsuggesting infection has been recently acquired.", [["P. jirovecii", "DISEASE", 13, 25], ["PCP", "DISEASE", 47, 50], ["infection", "DISEASE", 129, 138], ["PCP", "CHEMICAL", 47, 50], ["P. jirovecii", "ORGANISM", 13, 25], ["patients", "ORGANISM", 29, 37], ["P. jirovecii", "SPECIES", 13, 25], ["patients", "SPECIES", 29, 37], ["P. jirovecii", "SPECIES", 13, 25], ["P. jirovecii", "PROBLEM", 13, 25], ["birthsuggesting infection", "PROBLEM", 113, 138], ["jirovecii", "OBSERVATION", 16, 25], ["infection", "OBSERVATION", 129, 138]]], ["Taken together, these data suggest that PCP arises by reinfection from an exogenous source.Mycobacteria Other Than TuberculosisThe clinical presentation of PCP is nonspecific, with an onset of progressive exertional dyspnea over days or weeks, together with a dry cough with or without expectoration of minimal quantities of mucoid sputum.", [["mucoid sputum", "ANATOMY", 325, 338], ["PCP", "CHEMICAL", 40, 43], ["Tuberculosis", "DISEASE", 115, 127], ["PCP", "DISEASE", 156, 159], ["exertional dyspnea", "DISEASE", 205, 223], ["dry cough", "DISEASE", 260, 269], ["PCP", "CHEMICAL", 40, 43], ["PCP", "CHEMICAL", 156, 159], ["PCP", "SIMPLE_CHEMICAL", 40, 43], ["mucoid sputum", "ORGANISM_SUBSTANCE", 325, 338], ["reinfection", "PROBLEM", 54, 65], ["an exogenous source", "PROBLEM", 71, 90], ["Mycobacteria", "PROBLEM", 91, 103], ["Tuberculosis", "PROBLEM", 115, 127], ["progressive exertional dyspnea", "PROBLEM", 193, 223], ["a dry cough", "PROBLEM", 258, 269], ["expectoration of minimal quantities of mucoid sputum", "PROBLEM", 286, 338], ["reinfection", "OBSERVATION", 54, 65], ["exogenous source", "OBSERVATION", 74, 90], ["Tuberculosis", "OBSERVATION", 115, 127], ["nonspecific", "OBSERVATION_MODIFIER", 163, 174], ["progressive", "OBSERVATION_MODIFIER", 193, 204], ["exertional", "OBSERVATION_MODIFIER", 205, 215], ["dyspnea", "OBSERVATION", 216, 223], ["cough", "OBSERVATION", 264, 269], ["mucoid", "OBSERVATION_MODIFIER", 325, 331], ["sputum", "OBSERVATION", 332, 338]]], ["Patients often complain of an inability to take a deep breath, which is not due to pleurisy (Table 34-5) .", [["pleurisy", "DISEASE", 83, 91], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["an inability to take a deep breath", "PROBLEM", 27, 61], ["pleurisy", "PROBLEM", 83, 91], ["not due to", "UNCERTAINTY", 72, 82], ["pleurisy", "OBSERVATION", 83, 91]]], ["Fever is common, yet patients rarely complain of temperatures or sweats.", [["Fever", "DISEASE", 0, 5], ["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["Fever", "PROBLEM", 0, 5], ["temperatures", "PROBLEM", 49, 61], ["sweats", "PROBLEM", 65, 71]]], ["In HIV-infected patients, the presentation is usually more insidious than in patients receiving immunosuppressive therapy, with a median time to diagnosis from onset of symptoms of more than 3 weeks in those with HIV compared with less than 1 week in non-HIV-infected patients.", [["HIV-infected", "DISEASE", 3, 15], ["HIV", "DISEASE", 213, 216], ["non-HIV-infected", "DISEASE", 251, 267], ["HIV", "ORGANISM", 3, 6], ["patients", "ORGANISM", 16, 24], ["patients", "ORGANISM", 77, 85], ["patients", "ORGANISM", 268, 276], ["HIV", "SPECIES", 3, 6], ["patients", "SPECIES", 16, 24], ["patients", "SPECIES", 77, 85], ["patients", "SPECIES", 268, 276], ["HIV", "SPECIES", 3, 6], ["HIV", "SPECIES", 213, 216], ["immunosuppressive therapy", "TREATMENT", 96, 121], ["symptoms", "PROBLEM", 169, 177], ["HIV", "PROBLEM", 213, 216], ["infected patients", "OBSERVATION_MODIFIER", 7, 24], ["infected", "OBSERVATION", 259, 267]]], ["In a small proportion of HIV-positive individuals, the disease course of PCP is fulminant, with an interval of only 5-7 days between onset of symptoms and progression to development of respiratory failure.", [["respiratory", "ANATOMY", 185, 196], ["HIV-positive", "DISEASE", 25, 37], ["PCP", "DISEASE", 73, 76], ["fulminant", "DISEASE", 80, 89], ["respiratory failure", "DISEASE", 185, 204], ["PCP", "CHEMICAL", 73, 76], ["HIV", "ORGANISM", 25, 28], ["individuals", "ORGANISM", 38, 49], ["HIV", "SPECIES", 25, 28], ["HIV-positive individuals", "PROBLEM", 25, 49], ["fulminant", "PROBLEM", 80, 89], ["symptoms", "PROBLEM", 142, 150], ["respiratory failure", "PROBLEM", 185, 204], ["small", "OBSERVATION_MODIFIER", 5, 10], ["positive individuals", "OBSERVATION_MODIFIER", 29, 49], ["fulminant", "OBSERVATION_MODIFIER", 80, 89], ["respiratory failure", "OBSERVATION", 185, 204]]], ["In others, it may be much more indolent, with respiratory symptoms that worsen almost imperceptibly over several months.", [["respiratory", "ANATOMY", 46, 57], ["respiratory symptoms", "PROBLEM", 46, 66]]], ["Rarely, PCP may present without respiratory symptoms as a fever of undetermined origin.Mycobacteria Other Than TuberculosisClinical examination is usually remarkable only for the absence of physical signs; occasionally, fine, basal, end-inspiratory crackles are audible.", [["respiratory", "ANATOMY", 32, 43], ["PCP", "DISEASE", 8, 11], ["respiratory symptoms", "DISEASE", 32, 52], ["fever", "DISEASE", 58, 63], ["PCP", "CHEMICAL", 8, 11], ["respiratory symptoms", "PROBLEM", 32, 52], ["a fever", "PROBLEM", 56, 63], ["Mycobacteria", "TEST", 87, 99], ["TuberculosisClinical examination", "TEST", 111, 143], ["end-inspiratory crackles", "PROBLEM", 233, 257], ["basal", "ANATOMY_MODIFIER", 226, 231], ["inspiratory crackles", "OBSERVATION", 237, 257]]], ["Features that would suggest an alternative diagnosis include a cough productive of purulent sputum or hemoptysis, chest pain (particularly pleural pain), and signs of focal consolidation or pleural effusion (see Table 34 -5).", [["purulent sputum", "ANATOMY", 83, 98], ["chest", "ANATOMY", 114, 119], ["pleural", "ANATOMY", 139, 146], ["pleural", "ANATOMY", 190, 197], ["cough", "DISEASE", 63, 68], ["purulent sputum", "DISEASE", 83, 98], ["hemoptysis", "DISEASE", 102, 112], ["chest pain", "DISEASE", 114, 124], ["pleural pain", "DISEASE", 139, 151], ["pleural effusion", "DISEASE", 190, 206], ["chest", "ORGANISM_SUBDIVISION", 114, 119], ["pleural", "ORGAN", 139, 146], ["a cough", "PROBLEM", 61, 68], ["purulent sputum", "PROBLEM", 83, 98], ["hemoptysis", "PROBLEM", 102, 112], ["chest pain", "PROBLEM", 114, 124], ["pleural pain", "PROBLEM", 139, 151], ["focal consolidation", "PROBLEM", 167, 186], ["pleural effusion", "PROBLEM", 190, 206], ["cough", "OBSERVATION", 63, 68], ["purulent", "OBSERVATION_MODIFIER", 83, 91], ["sputum", "OBSERVATION", 92, 98], ["hemoptysis", "OBSERVATION", 102, 112], ["chest", "ANATOMY", 114, 119], ["pleural", "ANATOMY", 139, 146], ["pain", "OBSERVATION", 147, 151], ["focal", "OBSERVATION_MODIFIER", 167, 172], ["consolidation", "OBSERVATION", 173, 186], ["pleural", "ANATOMY", 190, 197], ["effusion", "OBSERVATION", 198, 206]]], ["It should be noted that infection with more than one pathogen occurs in almost one fifth of individuals, and thus symptoms may be the product of several agents.Mycobacteria Other Than TuberculosisThe chest radiograph in PCP is typically unremarkable initially.", [["chest", "ANATOMY", 200, 205], ["infection", "DISEASE", 24, 33], ["Tuberculosis", "DISEASE", 184, 196], ["PCP", "DISEASE", 220, 223], ["chest", "ORGAN", 200, 205], ["infection", "PROBLEM", 24, 33], ["one pathogen", "PROBLEM", 49, 61], ["symptoms", "PROBLEM", 114, 122], ["several agents", "TREATMENT", 145, 159], ["Mycobacteria", "PROBLEM", 160, 172], ["Tuberculosis", "PROBLEM", 184, 196], ["The chest radiograph", "TEST", 196, 216], ["infection", "OBSERVATION", 24, 33], ["Tuberculosis", "OBSERVATION", 184, 196], ["chest", "ANATOMY", 200, 205], ["unremarkable", "OBSERVATION", 237, 249]]], ["Later, diffuse reticular shadowing, especially in the perihilar regions, is seen and may progress to diffuse alveolar consolidation that resembles pulmonary edema if untreated or if the patient is seen late in disease.", [["reticular", "ANATOMY", 15, 24], ["perihilar regions", "ANATOMY", 54, 71], ["alveolar", "ANATOMY", 109, 117], ["pulmonary edema", "ANATOMY", 147, 162], ["pulmonary edema", "DISEASE", 147, 162], ["alveolar", "MULTI-TISSUE_STRUCTURE", 109, 117], ["pulmonary edema", "PATHOLOGICAL_FORMATION", 147, 162], ["patient", "ORGANISM", 186, 193], ["patient", "SPECIES", 186, 193], ["diffuse reticular shadowing", "PROBLEM", 7, 34], ["diffuse alveolar consolidation", "PROBLEM", 101, 131], ["pulmonary edema", "PROBLEM", 147, 162], ["diffuse", "OBSERVATION_MODIFIER", 7, 14], ["reticular", "OBSERVATION_MODIFIER", 15, 24], ["shadowing", "OBSERVATION", 25, 34], ["perihilar", "ANATOMY_MODIFIER", 54, 63], ["diffuse", "OBSERVATION_MODIFIER", 101, 108], ["alveolar", "ANATOMY_MODIFIER", 109, 117], ["consolidation", "OBSERVATION", 118, 131], ["pulmonary", "ANATOMY", 147, 156], ["edema", "OBSERVATION", 157, 162]]], ["At this stage, the lung may be massively consolidated and almost airless (Figure 34-7) .", [["lung", "ANATOMY", 19, 23], ["lung", "ORGAN", 19, 23], ["massively consolidated", "PROBLEM", 31, 53], ["lung", "ANATOMY", 19, 23], ["may be", "UNCERTAINTY", 24, 30], ["massively", "OBSERVATION_MODIFIER", 31, 40], ["consolidated", "OBSERVATION", 41, 53], ["almost", "OBSERVATION_MODIFIER", 58, 64], ["airless", "OBSERVATION_MODIFIER", 65, 72]]], ["Up to 20% of chest radiographs are atypical, showing lobar consolidation, honeycomb lung, multiple thin-walled cystic air space formation (pneumatoceles), intrapulmonary nodules, cavitary lesions, pneumothorax, and hilar and mediastinal lymphadenopathy.", [["chest", "ANATOMY", 13, 18], ["lobar", "ANATOMY", 53, 58], ["lung", "ANATOMY", 84, 88], ["cystic air space", "ANATOMY", 111, 127], ["pneumatoceles", "ANATOMY", 139, 152], ["intrapulmonary nodules", "ANATOMY", 155, 177], ["cavitary lesions", "ANATOMY", 179, 195], ["hilar", "ANATOMY", 215, 220], ["mediastinal lymphadenopathy", "ANATOMY", 225, 252], ["pneumatoceles", "DISEASE", 139, 152], ["cavitary lesions", "DISEASE", 179, 195], ["pneumothorax", "DISEASE", 197, 209], ["lymphadenopathy", "DISEASE", 237, 252], ["lung", "ORGAN", 84, 88], ["cystic air space", "TISSUE", 111, 127], ["pneumatoceles", "CANCER", 139, 152], ["intrapulmonary nodules", "PATHOLOGICAL_FORMATION", 155, 177], ["cavitary lesions", "CANCER", 179, 195], ["hilar", "CANCER", 215, 220], ["chest radiographs", "TEST", 13, 30], ["lobar consolidation", "PROBLEM", 53, 72], ["honeycomb lung", "PROBLEM", 74, 88], ["multiple thin-walled cystic air space formation (pneumatoceles)", "PROBLEM", 90, 153], ["intrapulmonary nodules", "PROBLEM", 155, 177], ["cavitary lesions", "PROBLEM", 179, 195], ["pneumothorax", "PROBLEM", 197, 209], ["hilar and mediastinal lymphadenopathy", "PROBLEM", 215, 252], ["chest", "ANATOMY", 13, 18], ["lobar", "ANATOMY_MODIFIER", 53, 58], ["consolidation", "OBSERVATION", 59, 72], ["honeycomb", "ANATOMY_MODIFIER", 74, 83], ["lung", "ANATOMY", 84, 88], ["multiple", "OBSERVATION_MODIFIER", 90, 98], ["thin", "OBSERVATION_MODIFIER", 99, 103], ["walled", "OBSERVATION_MODIFIER", 104, 110], ["cystic", "OBSERVATION_MODIFIER", 111, 117], ["air space formation", "OBSERVATION", 118, 137], ["intrapulmonary", "ANATOMY", 155, 169], ["nodules", "OBSERVATION", 170, 177], ["cavitary", "OBSERVATION_MODIFIER", 179, 187], ["lesions", "OBSERVATION", 188, 195], ["pneumothorax", "OBSERVATION", 197, 209], ["hilar", "ANATOMY", 215, 220], ["mediastinal", "ANATOMY", 225, 236], ["lymphadenopathy", "OBSERVATION", 237, 252]]], ["Predominantly apical changes, resembling tuberculosis, may occur in patients who have PCP develop having received anti-P. jirovecii prophylaxis with nebulized pentamidine (Figure 34 -8).", [["apical", "ANATOMY", 14, 20], ["tuberculosis", "DISEASE", 41, 53], ["PCP", "DISEASE", 86, 89], ["anti-P. jirovecii", "DISEASE", 114, 131], ["pentamidine", "CHEMICAL", 159, 170], ["PCP", "CHEMICAL", 86, 89], ["pentamidine", "CHEMICAL", 159, 170], ["apical", "MULTI-TISSUE_STRUCTURE", 14, 20], ["patients", "ORGANISM", 68, 76], ["anti-P. jirovecii", "ORGANISM", 114, 131], ["pentamidine", "SIMPLE_CHEMICAL", 159, 170], ["patients", "SPECIES", 68, 76], ["anti-P. jirovecii", "SPECIES", 114, 131], ["anti-P. jirovecii", "SPECIES", 114, 131], ["Predominantly apical changes", "PROBLEM", 0, 28], ["tuberculosis", "PROBLEM", 41, 53], ["anti-P. jirovecii prophylaxis", "TREATMENT", 114, 143], ["nebulized pentamidine", "TREATMENT", 149, 170], ["apical", "ANATOMY_MODIFIER", 14, 20], ["tuberculosis", "OBSERVATION", 41, 53]]], ["All these radiographic changes Chest radiograph Early: perihilar \"haze\" or bilateral interstitial shadowing Late: alveolar-interstitial changes or \"white out\"Mycobacteria Other Than Tuberculosis(marked alveolar consolidation with sparing of apices and costophrenic angles)Mycobacteria Other Than TuberculosisArterial blood gases PaO 2 : early, normal: late, low PaCO 2 : early, normal or low; late, normal or high are nonspecific, and similar changes occur with other pulmonary pathogens, including pyogenic bacterial, mycobacterial, and fungal infection, as well as Kaposi sarcoma and nonspecific interstitial pneumonitis.", [["interstitial", "ANATOMY", 85, 97], ["alveolar", "ANATOMY", 114, 122], ["interstitial", "ANATOMY", 123, 135], ["alveolar", "ANATOMY", 202, 210], ["apices", "ANATOMY", 241, 247], ["blood", "ANATOMY", 317, 322], ["pulmonary", "ANATOMY", 468, 477], ["Kaposi sarcoma", "ANATOMY", 567, 581], ["interstitial", "ANATOMY", 598, 610], ["haze", "DISEASE", 66, 70], ["Tuberculosis", "DISEASE", 182, 194], ["pyogenic bacterial, mycobacterial, and fungal infection", "DISEASE", 499, 554], ["Kaposi sarcoma", "DISEASE", 567, 581], ["interstitial pneumonitis", "DISEASE", 598, 622], ["alveolar", "MULTI-TISSUE_STRUCTURE", 202, 210], ["apices", "MULTI-TISSUE_STRUCTURE", 241, 247], ["blood", "ORGANISM_SUBSTANCE", 317, 322], ["PaCO 2", "GENE_OR_GENE_PRODUCT", 362, 368], ["pulmonary", "ORGAN", 468, 477], ["Kaposi sarcoma", "CANCER", 567, 581], ["All these radiographic changes", "TEST", 0, 30], ["Chest radiograph", "TEST", 31, 47], ["perihilar \"haze", "PROBLEM", 55, 70], ["bilateral interstitial shadowing", "PROBLEM", 75, 107], ["alveolar-interstitial changes", "PROBLEM", 114, 143], ["\"white out\"Mycobacteria", "PROBLEM", 147, 170], ["Tuberculosis(marked alveolar consolidation", "PROBLEM", 182, 224], ["sparing of apices and costophrenic angles)", "PROBLEM", 230, 272], ["Mycobacteria", "TEST", 272, 284], ["TuberculosisArterial blood gases PaO", "TEST", 296, 332], ["other pulmonary pathogens", "PROBLEM", 462, 487], ["pyogenic bacterial", "PROBLEM", 499, 517], ["mycobacterial", "PROBLEM", 519, 532], ["fungal infection", "PROBLEM", 538, 554], ["Kaposi sarcoma", "PROBLEM", 567, 581], ["nonspecific interstitial pneumonitis", "PROBLEM", 586, 622], ["Chest", "ANATOMY", 31, 36], ["perihilar", "ANATOMY_MODIFIER", 55, 64], ["haze", "OBSERVATION", 66, 70], ["bilateral", "ANATOMY_MODIFIER", 75, 84], ["interstitial", "ANATOMY_MODIFIER", 85, 97], ["shadowing", "OBSERVATION_MODIFIER", 98, 107], ["Late", "OBSERVATION_MODIFIER", 108, 112], ["alveolar", "ANATOMY_MODIFIER", 114, 122], ["interstitial", "ANATOMY_MODIFIER", 123, 135], ["Tuberculosis", "OBSERVATION", 182, 194], ["marked", "OBSERVATION_MODIFIER", 195, 201], ["alveolar", "ANATOMY_MODIFIER", 202, 210], ["consolidation", "OBSERVATION", 211, 224], ["apices", "ANATOMY_MODIFIER", 241, 247], ["costophrenic angles", "ANATOMY", 252, 271], ["normal", "OBSERVATION", 378, 384], ["low", "OBSERVATION_MODIFIER", 388, 391], ["normal", "OBSERVATION", 399, 405], ["high", "OBSERVATION_MODIFIER", 409, 413], ["nonspecific", "OBSERVATION_MODIFIER", 418, 429], ["pulmonary", "ANATOMY", 468, 477], ["pathogens", "OBSERVATION", 478, 487], ["pyogenic", "OBSERVATION_MODIFIER", 499, 507], ["mycobacterial", "OBSERVATION", 519, 532], ["fungal", "OBSERVATION_MODIFIER", 538, 544], ["infection", "OBSERVATION", 545, 554], ["Kaposi sarcoma", "OBSERVATION", 567, 581], ["nonspecific", "OBSERVATION_MODIFIER", 586, 597], ["interstitial", "ANATOMY_MODIFIER", 598, 610], ["pneumonitis", "OBSERVATION", 611, 622]]], ["Respiratory symptoms in an immunosuppressed, HIV-infected individual with a negative chest radiograph should not be discounted, because over an interval of 2-3 days radiographic abnormalities may appear.", [["Respiratory", "ANATOMY", 0, 11], ["Respiratory symptoms", "DISEASE", 0, 20], ["HIV-infected", "DISEASE", 45, 57], ["chest", "ORGAN", 85, 90], ["HIV-", "SPECIES", 45, 49], ["HIV", "SPECIES", 45, 48], ["Respiratory symptoms", "PROBLEM", 0, 20], ["HIV", "PROBLEM", 45, 48], ["a negative chest radiograph", "TEST", 74, 101], ["radiographic abnormalities", "PROBLEM", 165, 191], ["immunosuppressed", "OBSERVATION", 27, 43], ["chest", "ANATOMY", 85, 90]]], ["The diagnosis of PCP is made by demonstration of the organism in induced sputum, BAL fluid, or lung biopsy material by use of histochemical or immunofluorescence techniques.", [["sputum", "ANATOMY", 73, 79], ["BAL fluid", "ANATOMY", 81, 90], ["lung biopsy", "ANATOMY", 95, 106], ["PCP", "DISEASE", 17, 20], ["PCP", "CHEMICAL", 17, 20], ["BAL fluid", "ORGANISM_SUBSTANCE", 81, 90], ["lung biopsy material", "MULTI-TISSUE_STRUCTURE", 95, 115], ["the organism", "PROBLEM", 49, 61], ["induced sputum", "PROBLEM", 65, 79], ["BAL fluid", "TEST", 81, 90], ["lung biopsy material", "TEST", 95, 115], ["histochemical or immunofluorescence techniques", "TEST", 126, 172], ["sputum", "OBSERVATION", 73, 79], ["lung", "ANATOMY", 95, 99], ["biopsy", "OBSERVATION", 100, 106]]], ["The early promise of molecular diagnostic techniques has not been borne out.Fungal InfectionsMany fungal infections of the lung are confined to specific geographic regions, although with widespread travel, they may present in patients outside these areas.", [["lung", "ANATOMY", 123, 127], ["Fungal Infections", "DISEASE", 76, 93], ["fungal infections", "DISEASE", 98, 115], ["lung", "ORGAN", 123, 127], ["patients", "ORGANISM", 226, 234], ["patients", "SPECIES", 226, 234], ["Fungal Infections", "PROBLEM", 76, 93], ["Many fungal infections of the lung", "PROBLEM", 93, 127], ["early", "OBSERVATION_MODIFIER", 4, 9], ["promise", "OBSERVATION_MODIFIER", 10, 17], ["Infections", "OBSERVATION", 83, 93], ["fungal", "OBSERVATION_MODIFIER", 98, 104], ["infections", "OBSERVATION", 105, 115], ["lung", "ANATOMY", 123, 127], ["geographic", "OBSERVATION_MODIFIER", 153, 163], ["widespread", "OBSERVATION_MODIFIER", 187, 197]]], ["Candida, Aspergillus, and Cryptococcus species are ubiquitous and occur worldwide.Candidal InfectionIn contrast to infections of the oropharynx and esophagus, candidal infection of the trachea, bronchi, and lungs is rare in HIV-infected patients, as are candidemia, disseminated candidiasis, and deep focal candidiasis.", [["oropharynx", "ANATOMY", 133, 143], ["esophagus", "ANATOMY", 148, 157], ["candidal", "ANATOMY", 159, 167], ["trachea", "ANATOMY", 185, 192], ["bronchi", "ANATOMY", 194, 201], ["lungs", "ANATOMY", 207, 212], ["focal candidiasis", "ANATOMY", 301, 318], ["infections of the oropharynx and esophagus", "DISEASE", 115, 157], ["candidal infection", "DISEASE", 159, 177], ["HIV-infected", "DISEASE", 224, 236], ["candidemia", "DISEASE", 254, 264], ["disseminated candidiasis", "DISEASE", 266, 290], ["candidiasis", "DISEASE", 307, 318], ["Candida", "ORGANISM", 0, 7], ["Cryptococcus species", "ORGANISM", 26, 46], ["oropharynx", "ORGAN", 133, 143], ["esophagus", "ORGAN", 148, 157], ["trachea", "MULTI-TISSUE_STRUCTURE", 185, 192], ["bronchi", "MULTI-TISSUE_STRUCTURE", 194, 201], ["lungs", "ORGAN", 207, 212], ["HIV", "ORGANISM", 224, 227], ["patients", "ORGANISM", 237, 245], ["focal candidiasis", "PATHOLOGICAL_FORMATION", 301, 318], ["HIV", "SPECIES", 224, 227], ["patients", "SPECIES", 237, 245], ["HIV", "SPECIES", 224, 227], ["Candida", "PROBLEM", 0, 7], ["Aspergillus", "PROBLEM", 9, 20], ["Cryptococcus species", "PROBLEM", 26, 46], ["Candidal InfectionIn contrast", "TREATMENT", 82, 111], ["infections of the oropharynx and esophagus", "PROBLEM", 115, 157], ["candidal infection of the trachea, bronchi, and lungs", "PROBLEM", 159, 212], ["HIV", "PROBLEM", 224, 227], ["candidemia", "PROBLEM", 254, 264], ["disseminated candidiasis", "PROBLEM", 266, 290], ["deep focal candidiasis", "PROBLEM", 296, 318], ["Aspergillus", "OBSERVATION", 9, 20], ["Cryptococcus species", "OBSERVATION", 26, 46], ["infections", "OBSERVATION", 115, 125], ["oropharynx", "ANATOMY", 133, 143], ["esophagus", "ANATOMY", 148, 157], ["candidal", "OBSERVATION_MODIFIER", 159, 167], ["infection", "OBSERVATION", 168, 177], ["trachea", "ANATOMY", 185, 192], ["bronchi", "ANATOMY", 194, 201], ["lungs", "ANATOMY", 207, 212], ["rare", "OBSERVATION_MODIFIER", 216, 220], ["infected", "OBSERVATION_MODIFIER", 228, 236], ["candidemia", "OBSERVATION", 254, 264], ["disseminated", "OBSERVATION_MODIFIER", 266, 278], ["candidiasis", "OBSERVATION", 279, 290], ["deep", "OBSERVATION_MODIFIER", 296, 300], ["focal", "OBSERVATION_MODIFIER", 301, 306], ["candidiasis", "OBSERVATION", 307, 318]]], ["The clinical presentation of pulmonary candidal infection has no specific features.", [["pulmonary", "ANATOMY", 29, 38], ["pulmonary candidal infection", "DISEASE", 29, 57], ["pulmonary", "ORGAN", 29, 38], ["candidal", "PATHOLOGICAL_FORMATION", 39, 47], ["pulmonary candidal infection", "PROBLEM", 29, 57], ["pulmonary", "ANATOMY", 29, 38], ["candidal", "OBSERVATION_MODIFIER", 39, 47], ["infection", "OBSERVATION", 48, 57], ["no", "UNCERTAINTY", 62, 64], ["specific", "OBSERVATION_MODIFIER", 65, 73]]], ["Chest radiography is equally nonspecific-it may be negative or show patchy infiltrates.", [["Chest radiography", "TEST", 0, 17], ["patchy infiltrates", "PROBLEM", 68, 86], ["nonspecific", "OBSERVATION", 29, 40], ["patchy", "OBSERVATION_MODIFIER", 68, 74], ["infiltrates", "OBSERVATION", 75, 86]]], ["Isolation of Candida from sputum may simply represent colonization and does not mean the patient has candidal pneumonia.", [["sputum", "ANATOMY", 26, 32], ["pneumonia", "DISEASE", 110, 119], ["sputum", "ORGANISM_SUBSTANCE", 26, 32], ["patient", "ORGANISM", 89, 96], ["patient", "SPECIES", 89, 96], ["Candida from sputum", "PROBLEM", 13, 32], ["colonization", "PROBLEM", 54, 66], ["candidal pneumonia", "PROBLEM", 101, 119], ["Candida", "OBSERVATION", 13, 20], ["sputum", "OBSERVATION", 26, 32], ["may simply represent", "UNCERTAINTY", 33, 53], ["colonization", "OBSERVATION", 54, 66], ["candidal", "OBSERVATION_MODIFIER", 101, 109], ["pneumonia", "OBSERVATION", 110, 119]]], ["Indirect evidence may be obtained from positive cultures or rising antibody titers.", [["positive cultures", "PROBLEM", 39, 56], ["rising antibody titers", "PROBLEM", 60, 82], ["may be", "UNCERTAINTY", 18, 24]]], ["However, in HIVinfected patients, a high antibody titer alone is a less reliable indicator, and antibodies may be absent in proven cases of invasive candidal infection.", [["candidal", "ANATOMY", 149, 157], ["candidal infection", "DISEASE", 149, 167], ["patients", "ORGANISM", 24, 32], ["candidal", "CANCER", 149, 157], ["antibodies", "PROTEIN", 96, 106], ["patients", "SPECIES", 24, 32], ["a high antibody titer", "PROBLEM", 34, 55], ["antibodies", "TEST", 96, 106], ["invasive candidal infection", "PROBLEM", 140, 167], ["invasive", "OBSERVATION_MODIFIER", 140, 148], ["candidal", "OBSERVATION_MODIFIER", 149, 157], ["infection", "OBSERVATION", 158, 167]]], ["Some correlation occurs between identification of large quantities of Candida species in BAL fluid and Candida species as the cause of pneumonia.", [["BAL fluid", "ANATOMY", 89, 98], ["pneumonia", "DISEASE", 135, 144], ["Candida species", "ORGANISM", 70, 85], ["BAL fluid", "ORGANISM_SUBSTANCE", 89, 98], ["Candida species", "ORGANISM", 103, 118], ["Candida species", "PROBLEM", 70, 85], ["BAL fluid", "TEST", 89, 98], ["Candida species", "PROBLEM", 103, 118], ["pneumonia", "PROBLEM", 135, 144], ["large", "OBSERVATION_MODIFIER", 50, 55], ["quantities", "OBSERVATION_MODIFIER", 56, 66], ["Candida species", "OBSERVATION", 70, 85], ["BAL fluid", "OBSERVATION", 89, 98], ["Candida species", "OBSERVATION", 103, 118], ["pneumonia", "OBSERVATION", 135, 144]]], ["Definitive diagnosis is made by lung biopsy.Aspergillus InfectionBy contrast with patients immunosuppressed and rendered neutropenic by systemic chemotherapy, infection with Aspergillus species is relatively rare in HIV-positive individuals.", [["lung", "ANATOMY", 32, 36], ["neutropenic", "DISEASE", 121, 132], ["infection", "DISEASE", 159, 168], ["Aspergillus species", "DISEASE", 174, 193], ["HIV-positive", "DISEASE", 216, 228], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 32, 43], ["patients", "ORGANISM", 82, 90], ["Aspergillus species", "ORGANISM", 174, 193], ["HIV", "ORGANISM", 216, 219], ["patients", "SPECIES", 82, 90], ["HIV", "SPECIES", 216, 219], ["HIV", "SPECIES", 216, 219], ["lung biopsy", "TEST", 32, 43], ["Aspergillus InfectionBy contrast", "PROBLEM", 44, 76], ["neutropenic", "PROBLEM", 121, 132], ["systemic chemotherapy", "TREATMENT", 136, 157], ["infection", "PROBLEM", 159, 168], ["Aspergillus species", "PROBLEM", 174, 193], ["lung", "ANATOMY", 32, 36], ["biopsy", "OBSERVATION", 37, 43], ["neutropenic", "OBSERVATION_MODIFIER", 121, 132], ["infection", "OBSERVATION", 159, 168], ["Aspergillus species", "OBSERVATION", 174, 193]]], ["Risk factors for aspergillosis are neutropenia, which is commonly drug induced (zidovudine or ganciclovir), or patient's receipt of corticosteroids.", [["aspergillosis", "DISEASE", 17, 30], ["neutropenia", "DISEASE", 35, 46], ["zidovudine", "CHEMICAL", 80, 90], ["ganciclovir", "CHEMICAL", 94, 105], ["zidovudine", "CHEMICAL", 80, 90], ["ganciclovir", "CHEMICAL", 94, 105], ["corticosteroids", "CHEMICAL", 132, 147], ["zidovudine", "SIMPLE_CHEMICAL", 80, 90], ["ganciclovir", "SIMPLE_CHEMICAL", 94, 105], ["patient", "ORGANISM", 111, 118], ["corticosteroids", "SIMPLE_CHEMICAL", 132, 147], ["patient", "SPECIES", 111, 118], ["Risk factors", "PROBLEM", 0, 12], ["aspergillosis", "PROBLEM", 17, 30], ["neutropenia", "PROBLEM", 35, 46], ["zidovudine", "TREATMENT", 80, 90], ["ganciclovir", "TREATMENT", 94, 105], ["corticosteroids", "TREATMENT", 132, 147], ["aspergillosis", "OBSERVATION", 17, 30]]], ["Fever, cough, and dyspnea are the most common presenting symptoms, but pleuritic chest pain and hemoptysis are found in approximately one third of patients.Aspergillus InfectionPatterns of pulmonary disease include cavitating upper lobe disease, focal radiographic opacities resembling bacterial pneumonia, bilateral diffuse and patchy opacities (nodular or reticular-nodular in pattern), pseudomembranous aspergillosis, which may obstruct the lumen of airways, and tracheobronchitis.", [["chest", "ANATOMY", 81, 86], ["pulmonary", "ANATOMY", 189, 198], ["upper lobe", "ANATOMY", 226, 236], ["nodular", "ANATOMY", 347, 354], ["reticular-nodular", "ANATOMY", 358, 375], ["lumen", "ANATOMY", 444, 449], ["airways", "ANATOMY", 453, 460], ["Fever", "DISEASE", 0, 5], ["cough", "DISEASE", 7, 12], ["dyspnea", "DISEASE", 18, 25], ["chest pain", "DISEASE", 81, 91], ["hemoptysis", "DISEASE", 96, 106], ["pulmonary disease", "DISEASE", 189, 206], ["cavitating upper lobe disease", "DISEASE", 215, 244], ["opacities", "DISEASE", 265, 274], ["pneumonia", "DISEASE", 296, 305], ["opacities", "DISEASE", 336, 345], ["pseudomembranous aspergillosis", "DISEASE", 389, 419], ["tracheobronchitis", "DISEASE", 466, 483], ["chest", "ORGANISM_SUBDIVISION", 81, 86], ["patients", "ORGANISM", 147, 155], ["pulmonary", "ORGAN", 189, 198], ["upper lobe", "MULTI-TISSUE_STRUCTURE", 226, 236], ["pseudomembranous aspergillosis", "PATHOLOGICAL_FORMATION", 389, 419], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 444, 449], ["airways", "MULTI-TISSUE_STRUCTURE", 453, 460], ["patients", "SPECIES", 147, 155], ["Fever", "PROBLEM", 0, 5], ["cough", "PROBLEM", 7, 12], ["dyspnea", "PROBLEM", 18, 25], ["presenting symptoms", "PROBLEM", 46, 65], ["pleuritic chest pain", "PROBLEM", 71, 91], ["hemoptysis", "PROBLEM", 96, 106], ["Aspergillus", "PROBLEM", 156, 167], ["pulmonary disease", "PROBLEM", 189, 206], ["cavitating upper lobe disease", "PROBLEM", 215, 244], ["focal radiographic opacities", "PROBLEM", 246, 274], ["bacterial pneumonia", "PROBLEM", 286, 305], ["bilateral diffuse and patchy opacities", "PROBLEM", 307, 345], ["nodular or reticular-nodular in pattern)", "PROBLEM", 347, 387], ["pseudomembranous aspergillosis", "PROBLEM", 389, 419], ["tracheobronchitis", "PROBLEM", 466, 483], ["cough", "OBSERVATION", 7, 12], ["pleuritic", "OBSERVATION_MODIFIER", 71, 80], ["chest", "ANATOMY", 81, 86], ["pain", "OBSERVATION", 87, 91], ["hemoptysis", "OBSERVATION", 96, 106], ["pulmonary", "ANATOMY", 189, 198], ["disease", "OBSERVATION", 199, 206], ["cavitating", "OBSERVATION_MODIFIER", 215, 225], ["upper lobe", "ANATOMY", 226, 236], ["focal", "OBSERVATION_MODIFIER", 246, 251], ["radiographic opacities", "OBSERVATION", 252, 274], ["bacterial", "OBSERVATION_MODIFIER", 286, 295], ["pneumonia", "OBSERVATION", 296, 305], ["bilateral", "ANATOMY_MODIFIER", 307, 316], ["diffuse", "OBSERVATION_MODIFIER", 317, 324], ["patchy", "OBSERVATION_MODIFIER", 329, 335], ["opacities", "OBSERVATION", 336, 345], ["nodular", "OBSERVATION_MODIFIER", 347, 354], ["reticular", "OBSERVATION_MODIFIER", 358, 367], ["nodular", "OBSERVATION_MODIFIER", 368, 375], ["pseudomembranous", "OBSERVATION_MODIFIER", 389, 405], ["aspergillosis", "OBSERVATION", 406, 419], ["lumen", "ANATOMY_MODIFIER", 444, 449], ["airways", "ANATOMY", 453, 460], ["tracheobronchitis", "OBSERVATION", 466, 483]]], ["Diagnosis of pulmonary aspergillosis is made by the identification of fungus in sputum, sputum casts, or BAL fluid associated with respiratory tract tissue invasion ( Figure 34 -9).", [["pulmonary aspergillosis", "ANATOMY", 13, 36], ["sputum", "ANATOMY", 80, 86], ["sputum", "ANATOMY", 88, 94], ["BAL fluid", "ANATOMY", 105, 114], ["respiratory tract tissue", "ANATOMY", 131, 155], ["pulmonary aspergillosis", "DISEASE", 13, 36], ["pulmonary", "ORGAN", 13, 22], ["sputum", "ORGANISM_SUBSTANCE", 80, 86], ["tissue", "TISSUE", 149, 155], ["pulmonary aspergillosis", "PROBLEM", 13, 36], ["fungus in sputum", "PROBLEM", 70, 86], ["sputum casts", "TEST", 88, 100], ["BAL fluid", "PROBLEM", 105, 114], ["respiratory tract tissue invasion", "PROBLEM", 131, 164], ["Figure", "TEST", 167, 173], ["pulmonary", "ANATOMY", 13, 22], ["aspergillosis", "OBSERVATION", 23, 36], ["fungus", "OBSERVATION", 70, 76], ["BAL fluid", "OBSERVATION", 105, 114], ["respiratory tract", "ANATOMY", 131, 148]]], ["The role of antigen testing (such as galactomannan assays), which is commonplace in hematology patients at risk of invasive aspergillus, has not been clearly defined in HIV-infected individuals.Cryptococcal InfectionInfection may present in one of two ways: either as primary cryptococcosis or complicating cryptococcal meningitis as part of disseminated infection with cryptococcemia, pneumonia, and cutaneous disease (umbilicated papules mimicking molluscum contagiosum; Figure 34 -10).", [["invasive aspergillus", "ANATOMY", 115, 135], ["cutaneous", "ANATOMY", 401, 410], ["papules", "ANATOMY", 432, 439], ["aspergillus", "DISEASE", 124, 135], ["HIV-infected", "DISEASE", 169, 181], ["Cryptococcal InfectionInfection", "DISEASE", 194, 225], ["cryptococcosis", "DISEASE", 276, 290], ["cryptococcal meningitis", "DISEASE", 307, 330], ["infection", "DISEASE", 355, 364], ["cryptococcemia", "DISEASE", 370, 384], ["pneumonia", "DISEASE", 386, 395], ["cutaneous disease", "DISEASE", 401, 418], ["papules", "DISEASE", 432, 439], ["molluscum contagiosum", "DISEASE", 450, 471], ["patients", "ORGANISM", 95, 103], ["HIV", "ORGANISM", 169, 172], ["individuals", "ORGANISM", 182, 193], ["cutaneous", "ORGANISM_SUBDIVISION", 401, 410], ["papules", "ORGANISM_SUBDIVISION", 432, 439], ["patients", "SPECIES", 95, 103], ["HIV", "SPECIES", 169, 172], ["HIV", "SPECIES", 169, 172], ["antigen testing", "TEST", 12, 27], ["galactomannan assays", "TEST", 37, 57], ["invasive aspergillus", "PROBLEM", 115, 135], ["infected individuals", "PROBLEM", 173, 193], ["Cryptococcal InfectionInfection", "PROBLEM", 194, 225], ["primary cryptococcosis", "PROBLEM", 268, 290], ["cryptococcal meningitis", "PROBLEM", 307, 330], ["disseminated infection", "PROBLEM", 342, 364], ["cryptococcemia", "PROBLEM", 370, 384], ["pneumonia", "PROBLEM", 386, 395], ["cutaneous disease", "PROBLEM", 401, 418], ["umbilicated papules mimicking molluscum contagiosum", "PROBLEM", 420, 471], ["Figure", "TEST", 473, 479], ["invasive", "OBSERVATION_MODIFIER", 115, 123], ["aspergillus", "OBSERVATION", 124, 135], ["infected", "OBSERVATION", 173, 181], ["InfectionInfection", "OBSERVATION", 207, 225], ["primary", "OBSERVATION_MODIFIER", 268, 275], ["cryptococcosis", "OBSERVATION", 276, 290], ["complicating", "UNCERTAINTY", 294, 306], ["cryptococcal", "OBSERVATION_MODIFIER", 307, 319], ["meningitis", "OBSERVATION", 320, 330], ["disseminated", "OBSERVATION_MODIFIER", 342, 354], ["infection", "OBSERVATION", 355, 364], ["pneumonia", "OBSERVATION", 386, 395], ["cutaneous disease", "OBSERVATION", 401, 418], ["papules", "OBSERVATION_MODIFIER", 432, 439]]], ["Primary pulmonary cryptococcosis presents in a very nonspecific way and is frequently indistinguishable from other pulmonary infections.", [["pulmonary", "ANATOMY", 8, 17], ["pulmonary", "ANATOMY", 115, 124], ["Primary pulmonary cryptococcosis", "DISEASE", 0, 32], ["pulmonary infections", "DISEASE", 115, 135], ["pulmonary", "ORGAN", 8, 17], ["pulmonary", "ORGAN", 115, 124], ["Primary pulmonary cryptococcosis", "PROBLEM", 0, 32], ["other pulmonary infections", "PROBLEM", 109, 135], ["pulmonary", "ANATOMY", 8, 17], ["cryptococcosis", "OBSERVATION", 18, 32], ["pulmonary", "ANATOMY", 115, 124], ["infections", "OBSERVATION", 125, 135]]], ["In disseminated infection, the presentation is frequently overshadowed by headache, fever, and malaise (caused by meningitis).", [["infection", "DISEASE", 16, 25], ["headache", "DISEASE", 74, 82], ["fever", "DISEASE", 84, 89], ["meningitis", "DISEASE", 114, 124], ["disseminated infection", "PROBLEM", 3, 25], ["headache", "PROBLEM", 74, 82], ["fever", "PROBLEM", 84, 89], ["malaise", "PROBLEM", 95, 102], ["meningitis", "PROBLEM", 114, 124], ["disseminated", "OBSERVATION_MODIFIER", 3, 15], ["infection", "OBSERVATION", 16, 25], ["headache", "OBSERVATION", 74, 82], ["meningitis", "OBSERVATION", 114, 124]]], ["Examination may reveal skin lesions, lymphadenopathy, and meningism.", [["skin lesions", "ANATOMY", 23, 35], ["skin lesions", "DISEASE", 23, 35], ["lymphadenopathy", "DISEASE", 37, 52], ["meningism", "DISEASE", 58, 67], ["skin lesions", "PATHOLOGICAL_FORMATION", 23, 35], ["Examination", "TEST", 0, 11], ["skin lesions", "PROBLEM", 23, 35], ["lymphadenopathy", "PROBLEM", 37, 52], ["meningism", "PROBLEM", 58, 67], ["skin", "ANATOMY", 23, 27], ["lesions", "OBSERVATION", 28, 35], ["lymphadenopathy", "OBSERVATION", 37, 52]]], ["In the chest, signs may be absent or crackles may be audible.", [["chest", "ANATOMY", 7, 12], ["chest", "ORGAN", 7, 12], ["crackles", "PROBLEM", 37, 45], ["chest", "ANATOMY", 7, 12], ["signs may be", "UNCERTAINTY", 14, 26], ["absent", "OBSERVATION", 27, 33], ["crackles", "OBSERVATION", 37, 45]]], ["Arterial blood gas tensions may be normal or show hypoxemia.", [["Arterial blood", "ANATOMY", 0, 14], ["hypoxemia", "DISEASE", 50, 59], ["Arterial", "MULTI-TISSUE_STRUCTURE", 0, 8], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["Arterial blood gas tensions", "TEST", 0, 27], ["hypoxemia", "PROBLEM", 50, 59], ["normal", "OBSERVATION", 35, 41], ["hypoxemia", "OBSERVATION", 50, 59]]], ["The most common abnormality on the chest radiograph is focal or diffuse interstitial infiltrates.", [["chest", "ANATOMY", 35, 40], ["diffuse interstitial infiltrates", "ANATOMY", 64, 96], ["chest", "ORGANISM_SUBDIVISION", 35, 40], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 72, 96], ["The most common abnormality", "PROBLEM", 0, 27], ["the chest radiograph", "TEST", 31, 51], ["diffuse interstitial infiltrates", "PROBLEM", 64, 96], ["most", "OBSERVATION_MODIFIER", 4, 8], ["common", "OBSERVATION_MODIFIER", 9, 15], ["abnormality", "OBSERVATION", 16, 27], ["chest", "ANATOMY", 35, 40], ["focal", "OBSERVATION_MODIFIER", 55, 60], ["diffuse", "OBSERVATION_MODIFIER", 64, 71], ["interstitial", "ANATOMY_MODIFIER", 72, 84], ["infiltrates", "OBSERVATION", 85, 96]]], ["Less frequently, masses, mediastinal or hilar lymphadenopathy, nodules, and effusion are noted.Cryptococcal InfectionThe diagnosis of cryptococcal pulmonary infection ( Figure 34 -11) is made by identification of Cryptococcus neoformans (by staining with India ink or mucicarmine, and by culture) in sputum, BAL fluid, pleural fluid, or lung biopsy.", [["masses", "ANATOMY", 17, 23], ["mediastinal", "ANATOMY", 25, 36], ["hilar lymphadenopathy", "ANATOMY", 40, 61], ["nodules", "ANATOMY", 63, 70], ["pulmonary", "ANATOMY", 147, 156], ["sputum", "ANATOMY", 300, 306], ["BAL fluid", "ANATOMY", 308, 317], ["pleural fluid", "ANATOMY", 319, 332], ["lung", "ANATOMY", 337, 341], ["lymphadenopathy", "DISEASE", 46, 61], ["effusion", "DISEASE", 76, 84], ["Cryptococcal Infection", "DISEASE", 95, 117], ["cryptococcal pulmonary infection", "DISEASE", 134, 166], ["Cryptococcus neoformans", "DISEASE", 213, 236], ["masses", "CANCER", 17, 23], ["mediastinal", "CANCER", 25, 36], ["hilar lymphadenopathy", "CANCER", 40, 61], ["nodules", "CANCER", 63, 70], ["pulmonary", "ORGAN", 147, 156], ["Cryptococcus neoformans", "ORGANISM", 213, 236], ["mucicarmine", "SIMPLE_CHEMICAL", 268, 279], ["BAL fluid", "ORGANISM_SUBSTANCE", 308, 317], ["pleural fluid", "MULTI-TISSUE_STRUCTURE", 319, 332], ["lung biopsy", "MULTI-TISSUE_STRUCTURE", 337, 348], ["Cryptococcus neoformans", "SPECIES", 213, 236], ["Cryptococcus neoformans", "SPECIES", 213, 236], ["masses, mediastinal or hilar lymphadenopathy", "PROBLEM", 17, 61], ["nodules", "PROBLEM", 63, 70], ["effusion", "PROBLEM", 76, 84], ["Cryptococcal Infection", "PROBLEM", 95, 117], ["cryptococcal pulmonary infection", "PROBLEM", 134, 166], ["Cryptococcus neoformans", "PROBLEM", 213, 236], ["mucicarmine", "TREATMENT", 268, 279], ["culture", "TEST", 288, 295], ["sputum", "TEST", 300, 306], ["BAL fluid", "TEST", 308, 317], ["pleural fluid", "PROBLEM", 319, 332], ["lung biopsy", "TEST", 337, 348], ["masses", "OBSERVATION", 17, 23], ["mediastinal", "ANATOMY", 25, 36], ["hilar", "ANATOMY", 40, 45], ["lymphadenopathy", "OBSERVATION", 46, 61], ["nodules", "OBSERVATION", 63, 70], ["effusion", "OBSERVATION", 76, 84], ["Infection", "OBSERVATION", 108, 117], ["cryptococcal", "OBSERVATION_MODIFIER", 134, 146], ["pulmonary", "ANATOMY", 147, 156], ["infection", "OBSERVATION", 157, 166], ["Cryptococcus neoformans", "OBSERVATION", 213, 236], ["BAL", "ANATOMY", 308, 311], ["fluid", "OBSERVATION", 312, 317], ["pleural", "ANATOMY", 319, 326], ["fluid", "OBSERVATION", 327, 332], ["lung", "ANATOMY", 337, 341], ["biopsy", "OBSERVATION", 342, 348]]], ["Cryptococcal antigen may be detected in serum by use of the cryptococcal latex agglutination (CrAg) test.", [["serum", "ANATOMY", 40, 45], ["Cryptococcal antigen", "GENE_OR_GENE_PRODUCT", 0, 20], ["serum", "ORGANISM_SUBSTANCE", 40, 45], ["Cryptococcal antigen", "PROTEIN", 0, 20], ["Cryptococcal antigen", "TEST", 0, 20], ["the cryptococcal latex agglutination", "TEST", 56, 92], ["CrAg) test", "TEST", 94, 104]]], ["Titers are usually high but may be negative in primary pulmonary cryptococcosis, in which case BAL fluid (CrAg) is positive.", [["pulmonary", "ANATOMY", 55, 64], ["BAL fluid", "ANATOMY", 95, 104], ["primary pulmonary cryptococcosis", "DISEASE", 47, 79], ["pulmonary", "ORGAN", 55, 64], ["BAL", "ORGANISM_SUBSTANCE", 95, 98], ["CrAg", "CANCER", 106, 110], ["Titers", "TEST", 0, 6], ["primary pulmonary cryptococcosis", "PROBLEM", 47, 79], ["BAL fluid (CrAg)", "TEST", 95, 111], ["pulmonary", "ANATOMY", 55, 64], ["cryptococcosis", "OBSERVATION", 65, 79]]], ["In patients with disseminated infection, C. neoformans may also be cultured from blood and cerebrospinal fluid.", [["blood", "ANATOMY", 81, 86], ["cerebrospinal fluid", "ANATOMY", 91, 110], ["infection", "DISEASE", 30, 39], ["patients", "ORGANISM", 3, 11], ["C. neoformans", "ORGANISM", 41, 54], ["blood", "ORGANISM_SUBSTANCE", 81, 86], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 91, 110], ["patients", "SPECIES", 3, 11], ["C. neoformans", "SPECIES", 41, 54], ["C. neoformans", "SPECIES", 41, 54], ["disseminated infection", "PROBLEM", 17, 39], ["C. neoformans", "PROBLEM", 41, 54], ["blood and cerebrospinal fluid", "TEST", 81, 110], ["disseminated", "OBSERVATION_MODIFIER", 17, 29], ["infection", "OBSERVATION", 30, 39], ["neoformans", "OBSERVATION", 44, 54], ["cerebrospinal", "ANATOMY", 91, 104], ["fluid", "OBSERVATION", 105, 110]]], ["The mortality rate is high in this disseminated form (up to 80%).Endemic MycosesThe endemic mycoses caused by Histoplasma capsulatum, Coccidioides immitis, and Blastomyces dermatitidis are found in HIV-infected patients living in North America (especially the Mississippi and Ohio River valleys).", [["mycoses", "DISEASE", 92, 99], ["Histoplasma capsulatum", "DISEASE", 110, 132], ["Coccidioides immitis", "DISEASE", 134, 154], ["Blastomyces dermatitidis", "DISEASE", 160, 184], ["HIV-infected", "DISEASE", 198, 210], ["Histoplasma capsulatum", "ORGANISM", 110, 132], ["Coccidioides immitis", "ORGANISM", 134, 154], ["Blastomyces dermatitidis", "ORGANISM", 160, 184], ["HIV", "ORGANISM", 198, 201], ["patients", "ORGANISM", 211, 219], ["Histoplasma capsulatum", "SPECIES", 110, 132], ["Coccidioides immitis", "SPECIES", 134, 154], ["Blastomyces dermatitidis", "SPECIES", 160, 184], ["HIV", "SPECIES", 198, 201], ["patients", "SPECIES", 211, 219], ["Histoplasma capsulatum", "SPECIES", 110, 132], ["Coccidioides immitis", "SPECIES", 134, 154], ["Blastomyces dermatitidis", "SPECIES", 160, 184], ["HIV", "SPECIES", 198, 201], ["The mortality rate", "TEST", 0, 18], ["Endemic Mycoses", "PROBLEM", 65, 80], ["The endemic mycoses", "PROBLEM", 80, 99], ["Histoplasma capsulatum", "PROBLEM", 110, 132], ["Coccidioides immitis", "PROBLEM", 134, 154], ["Blastomyces dermatitidis", "PROBLEM", 160, 184], ["HIV", "PROBLEM", 198, 201], ["high", "OBSERVATION_MODIFIER", 22, 26], ["disseminated", "OBSERVATION", 35, 47], ["Mycoses", "OBSERVATION", 73, 80], ["endemic", "OBSERVATION_MODIFIER", 84, 91], ["mycoses", "OBSERVATION", 92, 99], ["Histoplasma capsulatum", "OBSERVATION", 110, 132], ["Coccidioides immitis", "OBSERVATION", 134, 154], ["Blastomyces dermatitidis", "OBSERVATION", 160, 184], ["infected", "OBSERVATION_MODIFIER", 202, 210]]], ["Histoplasmosis is also found in Southeast Asia, the Caribbean Islands, and South America.", [["Histoplasmosis", "DISEASE", 0, 14], ["Histoplasmosis", "PROBLEM", 0, 14]]], ["Coccidioidomycosis is endemic in the southwest United States (southern California), northern Mexico, and in parts of Argentina and Brazil.", [["Coccidioidomycosis", "DISEASE", 0, 18], ["Coccidioidomycosis", "PROBLEM", 0, 18], ["endemic", "OBSERVATION_MODIFIER", 22, 29]]], ["Blastomycosis has a similar distribution, with an extension north into Canada.HistoplasmosisProgressive, disseminated histoplasmosis in patients with HIV typically presents with a subacute onset of fever and weight loss; approximately 50% of patients have mild respiratory symptoms with a nonproductive cough and dyspnea.", [["respiratory", "ANATOMY", 261, 272], ["Blastomycosis", "DISEASE", 0, 13], ["histoplasmosis", "DISEASE", 118, 132], ["HIV", "DISEASE", 150, 153], ["fever", "DISEASE", 198, 203], ["weight loss", "DISEASE", 208, 219], ["respiratory symptoms", "DISEASE", 261, 281], ["cough", "DISEASE", 303, 308], ["dyspnea", "DISEASE", 313, 320], ["patients", "ORGANISM", 136, 144], ["patients", "ORGANISM", 242, 250], ["patients", "SPECIES", 136, 144], ["HIV", "SPECIES", 150, 153], ["patients", "SPECIES", 242, 250], ["HIV", "SPECIES", 150, 153], ["Blastomycosis", "PROBLEM", 0, 13], ["HistoplasmosisProgressive", "PROBLEM", 78, 103], ["disseminated histoplasmosis", "PROBLEM", 105, 132], ["HIV", "PROBLEM", 150, 153], ["fever", "PROBLEM", 198, 203], ["weight loss", "PROBLEM", 208, 219], ["mild respiratory symptoms", "PROBLEM", 256, 281], ["a nonproductive cough", "PROBLEM", 287, 308], ["dyspnea", "PROBLEM", 313, 320], ["similar", "OBSERVATION_MODIFIER", 20, 27], ["distribution", "OBSERVATION_MODIFIER", 28, 40], ["Canada", "OBSERVATION_MODIFIER", 71, 77], ["disseminated", "OBSERVATION_MODIFIER", 105, 117], ["histoplasmosis", "OBSERVATION", 118, 132], ["subacute", "OBSERVATION_MODIFIER", 180, 188], ["fever", "OBSERVATION", 198, 203], ["weight loss", "OBSERVATION_MODIFIER", 208, 219], ["mild", "OBSERVATION_MODIFIER", 256, 260], ["respiratory symptoms", "OBSERVATION", 261, 281], ["nonproductive", "OBSERVATION_MODIFIER", 289, 302], ["cough", "OBSERVATION", 303, 308]]], ["Hepatosplenomegaly is frequently found on examination, and a rash (similar to that produced by Cryptococcus species) may be seen.", [["Hepatosplenomegaly", "DISEASE", 0, 18], ["rash", "DISEASE", 61, 65], ["Cryptococcus species", "ORGANISM", 95, 115], ["Hepatosplenomegaly", "PROBLEM", 0, 18], ["examination", "TEST", 42, 53], ["a rash", "PROBLEM", 59, 65], ["Cryptococcus species", "PROBLEM", 95, 115], ["rash", "OBSERVATION", 61, 65], ["Cryptococcus species", "OBSERVATION", 95, 115], ["may be seen", "UNCERTAINTY", 117, 128]]], ["Rarely, the presentation may be rapidly fulminant, with clinical features of the sepsis syndrome, including anemia or disseminated intravascular coagulation.", [["intravascular", "ANATOMY", 131, 144], ["fulminant", "DISEASE", 40, 49], ["sepsis", "DISEASE", 81, 87], ["anemia", "DISEASE", 108, 114], ["disseminated intravascular coagulation", "DISEASE", 118, 156], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 131, 144], ["rapidly fulminant", "PROBLEM", 32, 49], ["the sepsis syndrome", "PROBLEM", 77, 96], ["anemia", "PROBLEM", 108, 114], ["disseminated intravascular coagulation", "PROBLEM", 118, 156], ["may be", "UNCERTAINTY", 25, 31], ["rapidly", "OBSERVATION_MODIFIER", 32, 39], ["fulminant", "OBSERVATION", 40, 49], ["sepsis syndrome", "OBSERVATION", 81, 96], ["disseminated", "OBSERVATION_MODIFIER", 118, 130], ["intravascular coagulation", "OBSERVATION", 131, 156]]], ["The chest radiograph may be unremarkable (in up to one third of patients), although characteristic abnormalities are bilateral, widespread nodules 2-4 mm in size.", [["chest", "ANATOMY", 4, 9], ["nodules", "ANATOMY", 139, 146], ["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["The chest radiograph", "TEST", 0, 20], ["characteristic abnormalities", "PROBLEM", 84, 112], ["widespread nodules", "PROBLEM", 128, 146], ["chest", "ANATOMY", 4, 9], ["unremarkable", "OBSERVATION", 28, 40], ["characteristic", "OBSERVATION_MODIFIER", 84, 98], ["abnormalities", "OBSERVATION", 99, 112], ["bilateral", "ANATOMY_MODIFIER", 117, 126], ["widespread", "OBSERVATION_MODIFIER", 128, 138], ["nodules", "OBSERVATION", 139, 146], ["2-4 mm", "OBSERVATION_MODIFIER", 147, 153], ["size", "OBSERVATION_MODIFIER", 157, 161]]], ["Other radiographic features are nonspecific and include interstitial infiltrates, reticular nodular shadowing, and alveolar consolidation.", [["interstitial infiltrates", "ANATOMY", 56, 80], ["reticular nodular", "ANATOMY", 82, 99], ["alveolar", "ANATOMY", 115, 123], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 56, 80], ["reticular nodular", "PATHOLOGICAL_FORMATION", 82, 99], ["alveolar", "MULTI-TISSUE_STRUCTURE", 115, 123], ["Other radiographic features", "TEST", 0, 27], ["interstitial infiltrates", "PROBLEM", 56, 80], ["reticular nodular shadowing", "PROBLEM", 82, 109], ["alveolar consolidation", "PROBLEM", 115, 137], ["nonspecific", "OBSERVATION_MODIFIER", 32, 43], ["interstitial", "ANATOMY_MODIFIER", 56, 68], ["infiltrates", "OBSERVATION", 69, 80], ["reticular", "OBSERVATION_MODIFIER", 82, 91], ["nodular", "OBSERVATION_MODIFIER", 92, 99], ["shadowing", "OBSERVATION", 100, 109], ["alveolar", "ANATOMY_MODIFIER", 115, 123], ["consolidation", "OBSERVATION", 124, 137]]], ["Histoplasmosis may disseminate to the central nervous system and produce meningoencephalitis or mass lesions.", [["central nervous system", "ANATOMY", 38, 60], ["mass lesions", "ANATOMY", 96, 108], ["Histoplasmosis", "DISEASE", 0, 14], ["meningoencephalitis", "DISEASE", 73, 92], ["central nervous system", "ANATOMICAL_SYSTEM", 38, 60], ["mass lesions", "PATHOLOGICAL_FORMATION", 96, 108], ["Histoplasmosis", "PROBLEM", 0, 14], ["meningoencephalitis", "PROBLEM", 73, 92], ["mass lesions", "PROBLEM", 96, 108], ["central", "ANATOMY_MODIFIER", 38, 45], ["nervous system", "ANATOMY", 46, 60], ["meningoencephalitis", "OBSERVATION", 73, 92], ["mass", "OBSERVATION", 96, 100]]], ["The diagnosis is made reliably by identification of the organism in Wright-stained peripheral blood or by Giemsa staining of bone marrow, lymph node, skin, sputum, BAL fluid, or lung tissue.", [["peripheral blood", "ANATOMY", 83, 99], ["bone marrow", "ANATOMY", 125, 136], ["lymph node", "ANATOMY", 138, 148], ["skin", "ANATOMY", 150, 154], ["sputum", "ANATOMY", 156, 162], ["BAL fluid", "ANATOMY", 164, 173], ["lung tissue", "ANATOMY", 178, 189], ["peripheral blood", "ORGANISM_SUBSTANCE", 83, 99], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 125, 136], ["lymph node", "MULTI-TISSUE_STRUCTURE", 138, 148], ["skin", "ORGAN", 150, 154], ["sputum", "ORGANISM_SUBSTANCE", 156, 162], ["BAL fluid", "TISSUE", 164, 173], ["lung tissue", "TISSUE", 178, 189], ["the organism", "PROBLEM", 52, 64], ["Giemsa staining", "TEST", 106, 121], ["bone marrow", "TEST", 125, 136], ["lymph node", "TEST", 138, 148], ["skin, sputum, BAL fluid", "TEST", 150, 173], ["lung tissue", "PROBLEM", 178, 189], ["peripheral", "ANATOMY_MODIFIER", 83, 93], ["blood", "ANATOMY", 94, 99], ["bone marrow", "ANATOMY", 125, 136], ["lymph node", "OBSERVATION", 138, 148], ["skin", "ANATOMY", 150, 154], ["sputum", "OBSERVATION", 156, 162], ["BAL", "ANATOMY", 164, 167], ["fluid", "OBSERVATION", 168, 173], ["lung", "ANATOMY", 178, 182], ["tissue", "OBSERVATION", 183, 189]]], ["It is important that identification is confirmed by detection of H. capsulatum var. capsulatum polysaccharide antigen by radioimmunoassay, which has a high sensitivity.", [["H. capsulatum", "ORGANISM", 65, 78], ["capsulatum polysaccharide antigen", "GENE_OR_GENE_PRODUCT", 84, 117], ["polysaccharide antigen", "PROTEIN", 95, 117], ["H. capsulatum", "SPECIES", 65, 78], ["capsulatum", "SPECIES", 84, 94], ["H. capsulatum", "SPECIES", 65, 78], ["capsulatum", "SPECIES", 84, 94], ["H. capsulatum var", "PROBLEM", 65, 82], ["capsulatum polysaccharide antigen", "TEST", 84, 117], ["radioimmunoassay", "TEST", 121, 137], ["a high sensitivity", "PROBLEM", 149, 167], ["capsulatum var", "OBSERVATION", 68, 82]]], ["False-positive results may occur in patients infected with Blastomycosis and Coccidioides species.", [["Blastomycosis and Coccidioides species", "DISEASE", 59, 97], ["patients", "ORGANISM", 36, 44], ["Coccidioides species", "ORGANISM", 77, 97], ["patients", "SPECIES", 36, 44], ["False", "TEST", 0, 5], ["Blastomycosis", "PROBLEM", 59, 72], ["Coccidioides species", "PROBLEM", 77, 97], ["Blastomycosis", "OBSERVATION", 59, 72], ["Coccidioides species", "OBSERVATION", 77, 97]]], ["Tests for Histoplasma antibodies by complement fixation or immunodiffusion may be negative in immunosuppressed, HIV-positive patients.CoccidioidomycosisThe clinical presentation of coccidioidomycosis is variable.", [["HIV-positive", "DISEASE", 112, 124], ["Coccidioidomycosis", "DISEASE", 134, 152], ["coccidioidomycosis", "DISEASE", 181, 199], ["Histoplasma antibodies", "GENE_OR_GENE_PRODUCT", 10, 32], ["HIV", "ORGANISM", 112, 115], ["patients", "ORGANISM", 125, 133], ["Histoplasma antibodies", "PROTEIN", 10, 32], ["HIV", "SPECIES", 112, 115], ["patients", "SPECIES", 125, 133], ["HIV", "SPECIES", 112, 115], ["Tests", "TEST", 0, 5], ["Histoplasma antibodies", "TEST", 10, 32], ["complement fixation", "TEST", 36, 55], ["immunodiffusion", "TEST", 59, 74], ["Coccidioidomycosis", "PROBLEM", 134, 152], ["coccidioidomycosis", "PROBLEM", 181, 199], ["coccidioidomycosis", "OBSERVATION", 181, 199], ["variable", "OBSERVATION_MODIFIER", 203, 211]]], ["The chest radiograph may show focal pulmonary disease with focal alveolar infiltrates, adenopathy, and intrapulmonary cavities or, alternately, diffuse reticular infiltrates.", [["chest", "ANATOMY", 4, 9], ["pulmonary", "ANATOMY", 36, 45], ["alveolar", "ANATOMY", 65, 73], ["intrapulmonary cavities", "ANATOMY", 103, 126], ["reticular infiltrates", "ANATOMY", 152, 173], ["pulmonary disease", "DISEASE", 36, 53], ["adenopathy", "DISEASE", 87, 97], ["pulmonary", "ORGAN", 36, 45], ["alveolar infiltrates", "PATHOLOGICAL_FORMATION", 65, 85], ["reticular infiltrates", "PATHOLOGICAL_FORMATION", 152, 173], ["The chest radiograph", "TEST", 0, 20], ["focal pulmonary disease", "PROBLEM", 30, 53], ["focal alveolar infiltrates", "PROBLEM", 59, 85], ["adenopathy", "PROBLEM", 87, 97], ["intrapulmonary cavities", "PROBLEM", 103, 126], ["diffuse reticular infiltrates", "PROBLEM", 144, 173], ["chest", "ANATOMY", 4, 9], ["focal", "OBSERVATION_MODIFIER", 30, 35], ["pulmonary", "ANATOMY", 36, 45], ["disease", "OBSERVATION", 46, 53], ["focal", "OBSERVATION_MODIFIER", 59, 64], ["alveolar", "ANATOMY_MODIFIER", 65, 73], ["infiltrates", "OBSERVATION", 74, 85], ["adenopathy", "OBSERVATION", 87, 97], ["intrapulmonary", "ANATOMY", 103, 117], ["cavities", "ANATOMY_MODIFIER", 118, 126], ["diffuse", "OBSERVATION_MODIFIER", 144, 151], ["reticular", "OBSERVATION_MODIFIER", 152, 161], ["infiltrates", "OBSERVATION", 162, 173]]], ["Diagnosis is made by isolation of the organism in sputum or BAL fluid.", [["sputum", "ANATOMY", 50, 56], ["BAL fluid", "ANATOMY", 60, 69], ["sputum", "ORGANISM_SUBSTANCE", 50, 56], ["BAL fluid", "ORGANISM_SUBSTANCE", 60, 69], ["the organism in sputum", "PROBLEM", 34, 56], ["BAL fluid", "TEST", 60, 69], ["BAL fluid", "OBSERVATION", 60, 69]]], ["Disseminated disease is identified by isolating the fungus in blood, urine, or cerebrospinal fluid.", [["fungus", "ANATOMY", 52, 58], ["blood", "ANATOMY", 62, 67], ["urine", "ANATOMY", 69, 74], ["cerebrospinal fluid", "ANATOMY", 79, 98], ["Disseminated disease", "DISEASE", 0, 20], ["blood", "ORGANISM_SUBSTANCE", 62, 67], ["urine", "ORGANISM_SUBSTANCE", 69, 74], ["cerebrospinal fluid", "ORGANISM_SUBSTANCE", 79, 98], ["Disseminated disease", "PROBLEM", 0, 20], ["the fungus in blood, urine, or cerebrospinal fluid", "PROBLEM", 48, 98], ["disease", "OBSERVATION", 13, 20], ["fungus", "OBSERVATION", 52, 58], ["cerebrospinal", "ANATOMY", 79, 92], ["fluid", "OBSERVATION", 93, 98]]], ["Serologic tests may also be used for diagnosis.BlastomycosisBlastomycosis presents in patients who have advanced HIV infection, when CD4 lymphocyte counts are usually less than 200 cells/mL.", [["CD4 lymphocyte", "ANATOMY", 133, 147], ["cells", "ANATOMY", 181, 186], ["BlastomycosisBlastomycosis", "DISEASE", 47, 73], ["HIV infection", "DISEASE", 113, 126], ["patients", "ORGANISM", 86, 94], ["HIV", "ORGANISM", 113, 116], ["CD4 lymphocyte", "CELL", 133, 147], ["cells", "CELL", 181, 186], ["CD4 lymphocyte", "CELL_TYPE", 133, 147], ["patients", "SPECIES", 86, 94], ["HIV", "SPECIES", 113, 116], ["HIV", "SPECIES", 113, 116], ["Serologic tests", "TEST", 0, 15], ["BlastomycosisBlastomycosis", "PROBLEM", 47, 73], ["advanced HIV infection", "PROBLEM", 104, 126], ["CD4 lymphocyte counts", "TEST", 133, 154], ["Blastomycosis", "OBSERVATION", 60, 73], ["advanced", "OBSERVATION_MODIFIER", 104, 112], ["HIV", "OBSERVATION_MODIFIER", 113, 116], ["infection", "OBSERVATION", 117, 126]]], ["Clinical symptoms include cough, fever, dyspnea, and weight loss.", [["cough", "DISEASE", 26, 31], ["fever", "DISEASE", 33, 38], ["dyspnea", "DISEASE", 40, 47], ["weight loss", "DISEASE", 53, 64], ["Clinical symptoms", "PROBLEM", 0, 17], ["cough", "PROBLEM", 26, 31], ["fever", "PROBLEM", 33, 38], ["dyspnea", "PROBLEM", 40, 47], ["weight loss", "PROBLEM", 53, 64], ["cough", "OBSERVATION", 26, 31], ["weight loss", "OBSERVATION", 53, 64]]], ["Patients may present late in respiratory failure.", [["respiratory", "ANATOMY", 29, 40], ["respiratory failure", "DISEASE", 29, 48], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["respiratory failure", "PROBLEM", 29, 48], ["late", "OBSERVATION_MODIFIER", 21, 25], ["respiratory failure", "OBSERVATION", 29, 48]]], ["Disseminated disease can occur with both pulmonary and extrapulmonary features.", [["pulmonary", "ANATOMY", 41, 50], ["extrapulmonary", "ANATOMY", 55, 69], ["Disseminated disease", "DISEASE", 0, 20], ["pulmonary", "ORGAN", 41, 50], ["Disseminated disease", "PROBLEM", 0, 20], ["both pulmonary and extrapulmonary features", "PROBLEM", 36, 78], ["disease", "OBSERVATION", 13, 20], ["both", "ANATOMY_MODIFIER", 36, 40], ["pulmonary", "ANATOMY", 41, 50], ["extrapulmonary", "ANATOMY", 55, 69]]], ["There is frequently multiple involvement of the skin, liver, brain, and meninges.", [["skin", "ANATOMY", 48, 52], ["liver", "ANATOMY", 54, 59], ["brain", "ANATOMY", 61, 66], ["meninges", "ANATOMY", 72, 80], ["skin", "ORGAN", 48, 52], ["liver", "ORGAN", 54, 59], ["brain", "ORGAN", 61, 66], ["meninges", "ORGAN", 72, 80], ["frequently multiple involvement of the skin, liver, brain, and meninges", "PROBLEM", 9, 80], ["frequently", "OBSERVATION_MODIFIER", 9, 19], ["multiple", "OBSERVATION_MODIFIER", 20, 28], ["involvement", "OBSERVATION", 29, 40], ["skin", "ANATOMY", 48, 52], ["liver", "ANATOMY", 54, 59], ["brain", "ANATOMY", 61, 66], ["meninges", "ANATOMY", 72, 80]]], ["Chest radiographic abnormalities include focal pneumonic change, miliary shadowing, or diffuse interstitial infiltrates.", [["diffuse interstitial infiltrates", "ANATOMY", 87, 119], ["miliary shadowing", "DISEASE", 65, 82], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 95, 119], ["Chest radiographic abnormalities", "TEST", 0, 32], ["focal pneumonic change", "PROBLEM", 41, 63], ["miliary shadowing", "PROBLEM", 65, 82], ["diffuse interstitial infiltrates", "PROBLEM", 87, 119], ["focal", "OBSERVATION_MODIFIER", 41, 46], ["pneumonic", "OBSERVATION", 47, 56], ["miliary", "OBSERVATION_MODIFIER", 65, 72], ["shadowing", "OBSERVATION_MODIFIER", 73, 82], ["diffuse", "OBSERVATION_MODIFIER", 87, 94], ["interstitial", "ANATOMY_MODIFIER", 95, 107], ["infiltrates", "OBSERVATION", 108, 119]]], ["Diagnosis is made by culture from BAL fluid, skin, and blood.", [["BAL fluid", "ANATOMY", 34, 43], ["skin", "ANATOMY", 45, 49], ["blood", "ANATOMY", 55, 60], ["BAL fluid", "ORGANISM_SUBSTANCE", 34, 43], ["skin", "ORGAN", 45, 49], ["blood", "ORGANISM_SUBSTANCE", 55, 60], ["culture from BAL fluid", "TEST", 21, 43], ["blood", "TEST", 55, 60], ["skin", "ANATOMY", 45, 49], ["blood", "ANATOMY", 55, 60]]], ["In this infection, cytologic or histologic diagnosis is important for early diagnosis, because culture of the organism may take 2-4 weeks.", [["infection", "DISEASE", 8, 17], ["this infection", "PROBLEM", 3, 17], ["culture", "TEST", 95, 102], ["the organism", "PROBLEM", 106, 118], ["infection", "OBSERVATION", 8, 17]]], ["The mortality rate is high in patients with disseminated infection.PENICILLIUM MARNEFFEI INFECTIONP. marneffei infection is particularly common in Southeast Asia.", [["infection", "DISEASE", 57, 66], ["marneffei infection", "DISEASE", 101, 120], ["patients", "ORGANISM", 30, 38], ["marneffei", "ORGANISM", 101, 110], ["patients", "SPECIES", 30, 38], ["marneffei", "SPECIES", 101, 110], ["marneffei", "SPECIES", 101, 110], ["The mortality rate", "TEST", 0, 18], ["disseminated infection", "PROBLEM", 44, 66], ["PENICILLIUM MARNEFFEI INFECTIONP", "PROBLEM", 67, 99], ["marneffei infection", "PROBLEM", 101, 120], ["high", "OBSERVATION_MODIFIER", 22, 26], ["disseminated", "OBSERVATION_MODIFIER", 44, 56], ["infection", "OBSERVATION", 57, 66], ["MARNEFFEI INFECTIONP", "OBSERVATION", 79, 99], ["infection", "OBSERVATION", 111, 120]]], ["Most HIV-infected patients present with disseminated infection and solitary skin or oral mucosal lesions, or with multiple infiltrates in the liver or spleen, or bone marrow (leading to presentation with pancytopenia).", [["skin", "ANATOMY", 76, 80], ["oral mucosal lesions", "ANATOMY", 84, 104], ["liver", "ANATOMY", 142, 147], ["spleen", "ANATOMY", 151, 157], ["bone marrow", "ANATOMY", 162, 173], ["HIV-infected", "DISEASE", 5, 17], ["infection", "DISEASE", 53, 62], ["pancytopenia", "DISEASE", 204, 216], ["HIV", "ORGANISM", 5, 8], ["patients", "ORGANISM", 18, 26], ["skin", "ORGAN", 76, 80], ["oral mucosal lesions", "PATHOLOGICAL_FORMATION", 84, 104], ["liver", "ORGAN", 142, 147], ["spleen", "ORGAN", 151, 157], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 162, 173], ["HIV", "SPECIES", 5, 8], ["patients", "SPECIES", 18, 26], ["HIV", "SPECIES", 5, 8], ["disseminated infection", "PROBLEM", 40, 62], ["solitary skin or oral mucosal lesions", "PROBLEM", 67, 104], ["multiple infiltrates in the liver or spleen", "PROBLEM", 114, 157], ["bone marrow", "PROBLEM", 162, 173], ["pancytopenia", "PROBLEM", 204, 216], ["infected", "OBSERVATION", 9, 17], ["disseminated", "OBSERVATION_MODIFIER", 40, 52], ["infection", "OBSERVATION", 53, 62], ["solitary", "OBSERVATION_MODIFIER", 67, 75], ["skin", "ANATOMY", 76, 80], ["oral mucosal", "ANATOMY", 84, 96], ["lesions", "OBSERVATION", 97, 104], ["multiple", "OBSERVATION_MODIFIER", 114, 122], ["infiltrates", "OBSERVATION", 123, 134], ["liver", "ANATOMY", 142, 147], ["spleen", "ANATOMY", 151, 157], ["bone marrow", "ANATOMY", 162, 173], ["pancytopenia", "OBSERVATION", 204, 216]]], ["Pulmonary infection has no specific clinical features, and chest radiographs may be negative or show diffuse, small nodular infiltrates.", [["Pulmonary", "ANATOMY", 0, 9], ["chest", "ANATOMY", 59, 64], ["nodular infiltrates", "ANATOMY", 116, 135], ["Pulmonary infection", "DISEASE", 0, 19], ["Pulmonary", "ORGAN", 0, 9], ["nodular infiltrates", "PATHOLOGICAL_FORMATION", 116, 135], ["Pulmonary infection", "PROBLEM", 0, 19], ["chest radiographs", "TEST", 59, 76], ["diffuse, small nodular infiltrates", "PROBLEM", 101, 135], ["infection", "OBSERVATION", 10, 19], ["no", "UNCERTAINTY", 24, 26], ["chest", "ANATOMY", 59, 64], ["diffuse", "OBSERVATION_MODIFIER", 101, 108], ["small", "OBSERVATION_MODIFIER", 110, 115], ["nodular", "OBSERVATION_MODIFIER", 116, 123], ["infiltrates", "OBSERVATION", 124, 135]]], ["Diagnosis is made by identifying the organism in bone marrow, skin biopsy samples, blood films, or BAL fluid.", [["bone marrow", "ANATOMY", 49, 60], ["skin biopsy samples", "ANATOMY", 62, 81], ["blood", "ANATOMY", 83, 88], ["BAL fluid", "ANATOMY", 99, 108], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 49, 60], ["skin biopsy samples", "ORGANISM_SUBSTANCE", 62, 81], ["blood", "ORGANISM_SUBSTANCE", 83, 88], ["BAL fluid", "ORGANISM_SUBSTANCE", 99, 108], ["the organism in bone marrow", "PROBLEM", 33, 60], ["skin biopsy samples", "TEST", 62, 81], ["blood films", "TEST", 83, 94], ["BAL fluid", "TEST", 99, 108], ["bone marrow", "ANATOMY", 49, 60], ["skin", "ANATOMY", 62, 66], ["BAL", "ANATOMY", 99, 102], ["fluid", "OBSERVATION", 103, 108]]], ["The differential diagnosis of P. marneffei infection includes both PCP and tuberculosis.Community-Based Respiratory Viral InfectionsThese occur with equal frequency in HIV-infected and non-HIV-infected patients; however, respiratory complications after influenza infection are increased in patients affected with underlying conditions such as cardiac or pulmonary disease and immunosuppression.", [["respiratory", "ANATOMY", 221, 232], ["cardiac", "ANATOMY", 343, 350], ["pulmonary", "ANATOMY", 354, 363], ["P. marneffei infection", "DISEASE", 30, 52], ["PCP", "DISEASE", 67, 70], ["tuberculosis", "DISEASE", 75, 87], ["Respiratory Viral Infections", "DISEASE", 104, 132], ["HIV-infected and non-HIV-infected", "DISEASE", 168, 201], ["respiratory complications", "DISEASE", 221, 246], ["influenza infection", "DISEASE", 253, 272], ["cardiac or pulmonary disease", "DISEASE", 343, 371], ["PCP", "CHEMICAL", 67, 70], ["P. marneffei", "ORGANISM", 30, 42], ["patients", "ORGANISM", 202, 210], ["patients", "ORGANISM", 290, 298], ["cardiac", "ORGAN", 343, 350], ["pulmonary", "ORGAN", 354, 363], ["P. marneffei", "SPECIES", 30, 42], ["HIV-", "SPECIES", 168, 172], ["patients", "SPECIES", 202, 210], ["patients", "SPECIES", 290, 298], ["P. marneffei", "SPECIES", 30, 42], ["HIV", "SPECIES", 168, 171], ["P. marneffei infection", "PROBLEM", 30, 52], ["tuberculosis", "PROBLEM", 75, 87], ["Respiratory Viral Infections", "PROBLEM", 104, 132], ["HIV", "PROBLEM", 168, 171], ["non-HIV", "PROBLEM", 185, 192], ["respiratory complications", "PROBLEM", 221, 246], ["influenza infection", "PROBLEM", 253, 272], ["underlying conditions", "PROBLEM", 313, 334], ["cardiac or pulmonary disease", "PROBLEM", 343, 371], ["immunosuppression", "TREATMENT", 376, 393], ["differential diagnosis of", "UNCERTAINTY", 4, 29], ["P.", "OBSERVATION_MODIFIER", 30, 32], ["marneffei infection", "OBSERVATION", 33, 52], ["tuberculosis", "OBSERVATION", 75, 87], ["Respiratory", "ANATOMY", 104, 115], ["Viral Infections", "OBSERVATION", 116, 132], ["equal frequency", "OBSERVATION_MODIFIER", 149, 164], ["respiratory", "ANATOMY", 221, 232], ["complications", "OBSERVATION", 233, 246], ["increased", "OBSERVATION_MODIFIER", 277, 286], ["cardiac", "ANATOMY", 343, 350], ["pulmonary", "ANATOMY", 354, 363], ["disease", "OBSERVATION", 364, 371], ["immunosuppression", "OBSERVATION", 376, 393]]], ["In prospective studies of HIVinfected patients undergoing bronchoscopy for evaluation of suspected lower respiratory tract disease, the communityacquired respiratory viral infections (i.e., influenza, parainfluenza, respiratory syncytial virus, rhinovirus, coronavirus and adenovirus) are found only rarely, if at all.CytomegalovirusCMV chronically infects most HIV-infected individuals, and up to 90% of homosexual HIV-infected men shed CMV intermittently in urine, semen, and saliva.", [["lower respiratory tract", "ANATOMY", 99, 122], ["urine", "ANATOMY", 460, 465], ["semen", "ANATOMY", 467, 472], ["lower respiratory tract disease", "DISEASE", 99, 130], ["respiratory viral infections", "DISEASE", 154, 182], ["influenza", "DISEASE", 190, 199], ["parainfluenza", "DISEASE", 201, 214], ["respiratory syncytial virus, rhinovirus, coronavirus and adenovirus)", "DISEASE", 216, 284], ["CytomegalovirusCMV", "CHEMICAL", 318, 336], ["HIV-infected", "DISEASE", 362, 374], ["HIV-infected", "DISEASE", 416, 428], ["patients", "ORGANISM", 38, 46], ["lower", "ORGANISM_SUBDIVISION", 99, 104], ["respiratory tract", "ORGANISM_SUBDIVISION", 105, 122], ["parainfluenza", "ORGANISM", 201, 214], ["respiratory syncytial virus", "ORGANISM", 216, 243], ["rhinovirus", "ORGANISM", 245, 255], ["coronavirus", "ORGANISM", 257, 268], ["adenovirus", "ORGANISM", 273, 283], ["CytomegalovirusCMV", "ORGANISM", 318, 336], ["HIV", "ORGANISM", 362, 365], ["individuals", "ORGANISM", 375, 386], ["homosexual HIV", "ORGANISM", 405, 419], ["men", "ORGANISM", 429, 432], ["CMV", "ORGANISM", 438, 441], ["urine", "ORGANISM_SUBSTANCE", 460, 465], ["semen", "ORGANISM_SUBSTANCE", 467, 472], ["saliva", "ORGANISM_SUBSTANCE", 478, 484], ["patients", "SPECIES", 38, 46], ["parainfluenza", "SPECIES", 201, 214], ["respiratory syncytial virus", "SPECIES", 216, 243], ["rhinovirus, coronavirus", "SPECIES", 245, 268], ["HIV-", "SPECIES", 362, 366], ["HIV-", "SPECIES", 416, 420], ["men", "SPECIES", 429, 432], ["respiratory syncytial virus", "SPECIES", 216, 243], ["HIV", "SPECIES", 362, 365], ["HIV", "SPECIES", 416, 419], ["CMV", "SPECIES", 438, 441], ["bronchoscopy", "TEST", 58, 70], ["evaluation", "TEST", 75, 85], ["suspected lower respiratory tract disease", "PROBLEM", 89, 130], ["the communityacquired respiratory viral infections", "PROBLEM", 132, 182], ["influenza", "PROBLEM", 190, 199], ["parainfluenza", "PROBLEM", 201, 214], ["respiratory syncytial virus", "PROBLEM", 216, 243], ["rhinovirus", "PROBLEM", 245, 255], ["coronavirus", "PROBLEM", 257, 268], ["adenovirus", "PROBLEM", 273, 283], ["CytomegalovirusCMV", "TEST", 318, 336], ["infected individuals", "PROBLEM", 366, 386], ["homosexual HIV", "PROBLEM", 405, 419], ["CMV", "TEST", 438, 441], ["saliva", "PROBLEM", 478, 484], ["lower", "ANATOMY_MODIFIER", 99, 104], ["respiratory tract", "ANATOMY", 105, 122], ["viral infections", "OBSERVATION", 166, 182], ["respiratory syncytial", "ANATOMY", 216, 237]]], ["Clinical disease may be caused by CMV in patients who have advanced HIV infection and CD4 counts <100 cells/mL.", [["cells", "ANATOMY", 102, 107], ["HIV infection", "DISEASE", 68, 81], ["CMV", "ORGANISM", 34, 37], ["patients", "ORGANISM", 41, 49], ["HIV", "ORGANISM", 68, 71], ["CD4", "GENE_OR_GENE_PRODUCT", 86, 89], ["CD4", "PROTEIN", 86, 89], ["patients", "SPECIES", 41, 49], ["HIV", "SPECIES", 68, 71], ["CMV", "SPECIES", 34, 37], ["HIV", "SPECIES", 68, 71], ["Clinical disease", "PROBLEM", 0, 16], ["CMV", "PROBLEM", 34, 37], ["advanced HIV infection", "PROBLEM", 59, 81], ["CD4 counts", "TEST", 86, 96], ["may be caused", "UNCERTAINTY", 17, 30], ["CMV", "OBSERVATION", 34, 37]]], ["Chorioretinitis is most frequently encountered, but encephalitis, adrenalitis, esophagitis, and colitis are also seen.", [["Chorioretinitis", "DISEASE", 0, 15], ["encephalitis", "DISEASE", 52, 64], ["adrenalitis", "DISEASE", 66, 77], ["esophagitis", "DISEASE", 79, 90], ["colitis", "DISEASE", 96, 103], ["colitis", "PATHOLOGICAL_FORMATION", 96, 103], ["Chorioretinitis", "PROBLEM", 0, 15], ["encephalitis", "PROBLEM", 52, 64], ["adrenalitis", "PROBLEM", 66, 77], ["esophagitis", "PROBLEM", 79, 90], ["colitis", "PROBLEM", 96, 103], ["most frequently", "OBSERVATION_MODIFIER", 19, 34], ["encephalitis", "OBSERVATION", 52, 64], ["esophagitis", "OBSERVATION", 79, 90], ["colitis", "OBSERVATION", 96, 103]]], ["Frequently, CMV is isolated from BAL fluid, being found in 40% of samples from patients with CD4 counts <100 cells/mL.", [["BAL fluid", "ANATOMY", 33, 42], ["samples", "ANATOMY", 66, 73], ["CD4", "ANATOMY", 93, 96], ["cells", "ANATOMY", 109, 114], ["CMV", "ORGANISM", 12, 15], ["BAL fluid", "ORGANISM_SUBSTANCE", 33, 42], ["samples", "CANCER", 66, 73], ["patients", "ORGANISM", 79, 87], ["CD4", "GENE_OR_GENE_PRODUCT", 93, 96], ["CD4", "PROTEIN", 93, 96], ["patients", "SPECIES", 79, 87], ["CMV", "SPECIES", 12, 15], ["CMV", "PROBLEM", 12, 15], ["BAL fluid", "TEST", 33, 42], ["CD4 counts", "TEST", 93, 103], ["cells", "TEST", 109, 114], ["CMV", "OBSERVATION", 12, 15], ["BAL fluid", "OBSERVATION", 33, 42]]], ["However, the role of CMV in causing disease in this context is unclear (see later).CytomegalovirusIn patients who have CMV as the sole identified pathogen, clinical presentation and chest radiographic abnormalities (usually diffuse interstitial infiltrates) are nonspecific.", [["chest", "ANATOMY", 182, 187], ["diffuse interstitial infiltrates", "ANATOMY", 224, 256], ["CMV", "ORGANISM", 21, 24], ["CytomegalovirusIn", "ORGANISM", 83, 100], ["patients", "ORGANISM", 101, 109], ["CMV", "ORGANISM", 119, 122], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 232, 256], ["patients", "SPECIES", 101, 109], ["CMV", "SPECIES", 119, 122], ["CMV", "PROBLEM", 21, 24], ["disease", "PROBLEM", 36, 43], ["CMV", "PROBLEM", 119, 122], ["chest radiographic abnormalities", "PROBLEM", 182, 214], ["usually diffuse interstitial infiltrates", "PROBLEM", 216, 256], ["CMV", "OBSERVATION", 21, 24], ["pathogen", "OBSERVATION", 146, 154], ["chest", "ANATOMY", 182, 187], ["diffuse", "OBSERVATION_MODIFIER", 224, 231], ["interstitial", "ANATOMY_MODIFIER", 232, 244], ["infiltrates", "OBSERVATION", 245, 256], ["nonspecific", "OBSERVATION_MODIFIER", 262, 273]]], ["Diagnosis of CMV pneumonitis is made by identifying characteristic intranuclear and intracytoplasmic inclusions, not only in cells in BAL fluid but also in lung biopsy specimens (Figure 34-12 ).LeishmaniasisPulmonary involvement with Leishmania species may rarely occur as part of the syndrome of visceral leishmaniasis in HIV-infected patients.", [["intranuclear", "ANATOMY", 67, 79], ["intracytoplasmic inclusions", "ANATOMY", 84, 111], ["cells", "ANATOMY", 125, 130], ["BAL fluid", "ANATOMY", 134, 143], ["lung biopsy specimens", "ANATOMY", 156, 177], ["visceral", "ANATOMY", 297, 305], ["CMV pneumonitis", "DISEASE", 13, 28], ["Leishmania species", "DISEASE", 234, 252], ["visceral leishmaniasis", "DISEASE", 297, 319], ["HIV-infected", "DISEASE", 323, 335], ["CMV", "ORGANISM", 13, 16], ["intranuclear", "CELLULAR_COMPONENT", 67, 79], ["intracytoplasmic inclusions", "CELLULAR_COMPONENT", 84, 111], ["cells", "CELL", 125, 130], ["BAL fluid", "ORGANISM_SUBSTANCE", 134, 143], ["lung biopsy specimens", "TISSUE", 156, 177], ["Leishmania species", "ORGANISM", 234, 252], ["visceral", "ORGANISM_SUBDIVISION", 297, 305], ["HIV", "ORGANISM", 323, 326], ["patients", "ORGANISM", 336, 344], ["HIV", "SPECIES", 323, 326], ["patients", "SPECIES", 336, 344], ["CMV", "SPECIES", 13, 16], ["HIV", "SPECIES", 323, 326], ["CMV pneumonitis", "PROBLEM", 13, 28], ["characteristic intranuclear and intracytoplasmic inclusions", "PROBLEM", 52, 111], ["BAL fluid", "TEST", 134, 143], ["lung biopsy specimens", "TEST", 156, 177], ["Figure", "TEST", 179, 185], ["LeishmaniasisPulmonary involvement", "PROBLEM", 194, 228], ["Leishmania species", "PROBLEM", 234, 252], ["the syndrome", "PROBLEM", 281, 293], ["visceral leishmaniasis", "PROBLEM", 297, 319], ["CMV pneumonitis", "OBSERVATION", 13, 28], ["intranuclear", "OBSERVATION_MODIFIER", 67, 79], ["intracytoplasmic inclusions", "OBSERVATION", 84, 111], ["not only", "UNCERTAINTY", 113, 121], ["BAL", "ANATOMY", 134, 137], ["fluid", "OBSERVATION", 138, 143], ["lung", "ANATOMY", 156, 160], ["biopsy", "OBSERVATION", 161, 167], ["Leishmania species", "OBSERVATION", 234, 252], ["visceral", "ANATOMY", 297, 305], ["leishmaniasis", "OBSERVATION", 306, 319], ["infected", "OBSERVATION_MODIFIER", 327, 335]]], ["Patients usually have advanced HIV disease with CD4 lymphocyte counts less than 300 cells/mL and present with unexplained fever, splenomegaly, and leukopenia.", [["CD4 lymphocyte", "ANATOMY", 48, 62], ["cells", "ANATOMY", 84, 89], ["HIV disease", "DISEASE", 31, 42], ["fever", "DISEASE", 122, 127], ["splenomegaly", "DISEASE", 129, 141], ["leukopenia", "DISEASE", 147, 157], ["Patients", "ORGANISM", 0, 8], ["HIV", "ORGANISM", 31, 34], ["CD4 lymphocyte", "CELL", 48, 62], ["CD4 lymphocyte", "CELL_TYPE", 48, 62], ["Patients", "SPECIES", 0, 8], ["HIV", "SPECIES", 31, 34], ["advanced HIV disease", "PROBLEM", 22, 42], ["CD4 lymphocyte counts", "TEST", 48, 69], ["unexplained fever", "PROBLEM", 110, 127], ["splenomegaly", "PROBLEM", 129, 141], ["leukopenia", "PROBLEM", 147, 157], ["advanced", "OBSERVATION_MODIFIER", 22, 30], ["HIV disease", "OBSERVATION", 31, 42], ["CD4 lymphocyte", "OBSERVATION", 48, 62], ["unexplained", "OBSERVATION_MODIFIER", 110, 121], ["fever", "OBSERVATION", 122, 127], ["splenomegaly", "OBSERVATION", 129, 141], ["leukopenia", "OBSERVATION", 147, 157]]], ["Respiratory symptoms are often absent.", [["Respiratory", "ANATOMY", 0, 11], ["Respiratory symptoms", "PROBLEM", 0, 20]]], ["Diagnosis of visceral leishmaniasis is most often made by staining a splenic or bone marrow aspirate and subsequent culture.", [["visceral leishmaniasis", "ANATOMY", 13, 35], ["splenic", "ANATOMY", 69, 76], ["bone marrow aspirate", "ANATOMY", 80, 100], ["visceral leishmaniasis", "DISEASE", 13, 35], ["visceral leishmaniasis", "PATHOLOGICAL_FORMATION", 13, 35], ["splenic", "TISSUE", 69, 76], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 80, 91], ["visceral leishmaniasis", "PROBLEM", 13, 35], ["bone marrow aspirate", "TEST", 80, 100], ["subsequent culture", "TEST", 105, 123], ["visceral", "ANATOMY", 13, 21], ["leishmaniasis", "OBSERVATION", 22, 35], ["splenic", "ANATOMY", 69, 76], ["bone", "ANATOMY", 80, 84]]], ["Occasionally, the parasite is found by chance in a skin or rectal biopsy or BAL fluid taken for other purposes.", [["skin", "ANATOMY", 51, 55], ["rectal biopsy", "ANATOMY", 59, 72], ["BAL fluid", "ANATOMY", 76, 85], ["skin", "ORGAN", 51, 55], ["rectal biopsy", "MULTI-TISSUE_STRUCTURE", 59, 72], ["BAL fluid", "ORGANISM_SUBSTANCE", 76, 85], ["a skin or rectal biopsy", "TEST", 49, 72], ["BAL fluid", "TEST", 76, 85], ["other purposes", "TEST", 96, 110], ["parasite", "OBSERVATION", 18, 26], ["skin", "ANATOMY", 51, 55], ["rectal", "ANATOMY", 59, 65], ["biopsy", "OBSERVATION", 66, 72]]], ["The chest radiograph may be negative or show reticular-nodular infiltrates.ToxoplasmosisToxoplasma gondii infection in patients who have AIDS usually occurs as a result of reactivation of latent, intracellular protozoa acquired in a primary infection.", [["chest", "ANATOMY", 4, 9], ["reticular-nodular infiltrates", "ANATOMY", 45, 74], ["intracellular", "ANATOMY", 196, 209], ["ToxoplasmosisToxoplasma gondii infection", "DISEASE", 75, 115], ["AIDS", "DISEASE", 137, 141], ["primary infection", "DISEASE", 233, 250], ["chest", "ORGAN", 4, 9], ["reticular-nodular infiltrates", "PATHOLOGICAL_FORMATION", 45, 74], ["ToxoplasmosisToxoplasma gondii", "ORGANISM", 75, 105], ["patients", "ORGANISM", 119, 127], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 196, 209], ["ToxoplasmosisToxoplasma gondii", "SPECIES", 75, 105], ["patients", "SPECIES", 119, 127], ["ToxoplasmosisToxoplasma gondii", "SPECIES", 75, 105], ["The chest radiograph", "TEST", 0, 20], ["reticular-nodular infiltrates", "PROBLEM", 45, 74], ["ToxoplasmosisToxoplasma gondii infection", "PROBLEM", 75, 115], ["AIDS", "PROBLEM", 137, 141], ["reactivation of latent, intracellular protozoa", "PROBLEM", 172, 218], ["a primary infection", "PROBLEM", 231, 250], ["chest", "ANATOMY", 4, 9], ["reticular", "OBSERVATION_MODIFIER", 45, 54], ["nodular", "OBSERVATION_MODIFIER", 55, 62], ["infiltrates", "OBSERVATION", 63, 74], ["infection", "OBSERVATION", 106, 115], ["primary", "OBSERVATION_MODIFIER", 233, 240], ["infection", "OBSERVATION", 241, 250]]], ["Patients are invariably systemically unwell, with malaise and pyrexia.", [["pyrexia", "DISEASE", 62, 69], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["invariably systemically unwell", "PROBLEM", 13, 43], ["malaise", "PROBLEM", 50, 57], ["pyrexia", "PROBLEM", 62, 69], ["systemically", "OBSERVATION_MODIFIER", 24, 36], ["unwell", "OBSERVATION", 37, 43], ["malaise", "OBSERVATION", 50, 57], ["pyrexia", "OBSERVATION", 62, 69]]], ["Clinical disease in association with HIV infection is most commonly seen in the central nervous system, where it produces single or multiple abscesses.", [["central nervous system", "ANATOMY", 80, 102], ["abscesses", "ANATOMY", 141, 150], ["HIV infection", "DISEASE", 37, 50], ["abscesses", "DISEASE", 141, 150], ["HIV", "ORGANISM", 37, 40], ["central nervous system", "ANATOMICAL_SYSTEM", 80, 102], ["abscesses", "PATHOLOGICAL_FORMATION", 141, 150], ["HIV", "SPECIES", 37, 40], ["HIV", "SPECIES", 37, 40], ["Clinical disease", "PROBLEM", 0, 16], ["HIV infection", "PROBLEM", 37, 50], ["single or multiple abscesses", "PROBLEM", 122, 150], ["disease", "OBSERVATION", 9, 16], ["HIV", "OBSERVATION_MODIFIER", 37, 40], ["infection", "OBSERVATION", 41, 50], ["central", "ANATOMY_MODIFIER", 80, 87], ["nervous system", "ANATOMY", 88, 102], ["single", "OBSERVATION_MODIFIER", 122, 128], ["multiple", "OBSERVATION_MODIFIER", 132, 140], ["abscesses", "OBSERVATION", 141, 150]]], ["Multisystem infection with T. gondii is uncommon in patients who have HIV infection.ToxoplasmosisToxoplasmic pneumonia is frequently difficult to distinguish from PCP.", [["infection", "DISEASE", 12, 21], ["T. gondii", "DISEASE", 27, 36], ["HIV infection", "DISEASE", 70, 83], ["pneumonia", "DISEASE", 109, 118], ["PCP", "DISEASE", 163, 166], ["PCP", "CHEMICAL", 163, 166], ["T. gondii", "ORGANISM", 27, 36], ["patients", "ORGANISM", 52, 60], ["HIV", "ORGANISM", 70, 73], ["T. gondii", "SPECIES", 27, 36], ["patients", "SPECIES", 52, 60], ["HIV", "SPECIES", 70, 73], ["T. gondii", "SPECIES", 27, 36], ["HIV", "SPECIES", 70, 73], ["Multisystem infection", "PROBLEM", 0, 21], ["T. gondii", "PROBLEM", 27, 36], ["HIV infection", "PROBLEM", 70, 83], ["ToxoplasmosisToxoplasmic pneumonia", "PROBLEM", 84, 118], ["PCP", "PROBLEM", 163, 166], ["infection", "OBSERVATION", 12, 21], ["HIV", "OBSERVATION_MODIFIER", 70, 73], ["infection", "OBSERVATION", 74, 83], ["pneumonia", "OBSERVATION", 109, 118]]], ["Nonproductive cough and dyspnea are the symptoms most commonly reported.", [["cough", "DISEASE", 14, 19], ["dyspnea", "DISEASE", 24, 31], ["Nonproductive cough", "PROBLEM", 0, 19], ["dyspnea", "PROBLEM", 24, 31], ["the symptoms", "PROBLEM", 36, 48], ["cough", "OBSERVATION", 14, 19]]], ["Chest radiographic abnormalities include diffuse interstitial infiltrates indistinguishable from those of PCP ( Figure 34-13) , as well as micronodular infiltrates, a coarse nodular infiltrate, cavitary change, and lobar consolidation.", [["diffuse interstitial infiltrates", "ANATOMY", 41, 73], ["micronodular infiltrates", "ANATOMY", 139, 163], ["nodular infiltrate", "ANATOMY", 174, 192], ["cavitary", "ANATOMY", 194, 202], ["lobar", "ANATOMY", 215, 220], ["PCP", "DISEASE", 106, 109], ["interstitial infiltrates", "PATHOLOGICAL_FORMATION", 49, 73], ["Chest radiographic abnormalities", "TEST", 0, 32], ["diffuse interstitial infiltrates", "PROBLEM", 41, 73], ["PCP", "TEST", 106, 109], ["Figure", "TEST", 112, 118], ["micronodular infiltrates", "PROBLEM", 139, 163], ["a coarse nodular infiltrate", "PROBLEM", 165, 192], ["cavitary change", "PROBLEM", 194, 209], ["lobar consolidation", "PROBLEM", 215, 234], ["diffuse", "OBSERVATION_MODIFIER", 41, 48], ["interstitial", "ANATOMY_MODIFIER", 49, 61], ["infiltrates", "OBSERVATION", 62, 73], ["micronodular", "OBSERVATION_MODIFIER", 139, 151], ["infiltrates", "OBSERVATION", 152, 163], ["coarse", "OBSERVATION_MODIFIER", 167, 173], ["nodular", "OBSERVATION_MODIFIER", 174, 181], ["infiltrate", "OBSERVATION", 182, 192], ["cavitary", "OBSERVATION_MODIFIER", 194, 202], ["lobar", "OBSERVATION_MODIFIER", 215, 220], ["consolidation", "OBSERVATION", 221, 234]]], ["The diagnosis is made by hematoxylin-eosin or Giemsa staining of BAL fluid that reveals cysts and trophozoites of T. gondii.", [["BAL fluid", "ANATOMY", 65, 74], ["cysts", "ANATOMY", 88, 93], ["trophozoites", "ANATOMY", 98, 110], ["hematoxylin", "CHEMICAL", 25, 36], ["eosin", "CHEMICAL", 37, 42], ["hematoxylin-eosin", "SIMPLE_CHEMICAL", 25, 42], ["Giemsa", "SIMPLE_CHEMICAL", 46, 52], ["BAL fluid", "ORGANISM_SUBSTANCE", 65, 74], ["cysts", "PATHOLOGICAL_FORMATION", 88, 93], ["trophozoites", "ORGANISM_SUBSTANCE", 98, 110], ["T. gondii", "ORGANISM", 114, 123], ["T. gondii", "SPECIES", 114, 123], ["T. gondii", "SPECIES", 114, 123], ["hematoxylin", "TEST", 25, 36], ["Giemsa staining", "TEST", 46, 61], ["BAL fluid", "TEST", 65, 74], ["cysts", "PROBLEM", 88, 93], ["trophozoites of T. gondii", "PROBLEM", 98, 123], ["BAL", "ANATOMY", 65, 68], ["cysts", "OBSERVATION", 88, 93]]], ["Staining of BAL fluid is not always positive; the diagnostic yield is increased either by staining of transbronchial biopsy material or by performing nucleic acid amplification procedures such as PCR to detect T. gondii DNA in BAL fluid.CryptosporidiosisThe most frequent manifestation of infection with Cryptosporidium species in HIV infection is a noninflammatory diarrhea that may be of high volume, intractable, and life threatening.", [["BAL fluid", "ANATOMY", 12, 21], ["BAL fluid", "ANATOMY", 227, 236], ["nucleic acid", "CHEMICAL", 150, 162], ["Cryptosporidiosis", "DISEASE", 237, 254], ["infection", "DISEASE", 289, 298], ["Cryptosporidium species", "DISEASE", 304, 327], ["HIV infection", "DISEASE", 331, 344], ["diarrhea", "DISEASE", 366, 374], ["BAL fluid", "ORGANISM_SUBSTANCE", 12, 21], ["gondii", "ORGANISM", 213, 219], ["DNA", "CELLULAR_COMPONENT", 220, 223], ["BAL fluid", "ORGANISM_SUBSTANCE", 227, 236], ["Cryptosporidium species", "ORGANISM", 304, 327], ["HIV", "ORGANISM", 331, 334], ["T. gondii", "SPECIES", 210, 219], ["HIV", "SPECIES", 331, 334], ["T. gondii", "SPECIES", 210, 219], ["HIV", "SPECIES", 331, 334], ["Staining of BAL fluid", "TEST", 0, 21], ["transbronchial biopsy material", "TEST", 102, 132], ["nucleic acid amplification procedures", "TREATMENT", 150, 187], ["PCR", "TEST", 196, 199], ["T. gondii DNA in BAL fluid", "PROBLEM", 210, 236], ["Cryptosporidiosis", "PROBLEM", 237, 254], ["infection", "PROBLEM", 289, 298], ["Cryptosporidium species", "PROBLEM", 304, 327], ["HIV infection", "PROBLEM", 331, 344], ["a noninflammatory diarrhea", "PROBLEM", 348, 374], ["high volume", "PROBLEM", 390, 401], ["BAL fluid", "OBSERVATION", 12, 21], ["increased", "OBSERVATION_MODIFIER", 70, 79], ["transbronchial", "ANATOMY", 102, 116], ["gondii DNA", "OBSERVATION", 213, 223], ["BAL fluid", "OBSERVATION", 227, 236], ["most frequent", "OBSERVATION_MODIFIER", 258, 271], ["infection", "OBSERVATION", 289, 298], ["Cryptosporidium species", "OBSERVATION", 304, 327], ["HIV", "OBSERVATION_MODIFIER", 331, 334], ["infection", "OBSERVATION", 335, 344], ["noninflammatory", "OBSERVATION_MODIFIER", 350, 365], ["may be of", "UNCERTAINTY", 380, 389], ["high volume", "OBSERVATION", 390, 401], ["intractable", "OBSERVATION_MODIFIER", 403, 414]]], ["Cryptosporidium species may colonize epithelial surfaces, including the trachea and lungs, occasionally resulting in pulmonary infection.", [["epithelial surfaces", "ANATOMY", 37, 56], ["trachea", "ANATOMY", 72, 79], ["lungs", "ANATOMY", 84, 89], ["pulmonary", "ANATOMY", 117, 126], ["pulmonary infection", "DISEASE", 117, 136], ["Cryptosporidium", "ORGANISM", 0, 15], ["epithelial surfaces", "TISSUE", 37, 56], ["trachea", "ORGAN", 72, 79], ["lungs", "ORGAN", 84, 89], ["pulmonary", "ORGAN", 117, 126], ["Cryptosporidium species", "PROBLEM", 0, 23], ["pulmonary infection", "PROBLEM", 117, 136], ["colonize epithelial surfaces", "OBSERVATION", 28, 56], ["trachea", "ANATOMY", 72, 79], ["lungs", "ANATOMY", 84, 89], ["pulmonary", "ANATOMY", 117, 126], ["infection", "OBSERVATION", 127, 136]]], ["Most cases of pulmonary cryptosporidiosis have co-pathology such as PCP or bacterial pneumonia; ascertaining the exact role of cryptosporidiosis as the cause of respiratory symptoms may be difficult.", [["pulmonary", "ANATOMY", 14, 23], ["respiratory", "ANATOMY", 161, 172], ["pulmonary cryptosporidiosis", "DISEASE", 14, 41], ["PCP", "DISEASE", 68, 71], ["bacterial pneumonia", "DISEASE", 75, 94], ["cryptosporidiosis", "DISEASE", 127, 144], ["respiratory symptoms", "DISEASE", 161, 181], ["pulmonary", "ORGAN", 14, 23], ["pulmonary cryptosporidiosis", "PROBLEM", 14, 41], ["co-pathology", "PROBLEM", 47, 59], ["PCP", "PROBLEM", 68, 71], ["bacterial pneumonia", "PROBLEM", 75, 94], ["cryptosporidiosis", "PROBLEM", 127, 144], ["respiratory symptoms", "PROBLEM", 161, 181], ["pulmonary", "ANATOMY", 14, 23], ["cryptosporidiosis", "OBSERVATION", 24, 41], ["bacterial", "OBSERVATION_MODIFIER", 75, 84], ["pneumonia", "OBSERVATION", 85, 94], ["cryptosporidiosis", "OBSERVATION", 127, 144]]], ["Diagnosis is made by Ziehl-Neelsen or auramine-rhodamine staining of BAL fluid or transbronchial biopsy specimens.MicrosporidiosisPulmonary Microsporidia infection may occur as part of systemic dissemination from gastrointestinal infection with Septata intestinalis or Encephalitozoon hellem.", [["BAL fluid", "ANATOMY", 69, 78], ["transbronchial biopsy specimens", "ANATOMY", 82, 113], ["gastrointestinal", "ANATOMY", 213, 229], ["Ziehl-Neelsen", "CHEMICAL", 21, 34], ["auramine-rhodamine", "CHEMICAL", 38, 56], ["Microsporidia infection", "DISEASE", 140, 163], ["gastrointestinal infection", "DISEASE", 213, 239], ["Septata intestinalis", "DISEASE", 245, 265], ["auramine", "CHEMICAL", 38, 46], ["rhodamine", "CHEMICAL", 47, 56], ["Ziehl-Neelsen", "SIMPLE_CHEMICAL", 21, 34], ["auramine", "SIMPLE_CHEMICAL", 38, 46], ["rhodamine", "SIMPLE_CHEMICAL", 47, 56], ["BAL fluid", "ORGANISM_SUBSTANCE", 69, 78], ["transbronchial biopsy specimens", "CANCER", 82, 113], ["gastrointestinal", "ORGANISM_SUBDIVISION", 213, 229], ["Septata intestinalis", "ORGANISM", 245, 265], ["Encephalitozoon hellem", "ORGANISM", 269, 291], ["Septata intestinalis", "SPECIES", 245, 265], ["Septata intestinalis", "SPECIES", 245, 265], ["Encephalitozoon hellem", "SPECIES", 269, 291], ["auramine", "TREATMENT", 38, 46], ["BAL fluid", "TEST", 69, 78], ["transbronchial biopsy specimens", "TEST", 82, 113], ["MicrosporidiosisPulmonary Microsporidia infection", "PROBLEM", 114, 163], ["systemic dissemination", "PROBLEM", 185, 207], ["gastrointestinal infection", "PROBLEM", 213, 239], ["Septata intestinalis", "PROBLEM", 245, 265], ["Encephalitozoon hellem", "PROBLEM", 269, 291], ["BAL", "ANATOMY", 69, 72], ["transbronchial", "ANATOMY", 82, 96], ["Microsporidia infection", "OBSERVATION", 140, 163], ["systemic", "OBSERVATION_MODIFIER", 185, 193], ["dissemination", "OBSERVATION", 194, 207], ["gastrointestinal", "ANATOMY", 213, 229], ["infection", "OBSERVATION", 230, 239], ["Encephalitozoon hellem", "OBSERVATION", 269, 291]]], ["The organism may be identified by conventional staining in BAL fluid.", [["BAL fluid", "ANATOMY", 59, 68], ["BAL fluid", "ORGANISM_SUBSTANCE", 59, 68], ["conventional staining in BAL fluid", "PROBLEM", 34, 68], ["may be identified", "UNCERTAINTY", 13, 30], ["staining", "OBSERVATION", 47, 55], ["BAL fluid", "OBSERVATION", 59, 68]]], ["Electron microscopy is necessary to distinguish the two species.StrongyloidiasisThe nematode Strong yloides stercoralis is endemic in warm countries worldwide.", [["Strongyloidiasis", "DISEASE", 64, 80], ["Strong yloides stercoralis", "DISEASE", 93, 119], ["nematode Strong yloides stercoralis", "ORGANISM", 84, 119], ["Strong yloides stercoralis", "SPECIES", 93, 119], ["Strong yloides stercoralis", "SPECIES", 93, 119], ["Electron microscopy", "TEST", 0, 19], ["the two species", "PROBLEM", 48, 63], ["Strongyloidiasis", "PROBLEM", 64, 80], ["nematode", "OBSERVATION_MODIFIER", 84, 92], ["Strong", "OBSERVATION_MODIFIER", 93, 99], ["endemic", "OBSERVATION_MODIFIER", 123, 130]]], ["In immunosuppressed patients, the organism has an increased ability to reproduce parthenogenetically in the gastrointestinal tract without the need for repeated exposure to new infection-so-called autoinfection.", [["gastrointestinal tract", "ANATOMY", 108, 130], ["infection", "DISEASE", 177, 186], ["autoinfection", "DISEASE", 197, 210], ["patients", "ORGANISM", 20, 28], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 108, 130], ["patients", "SPECIES", 20, 28], ["the organism", "PROBLEM", 30, 42], ["an increased ability", "PROBLEM", 47, 67], ["new infection", "PROBLEM", 173, 186], ["autoinfection", "PROBLEM", 197, 210], ["immunosuppressed", "OBSERVATION", 3, 19], ["increased", "OBSERVATION_MODIFIER", 50, 59], ["gastrointestinal tract", "ANATOMY", 108, 130], ["new", "OBSERVATION_MODIFIER", 173, 176], ["infection", "OBSERVATION", 177, 186]]], ["This results in a great increase in worm load and a hyperinfective state ensues; massive acute dissemination with S. stercoralis may occur in the lungs, kidneys, pancreas, and brain.", [["worm", "ANATOMY", 36, 40], ["lungs", "ANATOMY", 146, 151], ["kidneys", "ANATOMY", 153, 160], ["pancreas", "ANATOMY", 162, 170], ["brain", "ANATOMY", 176, 181], ["S. stercoralis", "DISEASE", 114, 128], ["worm", "ORGANISM_SUBDIVISION", 36, 40], ["S. stercoralis", "ORGANISM", 114, 128], ["lungs", "ORGAN", 146, 151], ["kidneys", "ORGAN", 153, 160], ["pancreas", "ORGAN", 162, 170], ["brain", "ORGAN", 176, 181], ["S. stercoralis", "SPECIES", 114, 128], ["S. stercoralis", "SPECIES", 114, 128], ["a great increase in worm load", "PROBLEM", 16, 45], ["a hyperinfective state ensues", "PROBLEM", 50, 79], ["massive acute dissemination", "PROBLEM", 81, 108], ["S. stercoralis", "PROBLEM", 114, 128], ["great", "OBSERVATION_MODIFIER", 18, 23], ["increase", "OBSERVATION_MODIFIER", 24, 32], ["worm load", "OBSERVATION", 36, 45], ["massive", "OBSERVATION_MODIFIER", 81, 88], ["acute", "OBSERVATION_MODIFIER", 89, 94], ["dissemination", "OBSERVATION", 95, 108], ["stercoralis", "OBSERVATION", 117, 128], ["lungs", "ANATOMY", 146, 151], ["kidneys", "ANATOMY", 153, 160], ["pancreas", "ANATOMY", 162, 170], ["brain", "ANATOMY", 176, 181]]], ["Although infection with S. stercoralis is more severe in immunocompromised patients, it is no more common in patients who have HIV infection.", [["infection", "DISEASE", 9, 18], ["S. stercoralis", "DISEASE", 24, 38], ["HIV infection", "DISEASE", 127, 140], ["S. stercoralis", "ORGANISM", 24, 38], ["patients", "ORGANISM", 75, 83], ["patients", "ORGANISM", 109, 117], ["HIV", "ORGANISM", 127, 130], ["S. stercoralis", "SPECIES", 24, 38], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 109, 117], ["HIV", "SPECIES", 127, 130], ["S. stercoralis", "SPECIES", 24, 38], ["HIV", "SPECIES", 127, 130], ["infection", "PROBLEM", 9, 18], ["S. stercoralis", "PROBLEM", 24, 38], ["HIV infection", "PROBLEM", 127, 140], ["infection", "OBSERVATION", 9, 18], ["stercoralis", "OBSERVATION", 27, 38], ["more severe", "OBSERVATION_MODIFIER", 42, 53], ["immunocompromised", "OBSERVATION", 57, 74], ["no more", "UNCERTAINTY", 91, 98], ["HIV", "OBSERVATION_MODIFIER", 127, 130], ["infection", "OBSERVATION", 131, 140]]], ["Presentation with hyperinfection may be with fever, hypotension secondary to bacterial sepsis, or disseminated intravascular coagulation.", [["intravascular", "ANATOMY", 111, 124], ["hyperinfection", "DISEASE", 18, 32], ["fever", "DISEASE", 45, 50], ["hypotension", "DISEASE", 52, 63], ["bacterial sepsis", "DISEASE", 77, 93], ["intravascular coagulation", "DISEASE", 111, 136], ["intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 111, 124], ["hyperinfection", "PROBLEM", 18, 32], ["fever", "PROBLEM", 45, 50], ["hypotension", "PROBLEM", 52, 63], ["bacterial sepsis", "PROBLEM", 77, 93], ["disseminated intravascular coagulation", "PROBLEM", 98, 136], ["hyperinfection", "OBSERVATION", 18, 32], ["may be with", "UNCERTAINTY", 33, 44], ["fever", "OBSERVATION", 45, 50], ["bacterial", "OBSERVATION_MODIFIER", 77, 86], ["sepsis", "OBSERVATION", 87, 93], ["disseminated", "OBSERVATION_MODIFIER", 98, 110], ["intravascular coagulation", "OBSERVATION", 111, 136]]], ["The clinical features of respiratory S. stercoralis infection are nonspecific.", [["respiratory S. stercoralis infection", "DISEASE", 25, 61], ["respiratory", "ORGANISM", 25, 36], ["S. stercoralis", "ORGANISM", 37, 51], ["S. stercoralis", "SPECIES", 37, 51], ["S. stercoralis", "SPECIES", 37, 51], ["respiratory S. stercoralis infection", "PROBLEM", 25, 61], ["respiratory S.", "OBSERVATION", 25, 39], ["stercoralis infection", "OBSERVATION", 40, 61], ["nonspecific", "OBSERVATION_MODIFIER", 66, 77]]], ["S. stercoralis in sputum or BAL fluid (Figure 34 -14) may be identified in HIV-positive patients in the absence of symptoms elsewhere; this can predate disseminated infection and, as such, requires prompt treatment.DIAGNOSISIt is apparent from the foregoing discussion that HIV-related pneumonia of any cause may present in a similar manner.", [["sputum", "ANATOMY", 18, 24], ["BAL fluid", "ANATOMY", 28, 37], ["S. stercoralis", "DISEASE", 0, 14], ["HIV-positive", "DISEASE", 75, 87], ["infection", "DISEASE", 165, 174], ["pneumonia", "DISEASE", 286, 295], ["S. stercoralis", "ORGANISM", 0, 14], ["sputum", "ORGANISM_SUBSTANCE", 18, 24], ["BAL fluid", "ORGANISM_SUBSTANCE", 28, 37], ["HIV", "ORGANISM", 75, 78], ["patients", "ORGANISM", 88, 96], ["HIV", "ORGANISM", 274, 277], ["S. stercoralis", "SPECIES", 0, 14], ["HIV", "SPECIES", 75, 78], ["patients", "SPECIES", 88, 96], ["S. stercoralis", "SPECIES", 0, 14], ["HIV", "SPECIES", 75, 78], ["HIV", "SPECIES", 274, 277], ["S. stercoralis in sputum", "TEST", 0, 24], ["BAL fluid (Figure", "TEST", 28, 45], ["symptoms", "PROBLEM", 115, 123], ["disseminated infection", "PROBLEM", 152, 174], ["prompt treatment", "TREATMENT", 198, 214], ["HIV", "PROBLEM", 274, 277], ["pneumonia", "PROBLEM", 286, 295], ["stercoralis", "OBSERVATION", 3, 14], ["sputum", "OBSERVATION", 18, 24], ["BAL fluid", "OBSERVATION", 28, 37], ["disseminated", "OBSERVATION_MODIFIER", 152, 164], ["infection", "OBSERVATION", 165, 174], ["pneumonia", "OBSERVATION", 286, 295]]], ["A wide range of investigations is available to aid diagnosis.", [["wide", "OBSERVATION_MODIFIER", 2, 6]]], ["If the subject is producing sputum, it is important to obtain samples for bacterial and mycobacterial detection.", [["sputum", "ANATOMY", 28, 34], ["samples", "ANATOMY", 62, 69], ["sputum", "ORGANISM_SUBSTANCE", 28, 34], ["sputum", "PROBLEM", 28, 34], ["bacterial and mycobacterial detection", "PROBLEM", 74, 111], ["sputum", "OBSERVATION", 28, 34]]], ["Three samples on consecutive days (preferably either with overnight or early morning production) is the critical first step in the diagnosis of pulmonary tuberculosis.", [["samples", "ANATOMY", 6, 13], ["pulmonary", "ANATOMY", 144, 153], ["pulmonary tuberculosis", "DISEASE", 144, 166], ["pulmonary", "ORGAN", 144, 153], ["pulmonary tuberculosis", "PROBLEM", 144, 166], ["pulmonary", "ANATOMY", 144, 153], ["tuberculosis", "OBSERVATION", 154, 166]]], ["This is considerably easier and safer for health care personnel than obtaining hypertonic saline-induced sputum or BAL fluid.", [["sputum", "ANATOMY", 105, 111], ["BAL fluid", "ANATOMY", 115, 124], ["saline", "SIMPLE_CHEMICAL", 90, 96], ["sputum", "ORGANISM_SUBSTANCE", 105, 111], ["BAL fluid", "ORGANISM_SUBSTANCE", 115, 124], ["hypertonic saline", "TREATMENT", 79, 96], ["induced sputum or BAL fluid", "PROBLEM", 97, 124], ["BAL", "ANATOMY", 115, 118], ["fluid", "OBSERVATION", 119, 124]]], ["Blood cultures are also important, because very high rates of bacteremia have been reported in both bacterial and mycobacterial disease (see earlier).DIAGNOSISA patient who is initially seen with symptoms and signs consistent with pneumonia should have chest radiography and arterial oxygen assessments performed at his or her first consultation.", [["Blood cultures", "ANATOMY", 0, 14], ["chest", "ANATOMY", 253, 258], ["arterial", "ANATOMY", 275, 283], ["bacteremia", "DISEASE", 62, 72], ["bacterial and mycobacterial disease", "DISEASE", 100, 135], ["pneumonia", "DISEASE", 231, 240], ["oxygen", "CHEMICAL", 284, 290], ["oxygen", "CHEMICAL", 284, 290], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["patient", "ORGANISM", 161, 168], ["arterial", "MULTI-TISSUE_STRUCTURE", 275, 283], ["oxygen", "SIMPLE_CHEMICAL", 284, 290], ["patient", "SPECIES", 161, 168], ["Blood cultures", "TEST", 0, 14], ["bacteremia", "PROBLEM", 62, 72], ["both bacterial and mycobacterial disease", "PROBLEM", 95, 135], ["symptoms", "PROBLEM", 196, 204], ["signs", "PROBLEM", 209, 214], ["pneumonia", "PROBLEM", 231, 240], ["chest radiography", "TEST", 253, 270], ["arterial oxygen assessments", "TEST", 275, 302], ["bacteremia", "OBSERVATION", 62, 72], ["bacterial", "OBSERVATION_MODIFIER", 100, 109], ["mycobacterial disease", "OBSERVATION", 114, 135], ["consistent with", "UNCERTAINTY", 215, 230], ["pneumonia", "OBSERVATION", 231, 240], ["chest", "ANATOMY", 253, 258], ["arterial", "ANATOMY", 275, 283]]], ["The question at this stage is usually whether this infectious episode is due to bacterial infection, tuberculosis, or PCP.", [["bacterial infection", "DISEASE", 80, 99], ["tuberculosis", "DISEASE", 101, 113], ["PCP", "DISEASE", 118, 121], ["PCP", "CHEMICAL", 118, 121], ["this infectious episode", "PROBLEM", 46, 69], ["bacterial infection", "PROBLEM", 80, 99], ["tuberculosis", "PROBLEM", 101, 113], ["PCP", "PROBLEM", 118, 121], ["infectious", "OBSERVATION", 51, 61], ["due to", "UNCERTAINTY", 73, 79], ["bacterial", "OBSERVATION_MODIFIER", 80, 89], ["infection", "OBSERVATION", 90, 99], ["tuberculosis", "OBSERVATION", 101, 113]]], ["In general, alveolar and interstitial shadowing is taken as evidence for PCP, although important caveats apply.Arterial Oxygen AssessmentsTranscutaneous pulse oximetry and arterial blood gas analysis are useful tests for hypoxemia.", [["alveolar", "ANATOMY", 12, 20], ["interstitial", "ANATOMY", 25, 37], ["Arterial", "ANATOMY", 111, 119], ["arterial blood", "ANATOMY", 172, 186], ["PCP", "DISEASE", 73, 76], ["Oxygen", "CHEMICAL", 120, 126], ["hypoxemia", "DISEASE", 221, 230], ["PCP", "CHEMICAL", 73, 76], ["Oxygen", "CHEMICAL", 120, 126], ["alveolar", "MULTI-TISSUE_STRUCTURE", 12, 20], ["interstitial", "MULTI-TISSUE_STRUCTURE", 25, 37], ["Arterial", "MULTI-TISSUE_STRUCTURE", 111, 119], ["blood", "ORGANISM_SUBSTANCE", 181, 186], ["alveolar and interstitial shadowing", "PROBLEM", 12, 47], ["PCP", "PROBLEM", 73, 76], ["Arterial Oxygen Assessments", "TEST", 111, 138], ["Transcutaneous pulse oximetry", "TEST", 138, 167], ["arterial blood gas analysis", "TEST", 172, 199], ["useful tests", "TEST", 204, 216], ["hypoxemia", "PROBLEM", 221, 230], ["alveolar", "ANATOMY", 12, 20], ["interstitial", "ANATOMY_MODIFIER", 25, 37], ["shadowing", "OBSERVATION", 38, 47]]], ["They can be used to distinguish an alveolar condition (i.e., PCP) from bacterial pneumonia.", [["alveolar", "ANATOMY", 35, 43], ["PCP", "DISEASE", 61, 64], ["pneumonia", "DISEASE", 81, 90], ["alveolar", "MULTI-TISSUE_STRUCTURE", 35, 43], ["an alveolar condition", "PROBLEM", 32, 53], ["bacterial pneumonia", "PROBLEM", 71, 90], ["alveolar", "ANATOMY", 35, 43], ["bacterial", "OBSERVATION_MODIFIER", 71, 80], ["pneumonia", "OBSERVATION", 81, 90]]], ["The alveolitis produces a greater impairment of oxygen transfer (especially during exercise), such that for a given clinical situation there will be more hypoxemia and a wider alveolararterial oxygen gradient (A-aO 2 ) in those with PCP.", [["alveolararterial", "ANATOMY", 176, 192], ["alveolitis", "DISEASE", 4, 14], ["oxygen", "CHEMICAL", 48, 54], ["hypoxemia", "DISEASE", 154, 163], ["oxygen", "CHEMICAL", 193, 199], ["PCP", "DISEASE", 233, 236], ["oxygen", "CHEMICAL", 48, 54], ["oxygen", "CHEMICAL", 193, 199], ["PCP", "CHEMICAL", 233, 236], ["oxygen", "SIMPLE_CHEMICAL", 48, 54], ["oxygen", "SIMPLE_CHEMICAL", 193, 199], ["The alveolitis", "PROBLEM", 0, 14], ["hypoxemia", "PROBLEM", 154, 163], ["a wider alveolararterial oxygen gradient", "PROBLEM", 168, 208], ["alveolitis", "OBSERVATION", 4, 14], ["greater", "OBSERVATION_MODIFIER", 26, 33], ["impairment", "OBSERVATION_MODIFIER", 34, 44], ["oxygen transfer", "OBSERVATION", 48, 63], ["hypoxemia", "OBSERVATION", 154, 163], ["oxygen gradient", "OBSERVATION", 193, 208]]], ["With pulse oximetry, this manifests as low oxygen saturations at rest that decrease further with exercise.", [["oxygen", "CHEMICAL", 43, 49], ["oxygen", "CHEMICAL", 43, 49], ["oxygen", "SIMPLE_CHEMICAL", 43, 49], ["pulse oximetry", "TEST", 5, 19], ["low oxygen saturations", "PROBLEM", 39, 61]]], ["In general, more information can be obtained from arterial blood gas analysis, although this advantage is offset by the need for direct arterial puncture.Arterial Oxygen AssessmentsOf patients with PCP, fewer than 10% have a normal PaO 2 and a normal A-aO 2 .", [["arterial blood", "ANATOMY", 50, 64], ["arterial", "ANATOMY", 136, 144], ["Arterial", "ANATOMY", 154, 162], ["Oxygen", "CHEMICAL", 163, 169], ["PCP", "DISEASE", 198, 201], ["Oxygen", "CHEMICAL", 163, 169], ["PCP", "CHEMICAL", 198, 201], ["arterial", "MULTI-TISSUE_STRUCTURE", 50, 58], ["blood", "ORGANISM_SUBSTANCE", 59, 64], ["arterial puncture", "MULTI-TISSUE_STRUCTURE", 136, 153], ["Arterial", "MULTI-TISSUE_STRUCTURE", 154, 162], ["patients", "ORGANISM", 184, 192], ["patients", "SPECIES", 184, 192], ["arterial blood gas analysis", "TEST", 50, 77], ["direct arterial puncture", "TEST", 129, 153], ["PCP", "TEST", 198, 201]]], ["These measures are sensitive, although not particularly specific for PCP, and similar results may occur with bacterial pneumonia, pulmonary Kaposi sarcoma, and M. tuberculosis infection.", [["pulmonary Kaposi sarcoma", "ANATOMY", 130, 154], ["PCP", "DISEASE", 69, 72], ["pneumonia", "DISEASE", 119, 128], ["pulmonary Kaposi sarcoma", "DISEASE", 130, 154], ["M. tuberculosis infection", "DISEASE", 160, 185], ["PCP", "CHEMICAL", 69, 72], ["pulmonary Kaposi sarcoma", "CANCER", 130, 154], ["M. tuberculosis", "ORGANISM", 160, 175], ["M. tuberculosis", "SPECIES", 160, 175], ["M. tuberculosis", "SPECIES", 160, 175], ["PCP", "PROBLEM", 69, 72], ["bacterial pneumonia", "PROBLEM", 109, 128], ["pulmonary Kaposi sarcoma", "PROBLEM", 130, 154], ["M. tuberculosis infection", "PROBLEM", 160, 185], ["bacterial", "OBSERVATION_MODIFIER", 109, 118], ["pneumonia", "OBSERVATION", 119, 128], ["pulmonary", "ANATOMY", 130, 139], ["Kaposi sarcoma", "OBSERVATION", 140, 154], ["M.", "OBSERVATION_MODIFIER", 160, 162], ["tuberculosis", "OBSERVATION_MODIFIER", 163, 175], ["infection", "OBSERVATION", 176, 185]]], ["The diagnostic value of identifying exercise-induced desaturation, measured by transcutaneous oximetry, has been validated only in HIV-infected patients who have PCP and a normal or \"near normal\" appearance on chest radiographs.", [["chest", "ANATOMY", 210, 215], ["desaturation", "DISEASE", 53, 65], ["HIV-infected", "DISEASE", 131, 143], ["PCP", "DISEASE", 162, 165], ["HIV", "ORGANISM", 131, 134], ["patients", "ORGANISM", 144, 152], ["chest", "ORGANISM_SUBDIVISION", 210, 215], ["patients", "SPECIES", 144, 152], ["HIV", "SPECIES", 131, 134], ["induced desaturation", "PROBLEM", 45, 65], ["transcutaneous oximetry", "TEST", 79, 102], ["PCP", "PROBLEM", 162, 165], ["chest radiographs", "TEST", 210, 227], ["normal", "OBSERVATION", 172, 178], ["chest", "ANATOMY", 210, 215]]], ["The test's value has not been confirmed in patients with abnormal chest radiographs because of PCP or other pathogens.", [["chest", "ANATOMY", 66, 71], ["PCP", "DISEASE", 95, 98], ["patients", "ORGANISM", 43, 51], ["chest", "ORGANISM_SUBDIVISION", 66, 71], ["patients", "SPECIES", 43, 51], ["The test's value", "TEST", 0, 16], ["abnormal chest radiographs", "TEST", 57, 83], ["PCP", "PROBLEM", 95, 98], ["other pathogens", "PROBLEM", 102, 117], ["chest", "ANATOMY", 66, 71], ["pathogens", "OBSERVATION", 108, 117]]], ["Exercise-induced desaturation may persist for many weeks after treatment and recovery from PCP, even in the absence of active pulmonary disease.Lung Function TestingAbnormalities of lung function are well documented with HIV infection.", [["pulmonary", "ANATOMY", 126, 135], ["Lung", "ANATOMY", 144, 148], ["lung", "ANATOMY", 182, 186], ["desaturation", "DISEASE", 17, 29], ["PCP", "DISEASE", 91, 94], ["pulmonary disease", "DISEASE", 126, 143], ["HIV infection", "DISEASE", 221, 234], ["PCP", "CHEMICAL", 91, 94], ["pulmonary", "ORGAN", 126, 135], ["Lung", "ORGAN", 144, 148], ["lung", "ORGAN", 182, 186], ["HIV", "ORGANISM", 221, 224], ["HIV", "SPECIES", 221, 224], ["induced desaturation", "PROBLEM", 9, 29], ["treatment", "TREATMENT", 63, 72], ["active pulmonary disease", "PROBLEM", 119, 143], ["Lung Function", "TEST", 144, 157], ["lung function", "TEST", 182, 195], ["HIV infection", "PROBLEM", 221, 234], ["desaturation", "OBSERVATION", 17, 29], ["active", "OBSERVATION_MODIFIER", 119, 125], ["pulmonary", "ANATOMY", 126, 135], ["disease", "OBSERVATION", 136, 143], ["lung", "ANATOMY", 182, 186], ["infection", "OBSERVATION", 225, 234]]], ["The most common of these relate to tests measuring gas exchange, rather than the size of the conducting airways.", [["airways", "ANATOMY", 104, 111], ["airways", "MULTI-TISSUE_STRUCTURE", 104, 111], ["tests", "TEST", 35, 40], ["gas exchange", "TEST", 51, 63], ["most common", "OBSERVATION_MODIFIER", 4, 15], ["gas exchange", "OBSERVATION", 51, 63], ["size", "OBSERVATION_MODIFIER", 81, 85], ["airways", "ANATOMY", 104, 111]]], ["In general, an overall reduction in diffusing capacity for carbon monoxide (DLCO) occurs at all stages of HIV infection, with the largest changes found in HIV-infected patients with PCP.", [["carbon monoxide", "CHEMICAL", 59, 74], ["HIV infection", "DISEASE", 106, 119], ["HIV-infected", "DISEASE", 155, 167], ["PCP", "DISEASE", 182, 185], ["carbon monoxide", "CHEMICAL", 59, 74], ["PCP", "CHEMICAL", 182, 185], ["carbon monoxide", "SIMPLE_CHEMICAL", 59, 74], ["HIV", "ORGANISM", 106, 109], ["HIV", "ORGANISM", 155, 158], ["patients", "ORGANISM", 168, 176], ["HIV", "SPECIES", 155, 158], ["patients", "SPECIES", 168, 176], ["HIV", "SPECIES", 106, 109], ["HIV", "SPECIES", 155, 158], ["diffusing capacity", "PROBLEM", 36, 54], ["carbon monoxide (DLCO)", "TREATMENT", 59, 81], ["HIV infection", "PROBLEM", 106, 119], ["PCP", "PROBLEM", 182, 185], ["reduction", "OBSERVATION_MODIFIER", 23, 32], ["HIV", "OBSERVATION_MODIFIER", 106, 109], ["infection", "OBSERVATION", 110, 119], ["largest", "OBSERVATION_MODIFIER", 130, 137]]], ["Thus, to some extent, patients who have probable PCP can be differentiated and treatment guided.", [["PCP", "DISEASE", 49, 52], ["PCP", "CHEMICAL", 49, 52], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["PCP", "PROBLEM", 49, 52]]], ["A normal DLCO in an individual who has symptoms but a negative or unchanged chest radiograph makes the diagnosis of PCP extremely unlikely.", [["PCP", "DISEASE", 116, 119], ["PCP", "CHEMICAL", 116, 119], ["symptoms", "PROBLEM", 39, 47], ["unchanged chest radiograph", "TEST", 66, 92], ["PCP", "PROBLEM", 116, 119], ["normal DLCO", "OBSERVATION", 2, 13], ["chest", "ANATOMY", 76, 81]]], ["Data from the North American PSPC cohort study suggest that individuals with rapid rates of decline in DLCO are at an increased risk for development of PCP.", [["PCP", "DISEASE", 152, 155], ["PCP", "CHEMICAL", 152, 155], ["PSPC cohort study", "TEST", 29, 46], ["decline in DLCO", "PROBLEM", 92, 107], ["PCP", "PROBLEM", 152, 155]]], ["Recent work suggests that HIV-infected smokers are at increased risk of early-onset emphysema.", [["HIV-infected", "DISEASE", 26, 38], ["emphysema", "DISEASE", 84, 93], ["HIV", "ORGANISM", 26, 29], ["smokers", "ORGANISM", 39, 46], ["emphysema", "PATHOLOGICAL_FORMATION", 84, 93], ["HIV-", "SPECIES", 26, 30], ["HIV", "SPECIES", 26, 29], ["HIV", "PROBLEM", 26, 29], ["early-onset emphysema", "PROBLEM", 72, 93], ["infected", "OBSERVATION_MODIFIER", 30, 38], ["smokers", "OBSERVATION", 39, 46], ["early", "OBSERVATION_MODIFIER", 72, 77], ["-onset", "OBSERVATION_MODIFIER", 77, 83], ["emphysema", "OBSERVATION", 84, 93]]], ["Smoking history must, therefore, be taken into account when assessing a patient's lung function results in the context of possible PCP.Computed Tomography ScanningHigh-resolution (fine-cut) CT scanning of the chest may be helpful when the chest radiograph is normal, unchanged, or equivocal.", [["lung", "ANATOMY", 82, 86], ["chest", "ANATOMY", 209, 214], ["chest", "ANATOMY", 239, 244], ["PCP", "DISEASE", 131, 134], ["PCP", "CHEMICAL", 131, 134], ["patient", "ORGANISM", 72, 79], ["lung", "ORGAN", 82, 86], ["chest", "ORGAN", 209, 214], ["chest", "ORGAN", 239, 244], ["patient", "SPECIES", 72, 79], ["a patient's lung function", "TEST", 70, 95], ["PCP", "PROBLEM", 131, 134], ["Computed Tomography Scanning", "TEST", 135, 163], ["CT scanning of the chest", "TEST", 190, 214], ["the chest radiograph", "TEST", 235, 255], ["lung", "ANATOMY", 82, 86], ["chest", "ANATOMY", 209, 214], ["chest", "ANATOMY", 239, 244], ["normal", "OBSERVATION", 259, 265], ["unchanged", "OBSERVATION_MODIFIER", 267, 276]]], ["The characteristic appearance of an alveolitis (i.e., areas of ground-glass attenuation through which the pulmonary vessels can be clearly identified) may be present, which indicates active pulmonary disease (Figure 34-15 ).", [["pulmonary vessels", "ANATOMY", 106, 123], ["pulmonary", "ANATOMY", 190, 199], ["alveolitis", "DISEASE", 36, 46], ["pulmonary disease", "DISEASE", 190, 207], ["pulmonary vessels", "MULTI-TISSUE_STRUCTURE", 106, 123], ["pulmonary", "ORGAN", 190, 199], ["an alveolitis", "PROBLEM", 33, 46], ["ground-glass attenuation", "PROBLEM", 63, 87], ["active pulmonary disease", "PROBLEM", 183, 207], ["Figure", "TEST", 209, 215], ["alveolitis", "OBSERVATION", 36, 46], ["areas", "OBSERVATION_MODIFIER", 54, 59], ["ground-", "OBSERVATION_MODIFIER", 63, 70], ["glass attenuation", "OBSERVATION", 70, 87], ["pulmonary vessels", "ANATOMY", 106, 123], ["active", "OBSERVATION_MODIFIER", 183, 189], ["pulmonary", "ANATOMY", 190, 199], ["disease", "OBSERVATION", 200, 207]]], ["This feature, however, is neither sensitive nor specific for PCP, although its sensitivity can be improved if evidence for reticulation and/or small cystic lesions is added to this.", [["cystic lesions", "ANATOMY", 149, 163], ["PCP", "DISEASE", 61, 64], ["PCP", "CHEMICAL", 61, 64], ["cystic lesions", "PATHOLOGICAL_FORMATION", 149, 163], ["PCP", "PROBLEM", 61, 64], ["reticulation", "PROBLEM", 123, 135], ["small cystic lesions", "PROBLEM", 143, 163], ["reticulation", "OBSERVATION", 123, 135], ["small", "OBSERVATION_MODIFIER", 143, 148], ["cystic", "OBSERVATION_MODIFIER", 149, 155], ["lesions", "OBSERVATION", 156, 163]]], ["Hence, a negative test result implies an alternative diagnosis.Lactate Dehydrogenase EnzymeIn the context of an HIV-infected patient who is seen with an acute or subacute pneumonitis, an elevated serum lactate dehydrogenase (LDH) enzyme level is strongly suggestive of PCP.", [["serum", "ANATOMY", 196, 201], ["Lactate", "CHEMICAL", 63, 70], ["HIV-infected", "DISEASE", 112, 124], ["pneumonitis", "DISEASE", 171, 182], ["lactate", "CHEMICAL", 202, 209], ["PCP", "DISEASE", 269, 272], ["Lactate", "CHEMICAL", 63, 70], ["lactate", "CHEMICAL", 202, 209], ["PCP", "CHEMICAL", 269, 272], ["Lactate Dehydrogenase", "GENE_OR_GENE_PRODUCT", 63, 84], ["HIV", "ORGANISM", 112, 115], ["patient", "ORGANISM", 125, 132], ["serum", "ORGANISM_SUBSTANCE", 196, 201], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 202, 223], ["LDH", "GENE_OR_GENE_PRODUCT", 225, 228], ["Lactate Dehydrogenase", "PROTEIN", 63, 84], ["serum lactate dehydrogenase", "PROTEIN", 196, 223], ["LDH", "PROTEIN", 225, 228], ["patient", "SPECIES", 125, 132], ["HIV", "SPECIES", 112, 115], ["a negative test", "TEST", 7, 22], ["Lactate Dehydrogenase EnzymeIn", "TEST", 63, 93], ["an acute or subacute pneumonitis", "PROBLEM", 150, 182], ["an elevated serum lactate dehydrogenase (LDH) enzyme level", "PROBLEM", 184, 242], ["PCP", "PROBLEM", 269, 272], ["HIV", "OBSERVATION", 112, 115], ["infected", "OBSERVATION", 116, 124], ["acute", "OBSERVATION_MODIFIER", 153, 158], ["subacute", "OBSERVATION_MODIFIER", 162, 170], ["pneumonitis", "OBSERVATION", 171, 182], ["elevated", "OBSERVATION_MODIFIER", 187, 195], ["strongly suggestive of", "UNCERTAINTY", 246, 268], ["PCP", "OBSERVATION", 269, 272]]], ["When interpreting such results, it is important to remember that other pulmonary disease processes (e.g., pulmonary embolism, nonspecific pneumonitis, and bacterial and mycobacterial pneumonia) and extrapulmonary disease (Castleman disease and lymphoma) may also cause elevations of LDH and may need to be considered in the correct clinical context.Lactate Dehydrogenase EnzymeFrom the previous information, it is evident that noninvasive tests cannot reliably distinguish the different infecting agents from each other but may be useful in excluding acute opportunistic disease.", [["pulmonary", "ANATOMY", 71, 80], ["pulmonary", "ANATOMY", 106, 115], ["extrapulmonary", "ANATOMY", 198, 212], ["lymphoma", "ANATOMY", 244, 252], ["pulmonary disease", "DISEASE", 71, 88], ["pulmonary embolism", "DISEASE", 106, 124], ["pneumonitis", "DISEASE", 138, 149], ["bacterial and mycobacterial pneumonia", "DISEASE", 155, 192], ["extrapulmonary disease", "DISEASE", 198, 220], ["Castleman disease and lymphoma", "DISEASE", 222, 252], ["Lactate", "CHEMICAL", 349, 356], ["opportunistic disease", "DISEASE", 557, 578], ["Lactate", "CHEMICAL", 349, 356], ["pulmonary", "ORGAN", 71, 80], ["pulmonary", "ORGAN", 106, 115], ["lymphoma", "CANCER", 244, 252], ["LDH", "GENE_OR_GENE_PRODUCT", 283, 286], ["Lactate Dehydrogenase", "GENE_OR_GENE_PRODUCT", 349, 370], ["Lactate Dehydrogenase", "PROTEIN", 349, 370], ["other pulmonary disease processes", "PROBLEM", 65, 98], ["pulmonary embolism", "PROBLEM", 106, 124], ["nonspecific pneumonitis", "PROBLEM", 126, 149], ["bacterial and mycobacterial pneumonia", "PROBLEM", 155, 192], ["extrapulmonary disease", "PROBLEM", 198, 220], ["Castleman disease", "PROBLEM", 222, 239], ["lymphoma", "PROBLEM", 244, 252], ["elevations of LDH", "PROBLEM", 269, 286], ["Lactate Dehydrogenase", "TEST", 349, 370], ["noninvasive tests", "TEST", 427, 444], ["acute opportunistic disease", "PROBLEM", 551, 578], ["pulmonary", "ANATOMY", 71, 80], ["disease", "OBSERVATION", 81, 88], ["pulmonary", "ANATOMY", 106, 115], ["embolism", "OBSERVATION", 116, 124], ["nonspecific", "OBSERVATION_MODIFIER", 126, 137], ["pneumonitis", "OBSERVATION", 138, 149], ["bacterial", "OBSERVATION_MODIFIER", 155, 164], ["mycobacterial", "OBSERVATION_MODIFIER", 169, 182], ["pneumonia", "OBSERVATION", 183, 192], ["extrapulmonary", "ANATOMY", 198, 212], ["disease", "OBSERVATION", 213, 220], ["Castleman disease", "OBSERVATION", 222, 239], ["lymphoma", "OBSERVATION", 244, 252], ["acute", "OBSERVATION_MODIFIER", 551, 556], ["opportunistic", "OBSERVATION", 557, 570]]], ["Thus, the clinician is left with either proceeding to diagnostic lung fluid or tissue sampling (by either induced sputum collection or bronchoscopy and BAL with or without transbronchial biopsy Table 34-7) or treating an unknown condition empirically.", [["lung fluid", "ANATOMY", 65, 75], ["tissue", "ANATOMY", 79, 85], ["sputum", "ANATOMY", 114, 120], ["BAL", "ANATOMY", 152, 155], ["lung fluid", "TISSUE", 65, 75], ["tissue", "TISSUE", 79, 85], ["diagnostic lung fluid", "TEST", 54, 75], ["tissue sampling", "TEST", 79, 94], ["induced sputum collection", "PROBLEM", 106, 131], ["bronchoscopy", "TEST", 135, 147], ["BAL", "TEST", 152, 155], ["transbronchial biopsy Table", "TEST", 172, 199], ["an unknown condition", "PROBLEM", 218, 238], ["lung", "ANATOMY", 65, 69], ["fluid", "OBSERVATION", 70, 75]]], ["HAART has also altered the investigation of respiratory disease.", [["respiratory", "ANATOMY", 44, 55], ["respiratory disease", "DISEASE", 44, 63], ["HAART", "TREATMENT", 0, 5], ["respiratory disease", "PROBLEM", 44, 63], ["respiratory disease", "OBSERVATION", 44, 63]]], ["The numbers of invasive procedures performed are falling and tend to be in patientsInduced SputumSpontaneously expectorated sputum is inadequate for diagnosis of PCP.", [["sputum", "ANATOMY", 124, 130], ["PCP", "DISEASE", 162, 165], ["PCP", "CHEMICAL", 162, 165], ["patients", "ORGANISM", 75, 83], ["patients", "SPECIES", 75, 83], ["invasive procedures", "TREATMENT", 15, 34], ["Induced SputumSpontaneously expectorated sputum", "PROBLEM", 83, 130], ["PCP", "PROBLEM", 162, 165], ["invasive", "OBSERVATION_MODIFIER", 15, 23]]], ["Sputum induction by inhalation of ultrasonically nebulized hypertonic saline may provide a suitable specimen (see Table 34 -7).", [["Sputum", "ANATOMY", 0, 6], ["specimen", "ANATOMY", 100, 108], ["Sputum", "ORGANISM_SUBSTANCE", 0, 6], ["Sputum induction", "TREATMENT", 0, 16], ["ultrasonically nebulized hypertonic saline", "TREATMENT", 34, 76]]], ["The technique requires close attention to detail and is much less useful when samples are purulent.", [["samples", "ANATOMY", 78, 85], ["purulent", "PROBLEM", 90, 98], ["purulent", "OBSERVATION", 90, 98]]], ["Sputum induction must be carried out away from other immunosuppressed patients and health care workers, ideally in a room with separate negative-pressure ventilation, to reduce the risk of nosocomial transmission of tuberculosis.", [["Sputum", "ANATOMY", 0, 6], ["tuberculosis", "DISEASE", 216, 228], ["Sputum", "ORGANISM_SUBSTANCE", 0, 6], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["Sputum induction", "TREATMENT", 0, 16], ["separate negative-pressure ventilation", "TREATMENT", 127, 165], ["tuberculosis", "PROBLEM", 216, 228], ["pressure ventilation", "OBSERVATION", 145, 165], ["nosocomial", "OBSERVATION", 189, 199], ["tuberculosis", "OBSERVATION", 216, 228]]], ["Although very specific (>95%), the sensitivity of induced sputum varies widely (55-90%), and therefore a negative result for P. jirovecii prompts further diagnostic studies.", [["sputum", "ANATOMY", 58, 64], ["P. jirovecii", "DISEASE", 125, 137], ["P. jirovecii", "ORGANISM", 125, 137], ["P. jirovecii", "SPECIES", 125, 137], ["P. jirovecii", "SPECIES", 125, 137], ["induced sputum varies", "PROBLEM", 50, 71], ["P. jirovecii", "PROBLEM", 125, 137], ["further diagnostic studies", "TEST", 146, 172]]], ["The use of immunofluorescence staining enhances the yield of induced sputum compared with standard cytochemistry.BronchoscopyFiberoptic bronchoscopy with BAL is commonly used to diagnose HIV-related pulmonary disease.", [["sputum", "ANATOMY", 69, 75], ["pulmonary", "ANATOMY", 199, 208], ["HIV-related pulmonary disease", "DISEASE", 187, 216], ["sputum", "ORGANISM_SUBSTANCE", 69, 75], ["HIV", "ORGANISM", 187, 190], ["pulmonary", "ORGAN", 199, 208], ["HIV", "SPECIES", 187, 190], ["HIV", "SPECIES", 187, 190], ["immunofluorescence staining", "TEST", 11, 38], ["induced sputum", "PROBLEM", 61, 75], ["standard cytochemistry", "TEST", 90, 112], ["BronchoscopyFiberoptic bronchoscopy", "TEST", 113, 148], ["BAL", "TREATMENT", 154, 157], ["pulmonary disease", "PROBLEM", 199, 216], ["pulmonary", "ANATOMY", 199, 208], ["disease", "OBSERVATION", 209, 216]]], ["When a good \"wedged\" sample is obtained, the test has a sensitivity of more than 90% for detection of P. jirovecii (Figure 34-16 ).", [["sample", "ANATOMY", 21, 27], ["P. jirovecii", "DISEASE", 102, 114], ["P. jirovecii", "ORGANISM", 102, 114], ["P. jirovecii", "SPECIES", 102, 114], ["P. jirovecii", "SPECIES", 102, 114], ["the test", "TEST", 41, 49], ["a sensitivity", "TEST", 54, 67], ["P. jirovecii", "PROBLEM", 102, 114]]], ["Just as with induced sputum, fluorescent staining methods increase the diagnostic yield, which makes it the procedure of choice in most centers.", [["sputum", "ANATOMY", 21, 27], ["sputum", "ORGANISM_SUBSTANCE", 21, 27], ["induced sputum", "PROBLEM", 13, 27], ["fluorescent staining methods", "TEST", 29, 57], ["the procedure of choice", "TREATMENT", 104, 127], ["sputum", "OBSERVATION", 21, 27]]], ["More technically demanding (both of the patient and the operator) than induced sputum collection, bronchoscopy and BAL have the advantage that direct inspection of the upper airway and bronchial tree can be performed and, if necessary, biopsies taken.", [["sputum", "ANATOMY", 79, 85], ["upper airway", "ANATOMY", 168, 180], ["bronchial tree", "ANATOMY", 185, 199], ["patient", "ORGANISM", 40, 47], ["upper airway", "MULTI-TISSUE_STRUCTURE", 168, 180], ["bronchial tree", "MULTI-TISSUE_STRUCTURE", 185, 199], ["patient", "SPECIES", 40, 47], ["induced sputum collection", "PROBLEM", 71, 96], ["bronchoscopy", "TEST", 98, 110], ["BAL", "TREATMENT", 115, 118], ["direct inspection of the upper airway", "TEST", 143, 180], ["biopsies", "TEST", 236, 244], ["upper", "ANATOMY_MODIFIER", 168, 173], ["airway", "ANATOMY", 174, 180], ["bronchial tree", "ANATOMY", 185, 199]]], ["Transbronchial biopsies may marginally increase the diagnostic yield of the procedure.", [["Transbronchial biopsies", "ANATOMY", 0, 23], ["Transbronchial biopsies", "TEST", 0, 23], ["the procedure", "TREATMENT", 72, 85]]], ["This is relevant for the diagnosis of mycobacterial disease, although the relatively high complication rate in HIV-infected individuals (pneumothorax and the possibility of significant pulmonary hemorrhage in up to 10%) outweighs the advantages of the technique for routine purposes.", [["pulmonary", "ANATOMY", 185, 194], ["mycobacterial disease", "DISEASE", 38, 59], ["HIV-infected", "DISEASE", 111, 123], ["pneumothorax", "DISEASE", 137, 149], ["pulmonary hemorrhage", "DISEASE", 185, 205], ["HIV", "ORGANISM", 111, 114], ["individuals", "ORGANISM", 124, 135], ["pulmonary", "ORGAN", 185, 194], ["HIV", "SPECIES", 111, 114], ["HIV", "SPECIES", 111, 114], ["mycobacterial disease", "PROBLEM", 38, 59], ["the relatively high complication rate", "PROBLEM", 70, 107], ["HIV", "PROBLEM", 111, 114], ["infected individuals", "PROBLEM", 115, 135], ["pneumothorax", "PROBLEM", 137, 149], ["significant pulmonary hemorrhage", "PROBLEM", 173, 205], ["the technique", "TEST", 248, 261], ["routine purposes", "TEST", 266, 282], ["mycobacterial disease", "OBSERVATION", 38, 59], ["high", "OBSERVATION_MODIFIER", 85, 89], ["complication", "OBSERVATION", 90, 102], ["pneumothorax", "OBSERVATION", 137, 149], ["possibility of", "UNCERTAINTY", 158, 172], ["significant", "OBSERVATION_MODIFIER", 173, 184], ["pulmonary", "ANATOMY", 185, 194], ["hemorrhage", "OBSERVATION", 195, 205]]], ["Samples of BAL fluid are examined for bacteria, mycobacteria, viruses, fungi, and protozoa.", [["Samples", "ANATOMY", 0, 7], ["BAL fluid", "ANATOMY", 11, 20], ["BAL fluid", "ORGANISM_SUBSTANCE", 11, 20], ["Samples of BAL fluid", "TEST", 0, 20], ["bacteria", "PROBLEM", 38, 46], ["mycobacteria", "PROBLEM", 48, 60], ["viruses", "PROBLEM", 62, 69], ["fungi", "TEST", 71, 76], ["protozoa", "PROBLEM", 82, 90], ["BAL fluid", "OBSERVATION", 11, 20], ["mycobacteria", "OBSERVATION", 48, 60]]], ["Inspection of the cellular component may also provide etiologic clues-cooperation of a pathology department with experience in opportunistic infection diagnosis is vital.", [["cellular", "ANATOMY", 18, 26], ["opportunistic infection", "DISEASE", 127, 150], ["cellular", "CELL", 18, 26], ["opportunistic", "OBSERVATION_MODIFIER", 127, 140], ["infection", "OBSERVATION", 141, 150]]], ["The drug interactions associated with antiretroviral protease inhibitor (PI) therapy mean that special care should be exercised when sedation is used with either benzodiazepine or opiate drugs.", [["benzodiazepine", "CHEMICAL", 162, 176], ["benzodiazepine", "CHEMICAL", 162, 176], ["PI", "SIMPLE_CHEMICAL", 73, 75], ["benzodiazepine", "SIMPLE_CHEMICAL", 162, 176], ["opiate drugs", "SIMPLE_CHEMICAL", 180, 192], ["The drug interactions", "PROBLEM", 0, 21], ["antiretroviral protease inhibitor", "TREATMENT", 38, 71], ["PI) therapy", "TREATMENT", 73, 84], ["special care", "TREATMENT", 95, 107], ["sedation", "TREATMENT", 133, 141], ["benzodiazepine", "TREATMENT", 162, 176], ["opiate drugs", "TREATMENT", 180, 192]]], ["Prolonged sedation and life-threatening arrhythmias have been reported.BronchoscopyA diagnostic strategy, therefore, includes sputum induction and, if results are nondiagnostic or if the test is unavailable, bronchoscopy and BAL.", [["sputum", "ANATOMY", 126, 132], ["arrhythmias", "DISEASE", 40, 51], ["Prolonged sedation", "TREATMENT", 0, 18], ["life-threatening arrhythmias", "PROBLEM", 23, 51], ["sputum induction", "TEST", 126, 142], ["the test", "TEST", 183, 191], ["bronchoscopy", "TEST", 208, 220], ["BAL", "TEST", 225, 228]]], ["If this does not yield a result, consideration is given to either a repeat bronchoscopy and BAL with transbronchial biopsies or surgical biopsy.", [["BAL", "ANATOMY", 92, 95], ["transbronchial biopsies", "MULTI-TISSUE_STRUCTURE", 101, 124], ["a repeat bronchoscopy", "TEST", 66, 87], ["BAL", "TEST", 92, 95], ["transbronchial biopsies", "TEST", 101, 124], ["surgical biopsy", "TEST", 128, 143], ["transbronchial", "ANATOMY", 101, 115]]], ["The latter can be performed as either an open lung or thoracoscopic procedure.", [["lung", "ANATOMY", 46, 50], ["lung", "ORGAN", 46, 50], ["an open lung", "TREATMENT", 38, 50], ["thoracoscopic procedure", "TREATMENT", 54, 77], ["lung", "ANATOMY", 46, 50], ["thoracoscopic", "OBSERVATION", 54, 67]]], ["Surgical biopsy has a high sensitivity.Empirical Diagnosis and TherapyAlthough empirical therapy is usually reserved for the management of presumed bacterial pneumonias, and at first sight may seem unwise when dealing with possible opportunistic infection, in reality PCP is almost invariably a diagnosis of exclusion, and certain clinical and laboratory features may guide the assessment of an HIV-infected individual's risk for this condition.", [["pneumonias", "DISEASE", 158, 168], ["opportunistic infection", "DISEASE", 232, 255], ["PCP", "DISEASE", 268, 271], ["HIV-infected", "DISEASE", 395, 407], ["HIV", "SPECIES", 395, 398], ["Surgical biopsy", "TEST", 0, 15], ["a high sensitivity", "PROBLEM", 20, 38], ["empirical therapy", "TREATMENT", 79, 96], ["bacterial pneumonias", "PROBLEM", 148, 168], ["opportunistic infection", "PROBLEM", 232, 255], ["the assessment", "TEST", 374, 388], ["an HIV", "PROBLEM", 392, 398], ["this condition", "PROBLEM", 430, 444], ["biopsy", "OBSERVATION", 9, 15], ["high sensitivity", "OBSERVATION_MODIFIER", 22, 38], ["bacterial", "OBSERVATION_MODIFIER", 148, 157], ["pneumonias", "OBSERVATION", 158, 168], ["opportunistic", "OBSERVATION_MODIFIER", 232, 245], ["infection", "OBSERVATION", 246, 255]]], ["The likelihood that P. jirovecii is the causative organism increases if the subject is not taking effective anti-Pneumocystis drug prophylaxis or has a previous medical history with clinical or laboratory features that suggest systemic immunosuppression (i.e., recurrent oral thrush, longstanding fever of unknown cause, clinical AIDS, or blood CD4 count <200 cells/mL).", [["oral", "ANATOMY", 271, 275], ["blood", "ANATOMY", 339, 344], ["cells", "ANATOMY", 360, 365], ["P. jirovecii", "DISEASE", 20, 32], ["oral thrush", "DISEASE", 271, 282], ["fever", "DISEASE", 297, 302], ["AIDS", "DISEASE", 330, 334], ["P. jirovecii", "ORGANISM", 20, 32], ["oral", "ORGANISM_SUBDIVISION", 271, 275], ["blood", "ORGANISM_SUBSTANCE", 339, 344], ["CD4", "PROTEIN", 345, 348], ["P. jirovecii", "SPECIES", 20, 32], ["P. jirovecii", "SPECIES", 20, 32], ["anti-Pneumocystis", "SPECIES", 108, 125], ["P. jirovecii", "PROBLEM", 20, 32], ["the causative organism", "PROBLEM", 36, 58], ["anti-Pneumocystis drug prophylaxis", "TREATMENT", 108, 142], ["systemic immunosuppression", "TREATMENT", 227, 253], ["recurrent oral thrush", "PROBLEM", 261, 282], ["longstanding fever", "PROBLEM", 284, 302], ["clinical AIDS", "PROBLEM", 321, 334], ["blood CD4 count", "TEST", 339, 354], ["jirovecii", "OBSERVATION", 23, 32], ["systemic", "OBSERVATION_MODIFIER", 227, 235], ["immunosuppression", "OBSERVATION", 236, 253], ["thrush", "OBSERVATION", 276, 282]]], ["Hence, some centers advocate use of empirical therapy for HIV-infected patients who are seen with symptoms and chest radiographic and blood gas abnormalities typical of mild PCP, without the need for bronchoscopy.", [["chest", "ANATOMY", 111, 116], ["blood", "ANATOMY", 134, 139], ["HIV-infected", "DISEASE", 58, 70], ["PCP", "DISEASE", 174, 177], ["PCP", "CHEMICAL", 174, 177], ["HIV", "ORGANISM", 58, 61], ["patients", "ORGANISM", 71, 79], ["chest", "ORGANISM_SUBDIVISION", 111, 116], ["blood", "ORGANISM_SUBSTANCE", 134, 139], ["HIV", "SPECIES", 58, 61], ["patients", "SPECIES", 71, 79], ["HIV", "SPECIES", 58, 61], ["empirical therapy", "TREATMENT", 36, 53], ["HIV", "PROBLEM", 58, 61], ["symptoms", "PROBLEM", 98, 106], ["chest radiographic", "TEST", 111, 129], ["blood gas abnormalities", "PROBLEM", 134, 157], ["mild PCP", "PROBLEM", 169, 177], ["bronchoscopy", "TEST", 200, 212], ["chest", "ANATOMY", 111, 116], ["mild", "OBSERVATION_MODIFIER", 169, 173], ["PCP", "OBSERVATION", 174, 177]]], ["Invasive measures are reserved for those with an atypical radiographic presentation, those who fail to respond to empirical therapy by day 5, and those who deteriorate at any stage.Empirical Diagnosis and TherapyMost clinicians in North America and the United Kingdom would seek to obtain a confirmed diagnosis in every case of suspected PCP.", [["PCP", "DISEASE", 338, 341], ["PCP", "CHEMICAL", 338, 341], ["Invasive measures", "TREATMENT", 0, 17], ["empirical therapy", "TREATMENT", 114, 131], ["Therapy", "TREATMENT", 205, 212]]], ["In practice, both strategies seem to be equally effective, although a number of caveats should be borne in mind when empirical treatment is given for PCP.", [["PCP", "DISEASE", 150, 153], ["PCP", "CHEMICAL", 150, 153], ["empirical treatment", "TREATMENT", 117, 136], ["effective", "OBSERVATION", 48, 57]]], ["Patients who have PCP typically take 4-7 days to show clinical signs of improvement, so a bronchoscopically proven diagnosis ensures that the treatment being given is correct, particularly in the first few days of therapy, when it may not be well tolerated.", [["PCP", "DISEASE", 18, 21], ["PCP", "CHEMICAL", 18, 21], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["the treatment", "TREATMENT", 138, 151], ["therapy", "TREATMENT", 214, 221]]], ["In addition, the diagnosis of PCP has implications for the infected individual, because it may influence the decision to start either HAART or anti-Pneumocystis prophylaxis.", [["PCP", "DISEASE", 30, 33], ["anti-Pneumocystis", "CHEMICAL", 143, 160], ["PCP", "CHEMICAL", 30, 33], ["anti-Pneumocystis", "SIMPLE_CHEMICAL", 143, 160], ["the infected individual", "PROBLEM", 55, 78], ["HAART", "TREATMENT", 134, 139], ["anti-Pneumocystis prophylaxis", "TREATMENT", 143, 172]]], ["Finally, empirical therapy requires the patient to be maximally adherent to treatment, because nonresolution of symptoms may be seen as failure of therapy rather than of compliance.Nucleic Acid DetectionMolecular biologic techniques (such as PCR) are increasingly used in the diagnosis of respiratory disease.", [["respiratory", "ANATOMY", 289, 300], ["respiratory disease", "DISEASE", 289, 308], ["patient", "ORGANISM", 40, 47], ["patient", "SPECIES", 40, 47], ["empirical therapy", "TREATMENT", 9, 26], ["treatment", "TREATMENT", 76, 85], ["symptoms", "PROBLEM", 112, 120], ["therapy", "TREATMENT", 147, 154], ["Nucleic Acid DetectionMolecular biologic techniques", "TREATMENT", 181, 232], ["PCR", "TEST", 242, 245], ["respiratory disease", "PROBLEM", 289, 308], ["respiratory disease", "OBSERVATION", 289, 308]]], ["Two examples of this are DNA amplification of loci of the P. jirovecii and M. tuberculosis genomes.", [["DNA", "CELLULAR_COMPONENT", 25, 28], ["P. jirovecii", "ORGANISM", 58, 70], ["M. tuberculosis", "ORGANISM", 75, 90], ["P. jirovecii", "SPECIES", 58, 70], ["M. tuberculosis", "SPECIES", 75, 90], ["P. jirovecii", "SPECIES", 58, 70], ["M. tuberculosis", "SPECIES", 75, 90], ["the P. jirovecii", "PROBLEM", 54, 70], ["M. tuberculosis genomes", "PROBLEM", 75, 98], ["jirovecii", "OBSERVATION", 61, 70], ["tuberculosis genomes", "OBSERVATION", 78, 98]]], ["The advantages of molecular methods are that the diagnosis may be made by use of samples that are more readily obtained than BAL fluid (i.e., expectorated sputum or nasopharyngeal secretions) and also that these methods are rapid (the answer may be available within a working day, compared with conventional mycobacterial culture, which may take weeks).", [["samples", "ANATOMY", 81, 88], ["BAL fluid", "ANATOMY", 125, 134], ["sputum", "ANATOMY", 155, 161], ["nasopharyngeal secretions", "ANATOMY", 165, 190], ["BAL fluid", "ORGANISM_SUBSTANCE", 125, 134], ["nasopharyngeal secretions", "ORGAN", 165, 190], ["BAL fluid", "TEST", 125, 134], ["expectorated sputum or nasopharyngeal secretions", "PROBLEM", 142, 190], ["conventional mycobacterial culture", "TEST", 295, 329], ["nasopharyngeal", "ANATOMY", 165, 179]]], ["Despite encouraging results in the research setting (sensitivity and specificity have been reported as 60-100% and 70-100%, respectively), problems persist when these techniques are applied to routine diagnostic samples.", [["samples", "ANATOMY", 212, 219], ["sensitivity", "TEST", 53, 64], ["specificity", "TEST", 69, 80], ["routine diagnostic samples", "TEST", 193, 219]]], ["These include extraction of nucleic acid from clinical material, cross-contamination with the products of previous assays, and clinical interpretation of a test result.", [["nucleic acid", "CHEMICAL", 28, 40], ["nucleic acid", "SIMPLE_CHEMICAL", 28, 40], ["extraction", "TREATMENT", 14, 24], ["nucleic acid", "PROBLEM", 28, 40], ["clinical material", "PROBLEM", 46, 63], ["cross-contamination", "PROBLEM", 65, 84], ["previous assays", "TEST", 106, 121], ["a test result", "TEST", 154, 167], ["nucleic acid", "OBSERVATION", 28, 40]]], ["Currently, TREATMENT Individuals infected with HIV, compared with the non-HIVinfected general population, have an increased likelihood of adverse reactions to therapy.", [["HIV", "DISEASE", 47, 50], ["HIV", "ORGANISM", 47, 50], ["HIV", "SPECIES", 47, 50], ["HIV", "SPECIES", 47, 50], ["HIV", "PROBLEM", 47, 50], ["adverse reactions", "PROBLEM", 138, 155], ["therapy", "TREATMENT", 159, 166], ["increased", "OBSERVATION_MODIFIER", 114, 123]]], ["This includes TMP/SMX (see later) and other antibacterial and antimycobacterial agents.", [["TMP", "CHEMICAL", 14, 17], ["SMX", "CHEMICAL", 18, 21], ["TMP", "CHEMICAL", 14, 17], ["SMX", "CHEMICAL", 18, 21], ["TMP", "SIMPLE_CHEMICAL", 14, 17], ["SMX", "SIMPLE_CHEMICAL", 18, 21], ["TMP/SMX", "TREATMENT", 14, 21], ["other antibacterial", "TREATMENT", 38, 57], ["antimycobacterial agents", "TREATMENT", 62, 86], ["antimycobacterial agents", "OBSERVATION", 62, 86]]], ["In addition, there are complex drug interactions with other medications, particularly components of HAART.", [["complex drug interactions", "PROBLEM", 23, 48], ["other medications", "TREATMENT", 54, 71], ["HAART", "TREATMENT", 100, 105], ["complex", "OBSERVATION_MODIFIER", 23, 30], ["drug interactions", "OBSERVATION", 31, 48], ["HAART", "OBSERVATION", 100, 105]]], ["Before instituting therapy for any infectious complication in an HIVinfected individual, it is important to consult with a physician experienced in the care of patients with HIV infection and to seek advice from a specialist pharmacist.Bacterial PneumoniaThe main organisms causing pneumonia in HIV-infected individuals are similar to those found in the general population with community-acquired pneumonia.", [["HIV infection", "DISEASE", 174, 187], ["Pneumonia", "DISEASE", 246, 255], ["pneumonia", "DISEASE", 282, 291], ["HIV-infected", "DISEASE", 295, 307], ["pneumonia", "DISEASE", 397, 406], ["patients", "ORGANISM", 160, 168], ["HIV", "ORGANISM", 174, 177], ["HIV", "ORGANISM", 295, 298], ["individuals", "ORGANISM", 308, 319], ["patients", "SPECIES", 160, 168], ["HIV", "SPECIES", 174, 177], ["HIV", "SPECIES", 295, 298], ["HIV", "SPECIES", 174, 177], ["Pneumonia", "SPECIES", 246, 255], ["HIV", "SPECIES", 295, 298], ["therapy", "TREATMENT", 19, 26], ["any infectious complication", "PROBLEM", 31, 58], ["HIV infection", "PROBLEM", 174, 187], ["Bacterial Pneumonia", "PROBLEM", 236, 255], ["pneumonia", "PROBLEM", 282, 291], ["HIV", "PROBLEM", 295, 298], ["infected individuals", "PROBLEM", 299, 319], ["community-acquired pneumonia", "PROBLEM", 378, 406], ["infectious", "OBSERVATION_MODIFIER", 35, 45], ["infection", "OBSERVATION", 178, 187], ["Pneumonia", "OBSERVATION", 246, 255], ["main", "OBSERVATION_MODIFIER", 259, 263], ["pneumonia", "OBSERVATION", 282, 291], ["infected", "OBSERVATION_MODIFIER", 299, 307], ["pneumonia", "OBSERVATION", 397, 406]]], ["Thus, bacterial pneumonia in HIV-infected patients should be treated in a similar manner to that in HIV-negative individuals, by use of the published American Thoracic Society (ATS) and British Thoracic Society (BTS) guidelines.", [["pneumonia", "DISEASE", 16, 25], ["HIV-infected", "DISEASE", 29, 41], ["HIV", "ORGANISM", 29, 32], ["patients", "ORGANISM", 42, 50], ["HIV", "ORGANISM", 100, 103], ["individuals", "ORGANISM", 113, 124], ["HIV", "SPECIES", 29, 32], ["patients", "SPECIES", 42, 50], ["HIV", "SPECIES", 29, 32], ["HIV", "SPECIES", 100, 103], ["bacterial pneumonia", "PROBLEM", 6, 25], ["HIV", "PROBLEM", 29, 32], ["bacterial", "OBSERVATION_MODIFIER", 6, 15], ["pneumonia", "OBSERVATION", 16, 25], ["infected", "OBSERVATION_MODIFIER", 33, 41], ["Thoracic", "ANATOMY", 159, 167], ["Thoracic", "ANATOMY", 194, 202]]], ["In addition, expert advice on local antibiotic resistance patterns should be sought from infectious disease or microbiology colleagues, because treatment is usually begun on an empirical basis before the causative organism is identified and antibiotic sensitivities known.", [["infectious disease", "DISEASE", 89, 107], ["local antibiotic resistance patterns", "TREATMENT", 30, 66], ["treatment", "TREATMENT", 144, 153], ["the causative organism", "PROBLEM", 200, 222], ["antibiotic sensitivities", "TEST", 241, 265]]], ["The same clinical and laboratory prognostic indices that are described for the general population apply to HIV-infected patients and should be documented on presentation.Bacterial PneumoniaResponse to appropriate antibiotic therapy is usually rapid and is similar to that seen in the non-HIV-infected individual.", [["HIV-infected", "DISEASE", 107, 119], ["non-HIV-infected", "DISEASE", 284, 300], ["HIV", "ORGANISM", 107, 110], ["patients", "ORGANISM", 120, 128], ["HIV", "SPECIES", 107, 110], ["patients", "SPECIES", 120, 128], ["HIV", "SPECIES", 107, 110], ["HIV", "PROBLEM", 107, 110], ["Bacterial PneumoniaResponse", "PROBLEM", 170, 197], ["appropriate antibiotic therapy", "TREATMENT", 201, 231], ["antibiotic therapy", "OBSERVATION", 213, 231], ["infected", "OBSERVATION", 292, 300]]], ["Early relapse of infection after successful treatment is well described.", [["infection", "DISEASE", 17, 26], ["infection", "PROBLEM", 17, 26], ["successful treatment", "TREATMENT", 33, 53], ["relapse", "OBSERVATION_MODIFIER", 6, 13], ["infection", "OBSERVATION", 17, 26]]], ["Those HIV-infected patients who have presumed PCP and are being treated empirically with high-dose TMP/ SMX, and who have infection with either S. pneumoniae or H. influenzae rather than P. jirovecii, may also improve.", [["HIV-infected", "DISEASE", 6, 18], ["PCP", "DISEASE", 46, 49], ["TMP", "CHEMICAL", 99, 102], ["SMX", "CHEMICAL", 104, 107], ["infection", "DISEASE", 122, 131], ["P. jirovecii", "DISEASE", 187, 199], ["PCP", "CHEMICAL", 46, 49], ["TMP", "CHEMICAL", 99, 102], ["SMX", "CHEMICAL", 104, 107], ["HIV", "ORGANISM", 6, 9], ["patients", "ORGANISM", 19, 27], ["TMP", "SIMPLE_CHEMICAL", 99, 102], ["SMX", "SIMPLE_CHEMICAL", 104, 107], ["S. pneumoniae", "ORGANISM", 144, 157], ["H. influenzae", "ORGANISM", 161, 174], ["P. jirovecii", "ORGANISM", 187, 199], ["HIV", "SPECIES", 6, 9], ["patients", "SPECIES", 19, 27], ["S. pneumoniae", "SPECIES", 144, 157], ["H. influenzae", "SPECIES", 161, 174], ["P. jirovecii", "SPECIES", 187, 199], ["HIV", "SPECIES", 6, 9], ["S. pneumoniae", "SPECIES", 144, 157], ["H. influenzae", "SPECIES", 161, 174], ["P. jirovecii", "SPECIES", 187, 199], ["PCP", "PROBLEM", 46, 49], ["high-dose TMP/ SMX", "TREATMENT", 89, 107], ["infection", "PROBLEM", 122, 131], ["S. pneumoniae", "PROBLEM", 144, 157], ["H. influenzae", "PROBLEM", 161, 174], ["P. jirovecii", "PROBLEM", 187, 199], ["infection", "OBSERVATION", 122, 131], ["pneumoniae", "OBSERVATION", 147, 157], ["jirovecii", "OBSERVATION", 190, 199]]], ["In addition, in those patients who are treated with benzylpenicillin for proven S. pneumoniae pneumonia but do not respond, and penicillin resistance can be discounted as the cause, it is important to consider whether there is a second pathologic process, such as PCP.", [["benzylpenicillin", "CHEMICAL", 52, 68], ["S. pneumoniae pneumonia", "DISEASE", 80, 103], ["penicillin", "CHEMICAL", 128, 138], ["PCP", "DISEASE", 264, 267], ["benzylpenicillin", "CHEMICAL", 52, 68], ["penicillin", "CHEMICAL", 128, 138], ["PCP", "CHEMICAL", 264, 267], ["patients", "ORGANISM", 22, 30], ["benzylpenicillin", "SIMPLE_CHEMICAL", 52, 68], ["S. pneumoniae", "ORGANISM", 80, 93], ["penicillin", "SIMPLE_CHEMICAL", 128, 138], ["patients", "SPECIES", 22, 30], ["S. pneumoniae", "SPECIES", 80, 93], ["S. pneumoniae", "SPECIES", 80, 93], ["benzylpenicillin", "TREATMENT", 52, 68], ["S. pneumoniae pneumonia", "PROBLEM", 80, 103], ["penicillin resistance", "TREATMENT", 128, 149], ["a second pathologic process", "PROBLEM", 227, 254], ["pneumoniae", "OBSERVATION_MODIFIER", 83, 93], ["pneumonia", "OBSERVATION", 94, 103]]], ["Co-pathogens are reported in up to 20% of cases of pneumonia.Pneumocystis jirovecii PneumoniaBefore instituting treatment, assessment of the severity of PCP should be performed on the basis of history, findings on examination, arterial blood gas estimations, and chest radiographic abnormalities.", [["arterial blood", "ANATOMY", 227, 241], ["chest", "ANATOMY", 263, 268], ["pneumonia", "DISEASE", 51, 60], ["Pneumocystis jirovecii", "DISEASE", 61, 83], ["PCP", "DISEASE", 153, 156], ["Pneumocystis jirovecii", "ORGANISM", 61, 83], ["arterial blood", "MULTI-TISSUE_STRUCTURE", 227, 241], ["chest", "ORGANISM_SUBDIVISION", 263, 268], ["Pneumocystis jirovecii", "SPECIES", 61, 83], ["Pneumocystis jirovecii", "SPECIES", 61, 83], ["pneumonia", "PROBLEM", 51, 60], ["Pneumocystis jirovecii", "PROBLEM", 61, 83], ["instituting treatment", "TREATMENT", 100, 121], ["examination", "TEST", 214, 225], ["arterial blood gas estimations", "TEST", 227, 257], ["chest radiographic abnormalities", "PROBLEM", 263, 295], ["pneumonia", "OBSERVATION", 51, 60], ["chest", "ANATOMY", 263, 268]]], ["Patients can then be stratified into those with mild, moderate, or severe disease (Table 34-8) .", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["mild, moderate, or severe disease", "PROBLEM", 48, 81], ["mild", "OBSERVATION_MODIFIER", 48, 52], ["moderate", "OBSERVATION_MODIFIER", 54, 62], ["severe", "OBSERVATION_MODIFIER", 67, 73], ["disease", "OBSERVATION", 74, 81]]], ["This is important, because some drugs are of unproven benefit and others are known to be ineffective for the treatment of severe disease.", [["severe disease", "PROBLEM", 122, 136], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["disease", "OBSERVATION", 129, 136]]], ["In addition, adjuvant glucocorticoid therapy may be given to patients with moderate or severe pneumonia.", [["pneumonia", "DISEASE", 94, 103], ["glucocorticoid", "SIMPLE_CHEMICAL", 22, 36], ["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["adjuvant glucocorticoid therapy", "TREATMENT", 13, 44], ["moderate or severe pneumonia", "PROBLEM", 75, 103], ["glucocorticoid therapy", "OBSERVATION", 22, 44], ["moderate", "OBSERVATION_MODIFIER", 75, 83], ["severe", "OBSERVATION_MODIFIER", 87, 93], ["pneumonia", "OBSERVATION", 94, 103]]], ["Patients with glucose-6-phosphate dehydrogenase deficiency should not receive TMP/SMX, dapsone, or primaquine, because these drugs increase the risk of hemolysis.Trimethoprim-SulfamethoxazoleSeveral drugs are effective in the treatment of PCP.", [["glucose-6-phosphate", "CHEMICAL", 14, 33], ["TMP", "CHEMICAL", 78, 81], ["SMX", "CHEMICAL", 82, 85], ["dapsone", "CHEMICAL", 87, 94], ["primaquine", "CHEMICAL", 99, 109], ["hemolysis", "DISEASE", 152, 161], ["Trimethoprim-SulfamethoxazoleSeveral", "CHEMICAL", 162, 198], ["PCP", "DISEASE", 239, 242], ["glucose-6-phosphate", "CHEMICAL", 14, 33], ["TMP", "CHEMICAL", 78, 81], ["SMX", "CHEMICAL", 82, 85], ["dapsone", "CHEMICAL", 87, 94], ["primaquine", "CHEMICAL", 99, 109], ["Trimethoprim", "CHEMICAL", 162, 174], ["PCP", "CHEMICAL", 239, 242], ["Patients", "ORGANISM", 0, 8], ["glucose-6-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 14, 47], ["TMP", "SIMPLE_CHEMICAL", 78, 81], ["SMX", "SIMPLE_CHEMICAL", 82, 85], ["dapsone", "SIMPLE_CHEMICAL", 87, 94], ["primaquine", "SIMPLE_CHEMICAL", 99, 109], ["Trimethoprim-SulfamethoxazoleSeveral drugs", "SIMPLE_CHEMICAL", 162, 204], ["glucose-6-phosphate dehydrogenase", "PROTEIN", 14, 47], ["Patients", "SPECIES", 0, 8], ["glucose", "TEST", 14, 21], ["phosphate dehydrogenase deficiency", "PROBLEM", 24, 58], ["TMP", "TREATMENT", 78, 81], ["SMX", "TREATMENT", 82, 85], ["dapsone", "TREATMENT", 87, 94], ["primaquine", "TREATMENT", 99, 109], ["these drugs", "TREATMENT", 119, 130], ["hemolysis", "PROBLEM", 152, 161], ["Trimethoprim", "TREATMENT", 162, 174], ["SulfamethoxazoleSeveral drugs", "TREATMENT", 175, 204], ["PCP", "PROBLEM", 239, 242], ["hemolysis", "OBSERVATION", 152, 161]]], ["TMP/ SMX is the drug of first choice (Tables 34-9 and 34-10).", [["TMP", "CHEMICAL", 0, 3], ["SMX", "CHEMICAL", 5, 8], ["TMP", "CHEMICAL", 0, 3], ["SMX", "CHEMICAL", 5, 8], ["TMP", "SIMPLE_CHEMICAL", 0, 3], ["SMX", "SIMPLE_CHEMICAL", 5, 8]]], ["Overall it is effective in 70-80% of individuals when used as firstline therapy.", [["individuals", "ORGANISM", 37, 48], ["firstline therapy", "TREATMENT", 62, 79], ["effective", "OBSERVATION_MODIFIER", 14, 23]]], ["Adverse reactions to TMP/SMX are common and usually become apparent between days 6 and 14 of treatment.", [["TMP", "CHEMICAL", 21, 24], ["SMX", "CHEMICAL", 25, 28], ["TMP", "CHEMICAL", 21, 24], ["SMX", "CHEMICAL", 25, 28], ["TMP", "SIMPLE_CHEMICAL", 21, 24], ["SMX", "SIMPLE_CHEMICAL", 25, 28], ["Adverse reactions", "PROBLEM", 0, 17], ["TMP/SMX", "TREATMENT", 21, 28], ["treatment", "TREATMENT", 93, 102]]], ["Neutropenia and anemia (in up to 40% of patients), rash and fever (up to 30%), and biochemical abnormalities of liver function (up to 15%) are the most frequent adverse reactions.", [["liver", "ANATOMY", 112, 117], ["Neutropenia", "DISEASE", 0, 11], ["anemia", "DISEASE", 16, 22], ["rash", "DISEASE", 51, 55], ["fever", "DISEASE", 60, 65], ["abnormalities of liver function", "DISEASE", 95, 126], ["patients", "ORGANISM", 40, 48], ["liver", "ORGAN", 112, 117], ["patients", "SPECIES", 40, 48], ["Neutropenia", "PROBLEM", 0, 11], ["anemia", "PROBLEM", 16, 22], ["rash", "PROBLEM", 51, 55], ["fever", "PROBLEM", 60, 65], ["biochemical abnormalities of liver function", "PROBLEM", 83, 126], ["the most frequent adverse reactions", "PROBLEM", 143, 178], ["anemia", "OBSERVATION", 16, 22], ["rash", "OBSERVATION", 51, 55], ["fever", "OBSERVATION", 60, 65], ["abnormalities", "OBSERVATION", 95, 108], ["liver", "ANATOMY", 112, 117]]], ["Hematologic toxicity induced by TMP/SMX is neither attenuated nor prevented by coadministration of folic or folinic acid.", [["toxicity", "DISEASE", 12, 20], ["TMP", "CHEMICAL", 32, 35], ["SMX", "CHEMICAL", 36, 39], ["folic", "CHEMICAL", 99, 104], ["folinic acid", "CHEMICAL", 108, 120], ["TMP", "CHEMICAL", 32, 35], ["SMX", "CHEMICAL", 36, 39], ["folic or folinic acid", "CHEMICAL", 99, 120], ["TMP", "SIMPLE_CHEMICAL", 32, 35], ["SMX", "SIMPLE_CHEMICAL", 36, 39], ["folic", "SIMPLE_CHEMICAL", 99, 104], ["folinic acid", "SIMPLE_CHEMICAL", 108, 120], ["Hematologic toxicity", "PROBLEM", 0, 20], ["TMP/SMX", "TEST", 32, 39], ["attenuated", "PROBLEM", 51, 61], ["folic or folinic acid", "TREATMENT", 99, 120]]], ["Furthermore, the use of these agents may be associated with reduced therapeutic success.", [["these agents", "TREATMENT", 24, 36]]], ["During treatment with TMP/ SMX, full blood count, liver function, and urea and electrolytes should be monitored at least twice weekly.Trimethoprim-SulfamethoxazoleIt is not known why HIV-infected individuals, especially those with higher CD4 counts, have such a high frequency of adverse reactions to TMP/SMX.", [["blood", "ANATOMY", 37, 42], ["liver", "ANATOMY", 50, 55], ["TMP", "CHEMICAL", 22, 25], ["SMX", "CHEMICAL", 27, 30], ["urea", "CHEMICAL", 70, 74], ["Trimethoprim-SulfamethoxazoleIt", "CHEMICAL", 134, 165], ["HIV-infected", "DISEASE", 183, 195], ["TMP", "CHEMICAL", 301, 304], ["SMX", "CHEMICAL", 305, 308], ["TMP", "CHEMICAL", 22, 25], ["SMX", "CHEMICAL", 27, 30], ["urea", "CHEMICAL", 70, 74], ["Trimethoprim-SulfamethoxazoleIt", "CHEMICAL", 134, 165], ["TMP", "CHEMICAL", 301, 304], ["SMX", "CHEMICAL", 305, 308], ["TMP", "SIMPLE_CHEMICAL", 22, 25], ["SMX", "SIMPLE_CHEMICAL", 27, 30], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["liver", "ORGAN", 50, 55], ["urea", "SIMPLE_CHEMICAL", 70, 74], ["electrolytes", "SIMPLE_CHEMICAL", 79, 91], ["Trimethoprim-SulfamethoxazoleIt", "SIMPLE_CHEMICAL", 134, 165], ["HIV", "ORGANISM", 183, 186], ["individuals", "ORGANISM", 196, 207], ["CD4", "GENE_OR_GENE_PRODUCT", 238, 241], ["TMP", "SIMPLE_CHEMICAL", 301, 304], ["SMX", "SIMPLE_CHEMICAL", 305, 308], ["CD4", "PROTEIN", 238, 241], ["HIV", "SPECIES", 183, 186], ["treatment", "TREATMENT", 7, 16], ["TMP/ SMX", "TEST", 22, 30], ["full blood count", "TEST", 32, 48], ["liver function", "TEST", 50, 64], ["urea", "TEST", 70, 74], ["electrolytes", "TEST", 79, 91], ["Trimethoprim", "TREATMENT", 134, 146], ["SulfamethoxazoleIt", "TREATMENT", 147, 165], ["HIV", "PROBLEM", 183, 186], ["infected individuals", "PROBLEM", 187, 207], ["higher CD4 counts", "PROBLEM", 231, 248], ["adverse reactions", "PROBLEM", 280, 297], ["TMP/SMX", "TREATMENT", 301, 308], ["liver", "ANATOMY", 50, 55]]], ["The optimum strategy for an HIV-infected patient who has PCP and who becomes intolerant of high-dose TMP/SMX has not been established.", [["HIV-infected", "DISEASE", 28, 40], ["PCP", "DISEASE", 57, 60], ["TMP", "CHEMICAL", 101, 104], ["SMX", "CHEMICAL", 105, 108], ["PCP", "CHEMICAL", 57, 60], ["TMP", "CHEMICAL", 101, 104], ["SMX", "CHEMICAL", 105, 108], ["HIV", "ORGANISM", 28, 31], ["patient", "ORGANISM", 41, 48], ["TMP", "SIMPLE_CHEMICAL", 101, 104], ["SMX", "SIMPLE_CHEMICAL", 105, 108], ["patient", "SPECIES", 41, 48], ["HIV", "SPECIES", 28, 31], ["The optimum strategy", "TREATMENT", 0, 20], ["high-dose TMP/SMX", "TREATMENT", 91, 108]]], ["Many physicians \"treat through\" minor rash, often adding an antihistamine and a short course of oral prednisolone (30 mg every 24 h, reducing to zero over 5 days).Other TherapyIf treatment with TMP/SMX fails, or is not tolerated by the patient, several alternative therapies are available (see Tables 34-9 and 34-10).Clindamycin-PrimaquineThe combination of clindamycin and primaquine is widely used for treatment of PCP whatever the severity, although there is no license in the United Kingdom or United States for this indication.", [["oral", "ANATOMY", 96, 100], ["rash", "DISEASE", 38, 42], ["prednisolone", "CHEMICAL", 101, 113], ["TherapyIf", "CHEMICAL", 169, 178], ["TMP", "CHEMICAL", 194, 197], ["SMX", "CHEMICAL", 198, 201], ["Clindamycin", "CHEMICAL", 317, 328], ["Primaquine", "CHEMICAL", 329, 339], ["clindamycin", "CHEMICAL", 358, 369], ["primaquine", "CHEMICAL", 374, 384], ["PCP", "DISEASE", 417, 420], ["prednisolone", "CHEMICAL", 101, 113], ["TMP", "CHEMICAL", 194, 197], ["SMX", "CHEMICAL", 198, 201], ["Clindamycin", "CHEMICAL", 317, 328], ["Primaquine", "CHEMICAL", 329, 339], ["clindamycin", "CHEMICAL", 358, 369], ["primaquine", "CHEMICAL", 374, 384], ["PCP", "CHEMICAL", 417, 420], ["oral", "ORGANISM_SUBDIVISION", 96, 100], ["prednisolone", "SIMPLE_CHEMICAL", 101, 113], ["TMP", "SIMPLE_CHEMICAL", 194, 197], ["SMX", "SIMPLE_CHEMICAL", 198, 201], ["patient", "ORGANISM", 236, 243], ["Clindamycin", "SIMPLE_CHEMICAL", 317, 328], ["clindamycin", "SIMPLE_CHEMICAL", 358, 369], ["primaquine", "SIMPLE_CHEMICAL", 374, 384], ["patient", "SPECIES", 236, 243], ["minor rash", "PROBLEM", 32, 42], ["an antihistamine", "TREATMENT", 57, 73], ["oral prednisolone", "TREATMENT", 96, 113], ["Other TherapyIf treatment", "TREATMENT", 163, 188], ["TMP/SMX fails", "TREATMENT", 194, 207], ["several alternative therapies", "TREATMENT", 245, 274], ["Clindamycin", "TREATMENT", 317, 328], ["Primaquine", "TREATMENT", 329, 339], ["clindamycin", "TREATMENT", 358, 369], ["primaquine", "TREATMENT", 374, 384], ["treatment", "TREATMENT", 404, 413], ["no", "UNCERTAINTY", 462, 464]]], ["The combination is as effective as oral TMP/SMX and oral trimethoprim-dapsone for the treatment of mild and moderate-severity disease.", [["oral", "ANATOMY", 35, 39], ["oral", "ANATOMY", 52, 56], ["TMP", "CHEMICAL", 40, 43], ["SMX", "CHEMICAL", 44, 47], ["trimethoprim-dapsone", "CHEMICAL", 57, 77], ["TMP", "CHEMICAL", 40, 43], ["SMX", "CHEMICAL", 44, 47], ["trimethoprim", "CHEMICAL", 57, 69], ["dapsone", "CHEMICAL", 70, 77], ["oral", "ORGANISM_SUBDIVISION", 35, 39], ["TMP", "SIMPLE_CHEMICAL", 40, 43], ["SMX", "SIMPLE_CHEMICAL", 44, 47], ["oral", "ORGANISM_SUBDIVISION", 52, 56], ["trimethoprim-dapsone", "SIMPLE_CHEMICAL", 57, 77], ["oral TMP/SMX", "TREATMENT", 35, 47], ["oral trimethoprim", "TREATMENT", 52, 69], ["dapsone", "TREATMENT", 70, 77], ["the treatment", "TREATMENT", 82, 95], ["mild and moderate-severity disease", "PROBLEM", 99, 133], ["mild", "OBSERVATION_MODIFIER", 99, 103], ["moderate", "OBSERVATION_MODIFIER", 108, 116], ["severity", "OBSERVATION_MODIFIER", 117, 125], ["disease", "OBSERVATION", 126, 133]]], ["As a second-line treatment it is effective in up to 90% of patients.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["a second-line treatment", "TREATMENT", 3, 26]]], ["Methemoglobinemia caused by primaquine occurs in up to 40% of patients.", [["Methemoglobinemia", "DISEASE", 0, 17], ["primaquine", "CHEMICAL", 28, 38], ["primaquine", "CHEMICAL", 28, 38], ["primaquine", "SIMPLE_CHEMICAL", 28, 38], ["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70], ["Methemoglobinemia", "PROBLEM", 0, 17], ["primaquine", "TREATMENT", 28, 38], ["primaquine", "OBSERVATION", 28, 38]]], ["If 15 mg four times daily of primaquine is used, rather than 30 mg four times daily, the likelihood of methemoglobinemia is reduced.", [["primaquine", "CHEMICAL", 29, 39], ["methemoglobinemia", "DISEASE", 103, 120], ["primaquine", "CHEMICAL", 29, 39], ["primaquine", "SIMPLE_CHEMICAL", 29, 39], ["primaquine", "TREATMENT", 29, 39], ["methemoglobinemia", "PROBLEM", 103, 120], ["methemoglobinemia", "OBSERVATION", 103, 120], ["reduced", "OBSERVATION_MODIFIER", 124, 131]]], ["Diarrhea develops in up to 33% of patients receiving clindamycin.", [["Diarrhea", "DISEASE", 0, 8], ["clindamycin", "CHEMICAL", 53, 64], ["clindamycin", "CHEMICAL", 53, 64], ["patients", "ORGANISM", 34, 42], ["clindamycin", "SIMPLE_CHEMICAL", 53, 64], ["patients", "SPECIES", 34, 42], ["Diarrhea", "PROBLEM", 0, 8], ["clindamycin", "TREATMENT", 53, 64]]], ["If this occurs, stool samples should be analyzed for the presence of Clostridium difficile toxin.Trimethoprim-DapsoneThis oral combination is as effective as oral TMP/SMX and oral clindamycin plus primaquine (see earlier) for treatment of mild and moderate-severity PCP.", [["stool samples", "ANATOMY", 16, 29], ["oral", "ANATOMY", 122, 126], ["oral", "ANATOMY", 158, 162], ["oral", "ANATOMY", 175, 179], ["Clostridium difficile", "DISEASE", 69, 90], ["Trimethoprim-DapsoneThis", "CHEMICAL", 97, 121], ["TMP", "CHEMICAL", 163, 166], ["SMX", "CHEMICAL", 167, 170], ["clindamycin", "CHEMICAL", 180, 191], ["primaquine", "CHEMICAL", 197, 207], ["PCP", "DISEASE", 266, 269], ["Trimethoprim", "CHEMICAL", 97, 109], ["TMP", "CHEMICAL", 163, 166], ["SMX", "CHEMICAL", 167, 170], ["clindamycin", "CHEMICAL", 180, 191], ["primaquine", "CHEMICAL", 197, 207], ["PCP", "CHEMICAL", 266, 269], ["stool samples", "ORGANISM_SUBSTANCE", 16, 29], ["Clostridium difficile toxin", "ORGANISM", 69, 96], ["Trimethoprim", "SIMPLE_CHEMICAL", 97, 109], ["oral", "ORGANISM_SUBDIVISION", 122, 126], ["oral", "ORGANISM_SUBDIVISION", 158, 162], ["TMP", "SIMPLE_CHEMICAL", 163, 166], ["SMX", "SIMPLE_CHEMICAL", 167, 170], ["oral", "ORGANISM_SUBDIVISION", 175, 179], ["clindamycin", "SIMPLE_CHEMICAL", 180, 191], ["primaquine", "SIMPLE_CHEMICAL", 197, 207], ["Clostridium difficile toxin", "PROTEIN", 69, 96], ["Clostridium difficile", "SPECIES", 69, 90], ["Clostridium difficile", "SPECIES", 69, 90], ["stool samples", "TEST", 16, 29], ["Clostridium difficile toxin", "PROBLEM", 69, 96], ["Trimethoprim", "TREATMENT", 97, 109], ["DapsoneThis oral combination", "TREATMENT", 110, 138], ["oral TMP/SMX", "TREATMENT", 158, 170], ["oral clindamycin", "TREATMENT", 175, 191], ["primaquine", "TREATMENT", 197, 207], ["treatment", "TREATMENT", 226, 235], ["mild and moderate-severity PCP", "PROBLEM", 239, 269], ["mild", "OBSERVATION_MODIFIER", 239, 243], ["moderate", "OBSERVATION_MODIFIER", 248, 256]]], ["The combination has not been shown to be effective in patients who have severe PCP.", [["PCP", "DISEASE", 79, 82], ["PCP", "CHEMICAL", 79, 82], ["patients", "ORGANISM", 54, 62], ["patients", "SPECIES", 54, 62], ["severe PCP", "PROBLEM", 72, 82], ["severe", "OBSERVATION_MODIFIER", 72, 78], ["PCP", "OBSERVATION", 79, 82]]], ["Most patients experience methemoglobinemia (caused by dapsone), which is usually asymptomatic.", [["methemoglobinemia", "DISEASE", 25, 42], ["dapsone", "CHEMICAL", 54, 61], ["dapsone", "CHEMICAL", 54, 61], ["patients", "ORGANISM", 5, 13], ["dapsone", "SIMPLE_CHEMICAL", 54, 61], ["patients", "SPECIES", 5, 13], ["methemoglobinemia", "PROBLEM", 25, 42], ["dapsone", "TREATMENT", 54, 61], ["methemoglobinemia", "OBSERVATION", 25, 42], ["asymptomatic", "OBSERVATION_MODIFIER", 81, 93]]], ["Up to one half of patients have mild hyperkalemia (<6.1 mmol/L) caused by trimethoprim.TrimetrexateA methotrexate analog, trimetrexate, is given intravenously together with folinic acid \"rescue\" to protect human cells from trimetrexate-induced toxicity.", [["intravenously", "ANATOMY", 145, 158], ["cells", "ANATOMY", 212, 217], ["hyperkalemia", "DISEASE", 37, 49], ["trimethoprim", "CHEMICAL", 74, 86], ["TrimetrexateA", "CHEMICAL", 87, 100], ["methotrexate", "CHEMICAL", 101, 113], ["trimetrexate", "CHEMICAL", 122, 134], ["folinic acid", "CHEMICAL", 173, 185], ["trimetrexate", "CHEMICAL", 223, 235], ["toxicity", "DISEASE", 244, 252], ["trimethoprim", "CHEMICAL", 74, 86], ["TrimetrexateA", "CHEMICAL", 87, 100], ["methotrexate", "CHEMICAL", 101, 113], ["trimetrexate", "CHEMICAL", 122, 134], ["folinic acid", "CHEMICAL", 173, 185], ["trimetrexate", "CHEMICAL", 223, 235], ["patients", "ORGANISM", 18, 26], ["trimethoprim", "SIMPLE_CHEMICAL", 74, 86], ["TrimetrexateA", "SIMPLE_CHEMICAL", 87, 100], ["methotrexate", "SIMPLE_CHEMICAL", 101, 113], ["trimetrexate", "SIMPLE_CHEMICAL", 122, 134], ["folinic acid", "SIMPLE_CHEMICAL", 173, 185], ["human", "ORGANISM", 206, 211], ["cells", "CELL", 212, 217], ["trimetrexate", "SIMPLE_CHEMICAL", 223, 235], ["human cells", "CELL_TYPE", 206, 217], ["patients", "SPECIES", 18, 26], ["human", "SPECIES", 206, 211], ["human", "SPECIES", 206, 211], ["mild hyperkalemia", "PROBLEM", 32, 49], ["trimethoprim", "TREATMENT", 74, 86], ["TrimetrexateA methotrexate analog", "TREATMENT", 87, 120], ["trimetrexate", "TREATMENT", 122, 134], ["folinic acid \"rescue", "TREATMENT", 173, 193], ["human cells", "PROBLEM", 206, 217], ["trimetrexate", "TREATMENT", 223, 235], ["induced toxicity", "PROBLEM", 236, 252], ["mild", "OBSERVATION_MODIFIER", 32, 36], ["hyperkalemia", "OBSERVATION", 37, 49]]], ["In patients who have moderate Regimen recommended by CDC/ NIH/IDSA, widely used in USA Methylprednisolone iv at 75% of dose given above for prednisoloneTrimetrexateMethylprednisolone Prednisolone 1 iv q24h, days 1-3 0.5 iv days 4-6 then 40 g po q24h reducing to 0, days 7-16Regimen widely used in United KingdomNB, None of these regimens for adjuvant glucocorticoid therapy have been compared in prospective clinical trials.Regimen widely used in United Kingdomto severe disease, trimetrexate-folinic acid is less effective than high-dose TMP/SMX, but serious treatment-limiting hematologic toxicity occurs less frequently with trimetrexate-folinic acid.AtovaquoneAtovaquone is licensed for the treatment of mild and moderate-severity PCP in patients who are intolerant of TMP/ SMX.", [["hematologic", "ANATOMY", 579, 590], ["Methylprednisolone", "CHEMICAL", 87, 105], ["prednisolone", "CHEMICAL", 140, 152], ["Trimetrexate", "CHEMICAL", 152, 164], ["Methylprednisolone", "CHEMICAL", 164, 182], ["Prednisolone", "CHEMICAL", 183, 195], ["trimetrexate-folinic acid", "CHEMICAL", 480, 505], ["TMP", "CHEMICAL", 539, 542], ["SMX", "CHEMICAL", 543, 546], ["toxicity", "DISEASE", 591, 599], ["trimetrexate-folinic acid", "CHEMICAL", 628, 653], ["Atovaquone", "CHEMICAL", 654, 664], ["Atovaquone", "CHEMICAL", 664, 674], ["PCP", "DISEASE", 735, 738], ["TMP", "CHEMICAL", 773, 776], ["SMX", "CHEMICAL", 778, 781], ["Methylprednisolone", "CHEMICAL", 87, 105], ["prednisolone", "CHEMICAL", 140, 152], ["Methylprednisolone", "CHEMICAL", 164, 182], ["Prednisolone", "CHEMICAL", 183, 195], ["trimetrexate-folinic acid", "CHEMICAL", 480, 505], ["TMP", "CHEMICAL", 539, 542], ["SMX", "CHEMICAL", 543, 546], ["trimetrexate", "CHEMICAL", 628, 640], ["folinic acid", "CHEMICAL", 641, 653], ["Atovaquone", "CHEMICAL", 664, 674], ["PCP", "CHEMICAL", 735, 738], ["TMP", "CHEMICAL", 773, 776], ["SMX", "CHEMICAL", 778, 781], ["patients", "ORGANISM", 3, 11], ["USA", "ORGANISM", 83, 86], ["Methylprednisolone", "SIMPLE_CHEMICAL", 87, 105], ["prednisolone", "SIMPLE_CHEMICAL", 140, 152], ["Trimetrexate", "SIMPLE_CHEMICAL", 152, 164], ["glucocorticoid", "SIMPLE_CHEMICAL", 351, 365], ["trimetrexate-folinic acid", "SIMPLE_CHEMICAL", 480, 505], ["TMP", "SIMPLE_CHEMICAL", 539, 542], ["SMX", "SIMPLE_CHEMICAL", 543, 546], ["hematologic", "CANCER", 579, 590], ["trimetrexate-folinic acid", "SIMPLE_CHEMICAL", 628, 653], ["Atovaquone", "SIMPLE_CHEMICAL", 654, 664], ["Atovaquone", "SIMPLE_CHEMICAL", 664, 674], ["patients", "ORGANISM", 742, 750], ["TMP", "SIMPLE_CHEMICAL", 773, 776], ["SMX", "SIMPLE_CHEMICAL", 778, 781], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 742, 750], ["moderate Regimen", "TREATMENT", 21, 37], ["USA Methylprednisolone iv", "TREATMENT", 83, 108], ["prednisolone", "TREATMENT", 140, 152], ["TrimetrexateMethylprednisolone Prednisolone", "TREATMENT", 152, 195], ["these regimens", "TREATMENT", 323, 337], ["adjuvant glucocorticoid therapy", "TREATMENT", 342, 373], ["Regimen", "TREATMENT", 424, 431], ["severe disease", "PROBLEM", 464, 478], ["trimetrexate-folinic acid", "TREATMENT", 480, 505], ["TMP/SMX", "TREATMENT", 539, 546], ["serious treatment", "TREATMENT", 552, 569], ["hematologic toxicity", "PROBLEM", 579, 599], ["trimetrexate-folinic acid", "TREATMENT", 628, 653], ["AtovaquoneAtovaquone", "TREATMENT", 654, 674], ["mild and moderate-severity PCP", "PROBLEM", 708, 738], ["TMP/ SMX", "TREATMENT", 773, 781], ["severe", "OBSERVATION_MODIFIER", 464, 470], ["disease", "OBSERVATION", 471, 478], ["mild", "OBSERVATION_MODIFIER", 708, 712], ["moderate", "OBSERVATION_MODIFIER", 717, 725]]], ["In tablet formulation (no longer available), this drug was less effective but was better tolerated than TMP/SMX or intravenous pentamidine for treatment of mild or moderateseverity PCP (see Tables 34-9 and 34-10).", [["intravenous", "ANATOMY", 115, 126], ["TMP", "CHEMICAL", 104, 107], ["SMX", "CHEMICAL", 108, 111], ["pentamidine", "CHEMICAL", 127, 138], ["PCP", "DISEASE", 181, 184], ["TMP", "CHEMICAL", 104, 107], ["SMX", "CHEMICAL", 108, 111], ["pentamidine", "CHEMICAL", 127, 138], ["PCP", "CHEMICAL", 181, 184], ["TMP", "SIMPLE_CHEMICAL", 104, 107], ["SMX", "SIMPLE_CHEMICAL", 108, 111], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 115, 126], ["pentamidine", "SIMPLE_CHEMICAL", 127, 138], ["TMP/SMX", "TREATMENT", 104, 111], ["intravenous pentamidine", "TREATMENT", 115, 138], ["treatment", "TREATMENT", 143, 152], ["mild or moderateseverity PCP", "PROBLEM", 156, 184], ["mild", "OBSERVATION_MODIFIER", 156, 160]]], ["There are no data from prospective studies that compare the liquid formulation (which has better bioavailability) with other treatment regimens.", [["prospective studies", "TEST", 23, 42], ["the liquid formulation", "TREATMENT", 56, 78], ["other treatment regimens", "TREATMENT", 119, 143], ["no", "UNCERTAINTY", 10, 12]]], ["Common adverse reactions include rash, fever, nausea and vomiting, and constipation.", [["rash", "DISEASE", 33, 37], ["fever", "DISEASE", 39, 44], ["nausea", "DISEASE", 46, 52], ["vomiting", "DISEASE", 57, 65], ["constipation", "DISEASE", 71, 83], ["Common adverse reactions", "PROBLEM", 0, 24], ["rash", "PROBLEM", 33, 37], ["fever", "PROBLEM", 39, 44], ["nausea", "PROBLEM", 46, 52], ["vomiting", "PROBLEM", 57, 65], ["constipation", "PROBLEM", 71, 83], ["rash", "OBSERVATION", 33, 37], ["fever", "OBSERVATION", 39, 44], ["constipation", "OBSERVATION", 71, 83]]], ["Absorption of atovaquone is increased if it is taken with food.Intravenous PentamidineIntravenous pentamidine is now seldom used for the treatment of mild or moderate-severity PCP because of its toxicity.", [["Intravenous", "ANATOMY", 63, 74], ["atovaquone", "CHEMICAL", 14, 24], ["Pentamidine", "CHEMICAL", 75, 86], ["pentamidine", "CHEMICAL", 98, 109], ["PCP", "DISEASE", 176, 179], ["toxicity", "DISEASE", 195, 203], ["atovaquone", "CHEMICAL", 14, 24], ["Pentamidine", "CHEMICAL", 75, 86], ["pentamidine", "CHEMICAL", 98, 109], ["PCP", "CHEMICAL", 176, 179], ["atovaquone", "SIMPLE_CHEMICAL", 14, 24], ["Pentamidine", "SIMPLE_CHEMICAL", 75, 86], ["pentamidine", "SIMPLE_CHEMICAL", 98, 109], ["atovaquone", "TREATMENT", 14, 24], ["Intravenous PentamidineIntravenous pentamidine", "TREATMENT", 63, 109], ["the treatment", "TREATMENT", 133, 146], ["mild or moderate-severity PCP", "PROBLEM", 150, 179], ["its toxicity", "PROBLEM", 191, 203], ["mild", "OBSERVATION_MODIFIER", 150, 154], ["moderate", "OBSERVATION_MODIFIER", 158, 166]]], ["Intravenous pentamidine may be used in patients who have severe PCP, despite its toxicity, if other agents have failed (see Tables 34-9 and 34-10).", [["pentamidine", "CHEMICAL", 12, 23], ["PCP", "DISEASE", 64, 67], ["toxicity", "DISEASE", 81, 89], ["pentamidine", "CHEMICAL", 12, 23], ["PCP", "CHEMICAL", 64, 67], ["pentamidine", "SIMPLE_CHEMICAL", 12, 23], ["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47], ["Intravenous pentamidine", "TREATMENT", 0, 23], ["severe PCP", "PROBLEM", 57, 67], ["its toxicity", "PROBLEM", 77, 89]]], ["Nephrotoxicity develops in almost 60% of patients given intravenous pentamidine (indicated by elevation in serum creatinine), leukopenia develops in approximately half, and up to 25% have symptomatic hypotension or nausea and vomiting.", [["intravenous", "ANATOMY", 56, 67], ["serum", "ANATOMY", 107, 112], ["Nephrotoxicity", "DISEASE", 0, 14], ["pentamidine", "CHEMICAL", 68, 79], ["creatinine", "CHEMICAL", 113, 123], ["leukopenia", "DISEASE", 126, 136], ["hypotension", "DISEASE", 200, 211], ["nausea", "DISEASE", 215, 221], ["vomiting", "DISEASE", 226, 234], ["pentamidine", "CHEMICAL", 68, 79], ["creatinine", "CHEMICAL", 113, 123], ["patients", "ORGANISM", 41, 49], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 56, 67], ["pentamidine", "SIMPLE_CHEMICAL", 68, 79], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["creatinine", "SIMPLE_CHEMICAL", 113, 123], ["patients", "SPECIES", 41, 49], ["Nephrotoxicity", "PROBLEM", 0, 14], ["intravenous pentamidine", "TREATMENT", 56, 79], ["elevation in serum creatinine", "PROBLEM", 94, 123], ["leukopenia", "PROBLEM", 126, 136], ["symptomatic hypotension", "PROBLEM", 188, 211], ["nausea", "PROBLEM", 215, 221], ["vomiting", "PROBLEM", 226, 234], ["leukopenia", "OBSERVATION", 126, 136], ["symptomatic", "OBSERVATION_MODIFIER", 188, 199], ["hypotension", "OBSERVATION", 200, 211]]], ["Hypoglycemia occurs in approximately 20% of patients.", [["Hypoglycemia", "DISEASE", 0, 12], ["patients", "ORGANISM", 44, 52], ["patients", "SPECIES", 44, 52], ["Hypoglycemia", "PROBLEM", 0, 12]]], ["Given the long half-life of the drug, this may occur up to several days after the discontinuation of treatment.", [["the discontinuation of treatment", "TREATMENT", 78, 110]]], ["Pancreatitis is also a recognized side effect.Adjuvant GlucocorticoidsFor patients who have moderate and severe PCP, adjuvant glucocorticoid therapy reduces the risk of respiratory failure by up to half and the risk of death by up to one third (see Tables 34-9 and 34-10).", [["respiratory", "ANATOMY", 169, 180], ["Pancreatitis", "DISEASE", 0, 12], ["PCP", "DISEASE", 112, 115], ["respiratory failure", "DISEASE", 169, 188], ["death", "DISEASE", 219, 224], ["PCP", "CHEMICAL", 112, 115], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["Pancreatitis", "PROBLEM", 0, 12], ["a recognized side effect", "PROBLEM", 21, 45], ["Adjuvant Glucocorticoids", "TREATMENT", 46, 70], ["moderate and severe PCP", "PROBLEM", 92, 115], ["adjuvant glucocorticoid therapy", "TREATMENT", 117, 148], ["respiratory failure", "PROBLEM", 169, 188], ["death", "PROBLEM", 219, 224], ["side effect", "OBSERVATION_MODIFIER", 34, 45], ["moderate", "OBSERVATION_MODIFIER", 92, 100], ["severe", "OBSERVATION_MODIFIER", 105, 111], ["glucocorticoid therapy", "OBSERVATION", 126, 148], ["respiratory failure", "OBSERVATION", 169, 188]]], ["Glucocorticoids are given to HIVinfected patients with confirmed or suspected PCP who have a PaO 2 <9.3 kPa (<70 mmHg) or an A-aO 2 of >4.7 kPa (<33 mmHg).", [["PCP", "DISEASE", 78, 81], ["PCP", "CHEMICAL", 78, 81], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Glucocorticoids", "TREATMENT", 0, 15], ["a PaO", "TEST", 91, 96], ["kPa", "TEST", 104, 107], ["an A", "TEST", 122, 126], ["kPa", "TEST", 140, 143]]], ["Oral or intravenous adjunctive therapy is given at the same time as (or within 72 h of starting) specific anti-P. jirovecii therapy.", [["Oral", "ANATOMY", 0, 4], ["intravenous", "ANATOMY", 8, 19], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 8, 19], ["anti-P. jirovecii", "ORGANISM", 106, 123], ["anti-P. jirovecii", "SPECIES", 106, 123], ["Oral or intravenous adjunctive therapy", "TREATMENT", 0, 38], ["specific anti-P. jirovecii therapy", "TREATMENT", 97, 131]]], ["Clearly, in some patients treatment is commenced on a presumptive basis, pending confirmation of the diagnosis.", [["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25]]], ["In prospective studies, adjuvant glucocorticoids have not been shown to be of benefit in patients with mild PCP.", [["glucocorticoids", "CHEMICAL", 33, 48], ["PCP", "DISEASE", 108, 111], ["PCP", "CHEMICAL", 108, 111], ["glucocorticoids", "SIMPLE_CHEMICAL", 33, 48], ["patients", "ORGANISM", 89, 97], ["patients", "SPECIES", 89, 97], ["prospective studies", "TEST", 3, 22], ["adjuvant glucocorticoids", "TREATMENT", 24, 48], ["mild PCP", "PROBLEM", 103, 111], ["mild", "OBSERVATION_MODIFIER", 103, 107], ["PCP", "OBSERVATION", 108, 111]]], ["However, it would be difficult to demonstrate this, given that survival in such cases approaches 95% with standard treatment.General Management of Pneumocystis jirovecii PneumoniaPatients with mild PCP may be treated with oral TMP/SMX as outpatients if they are able to manage at home, willing to attend the outpatient clinic for regular review, and that there is clinical and radiographic evidence of recovery.", [["oral", "ANATOMY", 222, 226], ["Pneumocystis jirovecii PneumoniaPatients", "DISEASE", 147, 187], ["PCP", "DISEASE", 198, 201], ["TMP", "CHEMICAL", 227, 230], ["SMX", "CHEMICAL", 231, 234], ["TMP", "CHEMICAL", 227, 230], ["SMX", "CHEMICAL", 231, 234], ["Pneumocystis jirovecii", "ORGANISM", 147, 169], ["oral", "ORGANISM_SUBDIVISION", 222, 226], ["TMP", "SIMPLE_CHEMICAL", 227, 230], ["SMX", "SIMPLE_CHEMICAL", 231, 234], ["Pneumocystis jirovecii", "SPECIES", 147, 169], ["Pneumocystis jirovecii", "SPECIES", 147, 169], ["standard treatment", "TREATMENT", 106, 124], ["General Management", "TREATMENT", 125, 143], ["Pneumocystis jirovecii", "PROBLEM", 147, 169], ["mild PCP", "PROBLEM", 193, 201], ["oral TMP/SMX", "TREATMENT", 222, 234], ["Pneumocystis jirovecii", "OBSERVATION", 147, 169], ["mild", "OBSERVATION_MODIFIER", 193, 197]]], ["If the patient is intolerant of oral TMP/SMX despite clinical recovery, either the treatment is given intravenously or treatment may be changed to oral clindamycin plus primaquine.", [["oral", "ANATOMY", 32, 36], ["intravenously", "ANATOMY", 102, 115], ["oral", "ANATOMY", 147, 151], ["TMP", "CHEMICAL", 37, 40], ["SMX", "CHEMICAL", 41, 44], ["clindamycin", "CHEMICAL", 152, 163], ["primaquine", "CHEMICAL", 169, 179], ["TMP", "CHEMICAL", 37, 40], ["SMX", "CHEMICAL", 41, 44], ["clindamycin", "CHEMICAL", 152, 163], ["primaquine", "CHEMICAL", 169, 179], ["patient", "ORGANISM", 7, 14], ["oral", "ORGANISM_SUBDIVISION", 32, 36], ["TMP", "SIMPLE_CHEMICAL", 37, 40], ["SMX", "SIMPLE_CHEMICAL", 41, 44], ["oral", "ORGANISM_SUBDIVISION", 147, 151], ["clindamycin", "SIMPLE_CHEMICAL", 152, 163], ["primaquine", "SIMPLE_CHEMICAL", 169, 179], ["patient", "SPECIES", 7, 14], ["oral TMP", "TREATMENT", 32, 40], ["SMX", "TREATMENT", 41, 44], ["the treatment", "TREATMENT", 79, 92], ["treatment", "TREATMENT", 119, 128], ["oral clindamycin", "TREATMENT", 147, 163], ["primaquine", "TREATMENT", 169, 179]]], ["All patients with moderate and severe PCP should be hospitalized and given intravenous TMP/SMX or intravenous clindamycin and oral primaquine (plus adjuvant steroids).", [["intravenous", "ANATOMY", 75, 86], ["intravenous", "ANATOMY", 98, 109], ["oral", "ANATOMY", 126, 130], ["PCP", "DISEASE", 38, 41], ["TMP", "CHEMICAL", 87, 90], ["SMX", "CHEMICAL", 91, 94], ["clindamycin", "CHEMICAL", 110, 121], ["primaquine", "CHEMICAL", 131, 141], ["steroids", "CHEMICAL", 157, 165], ["PCP", "CHEMICAL", 38, 41], ["TMP", "CHEMICAL", 87, 90], ["SMX", "CHEMICAL", 91, 94], ["clindamycin", "CHEMICAL", 110, 121], ["primaquine", "CHEMICAL", 131, 141], ["steroids", "CHEMICAL", 157, 165], ["patients", "ORGANISM", 4, 12], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 86], ["TMP", "SIMPLE_CHEMICAL", 87, 90], ["SMX", "SIMPLE_CHEMICAL", 91, 94], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 98, 109], ["clindamycin", "SIMPLE_CHEMICAL", 110, 121], ["oral", "ORGANISM_SUBDIVISION", 126, 130], ["primaquine", "SIMPLE_CHEMICAL", 131, 141], ["patients", "SPECIES", 4, 12], ["moderate and severe PCP", "PROBLEM", 18, 41], ["intravenous TMP", "TREATMENT", 75, 90], ["SMX", "TREATMENT", 91, 94], ["intravenous clindamycin", "TREATMENT", 98, 121], ["oral primaquine", "TREATMENT", 126, 141], ["adjuvant steroids", "TREATMENT", 148, 165], ["moderate", "OBSERVATION_MODIFIER", 18, 26], ["severe", "OBSERVATION_MODIFIER", 31, 37]]], ["Patients with moderate or severe disease who show clinical and radiographic response by day 7-10 of therapy may be switched to oral TMP/SMX to complete the remaining 14 days of treatment.General Management of Pneumocystis jirovecii PneumoniaIf the patient has failed to respond within 7-10 days or deteriorates before this time while receiving TMP/SMX, then treatment should be changed to clindamycin and primaquine or trimetrexate plus folinic acid.Deterioration in the Patient with Pneumocystis jirovecii PneumoniaDeterioration in a patient who is receiving anti-P. jirovecii therapy may occur for several reasons (Table 34-11) .", [["oral", "ANATOMY", 127, 131], ["TMP", "CHEMICAL", 132, 135], ["SMX", "CHEMICAL", 136, 139], ["Pneumocystis jirovecii", "DISEASE", 209, 231], ["TMP", "CHEMICAL", 344, 347], ["SMX", "CHEMICAL", 348, 351], ["clindamycin", "CHEMICAL", 389, 400], ["primaquine", "CHEMICAL", 405, 415], ["trimetrexate", "CHEMICAL", 419, 431], ["folinic acid", "CHEMICAL", 437, 449], ["Pneumocystis jirovecii PneumoniaDeterioration", "DISEASE", 484, 529], ["anti-P. jirovecii", "DISEASE", 560, 577], ["TMP", "CHEMICAL", 132, 135], ["SMX", "CHEMICAL", 136, 139], ["TMP", "CHEMICAL", 344, 347], ["SMX", "CHEMICAL", 348, 351], ["clindamycin", "CHEMICAL", 389, 400], ["primaquine", "CHEMICAL", 405, 415], ["trimetrexate", "CHEMICAL", 419, 431], ["folinic acid", "CHEMICAL", 437, 449], ["Patients", "ORGANISM", 0, 8], ["oral", "ORGANISM_SUBDIVISION", 127, 131], ["TMP", "SIMPLE_CHEMICAL", 132, 135], ["SMX", "SIMPLE_CHEMICAL", 136, 139], ["Pneumocystis jirovecii", "ORGANISM", 209, 231], ["patient", "ORGANISM", 248, 255], ["TMP", "SIMPLE_CHEMICAL", 344, 347], ["SMX", "SIMPLE_CHEMICAL", 348, 351], ["clindamycin", "SIMPLE_CHEMICAL", 389, 400], ["primaquine", "SIMPLE_CHEMICAL", 405, 415], ["trimetrexate", "SIMPLE_CHEMICAL", 419, 431], ["folinic acid", "SIMPLE_CHEMICAL", 437, 449], ["Pneumocystis jirovecii", "ORGANISM", 484, 506], ["patient", "ORGANISM", 535, 542], ["anti-P. jirovecii", "ORGANISM", 560, 577], ["Patients", "SPECIES", 0, 8], ["Pneumocystis jirovecii", "SPECIES", 209, 231], ["patient", "SPECIES", 248, 255], ["Patient", "SPECIES", 471, 478], ["Pneumocystis jirovecii", "SPECIES", 484, 506], ["patient", "SPECIES", 535, 542], ["anti-P. jirovecii", "SPECIES", 560, 577], ["Pneumocystis jirovecii", "SPECIES", 209, 231], ["Pneumocystis jirovecii", "SPECIES", 484, 506], ["anti-P. jirovecii", "SPECIES", 560, 577], ["moderate or severe disease", "PROBLEM", 14, 40], ["therapy", "TREATMENT", 100, 107], ["oral TMP/SMX", "TREATMENT", 127, 139], ["treatment", "TREATMENT", 177, 186], ["General Management", "TREATMENT", 187, 205], ["Pneumocystis jirovecii", "PROBLEM", 209, 231], ["TMP/SMX", "TREATMENT", 344, 351], ["treatment", "TREATMENT", 358, 367], ["clindamycin", "TREATMENT", 389, 400], ["primaquine", "TREATMENT", 405, 415], ["trimetrexate", "TREATMENT", 419, 431], ["folinic acid", "TREATMENT", 437, 449], ["Deterioration", "PROBLEM", 450, 463], ["Pneumocystis jirovecii PneumoniaDeterioration", "PROBLEM", 484, 529], ["anti-P. jirovecii therapy", "TREATMENT", 560, 585], ["moderate", "OBSERVATION_MODIFIER", 14, 22], ["severe", "OBSERVATION_MODIFIER", 26, 32], ["disease", "OBSERVATION", 33, 40], ["Pneumocystis jirovecii", "OBSERVATION", 209, 231], ["Pneumocystis jirovecii", "OBSERVATION", 484, 506]]], ["Before ascribing deterioration to treatment failure and considering a change in therapy, these alternatives should be evaluated carefully.", [["treatment failure", "PROBLEM", 34, 51], ["a change in therapy", "TREATMENT", 68, 87], ["these alternatives", "TREATMENT", 89, 107], ["treatment", "OBSERVATION_MODIFIER", 34, 43], ["failure", "OBSERVATION", 44, 51]]], ["It is also important to consider treating any co-pathogens present in BAL fluid, to perform bronchoscopy if the diagnosis was made empirically, to repeat the procedure, or to carry out open lung biopsy to confirm that the diagnosis is correct.Intensive CareMost centers advocate admission to the ICU for PCP with respiratory failure and for acute severe deterioration after bronchoscopy.", [["BAL fluid", "ANATOMY", 70, 79], ["lung", "ANATOMY", 190, 194], ["respiratory", "ANATOMY", 313, 324], ["PCP", "DISEASE", 304, 307], ["respiratory failure", "DISEASE", 313, 332], ["PCP", "CHEMICAL", 304, 307], ["BAL fluid", "ORGANISM_SUBSTANCE", 70, 79], ["lung", "ORGAN", 190, 194], ["any co-pathogens", "PROBLEM", 42, 58], ["BAL fluid", "TEST", 70, 79], ["bronchoscopy", "TEST", 92, 104], ["the procedure", "TREATMENT", 154, 167], ["open lung biopsy", "TEST", 185, 201], ["respiratory failure", "PROBLEM", 313, 332], ["acute severe deterioration", "PROBLEM", 341, 367], ["bronchoscopy", "TEST", 374, 386], ["lung", "ANATOMY", 190, 194], ["biopsy", "OBSERVATION", 195, 201], ["respiratory", "ANATOMY", 313, 324], ["failure", "OBSERVATION", 325, 332], ["acute", "OBSERVATION_MODIFIER", 341, 346], ["severe", "OBSERVATION_MODIFIER", 347, 353], ["deterioration", "OBSERVATION", 354, 367]]], ["The prognosis for severe PCP in such circumstances has improved over the past decade.", [["PCP", "DISEASE", 25, 28], ["PCP", "CHEMICAL", 25, 28], ["severe PCP", "PROBLEM", 18, 28], ["severe", "OBSERVATION_MODIFIER", 18, 24], ["PCP", "OBSERVATION", 25, 28], ["improved", "OBSERVATION_MODIFIER", 55, 63]]], ["This is likely because of a greater understanding of successful general ICU management of respiratory failure and acute respiratory distress syndrome (ARDS) rather than specific improvements in PCP care.", [["respiratory", "ANATOMY", 90, 101], ["respiratory", "ANATOMY", 120, 131], ["respiratory failure", "DISEASE", 90, 109], ["acute respiratory distress syndrome", "DISEASE", 114, 149], ["ARDS", "DISEASE", 151, 155], ["PCP", "DISEASE", 194, 197], ["successful general ICU management", "TREATMENT", 53, 86], ["respiratory failure", "PROBLEM", 90, 109], ["acute respiratory distress syndrome", "PROBLEM", 114, 149], ["ARDS", "PROBLEM", 151, 155], ["respiratory failure", "OBSERVATION", 90, 109], ["acute", "OBSERVATION_MODIFIER", 114, 119], ["respiratory distress", "OBSERVATION", 120, 140]]], ["Factors associated with poor outcome include increasing patient age, need for mechanical ventilation, and development of a pneumothorax.", [["pneumothorax", "DISEASE", 123, 135], ["patient", "ORGANISM", 56, 63], ["patient", "SPECIES", 56, 63], ["poor outcome", "PROBLEM", 24, 36], ["mechanical ventilation", "TREATMENT", 78, 100], ["a pneumothorax", "PROBLEM", 121, 135], ["mechanical ventilation", "OBSERVATION", 78, 100], ["pneumothorax", "OBSERVATION", 123, 135]]], ["The latter reflects both the association between this complication and PCP, as well as the subsequent difficulty in successful mechanical ventilation of such individuals.Treatment of TuberculosisThe treatment of HIV-related mycobacterial disease is complex.", [["PCP", "DISEASE", 71, 74], ["Tuberculosis", "DISEASE", 183, 195], ["HIV-related mycobacterial disease", "DISEASE", 212, 245], ["PCP", "CHEMICAL", 71, 74], ["HIV", "ORGANISM", 212, 215], ["HIV", "SPECIES", 212, 215], ["HIV", "SPECIES", 212, 215], ["this complication", "PROBLEM", 49, 66], ["successful mechanical ventilation", "TREATMENT", 116, 149], ["such individuals", "PROBLEM", 153, 169], ["Tuberculosis", "PROBLEM", 183, 195], ["HIV-related mycobacterial disease", "PROBLEM", 212, 245], ["mechanical ventilation", "OBSERVATION", 127, 149], ["Tuberculosis", "OBSERVATION", 183, 195], ["mycobacterial disease", "OBSERVATION", 224, 245]]], ["Not only do individuals have to take prolonged courses of relatively toxic agents, but also these antimycobacterial drugs have side effects similar to those of other prescribedOverlapping ToxicityIn the developed world, isoniazid-related peripheral neuropathy is rare in HIV-negative subjects taking pyridoxine.", [["Toxicity", "DISEASE", 188, 196], ["isoniazid", "CHEMICAL", 220, 229], ["peripheral neuropathy", "DISEASE", 238, 259], ["pyridoxine", "CHEMICAL", 300, 310], ["isoniazid", "CHEMICAL", 220, 229], ["pyridoxine", "CHEMICAL", 300, 310], ["isoniazid", "SIMPLE_CHEMICAL", 220, 229], ["pyridoxine", "SIMPLE_CHEMICAL", 300, 310], ["HIV", "SPECIES", 271, 274], ["relatively toxic agents", "TREATMENT", 58, 81], ["these antimycobacterial drugs", "TREATMENT", 92, 121], ["side effects", "PROBLEM", 127, 139], ["Overlapping Toxicity", "PROBLEM", 176, 196], ["isoniazid", "TREATMENT", 220, 229], ["peripheral neuropathy", "PROBLEM", 238, 259], ["pyridoxine", "TREATMENT", 300, 310], ["isoniazid", "OBSERVATION", 220, 229], ["peripheral", "ANATOMY_MODIFIER", 238, 248], ["neuropathy", "OBSERVATION", 249, 259]]], ["The nucleoside reverse transcriptase inhibitors (RTI) didanosine and stavudine, which are now less frequently used in the United States and the United Kingdom but which remain a mainstay of HAART in the developing world, can also cause a painful peripheral neuropathy.", [["nucleoside", "CHEMICAL", 4, 14], ["didanosine", "CHEMICAL", 54, 64], ["stavudine", "CHEMICAL", 69, 78], ["peripheral neuropathy", "DISEASE", 246, 267], ["nucleoside", "CHEMICAL", 4, 14], ["didanosine", "CHEMICAL", 54, 64], ["stavudine", "CHEMICAL", 69, 78], ["nucleoside reverse transcriptase", "GENE_OR_GENE_PRODUCT", 4, 36], ["didanosine", "SIMPLE_CHEMICAL", 54, 64], ["stavudine", "SIMPLE_CHEMICAL", 69, 78], ["nucleoside reverse transcriptase", "PROTEIN", 4, 36], ["The nucleoside reverse transcriptase inhibitors", "TREATMENT", 0, 47], ["didanosine", "TREATMENT", 54, 64], ["stavudine", "TREATMENT", 69, 78], ["HAART", "TREATMENT", 190, 195], ["a painful peripheral neuropathy", "PROBLEM", 236, 267], ["painful", "OBSERVATION_MODIFIER", 238, 245], ["peripheral", "ANATOMY_MODIFIER", 246, 256], ["neuropathy", "OBSERVATION", 257, 267]]], ["This complication develops in up to 30% of patients if stavudine and isoniazid are coadministered.", [["stavudine", "CHEMICAL", 55, 64], ["isoniazid", "CHEMICAL", 69, 78], ["stavudine", "CHEMICAL", 55, 64], ["isoniazid", "CHEMICAL", 69, 78], ["patients", "ORGANISM", 43, 51], ["stavudine", "SIMPLE_CHEMICAL", 55, 64], ["isoniazid", "SIMPLE_CHEMICAL", 69, 78], ["patients", "SPECIES", 43, 51], ["This complication", "PROBLEM", 0, 17], ["stavudine", "TREATMENT", 55, 64], ["isoniazid", "TREATMENT", 69, 78]]], ["Rash, fever, and biochemical hepatitis are common adverse events with rifamycins, pyrazinamide, and isoniazid (occurring more frequently in patients with tuberculosis who have HIV infection with hepatitis C coinfection).", [["Rash", "DISEASE", 0, 4], ["fever", "DISEASE", 6, 11], ["biochemical hepatitis", "DISEASE", 17, 38], ["rifamycins", "CHEMICAL", 70, 80], ["pyrazinamide", "CHEMICAL", 82, 94], ["isoniazid", "CHEMICAL", 100, 109], ["tuberculosis", "DISEASE", 154, 166], ["HIV infection", "DISEASE", 176, 189], ["hepatitis C coinfection", "DISEASE", 195, 218], ["rifamycins", "CHEMICAL", 70, 80], ["pyrazinamide", "CHEMICAL", 82, 94], ["isoniazid", "CHEMICAL", 100, 109], ["rifamycins", "SIMPLE_CHEMICAL", 70, 80], ["pyrazinamide", "SIMPLE_CHEMICAL", 82, 94], ["isoniazid", "SIMPLE_CHEMICAL", 100, 109], ["patients", "ORGANISM", 140, 148], ["hepatitis C", "ORGANISM", 195, 206], ["patients", "SPECIES", 140, 148], ["HIV", "SPECIES", 176, 179], ["HIV", "SPECIES", 176, 179], ["Rash", "PROBLEM", 0, 4], ["fever", "PROBLEM", 6, 11], ["biochemical hepatitis", "PROBLEM", 17, 38], ["common adverse events", "PROBLEM", 43, 64], ["rifamycins", "TREATMENT", 70, 80], ["pyrazinamide", "TREATMENT", 82, 94], ["isoniazid", "TREATMENT", 100, 109], ["tuberculosis", "PROBLEM", 154, 166], ["HIV infection", "PROBLEM", 176, 189], ["hepatitis C coinfection", "PROBLEM", 195, 218], ["fever", "OBSERVATION", 6, 11], ["hepatitis", "OBSERVATION", 29, 38]]], ["The nonnucleoside RTI drugs (e.g., nevirapine) have a similar toxicity profile.", [["nevirapine", "CHEMICAL", 35, 45], ["toxicity", "DISEASE", 62, 70], ["nevirapine", "CHEMICAL", 35, 45], ["nevirapine", "SIMPLE_CHEMICAL", 35, 45], ["The nonnucleoside RTI drugs", "TREATMENT", 0, 27], ["nevirapine", "TREATMENT", 35, 45], ["a similar toxicity profile", "PROBLEM", 52, 78]]], ["If treatment for both HIV and tuberculosis is co-administered, ascribing a cause may be problematic.Drug-Drug InteractionsDrug-drug interactions between medications used to treat tuberculosis and HIV infection occur because of their common pathway of metabolism through the hepatic cytochrome P-450 enzyme system.", [["hepatic", "ANATOMY", 274, 281], ["HIV and tuberculosis", "DISEASE", 22, 42], ["tuberculosis", "DISEASE", 179, 191], ["HIV infection", "DISEASE", 196, 209], ["HIV", "ORGANISM", 22, 25], ["Drug-Drug", "SIMPLE_CHEMICAL", 100, 109], ["HIV", "ORGANISM", 196, 199], ["hepatic", "ORGAN", 274, 281], ["cytochrome P-450", "GENE_OR_GENE_PRODUCT", 282, 298], ["hepatic cytochrome P-450 enzyme", "PROTEIN", 274, 305], ["HIV", "SPECIES", 22, 25], ["HIV", "SPECIES", 196, 199], ["HIV", "SPECIES", 22, 25], ["HIV", "SPECIES", 196, 199], ["treatment", "TREATMENT", 3, 12], ["both HIV", "PROBLEM", 17, 25], ["tuberculosis", "PROBLEM", 30, 42], ["medications", "TREATMENT", 153, 164], ["tuberculosis", "PROBLEM", 179, 191], ["HIV infection", "PROBLEM", 196, 209], ["the hepatic cytochrome", "TEST", 270, 292], ["enzyme system", "TEST", 299, 312], ["tuberculosis", "OBSERVATION", 30, 42], ["tuberculosis", "OBSERVATION", 179, 191], ["hepatic", "ANATOMY", 274, 281]]], ["Rifampin is a potent inducer of this enzyme (rifabutin less so), which may result in subtherapeutic levels of nonnucleoside RTI and PI antiretroviral drugs, with the potential for inadequate suppression of HIV replication and the development of resistance to HIV.", [["Rifampin", "CHEMICAL", 0, 8], ["rifabutin", "CHEMICAL", 45, 54], ["Rifampin", "CHEMICAL", 0, 8], ["rifabutin", "CHEMICAL", 45, 54], ["Rifampin", "SIMPLE_CHEMICAL", 0, 8], ["rifabutin", "SIMPLE_CHEMICAL", 45, 54], ["nonnucleoside RTI", "SIMPLE_CHEMICAL", 110, 127], ["PI", "SIMPLE_CHEMICAL", 132, 134], ["HIV", "ORGANISM", 206, 209], ["HIV", "ORGANISM", 259, 262], ["HIV", "SPECIES", 259, 262], ["HIV", "SPECIES", 206, 209], ["HIV", "SPECIES", 259, 262], ["Rifampin", "TREATMENT", 0, 8], ["this enzyme", "TEST", 32, 43], ["rifabutin", "TREATMENT", 45, 54], ["nonnucleoside RTI", "TREATMENT", 110, 127], ["PI antiretroviral drugs", "TREATMENT", 132, 155], ["HIV replication", "TREATMENT", 206, 221], ["HIV", "PROBLEM", 259, 262]]], ["In addition, the PI class of antiretroviral drugs inhibits the metabolism of rifamycins, which leads to increases in their plasma concentration and is associated with increased drug toxicity.", [["plasma", "ANATOMY", 123, 129], ["rifamycins", "CHEMICAL", 77, 87], ["toxicity", "DISEASE", 182, 190], ["rifamycins", "CHEMICAL", 77, 87], ["rifamycins", "SIMPLE_CHEMICAL", 77, 87], ["plasma", "ORGANISM_SUBSTANCE", 123, 129], ["antiretroviral drugs", "TREATMENT", 29, 49], ["rifamycins", "TREATMENT", 77, 87], ["their plasma concentration", "TEST", 117, 143], ["increased drug toxicity", "PROBLEM", 167, 190], ["antiretroviral drugs", "OBSERVATION", 29, 49], ["increases", "OBSERVATION_MODIFIER", 104, 113], ["associated with", "UNCERTAINTY", 151, 166], ["increased", "OBSERVATION_MODIFIER", 167, 176], ["drug toxicity", "OBSERVATION", 177, 190]]], ["The nonnucleoside RTI drugs are inducers of this enzyme pathway.", [["The nonnucleoside RTI drugs", "TREATMENT", 0, 27], ["this enzyme pathway", "TEST", 44, 63], ["nonnucleoside RTI", "OBSERVATION", 4, 21]]], ["Coadministration of rifabutin with efavirenz requires an increase in the dose of rifabutin to compensate for the increase in its metabolism induced by efavirenz (see later).Type and Duration of Therapy for TuberculosisThe optimal duration of treatment of tuberculosis, by use of a rifamycin-based regimen, in a patient who has HIV infection is unknown.", [["rifabutin", "CHEMICAL", 20, 29], ["efavirenz", "CHEMICAL", 35, 44], ["rifabutin", "CHEMICAL", 81, 90], ["efavirenz", "CHEMICAL", 151, 160], ["Tuberculosis", "DISEASE", 206, 218], ["tuberculosis", "DISEASE", 255, 267], ["rifamycin", "CHEMICAL", 281, 290], ["HIV infection", "DISEASE", 327, 340], ["rifabutin", "CHEMICAL", 20, 29], ["efavirenz", "CHEMICAL", 35, 44], ["rifabutin", "CHEMICAL", 81, 90], ["efavirenz", "CHEMICAL", 151, 160], ["rifamycin", "CHEMICAL", 281, 290], ["rifabutin", "SIMPLE_CHEMICAL", 20, 29], ["efavirenz", "SIMPLE_CHEMICAL", 35, 44], ["rifabutin", "SIMPLE_CHEMICAL", 81, 90], ["efavirenz", "SIMPLE_CHEMICAL", 151, 160], ["rifamycin", "SIMPLE_CHEMICAL", 281, 290], ["patient", "ORGANISM", 311, 318], ["HIV", "ORGANISM", 327, 330], ["patient", "SPECIES", 311, 318], ["HIV", "SPECIES", 327, 330], ["HIV", "SPECIES", 327, 330], ["Coadministration", "TREATMENT", 0, 16], ["rifabutin", "TREATMENT", 20, 29], ["efavirenz", "TREATMENT", 35, 44], ["rifabutin", "TREATMENT", 81, 90], ["the increase", "PROBLEM", 109, 121], ["efavirenz", "TREATMENT", 151, 160], ["Therapy", "TREATMENT", 194, 201], ["Tuberculosis", "PROBLEM", 206, 218], ["treatment", "TREATMENT", 242, 251], ["tuberculosis", "PROBLEM", 255, 267], ["a rifamycin-based regimen", "TREATMENT", 279, 304], ["HIV infection", "PROBLEM", 327, 340], ["rifabutin", "OBSERVATION", 20, 29], ["increase", "OBSERVATION_MODIFIER", 57, 65], ["increase", "OBSERVATION_MODIFIER", 113, 121], ["tuberculosis", "OBSERVATION", 255, 267], ["infection", "OBSERVATION", 331, 340]]], ["Current recommendations (Joint Tuberculosis Committee of the BTS and the ATS/CDC/Infectious Disease Society of North America [IDSA]) are to treat tuberculosis in HIV-infected patients in the same way as for the general population (i.e., for 6 months for drug-sensitive pulmonary TB).", [["pulmonary", "ANATOMY", 269, 278], ["Tuberculosis", "DISEASE", 31, 43], ["Infectious Disease", "DISEASE", 81, 99], ["tuberculosis", "DISEASE", 146, 158], ["HIV-infected", "DISEASE", 162, 174], ["drug-sensitive pulmonary TB", "DISEASE", 254, 281], ["HIV", "ORGANISM", 162, 165], ["patients", "ORGANISM", 175, 183], ["pulmonary", "ORGAN", 269, 278], ["HIV", "SPECIES", 162, 165], ["patients", "SPECIES", 175, 183], ["HIV", "SPECIES", 162, 165], ["the BTS", "TREATMENT", 57, 64], ["tuberculosis", "PROBLEM", 146, 158], ["drug-sensitive pulmonary TB", "PROBLEM", 254, 281], ["Joint", "ANATOMY", 25, 30], ["tuberculosis", "OBSERVATION", 146, 158], ["pulmonary", "ANATOMY", 269, 278], ["TB", "OBSERVATION", 279, 281]]], ["In addition, ATS/CDC/IDSA guidelines recommend that treatment be extended to 9 months in those who have cavitation on the original radiograph, continuing signs, or a positive culture after 2 months of therapy.", [["ATS/CDC/IDSA guidelines", "TREATMENT", 13, 36], ["treatment", "TREATMENT", 52, 61], ["cavitation", "PROBLEM", 104, 114], ["the original radiograph", "TEST", 118, 141], ["continuing signs", "PROBLEM", 143, 159], ["a positive culture", "PROBLEM", 164, 182], ["therapy", "TREATMENT", 201, 208], ["cavitation", "OBSERVATION", 104, 114]]], ["Recent work has highlighted the increased risk for development of rifampin monoresistance in HIV-infected individuals on treatment.", [["rifampin", "CHEMICAL", 66, 74], ["HIV-infected", "DISEASE", 93, 105], ["rifampin", "CHEMICAL", 66, 74], ["rifampin", "SIMPLE_CHEMICAL", 66, 74], ["HIV", "ORGANISM", 93, 96], ["individuals", "ORGANISM", 106, 117], ["HIV", "SPECIES", 93, 96], ["HIV", "SPECIES", 93, 96], ["rifampin monoresistance", "PROBLEM", 66, 89], ["HIV", "PROBLEM", 93, 96], ["infected individuals", "PROBLEM", 97, 117], ["treatment", "TREATMENT", 121, 130], ["rifampin", "OBSERVATION", 66, 74]]], ["This is especially so if intermittent regimens are used and may arise from a lack of efficacy of the other drugs present in the combination (e.g., intermittent isoniazid).", [["isoniazid", "CHEMICAL", 160, 169], ["isoniazid", "CHEMICAL", 160, 169], ["isoniazid", "SIMPLE_CHEMICAL", 160, 169], ["intermittent regimens", "TREATMENT", 25, 46], ["the other drugs", "TREATMENT", 97, 112], ["intermittent isoniazid)", "TREATMENT", 147, 170]]], ["Hence, daily medication regimens are recommended and should be closely supervised in all HIV-positive patients.", [["HIV", "ORGANISM", 89, 92], ["patients", "ORGANISM", 102, 110], ["patients", "SPECIES", 102, 110], ["HIV", "SPECIES", 89, 92], ["daily medication regimens", "TREATMENT", 7, 32]]], ["It should be remembered that although rifabutin is usually given three times a week with ritonavir-boosted protease inhibitors, this seems to achieve adequate rifamycin levels; there have been no reports of this leading to rifamycin resistance in patients who are appropriately adherent.", [["rifabutin", "CHEMICAL", 38, 47], ["ritonavir", "CHEMICAL", 89, 98], ["rifamycin", "CHEMICAL", 159, 168], ["rifamycin", "CHEMICAL", 223, 232], ["rifabutin", "CHEMICAL", 38, 47], ["ritonavir", "CHEMICAL", 89, 98], ["rifamycin", "CHEMICAL", 159, 168], ["rifamycin", "CHEMICAL", 223, 232], ["rifabutin", "SIMPLE_CHEMICAL", 38, 47], ["ritonavir", "SIMPLE_CHEMICAL", 89, 98], ["rifamycin", "SIMPLE_CHEMICAL", 159, 168], ["rifamycin", "SIMPLE_CHEMICAL", 223, 232], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 247, 255], ["rifabutin", "TREATMENT", 38, 47], ["ritonavir-boosted protease inhibitors", "TREATMENT", 89, 126], ["rifamycin resistance", "TREATMENT", 223, 243], ["rifabutin", "OBSERVATION", 38, 47], ["rifamycin resistance", "OBSERVATION", 223, 243]]], ["Directly observed therapy (DOT) is an important, although fairly labor-intensive, strategy that has the support of the World Health Organization.When to Start Antiretroviral Therapy in a Patient with TuberculosisThe best time to start therapy in patients being treated for tuberculosis is unknown.", [["Tuberculosis", "DISEASE", 200, 212], ["tuberculosis", "DISEASE", 273, 285], ["patients", "ORGANISM", 246, 254], ["Patient", "SPECIES", 187, 194], ["patients", "SPECIES", 246, 254], ["Antiretroviral Therapy", "TREATMENT", 159, 181], ["Tuberculosis", "PROBLEM", 200, 212], ["therapy", "TREATMENT", 235, 242], ["tuberculosis", "PROBLEM", 273, 285], ["tuberculosis", "OBSERVATION", 273, 285]]], ["Decision analyses show that early treatment with antiretroviral therapy leads to a marked reduction in further opportunistic disease.", [["opportunistic disease", "DISEASE", 111, 132], ["Decision analyses", "TEST", 0, 17], ["early treatment", "TREATMENT", 28, 43], ["antiretroviral therapy", "TREATMENT", 49, 71], ["a marked reduction", "PROBLEM", 81, 99], ["further opportunistic disease", "PROBLEM", 103, 132], ["marked", "OBSERVATION_MODIFIER", 83, 89], ["reduction", "OBSERVATION_MODIFIER", 90, 99], ["opportunistic disease", "OBSERVATION", 111, 132]]], ["Against this is balanced the risk of needing to discontinue antituberculosis therapy or HIV therapy because of drug toxicity or drug-drug interactions.", [["toxicity", "DISEASE", 116, 124], ["HIV", "SPECIES", 88, 91], ["antituberculosis therapy", "TREATMENT", 60, 84], ["HIV therapy", "TREATMENT", 88, 99], ["drug toxicity", "PROBLEM", 111, 124]]], ["IRIS is reported to be more likely if the treatments are started at the same time as each other.When to Start Antiretroviral Therapy in a Patient with TuberculosisPragmatically, delaying the start of antiretroviral therapy simplifies patient management and may reduce or prevent adverse drug reactions and drug-drug interactions and may also reduce the risk of IRIS.", [["IRIS", "DISEASE", 0, 4], ["Tuberculosis", "DISEASE", 151, 163], ["IRIS", "DISEASE", 361, 365], ["patient", "ORGANISM", 234, 241], ["Patient", "SPECIES", 138, 145], ["patient", "SPECIES", 234, 241], ["the treatments", "TREATMENT", 38, 52], ["Antiretroviral Therapy", "TREATMENT", 110, 132], ["Tuberculosis", "PROBLEM", 151, 163], ["antiretroviral therapy", "TREATMENT", 200, 222], ["patient management", "TREATMENT", 234, 252], ["adverse drug reactions", "PROBLEM", 279, 301], ["IRIS", "PROBLEM", 361, 365], ["Tuberculosis", "OBSERVATION", 151, 163], ["IRIS", "OBSERVATION", 361, 365]]], ["On the basis of current evidence, patients with CD4 counts >200 cells/mL have a low risk of HIV disease progression or death during 6 months of treatment for tuberculosis.", [["cells", "ANATOMY", 64, 69], ["HIV disease", "DISEASE", 92, 103], ["death", "DISEASE", 119, 124], ["tuberculosis", "DISEASE", 158, 170], ["patients", "ORGANISM", 34, 42], ["CD4", "GENE_OR_GENE_PRODUCT", 48, 51], ["HIV", "ORGANISM", 92, 95], ["CD4", "PROTEIN", 48, 51], ["patients", "SPECIES", 34, 42], ["HIV", "SPECIES", 92, 95], ["CD4 counts", "TEST", 48, 58], ["HIV disease progression", "PROBLEM", 92, 115], ["death", "PROBLEM", 119, 124], ["treatment", "TREATMENT", 144, 153], ["tuberculosis", "PROBLEM", 158, 170], ["low risk", "OBSERVATION_MODIFIER", 80, 88], ["HIV disease", "OBSERVATION", 92, 103], ["tuberculosis", "OBSERVATION", 158, 170]]], ["In these patients, the CD4 count should be closely monitored, and antiretroviral therapy may be deferred until treatment for tuberculosis is completed.", [["tuberculosis", "DISEASE", 125, 137], ["patients", "ORGANISM", 9, 17], ["CD4", "GENE_OR_GENE_PRODUCT", 23, 26], ["CD4", "PROTEIN", 23, 26], ["patients", "SPECIES", 9, 17], ["the CD4 count", "TEST", 19, 32], ["antiretroviral therapy", "TREATMENT", 66, 88], ["treatment", "TREATMENT", 111, 120], ["tuberculosis", "PROBLEM", 125, 137]]], ["In patients who have CD4 counts from 199-100 cells/mL, many centers currently delay starting antiretroviral therapy until after the first 2 months of treatment for tuberculosis have been completed; patients are given concomitant PCP prophylaxis.", [["cells", "ANATOMY", 45, 50], ["tuberculosis", "DISEASE", 164, 176], ["PCP", "CHEMICAL", 229, 232], ["PCP", "CHEMICAL", 229, 232], ["patients", "ORGANISM", 3, 11], ["CD4", "GENE_OR_GENE_PRODUCT", 21, 24], ["cells", "CELL", 45, 50], ["patients", "ORGANISM", 198, 206], ["CD4", "PROTEIN", 21, 24], ["patients", "SPECIES", 3, 11], ["patients", "SPECIES", 198, 206], ["CD4 counts", "TEST", 21, 31], ["antiretroviral therapy", "TREATMENT", 93, 115], ["treatment", "TREATMENT", 150, 159], ["tuberculosis", "PROBLEM", 164, 176], ["concomitant PCP prophylaxis", "TREATMENT", 217, 244]]], ["In patients who have CD4 counts of <99 cells/mL, antiretroviral therapy is started as soon as possible after beginning treatment for tuberculosis.", [["CD4", "ANATOMY", 21, 24], ["cells", "ANATOMY", 39, 44], ["tuberculosis", "DISEASE", 133, 145], ["patients", "ORGANISM", 3, 11], ["CD4", "GENE_OR_GENE_PRODUCT", 21, 24], ["CD4", "PROTEIN", 21, 24], ["patients", "SPECIES", 3, 11], ["CD4 counts", "TEST", 21, 31], ["antiretroviral therapy", "TREATMENT", 49, 71], ["tuberculosis", "PROBLEM", 133, 145], ["tuberculosis", "OBSERVATION", 133, 145]]], ["This is based on evidence that shows a significant short-term risk of HIV disease progression and death in this patient group if antiretroviral therapy is delayed.When to Start Antiretroviral Therapy in a Patient with TuberculosisTwo options exist for starting antiretroviral therapy in a patient already being treated for tuberculosis.", [["HIV disease", "DISEASE", 70, 81], ["death", "DISEASE", 98, 103], ["Tuberculosis", "DISEASE", 218, 230], ["tuberculosis", "DISEASE", 323, 335], ["HIV", "ORGANISM", 70, 73], ["patient", "ORGANISM", 112, 119], ["patient", "ORGANISM", 289, 296], ["patient", "SPECIES", 112, 119], ["Patient", "SPECIES", 205, 212], ["patient", "SPECIES", 289, 296], ["HIV", "SPECIES", 70, 73], ["HIV disease progression", "PROBLEM", 70, 93], ["death", "PROBLEM", 98, 103], ["antiretroviral therapy", "TREATMENT", 129, 151], ["Antiretroviral Therapy", "TREATMENT", 177, 199], ["Tuberculosis", "PROBLEM", 218, 230], ["antiretroviral therapy", "TREATMENT", 261, 283], ["tuberculosis", "PROBLEM", 323, 335], ["significant", "OBSERVATION_MODIFIER", 39, 50], ["short-term", "OBSERVATION_MODIFIER", 51, 61], ["HIV disease", "OBSERVATION", 70, 81], ["tuberculosis", "OBSERVATION", 323, 335]]], ["First, the rifampin-based regimen is continued, and antiretroviral therapy is commenced, for example, with a combination of two nucleoside RTIs and a non-nucleoside RTI, such as efavirenz (if the patient weighs <50 kg, the efavirenz dose is often increased to 800 mg once daily to compensate for rifampin-induced metabolism of efavirenz).", [["rifampin", "CHEMICAL", 11, 19], ["nucleoside", "CHEMICAL", 128, 138], ["RTIs", "DISEASE", 139, 143], ["efavirenz", "CHEMICAL", 178, 187], ["efavirenz", "CHEMICAL", 223, 232], ["rifampin", "CHEMICAL", 296, 304], ["efavirenz", "CHEMICAL", 327, 336], ["rifampin", "CHEMICAL", 11, 19], ["nucleoside", "CHEMICAL", 128, 138], ["efavirenz", "CHEMICAL", 178, 187], ["efavirenz", "CHEMICAL", 223, 232], ["rifampin", "CHEMICAL", 296, 304], ["efavirenz", "CHEMICAL", 327, 336], ["rifampin", "SIMPLE_CHEMICAL", 11, 19], ["nucleoside", "SIMPLE_CHEMICAL", 128, 138], ["efavirenz", "SIMPLE_CHEMICAL", 178, 187], ["patient", "ORGANISM", 196, 203], ["efavirenz", "SIMPLE_CHEMICAL", 223, 232], ["rifampin", "SIMPLE_CHEMICAL", 296, 304], ["efavirenz", "SIMPLE_CHEMICAL", 327, 336], ["patient", "SPECIES", 196, 203], ["the rifampin-based regimen", "TREATMENT", 7, 33], ["antiretroviral therapy", "TREATMENT", 52, 74], ["two nucleoside RTIs", "TREATMENT", 124, 143], ["a non-nucleoside RTI", "TREATMENT", 148, 168], ["efavirenz", "TREATMENT", 178, 187], ["the efavirenz dose", "TREATMENT", 219, 237], ["rifampin", "TREATMENT", 296, 304], ["efavirenz", "TREATMENT", 327, 336]]], ["Alternately, the rifampin is stopped and rifabutin is started: Antiretroviral therapy is given, with a combination of two nucleoside RTI drugs and either a single ritonavir-boosted PI or a nonnucleoside RTI.", [["rifampin", "CHEMICAL", 17, 25], ["rifabutin", "CHEMICAL", 41, 50], ["nucleoside", "CHEMICAL", 122, 132], ["ritonavir", "CHEMICAL", 163, 172], ["PI", "CHEMICAL", 181, 183], ["rifampin", "CHEMICAL", 17, 25], ["rifabutin", "CHEMICAL", 41, 50], ["nucleoside", "CHEMICAL", 122, 132], ["ritonavir", "CHEMICAL", 163, 172], ["rifampin", "SIMPLE_CHEMICAL", 17, 25], ["rifabutin", "SIMPLE_CHEMICAL", 41, 50], ["nucleoside", "SIMPLE_CHEMICAL", 122, 132], ["ritonavir", "SIMPLE_CHEMICAL", 163, 172], ["PI", "SIMPLE_CHEMICAL", 181, 183], ["the rifampin", "TREATMENT", 13, 25], ["rifabutin", "TREATMENT", 41, 50], ["Antiretroviral therapy", "TREATMENT", 63, 85], ["two nucleoside RTI drugs", "TREATMENT", 118, 142], ["a single ritonavir", "TREATMENT", 154, 172], ["a nonnucleoside RTI", "TREATMENT", 187, 206]]], ["Here the dose of rifabutin is adjusted to take into account the pharmacokinetic effect of the co-administered drug.", [["rifabutin", "CHEMICAL", 17, 26], ["rifabutin", "CHEMICAL", 17, 26], ["rifabutin", "SIMPLE_CHEMICAL", 17, 26], ["rifabutin", "TREATMENT", 17, 26], ["the co-administered drug", "TREATMENT", 90, 114]]], ["With a boosted PI, it is usually prescribed at a dose of 150 mg three times weekly and with efavirenz it is increased to 450 mg once a day.Immune Reconstitution Inflammatory SyndromeBefore the advent of antiretroviral therapy, it was recognized by tuberculosis physicians that patients who were apparently responding to their antimycobacterial treatment would sometimes have a short period of clinical deterioration develop.", [["efavirenz", "CHEMICAL", 92, 101], ["tuberculosis", "DISEASE", 248, 260], ["efavirenz", "CHEMICAL", 92, 101], ["PI", "SIMPLE_CHEMICAL", 15, 17], ["efavirenz", "SIMPLE_CHEMICAL", 92, 101], ["patients", "ORGANISM", 277, 285], ["patients", "SPECIES", 277, 285], ["a boosted PI", "TREATMENT", 5, 17], ["efavirenz", "TREATMENT", 92, 101], ["Immune Reconstitution Inflammatory SyndromeBefore", "TREATMENT", 139, 188], ["antiretroviral therapy", "TREATMENT", 203, 225], ["their antimycobacterial treatment", "TREATMENT", 320, 353], ["clinical deterioration", "PROBLEM", 393, 415], ["Inflammatory", "OBSERVATION_MODIFIER", 161, 173], ["antiretroviral therapy", "OBSERVATION", 203, 225]]], ["This \"paradoxical reaction\" (in the face of overall treatment response) was seen as an interesting and probable immunebased phenomenon of generally little consequence.", [["This \"paradoxical reaction", "PROBLEM", 0, 26], ["immunebased phenomenon", "PROBLEM", 112, 134], ["paradoxical", "OBSERVATION_MODIFIER", 6, 17], ["reaction", "OBSERVATION", 18, 26], ["probable", "UNCERTAINTY", 103, 111], ["immunebased phenomenon", "OBSERVATION", 112, 134]]], ["The widespread introduction of HAART has led to an increased awareness by clinicians of similar, but generally more severe, events in HIV-infected individuals.", [["HIV-infected", "DISEASE", 134, 146], ["HIV", "ORGANISM", 134, 137], ["individuals", "ORGANISM", 147, 158], ["HIV", "SPECIES", 134, 137], ["HIV", "SPECIES", 134, 137], ["HAART", "TREATMENT", 31, 36], ["an increased awareness", "PROBLEM", 48, 70], ["HIV", "PROBLEM", 134, 137], ["infected individuals", "PROBLEM", 138, 158], ["widespread", "OBSERVATION_MODIFIER", 4, 14], ["HAART", "OBSERVATION", 31, 36], ["increased", "OBSERVATION_MODIFIER", 51, 60], ["more severe", "OBSERVATION_MODIFIER", 111, 122]]], ["In the context of HIV, these are termed IRIS, or immune reconstitution disease.Immune Reconstitution Inflammatory SyndromeThey can present in a number of ways and with a range of opportunistic conditions.", [["IRIS", "DISEASE", 40, 44], ["immune reconstitution disease", "DISEASE", 49, 78], ["HIV", "ORGANISM", 18, 21], ["HIV", "SPECIES", 18, 21], ["HIV", "SPECIES", 18, 21], ["HIV", "PROBLEM", 18, 21], ["termed IRIS", "PROBLEM", 33, 44], ["immune reconstitution disease", "PROBLEM", 49, 78], ["Immune Reconstitution Inflammatory SyndromeThey", "PROBLEM", 79, 126], ["HIV", "OBSERVATION", 18, 21], ["IRIS", "OBSERVATION", 40, 44], ["immune reconstitution", "OBSERVATION", 49, 70], ["Inflammatory", "OBSERVATION", 101, 113]]], ["Perhaps the most common of these is similar to a paradoxical reaction.", [["a paradoxical reaction", "PROBLEM", 47, 69], ["most common", "OBSERVATION_MODIFIER", 12, 23], ["paradoxical", "OBSERVATION_MODIFIER", 49, 60], ["reaction", "OBSERVATION", 61, 69]]], ["Here, after initiation of antiretroviral therapy in a patient being treated for tuberculosis, for example, there arises the return of the original or the development of new symptoms and signs.", [["tuberculosis", "DISEASE", 80, 92], ["patient", "ORGANISM", 54, 61], ["patient", "SPECIES", 54, 61], ["antiretroviral therapy", "TREATMENT", 26, 48], ["tuberculosis", "PROBLEM", 80, 92], ["new symptoms", "PROBLEM", 169, 181], ["tuberculosis", "OBSERVATION", 80, 92], ["new", "OBSERVATION_MODIFIER", 169, 172], ["symptoms", "OBSERVATION", 173, 181]]], ["These are often of a systemic nature and may be associated with marked radiographic changes.", [["marked radiographic changes", "PROBLEM", 64, 91], ["systemic", "OBSERVATION", 21, 29], ["may be associated with", "UNCERTAINTY", 41, 63], ["marked", "OBSERVATION_MODIFIER", 64, 70], ["radiographic", "OBSERVATION", 71, 83]]], ["Examples of this include fever, dyspnea, lymphadenopathy, effusions, parenchymal pulmonary infiltrates, or expansion of cerebral tuberculomas.", [["effusions", "ANATOMY", 58, 67], ["parenchymal pulmonary", "ANATOMY", 69, 90], ["cerebral tuberculomas", "ANATOMY", 120, 141], ["fever", "DISEASE", 25, 30], ["dyspnea", "DISEASE", 32, 39], ["lymphadenopathy", "DISEASE", 41, 56], ["effusions", "DISEASE", 58, 67], ["parenchymal pulmonary infiltrates", "DISEASE", 69, 102], ["cerebral tuberculomas", "DISEASE", 120, 141], ["pulmonary", "ORGAN", 81, 90], ["cerebral tuberculomas", "PATHOLOGICAL_FORMATION", 120, 141], ["fever", "PROBLEM", 25, 30], ["dyspnea", "PROBLEM", 32, 39], ["lymphadenopathy", "PROBLEM", 41, 56], ["effusions", "PROBLEM", 58, 67], ["parenchymal pulmonary infiltrates", "PROBLEM", 69, 102], ["expansion of cerebral tuberculomas", "PROBLEM", 107, 141], ["fever", "OBSERVATION", 25, 30], ["dyspnea", "OBSERVATION", 32, 39], ["lymphadenopathy", "OBSERVATION", 41, 56], ["effusions", "OBSERVATION", 58, 67], ["parenchymal", "ANATOMY_MODIFIER", 69, 80], ["pulmonary", "ANATOMY", 81, 90], ["infiltrates", "OBSERVATION", 91, 102], ["expansion", "OBSERVATION_MODIFIER", 107, 116], ["cerebral", "ANATOMY", 120, 128], ["tuberculomas", "OBSERVATION", 129, 141]]], ["This form of IRIS is seen most frequently with mycobacteria (commonly tuberculosis or MAC), fungi (notably, Cryptococcus), and viruses (hepatitis and herpes viridae).Immune Reconstitution Inflammatory SyndromeIRIS develops in up to one third of HIV-infected patients being treated for tuberculosis when antiretroviral therapy is started.", [["IRIS", "DISEASE", 13, 17], ["tuberculosis", "DISEASE", 70, 82], ["Cryptococcus), and viruses (hepatitis and herpes viridae", "DISEASE", 108, 164], ["HIV-infected", "DISEASE", 245, 257], ["tuberculosis", "DISEASE", 285, 297], ["herpes viridae", "ORGANISM", 150, 164], ["HIV", "ORGANISM", 245, 248], ["patients", "ORGANISM", 258, 266], ["herpes viridae", "SPECIES", 150, 164], ["patients", "SPECIES", 258, 266], ["HIV", "SPECIES", 245, 248], ["IRIS", "PROBLEM", 13, 17], ["mycobacteria (commonly tuberculosis", "PROBLEM", 47, 82], ["MAC", "PROBLEM", 86, 89], ["fungi", "PROBLEM", 92, 97], ["Cryptococcus", "PROBLEM", 108, 120], ["viruses", "PROBLEM", 127, 134], ["hepatitis", "PROBLEM", 136, 145], ["herpes viridae", "TREATMENT", 150, 164], ["Immune Reconstitution Inflammatory SyndromeIRIS", "PROBLEM", 166, 213], ["HIV", "PROBLEM", 245, 248], ["tuberculosis", "PROBLEM", 285, 297], ["antiretroviral therapy", "TREATMENT", 303, 325], ["IRIS", "OBSERVATION", 13, 17], ["mycobacteria", "OBSERVATION", 47, 59], ["Cryptococcus", "OBSERVATION", 108, 120], ["viruses", "OBSERVATION", 127, 134], ["Inflammatory", "OBSERVATION_MODIFIER", 188, 200], ["infected", "OBSERVATION", 249, 257], ["tuberculosis", "OBSERVATION", 285, 297]]], ["The median onset of tuberculosis-related IRIS is approximately 4 weeks from beginning antituberculosis treatment or 2 weeks from commencing HAART.", [["tuberculosis", "DISEASE", 20, 32], ["IRIS", "DISEASE", 41, 45], ["tuberculosis", "PROBLEM", 20, 32], ["IRIS", "PROBLEM", 41, 45], ["beginning antituberculosis treatment", "TREATMENT", 76, 112], ["HAART", "TREATMENT", 140, 145], ["median onset", "OBSERVATION_MODIFIER", 4, 16], ["tuberculosis", "OBSERVATION", 20, 32], ["IRIS", "ANATOMY", 41, 45]]], ["It seems to be more likely in patients who have disseminated tuberculosis (and hence presumably more antigen present as well as more potential for significant inflammatory reactions) and a lower baseline blood CD4 count.", [["blood", "ANATOMY", 204, 209], ["tuberculosis", "DISEASE", 61, 73], ["patients", "ORGANISM", 30, 38], ["blood", "ORGANISM_SUBSTANCE", 204, 209], ["CD4", "GENE_OR_GENE_PRODUCT", 210, 213], ["CD4", "PROTEIN", 210, 213], ["patients", "SPECIES", 30, 38], ["disseminated tuberculosis", "PROBLEM", 48, 73], ["significant inflammatory reactions", "PROBLEM", 147, 181], ["a lower baseline blood CD4 count", "PROBLEM", 187, 219], ["seems to be more likely", "UNCERTAINTY", 3, 26], ["disseminated", "OBSERVATION_MODIFIER", 48, 60], ["tuberculosis", "OBSERVATION", 61, 73], ["inflammatory", "OBSERVATION", 159, 171]]], ["A rapid fall in HIV load, as well as a large increase in CD4 counts in response to HAART, may also predict IRIS.", [["IRIS", "DISEASE", 107, 111], ["HIV", "ORGANISM", 16, 19], ["CD4", "GENE_OR_GENE_PRODUCT", 57, 60], ["CD4", "PROTEIN", 57, 60], ["HIV", "SPECIES", 16, 19], ["A rapid fall in HIV load", "PROBLEM", 0, 24], ["a large increase in CD4 counts", "PROBLEM", 37, 67], ["HAART", "TREATMENT", 83, 88], ["IRIS", "PROBLEM", 107, 111], ["rapid", "OBSERVATION_MODIFIER", 2, 7], ["fall", "OBSERVATION", 8, 12], ["HIV load", "OBSERVATION", 16, 24], ["large", "OBSERVATION_MODIFIER", 39, 44], ["increase", "OBSERVATION_MODIFIER", 45, 53], ["CD4 counts", "OBSERVATION", 57, 67]]], ["The relationship between early use of HAART and low blood CD4 counts suggests that care must be taken when starting antiretrovirals in patients with TB at sites where rapid expansion of an inflammatory mass could be life threatening.", [["blood", "ANATOMY", 52, 57], ["TB", "DISEASE", 149, 151], ["blood", "ORGANISM_SUBSTANCE", 52, 57], ["patients", "ORGANISM", 135, 143], ["CD4", "PROTEIN", 58, 61], ["patients", "SPECIES", 135, 143], ["HAART", "TREATMENT", 38, 43], ["low blood CD4 counts", "TEST", 48, 68], ["antiretrovirals", "TREATMENT", 116, 131], ["TB at sites", "PROBLEM", 149, 160], ["an inflammatory mass", "PROBLEM", 186, 206], ["rapid", "OBSERVATION_MODIFIER", 167, 172], ["expansion", "OBSERVATION_MODIFIER", 173, 182], ["inflammatory", "OBSERVATION_MODIFIER", 189, 201], ["mass", "OBSERVATION", 202, 206]]], ["Examples of this would include cerebral, pericardial, or peritracheal disease (Figure 34-17) .Immune Reconstitution Inflammatory SyndromeIt is important to note that IRIS is currently a diagnosis of exclusion.", [["cerebral", "ANATOMY", 31, 39], ["pericardial", "ANATOMY", 41, 52], ["peritracheal", "ANATOMY", 57, 69], ["cerebral, pericardial, or peritracheal disease", "DISEASE", 31, 77], ["IRIS", "DISEASE", 166, 170], ["cerebral", "MULTI-TISSUE_STRUCTURE", 31, 39], ["pericardial", "MULTI-TISSUE_STRUCTURE", 41, 52], ["cerebral, pericardial, or peritracheal disease", "PROBLEM", 31, 77], ["cerebral", "ANATOMY", 31, 39], ["pericardial", "ANATOMY", 41, 52], ["peritracheal", "ANATOMY", 57, 69], ["disease", "OBSERVATION", 70, 77], ["Inflammatory", "OBSERVATION", 116, 128]]], ["There is no laboratory test available to assist with this; it should be made only after progressive or (multi) drug-resistant tuberculosis, poor drug adherence (to either antituberculosis or antiretroviral agents) and drug absorption, or an alternative pathologic process have been excluded as an explanation for the presentation.", [["tuberculosis", "DISEASE", 126, 138], ["laboratory test", "TEST", 12, 27], ["progressive or (multi) drug-resistant tuberculosis", "PROBLEM", 88, 138], ["poor drug adherence", "PROBLEM", 140, 159], ["antituberculosis", "TREATMENT", 171, 187], ["antiretroviral agents", "TREATMENT", 191, 212], ["drug absorption", "PROBLEM", 218, 233], ["an alternative pathologic process", "PROBLEM", 238, 271], ["no", "UNCERTAINTY", 9, 11], ["resistant", "OBSERVATION_MODIFIER", 116, 125], ["tuberculosis", "OBSERVATION", 126, 138], ["pathologic", "OBSERVATION", 253, 263]]], ["Criteria have been drawn up that seek to provide clinical diagnostic criteria (Table 34-12) .Immune Reconstitution Inflammatory SyndromeThe mechanism leading to IRIS is unclear.", [["IRIS", "DISEASE", 161, 165], ["Immune Reconstitution Inflammatory Syndrome", "PROBLEM", 93, 136], ["IRIS", "PROBLEM", 161, 165], ["Inflammatory Syndrome", "OBSERVATION", 115, 136], ["mechanism leading to", "UNCERTAINTY", 140, 160], ["IRIS", "OBSERVATION", 161, 165]]], ["It is not due to failure of treatment of tuberculosis or to another disease process; if anything, it is most likely to represent an exuberant and uncontrolled response to mycobacterial antigens (from both dead and live organisms).Immune Reconstitution Inflammatory SyndromeCurrent treatments include nonsteroidal antiinflammatory drugs or glucocorticoids.", [["nonsteroidal", "ANATOMY", 300, 312], ["tuberculosis", "DISEASE", 41, 53], ["glucocorticoids", "CHEMICAL", 339, 354], ["nonsteroidal antiinflammatory drugs", "SIMPLE_CHEMICAL", 300, 335], ["glucocorticoids", "SIMPLE_CHEMICAL", 339, 354], ["mycobacterial antigens", "PROTEIN", 171, 193], ["treatment", "TREATMENT", 28, 37], ["tuberculosis", "PROBLEM", 41, 53], ["another disease process", "PROBLEM", 60, 83], ["an exuberant", "PROBLEM", 129, 141], ["mycobacterial antigens", "PROBLEM", 171, 193], ["Immune Reconstitution Inflammatory SyndromeCurrent treatments", "TREATMENT", 230, 291], ["nonsteroidal antiinflammatory drugs", "TREATMENT", 300, 335], ["glucocorticoids", "TREATMENT", 339, 354], ["not due to", "UNCERTAINTY", 6, 16], ["tuberculosis", "OBSERVATION", 41, 53], ["most likely to represent", "UNCERTAINTY", 104, 128], ["exuberant", "OBSERVATION", 132, 141], ["uncontrolled", "OBSERVATION_MODIFIER", 146, 158], ["mycobacterial antigens", "OBSERVATION", 171, 193], ["Inflammatory", "OBSERVATION_MODIFIER", 252, 264]]], ["The latter are undoubtedly effective, although they can lead to hyperglycemia and hypertension.", [["hyperglycemia", "DISEASE", 64, 77], ["hypertension", "DISEASE", 82, 94], ["hyperglycemia", "PROBLEM", 64, 77], ["hypertension", "PROBLEM", 82, 94], ["effective", "OBSERVATION_MODIFIER", 27, 36], ["hyperglycemia", "OBSERVATION", 64, 77], ["hypertension", "OBSERVATION", 82, 94]]], ["Recent preliminary data suggest that the leukotriene receptor antagonist montelukast may be of benefit in IRIS (this drug is unlicensed for this indication).", [["leukotriene", "CHEMICAL", 41, 52], ["montelukast", "CHEMICAL", 73, 84], ["IRIS", "DISEASE", 106, 110], ["montelukast", "CHEMICAL", 73, 84], ["leukotriene receptor", "GENE_OR_GENE_PRODUCT", 41, 61], ["montelukast", "SIMPLE_CHEMICAL", 73, 84], ["Recent preliminary data", "TEST", 0, 23], ["the leukotriene receptor antagonist montelukast", "TREATMENT", 37, 84]]], ["Recurrent aspiration of lymph nodes or effusion may also be needed.", [["lymph nodes", "ANATOMY", 24, 35], ["aspiration of lymph nodes", "DISEASE", 10, 35], ["effusion", "DISEASE", 39, 47], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 24, 35], ["Recurrent aspiration of lymph nodes", "PROBLEM", 0, 35], ["effusion", "PROBLEM", 39, 47], ["aspiration", "OBSERVATION", 10, 20], ["lymph nodes", "OBSERVATION", 24, 35], ["effusion", "OBSERVATION", 39, 47]]], ["Although IRIS is often self-limiting, it may persist for several months.", [["IRIS", "DISEASE", 9, 13], ["IRIS", "PROBLEM", 9, 13], ["IRIS", "OBSERVATION", 9, 13]]], ["Rarely, temporary discontinuation of antiretroviral therapy is required.", [["antiretroviral therapy", "TREATMENT", 37, 59]]], ["In this situation there may be precipitous falls in CD4 counts; patients are at risk of other opportunistic infections.Immune Reconstitution Inflammatory SyndromeAttention has also focused on what is possibly more of a concern-the form of IRIS referred to as \"unmasking phenomenon.\"", [["CD4", "ANATOMY", 52, 55], ["opportunistic infections", "DISEASE", 94, 118], ["IRIS", "DISEASE", 239, 243], ["CD4", "GENE_OR_GENE_PRODUCT", 52, 55], ["patients", "ORGANISM", 64, 72], ["CD4", "PROTEIN", 52, 55], ["patients", "SPECIES", 64, 72], ["precipitous falls in CD4 counts", "PROBLEM", 31, 62], ["other opportunistic infections", "PROBLEM", 88, 118], ["Immune Reconstitution Inflammatory SyndromeAttention", "PROBLEM", 119, 171], ["IRIS", "PROBLEM", 239, 243], ["may be", "UNCERTAINTY", 24, 30], ["precipitous", "OBSERVATION_MODIFIER", 31, 42], ["falls", "OBSERVATION", 43, 48], ["CD4 counts", "OBSERVATION", 52, 62], ["opportunistic", "OBSERVATION_MODIFIER", 94, 107], ["infections", "OBSERVATION", 108, 118], ["Inflammatory", "OBSERVATION_MODIFIER", 141, 153], ["IRIS", "OBSERVATION", 239, 243]]], ["Here, individuals with presumably latent tuberculosis infection who start HAART have systemic active (and often infectious) tuberculosis develop within a 3-month period.", [["tuberculosis infection", "DISEASE", 41, 63], ["tuberculosis", "DISEASE", 124, 136], ["presumably latent tuberculosis infection", "PROBLEM", 23, 63], ["HAART", "TREATMENT", 74, 79], ["systemic active (and often infectious) tuberculosis", "PROBLEM", 85, 136], ["latent", "OBSERVATION_MODIFIER", 34, 40], ["tuberculosis", "OBSERVATION", 41, 53], ["active", "OBSERVATION_MODIFIER", 94, 100]]], ["Although it is likely that the patient's disease would have presented in time anyway and that some of the reported cases may, in fact, represent ascertainment bias, the current view is that this is real and represents an adverse effect of HAART.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["the patient's disease", "PROBLEM", 27, 48], ["HAART", "TREATMENT", 239, 244], ["is likely", "UNCERTAINTY", 12, 21], ["ascertainment bias", "OBSERVATION", 145, 163], ["adverse effect", "OBSERVATION", 221, 235], ["HAART", "OBSERVATION", 239, 244]]], ["Given that the people most at risk live in countries with limited facilities for pre-HAART screening, this has major implications for antiretroviral therapy roll-out programs in resource-poor areas.Treatment of Disseminated Mycobacterium avium-intracellulare Complex InfectionCombination antimycobacterial therapy by itself does not cure MAC infection.", [["infection", "DISEASE", 342, 351], ["people", "ORGANISM", 15, 21], ["Mycobacterium avium", "ORGANISM", 224, 243], ["-intracellulare", "ORGANISM", 243, 258], ["people", "SPECIES", 15, 21], ["Mycobacterium avium", "SPECIES", 224, 243], ["-intracellulare", "SPECIES", 243, 258], ["Mycobacterium avium", "SPECIES", 224, 243], ["pre-HAART screening", "TEST", 81, 100], ["antiretroviral therapy", "TREATMENT", 134, 156], ["Disseminated Mycobacterium avium", "PROBLEM", 211, 243], ["intracellulare Complex InfectionCombination antimycobacterial therapy", "TREATMENT", 244, 313], ["MAC infection", "PROBLEM", 338, 351], ["Disseminated", "OBSERVATION_MODIFIER", 211, 223], ["Mycobacterium avium", "OBSERVATION", 224, 243], ["intracellulare", "OBSERVATION_MODIFIER", 244, 258], ["Complex", "OBSERVATION_MODIFIER", 259, 266], ["InfectionCombination", "OBSERVATION_MODIFIER", 267, 287], ["antimycobacterial therapy", "OBSERVATION", 288, 313], ["infection", "OBSERVATION", 342, 351]]], ["A commonly used regimen is oral rifabutin, 300 mg once daily, with oral ethambutol, 15 mg/kg once daily, and oral clarithromycin, 500 mg once daily or every 12 h.", [["oral", "ANATOMY", 27, 31], ["oral", "ANATOMY", 67, 71], ["oral", "ANATOMY", 109, 113], ["rifabutin", "CHEMICAL", 32, 41], ["ethambutol", "CHEMICAL", 72, 82], ["clarithromycin", "CHEMICAL", 114, 128], ["rifabutin", "CHEMICAL", 32, 41], ["ethambutol", "CHEMICAL", 72, 82], ["clarithromycin", "CHEMICAL", 114, 128], ["oral", "ORGANISM_SUBDIVISION", 27, 31], ["rifabutin", "SIMPLE_CHEMICAL", 32, 41], ["oral", "ORGANISM_SUBDIVISION", 67, 71], ["ethambutol", "SIMPLE_CHEMICAL", 72, 82], ["oral", "ORGANISM_SUBDIVISION", 109, 113], ["clarithromycin", "SIMPLE_CHEMICAL", 114, 128], ["A commonly used regimen", "TREATMENT", 0, 23], ["oral rifabutin", "TREATMENT", 27, 41], ["oral ethambutol", "TREATMENT", 67, 82], ["oral clarithromycin", "TREATMENT", 109, 128]]], ["If clarithromycin is not used, oral rifabutin, 600 mg once daily, is given-the lower dose adjusting for yet more drug-drug interactions.", [["oral", "ANATOMY", 31, 35], ["clarithromycin", "CHEMICAL", 3, 17], ["rifabutin", "CHEMICAL", 36, 45], ["clarithromycin", "CHEMICAL", 3, 17], ["rifabutin", "CHEMICAL", 36, 45], ["clarithromycin", "SIMPLE_CHEMICAL", 3, 17], ["oral", "ORGANISM_SUBDIVISION", 31, 35], ["rifabutin", "SIMPLE_CHEMICAL", 36, 45], ["clarithromycin", "TREATMENT", 3, 17], ["oral rifabutin", "TREATMENT", 31, 45]]], ["Use of three drugs has no impact on overall outcome, although it reduces the risk of resistance and possibly enhances early mycobacterial killing.", [["mycobacterial", "ANATOMY", 124, 137], ["three drugs", "TREATMENT", 7, 18], ["resistance", "PROBLEM", 85, 95], ["enhances early mycobacterial killing", "PROBLEM", 109, 145], ["possibly", "UNCERTAINTY", 100, 108], ["enhances", "OBSERVATION_MODIFIER", 109, 117], ["early", "OBSERVATION_MODIFIER", 118, 123], ["mycobacterial killing", "OBSERVATION", 124, 145]]], ["In patients severely compromised by symptoms, intravenous amikacin, 7.5 mg/kg once daily for 2-4 weeks, is also given.", [["intravenous", "ANATOMY", 46, 57], ["amikacin", "CHEMICAL", 58, 66], ["amikacin", "CHEMICAL", 58, 66], ["patients", "ORGANISM", 3, 11], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 46, 57], ["amikacin", "SIMPLE_CHEMICAL", 58, 66], ["patients", "SPECIES", 3, 11], ["symptoms", "PROBLEM", 36, 44], ["intravenous amikacin", "TREATMENT", 46, 66]]], ["Trough blood levels must be measured to ensure toxic accumulation of amikacin does not occur.", [["blood", "ANATOMY", 7, 12], ["amikacin", "CHEMICAL", 69, 77], ["amikacin", "CHEMICAL", 69, 77], ["Trough", "ORGANISM_SUBSTANCE", 0, 6], ["blood", "ORGANISM_SUBSTANCE", 7, 12], ["amikacin", "SIMPLE_CHEMICAL", 69, 77], ["Trough blood levels", "TEST", 0, 19], ["toxic accumulation", "PROBLEM", 47, 65], ["amikacin", "TREATMENT", 69, 77]]], ["Fluoroquinolones such as moxifloxacin or levofloxacin may be extremely useful, because they have good antimycobacterial activity with limited side effects.", [["Fluoroquinolones", "CHEMICAL", 0, 16], ["moxifloxacin", "CHEMICAL", 25, 37], ["levofloxacin", "CHEMICAL", 41, 53], ["Fluoroquinolones", "CHEMICAL", 0, 16], ["moxifloxacin", "CHEMICAL", 25, 37], ["levofloxacin", "CHEMICAL", 41, 53], ["Fluoroquinolones", "SIMPLE_CHEMICAL", 0, 16], ["moxifloxacin", "SIMPLE_CHEMICAL", 25, 37], ["levofloxacin", "SIMPLE_CHEMICAL", 41, 53], ["Fluoroquinolones", "TREATMENT", 0, 16], ["moxifloxacin", "TREATMENT", 25, 37], ["levofloxacin", "TREATMENT", 41, 53], ["limited side effects", "PROBLEM", 134, 154], ["antimycobacterial activity", "OBSERVATION", 102, 128]]], ["At present, many of these agents are not licensed for this indication.", [["these agents", "TREATMENT", 20, 32]]], ["Given the concerns over XDR tuberculosis, it is important to ensure that patients are adherent to such treatments, and hence reduce the risk of fluoroquinolone resistance developing.Mycobacterium kansasii InfectionA frequently used regimen includes rifampin, isoniazid, and ethambutol in conventional doses; all drugs are given by mouth.Treatment of Fungal InfectionsThe treatment regimens for fungal infections complicating HIV infection are shown in Table 34 -13.CryptococcosisAfter initial treatment of cryptococcal infection, there is a high likelihood of relapse of infection; hence, lifelong secondary preventative therapy is needed unless antiretroviral therapy is commenced and results in sustained improvements in CD4 counts (>250 cells/mL) and suppression of HIV load in peripheral blood.", [["mouth", "ANATOMY", 331, 336], ["CD4", "ANATOMY", 723, 726], ["cells", "ANATOMY", 740, 745], ["peripheral blood", "ANATOMY", 781, 797], ["tuberculosis", "DISEASE", 28, 40], ["fluoroquinolone", "CHEMICAL", 144, 159], ["rifampin", "CHEMICAL", 249, 257], ["isoniazid", "CHEMICAL", 259, 268], ["ethambutol", "CHEMICAL", 274, 284], ["Fungal Infections", "DISEASE", 350, 367], ["fungal infections", "DISEASE", 394, 411], ["HIV infection", "DISEASE", 425, 438], ["CryptococcosisAfter", "CHEMICAL", 465, 484], ["cryptococcal infection", "DISEASE", 506, 528], ["infection", "DISEASE", 571, 580], ["fluoroquinolone", "CHEMICAL", 144, 159], ["rifampin", "CHEMICAL", 249, 257], ["isoniazid", "CHEMICAL", 259, 268], ["ethambutol", "CHEMICAL", 274, 284], ["patients", "ORGANISM", 73, 81], ["fluoroquinolone", "SIMPLE_CHEMICAL", 144, 159], ["rifampin", "SIMPLE_CHEMICAL", 249, 257], ["isoniazid", "SIMPLE_CHEMICAL", 259, 268], ["ethambutol", "SIMPLE_CHEMICAL", 274, 284], ["mouth", "ORGANISM_SUBDIVISION", 331, 336], ["CD4", "GENE_OR_GENE_PRODUCT", 723, 726], ["HIV", "ORGANISM", 769, 772], ["peripheral blood", "ORGANISM_SUBSTANCE", 781, 797], ["CD4", "PROTEIN", 723, 726], ["patients", "SPECIES", 73, 81], ["Mycobacterium kansasii", "SPECIES", 182, 204], ["HIV", "SPECIES", 425, 428], ["XDR tuberculosis", "SPECIES", 24, 40], ["Mycobacterium kansasii", "SPECIES", 182, 204], ["HIV", "SPECIES", 425, 428], ["HIV", "SPECIES", 769, 772], ["XDR tuberculosis", "PROBLEM", 24, 40], ["such treatments", "TREATMENT", 98, 113], ["fluoroquinolone resistance", "PROBLEM", 144, 170], ["Mycobacterium kansasii InfectionA", "PROBLEM", 182, 215], ["rifampin", "TREATMENT", 249, 257], ["isoniazid", "TREATMENT", 259, 268], ["ethambutol", "TREATMENT", 274, 284], ["all drugs", "TREATMENT", 308, 317], ["Fungal Infections", "PROBLEM", 350, 367], ["The treatment regimens", "TREATMENT", 367, 389], ["fungal infections", "PROBLEM", 394, 411], ["HIV infection", "PROBLEM", 425, 438], ["cryptococcal infection", "PROBLEM", 506, 528], ["infection", "PROBLEM", 571, 580], ["preventative therapy", "TREATMENT", 608, 628], ["antiretroviral therapy", "TREATMENT", 646, 668], ["CD4 counts", "TEST", 723, 733], ["HIV load in peripheral blood", "PROBLEM", 769, 797], ["XDR", "OBSERVATION_MODIFIER", 24, 27], ["tuberculosis", "OBSERVATION", 28, 40], ["fluoroquinolone resistance", "OBSERVATION", 144, 170], ["kansasii", "OBSERVATION", 196, 204], ["Fungal", "OBSERVATION_MODIFIER", 350, 356], ["Infections", "OBSERVATION", 357, 367], ["cryptococcal", "OBSERVATION_MODIFIER", 506, 518], ["infection", "OBSERVATION", 519, 528], ["high likelihood", "OBSERVATION_MODIFIER", 541, 556], ["relapse", "OBSERVATION_MODIFIER", 560, 567], ["infection", "OBSERVATION", 571, 580], ["HIV load", "OBSERVATION", 769, 777], ["peripheral", "ANATOMY_MODIFIER", 781, 791], ["blood", "ANATOMY", 792, 797]]], ["Secondary prophylaxis is most often oral fluconazole 200-400 mg four times daily.", [["oral", "ANATOMY", 36, 40], ["fluconazole", "CHEMICAL", 41, 52], ["fluconazole", "CHEMICAL", 41, 52], ["oral", "ORGANISM_SUBDIVISION", 36, 40], ["fluconazole", "SIMPLE_CHEMICAL", 41, 52], ["Secondary prophylaxis", "TREATMENT", 0, 21], ["oral fluconazole", "TREATMENT", 36, 52]]], ["Just as with mycobacterial disease, \"late\" IRIS events can occur after months or even years.", [["mycobacterial disease", "DISEASE", 13, 34], ["IRIS", "DISEASE", 43, 47], ["mycobacterial disease", "PROBLEM", 13, 34], ["late\" IRIS events", "PROBLEM", 37, 54], ["mycobacterial disease", "OBSERVATION", 13, 34]]], ["These should be investigated to exclude active disease and other conditions.HistoplasmosisOral itraconazole, 200 mg twice daily, is the current treatment of choice.", [["itraconazole", "CHEMICAL", 95, 107], ["itraconazole", "CHEMICAL", 95, 107], ["itraconazole", "SIMPLE_CHEMICAL", 95, 107], ["active disease and other conditions", "PROBLEM", 40, 75], ["HistoplasmosisOral itraconazole", "TREATMENT", 76, 107], ["active", "OBSERVATION_MODIFIER", 40, 46], ["disease", "OBSERVATION", 47, 54]]], ["The dose is adjusted to achieve blood trough drug levels that are above the standard lowest effective concentration.", [["blood", "ANATOMY", 32, 37], ["blood", "ORGANISM_SUBSTANCE", 32, 37], ["blood trough drug levels", "TEST", 32, 56]]], ["There are no data on the impact of antiretroviral therapy on which to base decisions about discontinuation of secondary prophylaxis.CoccidioidomycosisTreatment of this infection is difficult.", [["infection", "DISEASE", 168, 177], ["antiretroviral therapy", "TREATMENT", 35, 57], ["secondary prophylaxis", "TREATMENT", 110, 131], ["this infection", "PROBLEM", 163, 177], ["no", "UNCERTAINTY", 10, 12], ["secondary prophylaxis", "OBSERVATION", 110, 131], ["infection", "OBSERVATION", 168, 177]]], ["After initial treatment with amphotericin B, itraconazole or fluconazole may be given for long-term suppression.", [["amphotericin B", "CHEMICAL", 29, 43], ["itraconazole", "CHEMICAL", 45, 57], ["fluconazole", "CHEMICAL", 61, 72], ["amphotericin B", "CHEMICAL", 29, 43], ["itraconazole", "CHEMICAL", 45, 57], ["fluconazole", "CHEMICAL", 61, 72], ["amphotericin B", "SIMPLE_CHEMICAL", 29, 43], ["itraconazole", "SIMPLE_CHEMICAL", 45, 57], ["fluconazole", "SIMPLE_CHEMICAL", 61, 72], ["initial treatment", "TREATMENT", 6, 23], ["amphotericin B", "TREATMENT", 29, 43], ["itraconazole", "TREATMENT", 45, 57], ["fluconazole", "TREATMENT", 61, 72], ["long-term suppression", "TREATMENT", 90, 111]]], ["The overall prognosis is poor, with a 40% mortality rate despite therapy.", [["a 40% mortality rate", "TREATMENT", 36, 56], ["therapy", "TREATMENT", 65, 72]]], ["There are no data on the impact of antiretroviral therapy on which to base decisions about discontinuation of secondary prophylaxis.PENICILLIUM MARNEFFEI INFECTIONOral itraconazole has now replaced amphotericin B as the treatment of choice for P. marneffei infection, apart from the subgroup who are acutely unwell.", [["itraconazole", "CHEMICAL", 168, 180], ["amphotericin B", "CHEMICAL", 198, 212], ["P. marneffei infection", "DISEASE", 244, 266], ["itraconazole", "CHEMICAL", 168, 180], ["amphotericin B", "CHEMICAL", 198, 212], ["itraconazole", "SIMPLE_CHEMICAL", 168, 180], ["amphotericin B", "SIMPLE_CHEMICAL", 198, 212], ["P. marneffei", "ORGANISM", 244, 256], ["P. marneffei", "SPECIES", 244, 256], ["P. marneffei", "SPECIES", 244, 256], ["antiretroviral therapy", "TREATMENT", 35, 57], ["secondary prophylaxis", "TREATMENT", 110, 131], ["PENICILLIUM MARNEFFEI INFECTIONOral itraconazole", "TREATMENT", 132, 180], ["amphotericin B", "TREATMENT", 198, 212], ["P. marneffei infection", "PROBLEM", 244, 266], ["acutely unwell", "PROBLEM", 300, 314], ["no", "UNCERTAINTY", 10, 12], ["secondary prophylaxis", "OBSERVATION", 110, 131], ["marneffei infection", "OBSERVATION", 247, 266], ["unwell", "OBSERVATION", 308, 314]]], ["Fluconazole is less effective than itraconazole.", [["Fluconazole", "CHEMICAL", 0, 11], ["itraconazole", "CHEMICAL", 35, 47], ["Fluconazole", "CHEMICAL", 0, 11], ["itraconazole", "CHEMICAL", 35, 47], ["Fluconazole", "SIMPLE_CHEMICAL", 0, 11], ["itraconazole", "SIMPLE_CHEMICAL", 35, 47], ["Fluconazole", "TREATMENT", 0, 11], ["itraconazole", "TREATMENT", 35, 47], ["less effective", "OBSERVATION_MODIFIER", 15, 29]]], ["After initial treatment, lifelong suppressive therapy with itraconazole is needed.", [["itraconazole", "CHEMICAL", 59, 71], ["itraconazole", "CHEMICAL", 59, 71], ["itraconazole", "SIMPLE_CHEMICAL", 59, 71], ["initial treatment", "TREATMENT", 6, 23], ["lifelong suppressive therapy", "TREATMENT", 25, 53], ["itraconazole", "TREATMENT", 59, 71]]], ["There are no data on the impact of antiretroviral therapy on which to base decisions about discontinuation of secondary prophylaxis.Treatment of Parasitic InfectionsThe treatment regimens are shown in Table 34 -14.ToxoplasmosisA combination of sulfadiazine and pyrimethamine is the regimen of choice for T. gondii infection.", [["Parasitic Infections", "DISEASE", 145, 165], ["ToxoplasmosisA", "CHEMICAL", 214, 228], ["sulfadiazine", "CHEMICAL", 244, 256], ["pyrimethamine", "CHEMICAL", 261, 274], ["T. gondii infection", "DISEASE", 304, 323], ["sulfadiazine", "CHEMICAL", 244, 256], ["pyrimethamine", "CHEMICAL", 261, 274], ["ToxoplasmosisA", "SIMPLE_CHEMICAL", 214, 228], ["sulfadiazine", "SIMPLE_CHEMICAL", 244, 256], ["pyrimethamine", "SIMPLE_CHEMICAL", 261, 274], ["T. gondii", "ORGANISM", 304, 313], ["T. gondii", "SPECIES", 304, 313], ["T. gondii", "SPECIES", 304, 313], ["antiretroviral therapy", "TREATMENT", 35, 57], ["secondary prophylaxis", "TREATMENT", 110, 131], ["Parasitic Infections", "PROBLEM", 145, 165], ["The treatment regimens", "TREATMENT", 165, 187], ["ToxoplasmosisA", "TREATMENT", 214, 228], ["sulfadiazine", "TREATMENT", 244, 256], ["pyrimethamine", "TREATMENT", 261, 274], ["T. gondii infection", "PROBLEM", 304, 323], ["no", "UNCERTAINTY", 10, 12], ["secondary prophylaxis", "OBSERVATION", 110, 131], ["Parasitic", "OBSERVATION_MODIFIER", 145, 154], ["Infections", "OBSERVATION", 155, 165], ["sulfadiazine", "OBSERVATION", 244, 256], ["infection", "OBSERVATION", 314, 323]]], ["The most frequent dose-limiting side effects are rash and fever.", [["rash", "DISEASE", 49, 53], ["fever", "DISEASE", 58, 63], ["limiting side effects", "PROBLEM", 23, 44], ["rash", "PROBLEM", 49, 53], ["fever", "PROBLEM", 58, 63], ["rash", "OBSERVATION", 49, 53], ["fever", "OBSERVATION", 58, 63]]], ["Adequate hydration must be maintained to avoid the risk of sulfadiazine crystalluria and obstructive uropathy.", [["sulfadiazine", "CHEMICAL", 59, 71], ["crystalluria", "DISEASE", 72, 84], ["obstructive uropathy", "DISEASE", 89, 109], ["sulfadiazine", "CHEMICAL", 59, 71], ["sulfadiazine crystalluria", "SIMPLE_CHEMICAL", 59, 84], ["Adequate hydration", "TREATMENT", 0, 18], ["sulfadiazine crystalluria", "PROBLEM", 59, 84], ["obstructive uropathy", "PROBLEM", 89, 109], ["hydration", "OBSERVATION", 9, 18], ["sulfadiazine", "OBSERVATION_MODIFIER", 59, 71], ["crystalluria", "OBSERVATION", 72, 84], ["obstructive", "OBSERVATION_MODIFIER", 89, 100], ["uropathy", "OBSERVATION", 101, 109]]], ["Alternate regimens are given in Table 34 -14.", [["Alternate regimens", "TREATMENT", 0, 18]]], ["Once treatment is completed, lifelong maintenance is necessary to prevent relapse, unless antiretroviral therapy achieves adequate immune restoration (blood CD4 count >250 cells/mL and undetectable HIV load).Visceral LeishmaniasisVisceral leishmaniasis is usually treated with liposomal amphotericin B, although this is still associated with a high rate of relapse.", [["blood", "ANATOMY", 151, 156], ["cells", "ANATOMY", 172, 177], ["LeishmaniasisVisceral leishmaniasis", "DISEASE", 217, 252], ["amphotericin B", "CHEMICAL", 287, 301], ["amphotericin B", "CHEMICAL", 287, 301], ["blood", "ORGANISM_SUBSTANCE", 151, 156], ["liposomal amphotericin B", "SIMPLE_CHEMICAL", 277, 301], ["CD4", "PROTEIN", 157, 160], ["HIV", "SPECIES", 198, 201], ["treatment", "TREATMENT", 5, 14], ["relapse", "PROBLEM", 74, 81], ["antiretroviral therapy", "TREATMENT", 90, 112], ["blood CD4 count", "TEST", 151, 166], ["undetectable HIV load", "PROBLEM", 185, 206], ["Visceral LeishmaniasisVisceral leishmaniasis", "PROBLEM", 208, 252], ["liposomal amphotericin B", "TREATMENT", 277, 301], ["a high rate of relapse", "PROBLEM", 342, 364], ["LeishmaniasisVisceral", "ANATOMY", 217, 238], ["leishmaniasis", "OBSERVATION", 239, 252], ["relapse", "OBSERVATION", 357, 364]]], ["Second-line therapy (or first-line in resourcepoor environments) is to use sodium stibogluconate (see Table 34-14) . phenomena temporally associated with starting HAART.", [["sodium stibogluconate", "CHEMICAL", 75, 96], ["sodium stibogluconate", "CHEMICAL", 75, 96], ["sodium stibogluconate", "SIMPLE_CHEMICAL", 75, 96], ["Second-line therapy", "TREATMENT", 0, 19], ["first-line in resourcepoor environments", "TREATMENT", 24, 63], ["sodium stibogluconate", "TREATMENT", 75, 96], ["phenomena", "PROBLEM", 117, 126], ["HAART", "TREATMENT", 163, 168], ["line therapy", "OBSERVATION", 7, 19], ["HAART", "OBSERVATION", 163, 168]]], ["New or enlarging lymphadenopathy, cold abscesses, or other focal tissue involvement 2.", [["lymphadenopathy", "ANATOMY", 17, 32], ["abscesses", "ANATOMY", 39, 48], ["focal tissue", "ANATOMY", 59, 71], ["lymphadenopathy", "DISEASE", 17, 32], ["abscesses", "DISEASE", 39, 48], ["lymphadenopathy", "PATHOLOGICAL_FORMATION", 17, 32], ["tissue", "TISSUE", 65, 71], ["New or enlarging lymphadenopathy", "PROBLEM", 0, 32], ["cold abscesses", "PROBLEM", 34, 48], ["other focal tissue involvement 2", "PROBLEM", 53, 85], ["enlarging", "OBSERVATION_MODIFIER", 7, 16], ["lymphadenopathy", "OBSERVATION", 17, 32], ["cold", "OBSERVATION_MODIFIER", 34, 38], ["abscesses", "OBSERVATION", 39, 48], ["focal", "OBSERVATION_MODIFIER", 59, 64], ["tissue", "OBSERVATION", 65, 71]]], ["New or worsening central nervous system disease 3.", [["central nervous system", "ANATOMY", 17, 39], ["central nervous system disease", "DISEASE", 17, 47], ["central nervous system", "CANCER", 17, 39], ["New or worsening central nervous system disease", "PROBLEM", 0, 47], ["worsening", "OBSERVATION_MODIFIER", 7, 16], ["central nervous system disease", "OBSERVATION", 17, 47]]], ["New or worsening radiological features of tuberculosis 4.", [["tuberculosis", "DISEASE", 42, 54], ["New or worsening radiological features", "PROBLEM", 0, 38], ["tuberculosis", "PROBLEM", 42, 54], ["worsening", "OBSERVATION_MODIFIER", 7, 16], ["tuberculosis", "OBSERVATION", 42, 54]]], ["New or worsening serositis (pleural effusion, ascites, pericardial effusion, or arthritis.", [["pleural", "ANATOMY", 28, 35], ["ascites", "ANATOMY", 46, 53], ["pericardial", "ANATOMY", 55, 66], ["serositis", "DISEASE", 17, 26], ["pleural effusion", "DISEASE", 28, 44], ["ascites", "DISEASE", 46, 53], ["pericardial effusion", "DISEASE", 55, 75], ["arthritis", "DISEASE", 80, 89], ["pleural effusion", "PATHOLOGICAL_FORMATION", 28, 44], ["New or worsening serositis", "PROBLEM", 0, 26], ["pleural effusion", "PROBLEM", 28, 44], ["ascites", "PROBLEM", 46, 53], ["pericardial effusion", "PROBLEM", 55, 75], ["arthritis", "PROBLEM", 80, 89], ["worsening", "OBSERVATION_MODIFIER", 7, 16], ["serositis", "OBSERVATION", 17, 26], ["pleural", "ANATOMY", 28, 35], ["effusion", "OBSERVATION", 36, 44], ["ascites", "OBSERVATION", 46, 53], ["pericardial", "ANATOMY", 55, 66], ["effusion", "OBSERVATION", 67, 75], ["arthritis", "OBSERVATION", 80, 89]]], ["New or worsening constitutional symptoms such as fever, night sweats, and/or weight loss 6.", [["fever", "DISEASE", 49, 54], ["night sweats", "DISEASE", 56, 68], ["weight loss", "DISEASE", 77, 88], ["New or worsening constitutional symptoms", "PROBLEM", 0, 40], ["fever", "PROBLEM", 49, 54], ["night sweats", "PROBLEM", 56, 68], ["weight loss", "PROBLEM", 77, 88], ["worsening", "OBSERVATION_MODIFIER", 7, 16]]], ["Retrospective review indicating that a clinical or radiologic deterioration occurred with no change having been made to tuberculosis treatment C. Immune restoration, e.g., a rise in CD4 lymphocyte count in response to HAART D. A fall in HIV \"viral load\" in response to HAART Alternative diagnoses to be excluded Progressive underlying infection Treatment failure due to drug resistance (MDR or XDR) Treatment failure from poor adherence Adverse drug reaction Another diagnosis coexisting (e.g., non-Hodgkin lymphoma)STRONGYLOIDES STERCORALIS INFECTIONThe treatment of choice is ivermectin.", [["CD4 lymphocyte", "ANATOMY", 182, 196], ["non-Hodgkin lymphoma", "ANATOMY", 495, 515], ["tuberculosis", "DISEASE", 120, 132], ["infection", "DISEASE", 335, 344], ["Adverse drug reaction", "DISEASE", 437, 458], ["non-Hodgkin lymphoma", "DISEASE", 495, 515], ["ivermectin", "CHEMICAL", 578, 588], ["ivermectin", "CHEMICAL", 578, 588], ["CD4 lymphocyte", "CELL", 182, 196], ["HIV", "ORGANISM", 237, 240], ["non-Hodgkin lymphoma", "CANCER", 495, 515], ["ivermectin", "SIMPLE_CHEMICAL", 578, 588], ["CD4", "PROTEIN", 182, 185], ["HIV", "SPECIES", 237, 240], ["HIV", "SPECIES", 237, 240], ["Retrospective review", "TEST", 0, 20], ["a clinical or radiologic deterioration", "PROBLEM", 37, 75], ["tuberculosis treatment", "TREATMENT", 120, 142], ["Immune restoration", "TREATMENT", 146, 164], ["a rise", "PROBLEM", 172, 178], ["CD4 lymphocyte count", "TEST", 182, 202], ["HAART D.", "PROBLEM", 218, 226], ["A fall", "PROBLEM", 227, 233], ["HIV \"viral load\"", "PROBLEM", 237, 253], ["HAART", "TREATMENT", 269, 274], ["Progressive underlying infection", "PROBLEM", 312, 344], ["Treatment failure", "PROBLEM", 345, 362], ["drug resistance", "PROBLEM", 370, 385], ["Treatment failure", "PROBLEM", 399, 416], ["poor adherence Adverse drug reaction", "PROBLEM", 422, 458], ["non-Hodgkin lymphoma)", "PROBLEM", 495, 516], ["STRONGYLOIDES STERCORALIS INFECTIONThe treatment", "TREATMENT", 516, 564], ["ivermectin", "TREATMENT", 578, 588], ["CD4 lymphocyte count", "OBSERVATION", 182, 202], ["infection", "OBSERVATION", 335, 344], ["poor adherence", "OBSERVATION_MODIFIER", 422, 436], ["non-Hodgkin lymphoma", "OBSERVATION", 495, 515]]], ["Risk of treatment failure with thiabendazole in HIV-infected individuals is higher than that in non-HIV-infected patients.Treatment of Viral InfectionsCytomegalovirus pneumonitis is treated with intravenous ganciclovir, 5 mg/kg every 12 h, for 14 days.", [["intravenous", "ANATOMY", 195, 206], ["thiabendazole", "CHEMICAL", 31, 44], ["HIV-infected", "DISEASE", 48, 60], ["non-HIV-infected", "DISEASE", 96, 112], ["Viral Infections", "DISEASE", 135, 151], ["Cytomegalovirus pneumonitis", "DISEASE", 151, 178], ["ganciclovir", "CHEMICAL", 207, 218], ["thiabendazole", "CHEMICAL", 31, 44], ["ganciclovir", "CHEMICAL", 207, 218], ["thiabendazole", "SIMPLE_CHEMICAL", 31, 44], ["HIV", "ORGANISM", 48, 51], ["individuals", "ORGANISM", 61, 72], ["patients", "ORGANISM", 113, 121], ["Viral", "ORGANISM", 135, 140], ["Cytomegalovirus", "ORGANISM", 151, 166], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 195, 206], ["ganciclovir", "SIMPLE_CHEMICAL", 207, 218], ["HIV", "SPECIES", 48, 51], ["patients", "SPECIES", 113, 121], ["HIV", "SPECIES", 48, 51], ["treatment failure", "PROBLEM", 8, 25], ["thiabendazole", "TREATMENT", 31, 44], ["HIV", "PROBLEM", 48, 51], ["infected individuals", "PROBLEM", 52, 72], ["Viral InfectionsCytomegalovirus pneumonitis", "PROBLEM", 135, 178], ["intravenous ganciclovir", "TREATMENT", 195, 218], ["treatment", "OBSERVATION_MODIFIER", 8, 17], ["failure", "OBSERVATION", 18, 25], ["higher", "OBSERVATION_MODIFIER", 76, 82], ["infected", "OBSERVATION", 104, 112], ["Viral", "OBSERVATION_MODIFIER", 135, 140], ["Infections", "OBSERVATION", 141, 151], ["Cytomegalovirus pneumonitis", "OBSERVATION", 151, 178]]], ["Drug-induced neutropenia is managed with granulocyte colony-stimulating factor.", [["neutropenia", "DISEASE", 13, 24], ["granulocyte colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 41, 78], ["granulocyte colony-stimulating factor", "PROTEIN", 41, 78], ["Drug-induced neutropenia", "PROBLEM", 0, 24], ["granulocyte colony", "TREATMENT", 41, 59], ["neutropenia", "OBSERVATION", 13, 24], ["granulocyte colony", "OBSERVATION", 41, 59]]], ["Some centers use valganciclovir, an oral formulation of ganciclovir, at a dose of 900 mg orally every 12 h, to treat CMV pneumonitis.", [["oral", "ANATOMY", 36, 40], ["valganciclovir", "CHEMICAL", 17, 31], ["ganciclovir", "CHEMICAL", 56, 67], ["CMV pneumonitis", "DISEASE", 117, 132], ["valganciclovir", "CHEMICAL", 17, 31], ["ganciclovir", "CHEMICAL", 56, 67], ["valganciclovir", "SIMPLE_CHEMICAL", 17, 31], ["oral", "ORGANISM_SUBDIVISION", 36, 40], ["ganciclovir", "SIMPLE_CHEMICAL", 56, 67], ["CMV", "ORGANISM", 117, 120], ["CMV", "SPECIES", 117, 120], ["valganciclovir", "TREATMENT", 17, 31], ["an oral formulation of ganciclovir", "TREATMENT", 33, 67], ["CMV pneumonitis", "PROBLEM", 117, 132], ["CMV pneumonitis", "OBSERVATION", 117, 132]]], ["Side effects and their management are as for ganciclovir.", [["ganciclovir", "CHEMICAL", 45, 56], ["ganciclovir", "CHEMICAL", 45, 56], ["ganciclovir", "SIMPLE_CHEMICAL", 45, 56], ["Side effects", "PROBLEM", 0, 12], ["their management", "TREATMENT", 17, 33], ["ganciclovir", "TREATMENT", 45, 56]]], ["There are no data that demonstrate efficacy for cidofovir for treatment of CMV pneumonitis, but this agent is used as second-line therapy in many centers.", [["cidofovir", "CHEMICAL", 48, 57], ["CMV pneumonitis", "DISEASE", 75, 90], ["cidofovir", "CHEMICAL", 48, 57], ["cidofovir", "SIMPLE_CHEMICAL", 48, 57], ["CMV", "ORGANISM", 75, 78], ["CMV", "SPECIES", 75, 78], ["cidofovir", "TREATMENT", 48, 57], ["treatment", "TREATMENT", 62, 71], ["CMV pneumonitis", "PROBLEM", 75, 90], ["this agent", "TREATMENT", 96, 106], ["second-line therapy", "TREATMENT", 118, 137], ["CMV pneumonitis", "OBSERVATION", 75, 90], ["line therapy", "OBSERVATION", 125, 137]]], ["Phosphonoformate (foscarnet) can be used for treatment of CMV endorgan disease (e.g., pneumonitis), although it has an extensive toxicity profile.", [["Phosphonoformate", "CHEMICAL", 0, 16], ["foscarnet", "CHEMICAL", 18, 27], ["CMV endorgan disease", "DISEASE", 58, 78], ["pneumonitis", "DISEASE", 86, 97], ["toxicity", "DISEASE", 129, 137], ["Phosphonoformate", "CHEMICAL", 0, 16], ["foscarnet", "CHEMICAL", 18, 27], ["Phosphonoformate", "SIMPLE_CHEMICAL", 0, 16], ["foscarnet", "SIMPLE_CHEMICAL", 18, 27], ["CMV", "ORGANISM", 58, 61], ["CMV", "SPECIES", 58, 61], ["Phosphonoformate (foscarnet)", "TREATMENT", 0, 28], ["CMV endorgan disease", "PROBLEM", 58, 78], ["pneumonitis", "PROBLEM", 86, 97], ["an extensive toxicity profile", "PROBLEM", 116, 145], ["CMV", "OBSERVATION", 58, 61], ["pneumonitis", "OBSERVATION", 86, 97], ["extensive", "OBSERVATION_MODIFIER", 119, 128], ["toxicity", "OBSERVATION", 129, 137]]], ["It is also a moderately effective antiretroviral agent.", [["a moderately effective antiretroviral agent", "TREATMENT", 11, 54], ["moderately", "OBSERVATION_MODIFIER", 13, 23], ["effective", "OBSERVATION_MODIFIER", 24, 33], ["antiretroviral", "OBSERVATION", 34, 48]]], ["This effect is occasionally used as an adjunct in controlling nonresponsive viral infections.CLINICAL COURSE AND PREVENTIONWithin the past few years, drug therapy has radically altered the depressingly predictable nature of progressive HIV infection.", [["viral infections", "DISEASE", 76, 92], ["HIV infection", "DISEASE", 236, 249], ["HIV", "ORGANISM", 236, 239], ["HIV", "SPECIES", 236, 239], ["an adjunct", "TREATMENT", 36, 46], ["nonresponsive viral infections", "PROBLEM", 62, 92], ["drug therapy", "TREATMENT", 150, 162], ["progressive HIV infection", "PROBLEM", 224, 249], ["viral infections", "OBSERVATION", 76, 92], ["progressive", "OBSERVATION_MODIFIER", 224, 235], ["HIV", "OBSERVATION_MODIFIER", 236, 239], ["infection", "OBSERVATION", 240, 249]]], ["Combinations of specific opportunistic infection prophylaxis and antiretroviral therapy can reduce both the incidence and the mortality associated with common conditions.", [["opportunistic infection", "DISEASE", 25, 48], ["specific opportunistic infection prophylaxis", "TREATMENT", 16, 60], ["antiretroviral therapy", "TREATMENT", 65, 87], ["specific", "OBSERVATION_MODIFIER", 16, 24], ["opportunistic", "OBSERVATION_MODIFIER", 25, 38], ["infection", "OBSERVATION", 39, 48]]], ["The observational North American MACS cohort demonstrated that the risk of PCP in individuals with blood CD4 counts of <100 cells/mL can be reduced almost fourfold if both specific prophylaxis and HAART are taken (from 47% to 13%).", [["blood", "ANATOMY", 99, 104], ["cells", "ANATOMY", 124, 129], ["PCP", "DISEASE", 75, 78], ["PCP", "CHEMICAL", 75, 78], ["individuals", "ORGANISM", 82, 93], ["blood", "ORGANISM_SUBSTANCE", 99, 104], ["CD4", "PROTEIN", 105, 108], ["PCP in individuals", "PROBLEM", 75, 93], ["blood CD4 counts", "TEST", 99, 115], ["HAART", "TREATMENT", 197, 202]]], ["However, as common conditions are prevented, so other less treatable illnesses may arise.", [["treatable illnesses", "PROBLEM", 59, 78]]], ["The initial impact of P. jirovecii prophylaxis was a reduction in the incidence of PCP at the expense of an increase in cases of disseminated MAC infection, CMV infection, esophageal candidiasis, and wasting syndrome.", [["esophageal", "ANATOMY", 172, 182], ["P. jirovecii", "DISEASE", 22, 34], ["PCP", "DISEASE", 83, 86], ["MAC infection", "DISEASE", 142, 155], ["CMV infection", "DISEASE", 157, 170], ["esophageal candidiasis", "DISEASE", 172, 194], ["wasting syndrome", "DISEASE", 200, 216], ["PCP", "CHEMICAL", 83, 86], ["P. jirovecii", "ORGANISM", 22, 34], ["CMV", "ORGANISM", 157, 160], ["esophageal candidiasis", "PATHOLOGICAL_FORMATION", 172, 194], ["P. jirovecii", "SPECIES", 22, 34], ["P. jirovecii", "SPECIES", 22, 34], ["CMV", "SPECIES", 157, 160], ["P. jirovecii prophylaxis", "TREATMENT", 22, 46], ["a reduction", "TREATMENT", 51, 62], ["disseminated MAC infection", "PROBLEM", 129, 155], ["CMV infection", "PROBLEM", 157, 170], ["esophageal candidiasis", "PROBLEM", 172, 194], ["wasting syndrome", "PROBLEM", 200, 216], ["jirovecii prophylaxis", "OBSERVATION", 25, 46], ["increase", "OBSERVATION_MODIFIER", 108, 116], ["disseminated", "OBSERVATION_MODIFIER", 129, 141], ["MAC", "OBSERVATION_MODIFIER", 142, 145], ["infection", "OBSERVATION", 146, 155], ["CMV infection", "OBSERVATION", 157, 170], ["esophageal", "ANATOMY", 172, 182], ["candidiasis", "OBSERVATION", 183, 194], ["wasting syndrome", "OBSERVATION", 200, 216]]], ["New prophylactic therapies targeting those conditions associated with high morbidity and mortality (in particular MAC) have further improved survival.", [["New prophylactic therapies", "TREATMENT", 0, 26], ["high morbidity", "PROBLEM", 70, 84], ["improved", "OBSERVATION_MODIFIER", 132, 140], ["survival", "OBSERVATION_MODIFIER", 141, 149]]], ["It has become apparent that specific infection prophylaxis may also confer protection against other agents.", [["infection", "DISEASE", 37, 46], ["specific infection prophylaxis", "TREATMENT", 28, 58], ["other agents", "TREATMENT", 94, 106], ["infection", "OBSERVATION", 37, 46]]], ["This \"cross- prophylaxis\" is particularly seen with the use of TMP/SMX for Pneumocystis, which also provides cover against cerebral toxoplasmosis and several common bacterial infections (although not S. pneumoniae) and with macrolides for MAC infection, which further reduce the incidence of bacterial disease and also PCP.", [["cerebral", "ANATOMY", 123, 131], ["TMP", "CHEMICAL", 63, 66], ["SMX", "CHEMICAL", 67, 70], ["Pneumocystis", "CHEMICAL", 75, 87], ["cerebral toxoplasmosis", "DISEASE", 123, 145], ["bacterial infections", "DISEASE", 165, 185], ["macrolides", "CHEMICAL", 224, 234], ["MAC infection", "DISEASE", 239, 252], ["bacterial disease", "DISEASE", 292, 309], ["PCP", "DISEASE", 319, 322], ["TMP", "CHEMICAL", 63, 66], ["SMX", "CHEMICAL", 67, 70], ["macrolides", "CHEMICAL", 224, 234], ["PCP", "CHEMICAL", 319, 322], ["TMP", "SIMPLE_CHEMICAL", 63, 66], ["SMX", "SIMPLE_CHEMICAL", 67, 70], ["Pneumocystis", "ORGANISM", 75, 87], ["cerebral", "ORGAN", 123, 131], ["S. pneumoniae", "ORGANISM", 200, 213], ["macrolides", "SIMPLE_CHEMICAL", 224, 234], ["S. pneumoniae", "SPECIES", 200, 213], ["S. pneumoniae", "SPECIES", 200, 213], ["This \"cross- prophylaxis", "TREATMENT", 0, 24], ["TMP/SMX", "TREATMENT", 63, 70], ["Pneumocystis", "PROBLEM", 75, 87], ["cerebral toxoplasmosis", "PROBLEM", 123, 145], ["several common bacterial infections", "PROBLEM", 150, 185], ["S. pneumoniae", "PROBLEM", 200, 213], ["macrolides", "TREATMENT", 224, 234], ["MAC infection", "PROBLEM", 239, 252], ["bacterial disease", "PROBLEM", 292, 309], ["Pneumocystis", "OBSERVATION", 75, 87], ["cerebral", "ANATOMY", 123, 131], ["toxoplasmosis", "OBSERVATION", 132, 145], ["bacterial", "OBSERVATION_MODIFIER", 165, 174], ["infections", "OBSERVATION", 175, 185], ["infection", "OBSERVATION", 243, 252], ["bacterial disease", "OBSERVATION", 292, 309]]], ["Use of large amounts of antibiotic raises the possibility of future widespread drug resistance.", [["large amounts of antibiotic", "TREATMENT", 7, 34], ["future widespread drug resistance", "PROBLEM", 61, 94], ["large", "OBSERVATION_MODIFIER", 7, 12], ["amounts", "OBSERVATION_MODIFIER", 13, 20], ["raises the possibility of", "UNCERTAINTY", 35, 60], ["widespread", "OBSERVATION_MODIFIER", 68, 78], ["drug resistance", "OBSERVATION", 79, 94]]], ["This is clearly of concern, and recent reports suggest that, indeed, in some parts of the world the incidence of pneumococcal TMP/SMX resistance is rising.", [["TMP", "CHEMICAL", 126, 129], ["SMX", "CHEMICAL", 130, 133], ["TMP", "CHEMICAL", 126, 129], ["SMX", "CHEMICAL", 130, 133], ["pneumococcal", "ORGANISM", 113, 125], ["TMP", "SIMPLE_CHEMICAL", 126, 129], ["SMX", "SIMPLE_CHEMICAL", 130, 133], ["pneumococcal", "SPECIES", 113, 125], ["pneumococcal TMP", "TREATMENT", 113, 129], ["SMX resistance", "PROBLEM", 130, 144], ["SMX resistance", "OBSERVATION", 130, 144], ["rising", "OBSERVATION_MODIFIER", 148, 154]]], ["Current preventive therapies pertinent to lung disease focus on P. jirovecii, MAC, M. tuberculosis, and certain bacteria (Table 34-15 ).Pneumocystis jirovecii ProphylaxisNumerous studies have demonstrated the greatly increased risk in subjects who do not take adequate drug therapy with blood CD4 counts <200 cells/mL.", [["lung", "ANATOMY", 42, 46], ["blood", "ANATOMY", 287, 292], ["cells", "ANATOMY", 309, 314], ["lung disease", "DISEASE", 42, 54], ["P. jirovecii", "DISEASE", 64, 76], ["M. tuberculosis", "DISEASE", 83, 98], ["Pneumocystis jirovecii", "DISEASE", 136, 158], ["lung", "ORGAN", 42, 46], ["P. jirovecii", "ORGANISM", 64, 76], ["M. tuberculosis", "ORGANISM", 83, 98], ["Pneumocystis jirovecii", "ORGANISM", 136, 158], ["blood", "ORGANISM_SUBSTANCE", 287, 292], ["CD4", "PROTEIN", 293, 296], ["P. jirovecii", "SPECIES", 64, 76], ["M. tuberculosis", "SPECIES", 83, 98], ["Pneumocystis jirovecii", "SPECIES", 136, 158], ["P. jirovecii", "SPECIES", 64, 76], ["M. tuberculosis", "SPECIES", 83, 98], ["Pneumocystis jirovecii", "SPECIES", 136, 158], ["Current preventive therapies", "TREATMENT", 0, 28], ["lung disease focus", "PROBLEM", 42, 60], ["P. jirovecii", "PROBLEM", 64, 76], ["M. tuberculosis", "PROBLEM", 83, 98], ["certain bacteria", "PROBLEM", 104, 120], ["Pneumocystis jirovecii", "PROBLEM", 136, 158], ["adequate drug therapy", "TREATMENT", 260, 281], ["blood CD4 counts", "TEST", 287, 303], ["lung", "ANATOMY", 42, 46], ["disease", "OBSERVATION", 47, 54], ["jirovecii", "OBSERVATION", 67, 76], ["tuberculosis", "OBSERVATION", 86, 98]]], ["Clinical symptoms are also an independent risk factor for PCP, and hence the current guidelines recommend lifelong prophylaxis against P. jirovecii in HIV-infected adults who have had prior PCP, CD4 counts <200 cells/mL, constitutional symptoms (documented oral thrush or fever of unknown cause of <37.8 C that persists for more than 2 weeks), or clinical AIDS.", [["cells", "ANATOMY", 211, 216], ["oral", "ANATOMY", 257, 261], ["PCP", "DISEASE", 58, 61], ["P. jirovecii", "DISEASE", 135, 147], ["HIV-infected", "DISEASE", 151, 163], ["PCP", "DISEASE", 190, 193], ["oral thrush", "DISEASE", 257, 268], ["fever", "DISEASE", 272, 277], ["AIDS", "DISEASE", 356, 360], ["PCP", "CHEMICAL", 190, 193], ["P. jirovecii", "ORGANISM", 135, 147], ["HIV", "ORGANISM", 151, 154], ["adults", "ORGANISM", 164, 170], ["CD4", "GENE_OR_GENE_PRODUCT", 195, 198], ["oral", "ORGANISM_SUBDIVISION", 257, 261], ["CD4", "PROTEIN", 195, 198], ["P. jirovecii", "SPECIES", 135, 147], ["HIV", "SPECIES", 151, 154], ["P. jirovecii", "SPECIES", 135, 147], ["HIV", "SPECIES", 151, 154], ["Clinical symptoms", "PROBLEM", 0, 17], ["lifelong prophylaxis", "TREATMENT", 106, 126], ["P. jirovecii", "PROBLEM", 135, 147], ["prior PCP", "PROBLEM", 184, 193], ["CD4 counts", "TEST", 195, 205], ["constitutional symptoms", "PROBLEM", 221, 244], ["oral thrush", "PROBLEM", 257, 268], ["fever", "PROBLEM", 272, 277], ["clinical AIDS", "PROBLEM", 347, 360]]], ["The importance of secondary prophylaxis (i.e., used after an episode of PCP) becomes clear from historical data, which indicate a 60% risk of relapse in the first 12 months after infection.", [["PCP", "DISEASE", 72, 75], ["infection", "DISEASE", 179, 188], ["secondary prophylaxis", "TREATMENT", 18, 39], ["PCP", "PROBLEM", 72, 75], ["relapse", "PROBLEM", 142, 149], ["infection", "PROBLEM", 179, 188], ["secondary prophylaxis", "OBSERVATION", 18, 39], ["infection", "OBSERVATION", 179, 188]]], ["The increase in systemic and local immunity that occurs with HAART has led to several studies evaluating the need for prolonged prophylaxis in individuals with sustained elevations in blood CD4 counts and low HIV RNA load.", [["blood", "ANATOMY", 184, 189], ["blood", "ORGANISM_SUBSTANCE", 184, 189], ["CD4", "GENE_OR_GENE_PRODUCT", 190, 193], ["CD4", "PROTEIN", 190, 193], ["HIV", "SPECIES", 209, 212], ["The increase in systemic and local immunity", "PROBLEM", 0, 43], ["HAART", "TREATMENT", 61, 66], ["several studies", "TEST", 78, 93], ["prolonged prophylaxis", "TREATMENT", 118, 139], ["sustained elevations", "PROBLEM", 160, 180], ["blood CD4 counts", "TEST", 184, 200], ["low HIV RNA load", "PROBLEM", 205, 221], ["increase", "OBSERVATION_MODIFIER", 4, 12], ["systemic", "OBSERVATION_MODIFIER", 16, 24], ["local immunity", "OBSERVATION", 29, 43], ["low", "OBSERVATION_MODIFIER", 205, 208], ["HIV RNA load", "OBSERVATION", 209, 221]]], ["In summary, it seems that both primary and secondary PCP prophylaxis can be discontinued once CD4 counts are >200 cells/mL for more than 3 months.", [["CD4", "ANATOMY", 94, 97], ["cells", "ANATOMY", 114, 119], ["PCP", "CHEMICAL", 53, 56], ["PCP", "CHEMICAL", 53, 56], ["CD4", "GENE_OR_GENE_PRODUCT", 94, 97], ["cells", "CELL", 114, 119], ["CD4", "PROTEIN", 94, 97], ["secondary PCP prophylaxis", "TREATMENT", 43, 68], ["CD4 counts", "TEST", 94, 104]]], ["A caveat to this is that the patient should have a low or undetectable HIV RNA load, that the CD4 percentage is stable or rising and is >14%, and that the individual plans to continue HAART long term with good adherence.Pneumocystis jirovecii ProphylaxisThe risk of PCP recurrence is real if the CD4 count falls below 200 cells/mL.", [["CD4", "ANATOMY", 296, 299], ["cells", "ANATOMY", 322, 327], ["Pneumocystis jirovecii", "DISEASE", 220, 242], ["PCP", "DISEASE", 266, 269], ["PCP", "CHEMICAL", 266, 269], ["patient", "ORGANISM", 29, 36], ["HIV", "ORGANISM", 71, 74], ["CD4", "GENE_OR_GENE_PRODUCT", 94, 97], ["Pneumocystis jirovecii", "ORGANISM", 220, 242], ["CD4", "GENE_OR_GENE_PRODUCT", 296, 299], ["CD4", "PROTEIN", 94, 97], ["CD4", "PROTEIN", 296, 299], ["patient", "SPECIES", 29, 36], ["Pneumocystis jirovecii", "SPECIES", 220, 242], ["HIV", "SPECIES", 71, 74], ["Pneumocystis jirovecii", "SPECIES", 220, 242], ["a low or undetectable HIV RNA load", "PROBLEM", 49, 83], ["the CD4 percentage", "TEST", 90, 108], ["HAART", "TREATMENT", 184, 189], ["Pneumocystis jirovecii Prophylaxis", "TREATMENT", 220, 254], ["PCP recurrence", "PROBLEM", 266, 280], ["the CD4 count", "TEST", 292, 305], ["HIV RNA load", "OBSERVATION", 71, 83], ["stable", "OBSERVATION_MODIFIER", 112, 118], ["rising", "OBSERVATION_MODIFIER", 122, 128], ["jirovecii", "OBSERVATION", 233, 242], ["PCP", "OBSERVATION_MODIFIER", 266, 269], ["recurrence", "OBSERVATION", 270, 280]]], ["If this does happen, PCP prophylaxis should be restarted.", [["PCP", "CHEMICAL", 21, 24], ["PCP", "CHEMICAL", 21, 24], ["PCP", "SIMPLE_CHEMICAL", 21, 24], ["PCP prophylaxis", "TREATMENT", 21, 36]]], ["Similar algorithms have been successfully used for all the major infections except tuberculosis.", [["infections", "DISEASE", 65, 75], ["tuberculosis", "DISEASE", 83, 95], ["the major infections", "PROBLEM", 55, 75], ["tuberculosis", "PROBLEM", 83, 95], ["major", "OBSERVATION_MODIFIER", 59, 64], ["infections", "OBSERVATION", 65, 75], ["tuberculosis", "OBSERVATION", 83, 95]]], ["They all rely on an estimation of the general blood CD4 count above which clinical disease is highly unlikely.", [["blood", "ANATOMY", 46, 51], ["blood", "ORGANISM_SUBSTANCE", 46, 51], ["CD4", "GENE_OR_GENE_PRODUCT", 52, 55], ["CD4", "PROTEIN", 52, 55], ["the general blood CD4 count", "TEST", 34, 61], ["clinical disease", "PROBLEM", 74, 90], ["highly unlikely", "UNCERTAINTY", 94, 109]]], ["For example, secondary prophylaxis of MAC may be discontinued once the blood CD4 count is consistently >100 cells/mL.", [["blood", "ANATOMY", 71, 76], ["cells", "ANATOMY", 108, 113], ["MAC", "CHEMICAL", 38, 41], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["CD4", "GENE_OR_GENE_PRODUCT", 77, 80], ["cells", "CELL", 108, 113], ["CD4", "PROTEIN", 77, 80], ["secondary prophylaxis of MAC", "TREATMENT", 13, 41], ["the blood CD4 count", "TEST", 67, 86]]], ["This is a general guideline, however, and patients must be assessed on an individual basis.Trimethoprim-SulfamethoxazoleAs with treatment strategies, TMP/SMX is the drug of choice for prophylaxis (Table 34- 16) .", [["Trimethoprim-SulfamethoxazoleAs", "CHEMICAL", 91, 122], ["TMP", "CHEMICAL", 150, 153], ["SMX", "CHEMICAL", 154, 157], ["Trimethoprim-SulfamethoxazoleAs", "CHEMICAL", 91, 122], ["TMP", "CHEMICAL", 150, 153], ["SMX", "CHEMICAL", 154, 157], ["patients", "ORGANISM", 42, 50], ["Trimethoprim-SulfamethoxazoleAs", "SIMPLE_CHEMICAL", 91, 122], ["TMP", "SIMPLE_CHEMICAL", 150, 153], ["SMX", "SIMPLE_CHEMICAL", 154, 157], ["patients", "SPECIES", 42, 50], ["Trimethoprim", "TREATMENT", 91, 103], ["SulfamethoxazoleAs", "TREATMENT", 104, 122], ["treatment strategies", "TREATMENT", 128, 148], ["TMP/SMX", "TREATMENT", 150, 157], ["prophylaxis", "TREATMENT", 184, 195]]], ["It has the advantages of being highly effective for both primary and secondary prophylaxis (with 1-year risk of PCP while on the drug being 1.5 and 3.5%, respectively).", [["PCP", "DISEASE", 112, 115], ["secondary prophylaxis", "TREATMENT", 69, 90], ["secondary prophylaxis", "OBSERVATION", 69, 90]]], ["It is cheap, can be taken orally, acts systemically, and provides some cross-prophylaxis against other infections, such as toxoplasmosis, Salmonella species, Staphylococcus species, and H. influenzae.", [["infections", "DISEASE", 103, 113], ["toxoplasmosis", "DISEASE", 123, 136], ["Staphylococcus species", "DISEASE", 158, 180], ["H. influenzae", "DISEASE", 186, 199], ["Salmonella species", "ORGANISM", 138, 156], ["Staphylococcus species", "ORGANISM", 158, 180], ["H. influenzae", "ORGANISM", 186, 199], ["Staphylococcus species", "SPECIES", 158, 180], ["H. influenzae", "SPECIES", 186, 199], ["H. influenzae", "SPECIES", 186, 199], ["other infections", "PROBLEM", 97, 113], ["toxoplasmosis", "PROBLEM", 123, 136], ["Salmonella species", "PROBLEM", 138, 156], ["Staphylococcus species", "PROBLEM", 158, 180], ["H. influenzae", "PROBLEM", 186, 199], ["infections", "OBSERVATION", 103, 113], ["Staphylococcus species", "OBSERVATION", 158, 180]]], ["Its main disadvantage is that adverse reactions are common (see earlier), occurring in up to 50% of individuals taking the prophylactic dose.Trimethoprim-SulfamethoxazoleThe standard dose of TMP/SMX is one double-strength tablet (160 mg trimethoprim, 800 mg sulfamethoxazole) per day.", [["Trimethoprim-Sulfamethoxazole", "CHEMICAL", 141, 170], ["TMP", "CHEMICAL", 191, 194], ["SMX", "CHEMICAL", 195, 198], ["trimethoprim", "CHEMICAL", 237, 249], ["sulfamethoxazole", "CHEMICAL", 258, 274], ["Trimethoprim-Sulfamethoxazole", "CHEMICAL", 141, 170], ["TMP", "CHEMICAL", 191, 194], ["SMX", "CHEMICAL", 195, 198], ["trimethoprim", "CHEMICAL", 237, 249], ["sulfamethoxazole", "CHEMICAL", 258, 274], ["Trimethoprim-Sulfamethoxazole", "SIMPLE_CHEMICAL", 141, 170], ["TMP", "SIMPLE_CHEMICAL", 191, 194], ["SMX", "SIMPLE_CHEMICAL", 195, 198], ["trimethoprim", "SIMPLE_CHEMICAL", 237, 249], ["sulfamethoxazole", "SIMPLE_CHEMICAL", 258, 274], ["adverse reactions", "PROBLEM", 30, 47], ["the prophylactic dose", "TREATMENT", 119, 140], ["Trimethoprim", "TREATMENT", 141, 153], ["Sulfamethoxazole", "TREATMENT", 154, 170], ["TMP/SMX", "TREATMENT", 191, 198], ["double-strength tablet", "TREATMENT", 206, 228], ["trimethoprim", "TREATMENT", 237, 249], ["main", "OBSERVATION_MODIFIER", 4, 8], ["disadvantage", "OBSERVATION_MODIFIER", 9, 21]]], ["Other regimens have been tried; these include one \"double-strength\" tablet three times weekly and one single-strength tablet per day.", [["Other regimens", "TREATMENT", 0, 14], ["one \"double-strength\" tablet", "TREATMENT", 46, 74]]], ["In general, when used for primary prophylaxis, these regimens are tolerated well (if not better than the standard) and seem as efficacious as one double-strength tablet per day.", [["primary prophylaxis", "TREATMENT", 26, 45], ["these regimens", "TREATMENT", 47, 61]]], ["The data are less clear on secondary prophylaxis, in which subjects are at a much higher risk of recurrent PCP.", [["PCP", "DISEASE", 107, 110], ["PCP", "CHEMICAL", 107, 110], ["secondary prophylaxis", "TREATMENT", 27, 48], ["recurrent PCP", "PROBLEM", 97, 110], ["less clear", "OBSERVATION_MODIFIER", 13, 23], ["recurrent", "OBSERVATION_MODIFIER", 97, 106], ["PCP", "OBSERVATION", 107, 110]]], ["Attempts to desensitize patients who are intolerant of TMP/ SMX have met with some success.DapsoneIn patients who cannot tolerate TMP/SMX, dapsone is a safe and inexpensive alternative.", [["TMP", "CHEMICAL", 55, 58], ["SMX", "CHEMICAL", 60, 63], ["DapsoneIn", "CHEMICAL", 91, 100], ["TMP", "CHEMICAL", 130, 133], ["SMX", "CHEMICAL", 134, 137], ["dapsone", "CHEMICAL", 139, 146], ["TMP", "CHEMICAL", 55, 58], ["SMX", "CHEMICAL", 60, 63], ["TMP", "CHEMICAL", 130, 133], ["SMX", "CHEMICAL", 134, 137], ["dapsone", "CHEMICAL", 139, 146], ["patients", "ORGANISM", 24, 32], ["TMP", "SIMPLE_CHEMICAL", 55, 58], ["SMX", "SIMPLE_CHEMICAL", 60, 63], ["patients", "ORGANISM", 101, 109], ["TMP", "SIMPLE_CHEMICAL", 130, 133], ["SMX", "SIMPLE_CHEMICAL", 134, 137], ["dapsone", "SIMPLE_CHEMICAL", 139, 146], ["patients", "SPECIES", 24, 32], ["patients", "SPECIES", 101, 109], ["TMP/ SMX", "TREATMENT", 55, 63], ["TMP/SMX", "TREATMENT", 130, 137], ["dapsone", "TREATMENT", 139, 146]]], ["It has been studied in a number of trials as both primary and secondary prophylaxis and is effective at an oral dose of 100 mg/day.", [["oral", "ANATOMY", 107, 111], ["oral", "ORGANISM_SUBDIVISION", 107, 111], ["secondary prophylaxis", "TREATMENT", 62, 83], ["secondary prophylaxis", "OBSERVATION", 62, 83]]], ["When combined with pyrimethamine (25 mg three times weekly), it provides a degree of cross-prophylaxis against toxoplasmosis.", [["pyrimethamine", "CHEMICAL", 19, 32], ["toxoplasmosis", "DISEASE", 111, 124], ["pyrimethamine", "CHEMICAL", 19, 32], ["pyrimethamine", "SIMPLE_CHEMICAL", 19, 32], ["pyrimethamine", "TREATMENT", 19, 32], ["cross-prophylaxis", "TREATMENT", 85, 102], ["toxoplasmosis", "PROBLEM", 111, 124], ["toxoplasmosis", "OBSERVATION", 111, 124]]], ["Before starting dapsone, patients are tested for glucose-6-phosphate dehydrogenase deficiency.PentamidineNebulized pentamidine has largely fallen from use as a prophylactic agent.", [["dapsone", "CHEMICAL", 16, 23], ["glucose-6-phosphate", "CHEMICAL", 49, 68], ["Pentamidine", "CHEMICAL", 94, 105], ["pentamidine", "CHEMICAL", 115, 126], ["dapsone", "CHEMICAL", 16, 23], ["glucose-6-phosphate", "CHEMICAL", 49, 68], ["Pentamidine", "CHEMICAL", 94, 105], ["pentamidine", "CHEMICAL", 115, 126], ["dapsone", "SIMPLE_CHEMICAL", 16, 23], ["patients", "ORGANISM", 25, 33], ["glucose-6-phosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 49, 82], ["Pentamidine", "SIMPLE_CHEMICAL", 94, 105], ["pentamidine", "SIMPLE_CHEMICAL", 115, 126], ["glucose-6-phosphate dehydrogenase", "PROTEIN", 49, 82], ["patients", "SPECIES", 25, 33], ["dapsone", "TREATMENT", 16, 23], ["glucose", "TEST", 49, 56], ["phosphate dehydrogenase deficiency", "PROBLEM", 59, 93], ["PentamidineNebulized pentamidine", "TREATMENT", 94, 126], ["a prophylactic agent", "TREATMENT", 158, 178]]], ["This is despite it being better tolerated and having a similar efficacy to TMP/SMX for primary preventive therapy.", [["TMP", "CHEMICAL", 75, 78], ["SMX", "CHEMICAL", 79, 82], ["TMP", "CHEMICAL", 75, 78], ["SMX", "CHEMICAL", 79, 82], ["TMP", "SIMPLE_CHEMICAL", 75, 78], ["SMX", "SIMPLE_CHEMICAL", 79, 82], ["TMP/SMX", "TREATMENT", 75, 82], ["primary preventive therapy", "TREATMENT", 87, 113]]], ["However, its breakthrough rate is higher in subjects who have lower CD4 counts (i.e., <100 cells/mL) and in those who take it as secondary prophylaxis.", [["CD4", "ANATOMY", 68, 71], ["cells", "ANATOMY", 91, 96], ["CD4", "GENE_OR_GENE_PRODUCT", 68, 71], ["CD4", "PROTEIN", 68, 71], ["its breakthrough rate", "PROBLEM", 9, 30], ["lower CD4 counts", "PROBLEM", 62, 78], ["secondary prophylaxis", "TREATMENT", 129, 150], ["breakthrough", "OBSERVATION_MODIFIER", 13, 25], ["higher", "OBSERVATION_MODIFIER", 34, 40]]], ["Other disadvantages include equipment costs and complexity (alveolar deposition is crucial, and hence the nebulizer system used is important), the risk of transmission of respiratory disease (e.g., tuberculosis) to other patients and staff during the nebulization procedure, an alteration in the clinical presentation of PCP while on pentamidine (increased frequency of radiographic upper zone shadowing, increased incidence of pneumothorax), and a lack of systemic protection against Pneumocystis and other infectious agents.", [["alveolar", "ANATOMY", 60, 68], ["respiratory", "ANATOMY", 171, 182], ["respiratory disease", "DISEASE", 171, 190], ["tuberculosis", "DISEASE", 198, 210], ["PCP", "DISEASE", 321, 324], ["pentamidine", "CHEMICAL", 334, 345], ["pneumothorax", "DISEASE", 428, 440], ["Pneumocystis", "DISEASE", 485, 497], ["PCP", "CHEMICAL", 321, 324], ["pentamidine", "CHEMICAL", 334, 345], ["alveolar", "MULTI-TISSUE_STRUCTURE", 60, 68], ["patients", "ORGANISM", 221, 229], ["pentamidine", "SIMPLE_CHEMICAL", 334, 345], ["upper", "ORGANISM_SUBDIVISION", 383, 388], ["Pneumocystis", "ORGANISM", 485, 497], ["patients", "SPECIES", 221, 229], ["equipment costs", "TREATMENT", 28, 43], ["complexity (alveolar deposition", "TREATMENT", 48, 79], ["the nebulizer system", "TREATMENT", 102, 122], ["respiratory disease", "PROBLEM", 171, 190], ["tuberculosis", "PROBLEM", 198, 210], ["the nebulization procedure", "TREATMENT", 247, 273], ["pentamidine", "TREATMENT", 334, 345], ["radiographic upper zone shadowing", "PROBLEM", 370, 403], ["pneumothorax", "PROBLEM", 428, 440], ["systemic protection", "TREATMENT", 457, 476], ["Pneumocystis", "PROBLEM", 485, 497], ["other infectious agents", "TREATMENT", 502, 525], ["alveolar", "ANATOMY", 60, 68], ["respiratory disease", "OBSERVATION", 171, 190], ["increased", "OBSERVATION_MODIFIER", 405, 414], ["pneumothorax", "OBSERVATION", 428, 440], ["Pneumocystis", "OBSERVATION", 485, 497]]], ["There is also an acute bronchoconstriction effect during nebulization.", [["an acute bronchoconstriction effect", "PROBLEM", 14, 49], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["bronchoconstriction effect", "OBSERVATION", 23, 49], ["nebulization", "OBSERVATION_MODIFIER", 57, 69]]], ["Long-term follow-up studies have not demonstrated any significant negative effect on lung function.AtovaquoneAtovaquone oral suspension is used as a second-line prophylactic agent in subjects intolerant of TMP/SMX.", [["lung", "ANATOMY", 85, 89], ["oral", "ANATOMY", 120, 124], ["Atovaquone", "CHEMICAL", 99, 109], ["Atovaquone", "CHEMICAL", 109, 119], ["TMP", "CHEMICAL", 206, 209], ["SMX", "CHEMICAL", 210, 213], ["Atovaquone", "CHEMICAL", 99, 109], ["TMP", "CHEMICAL", 206, 209], ["SMX", "CHEMICAL", 210, 213], ["lung", "ORGAN", 85, 89], ["Atovaquone", "SIMPLE_CHEMICAL", 99, 109], ["TMP", "SIMPLE_CHEMICAL", 206, 209], ["SMX", "SIMPLE_CHEMICAL", 210, 213], ["follow-up studies", "TEST", 10, 27], ["AtovaquoneAtovaquone oral suspension", "TREATMENT", 99, 135], ["a second-line prophylactic agent", "TREATMENT", 147, 179], ["TMP/SMX", "TREATMENT", 206, 213], ["significant", "OBSERVATION_MODIFIER", 54, 65], ["negative", "OBSERVATION", 66, 74], ["lung", "ANATOMY", 85, 89]]], ["It seems to have similar efficacy to dapsone (given together with weekly pyrimethamine), with a reduced incidence of side effects, of which the most frequent are rash, fever, and gastrointestinal disturbance.AzithromycinAzithromycin is used in many centers as a third-line prophylactic agent.", [["gastrointestinal", "ANATOMY", 179, 195], ["dapsone", "CHEMICAL", 37, 44], ["pyrimethamine", "CHEMICAL", 73, 86], ["rash", "DISEASE", 162, 166], ["fever", "DISEASE", 168, 173], ["gastrointestinal disturbance", "DISEASE", 179, 207], ["AzithromycinAzithromycin", "CHEMICAL", 208, 232], ["dapsone", "CHEMICAL", 37, 44], ["pyrimethamine", "CHEMICAL", 73, 86], ["AzithromycinAzithromycin", "CHEMICAL", 208, 232], ["dapsone", "SIMPLE_CHEMICAL", 37, 44], ["pyrimethamine", "SIMPLE_CHEMICAL", 73, 86], ["gastrointestinal", "ORGAN", 179, 195], ["AzithromycinAzithromycin", "SIMPLE_CHEMICAL", 208, 232], ["dapsone", "TREATMENT", 37, 44], ["pyrimethamine", "TREATMENT", 73, 86], ["side effects", "PROBLEM", 117, 129], ["rash", "PROBLEM", 162, 166], ["fever", "PROBLEM", 168, 173], ["gastrointestinal disturbance", "PROBLEM", 179, 207], ["AzithromycinAzithromycin", "TREATMENT", 208, 232], ["a third-line prophylactic agent", "TREATMENT", 260, 291], ["side effects", "OBSERVATION_MODIFIER", 117, 129], ["rash", "OBSERVATION", 162, 166], ["fever", "OBSERVATION", 168, 173], ["gastrointestinal", "ANATOMY", 179, 195]]], ["It is given at a dose of 1250 mg once weekly, and may provide protection against some bacterial infections, as well as MAC.Predictors of Pneumocystis Prophylaxis FailureA low blood CD4 count (<50 cells/mL) is the current best laboratory predictor of prophylaxis failure.", [["blood", "ANATOMY", 175, 180], ["cells", "ANATOMY", 196, 201], ["bacterial infections", "DISEASE", 86, 106], ["Pneumocystis", "DISEASE", 137, 149], ["Pneumocystis", "ORGANISM", 137, 149], ["blood", "ORGANISM_SUBSTANCE", 175, 180], ["CD4", "PROTEIN", 181, 184], ["some bacterial infections", "PROBLEM", 81, 106], ["Pneumocystis Prophylaxis", "TREATMENT", 137, 161], ["blood CD4 count", "TEST", 175, 190], ["prophylaxis failure", "PROBLEM", 250, 269], ["bacterial", "OBSERVATION_MODIFIER", 86, 95], ["infections", "OBSERVATION", 96, 106], ["Pneumocystis", "OBSERVATION", 137, 149]]], ["This is not particularly surprising given that the median blood CD4 count of subjects not on prophylaxis who have PCP develop is below 50 cells/mL.", [["blood", "ANATOMY", 58, 63], ["cells", "ANATOMY", 138, 143], ["PCP", "DISEASE", 114, 117], ["PCP", "CHEMICAL", 114, 117], ["blood", "ORGANISM_SUBSTANCE", 58, 63], ["CD4", "GENE_OR_GENE_PRODUCT", 64, 67], ["cells", "CELL", 138, 143], ["CD4", "PROTEIN", 64, 67], ["the median blood CD4 count", "TEST", 47, 73], ["prophylaxis", "TREATMENT", 93, 104], ["not particularly", "UNCERTAINTY", 8, 24]]], ["Persistent fever of unknown cause is an important clinical risk factor for PCP.", [["fever", "DISEASE", 11, 16], ["PCP", "DISEASE", 75, 78], ["PCP", "CHEMICAL", 75, 78], ["Persistent fever", "PROBLEM", 0, 16], ["PCP", "PROBLEM", 75, 78], ["fever", "OBSERVATION", 11, 16]]], ["Used as preventive therapy, TMP/ SMX significantly reduces the chance for development of Pneumocystis.", [["TMP", "CHEMICAL", 28, 31], ["SMX", "CHEMICAL", 33, 36], ["Pneumocystis", "DISEASE", 89, 101], ["TMP", "CHEMICAL", 28, 31], ["SMX", "CHEMICAL", 33, 36], ["TMP", "SIMPLE_CHEMICAL", 28, 31], ["SMX", "SIMPLE_CHEMICAL", 33, 36], ["Pneumocystis", "ORGANISM", 89, 101], ["preventive therapy", "TREATMENT", 8, 26], ["TMP/ SMX", "TREATMENT", 28, 36], ["Pneumocystis", "PROBLEM", 89, 101], ["Pneumocystis", "OBSERVATION", 89, 101]]], ["The PSPC cohort study revealed that 21% of subjects with a CD4 count <200 cells/mL were not receiving any form of PCP prophylaxis.Bacterial Infection ProphylaxisThe effective and safe (i.e., replication incompetent) bacterial vaccines that are available would be expected to be widely used to prevent HIV-related disease.", [["cells", "ANATOMY", 74, 79], ["PCP", "CHEMICAL", 114, 117], ["HIV-related disease", "DISEASE", 301, 320], ["PCP", "CHEMICAL", 114, 117], ["subjects", "ORGANISM", 43, 51], ["HIV", "ORGANISM", 301, 304], ["CD4", "PROTEIN", 59, 62], ["HIV", "SPECIES", 301, 304], ["HIV", "SPECIES", 301, 304], ["The PSPC cohort study", "TEST", 0, 21], ["a CD4 count", "TEST", 57, 68], ["PCP prophylaxis", "TREATMENT", 114, 129], ["Bacterial Infection Prophylaxis", "TREATMENT", 130, 161], ["safe (i.e., replication incompetent)", "TREATMENT", 179, 215], ["bacterial vaccines", "TREATMENT", 216, 234], ["HIV-related disease", "PROBLEM", 301, 320], ["Infection", "OBSERVATION", 140, 149]]], ["In fact, uptake of both pneumococcal and the H. influenzae type b (Hib) vaccines is poor (current estimates for the former are at most only 40% of the infected population with the recommended 23-valent vaccine).", [["H. influenzae type b (Hib)", "ORGANISM", 45, 71], ["H. influenzae", "SPECIES", 45, 58], ["pneumococcal", "SPECIES", 24, 36], ["H. influenzae", "SPECIES", 45, 58], ["both pneumococcal", "TREATMENT", 19, 36], ["the H. influenzae type b (Hib) vaccines", "TREATMENT", 41, 80], ["23-valent vaccine", "TREATMENT", 192, 209], ["uptake", "OBSERVATION_MODIFIER", 9, 15], ["pneumococcal", "OBSERVATION_MODIFIER", 24, 36]]], ["One reason for this may be that the protection conferred by vaccination (90%) in the general population is not seen in immunosuppressed HIV-infected individuals, reflecting their inability to generate adequate memory B-cell responses (especially those subjects with CD4 counts <200 cells/mL).", [["B-cell", "ANATOMY", 217, 223], ["cells", "ANATOMY", 282, 287], ["HIV-infected", "DISEASE", 136, 148], ["HIV", "ORGANISM", 136, 139], ["individuals", "ORGANISM", 149, 160], ["memory B-cell", "CELL", 210, 223], ["CD4", "GENE_OR_GENE_PRODUCT", 266, 269], ["CD4", "PROTEIN", 266, 269], ["HIV-", "SPECIES", 136, 140], ["HIV", "SPECIES", 136, 139], ["immunosuppressed HIV", "PROBLEM", 119, 139], ["infected individuals", "PROBLEM", 140, 160], ["CD4 counts", "TEST", 266, 276], ["not seen", "UNCERTAINTY", 107, 115]]], ["However, in North America, CDC/IDSA recommend the pneumococcal vaccine as a single dose as soon as HIV infection is diagnosed, with a booster at 5 years, or if an individual's blood CD4 count was <200 cells/mL and subsequently increased on HAART.", [["blood", "ANATOMY", 176, 181], ["cells", "ANATOMY", 201, 206], ["HIV infection", "DISEASE", 99, 112], ["pneumococcal", "ORGANISM", 50, 62], ["HIV", "ORGANISM", 99, 102], ["blood", "ORGANISM_SUBSTANCE", 176, 181], ["CD4", "GENE_OR_GENE_PRODUCT", 182, 185], ["CD4", "PROTEIN", 182, 185], ["pneumococcal", "SPECIES", 50, 62], ["HIV", "SPECIES", 99, 102], ["the pneumococcal vaccine", "TREATMENT", 46, 70], ["HIV infection", "PROBLEM", 99, 112], ["an individual's blood CD4 count", "TEST", 160, 191], ["HAART", "TREATMENT", 240, 245], ["increased", "OBSERVATION_MODIFIER", 227, 236]]], ["Several studies show pneumococcal immunization reduces the risk of invasive pneumococcal infection in this population.", [["pneumococcal infection", "DISEASE", 76, 98], ["pneumococcal", "ORGANISM", 21, 33], ["pneumococcal", "ORGANISM", 76, 88], ["pneumococcal", "SPECIES", 21, 33], ["pneumococcal", "SPECIES", 76, 88], ["Several studies", "TEST", 0, 15], ["pneumococcal immunization", "TREATMENT", 21, 46], ["invasive pneumococcal infection", "PROBLEM", 67, 98], ["pneumococcal", "OBSERVATION", 21, 33], ["invasive", "OBSERVATION_MODIFIER", 67, 75], ["pneumococcal", "OBSERVATION_MODIFIER", 76, 88], ["infection", "OBSERVATION", 89, 98]]], ["This does not seem to be the case in a developing world setting, where not only is the 23-valent vaccine ineffective against both invasive and noninvasive pneumococcal disease, but the overall incidence of pneumonia is increased.", [["pneumococcal disease", "DISEASE", 155, 175], ["pneumonia", "DISEASE", 206, 215], ["pneumococcal", "SPECIES", 155, 167], ["the 23-valent vaccine", "TREATMENT", 83, 104], ["both invasive and noninvasive pneumococcal disease", "PROBLEM", 125, 175], ["pneumonia", "PROBLEM", 206, 215], ["pneumococcal disease", "OBSERVATION", 155, 175], ["pneumonia", "OBSERVATION", 206, 215], ["increased", "OBSERVATION_MODIFIER", 219, 228]]], ["Infection with H. influenzae type b is much less common in HIV-infected adults and, therefore, immunization with Hib vaccine is not routinely recommended.Bacterial Infection ProphylaxisThere is little evidence to suggest that the high frequency of bacterial infections in the HIV population is related to bacterial colonization.", [["H. influenzae type b", "DISEASE", 15, 35], ["HIV-infected", "DISEASE", 59, 71], ["bacterial infections", "DISEASE", 248, 268], ["H. influenzae type b", "ORGANISM", 15, 35], ["HIV", "ORGANISM", 59, 62], ["adults", "ORGANISM", 72, 78], ["Hib", "ORGANISM", 113, 116], ["H. influenzae", "SPECIES", 15, 28], ["HIV", "SPECIES", 59, 62], ["HIV", "SPECIES", 276, 279], ["H. influenzae", "SPECIES", 15, 28], ["HIV", "SPECIES", 59, 62], ["HIV", "SPECIES", 276, 279], ["Infection", "PROBLEM", 0, 9], ["H. influenzae type b", "PROBLEM", 15, 35], ["immunization", "TREATMENT", 95, 107], ["Hib vaccine", "TREATMENT", 113, 124], ["Bacterial Infection", "PROBLEM", 154, 173], ["Prophylaxis", "TREATMENT", 174, 185], ["bacterial infections", "PROBLEM", 248, 268], ["the HIV population", "PROBLEM", 272, 290], ["bacterial colonization", "PROBLEM", 305, 327], ["influenzae", "OBSERVATION", 18, 28], ["Infection", "OBSERVATION", 164, 173], ["little evidence to suggest", "UNCERTAINTY", 194, 220], ["high", "OBSERVATION_MODIFIER", 230, 234], ["bacterial", "OBSERVATION_MODIFIER", 248, 257], ["infections", "OBSERVATION", 258, 268], ["HIV", "OBSERVATION", 276, 279], ["related to", "UNCERTAINTY", 294, 304], ["bacterial colonization", "OBSERVATION", 305, 327]]], ["Therefore, continuous antibiotics are rarely indicated, although both TMP/SMX and the macrolides (clarithromycin and azithromycin) given as long-term prophylaxis for opportunistic infections have been shown to reduce the incidence of bacterial pneumonia, sinusitis/otitis media, and infectious diarrhea.", [["TMP", "CHEMICAL", 70, 73], ["SMX", "CHEMICAL", 74, 77], ["macrolides", "CHEMICAL", 86, 96], ["clarithromycin", "CHEMICAL", 98, 112], ["azithromycin", "CHEMICAL", 117, 129], ["opportunistic infections", "DISEASE", 166, 190], ["bacterial pneumonia", "DISEASE", 234, 253], ["sinusitis/otitis media", "DISEASE", 255, 277], ["infectious diarrhea", "DISEASE", 283, 302], ["TMP", "CHEMICAL", 70, 73], ["SMX", "CHEMICAL", 74, 77], ["macrolides", "CHEMICAL", 86, 96], ["clarithromycin", "CHEMICAL", 98, 112], ["azithromycin", "CHEMICAL", 117, 129], ["TMP", "SIMPLE_CHEMICAL", 70, 73], ["SMX", "SIMPLE_CHEMICAL", 74, 77], ["macrolides", "SIMPLE_CHEMICAL", 86, 96], ["clarithromycin", "SIMPLE_CHEMICAL", 98, 112], ["azithromycin", "SIMPLE_CHEMICAL", 117, 129], ["continuous antibiotics", "TREATMENT", 11, 33], ["TMP/SMX", "TREATMENT", 70, 77], ["the macrolides", "TREATMENT", 82, 96], ["clarithromycin", "TREATMENT", 98, 112], ["azithromycin", "TREATMENT", 117, 129], ["long-term prophylaxis", "TREATMENT", 140, 161], ["opportunistic infections", "PROBLEM", 166, 190], ["bacterial pneumonia", "PROBLEM", 234, 253], ["sinusitis", "PROBLEM", 255, 264], ["otitis media", "PROBLEM", 265, 277], ["infectious diarrhea", "PROBLEM", 283, 302], ["bacterial", "OBSERVATION_MODIFIER", 234, 243], ["pneumonia", "OBSERVATION", 244, 253], ["sinusitis", "OBSERVATION", 255, 264], ["otitis", "OBSERVATION", 265, 271], ["infectious", "OBSERVATION_MODIFIER", 283, 293]]], ["The use of TMP/SMX also confers a survival advantage in many studies performed in resource-poor settings.", [["TMP", "CHEMICAL", 11, 14], ["SMX", "CHEMICAL", 15, 18], ["TMP", "CHEMICAL", 11, 14], ["SMX", "CHEMICAL", 15, 18], ["TMP", "SIMPLE_CHEMICAL", 11, 14], ["SMX", "SIMPLE_CHEMICAL", 15, 18], ["TMP/SMX", "TREATMENT", 11, 18], ["a survival advantage", "TREATMENT", 32, 52], ["many studies", "TEST", 56, 68]]], ["There is little evidence, however, that TMP/SMX protects against pneumococcal infection.Mycobacterium tuberculosis ProphylaxisThe interaction between HIV and tuberculosis is of fundamental importance, because the annual risk for the development of clinical tuberculosis in a given individual is estimated to be 5-15% (i.e., similar to a non-HIV-infected subject's lifetime risk).", [["TMP", "CHEMICAL", 40, 43], ["SMX", "CHEMICAL", 44, 47], ["pneumococcal infection", "DISEASE", 65, 87], ["Mycobacterium tuberculosis", "DISEASE", 88, 114], ["HIV and tuberculosis", "DISEASE", 150, 170], ["tuberculosis", "DISEASE", 257, 269], ["non-HIV-infected", "DISEASE", 337, 353], ["TMP", "CHEMICAL", 40, 43], ["SMX", "CHEMICAL", 44, 47], ["TMP", "SIMPLE_CHEMICAL", 40, 43], ["SMX", "SIMPLE_CHEMICAL", 44, 47], ["pneumococcal", "ORGANISM", 65, 77], ["Mycobacterium tuberculosis", "ORGANISM", 88, 114], ["HIV", "ORGANISM", 150, 153], ["Mycobacterium tuberculosis", "SPECIES", 88, 114], ["HIV", "SPECIES", 150, 153], ["pneumococcal", "SPECIES", 65, 77], ["Mycobacterium tuberculosis", "SPECIES", 88, 114], ["HIV", "SPECIES", 150, 153], ["TMP/SMX", "TREATMENT", 40, 47], ["pneumococcal infection", "PROBLEM", 65, 87], ["Mycobacterium tuberculosis Prophylaxis", "TREATMENT", 88, 126], ["HIV", "PROBLEM", 150, 153], ["tuberculosis", "PROBLEM", 158, 170], ["clinical tuberculosis", "PROBLEM", 248, 269], ["little evidence", "UNCERTAINTY", 9, 24], ["pneumococcal", "OBSERVATION_MODIFIER", 65, 77], ["infection", "OBSERVATION", 78, 87], ["tuberculosis", "OBSERVATION", 102, 114], ["tuberculosis", "OBSERVATION", 257, 269]]], ["HIV-infected individuals with pulmonary tuberculosis are less likely to be smear positive than their HIV-negative counterparts, although they can still transmit tuberculosis.", [["pulmonary", "ANATOMY", 30, 39], ["HIV-infected", "DISEASE", 0, 12], ["pulmonary tuberculosis", "DISEASE", 30, 52], ["tuberculosis", "DISEASE", 161, 173], ["HIV", "ORGANISM", 0, 3], ["individuals", "ORGANISM", 13, 24], ["pulmonary", "ORGAN", 30, 39], ["HIV", "ORGANISM", 101, 104], ["HIV-", "SPECIES", 0, 4], ["HIV", "SPECIES", 0, 3], ["HIV", "SPECIES", 101, 104], ["HIV", "PROBLEM", 0, 3], ["infected individuals", "PROBLEM", 4, 24], ["pulmonary tuberculosis", "PROBLEM", 30, 52], ["smear positive", "PROBLEM", 75, 89], ["transmit tuberculosis", "PROBLEM", 152, 173], ["infected", "OBSERVATION_MODIFIER", 4, 12], ["pulmonary", "ANATOMY", 30, 39], ["tuberculosis", "OBSERVATION", 40, 52], ["less likely", "UNCERTAINTY", 57, 68], ["tuberculosis", "OBSERVATION", 161, 173]]], ["Thus, within a community, tuberculosis prevention involves case finding and treatment of active disease, as well as specific prophylactic drug therapies for those exposed.", [["tuberculosis", "DISEASE", 26, 38], ["tuberculosis prevention", "TREATMENT", 26, 49], ["active disease", "PROBLEM", 89, 103], ["specific prophylactic drug therapies", "TREATMENT", 116, 152], ["tuberculosis", "OBSERVATION", 26, 38], ["active", "OBSERVATION_MODIFIER", 89, 95], ["disease", "OBSERVATION", 96, 103]]], ["If possible, HIV-positive subjects should make every effort to avoid encountering tuberculosis (e.g., at work, homeless shelter, health care facility).Mycobacterium tuberculosis ProphylaxisOne of the problems with standard methods of tuberculosis contact tracing in HIV infection is that both tuberculin skin test results and chest radiology may be unreliable.", [["skin", "ANATOMY", 304, 308], ["chest", "ANATOMY", 326, 331], ["tuberculosis", "DISEASE", 82, 94], ["Mycobacterium tuberculosis", "DISEASE", 151, 177], ["tuberculosis", "DISEASE", 234, 246], ["HIV infection", "DISEASE", 266, 279], ["HIV", "ORGANISM", 13, 16], ["Mycobacterium tuberculosis", "ORGANISM", 151, 177], ["HIV", "ORGANISM", 266, 269], ["skin", "ORGAN", 304, 308], ["chest", "ORGAN", 326, 331], ["Mycobacterium tuberculosis", "SPECIES", 151, 177], ["HIV", "SPECIES", 266, 269], ["HIV", "SPECIES", 13, 16], ["Mycobacterium tuberculosis", "SPECIES", 151, 177], ["HIV", "SPECIES", 266, 269], ["HIV", "PROBLEM", 13, 16], ["positive subjects", "PROBLEM", 17, 34], ["encountering tuberculosis", "PROBLEM", 69, 94], ["Mycobacterium tuberculosis", "PROBLEM", 151, 177], ["the problems", "PROBLEM", 196, 208], ["tuberculosis", "PROBLEM", 234, 246], ["HIV infection", "PROBLEM", 266, 279], ["both tuberculin skin test", "TEST", 288, 313], ["chest radiology", "TEST", 326, 341], ["tuberculosis", "OBSERVATION", 234, 246], ["chest", "ANATOMY", 326, 331]]], ["However, in the absence of bacillus Calmette-Gu\u00e9rin (BCG) immunization, a positive PPD (e.g., <5 mm induration with 5 tuberculin units) indicates a greatly increased risk (6-to 23-fold compared with nonanergic, PPD-negative, HIV-infected subjects) of future active disease.", [["bacillus Calmette-Gu\u00e9rin", "CHEMICAL", 27, 51], ["HIV-infected", "DISEASE", 225, 237], ["bacillus Calmette-Gu\u00e9rin", "ORGANISM", 27, 51], ["BCG", "ORGANISM", 53, 56], ["HIV", "ORGANISM", 225, 228], ["HIV", "SPECIES", 225, 228], ["bacillus Calmette-Gu\u00e9rin", "SPECIES", 27, 51], ["HIV", "SPECIES", 225, 228], ["bacillus Calmette", "TREATMENT", 27, 44], ["Gu\u00e9rin (BCG)", "TREATMENT", 45, 57], ["immunization", "TREATMENT", 58, 70], ["a positive PPD", "PROBLEM", 72, 86], ["5 mm induration", "PROBLEM", 95, 110], ["5 tuberculin units", "TREATMENT", 116, 134], ["a greatly increased risk", "PROBLEM", 146, 170], ["nonanergic", "TEST", 199, 209], ["PPD", "TEST", 211, 214], ["HIV", "PROBLEM", 225, 228], ["future active disease", "PROBLEM", 251, 272], ["greatly", "OBSERVATION_MODIFIER", 148, 155], ["increased", "OBSERVATION_MODIFIER", 156, 165], ["active", "OBSERVATION_MODIFIER", 258, 264], ["disease", "OBSERVATION", 265, 272]]], ["The chance that HIV-infected subjects may contract disseminated infection if given BCG means that (having excluded active infection) the only option in these circumstances is to use a preventative drug regimen.", [["HIV-infected", "DISEASE", 16, 28], ["infection", "DISEASE", 64, 73], ["infection", "DISEASE", 122, 131], ["HIV", "ORGANISM", 16, 19], ["subjects", "ORGANISM", 29, 37], ["HIV", "SPECIES", 16, 19], ["HIV", "SPECIES", 16, 19], ["HIV", "PROBLEM", 16, 19], ["infected subjects", "PROBLEM", 20, 37], ["disseminated infection", "PROBLEM", 51, 73], ["BCG", "PROBLEM", 83, 86], ["active infection", "PROBLEM", 115, 131], ["a preventative drug regimen", "TREATMENT", 182, 209], ["infected", "OBSERVATION", 20, 28], ["disseminated", "OBSERVATION_MODIFIER", 51, 63], ["infection", "OBSERVATION", 64, 73], ["active", "OBSERVATION_MODIFIER", 115, 121], ["infection", "OBSERVATION", 122, 131]]], ["Options include at least 6 months of isoniazid (together with pyridoxine to prevent peripheral neuropathy).", [["isoniazid", "CHEMICAL", 37, 46], ["pyridoxine", "CHEMICAL", 62, 72], ["peripheral neuropathy", "DISEASE", 84, 105], ["isoniazid", "CHEMICAL", 37, 46], ["pyridoxine", "CHEMICAL", 62, 72], ["isoniazid", "SIMPLE_CHEMICAL", 37, 46], ["pyridoxine", "SIMPLE_CHEMICAL", 62, 72], ["isoniazid", "TREATMENT", 37, 46], ["pyridoxine", "TREATMENT", 62, 72], ["peripheral neuropathy", "PROBLEM", 84, 105], ["peripheral", "ANATOMY", 84, 94], ["neuropathy", "OBSERVATION", 95, 105]]], ["This is safe and well tolerated, although compliance is a problem (especially with regimens longer than 6 months), and DOT may need to be instituted (e.g., 900 mg isoniazid twice weekly).", [["isoniazid", "CHEMICAL", 163, 172], ["isoniazid", "CHEMICAL", 163, 172], ["DOT", "SIMPLE_CHEMICAL", 119, 122], ["isoniazid", "SIMPLE_CHEMICAL", 163, 172], ["regimens", "TREATMENT", 83, 91], ["DOT", "TREATMENT", 119, 122]]], ["There is little evidence to suggest that this single-agent regimen leads to isoniazid resistance, which probably reflects the low mycobacterial load present in such individuals.Mycobacterium tuberculosis ProphylaxisAttempts to shorten the length of treatment for latent infection have produced variable results.", [["isoniazid", "CHEMICAL", 76, 85], ["Mycobacterium tuberculosis", "DISEASE", 177, 203], ["infection", "DISEASE", 270, 279], ["isoniazid", "CHEMICAL", 76, 85], ["isoniazid", "SIMPLE_CHEMICAL", 76, 85], ["Mycobacterium tuberculosis", "ORGANISM", 177, 203], ["Mycobacterium tuberculosis", "SPECIES", 177, 203], ["Mycobacterium tuberculosis", "SPECIES", 177, 203], ["this single-agent regimen", "TREATMENT", 41, 66], ["isoniazid resistance", "PROBLEM", 76, 96], ["the low mycobacterial load", "PROBLEM", 122, 148], ["Mycobacterium tuberculosis ProphylaxisAttempts", "PROBLEM", 177, 223], ["treatment", "TREATMENT", 249, 258], ["latent infection", "PROBLEM", 263, 279], ["little evidence to suggest", "UNCERTAINTY", 9, 35], ["isoniazid resistance", "OBSERVATION", 76, 96], ["probably reflects", "UNCERTAINTY", 104, 121], ["low", "OBSERVATION_MODIFIER", 126, 129], ["mycobacterial load", "OBSERVATION", 130, 148], ["tuberculosis", "OBSERVATION", 191, 203], ["infection", "OBSERVATION", 270, 279]]], ["Recent studies used rifampin and pyrazinamide for short-course prophylaxis (2 months).", [["rifampin", "CHEMICAL", 20, 28], ["pyrazinamide", "CHEMICAL", 33, 45], ["rifampin", "CHEMICAL", 20, 28], ["pyrazinamide", "CHEMICAL", 33, 45], ["rifampin", "SIMPLE_CHEMICAL", 20, 28], ["pyrazinamide", "SIMPLE_CHEMICAL", 33, 45], ["Recent studies", "TEST", 0, 14], ["rifampin", "TREATMENT", 20, 28], ["pyrazinamide", "TREATMENT", 33, 45], ["short-course prophylaxis", "TREATMENT", 50, 74]]], ["This was as effective as 12 months of isoniazid in HIV-coinfected individuals, although it was associated with fatal hepatotoxicity (almost exclusively in the HIV-negative population).", [["isoniazid", "CHEMICAL", 38, 47], ["HIV-coinfected", "DISEASE", 51, 65], ["hepatotoxicity", "DISEASE", 117, 131], ["isoniazid", "CHEMICAL", 38, 47], ["isoniazid", "SIMPLE_CHEMICAL", 38, 47], ["HIV", "ORGANISM", 51, 54], ["individuals", "ORGANISM", 66, 77], ["HIV", "SPECIES", 51, 54], ["HIV", "SPECIES", 159, 162], ["isoniazid", "TREATMENT", 38, 47], ["coinfected individuals", "PROBLEM", 55, 77], ["fatal hepatotoxicity", "PROBLEM", 111, 131], ["fatal", "OBSERVATION_MODIFIER", 111, 116], ["hepatotoxicity", "OBSERVATION", 117, 131]]], ["If used, liver function should be closely monitored, and it is recommended that this regimen not be given to patients with preexisting liver disease (e.g., because of alcohol or viral hepatitis).", [["liver", "ANATOMY", 9, 14], ["liver", "ANATOMY", 135, 140], ["liver disease", "DISEASE", 135, 148], ["alcohol", "CHEMICAL", 167, 174], ["viral hepatitis", "DISEASE", 178, 193], ["alcohol", "CHEMICAL", 167, 174], ["liver", "ORGAN", 9, 14], ["patients", "ORGANISM", 109, 117], ["liver", "ORGAN", 135, 140], ["alcohol", "SIMPLE_CHEMICAL", 167, 174], ["patients", "SPECIES", 109, 117], ["liver function", "TEST", 9, 23], ["this regimen", "TREATMENT", 80, 92], ["preexisting liver disease", "PROBLEM", 123, 148], ["viral hepatitis", "PROBLEM", 178, 193], ["liver", "ANATOMY", 9, 14], ["liver", "ANATOMY", 135, 140], ["disease", "OBSERVATION", 141, 148], ["viral hepatitis", "OBSERVATION", 178, 193]]], ["Because rifampin should not be used by subjects taking PIs, this may also limit widespread application of the two-drug regimen.", [["rifampin", "CHEMICAL", 8, 16], ["rifampin", "CHEMICAL", 8, 16], ["rifampin", "SIMPLE_CHEMICAL", 8, 16], ["rifampin", "TREATMENT", 8, 16], ["PIs", "TREATMENT", 55, 58], ["the two-drug regimen", "TREATMENT", 106, 126]]], ["The same applies to combinations of isoniazid and rifampin taken for at least 3 months, which are also effective in HIVnegative individuals.", [["isoniazid", "CHEMICAL", 36, 45], ["rifampin", "CHEMICAL", 50, 58], ["isoniazid", "CHEMICAL", 36, 45], ["rifampin", "CHEMICAL", 50, 58], ["isoniazid", "SIMPLE_CHEMICAL", 36, 45], ["rifampin", "SIMPLE_CHEMICAL", 50, 58], ["isoniazid", "TREATMENT", 36, 45], ["rifampin", "TREATMENT", 50, 58]]], ["Alternate protocols also exist for subjects thought to be resistant to first-line prophylactic agents.", [["Alternate protocols", "TREATMENT", 0, 19], ["first-line prophylactic agents", "TREATMENT", 71, 101]]], ["It is recommended that HIV-infected subjects who have had close contact with an active case of tuberculosis should also receive prophylaxis.", [["HIV-infected", "DISEASE", 23, 35], ["tuberculosis", "DISEASE", 95, 107], ["HIV", "ORGANISM", 23, 26], ["subjects", "ORGANISM", 36, 44], ["HIV", "SPECIES", 23, 26], ["HIV", "SPECIES", 23, 26], ["tuberculosis", "PROBLEM", 95, 107], ["prophylaxis", "TREATMENT", 128, 139], ["tuberculosis", "OBSERVATION", 95, 107]]], ["There is little evidence to suggest that anergy confers an increased risk for development of clinical disease.", [["anergy", "DISEASE", 41, 47], ["anergy", "PROBLEM", 41, 47], ["clinical disease", "PROBLEM", 93, 109], ["little evidence to suggest", "UNCERTAINTY", 9, 35], ["anergy", "OBSERVATION", 41, 47], ["increased", "OBSERVATION_MODIFIER", 59, 68]]], ["However, patients who have not had BCG, have a negative skin test, and have started HAART may benefit from regular skin tests, because some studies suggest that cutaneous responses may return with increasing CD4 counts, and that this may help in identifying newly infected individuals requiring prophylaxis.Mycobacterium tuberculosis ProphylaxisIn populations where the prevalence of tuberculosis is low and BCG may be given during childhood or adolescence (e.g., the United Kingdom), the value of PPD testing is more limited.", [["skin", "ANATOMY", 56, 60], ["skin", "ANATOMY", 115, 119], ["cutaneous", "ANATOMY", 161, 170], ["Mycobacterium tuberculosis", "DISEASE", 307, 333], ["tuberculosis", "DISEASE", 384, 396], ["patients", "ORGANISM", 9, 17], ["skin", "ORGAN", 56, 60], ["skin", "ORGAN", 115, 119], ["CD4", "GENE_OR_GENE_PRODUCT", 208, 211], ["Mycobacterium tuberculosis", "ORGANISM", 307, 333], ["CD4", "PROTEIN", 208, 211], ["patients", "SPECIES", 9, 17], ["Mycobacterium tuberculosis", "SPECIES", 307, 333], ["Mycobacterium tuberculosis", "SPECIES", 307, 333], ["BCG", "PROBLEM", 35, 38], ["skin test", "TEST", 56, 65], ["HAART", "TREATMENT", 84, 89], ["regular skin tests", "TEST", 107, 125], ["some studies", "TEST", 135, 147], ["cutaneous responses", "PROBLEM", 161, 180], ["increasing CD4 counts", "PROBLEM", 197, 218], ["newly infected individuals", "PROBLEM", 258, 284], ["prophylaxis", "TREATMENT", 295, 306], ["Mycobacterium tuberculosis", "PROBLEM", 307, 333], ["tuberculosis", "PROBLEM", 384, 396], ["BCG", "PROBLEM", 408, 411], ["the value of PPD testing", "TEST", 485, 509], ["skin", "ANATOMY", 56, 60], ["skin", "ANATOMY", 115, 119], ["infected", "OBSERVATION", 264, 272], ["tuberculosis", "OBSERVATION", 384, 396], ["low", "OBSERVATION_MODIFIER", 400, 403]]], ["Here, an arbitrary cutoff of 10 mm for tuberculin reactions is used to define who should receive preventive therapy.", [["an arbitrary cutoff", "TEST", 6, 25], ["tuberculin reactions", "PROBLEM", 39, 59], ["preventive therapy", "TREATMENT", 97, 115]]], ["The introduction of immune-based blood tests that can accurately distinguish between BCG vaccination and tuberculosis infection may be helpful when screening for evidence of latent tuberculosis.", [["blood", "ANATOMY", 33, 38], ["tuberculosis infection", "DISEASE", 105, 127], ["tuberculosis", "DISEASE", 181, 193], ["blood", "ORGANISM_SUBSTANCE", 33, 38], ["immune-based blood tests", "TEST", 20, 44], ["BCG vaccination", "TREATMENT", 85, 100], ["tuberculosis infection", "PROBLEM", 105, 127], ["screening", "TEST", 148, 157], ["latent tuberculosis", "PROBLEM", 174, 193], ["tuberculosis", "OBSERVATION", 105, 117], ["latent", "OBSERVATION_MODIFIER", 174, 180], ["tuberculosis", "OBSERVATION", 181, 193]]], ["The two currently available commercial tests use fairly specific CD4-directed mycobacterial antigen responses with consequent production of detectable interferon-g.", [["CD4", "GENE_OR_GENE_PRODUCT", 65, 68], ["CD4", "PROTEIN", 65, 68], ["interferon", "PROTEIN", 151, 161], ["commercial tests", "TEST", 28, 44], ["detectable interferon", "TREATMENT", 140, 161]]], ["The need for reasonably intact CD4 function means that they may, in fact, be less useful in HIV infection, especially in those subjects with very low blood CD4 counts, who are possibly at greatest risk of developing active tuberculosis.Mycobacterium tuberculosis ProphylaxisSecondary tuberculosis prophylaxis may be important, because studies indicate a high rate of relapse in endemic areas.", [["blood", "ANATOMY", 150, 155], ["HIV infection", "DISEASE", 92, 105], ["tuberculosis", "DISEASE", 223, 235], ["Mycobacterium tuberculosis", "DISEASE", 236, 262], ["tuberculosis", "DISEASE", 284, 296], ["CD4", "GENE_OR_GENE_PRODUCT", 31, 34], ["HIV", "ORGANISM", 92, 95], ["blood", "ORGANISM_SUBSTANCE", 150, 155], ["CD4", "GENE_OR_GENE_PRODUCT", 156, 159], ["Mycobacterium tuberculosis", "ORGANISM", 236, 262], ["CD4", "PROTEIN", 31, 34], ["CD4", "PROTEIN", 156, 159], ["Mycobacterium tuberculosis", "SPECIES", 236, 262], ["HIV", "SPECIES", 92, 95], ["Mycobacterium tuberculosis", "SPECIES", 236, 262], ["HIV infection", "PROBLEM", 92, 105], ["very low blood CD4 counts", "PROBLEM", 141, 166], ["developing active tuberculosis", "PROBLEM", 205, 235], ["Mycobacterium tuberculosis", "PROBLEM", 236, 262], ["ProphylaxisSecondary tuberculosis prophylaxis", "TREATMENT", 263, 308], ["a high rate of relapse in endemic areas", "PROBLEM", 352, 391], ["CD4", "OBSERVATION", 31, 34], ["infection", "OBSERVATION", 96, 105], ["active", "OBSERVATION_MODIFIER", 216, 222], ["tuberculosis", "OBSERVATION", 223, 235], ["relapse", "OBSERVATION", 367, 374], ["endemic", "OBSERVATION_MODIFIER", 378, 385]]], ["Here, no specific guidelines exist, although 6 months of isoniazid and rifampin after a full treatment course shows a greatly reduced risk of relapse within the subsequent 2 years.", [["isoniazid", "CHEMICAL", 57, 66], ["rifampin", "CHEMICAL", 71, 79], ["isoniazid", "CHEMICAL", 57, 66], ["rifampin", "CHEMICAL", 71, 79], ["isoniazid", "SIMPLE_CHEMICAL", 57, 66], ["rifampin", "SIMPLE_CHEMICAL", 71, 79], ["isoniazid", "TREATMENT", 57, 66], ["rifampin", "TREATMENT", 71, 79], ["a full treatment course", "TREATMENT", 86, 109], ["reduced", "OBSERVATION_MODIFIER", 126, 133], ["relapse", "OBSERVATION", 142, 149]]], ["Whether this is enough to prevent clinical disease (which may also arise from reinfection in areas of high tuberculosis prevalence) without concomitant antiretroviral therapy is unclear.", [["tuberculosis", "DISEASE", 107, 119], ["clinical disease", "PROBLEM", 34, 50], ["reinfection", "PROBLEM", 78, 89], ["high tuberculosis prevalence", "PROBLEM", 102, 130], ["concomitant antiretroviral therapy", "TREATMENT", 140, 174], ["high", "OBSERVATION_MODIFIER", 102, 106], ["tuberculosis", "OBSERVATION", 107, 119], ["antiretroviral therapy", "OBSERVATION", 152, 174]]], ["In the developed world, secondary prophylaxis is usually not recommended.Mycobacterium tuberculosis ProphylaxisThe use of HAART also can reduce the risk of tuberculosis in endemic areas.", [["Mycobacterium tuberculosis", "DISEASE", 73, 99], ["tuberculosis", "DISEASE", 156, 168], ["Mycobacterium tuberculosis", "ORGANISM", 73, 99], ["Mycobacterium tuberculosis", "SPECIES", 73, 99], ["Mycobacterium tuberculosis", "SPECIES", 73, 99], ["secondary prophylaxis", "TREATMENT", 24, 45], ["Mycobacterium tuberculosis Prophylaxis", "TREATMENT", 73, 111], ["HAART", "TREATMENT", 122, 127], ["tuberculosis in endemic areas", "PROBLEM", 156, 185], ["tuberculosis", "OBSERVATION", 87, 99], ["tuberculosis", "OBSERVATION", 156, 168], ["endemic", "OBSERVATION_MODIFIER", 172, 179]]], ["Work in South Africa indicates that this is most beneficial in patients with advanced disease and leads to a reduction in RR of at least 80%.Mycobacterium avium-intracellulare Complex ProphylaxisData from North America indicate that the prevention of disseminated MAC infection has an effect on survival (25% reduction in mortality rate in subjects taking clarithromycin).", [["MAC infection", "DISEASE", 264, 277], ["clarithromycin", "CHEMICAL", 356, 370], ["clarithromycin", "CHEMICAL", 356, 370], ["patients", "ORGANISM", 63, 71], ["Mycobacterium avium-intracellulare", "ORGANISM", 141, 175], ["clarithromycin", "SIMPLE_CHEMICAL", 356, 370], ["patients", "SPECIES", 63, 71], ["Mycobacterium avium", "SPECIES", 141, 160], ["-intracellulare", "SPECIES", 160, 175], ["Mycobacterium avium", "SPECIES", 141, 160], ["advanced disease", "PROBLEM", 77, 93], ["RR", "TEST", 122, 124], ["Mycobacterium avium", "PROBLEM", 141, 160], ["disseminated MAC infection", "PROBLEM", 251, 277], ["survival", "TREATMENT", 295, 303], ["clarithromycin", "TREATMENT", 356, 370], ["reduction", "OBSERVATION_MODIFIER", 109, 118], ["intracellulare", "OBSERVATION_MODIFIER", 161, 175], ["disseminated", "OBSERVATION_MODIFIER", 251, 263], ["MAC", "OBSERVATION_MODIFIER", 264, 267], ["infection", "OBSERVATION", 268, 277]]], ["The US guidelines advise prophylaxis with a macrolide (either clarithromycin, 500 mg orally twice per day, or azithromycin, 1250 mg orally, once a week) in all HIV-infected individuals with blood CD4 counts >50 cells/mL.", [["blood", "ANATOMY", 190, 195], ["cells", "ANATOMY", 211, 216], ["macrolide", "CHEMICAL", 44, 53], ["clarithromycin", "CHEMICAL", 62, 76], ["azithromycin", "CHEMICAL", 110, 122], ["HIV-infected", "DISEASE", 160, 172], ["macrolide", "CHEMICAL", 44, 53], ["clarithromycin", "CHEMICAL", 62, 76], ["azithromycin", "CHEMICAL", 110, 122], ["macrolide", "SIMPLE_CHEMICAL", 44, 53], ["clarithromycin", "SIMPLE_CHEMICAL", 62, 76], ["azithromycin", "SIMPLE_CHEMICAL", 110, 122], ["HIV", "ORGANISM", 160, 163], ["individuals", "ORGANISM", 173, 184], ["blood", "ORGANISM_SUBSTANCE", 190, 195], ["CD4", "GENE_OR_GENE_PRODUCT", 196, 199], ["CD4", "PROTEIN", 196, 199], ["HIV", "SPECIES", 160, 163], ["The US guidelines", "TREATMENT", 0, 17], ["a macrolide", "TREATMENT", 42, 53], ["clarithromycin", "TREATMENT", 62, 76], ["azithromycin", "TREATMENT", 110, 122], ["blood CD4 counts", "TEST", 190, 206]]], ["In Europe, where the prevalence of disseminated MAC infection is probably lower (perhaps because of previous BCG vaccination), this may be less relevant.", [["MAC infection", "DISEASE", 48, 61], ["disseminated MAC infection", "PROBLEM", 35, 61], ["previous BCG vaccination", "TREATMENT", 100, 124], ["disseminated", "OBSERVATION_MODIFIER", 35, 47], ["MAC", "OBSERVATION_MODIFIER", 48, 51], ["infection", "OBSERVATION", 52, 61], ["probably", "UNCERTAINTY", 65, 73], ["lower", "OBSERVATION_MODIFIER", 74, 79], ["may be", "UNCERTAINTY", 132, 138], ["less", "OBSERVATION_MODIFIER", 139, 143]]], ["Here, surveillance cultures of blood may be more cost-effective in the at-risk HIV population with low CD4 counts.", [["blood", "ANATOMY", 31, 36], ["blood", "ORGANISM_SUBSTANCE", 31, 36], ["CD4", "GENE_OR_GENE_PRODUCT", 103, 106], ["CD4", "PROTEIN", 103, 106], ["HIV", "SPECIES", 79, 82], ["surveillance cultures", "TEST", 6, 27], ["blood", "PROBLEM", 31, 36], ["low CD4 counts", "PROBLEM", 99, 113]]], ["Routine stool and sputum cultures probably do not add much to this strategy, because disseminated MAC is much more common than isolated organ disease.Mycobacterium avium-intracellulare Complex ProphylaxisSingle-agent prophylaxis may lead to antibiotic resistance.", [["stool", "ANATOMY", 8, 13], ["sputum cultures", "ANATOMY", 18, 33], ["organ", "ANATOMY", 136, 141], ["MAC", "DISEASE", 98, 101], ["organ disease", "DISEASE", 136, 149], ["stool", "ORGANISM_SUBSTANCE", 8, 13], ["organ", "ORGAN", 136, 141], ["Mycobacterium avium-intracellulare", "ORGANISM", 150, 184], ["Mycobacterium avium", "SPECIES", 150, 169], ["-intracellulare", "SPECIES", 169, 184], ["Mycobacterium avium", "SPECIES", 150, 169], ["Routine stool and sputum cultures", "TEST", 0, 33], ["disseminated MAC", "PROBLEM", 85, 101], ["isolated organ disease", "PROBLEM", 127, 149], ["Mycobacterium avium", "PROBLEM", 150, 169], ["intracellulare Complex ProphylaxisSingle-agent prophylaxis", "TREATMENT", 170, 228], ["antibiotic resistance", "TREATMENT", 241, 262], ["disseminated", "OBSERVATION_MODIFIER", 85, 97], ["MAC", "OBSERVATION", 98, 101], ["more common", "OBSERVATION_MODIFIER", 110, 121], ["organ", "ANATOMY", 136, 141], ["disease", "OBSERVATION", 142, 149], ["intracellulare", "OBSERVATION_MODIFIER", 170, 184]]], ["This does not seem to be reduced by the addition of a second drug (rifabutin) to the prophylactic regimen.", [["rifabutin", "CHEMICAL", 67, 76], ["rifabutin", "CHEMICAL", 67, 76], ["rifabutin", "SIMPLE_CHEMICAL", 67, 76], ["a second drug (rifabutin)", "TREATMENT", 52, 77], ["the prophylactic regimen", "TREATMENT", 81, 105]]], ["The latter is now a second-line prophylactic agent, largely as a result of its rather worse protective effect and its adverse interaction profile with PIs.", [["a second-line prophylactic agent", "TREATMENT", 18, 50], ["PIs", "PROBLEM", 151, 154]]], ["As mentioned earlier, if an individual sustains a rise in CD4 count >100 cells/mL for >6 months, it is safe to discontinue prophylaxis.Pneumocystis jiroveciiSeveral clinical and laboratory features have prognostic significance in HIV-infected individuals with PCP (Box 34-2).", [["cells", "ANATOMY", 73, 78], ["Pneumocystis jiroveciiSeveral", "DISEASE", 135, 164], ["HIV-infected", "DISEASE", 230, 242], ["PCP", "DISEASE", 260, 263], ["PCP", "CHEMICAL", 260, 263], ["CD4", "GENE_OR_GENE_PRODUCT", 58, 61], ["HIV", "ORGANISM", 230, 233], ["individuals", "ORGANISM", 243, 254], ["CD4", "PROTEIN", 58, 61], ["HIV", "SPECIES", 230, 233], ["HIV", "SPECIES", 230, 233], ["CD4 count", "TEST", 58, 67], ["prophylaxis", "TREATMENT", 123, 134], ["Pneumocystis jiroveciiSeveral clinical and laboratory features", "PROBLEM", 135, 197], ["HIV", "PROBLEM", 230, 233], ["PCP (Box", "TEST", 260, 268]]], ["A severity score on the basis of the serum LDH levels, the A-aO 2 , and the percentage of neutrophils in the BAL fluid can predict survival reasonably accurately, with the highest scores indicating the worst outcome.", [["serum", "ANATOMY", 37, 42], ["neutrophils", "ANATOMY", 90, 101], ["BAL fluid", "ANATOMY", 109, 118], ["serum", "ORGANISM_SUBSTANCE", 37, 42], ["LDH", "GENE_OR_GENE_PRODUCT", 43, 46], ["A-aO 2", "GENE_OR_GENE_PRODUCT", 59, 65], ["neutrophils", "CELL", 90, 101], ["LDH", "PROTEIN", 43, 46], ["neutrophils", "CELL_TYPE", 90, 101], ["A severity score", "PROBLEM", 0, 16], ["the serum LDH levels", "TEST", 33, 53], ["the A-aO", "TEST", 55, 63], ["neutrophils", "TEST", 90, 101], ["the BAL fluid", "TEST", 105, 118], ["neutrophils", "OBSERVATION", 90, 101], ["BAL fluid", "OBSERVATION", 109, 118]]], ["Other workers have shown that increased age (<50 years) leads to an increased mortality rate-in part as a result of late, \"unsuspected\" diagnosis.", [["an increased mortality rate", "PROBLEM", 65, 92], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["increased", "OBSERVATION_MODIFIER", 68, 77], ["mortality", "OBSERVATION", 78, 87]]], ["The overall mortality rate from an episode of PCP is approximately 14% and has not changed since the advent of HAART.Pneumocystis jiroveciiAmong individuals with access to HAART, post-PCP survival has improved.", [["PCP", "DISEASE", 46, 49], ["Pneumocystis jiroveciiAmong", "DISEASE", 117, 144], ["PCP", "CHEMICAL", 184, 187], ["PCP", "CHEMICAL", 46, 49], ["Pneumocystis jiroveciiAmong", "SPECIES", 117, 144], ["PCP", "TEST", 46, 49], ["HAART", "TREATMENT", 111, 116], ["Pneumocystis jiroveciiAmong individuals", "PROBLEM", 117, 156], ["HAART", "TREATMENT", 172, 177], ["overall", "OBSERVATION_MODIFIER", 4, 11], ["mortality", "OBSERVATION_MODIFIER", 12, 21], ["improved", "OBSERVATION_MODIFIER", 201, 209]]], ["In 1981, the median survival after PCP was 9 months.", [["PCP", "DISEASE", 35, 38], ["PCP", "CHEMICAL", 35, 38]]], ["The introduction of HAART has led to a further improvement, with survival in the period up to year 2000 of 40 months.", [["HAART", "TREATMENT", 20, 25]]], ["In those without access to HAART and/or prophylaxis, survival post-PCP, unfortunately, remains poor.Bacterial InfectionIn general, mortality from bacterial respiratory infection in HIV-infected individuals is similar to that seen in the general population.", [["respiratory", "ANATOMY", 156, 167], ["PCP", "DISEASE", 67, 70], ["bacterial respiratory infection", "DISEASE", 146, 177], ["HIV-infected", "DISEASE", 181, 193], ["HIV", "ORGANISM", 181, 184], ["individuals", "ORGANISM", 194, 205], ["HIV", "SPECIES", 181, 184], ["HIV", "SPECIES", 181, 184], ["HAART", "TREATMENT", 27, 32], ["prophylaxis", "TREATMENT", 40, 51], ["Bacterial InfectionIn", "PROBLEM", 100, 121], ["bacterial respiratory infection", "PROBLEM", 146, 177], ["HIV", "PROBLEM", 181, 184], ["infected individuals", "PROBLEM", 185, 205], ["poor", "OBSERVATION", 95, 99], ["bacterial", "OBSERVATION_MODIFIER", 146, 155], ["respiratory infection", "OBSERVATION", 156, 177]]], ["Clinical and laboratory markers of disease severity that have been defined in the adult general population (e.g., those described in the ATS or the BTS Guidelines for the management of community-acquired pneumonia in adults) apply to HIV-infected patients.", [["pneumonia", "DISEASE", 204, 213], ["HIV-infected", "DISEASE", 234, 246], ["HIV", "ORGANISM", 234, 237], ["patients", "ORGANISM", 247, 255], ["HIV", "SPECIES", 234, 237], ["patients", "SPECIES", 247, 255], ["HIV", "SPECIES", 234, 237], ["disease severity", "PROBLEM", 35, 51], ["the BTS Guidelines", "TREATMENT", 144, 162], ["the management", "TREATMENT", 167, 181], ["community-acquired pneumonia", "PROBLEM", 185, 213], ["HIV", "PROBLEM", 234, 237], ["pneumonia", "OBSERVATION", 204, 213]]], ["These are confusion, raised respiratory rate, abnormal renal function, and low blood pressure.", [["respiratory", "ANATOMY", 28, 39], ["renal", "ANATOMY", 55, 60], ["blood", "ANATOMY", 79, 84], ["confusion", "DISEASE", 10, 19], ["renal", "ORGAN", 55, 60], ["blood", "ORGANISM_SUBSTANCE", 79, 84], ["confusion", "PROBLEM", 10, 19], ["raised respiratory rate", "PROBLEM", 21, 44], ["abnormal renal function", "PROBLEM", 46, 69], ["low blood pressure", "PROBLEM", 75, 93], ["confusion", "OBSERVATION", 10, 19], ["respiratory rate", "OBSERVATION", 28, 44], ["renal", "ANATOMY", 55, 60], ["low blood pressure", "OBSERVATION", 75, 93]]], ["Recurrent pneumonia is common (reported in up to 55% of cases) and may lead to chronic pulmonary disease (see earlier).Mycobacterium TuberculosisAlthough tuberculosis normally responds to standard multipledrug therapy, work from Africa has highlighted the increased mortality rate in HIV-infected compared with non-HIVinfected individuals.", [["pulmonary", "ANATOMY", 87, 96], ["pneumonia", "DISEASE", 10, 19], ["chronic pulmonary disease", "DISEASE", 79, 104], ["Mycobacterium Tuberculosis", "DISEASE", 119, 145], ["tuberculosis", "DISEASE", 154, 166], ["HIV-infected", "DISEASE", 284, 296], ["pulmonary", "ORGAN", 87, 96], ["Mycobacterium Tuberculosis", "ORGANISM", 119, 145], ["HIV", "SPECIES", 284, 287], ["Recurrent pneumonia", "PROBLEM", 0, 19], ["chronic pulmonary disease", "PROBLEM", 79, 104], ["Mycobacterium Tuberculosis", "PROBLEM", 119, 145], ["tuberculosis", "PROBLEM", 154, 166], ["standard multipledrug therapy", "TREATMENT", 188, 217], ["the increased mortality rate", "PROBLEM", 252, 280], ["HIV", "PROBLEM", 284, 287], ["non-HIVinfected individuals", "PROBLEM", 311, 338], ["pneumonia", "OBSERVATION", 10, 19], ["may lead to", "UNCERTAINTY", 67, 78], ["chronic", "OBSERVATION_MODIFIER", 79, 86], ["pulmonary", "ANATOMY", 87, 96], ["disease", "OBSERVATION", 97, 104], ["Tuberculosis", "OBSERVATION", 133, 145], ["tuberculosis", "OBSERVATION", 154, 166], ["increased", "OBSERVATION_MODIFIER", 256, 265]]], ["A relationship has also been described between mortality and declining blood CD4 count: HIVinfected patients with CD4 counts <200 cells/mL have a mortality rate of 10% compared with 4% in those with CD4 counts from 200-499 cells/mL.", [["blood", "ANATOMY", 71, 76], ["cells", "ANATOMY", 130, 135], ["cells", "ANATOMY", 223, 228], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["CD4", "GENE_OR_GENE_PRODUCT", 77, 80], ["patients", "ORGANISM", 100, 108], ["CD4", "GENE_OR_GENE_PRODUCT", 114, 117], ["CD4", "GENE_OR_GENE_PRODUCT", 199, 202], ["CD4", "PROTEIN", 77, 80], ["CD4", "PROTEIN", 114, 117], ["CD4", "PROTEIN", 199, 202], ["patients", "SPECIES", 100, 108], ["blood CD4 count", "TEST", 71, 86], ["CD4 counts", "TEST", 114, 124], ["a mortality rate", "TEST", 144, 160], ["CD4 counts", "TEST", 199, 209]]], ["Compared with HIV-infected individuals without tuberculosis, the main effect on mortality is seen in patients with higher CD4 counts (>200 cells/mL), where the relative risk of death is three times that of the nontuberculous population.Mycobacterium avium-intracellulare ComplexSeveral case-controlled studies have indicated that in the absence of effective treatments, MAC-infected patients have a reduced survival compared with blood CD4 level-matched control subjects (approximately 4 months vs 9 months, respectively).", [["CD4", "ANATOMY", 122, 125], ["cells", "ANATOMY", 139, 144], ["blood", "ANATOMY", 430, 435], ["HIV-infected", "DISEASE", 14, 26], ["tuberculosis", "DISEASE", 47, 59], ["death", "DISEASE", 177, 182], ["MAC-infected", "DISEASE", 370, 382], ["HIV", "ORGANISM", 14, 17], ["individuals", "ORGANISM", 27, 38], ["patients", "ORGANISM", 101, 109], ["CD4", "GENE_OR_GENE_PRODUCT", 122, 125], ["Mycobacterium avium-intracellulare", "ORGANISM", 236, 270], ["patients", "ORGANISM", 383, 391], ["blood", "ORGANISM_SUBSTANCE", 430, 435], ["CD4", "GENE_OR_GENE_PRODUCT", 436, 439], ["CD4", "PROTEIN", 122, 125], ["CD4", "PROTEIN", 436, 439], ["HIV", "SPECIES", 14, 17], ["patients", "SPECIES", 101, 109], ["Mycobacterium avium", "SPECIES", 236, 255], ["-intracellulare", "SPECIES", 255, 270], ["patients", "SPECIES", 383, 391], ["HIV", "SPECIES", 14, 17], ["Mycobacterium avium", "SPECIES", 236, 255], ["tuberculosis", "PROBLEM", 47, 59], ["higher CD4 counts", "TEST", 115, 132], ["death", "PROBLEM", 177, 182], ["the nontuberculous population", "PROBLEM", 206, 235], ["Mycobacterium avium", "TEST", 236, 255], ["effective treatments", "TREATMENT", 348, 368], ["MAC", "TREATMENT", 370, 373], ["a reduced survival", "PROBLEM", 397, 415], ["blood CD4 level", "TEST", 430, 445], ["without", "UNCERTAINTY", 39, 46], ["tuberculosis", "OBSERVATION", 47, 59], ["main", "OBSERVATION_MODIFIER", 65, 69], ["effect", "OBSERVATION_MODIFIER", 70, 76], ["death", "OBSERVATION", 177, 182], ["nontuberculous", "OBSERVATION", 210, 224], ["intracellulare", "OBSERVATION_MODIFIER", 256, 270], ["infected", "OBSERVATION", 374, 382]]], ["Currently available treatment regimens may reduce this difference, although severe anemia seems to be an independent predictor of mortality.CytomegalovirusThe presence of CMV in BAL fluid also containing P. jirovecii has been related to outcome (see earlier).", [["BAL fluid", "ANATOMY", 178, 187], ["anemia", "DISEASE", 83, 89], ["P. jirovecii", "DISEASE", 204, 216], ["Cytomegalovirus", "ORGANISM", 140, 155], ["CMV", "ORGANISM", 171, 174], ["BAL fluid", "ORGANISM_SUBSTANCE", 178, 187], ["P. jirovecii", "ORGANISM", 204, 216], ["P. jirovecii", "SPECIES", 204, 216], ["CMV", "SPECIES", 171, 174], ["P. jirovecii", "SPECIES", 204, 216], ["treatment regimens", "TREATMENT", 20, 38], ["severe anemia", "PROBLEM", 76, 89], ["Cytomegalovirus", "PROBLEM", 140, 155], ["CMV in BAL fluid", "TREATMENT", 171, 187], ["P. jirovecii", "PROBLEM", 204, 216], ["severe", "OBSERVATION_MODIFIER", 76, 82], ["anemia", "OBSERVATION", 83, 89], ["CMV", "OBSERVATION", 171, 174], ["BAL fluid", "OBSERVATION", 178, 187], ["jirovecii", "OBSERVATION", 207, 216]]], ["The mortality rate at 3 and 6 months after bronchoscopy is greater in those with CMV detected at bronchoscopy.", [["CMV", "ORGANISM", 81, 84], ["CMV", "SPECIES", 81, 84], ["The mortality rate", "TEST", 0, 18], ["bronchoscopy", "TEST", 43, 55], ["CMV", "TREATMENT", 81, 84], ["bronchoscopy", "TEST", 97, 109], ["greater", "OBSERVATION_MODIFIER", 59, 66]]], ["However, CMV recovered as a sole pathogen does not impact on survival.PITFALLS AND CONTROVERSIESThe Effect of Antiretroviral Therapy on Opportunistic InfectionsPITFALLS AND CONTROVERSIESThe introduction of HAART, together with the wide availability of accurate methods of determining plasma RNA viral load, has led to profound changes in both clinical practice and HIV outcome.", [["plasma", "ANATOMY", 284, 290], ["CMV", "ORGANISM", 9, 12], ["plasma", "ORGANISM_SUBSTANCE", 284, 290], ["CMV", "SPECIES", 9, 12], ["HIV", "SPECIES", 365, 368], ["CMV", "PROBLEM", 9, 12], ["a sole pathogen", "PROBLEM", 26, 41], ["Antiretroviral Therapy", "TREATMENT", 110, 132], ["HAART", "TREATMENT", 206, 211], ["plasma RNA viral load", "PROBLEM", 284, 305], ["profound changes", "PROBLEM", 318, 334], ["HIV outcome", "PROBLEM", 365, 376], ["CMV", "OBSERVATION", 9, 12]]], ["Although it is still the case that respiratory disease remains above non-HIV infected background levels, in particular, bacterial pneumonia, TB, and lung cancer are more common, despite apparently effective HAART, in HIV-infected subjects.", [["respiratory", "ANATOMY", 35, 46], ["lung cancer", "ANATOMY", 149, 160], ["respiratory disease", "DISEASE", 35, 54], ["pneumonia", "DISEASE", 130, 139], ["TB", "DISEASE", 141, 143], ["lung cancer", "DISEASE", 149, 160], ["HIV-infected", "DISEASE", 217, 229], ["lung cancer", "CANCER", 149, 160], ["HIV-infected subjects", "ORGANISM", 217, 238], ["HIV", "SPECIES", 217, 220], ["HIV", "SPECIES", 217, 220], ["respiratory disease", "PROBLEM", 35, 54], ["non-HIV infected background levels", "PROBLEM", 69, 103], ["bacterial pneumonia", "PROBLEM", 120, 139], ["TB", "PROBLEM", 141, 143], ["lung cancer", "PROBLEM", 149, 160], ["respiratory", "ANATOMY", 35, 46], ["disease", "OBSERVATION", 47, 54], ["bacterial", "OBSERVATION_MODIFIER", 120, 129], ["pneumonia", "OBSERVATION", 130, 139], ["TB", "OBSERVATION_MODIFIER", 141, 143], ["lung", "ANATOMY", 149, 153], ["cancer", "OBSERVATION", 154, 160], ["effective", "OBSERVATION_MODIFIER", 197, 206], ["HAART", "OBSERVATION", 207, 212]]], ["Overall data indicate that clinical progression is rare in subjects who are able to adhere rigorously to at least 95% of their antiretroviral drug regimen.", [["their antiretroviral drug regimen", "TREATMENT", 121, 154]]], ["Mortality rates have fallen by 80% for almost all conditions, and it seems that a damaged immune system can, to a clinically significant extent, be reconstituted for a period of at least several years.", [["immune system", "ANATOMY", 90, 103], ["Mortality rates", "TEST", 0, 15], ["a damaged immune system", "PROBLEM", 80, 103]]], ["Hence, clinicians need to consider not only opportunistic infection or malignancy within their diagnostic workup but also the effects of drug therapy itself.", [["infection", "DISEASE", 58, 67], ["malignancy", "DISEASE", 71, 81], ["opportunistic infection", "PROBLEM", 44, 67], ["malignancy", "PROBLEM", 71, 81], ["their diagnostic workup", "TEST", 89, 112], ["drug therapy", "TREATMENT", 137, 149], ["infection", "OBSERVATION", 58, 67], ["malignancy", "OBSERVATION", 71, 81]]], ["The side effect profile of HAART (e.g., metabolic and mitochondrial toxicities, liver damage, and neuropsychiatric disorders), as well as the large number of drug-drug interactions, makes this a very complex area of management.", [["mitochondrial", "ANATOMY", 54, 67], ["liver", "ANATOMY", 80, 85], ["toxicities", "DISEASE", 68, 78], ["liver damage", "DISEASE", 80, 92], ["neuropsychiatric disorders", "DISEASE", 98, 124], ["mitochondrial", "CELLULAR_COMPONENT", 54, 67], ["liver", "ORGAN", 80, 85], ["HAART (e.g., metabolic and mitochondrial toxicities", "PROBLEM", 27, 78], ["liver damage", "PROBLEM", 80, 92], ["neuropsychiatric disorders", "PROBLEM", 98, 124], ["side effect", "OBSERVATION_MODIFIER", 4, 15], ["HAART", "OBSERVATION", 27, 32], ["mitochondrial toxicities", "OBSERVATION", 54, 78], ["liver", "ANATOMY", 80, 85], ["damage", "OBSERVATION", 86, 92], ["large", "OBSERVATION_MODIFIER", 142, 147], ["number", "OBSERVATION_MODIFIER", 148, 154]]], ["The best example of this is HIV-related tuberculosis.", [["tuberculosis", "DISEASE", 40, 52], ["HIV", "ORGANISM", 28, 31], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 28, 31], ["HIV-related tuberculosis", "PROBLEM", 28, 52], ["HIV", "OBSERVATION", 28, 31], ["tuberculosis", "OBSERVATION", 40, 52]]], ["Here, not only is there overlapping toxicity and pharmacologic interaction, but IRIS is common.", [["toxicity", "DISEASE", 36, 44], ["IRIS", "DISEASE", 80, 84], ["overlapping toxicity", "PROBLEM", 24, 44], ["pharmacologic interaction", "PROBLEM", 49, 74], ["toxicity", "OBSERVATION", 36, 44]]], ["Studies should inform the decision on when to start HAART in patients already on antituberculosis medication.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["HAART", "TREATMENT", 52, 57], ["antituberculosis medication", "TREATMENT", 81, 108]]], ["Other work needs to focus on understanding BOX 34-2 Prognostic Factors Associated with Poor Outcome in Pneumocystis jirovecii Pneumonia On admission Patient's age No previous knowledge of HIV status Tachypnea (respiratory rate >30/min) Second or subsequent episode of Pneumocystis jirovecii pneumonia Poor oxygenation \u00c0 PaO 2 <7.0 kPa (<53 mmHg) or A-aO 2 >4.0 kPa (>30 mmHg) Low serum albumin (<35 g/dL) Low hemoglobin (<12.0 g/dL) Peripheral blood leukocytosis (>10.8 \u00c2 10 9 /L) Elevated serum lactate dehydrogenase levels (>300 IU/L) CD4 count <50 cells/mL Marked chest radiographic abnormalitiesdiffuse bilateral interstitial infiltrates with or without alveolar consolidation Medical comorbidity (e.g., pregnancy)Following admissionAt bronchoscopy 1.", [["serum", "ANATOMY", 380, 385], ["Peripheral blood", "ANATOMY", 433, 449], ["serum", "ANATOMY", 490, 495], ["cells", "ANATOMY", 551, 556], ["chest", "ANATOMY", 567, 572], ["interstitial infiltrates", "ANATOMY", 617, 641], ["alveolar", "ANATOMY", 658, 666], ["Pneumocystis jirovecii Pneumonia", "DISEASE", 103, 135], ["Tachypnea", "DISEASE", 199, 208], ["Pneumocystis jirovecii pneumonia", "DISEASE", 268, 300], ["blood leukocytosis", "DISEASE", 444, 462], ["lactate", "CHEMICAL", 496, 503], ["lactate", "CHEMICAL", 496, 503], ["HIV", "ORGANISM", 188, 191], ["serum", "ORGANISM_SUBSTANCE", 380, 385], ["albumin", "GENE_OR_GENE_PRODUCT", 386, 393], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 409, 419], ["blood", "ORGANISM_SUBSTANCE", 444, 449], ["serum", "ORGANISM_SUBSTANCE", 490, 495], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 496, 517], ["CD4", "GENE_OR_GENE_PRODUCT", 537, 540], ["alveolar", "MULTI-TISSUE_STRUCTURE", 658, 666], ["hemoglobin", "PROTEIN", 409, 419], ["serum lactate dehydrogenase", "PROTEIN", 490, 517], ["CD4", "PROTEIN", 537, 540], ["Pneumocystis jirovecii", "SPECIES", 103, 125], ["Patient", "SPECIES", 149, 156], ["HIV", "SPECIES", 188, 191], ["Pneumocystis jirovecii", "SPECIES", 268, 290], ["Pneumocystis jirovecii", "SPECIES", 103, 125], ["HIV", "SPECIES", 188, 191], ["Pneumocystis jirovecii", "SPECIES", 268, 290], ["Pneumocystis jirovecii Pneumonia", "PROBLEM", 103, 135], ["HIV status", "PROBLEM", 188, 198], ["Tachypnea", "PROBLEM", 199, 208], ["respiratory rate", "TEST", 210, 226], ["Pneumocystis jirovecii pneumonia", "PROBLEM", 268, 300], ["PaO", "TEST", 320, 323], ["kPa", "TEST", 331, 334], ["A", "TEST", 349, 350], ["aO", "TEST", 351, 353], ["kPa", "TEST", 361, 364], ["Low serum albumin", "TEST", 376, 393], ["Low hemoglobin", "TEST", 405, 419], ["Peripheral blood leukocytosis", "TEST", 433, 462], ["Elevated serum lactate dehydrogenase levels", "PROBLEM", 481, 524], ["IU", "TEST", 531, 533], ["CD4 count", "TEST", 537, 546], ["cells", "TEST", 551, 556], ["Marked chest radiographic abnormalitiesdiffuse bilateral interstitial infiltrates", "PROBLEM", 560, 641], ["alveolar consolidation", "PROBLEM", 658, 680], ["admissionAt bronchoscopy", "TREATMENT", 728, 752], ["Pneumocystis jirovecii", "OBSERVATION", 103, 125], ["Pneumocystis jirovecii", "OBSERVATION", 268, 290], ["Peripheral", "ANATOMY_MODIFIER", 433, 443], ["blood", "ANATOMY", 444, 449], ["leukocytosis", "OBSERVATION", 450, 462], ["chest", "ANATOMY", 567, 572], ["bilateral", "ANATOMY_MODIFIER", 607, 616], ["interstitial", "ANATOMY_MODIFIER", 617, 629], ["infiltrates", "OBSERVATION", 630, 641], ["without", "UNCERTAINTY", 650, 657], ["alveolar", "ANATOMY_MODIFIER", 658, 666], ["consolidation", "OBSERVATION", 667, 680]]], ["In bronchoalveolar lavage fluid detection of a.", [["bronchoalveolar lavage fluid", "ANATOMY", 3, 31], ["bronchoalveolar lavage", "ORGANISM_SUBSTANCE", 3, 25], ["a.", "SPECIES", 45, 47], ["bronchoalveolar lavage fluid detection", "TEST", 3, 41], ["bronchoalveolar", "OBSERVATION", 3, 18], ["lavage fluid", "OBSERVATION", 19, 31]]], ["Copathology CMV bacteria b.", [["CMV", "ORGANISM", 12, 15], ["CMV bacteria b.", "PROBLEM", 12, 27]]], ["Neutrophilia (>5%) 2.", [["Neutrophilia", "DISEASE", 0, 12], ["Neutrophilia", "TEST", 0, 12]]], ["Detection of pulmonary Kaposi sarcoma Serum lactate dehydrogenase levels that remain elevated Development of pneumothorax High APACHE II score on admission to the ICU Need for mechanical ventilation why full pulmonary immunity is not restored.", [["pulmonary", "ANATOMY", 208, 217], ["pulmonary Kaposi sarcoma", "DISEASE", 13, 37], ["lactate", "CHEMICAL", 44, 51], ["pneumothorax", "DISEASE", 109, 121], ["lactate", "CHEMICAL", 44, 51], ["Serum", "ORGANISM_SUBSTANCE", 38, 43], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 44, 65], ["pulmonary", "ORGAN", 208, 217], ["lactate dehydrogenase", "PROTEIN", 44, 65], ["pulmonary Kaposi sarcoma", "PROBLEM", 13, 37], ["Serum lactate dehydrogenase levels", "TEST", 38, 72], ["elevated", "PROBLEM", 85, 93], ["pneumothorax", "PROBLEM", 109, 121], ["High APACHE II score", "PROBLEM", 122, 142], ["mechanical ventilation", "TREATMENT", 176, 198], ["pulmonary", "ANATOMY", 13, 22], ["Kaposi sarcoma", "OBSERVATION", 23, 37], ["elevated", "OBSERVATION_MODIFIER", 85, 93], ["pneumothorax", "OBSERVATION", 109, 121], ["pulmonary", "ANATOMY", 208, 217], ["immunity", "OBSERVATION", 218, 226]]], ["This may reflect abnormalities in the innate immune response, which is currently poorly described in HIV infection.Predictors of DiseaseDespite the benefits of HAART, it is likely that in the long term many patients will progress to severe disease.", [["HIV infection", "DISEASE", 101, 114], ["HIV", "ORGANISM", 101, 104], ["patients", "ORGANISM", 207, 215], ["HIV", "SPECIES", 101, 104], ["patients", "SPECIES", 207, 215], ["HIV", "SPECIES", 101, 104], ["abnormalities", "PROBLEM", 17, 30], ["HIV infection", "PROBLEM", 101, 114], ["HAART", "TREATMENT", 160, 165], ["severe disease", "PROBLEM", 233, 247], ["may reflect", "UNCERTAINTY", 5, 16], ["abnormalities", "OBSERVATION", 17, 30], ["immune response", "OBSERVATION", 45, 60], ["HIV", "OBSERVATION_MODIFIER", 101, 104], ["infection", "OBSERVATION", 105, 114], ["severe", "OBSERVATION_MODIFIER", 233, 239], ["disease", "OBSERVATION", 240, 247]]], ["There is currently little research in this area.", [["little", "OBSERVATION_MODIFIER", 19, 25], ["research", "OBSERVATION", 26, 34]]], ["An example of this would be assessing the risk of an individual for development of active tuberculosis.", [["tuberculosis", "DISEASE", 90, 102], ["active tuberculosis", "PROBLEM", 83, 102], ["active", "OBSERVATION_MODIFIER", 83, 89], ["tuberculosis", "OBSERVATION", 90, 102]]], ["It is clear that much of the excess mortality in HIV-tuberculosis coinfection occurs early in HIV infection.", [["HIV-tuberculosis coinfection", "DISEASE", 49, 77], ["HIV infection", "DISEASE", 94, 107], ["HIV-tuberculosis", "ORGANISM", 49, 65], ["HIV", "ORGANISM", 94, 97], ["HIV-tuberculosis", "SPECIES", 49, 65], ["HIV", "SPECIES", 94, 97], ["HIV-tuberculosis", "SPECIES", 49, 65], ["HIV", "SPECIES", 94, 97], ["the excess mortality", "PROBLEM", 25, 45], ["HIV", "PROBLEM", 49, 52], ["tuberculosis coinfection", "PROBLEM", 53, 77], ["HIV infection", "PROBLEM", 94, 107], ["clear", "OBSERVATION", 6, 11], ["tuberculosis", "OBSERVATION", 53, 65], ["infection", "OBSERVATION", 98, 107]]], ["Thus, if tests can be devised that indicate who has latent tuberculosis infection (and who is, therefore, most likely to have clinical disease develop), steps can be taken to prevent illness.Predictors of DiseaseAs discussed previously, immune-based tests have shown promise in immunocompetent individuals with tuberculosis infection.", [["tuberculosis infection", "DISEASE", 59, 81], ["tuberculosis infection", "DISEASE", 311, 333], ["tests", "TEST", 9, 14], ["latent tuberculosis infection", "PROBLEM", 52, 81], ["clinical disease develop", "PROBLEM", 126, 150], ["illness", "PROBLEM", 183, 190], ["immune-based tests", "TEST", 237, 255], ["tuberculosis infection", "PROBLEM", 311, 333], ["latent", "OBSERVATION_MODIFIER", 52, 58], ["tuberculosis", "OBSERVATION", 59, 71], ["immunocompetent", "OBSERVATION", 278, 293], ["tuberculosis", "OBSERVATION", 311, 323]]], ["If these can be refined to work consistently in patients with HIV infection at a reasonable cost, there is the possibility of targeting those at risk of future tuberculosis, or of tuberculosis \"unmasking\" after starting HAART.Predictors of DiseaseThe other role for a test such as this would be in rapid diagnosis of active tuberculosis.", [["HIV infection", "DISEASE", 62, 75], ["tuberculosis", "DISEASE", 160, 172], ["tuberculosis", "DISEASE", 180, 192], ["Disease", "DISEASE", 240, 247], ["tuberculosis", "DISEASE", 324, 336], ["patients", "ORGANISM", 48, 56], ["HIV", "ORGANISM", 62, 65], ["patients", "SPECIES", 48, 56], ["HIV", "SPECIES", 62, 65], ["HIV", "SPECIES", 62, 65], ["HIV infection", "PROBLEM", 62, 75], ["future tuberculosis", "PROBLEM", 153, 172], ["tuberculosis", "PROBLEM", 180, 192], ["HAART", "TREATMENT", 220, 225], ["Disease", "PROBLEM", 240, 247], ["a test", "TEST", 266, 272], ["active tuberculosis", "PROBLEM", 317, 336], ["tuberculosis", "OBSERVATION", 160, 172], ["tuberculosis", "OBSERVATION", 180, 192], ["Disease", "OBSERVATION", 240, 247], ["active", "OBSERVATION_MODIFIER", 317, 323], ["tuberculosis", "OBSERVATION", 324, 336]]], ["It is common to be faced with a patient who has nonspecific symptoms and a wide differential diagnosis.", [["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39], ["nonspecific symptoms", "PROBLEM", 48, 68]]], ["A quantitative test would help resolve some of these dilemmas by indicating the chance of the condition being caused by a particular disease.", [["A quantitative test", "TEST", 0, 19], ["the condition", "PROBLEM", 90, 103], ["a particular disease", "PROBLEM", 120, 140]]], ["An example would be the patient from an endemic tuberculosis area, with low CD4 counts, who has both pulmonary and central nervous system disease.", [["pulmonary", "ANATOMY", 101, 110], ["central nervous system", "ANATOMY", 115, 137], ["tuberculosis", "DISEASE", 48, 60], ["pulmonary and central nervous system disease", "DISEASE", 101, 145], ["patient", "ORGANISM", 24, 31], ["CD4", "GENE_OR_GENE_PRODUCT", 76, 79], ["pulmonary", "ORGAN", 101, 110], ["central nervous system", "ANATOMICAL_SYSTEM", 115, 137], ["CD4", "PROTEIN", 76, 79], ["patient", "SPECIES", 24, 31], ["an endemic tuberculosis area", "PROBLEM", 37, 65], ["low CD4 counts", "PROBLEM", 72, 86], ["both pulmonary and central nervous system disease", "PROBLEM", 96, 145], ["endemic", "OBSERVATION_MODIFIER", 40, 47], ["tuberculosis", "OBSERVATION", 48, 60], ["low CD4 counts", "OBSERVATION", 72, 86], ["pulmonary", "ANATOMY", 101, 110], ["central", "ANATOMY_MODIFIER", 115, 122], ["nervous system disease", "OBSERVATION", 123, 145]]], ["Is this tuberculosis, toxoplasmosis, cryptococcosis, or viral or bacterial infection?", [["tuberculosis", "DISEASE", 8, 20], ["toxoplasmosis", "DISEASE", 22, 35], ["cryptococcosis", "DISEASE", 37, 51], ["viral or bacterial infection", "DISEASE", 56, 84], ["this tuberculosis", "PROBLEM", 3, 20], ["toxoplasmosis", "PROBLEM", 22, 35], ["cryptococcosis", "PROBLEM", 37, 51], ["viral or bacterial infection", "PROBLEM", 56, 84], ["tuberculosis", "OBSERVATION", 8, 20], ["toxoplasmosis", "OBSERVATION", 22, 35], ["cryptococcosis", "OBSERVATION", 37, 51], ["viral", "OBSERVATION_MODIFIER", 56, 61], ["bacterial", "OBSERVATION_MODIFIER", 65, 74], ["infection", "OBSERVATION", 75, 84]]], ["Any such test for tuberculosis would also have to distinguish between the different states of old (treated), old (inactive), old (latent), and active.", [["tuberculosis", "DISEASE", 18, 30], ["Any such test", "TEST", 0, 13], ["tuberculosis", "PROBLEM", 18, 30], ["active", "OBSERVATION_MODIFIER", 143, 149]]], ["Although not insurmountable, at present, this is not possible.Predictors of DiseaseRapid diagnostic assays that assess organism viability are also important.", [["DiseaseRapid diagnostic assays", "TEST", 76, 106], ["organism viability", "PROBLEM", 119, 137], ["not", "UNCERTAINTY", 9, 12], ["insurmountable", "OBSERVATION_MODIFIER", 13, 27], ["not possible", "UNCERTAINTY", 49, 61]]], ["If a clinician can receive early feedback on whether treatment is producing a suitable killing effect, therapy can be tailored to the individual.", [["treatment", "TREATMENT", 53, 62], ["a suitable killing effect", "TREATMENT", 76, 101], ["therapy", "TREATMENT", 103, 110]]], ["This enables regimens to be \"dose adjusted\" as needed and removes the element of concern that is often present when patients are slow to respond.", [["patients", "ORGANISM", 116, 124], ["patients", "SPECIES", 116, 124], ["This enables regimens", "TREATMENT", 0, 21], ["slow to respond", "PROBLEM", 129, 144]]], ["Examples of this would be in the treatment of PCP or mycobacterial disease.Bacterial InfectionsThe frequency of bacterial infection (often recurrent) with its attendant sequelae makes effective strategies for vaccination an important priority.", [["PCP", "DISEASE", 46, 49], ["mycobacterial disease", "DISEASE", 53, 74], ["Infections", "DISEASE", 85, 95], ["bacterial infection", "DISEASE", 112, 131], ["PCP", "PROBLEM", 46, 49], ["mycobacterial disease", "PROBLEM", 53, 74], ["Bacterial Infections", "PROBLEM", 75, 95], ["bacterial infection", "PROBLEM", 112, 131], ["its attendant sequelae", "PROBLEM", 155, 177], ["effective strategies", "TREATMENT", 184, 204], ["vaccination", "TREATMENT", 209, 220], ["mycobacterial disease", "OBSERVATION", 53, 74], ["Infections", "OBSERVATION", 85, 95], ["bacterial", "OBSERVATION_MODIFIER", 112, 121], ["infection", "OBSERVATION", 122, 131]]], ["It is uncertain why there is a differential response to vaccination; even in the United States, African Americans do not seem to derive the same benefit as whites.", [["vaccination", "TREATMENT", 56, 67]]], ["This needs further research, together with more emphasis on identifying the local immune response present in the lung in such individuals.Bacterial InfectionsBacterial infections may be clinically indistinguishable from other pathogens, and only two thirds of all respiratory infections are formally diagnosed.", [["lung", "ANATOMY", 113, 117], ["respiratory", "ANATOMY", 264, 275], ["Bacterial infections", "DISEASE", 158, 178], ["respiratory infections", "DISEASE", 264, 286], ["lung", "ORGAN", 113, 117], ["Bacterial InfectionsBacterial infections", "PROBLEM", 138, 178], ["other pathogens", "PROBLEM", 220, 235], ["all respiratory infections", "PROBLEM", 260, 286], ["lung", "ANATOMY", 113, 117], ["Infections", "OBSERVATION", 148, 158], ["infections", "OBSERVATION", 168, 178], ["pathogens", "OBSERVATION", 226, 235], ["all", "OBSERVATION_MODIFIER", 260, 263], ["respiratory infections", "OBSERVATION", 264, 286]]], ["The use of rapid antigen tests may be one way forward.", [["rapid antigen tests", "TEST", 11, 30]]], ["This is especially so given the high incidence of (potentially fatal) bacteremia present in such populations.", [["bacteremia", "DISEASE", 70, 80], ["fatal) bacteremia", "PROBLEM", 63, 80], ["bacteremia", "OBSERVATION", 70, 80]]], ["For maximum benefit, this needs to use a system that is simple and cheap, and hence suitable to both resourcerich and resource-poor countries.Mycobacterial DiseasesM. tuberculosis is globally the most important HIV-related pathogen.", [["tuberculosis", "DISEASE", 167, 179], ["HIV", "ORGANISM", 211, 214], ["tuberculosis", "SPECIES", 167, 179], ["HIV", "SPECIES", 211, 214], ["tuberculosis", "SPECIES", 167, 179], ["HIV", "SPECIES", 211, 214], ["a system", "TREATMENT", 39, 47], ["Mycobacterial DiseasesM", "PROBLEM", 142, 165], ["tuberculosis", "PROBLEM", 167, 179], ["related pathogen", "PROBLEM", 215, 231]]], ["Strategies of control and prevention are vital to ensure that millions of people do not become coinfected and that those who are do not go on to have clinical disease develop.", [["people", "ORGANISM", 74, 80], ["people", "SPECIES", 74, 80], ["Strategies of control", "TREATMENT", 0, 21], ["clinical disease develop", "PROBLEM", 150, 174]]], ["Rapid diagnostics are critical.", [["Rapid diagnostics", "TEST", 0, 17]]], ["The encouraging reports of the simple and cheap method of MODS to both diagnose tuberculosis and then provide resistance data in field settings (see earlier) argues for large-scale roll out and evaluation.Mycobacterial DiseasesBeyond public health measures, such as DOT, fixed-dose combination drugs, case management, and education, research needs to improve on current drug therapy.", [["MODS", "DISEASE", 58, 62], ["tuberculosis", "DISEASE", 80, 92], ["MODS", "PROBLEM", 58, 62], ["resistance data", "TEST", 110, 125], ["evaluation", "TEST", 194, 204], ["Mycobacterial Diseases", "PROBLEM", 205, 227], ["DOT", "TREATMENT", 266, 269], ["fixed-dose combination drugs", "TREATMENT", 271, 299], ["case management", "TREATMENT", 301, 316], ["current drug therapy", "TREATMENT", 362, 382], ["tuberculosis", "OBSERVATION", 80, 92]]], ["Long-acting preparations such as rifapentine show promise but, as the problem with rifampicin monoresistance demonstrates, there is still much work to be done.", [["rifapentine", "CHEMICAL", 33, 44], ["rifampicin", "CHEMICAL", 83, 93], ["rifapentine", "CHEMICAL", 33, 44], ["rifampicin", "CHEMICAL", 83, 93], ["rifapentine", "SIMPLE_CHEMICAL", 33, 44], ["rifampicin", "SIMPLE_CHEMICAL", 83, 93], ["Long-acting preparations", "TREATMENT", 0, 24], ["rifapentine", "TREATMENT", 33, 44], ["rifampicin monoresistance", "TREATMENT", 83, 108]]], ["For the first time in many years, there are several antimycobacterial drugs that are in various stages of clinical trials.", [["several antimycobacterial drugs", "TREATMENT", 44, 75], ["clinical trials", "TREATMENT", 106, 121], ["antimycobacterial drugs", "OBSERVATION", 52, 75]]], ["All are promising, and several have novel mechanisms of action.", [["promising", "OBSERVATION_MODIFIER", 8, 17]]], ["The Global Alliance and the WHO \"Stop TB\" campaigns have been crucial in this regard.", [["Global", "OBSERVATION_MODIFIER", 4, 10]]], ["The fluoroquinolones, moxifloxacin and gatifloxacin, are closest to the market.", [["fluoroquinolones", "CHEMICAL", 4, 20], ["moxifloxacin", "CHEMICAL", 22, 34], ["gatifloxacin", "CHEMICAL", 39, 51], ["fluoroquinolones", "CHEMICAL", 4, 20], ["moxifloxacin", "CHEMICAL", 22, 34], ["gatifloxacin", "CHEMICAL", 39, 51], ["fluoroquinolones", "SIMPLE_CHEMICAL", 4, 20], ["moxifloxacin", "SIMPLE_CHEMICAL", 22, 34], ["gatifloxacin", "SIMPLE_CHEMICAL", 39, 51], ["The fluoroquinolones", "TREATMENT", 0, 20], ["moxifloxacin", "TREATMENT", 22, 34], ["gatifloxacin", "TREATMENT", 39, 51]]], ["They are potent drugs with considerable ability both to kill and also sterilize mycobacteria-infected sites.", [["sites", "ANATOMY", 102, 107], ["potent drugs", "TREATMENT", 9, 21], ["mycobacteria", "PROBLEM", 80, 92], ["infected sites", "PROBLEM", 93, 107], ["infected", "OBSERVATION", 93, 101]]], ["Trials of treatment-shortening regimens are ongoing worldwide.Mycobacterial DiseasesVaccination against M. tuberculosis with BCG has understandably not been widely used in an immunosuppressed HIV-infected population.", [["M. tuberculosis", "DISEASE", 104, 119], ["BCG", "CHEMICAL", 125, 128], ["HIV-infected", "DISEASE", 192, 204], ["M. tuberculosis", "ORGANISM", 104, 119], ["HIV", "ORGANISM", 192, 195], ["M. tuberculosis", "SPECIES", 104, 119], ["M. tuberculosis", "SPECIES", 104, 119], ["HIV", "SPECIES", 192, 195], ["treatment", "TREATMENT", 10, 19], ["shortening regimens", "TREATMENT", 20, 39], ["Mycobacterial DiseasesVaccination", "PROBLEM", 62, 95], ["M. tuberculosis", "PROBLEM", 104, 119], ["BCG", "PROBLEM", 125, 128], ["infected", "OBSERVATION", 196, 204]]], ["However, a safe vaccine may be the only affordable way of protecting large parts of the world from tuberculosis.", [["tuberculosis", "DISEASE", 99, 111], ["a safe vaccine", "TREATMENT", 9, 23], ["tuberculosis", "PROBLEM", 99, 111], ["tuberculosis", "OBSERVATION", 99, 111]]], ["So far there seems to be more success in vaccines to either enhance or replace the primary protective effects of BCG.", [["vaccines", "TREATMENT", 41, 49], ["the primary protective effects of BCG", "TREATMENT", 79, 116]]], ["The use of immunotherapy (e.g., with heat-killed Mycobacterium vaccae) in combination with chemotherapy has been disappointing in clinical trials.Pneumocystis jiroveciiNewer methods of diagnosis (e.g., PCR tests on saliva) may prove invaluable for quick and easy disease confirmation, although their applicability to routine samples needs further evaluation.Pneumocystis jiroveciiP. jirovecii prophylaxis was the first important HIV treatment widely available.", [["samples", "ANATOMY", 325, 332], ["Pneumocystis jiroveciiP", "DISEASE", 358, 381], ["jirovecii", "DISEASE", 383, 392], ["Mycobacterium vaccae", "ORGANISM", 49, 69], ["saliva", "ORGANISM_SUBSTANCE", 215, 221], ["jirovecii", "ORGANISM", 383, 392], ["HIV", "ORGANISM", 429, 432], ["Mycobacterium vaccae", "SPECIES", 49, 69], ["jirovecii", "SPECIES", 383, 392], ["Mycobacterium vaccae", "SPECIES", 49, 69], ["Pneumocystis jiroveciiP", "SPECIES", 358, 381], ["jirovecii", "SPECIES", 383, 392], ["HIV", "SPECIES", 429, 432], ["immunotherapy", "TREATMENT", 11, 24], ["heat-killed Mycobacterium vaccae", "TREATMENT", 37, 69], ["chemotherapy", "TREATMENT", 91, 103], ["PCR tests", "TEST", 202, 211], ["quick and easy disease confirmation", "PROBLEM", 248, 283], ["routine samples", "TEST", 317, 332], ["further evaluation", "TEST", 339, 357], ["Pneumocystis jiroveciiP", "PROBLEM", 358, 381], ["jirovecii prophylaxis", "TREATMENT", 383, 404], ["HIV treatment", "TREATMENT", 429, 442]]], ["However, despite the efficacy of TMP/SMX, compliance remains a problem.", [["TMP", "CHEMICAL", 33, 36], ["SMX", "CHEMICAL", 37, 40], ["TMP", "CHEMICAL", 33, 36], ["SMX", "CHEMICAL", 37, 40], ["TMP", "SIMPLE_CHEMICAL", 33, 36], ["SMX", "SIMPLE_CHEMICAL", 37, 40], ["TMP/SMX", "TREATMENT", 33, 40]]], ["Regimens that use a gradual increase in dosage when starting prophylaxis may help.", [["Regimens", "TREATMENT", 0, 8], ["a gradual increase in dosage", "TREATMENT", 18, 46], ["prophylaxis", "TREATMENT", 61, 72]]], ["One concern with widespread use of prophylaxis is that resistance will start to occur to TMP/SMX.", [["TMP", "CHEMICAL", 89, 92], ["SMX", "CHEMICAL", 93, 96], ["TMP", "CHEMICAL", 89, 92], ["SMX", "CHEMICAL", 93, 96], ["TMP", "SIMPLE_CHEMICAL", 89, 92], ["SMX", "SIMPLE_CHEMICAL", 93, 96], ["prophylaxis", "TREATMENT", 35, 46], ["widespread", "OBSERVATION_MODIFIER", 17, 27]]], ["Reports have indicated that there are mutations in the P. jirovecii dihydropteroate synthase gene that confer resistance.", [["dihydropteroate", "CHEMICAL", 68, 83], ["dihydropteroate", "CHEMICAL", 68, 83], ["P. jirovecii", "ORGANISM", 55, 67], ["dihydropteroate synthase", "GENE_OR_GENE_PRODUCT", 68, 92], ["P. jirovecii dihydropteroate synthase gene", "DNA", 55, 97], ["P. jirovecii", "SPECIES", 55, 67], ["P. jirovecii", "SPECIES", 55, 67], ["mutations", "PROBLEM", 38, 47], ["the P. jirovecii dihydropteroate synthase gene", "TREATMENT", 51, 97]]], ["These seem to be increasing over time, although they do not seem to be present in many patients who fail treatment for PCP with TMP/SMX.", [["PCP", "DISEASE", 119, 122], ["TMP", "CHEMICAL", 128, 131], ["SMX", "CHEMICAL", 132, 135], ["PCP", "CHEMICAL", 119, 122], ["TMP", "CHEMICAL", 128, 131], ["SMX", "CHEMICAL", 132, 135], ["patients", "ORGANISM", 87, 95], ["TMP", "SIMPLE_CHEMICAL", 128, 131], ["SMX", "SIMPLE_CHEMICAL", 132, 135], ["patients", "SPECIES", 87, 95], ["TMP/SMX", "TREATMENT", 128, 135], ["seem to be", "UNCERTAINTY", 6, 16], ["increasing", "OBSERVATION_MODIFIER", 17, 27]]], ["The implications of this are uncertain but could include a greater likelihood of treatment failure and the possibility of worsening patterns of global bacterial drug resistance.Smoking-Related DiseasesHIV-infected populations in the developed world have high rates of smoking.", [["DiseasesHIV-infected", "DISEASE", 193, 213], ["smoking", "CHEMICAL", 268, 275], ["treatment failure", "PROBLEM", 81, 98], ["global bacterial drug resistance", "PROBLEM", 144, 176], ["Related DiseasesHIV", "PROBLEM", 185, 204], ["infected populations", "PROBLEM", 205, 225], ["worsening", "OBSERVATION_MODIFIER", 122, 131], ["global", "OBSERVATION_MODIFIER", 144, 150], ["bacterial drug resistance", "OBSERVATION", 151, 176], ["infected", "OBSERVATION_MODIFIER", 205, 213], ["populations", "OBSERVATION_MODIFIER", 214, 225]]], ["The evidence that this is harmful above those effects seen in the general population continues to accrue.", [["harmful", "OBSERVATION_MODIFIER", 26, 33]]], ["The accelerated course of both obstructive lung disease and cancer, together with the increased risk of respiratory infection in smokers, persuasively argues the case for targeted smoking cessation.", [["lung", "ANATOMY", 43, 47], ["cancer", "ANATOMY", 60, 66], ["respiratory", "ANATOMY", 104, 115], ["obstructive lung disease", "DISEASE", 31, 55], ["cancer", "DISEASE", 60, 66], ["respiratory infection", "DISEASE", 104, 125], ["lung", "ORGAN", 43, 47], ["cancer", "CANCER", 60, 66], ["both obstructive lung disease", "PROBLEM", 26, 55], ["cancer", "PROBLEM", 60, 66], ["respiratory infection", "PROBLEM", 104, 125], ["accelerated", "OBSERVATION_MODIFIER", 4, 15], ["course", "OBSERVATION_MODIFIER", 16, 22], ["both", "OBSERVATION_MODIFIER", 26, 30], ["obstructive", "OBSERVATION_MODIFIER", 31, 42], ["lung", "ANATOMY", 43, 47], ["disease", "OBSERVATION", 48, 55], ["cancer", "OBSERVATION", 60, 66], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["respiratory", "ANATOMY", 104, 115], ["infection", "OBSERVATION", 116, 125]]], ["That HIV infection and HAART have profound (and probably negative) effects on blood lipids and insulin resistance further support the need to reduce smoking rates in this population.", [["blood", "ANATOMY", 78, 83], ["HIV infection", "DISEASE", 5, 18], ["smoking", "CHEMICAL", 149, 156], ["HIV", "ORGANISM", 5, 8], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["insulin", "GENE_OR_GENE_PRODUCT", 95, 102], ["HIV", "SPECIES", 5, 8], ["HIV", "SPECIES", 5, 8], ["HIV infection", "PROBLEM", 5, 18], ["HAART", "TREATMENT", 23, 28], ["blood lipids", "TEST", 78, 90], ["insulin resistance", "TREATMENT", 95, 113], ["infection", "OBSERVATION", 9, 18], ["probably", "UNCERTAINTY", 48, 56], ["negative", "OBSERVATION", 57, 65]]], ["It seems that we are starting to see increased rates of cardiovascular disease in this now aging population.Smoking-Related DiseasesThe natural history of HIV-related respiratory disease continues to evolve.", [["cardiovascular", "ANATOMY", 56, 70], ["respiratory", "ANATOMY", 167, 178], ["cardiovascular disease", "DISEASE", 56, 78], ["Smoking", "DISEASE", 108, 115], ["HIV-related respiratory disease", "DISEASE", 155, 186], ["cardiovascular", "ANATOMICAL_SYSTEM", 56, 70], ["HIV", "ORGANISM", 155, 158], ["HIV", "SPECIES", 155, 158], ["HIV", "SPECIES", 155, 158], ["cardiovascular disease", "PROBLEM", 56, 78], ["Related Diseases", "PROBLEM", 116, 132], ["HIV", "PROBLEM", 155, 158], ["respiratory disease", "PROBLEM", 167, 186], ["cardiovascular disease", "OBSERVATION", 56, 78], ["respiratory disease", "OBSERVATION", 167, 186]]], ["HAART and newer therapeutic strategies have made a significant impact on morbidity and mortality.", [["HAART", "TREATMENT", 0, 5], ["newer therapeutic strategies", "TREATMENT", 10, 38]]], ["Yet individuals continue to become HIV infected, progress, and die from an ever-expanding range of conditions.", [["HIV infected", "DISEASE", 35, 47], ["HIV", "SPECIES", 35, 38], ["HIV", "SPECIES", 35, 38], ["HIV infected", "PROBLEM", 35, 47], ["infected", "OBSERVATION", 39, 47]]], ["P. jirovecii remains the most common AIDS-defining event in the developed world, whereas M. tuberculosis is globally the most common cause of death.", [["P. jirovecii", "DISEASE", 0, 12], ["AIDS", "DISEASE", 37, 41], ["tuberculosis", "DISEASE", 92, 104], ["death", "DISEASE", 142, 147], ["P. jirovecii", "ORGANISM", 0, 12], ["M. tuberculosis", "ORGANISM", 89, 104], ["P. jirovecii", "SPECIES", 0, 12], ["M. tuberculosis", "SPECIES", 89, 104], ["P. jirovecii", "SPECIES", 0, 12], ["M. tuberculosis", "SPECIES", 89, 104], ["P. jirovecii", "PROBLEM", 0, 12], ["death", "PROBLEM", 142, 147], ["jirovecii", "OBSERVATION", 3, 12], ["tuberculosis", "OBSERVATION", 92, 104]]], ["Bacterial respiratory infection is not far behind.", [["respiratory", "ANATOMY", 10, 21], ["respiratory infection", "DISEASE", 10, 31], ["Bacterial respiratory infection", "PROBLEM", 0, 31], ["respiratory", "ANATOMY", 10, 21], ["infection", "OBSERVATION", 22, 31]]], ["Given the huge number of individuals with HIV infection, the only effective way to manage this disease is to find simple ways of treating HIV itself, and thus contain the worst ravages of this illness.", [["HIV infection", "DISEASE", 42, 55], ["HIV", "DISEASE", 138, 141], ["HIV", "ORGANISM", 42, 45], ["HIV", "ORGANISM", 138, 141], ["HIV", "SPECIES", 42, 45], ["HIV", "SPECIES", 138, 141], ["HIV", "SPECIES", 42, 45], ["HIV", "SPECIES", 138, 141], ["HIV infection", "PROBLEM", 42, 55], ["this disease", "PROBLEM", 90, 102], ["treating HIV itself", "PROBLEM", 129, 148], ["this illness", "PROBLEM", 188, 200], ["huge", "OBSERVATION_MODIFIER", 10, 14], ["infection", "OBSERVATION", 46, 55]]]], "PMC7472684": [["IntroductionThe manufacturing industry can directly reflect a country\u2019s productivity level, and energy is an important material basis for human survival and development.", [["human", "ORGANISM", 138, 143], ["human", "SPECIES", 138, 143], ["human", "SPECIES", 138, 143], ["human survival", "TREATMENT", 138, 152]]], ["According to Ref National bureau of statistics (2002), in the past decade, the total energy consumption of the manufacturing industry has been on a steady trend, accounting for about 57% of the total energy consumption of the whole country; however, the gross domestic product (GDP) of the manufacturing industry only accounts for about 31% of the total, showing a sharp downward trend.", [["GDP", "CHEMICAL", 278, 281], ["a sharp downward trend", "PROBLEM", 363, 385]]], ["It shows that the energy consumed by the manufacturing industry is not proportional to its contribution to the national GDP, and the consumption structure of the manufacturing energy needs to be further improved.IntroductionNatural gas is a kind of high-quality, efficient, and clean low-carbon energy.", [["GDP", "CHEMICAL", 120, 123], ["GDP", "CHEMICAL", 120, 123], ["carbon", "CHEMICAL", 288, 294], ["GDP", "SIMPLE_CHEMICAL", 120, 123], ["the national GDP", "TEST", 107, 123], ["improved", "OBSERVATION_MODIFIER", 203, 211], ["carbon energy", "OBSERVATION", 288, 301]]], ["With the reform of natural gas prices and the vigorous promotion of natural gas development in the 13th five-year plan, the development of natural gas will usher in historic opportunities.", [["natural gas prices", "TREATMENT", 19, 37], ["gas prices", "OBSERVATION", 27, 37], ["vigorous", "OBSERVATION_MODIFIER", 46, 54], ["natural gas", "OBSERVATION", 68, 79], ["natural gas", "OBSERVATION", 139, 150]]], ["According to Ref National bureau of statistics (2002), in the past decade, the consumption of natural gas in the manufacturing industry has been on an upward trend, accounting for about 40% of the national consumption of natural gas, indicating that the 18th national congress of the communist party of China proposed to vigorously promote the construction of ecological civilization and play a positive role in promoting the use of natural gas; however, the consumption of natural gas in manufacturing industry only accounts for about 0.34% of the total energy consumption in the manufacturing industry, and the natural gas consumption of manufacturing industry accounts for less than 0.4% of manufacturing GDP.", [["GDP", "CHEMICAL", 708, 711], ["GDP", "CHEMICAL", 708, 711], ["GDP", "SIMPLE_CHEMICAL", 708, 711], ["natural gas", "PROBLEM", 94, 105], ["ecological civilization", "TREATMENT", 360, 383], ["natural gas", "OBSERVATION", 94, 105], ["natural gas", "OBSERVATION", 221, 232]]], ["It shows that the government\u2019s actions on the development of the natural gas manufacturing industry still needs to be accelerated.", [["the natural gas manufacturing industry", "TREATMENT", 61, 99]]], ["As a consequence, China is in the stage of reforming the energy consumption system, and the situation of the market and economics is changing fast.", [["energy consumption", "OBSERVATION", 57, 75]]], ["Thus a tool which is efficient in dealing with uncertainties with small samples is needed.IntroductionGrey system theory proposed by Deng is such a tool which is available to deal with the problems described above (Ref Julong (1986)), in which the grey models play a key role.", [["small samples", "TREATMENT", 66, 79]]], ["Unlike the white box models, such as the differential equations in Refs Wang et al. (2019), or the black box models, like the machine learning models in Refs Yang et al. (2019), Pei et al. (2019), Fan et al. (2019), the grey models essentially try to combine the merits of these models in order to take most advantages of the infomation.", [["the white box models", "PROBLEM", 7, 27], ["the black box models", "PROBLEM", 95, 115], ["these models", "TREATMENT", 273, 285]]], ["Moreover,it was proved to be very efficient in small sample modeling for time series forecasting in Ref Lifeng et al. (2013).", [["small", "OBSERVATION_MODIFIER", 47, 52]]], ["Within such priority, the grey models have been applied in a wide variety of fields in recent years, such as dollar to euro price forecasting in Ref Kayacan et al. (2010), passenger demand growth forecasting in the air transportation industry in Ref Ben\u00edtez et al. (2013), the actual cost and the cost at completion of a project forecasting in Ref San Crist\u00f3bal et al. (2015), the scrapped vehicles forecasting in Ref Ene and \u00d6zt\u00fcrk (2017), short-term freeway traffic parameter prediction in Ref Bezuglov and Comert (2016) , the e-waste in Washington in Ref Duman et al. (2019), total natural gas consumption forecasting in Ref Zeng et al. (2020), pollutant forecasting in Xiong et al. (2020), traffic flow prediction Ref Xiao et al. (2020), etc. But it was also pointed out by Wu that the conventional grey models based on first-order accumulation is not flexible enough to deal with more complex sequences; thus the fractional order accumulation was introduced for grey models in Ref Lifeng et al. (2013).", [["total natural gas consumption", "TREATMENT", 579, 608], ["the conventional grey models", "TEST", 786, 814], ["the fractional order accumulation", "PROBLEM", 914, 947]]], ["A series of theoretical analysis was also provided in the following research, such as the sensitivity of initial condition in Ref Lifeng et al. (2015), ability of mining new information in Ref Lifeng and Bin (2017).", [["theoretical analysis", "TEST", 12, 32]]], ["Within such advantages the fractional grey models soon become popular and were applied in many new fields in recent years, such as transaction counts forecasting in Ref Gatabazi et al. (2019), and even the new coronavirus (COVID-19) cases forecasting in Ref Utkucan and Tezcan (2020).IntroductionOn the other hand, the fractional order grey models are also suitable for energy forecasting with its high flexibility and effectiveness in small sample modeling.", [["coronavirus", "DISEASE", 210, 221], ["coronavirus", "ORGANISM", 210, 221], ["the fractional grey models", "PROBLEM", 23, 49], ["small sample modeling", "PROBLEM", 436, 457], ["new", "OBSERVATION_MODIFIER", 95, 98], ["small", "OBSERVATION_MODIFIER", 436, 441]]], ["Wu et al. proposed the FGM(1,1) and made a more accurate prediction of the coal mine drainage volume in Ref Lifeng et al. (2014).", [["coal", "CHEMICAL", 75, 79], ["the coal mine drainage volume", "TREATMENT", 71, 100], ["drainage volume", "OBSERVATION", 85, 100]]], ["Wang et al. established a novel hybrid forecasting model based on an improved grey forecasting mode optimized by a multi-objective ant lion optimization algorithm and solved the problem of accuracy and stability of annual power consumption data in Ref Wang et al. (2018).", [["a multi-objective ant lion optimization algorithm", "TREATMENT", 113, 162], ["accuracy", "TEST", 189, 197]]], ["Wu et al. used the GM(1,1) model with the fractional order accumulation (FGM(1,1)) to predict the future trend of air quality, and the results can be directly exploited in the decision-making processes for air quality management in Ref Lifeng et al. (2018).", [["GM", "CHEMICAL", 19, 21], ["the GM(1,1) model", "TREATMENT", 15, 32], ["air quality management", "TREATMENT", 206, 228], ["air quality", "OBSERVATION", 114, 125]]], ["Moonchai et al. proposed a novel method based on the modification of the multivariate grey forecasting model and applied it to the consumption forecast of renewable energy in Ref Moonchai and Chutsagulprom (2020).", [["a novel method", "TREATMENT", 25, 39]]], ["Based on the new information priority principle and combined with grey buffer operator technology, Zeng B. realized the scientific forecast of shale gas production in my country in Ref Zeng et al. (2020).", [["grey buffer operator technology", "TREATMENT", 66, 97]]], ["Utkucan S. built a fractional nonlinear grey Bernoulli model, briefly as FANGBM(1,1) to forecast of Turkey\u2019s total renewable and hydro energy in Ref \u015eahin (2020).IntroductionHowever, it should be noticed that the existing fractional order grey models only use a unified fractional order.", [["a fractional nonlinear grey Bernoulli model", "PROBLEM", 17, 60], ["a unified fractional order", "TREATMENT", 260, 286], ["grey Bernoulli", "OBSERVATION", 40, 54]]], ["As will be discussed in this work, such operation will limit the advantages of the fractional order accumulation, leading to less flexibility of the fractional grey models.", [["such operation", "TREATMENT", 35, 49], ["fractional grey models", "OBSERVATION", 149, 171]]], ["Io present a more flexible modeling formulation, a time-delayed fractional discrete grey model with multiple fractional orders (TDF-", [["TDF-", "CHEMICAL", 128, 132], ["a more flexible modeling formulation", "TREATMENT", 11, 47]]]], "PMC7481835": [["Faced with a new disease, clinicians understandably resort to what they know.", [["a new disease", "PROBLEM", 11, 24], ["new", "OBSERVATION_MODIFIER", 13, 16], ["disease", "OBSERVATION", 17, 24]]], ["For example, we know severe viral pneumonia secondary to influenza, so when we began seeing COVID-19, our first impression was that it was a similar disease, so we felt we knew how to manage it.", [["pneumonia", "DISEASE", 34, 43], ["influenza", "DISEASE", 57, 66], ["severe viral pneumonia", "PROBLEM", 21, 43], ["influenza", "PROBLEM", 57, 66], ["a similar disease", "PROBLEM", 139, 156], ["severe", "OBSERVATION_MODIFIER", 21, 27], ["viral", "OBSERVATION_MODIFIER", 28, 33], ["pneumonia", "OBSERVATION", 34, 43], ["influenza", "OBSERVATION", 57, 66]]], ["However, it soon became clear that COVID-19 was strikingly different.", [["COVID-19", "CHEMICAL", 35, 43], ["COVID", "TEST", 35, 40]]], ["First, there was the high transmission rate including spread within hospitals and health care workers 1\u2014but this could simply have been due to a new disease in a na\u00efve population.", [["a new disease", "PROBLEM", 143, 156], ["new", "OBSERVATION_MODIFIER", 145, 148], ["disease", "OBSERVATION", 149, 156]]], ["After all, influenza is also quite contagious.", [["influenza", "DISEASE", 11, 20], ["influenza", "PROBLEM", 11, 20], ["influenza", "OBSERVATION", 11, 20]]], ["Second, the numbers of patients with severe disease also seemed significantly greater, but this too could simply have been a function of the overall number of infected patients.", [["patients", "ORGANISM", 23, 31], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 23, 31], ["patients", "SPECIES", 168, 176], ["severe disease", "PROBLEM", 37, 51], ["severe", "OBSERVATION_MODIFIER", 37, 43], ["disease", "OBSERVATION", 44, 51], ["significantly", "OBSERVATION_MODIFIER", 64, 77], ["greater", "OBSERVATION_MODIFIER", 78, 85], ["infected", "OBSERVATION", 159, 167]]], ["We now know that at least 80% of patients with COVID-19 have mild or even asymptomatic disease and the majority of patients who develop critical illness with COVID-19 are over 70 years of age, suffer from underlying disease or both.", [["patients", "ORGANISM", 33, 41], ["patients", "ORGANISM", 115, 123], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 115, 123], ["COVID", "TEST", 47, 52], ["mild or even asymptomatic disease", "PROBLEM", 61, 94], ["critical illness", "PROBLEM", 136, 152], ["COVID", "TEST", 158, 163], ["underlying disease", "PROBLEM", 205, 223], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["asymptomatic", "OBSERVATION_MODIFIER", 74, 86], ["disease", "OBSERVATION", 87, 94], ["disease", "OBSERVATION", 216, 223]]], ["Still, we are seeing cases of severe COVID-19 across all age groups and occasionally in the previously healthy.", [["COVID", "DISEASE", 37, 42], ["severe COVID", "PROBLEM", 30, 42]]], ["Overall case-fatality rates from COVID-19 have ranged from 1-10%, making it much worse than seasonal influenza but not nearly as deadly as the two other novel beta-corona virus infections from the past\u2014Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS).", [["influenza", "DISEASE", 101, 110], ["infections", "DISEASE", 177, 187], ["acute respiratory syndrome", "DISEASE", 209, 235], ["SARS", "DISEASE", 237, 241], ["Middle East respiratory syndrome", "DISEASE", 247, 279], ["MERS", "DISEASE", 281, 285], ["beta-corona virus", "ORGANISM", 159, 176], ["beta-corona virus", "SPECIES", 159, 176], ["Middle East respiratory syndrome (MERS)", "SPECIES", 247, 286], ["fatality rates", "TEST", 13, 27], ["COVID", "TEST", 33, 38], ["seasonal influenza", "PROBLEM", 92, 110], ["the two other novel beta-corona virus infections", "PROBLEM", 139, 187], ["Severe acute respiratory syndrome", "PROBLEM", 202, 235], ["SARS)", "PROBLEM", 237, 242], ["Middle East respiratory syndrome", "PROBLEM", 247, 279], ["influenza", "OBSERVATION", 101, 110], ["acute", "OBSERVATION_MODIFIER", 209, 214], ["respiratory syndrome", "OBSERVATION", 215, 235], ["Middle", "ANATOMY_MODIFIER", 247, 253], ["respiratory syndrome", "OBSERVATION", 259, 279]]]], "PMC7137076": [["In the past decade, scientific and health systems have been challenged by an increase in the emergence of infectious diseases such as Middle East respiratory syndrome coronavirus, chikungunya, Ebola virus disease, and Zika virus.1, 2, 3, 4 An effective and global public health response to these crises depends on our ability to anticipate these events and our level of preparedness.", [["infectious diseases", "DISEASE", 106, 125], ["Middle East respiratory syndrome coronavirus", "DISEASE", 134, 178], ["chikungunya", "DISEASE", 180, 191], ["Ebola virus disease", "DISEASE", 193, 212], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 134, 178], ["Ebola virus", "ORGANISM", 193, 204], ["Zika virus", "ORGANISM", 218, 228], ["Ebola virus", "SPECIES", 193, 204], ["Zika virus", "SPECIES", 218, 228], ["Middle East respiratory syndrome coronavirus", "SPECIES", 134, 178], ["Ebola virus", "SPECIES", 193, 204], ["Zika virus", "SPECIES", 218, 228], ["infectious diseases", "PROBLEM", 106, 125], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 134, 178], ["chikungunya", "PROBLEM", 180, 191], ["Ebola virus disease", "PROBLEM", 193, 212], ["Zika virus", "PROBLEM", 218, 228], ["these crises", "PROBLEM", 290, 302], ["these events", "PROBLEM", 340, 352], ["increase", "OBSERVATION_MODIFIER", 77, 85], ["infectious", "OBSERVATION", 106, 116], ["Middle", "ANATOMY_MODIFIER", 134, 140], ["respiratory syndrome coronavirus", "OBSERVATION", 146, 178], ["Ebola virus disease", "OBSERVATION", 193, 212]]], ["However, the development of research programmes in response to a rapidly emerging infectious disease in an emergency context is a challenge.", [["infectious disease", "DISEASE", 82, 100], ["a rapidly emerging infectious disease", "PROBLEM", 63, 100], ["infectious", "OBSERVATION", 82, 92]]], ["Any delay in the response can result in serious consequences for the evolution of the crisis.5", [["Any delay", "PROBLEM", 0, 9], ["the crisis", "PROBLEM", 82, 92], ["crisis", "OBSERVATION", 86, 92]]]], "8aba6975d8bd8819c2490dedf131893850f5aa1c": [["IntroductionMesenchymal stem cells (MSCs) are adult stem cells that can be isolated from many tissues, and they have different types, such as chondrocyte, adipocyte or osteocyte (El, 2011) .", [["Mesenchymal stem cells", "ANATOMY", 12, 34], ["MSCs", "ANATOMY", 36, 40], ["adult stem cells", "ANATOMY", 46, 62], ["tissues", "ANATOMY", 94, 101], ["chondrocyte", "ANATOMY", 142, 153], ["adipocyte", "ANATOMY", 155, 164], ["osteocyte", "ANATOMY", 168, 177], ["Mesenchymal stem cells", "CELL", 12, 34], ["MSCs", "CELL", 36, 40], ["adult stem cells", "CELL", 46, 62], ["tissues", "TISSUE", 94, 101], ["chondrocyte", "CELL", 142, 153], ["adipocyte", "CELL", 155, 164], ["osteocyte", "CELL", 168, 177], ["Mesenchymal stem cells", "CELL_TYPE", 12, 34], ["MSCs", "CELL_TYPE", 36, 40], ["adult stem cells", "CELL_TYPE", 46, 62], ["adipocyte", "CELL_TYPE", 155, 164], ["IntroductionMesenchymal stem cells (MSCs", "TREATMENT", 0, 40], ["adult stem cells", "PROBLEM", 46, 62], ["Mesenchymal stem cells", "OBSERVATION", 12, 34], ["stem cells", "OBSERVATION", 52, 62], ["different types", "OBSERVATION_MODIFIER", 117, 132], ["adipocyte", "ANATOMY", 155, 164], ["osteocyte", "ANATOMY", 168, 177]]], ["MSCs also have strong immunomodulation abilities; e.g., they suppress immune cells through the secretion of cytokines, such as prostaglandin E2 (PGE2), indoleamine 2,3 dioxygenase (IDO), hepatocyte growth factor (HGF), and soluble human leukocyte antigen G (sHLA-G) and transform growth factor beta (TGF-b) and interleukin 10 (IL-10) (Budoni et al., 2013; \u00d6zdemir et al., 2016) .", [["MSCs", "ANATOMY", 0, 4], ["immune cells", "ANATOMY", 70, 82], ["prostaglandin E2", "CHEMICAL", 127, 143], ["PGE2", "CHEMICAL", 145, 149], ["indoleamine", "CHEMICAL", 152, 163], ["prostaglandin E2", "CHEMICAL", 127, 143], ["PGE2", "CHEMICAL", 145, 149], ["indoleamine", "CHEMICAL", 152, 163], ["MSCs", "CELL", 0, 4], ["immune cells", "CELL", 70, 82], ["prostaglandin E2", "SIMPLE_CHEMICAL", 127, 143], ["PGE2", "SIMPLE_CHEMICAL", 145, 149], ["indoleamine 2,3 dioxygenase", "GENE_OR_GENE_PRODUCT", 152, 179], ["IDO", "GENE_OR_GENE_PRODUCT", 181, 184], ["hepatocyte growth factor", "GENE_OR_GENE_PRODUCT", 187, 211], ["HGF", "GENE_OR_GENE_PRODUCT", 213, 216], ["human leukocyte antigen G", "GENE_OR_GENE_PRODUCT", 231, 256], ["HLA-G", "GENE_OR_GENE_PRODUCT", 259, 264], ["transform growth factor beta", "GENE_OR_GENE_PRODUCT", 270, 298], ["TGF-b", "GENE_OR_GENE_PRODUCT", 300, 305], ["interleukin 10", "GENE_OR_GENE_PRODUCT", 311, 325], ["IL-10", "GENE_OR_GENE_PRODUCT", 327, 332], ["MSCs", "CELL_TYPE", 0, 4], ["immune cells", "CELL_TYPE", 70, 82], ["cytokines", "PROTEIN", 108, 117], ["prostaglandin E2", "PROTEIN", 127, 143], ["PGE2", "PROTEIN", 145, 149], ["indoleamine 2,3 dioxygenase", "PROTEIN", 152, 179], ["IDO", "PROTEIN", 181, 184], ["hepatocyte growth factor", "PROTEIN", 187, 211], ["HGF", "PROTEIN", 213, 216], ["soluble human leukocyte antigen G", "PROTEIN", 223, 256], ["HLA", "PROTEIN", 259, 262], ["TGF", "PROTEIN", 300, 303], ["interleukin 10", "PROTEIN", 311, 325], ["human", "SPECIES", 231, 236], ["human", "SPECIES", 231, 236], ["MSCs", "PROBLEM", 0, 4], ["strong immunomodulation abilities", "PROBLEM", 15, 48], ["immune cells", "PROBLEM", 70, 82], ["cytokines", "TREATMENT", 108, 117], ["prostaglandin E2 (PGE2", "TREATMENT", 127, 149], ["indoleamine 2,3 dioxygenase (IDO)", "TEST", 152, 185], ["hepatocyte growth factor", "TEST", 187, 211], ["HGF", "TEST", 213, 216], ["soluble human leukocyte antigen", "TEST", 223, 254], ["G", "TEST", 255, 256], ["HLA", "TEST", 259, 262], ["G", "TEST", 263, 264], ["transform growth", "TEST", 270, 286], ["beta", "TEST", 294, 298], ["TGF", "TEST", 300, 303], ["interleukin", "TEST", 311, 322], ["IL", "TEST", 327, 329], ["strong", "OBSERVATION_MODIFIER", 15, 21], ["immunomodulation", "OBSERVATION", 22, 38], ["hepatocyte", "ANATOMY", 187, 197]]], ["Due to these unique properties, MSCs are clinically used in the treatment of graft versus host disease (GVHD) caused by uncontrolled activation of immune cells (Sangiorgi and Panepucci, 2016) and certain autoimmune diseases, including rheumatoid arthritis (RA), Crohn's disease, and systemic lupus erythematosus (SLE) (Dazzi and Krampera, 2011) .", [["MSCs", "ANATOMY", 32, 36], ["graft", "ANATOMY", 77, 82], ["immune cells", "ANATOMY", 147, 159], ["graft versus host disease", "DISEASE", 77, 102], ["GVHD", "DISEASE", 104, 108], ["autoimmune diseases", "DISEASE", 204, 223], ["rheumatoid arthritis", "DISEASE", 235, 255], ["RA", "DISEASE", 257, 259], ["Crohn's disease", "DISEASE", 262, 277], ["systemic lupus erythematosus", "DISEASE", 283, 311], ["SLE", "DISEASE", 313, 316], ["MSCs", "CELL", 32, 36], ["graft", "TISSUE", 77, 82], ["immune cells", "CELL", 147, 159], ["MSCs", "CELL_TYPE", 32, 36], ["immune cells", "CELL_TYPE", 147, 159], ["MSCs", "PROBLEM", 32, 36], ["graft versus host disease", "PROBLEM", 77, 102], ["GVHD", "PROBLEM", 104, 108], ["uncontrolled activation of immune cells", "PROBLEM", 120, 159], ["certain autoimmune diseases", "PROBLEM", 196, 223], ["rheumatoid arthritis", "PROBLEM", 235, 255], ["Crohn's disease", "PROBLEM", 262, 277], ["systemic lupus erythematosus", "PROBLEM", 283, 311], ["graft versus host disease", "OBSERVATION", 77, 102], ["immune cells", "OBSERVATION", 147, 159], ["autoimmune diseases", "OBSERVATION", 204, 223], ["rheumatoid arthritis", "OBSERVATION", 235, 255], ["RA", "ANATOMY", 257, 259], ["Crohn", "OBSERVATION", 262, 267], ["systemic", "OBSERVATION_MODIFIER", 283, 291], ["lupus erythematosus", "OBSERVATION", 292, 311]]], ["However, the clinical responses of patients to MSC treatment are variable, ranging from good responses to only temporary or no effect (Mastri et al., 2014; Silva et al., 2018) .", [["MSC", "ANATOMY", 47, 50], ["patients", "ORGANISM", 35, 43], ["MSC", "CELL", 47, 50], ["MSC", "CELL_TYPE", 47, 50], ["patients", "SPECIES", 35, 43], ["MSC treatment", "TREATMENT", 47, 60]]], ["The immunomodulatory effects of MSCs occur in a non-specific and nonselective manner.", [["MSCs", "ANATOMY", 32, 36], ["MSCs", "CELL", 32, 36], ["MSCs", "CELL_TYPE", 32, 36], ["MSCs", "PROBLEM", 32, 36], ["immunomodulatory effects", "OBSERVATION", 4, 28]]], ["When MSCs are activated, they produce certain cytokines, such as PGE2, IDO, HGF, TGF-b and IL-10, which suppress almost all immune cells (El, 2011; \u00d6zdemir et al., 2016; Cho et al., 2014) .", [["MSCs", "ANATOMY", 5, 9], ["immune cells", "ANATOMY", 124, 136], ["PGE2", "CHEMICAL", 65, 69], ["PGE2", "CHEMICAL", 65, 69], ["MSCs", "CELL", 5, 9], ["PGE2", "GENE_OR_GENE_PRODUCT", 65, 69], ["IDO", "GENE_OR_GENE_PRODUCT", 71, 74], ["HGF", "GENE_OR_GENE_PRODUCT", 76, 79], ["TGF-b", "GENE_OR_GENE_PRODUCT", 81, 86], ["IL-10", "GENE_OR_GENE_PRODUCT", 91, 96], ["immune cells", "CELL", 124, 136], ["MSCs", "CELL_TYPE", 5, 9], ["cytokines", "PROTEIN", 46, 55], ["PGE2", "PROTEIN", 65, 69], ["IDO", "PROTEIN", 71, 74], ["HGF", "PROTEIN", 76, 79], ["TGF-b and IL-10", "PROTEIN", 81, 96], ["immune cells", "CELL_TYPE", 124, 136], ["PGE2", "TEST", 65, 69], ["IDO", "TEST", 71, 74], ["HGF", "TEST", 76, 79], ["TGF", "TEST", 81, 84], ["IL", "TEST", 91, 93]]], ["However, this suppressive effect only lasts for the lifespan of MSCs.", [["MSCs", "ANATOMY", 64, 68], ["MSCs", "CELL", 64, 68], ["MSCs", "CELL_TYPE", 64, 68], ["the lifespan of MSCs", "TREATMENT", 48, 68]]], ["In both pathogen-related infections and autoimmune pathologies, antigen presentation is a crucial step for T cell activation and lineage specific differentiation.", [["T cell", "ANATOMY", 107, 113], ["infections", "DISEASE", 25, 35], ["autoimmune pathologies", "DISEASE", 40, 62], ["T cell", "CELL", 107, 113], ["related infections", "PROBLEM", 17, 35], ["autoimmune pathologies", "PROBLEM", 40, 62], ["T cell activation", "PROBLEM", 107, 124], ["both", "OBSERVATION_MODIFIER", 3, 7], ["pathogen", "OBSERVATION", 8, 16], ["infections", "OBSERVATION", 25, 35]]], ["During T cell activation, antigen-specific memory cells are formed, resulting in a life-long response (Berard and Tough, 2002; Gray et al., 1991) .", [["T cell", "ANATOMY", 7, 13], ["memory cells", "ANATOMY", 43, 55], ["T cell", "CELL", 7, 13], ["antigen", "GENE_OR_GENE_PRODUCT", 26, 33], ["memory cells", "CELL", 43, 55], ["memory cells", "CELL_TYPE", 43, 55], ["T cell activation", "TEST", 7, 24], ["antigen", "TEST", 26, 33], ["memory cells", "OBSERVATION", 43, 55]]], ["To gain a sustainable immune response, T cells should be activated or inhibited by antigen-presenting cells.", [["T cells", "ANATOMY", 39, 46], ["cells", "ANATOMY", 102, 107], ["T cells", "CELL", 39, 46], ["cells", "CELL", 102, 107], ["T cells", "CELL_TYPE", 39, 46], ["antigen-presenting cells", "CELL_TYPE", 83, 107], ["T cells", "PROBLEM", 39, 46]]], ["MSCs are not antigen-presenting cells, and under normal conditions, their major histocompatibility antigen expressions (MHC) are either weak or absent (Dominici et al., 2006; Shi et al., 2018) .IntroductionMacrophages are a part of innate immunity, and they play important roles in the antigen presentation and the regulation of immune response.", [["MSCs", "ANATOMY", 0, 4], ["cells", "ANATOMY", 32, 37], ["Macrophages", "ANATOMY", 206, 217], ["MSCs", "CELL", 0, 4], ["cells", "CELL", 32, 37], ["major histocompatibility antigen", "GENE_OR_GENE_PRODUCT", 74, 106], ["Macrophages", "CELL", 206, 217], ["MSCs", "CELL_TYPE", 0, 4], ["antigen-presenting cells", "CELL_TYPE", 13, 37], ["major histocompatibility antigen", "PROTEIN", 74, 106], ["MHC", "PROTEIN", 120, 123], ["Macrophages", "CELL_TYPE", 206, 217], ["MSCs", "PROBLEM", 0, 4], ["immune response", "OBSERVATION", 329, 344]]], ["According to the exposed type of cytokine and antigen, macrophages can alter their phenotype and function.", [["macrophages", "ANATOMY", 55, 66], ["macrophages", "CELL", 55, 66], ["cytokine", "PROTEIN", 33, 41], ["macrophages", "CELL_TYPE", 55, 66]]], ["It has been shown that IFN-g, LPS and TNF-a stimulation leads to the upregulation of MHC-II, CD80 and CD64 expressions of the cell surface and an increase in iNOS, IL-1b, IL-12 and IL-6 production of macrophages.", [["cell surface", "ANATOMY", 126, 138], ["macrophages", "ANATOMY", 200, 211], ["LPS", "CHEMICAL", 30, 33], ["IFN-g", "GENE_OR_GENE_PRODUCT", 23, 28], ["LPS", "SIMPLE_CHEMICAL", 30, 33], ["TNF", "GENE_OR_GENE_PRODUCT", 38, 41], ["MHC-II", "GENE_OR_GENE_PRODUCT", 85, 91], ["CD80", "GENE_OR_GENE_PRODUCT", 93, 97], ["CD64", "GENE_OR_GENE_PRODUCT", 102, 106], ["cell surface", "CELLULAR_COMPONENT", 126, 138], ["iNOS", "GENE_OR_GENE_PRODUCT", 158, 162], ["IL-1b", "GENE_OR_GENE_PRODUCT", 164, 169], ["IL-12", "GENE_OR_GENE_PRODUCT", 171, 176], ["IL-6", "GENE_OR_GENE_PRODUCT", 181, 185], ["macrophages", "CELL", 200, 211], ["IFN", "PROTEIN", 23, 26], ["TNF", "PROTEIN", 38, 41], ["MHC-II", "PROTEIN", 85, 91], ["CD80", "PROTEIN", 93, 97], ["CD64", "PROTEIN", 102, 106], ["iNOS", "PROTEIN", 158, 162], ["macrophages", "CELL_TYPE", 200, 211], ["IFN", "TEST", 23, 26], ["LPS", "TEST", 30, 33], ["TNF", "TEST", 38, 41], ["a stimulation", "TREATMENT", 42, 55], ["CD80", "TEST", 93, 97], ["CD64 expressions", "TEST", 102, 118], ["the cell surface", "TEST", 122, 138], ["iNOS", "TEST", 158, 162], ["IL", "TEST", 164, 166], ["IL", "TEST", 171, 173], ["IL", "TREATMENT", 181, 183], ["macrophages", "PROBLEM", 200, 211], ["CD80", "ANATOMY", 93, 97], ["increase", "OBSERVATION_MODIFIER", 146, 154], ["iNOS", "OBSERVATION", 158, 162], ["macrophages", "ANATOMY", 200, 211]]], ["This type of macrophages is called M1, which activate Th1 immune cells important to the immune response of intracellular pathogens and tumor resistance (Ambarus et al., 2012; Martinez and Gordon, 2014) .", [["macrophages", "ANATOMY", 13, 24], ["M1", "ANATOMY", 35, 37], ["Th1 immune cells", "ANATOMY", 54, 70], ["intracellular", "ANATOMY", 107, 120], ["tumor", "ANATOMY", 135, 140], ["tumor", "DISEASE", 135, 140], ["macrophages", "CELL", 13, 24], ["M1", "CELL", 35, 37], ["Th1 immune cells", "CELL", 54, 70], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 107, 120], ["tumor", "CANCER", 135, 140], ["macrophages", "CELL_TYPE", 13, 24], ["Th1 immune cells", "CELL_TYPE", 54, 70], ["intracellular pathogens", "PROBLEM", 107, 130], ["tumor resistance", "PROBLEM", 135, 151], ["macrophages", "OBSERVATION", 13, 24], ["intracellular pathogens", "OBSERVATION", 107, 130], ["tumor resistance", "OBSERVATION", 135, 151]]], ["Another macrophage group, called M2 macrophages, antagonize the effects of M1 macrophages.", [["macrophage", "ANATOMY", 8, 18], ["M2 macrophages", "ANATOMY", 33, 47], ["M1 macrophages", "ANATOMY", 75, 89], ["macrophage", "CELL", 8, 18], ["M2 macrophages", "CELL", 33, 47], ["M1 macrophages", "CELL", 75, 89], ["M2 macrophages", "CELL_LINE", 33, 47], ["M1 macrophages", "CELL_TYPE", 75, 89]]], ["M2 macrophages are further divided into the subgroups of M2a, M2b and M2c according to cytokine and antigen stimulation.", [["M2 macrophages", "ANATOMY", 0, 14], ["M2 macrophages", "CELL", 0, 14], ["M2a", "GENE_OR_GENE_PRODUCT", 57, 60], ["M2b", "GENE_OR_GENE_PRODUCT", 62, 65], ["M2c", "GENE_OR_GENE_PRODUCT", 70, 73], ["antigen", "GENE_OR_GENE_PRODUCT", 100, 107], ["M2 macrophages", "CELL_LINE", 0, 14], ["cytokine", "PROTEIN", 87, 95], ["cytokine and antigen stimulation", "TREATMENT", 87, 119]]], ["IL-4 stimulation is specific to the development of the M2a macrophage phenotype.", [["M2a macrophage", "ANATOMY", 55, 69], ["IL-4", "GENE_OR_GENE_PRODUCT", 0, 4], ["M2a macrophage", "CELL", 55, 69], ["IL-4", "PROTEIN", 0, 4], ["IL-4 stimulation", "TREATMENT", 0, 16], ["the M2a macrophage phenotype", "PROBLEM", 51, 79], ["M2a macrophage phenotype", "OBSERVATION", 55, 79]]], ["Through IL-4 stimulation, the cell surface expressions of CD200R and CD206 increase but CD14 decreases.", [["cell surface", "ANATOMY", 30, 42], ["IL-4", "GENE_OR_GENE_PRODUCT", 8, 12], ["cell", "CELL", 30, 34], ["CD200R", "GENE_OR_GENE_PRODUCT", 58, 64], ["CD206", "GENE_OR_GENE_PRODUCT", 69, 74], ["CD14", "GENE_OR_GENE_PRODUCT", 88, 92], ["IL", "PROTEIN", 8, 10], ["CD200R", "PROTEIN", 58, 64], ["CD206", "PROTEIN", 69, 74], ["CD14", "PROTEIN", 88, 92], ["IL-4 stimulation", "TREATMENT", 8, 24], ["the cell surface expressions", "TEST", 26, 54], ["CD200R", "TREATMENT", 58, 64], ["CD14 decreases", "PROBLEM", 88, 102]]], ["Furthermore, the production of Arginase and IL-10 increases (Ambarus et al., 2012; Van Dyken and Locksley, 2013) .", [["Arginase", "GENE_OR_GENE_PRODUCT", 31, 39], ["IL-10", "GENE_OR_GENE_PRODUCT", 44, 49], ["Arginase", "PROTEIN", 31, 39], ["IL", "PROTEIN", 44, 46], ["Arginase and IL", "TREATMENT", 31, 46]]], ["M2a macrophages are important for the activation of Th2 cells responsible for immune responses, including encapsulation of parasites and allergy (Martinez and Gordon, 2014; Martinez et al., 2009) .", [["M2a macrophages", "ANATOMY", 0, 15], ["Th2 cells", "ANATOMY", 52, 61], ["allergy", "DISEASE", 137, 144], ["M2a macrophages", "CELL", 0, 15], ["Th2 cells", "CELL", 52, 61], ["M2a macrophages", "CELL_TYPE", 0, 15], ["Th2 cells", "CELL_TYPE", 52, 61], ["M2a macrophages", "PROBLEM", 0, 15], ["Th2 cells", "PROBLEM", 52, 61], ["immune responses", "PROBLEM", 78, 94], ["parasites", "PROBLEM", 123, 132], ["allergy", "PROBLEM", 137, 144], ["Th2 cells", "OBSERVATION", 52, 61]]], ["For the emergence of the M2b phenotype, immune complexes and TLR stimulation are required.", [["M2b", "GENE_OR_GENE_PRODUCT", 25, 28], ["TLR", "GENE_OR_GENE_PRODUCT", 61, 64], ["immune complexes", "PROTEIN", 40, 56], ["TLR", "PROTEIN", 61, 64], ["the M2b phenotype", "TREATMENT", 21, 38], ["immune complexes", "TREATMENT", 40, 56], ["TLR stimulation", "TREATMENT", 61, 76]]], ["An appropriate stimulation would increase the IL-10 production of M2b cells but decrease IL-12 production (Anderson and Mosser, 2002; Sironi et al., 2006) .", [["M2b cells", "ANATOMY", 66, 75], ["IL-10", "GENE_OR_GENE_PRODUCT", 46, 51], ["M2b cells", "CELL", 66, 75], ["IL-12", "GENE_OR_GENE_PRODUCT", 89, 94], ["IL", "PROTEIN", 46, 48], ["M2b cells", "CELL_LINE", 66, 75], ["IL", "PROTEIN", 89, 91], ["An appropriate stimulation", "TREATMENT", 0, 26], ["the IL-10 production of M2b cells", "TREATMENT", 42, 75]]], ["M2c is another subset of M2 macrophages, which are activated by IL-10 stimulation.", [["M2 macrophages", "ANATOMY", 25, 39], ["M2c", "GENE_OR_GENE_PRODUCT", 0, 3], ["M2 macrophages", "CELL", 25, 39], ["IL-10", "GENE_OR_GENE_PRODUCT", 64, 69], ["M2c", "CELL_LINE", 0, 3], ["M2 macrophages", "CELL_TYPE", 25, 39], ["IL", "PROTEIN", 64, 66], ["M2 macrophages", "OBSERVATION", 25, 39]]], ["An increase in the CD163 and CD16 expressions and upregulation of IL-10 and TGF-b production caused by IL-10 stimuli, are specific to the M2c phenotype (Ambarus et al., 2012; Schwarz et al., 2013) .IntroductionIn the current literature, there are several studies showing that MSCs could inhibit pro-inflammatory M1 macrophages and stimulate anti-inflammatory M2 macrophages (Cho et al., 2014; Vasandan et al., 2016) .", [["MSCs", "ANATOMY", 276, 280], ["M1 macrophages", "ANATOMY", 312, 326], ["anti-inflammatory M2 macrophages", "ANATOMY", 341, 373], ["CD163", "GENE_OR_GENE_PRODUCT", 19, 24], ["CD16", "GENE_OR_GENE_PRODUCT", 29, 33], ["IL-10", "GENE_OR_GENE_PRODUCT", 66, 71], ["TGF-b", "GENE_OR_GENE_PRODUCT", 76, 81], ["IL-10", "GENE_OR_GENE_PRODUCT", 103, 108], ["MSCs", "CELL", 276, 280], ["M1 macrophages", "CELL", 312, 326], ["M2 macrophages", "CELL", 359, 373], ["CD163", "PROTEIN", 19, 24], ["CD16", "PROTEIN", 29, 33], ["TGF", "PROTEIN", 76, 79], ["IL", "PROTEIN", 103, 105], ["MSCs", "CELL_TYPE", 276, 280], ["pro-inflammatory M1 macrophages", "CELL_TYPE", 295, 326], ["anti-inflammatory M2 macrophages", "CELL_TYPE", 341, 373], ["the CD163", "TEST", 15, 24], ["CD16 expressions", "TEST", 29, 45], ["upregulation of IL", "TEST", 50, 68], ["TGF", "TEST", 76, 79], ["several studies", "TEST", 247, 262], ["MSCs", "PROBLEM", 276, 280], ["pro-inflammatory M1 macrophages", "PROBLEM", 295, 326], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["CD163", "OBSERVATION", 19, 24]]], ["However, it has not been yet fully clarified whether these differentiated macrophages are functional.", [["macrophages", "ANATOMY", 74, 85], ["macrophages", "CELL", 74, 85], ["differentiated macrophages", "CELL_TYPE", 59, 85], ["differentiated", "OBSERVATION_MODIFIER", 59, 73], ["macrophages", "OBSERVATION", 74, 85]]], ["As a professional antigen-presenting cell, te macrophages can help to transfer the immunomodulation effects of MSCs to the adaptive immune cells.", [["antigen-presenting cell", "ANATOMY", 18, 41], ["te macrophages", "ANATOMY", 43, 57], ["MSCs", "ANATOMY", 111, 115], ["immune cells", "ANATOMY", 132, 144], ["cell", "CELL", 37, 41], ["te macrophages", "CELL", 43, 57], ["MSCs", "CELL", 111, 115], ["immune cells", "CELL", 132, 144], ["professional antigen-presenting cell", "CELL_TYPE", 5, 41], ["macrophages", "CELL_TYPE", 46, 57], ["MSCs", "CELL_TYPE", 111, 115], ["adaptive immune cells", "CELL_TYPE", 123, 144], ["the immunomodulation effects of MSCs", "TREATMENT", 79, 115]]], ["In this study, we aimed to investigate the interactions of macrophage and MSCs, and the resulting effects of these interactions on CD4 T cells.", [["macrophage", "ANATOMY", 59, 69], ["MSCs", "ANATOMY", 74, 78], ["CD4 T cells", "ANATOMY", 131, 142], ["macrophage", "CELL", 59, 69], ["MSCs", "CELL", 74, 78], ["CD4 T cells", "CELL", 131, 142], ["macrophage", "CELL_TYPE", 59, 69], ["MSCs", "CELL_TYPE", 74, 78], ["CD4 T cells", "CELL_TYPE", 131, 142], ["this study", "TEST", 3, 13], ["macrophage and MSCs", "TREATMENT", 59, 78]]], ["For this purpose, we differentiated the macrophage cells into M1, M2a and M2c phenotypes to observe the effects on CD4 T cells with known macrophage phenotypes.", [["macrophage cells", "ANATOMY", 40, 56], ["M1", "ANATOMY", 62, 64], ["M2a", "ANATOMY", 66, 69], ["CD4 T cells", "ANATOMY", 115, 126], ["macrophage", "ANATOMY", 138, 148], ["macrophage cells", "CELL", 40, 56], ["M1", "CELL", 62, 64], ["M2a", "CELL", 66, 69], ["M2c", "CELL", 74, 77], ["CD4 T cells", "CELL", 115, 126], ["macrophage", "CELL", 138, 148], ["macrophage cells", "CELL_TYPE", 40, 56], ["CD4 T cells", "CELL_TYPE", 115, 126], ["M2c phenotypes", "PROBLEM", 74, 88], ["CD4 T cells", "PROBLEM", 115, 126], ["known macrophage phenotypes", "PROBLEM", 132, 159], ["macrophage cells", "OBSERVATION", 40, 56], ["M1", "ANATOMY", 62, 64], ["macrophage phenotypes", "OBSERVATION", 138, 159]]], ["In addition, we generated MSC-educated macrophage (MEM) cells by direct and indirect co-culture and compared their effects on CD4 T cells with known macrophage phenotypes.Material and methodsThe protocol, sample collection procedures and informed consent form of this study were approved by Ethical committee of Ege University (16-5.2/1).", [["MSC", "ANATOMY", 26, 29], ["macrophage", "ANATOMY", 39, 49], ["MEM) cells", "ANATOMY", 51, 61], ["CD4 T cells", "ANATOMY", 126, 137], ["macrophage", "ANATOMY", 149, 159], ["MSC", "CELL", 26, 29], ["macrophage (MEM) cells", "CELL", 39, 61], ["CD4 T cells", "CELL", 126, 137], ["macrophage", "CELL", 149, 159], ["MSC-educated macrophage (MEM) cells", "CELL_LINE", 26, 61], ["CD4 T cells", "CELL_TYPE", 126, 137], ["indirect co-culture", "TEST", 76, 95], ["CD4 T cells", "PROBLEM", 126, 137], ["known macrophage phenotypes", "PROBLEM", 143, 170], ["The protocol", "TREATMENT", 191, 203], ["sample collection procedures", "TEST", 205, 233], ["this study", "TEST", 263, 273], ["macrophage phenotypes", "OBSERVATION", 149, 170]]], ["To perform cell culture experiments, after informed consent blood samples collected from three female (23, 36 and 37 age) and three male (24, 27 and 39 age) healthy volunteers.", [["cell culture", "ANATOMY", 11, 23], ["blood samples", "ANATOMY", 60, 73], ["cell", "CELL", 11, 15], ["blood samples", "ORGANISM_SUBSTANCE", 60, 73], ["volunteers", "ORGANISM", 165, 175], ["cell culture experiments", "TEST", 11, 35], ["blood samples", "TEST", 60, 73]]], ["Peripheral blood mononuclear cells (PBMCs) were isolated by using density centrifugation (Ficoll-Paque) method.Cell cultureHuman adipose tissue derived MSCs (PCS-500-011\u2122) were purchased from American Type Culture Collection (ATCC).", [["Peripheral blood mononuclear cells", "ANATOMY", 0, 34], ["PBMCs", "ANATOMY", 36, 41], ["Cell cultureHuman adipose tissue", "ANATOMY", 111, 143], ["MSCs", "ANATOMY", 152, 156], ["PCS-500-011\u2122", "CHEMICAL", 158, 170], ["Peripheral blood mononuclear cells", "CELL", 0, 34], ["PBMCs", "CELL", 36, 41], ["Cell", "CELL", 111, 115], ["adipose tissue", "TISSUE", 129, 143], ["derived MSCs", "CELL", 144, 156], ["PCS-500-011\u2122", "CELL", 158, 170], ["Peripheral blood mononuclear cells", "CELL_TYPE", 0, 34], ["PBMCs", "CELL_TYPE", 36, 41], ["MSCs", "CELL_TYPE", 152, 156], ["Peripheral blood mononuclear cells", "TEST", 0, 34], ["PBMCs", "TEST", 36, 41], ["density centrifugation (Ficoll-Paque) method", "TREATMENT", 66, 110], ["Cell cultureHuman adipose tissue", "TEST", 111, 143], ["MSCs", "TEST", 152, 156], ["PCS", "TEST", 158, 161], ["blood", "ANATOMY", 11, 16], ["mononuclear cells", "OBSERVATION", 17, 34], ["adipose tissue", "OBSERVATION", 129, 143]]], ["Frozen cells were thawed in 37\u00b0C and cultured by using DMEM-F12 (Biosera, USA) medium that including 10% fetal bovine serum (FBS) (Biosera, USA), 100 U/ml penicillin, 100 \u03bcg/ml streptomycin (Biosera, USA) and 1% 2 mM L-glutamate (Biosera, USA) at 37\u00b0C and %5 CO2 incubator.", [["Frozen cells", "ANATOMY", 0, 12], ["fetal bovine serum", "ANATOMY", 105, 123], ["FBS", "ANATOMY", 125, 128], ["penicillin", "CHEMICAL", 155, 165], ["streptomycin", "CHEMICAL", 177, 189], ["L-glutamate", "CHEMICAL", 217, 228], ["penicillin", "CHEMICAL", 155, 165], ["streptomycin", "CHEMICAL", 177, 189], ["L-glutamate", "CHEMICAL", 217, 228], ["CO2", "CHEMICAL", 259, 262], ["Frozen cells", "CELL", 0, 12], ["C", "CELL", 31, 32], ["DMEM-F12", "CELL", 55, 63], ["bovine", "ORGANISM", 111, 117], ["serum", "ORGANISM_SUBSTANCE", 118, 123], ["FBS", "ORGANISM_SUBSTANCE", 125, 128], ["penicillin", "SIMPLE_CHEMICAL", 155, 165], ["streptomycin", "SIMPLE_CHEMICAL", 177, 189], ["L-glutamate", "SIMPLE_CHEMICAL", 217, 228], ["bovine", "SPECIES", 111, 117], ["bovine", "SPECIES", 111, 117], ["Frozen cells", "TEST", 0, 12], ["DMEM", "TEST", 55, 59], ["fetal bovine serum", "TEST", 105, 123], ["FBS", "TEST", 125, 128], ["penicillin", "TREATMENT", 155, 165], ["streptomycin", "TREATMENT", 177, 189]]], ["Cells were controlled daily, and sub cultured when they reached 70-80 % confluence.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["Cells", "TEST", 0, 5]]], ["3th passage MSCs were used to perform co-culture experiments.Cell cultureTo obtain macrophage cells from PBMCs, the cells of each subjects were cultured by using RPMI 1640 (Biosera, USA) medium that including 10% fetal bovine serum (FBS) (Biosera, USA), 100 U/ml penicillin, 100 \u03bcg/ml streptomycin (Biosera, USA) and 1% 2 mM L-glutamate (Biosera, USA) at 37\u00b0C and %5 CO2 incubator for 4 h.", [["MSCs", "ANATOMY", 12, 16], ["Cell", "ANATOMY", 61, 65], ["macrophage cells", "ANATOMY", 83, 99], ["PBMCs", "ANATOMY", 105, 110], ["cells", "ANATOMY", 116, 121], ["fetal bovine serum", "ANATOMY", 213, 231], ["FBS", "ANATOMY", 233, 236], ["penicillin", "CHEMICAL", 263, 273], ["streptomycin", "CHEMICAL", 285, 297], ["L-glutamate", "CHEMICAL", 325, 336], ["penicillin", "CHEMICAL", 263, 273], ["streptomycin", "CHEMICAL", 285, 297], ["L-glutamate", "CHEMICAL", 325, 336], ["CO2", "CHEMICAL", 367, 370], ["MSCs", "CELL", 12, 16], ["Cell", "CELL", 61, 65], ["macrophage cells", "CELL", 83, 99], ["PBMCs", "CELL", 105, 110], ["cells", "CELL", 116, 121], ["bovine", "ORGANISM", 219, 225], ["serum", "ORGANISM_SUBSTANCE", 226, 231], ["FBS", "ORGANISM_SUBSTANCE", 233, 236], ["penicillin", "SIMPLE_CHEMICAL", 263, 273], ["streptomycin", "SIMPLE_CHEMICAL", 285, 297], ["L-glutamate", "SIMPLE_CHEMICAL", 325, 336], ["3th passage MSCs", "CELL_LINE", 0, 16], ["macrophage cells", "CELL_TYPE", 83, 99], ["PBMCs", "CELL_TYPE", 105, 110], ["bovine", "SPECIES", 219, 225], ["bovine", "SPECIES", 219, 225], ["3th passage MSCs", "TREATMENT", 0, 16], ["co-culture experiments", "TEST", 38, 60], ["Cell cultureTo", "TEST", 61, 75], ["macrophage cells", "PROBLEM", 83, 99], ["PBMCs", "TEST", 105, 110], ["RPMI", "TEST", 162, 166], ["fetal bovine serum", "TEST", 213, 231], ["FBS", "TEST", 233, 236], ["penicillin", "TREATMENT", 263, 273], ["streptomycin", "TREATMENT", 285, 297], ["passage MSCs", "OBSERVATION", 4, 16], ["macrophage cells", "OBSERVATION", 83, 99]]], ["After the culture period, non-adherent cells were washed with phosphate-buffered saline (PBS) and cultured in different culture plate by using RPMI 1640 complete medium and 10 ng/ml human IL-2 (Reprokine Ltd, Israel) till to co-culture experiments.", [["cells", "ANATOMY", 39, 44], ["phosphate", "CHEMICAL", 62, 71], ["phosphate", "CHEMICAL", 62, 71], ["cells", "CELL", 39, 44], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 62, 87], ["human", "ORGANISM", 182, 187], ["IL-2", "GENE_OR_GENE_PRODUCT", 188, 192], ["non-adherent cells", "CELL_TYPE", 26, 44], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 182, 187], ["the culture", "TEST", 6, 17], ["non-adherent cells", "PROBLEM", 26, 44], ["phosphate-buffered saline (PBS", "TREATMENT", 62, 92], ["non-adherent cells", "OBSERVATION", 26, 44]]], ["Adherent cells were detached by Trypsin-EDTA (Biosera, USA) and divided as 3 \u00d7 10 5 cells per well in two 6 well plates.", [["cells", "ANATOMY", 9, 14], ["cells", "ANATOMY", 84, 89], ["Trypsin-EDTA", "CHEMICAL", 32, 44], ["EDTA", "CHEMICAL", 40, 44], ["Adherent cells", "CELL", 0, 14], ["Trypsin-EDTA", "SIMPLE_CHEMICAL", 32, 44], ["cells", "CELL", 84, 89], ["Adherent cells", "PROBLEM", 0, 14], ["Trypsin", "TEST", 32, 39], ["cells", "OBSERVATION", 9, 14]]], ["Cells were cultured by using RPMI 1640 complete medium and human 25 ng/ml macrophage colony-stimulating factor (M-CSF) (Reprokine Ltd, Israel) at 37\u00b0C and %5 CO2 incubator for 4 days.Cell cultureAfter the culture period, to stimulation of M1 macrophage phenotype different wells of each plates were cultured with RPMI 1640 complete medium and 50 ng/ml IFN-g (Reprokine Ltd, Israel), 50 ng/ml TNF-a (Reprokine Ltd, Israel) and 50 ng/ml GM-CSF (Reprokine Ltd, Israel), to M2a phenotype 50 ng/ml IL-4 (Reprokine Ltd, Israel) and to M2c 50 ng/ml IL-10 (Reprokine Ltd, Israel) and 50 ng/ml TGF-b1 (Reprokine Ltd, Israel).", [["Cells", "ANATOMY", 0, 5], ["Cell", "ANATOMY", 183, 187], ["M1 macrophage", "ANATOMY", 239, 252], ["GM", "CHEMICAL", 435, 437], ["CO2", "CHEMICAL", 158, 161], ["Cells", "CELL", 0, 5], ["human", "ORGANISM", 59, 64], ["macrophage colony-stimulating factor", "GENE_OR_GENE_PRODUCT", 74, 110], ["M-CSF", "GENE_OR_GENE_PRODUCT", 112, 117], ["Cell", "CELL", 183, 187], ["M1 macrophage", "CELL", 239, 252], ["Reprokine Ltd", "SIMPLE_CHEMICAL", 359, 372], ["Israel", "SIMPLE_CHEMICAL", 374, 380], ["TNF", "GENE_OR_GENE_PRODUCT", 392, 395], ["Reprokine Ltd", "SIMPLE_CHEMICAL", 399, 412], ["Israel", "SIMPLE_CHEMICAL", 414, 420], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 435, 441], ["M2a", "ORGANISM", 470, 473], ["IL-4", "SIMPLE_CHEMICAL", 493, 497], ["Reprokine Ltd", "SIMPLE_CHEMICAL", 499, 512], ["Israel", "SIMPLE_CHEMICAL", 514, 520], ["IL-10", "SIMPLE_CHEMICAL", 542, 547], ["Reprokine Ltd", "SIMPLE_CHEMICAL", 549, 562], ["Israel", "SIMPLE_CHEMICAL", 564, 570], ["TGF-b1", "GENE_OR_GENE_PRODUCT", 585, 591], ["macrophage colony-stimulating factor", "PROTEIN", 74, 110], ["IFN", "PROTEIN", 352, 355], ["TNF", "PROTEIN", 392, 395], ["CSF", "PROTEIN", 438, 441], ["TGF", "PROTEIN", 585, 588], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["RPMI", "TEST", 29, 33], ["macrophage colony", "TEST", 74, 91], ["Cell cultureAfter", "TEST", 183, 200], ["the culture", "TEST", 201, 212], ["each plates", "TEST", 282, 293], ["RPMI", "TEST", 313, 317], ["M2a phenotype", "TREATMENT", 470, 483], ["M2c", "TREATMENT", 529, 532]]], ["To generate the MSC educated macrophages (MEM), cells were direct co-cultured with 1 \u00d7 10 5 (Dazzi and Krampera, 2011) MSCs (MEM-D) and indirect by using 0.4 \u03bcm pore sized inserts (MEM-ID) and added 25 ng/ml M-CSF and 25 ng/ml GM-CSF.", [["MSC", "ANATOMY", 16, 19], ["macrophages", "ANATOMY", 29, 40], ["MEM", "ANATOMY", 42, 45], ["cells", "ANATOMY", 48, 53], ["MSCs", "ANATOMY", 119, 123], ["GM", "CHEMICAL", 227, 229], ["MSC", "CELL", 16, 19], ["macrophages", "CELL", 29, 40], ["MEM", "CELL", 42, 45], ["cells", "CELL", 48, 53], ["MSCs", "CELL", 119, 123], ["MEM-D", "CELL", 125, 130], ["M-CSF", "GENE_OR_GENE_PRODUCT", 208, 213], ["GM-CSF", "GENE_OR_GENE_PRODUCT", 227, 233], ["MSC educated macrophages", "CELL_LINE", 16, 40], ["MEM", "CELL_LINE", 42, 45], ["MSCs", "CELL_TYPE", 119, 123], ["CSF", "PROTEIN", 210, 213], ["CSF", "PROTEIN", 230, 233], ["0.4 \u03bcm pore sized inserts (MEM-ID)", "TREATMENT", 154, 188]]], ["One well of each plate were remained as unstimulated control cells.", [["cells", "ANATOMY", 61, 66], ["cells", "CELL", 61, 66], ["unstimulated control cells", "CELL_TYPE", 40, 66]]], ["All cells cultured at 37\u00b0C and %5 CO2 incubator for 3 days.", [["cells", "ANATOMY", 4, 9], ["CO2", "CHEMICAL", 34, 37], ["cells", "CELL", 4, 9], ["All cells", "TEST", 0, 9]]], ["Then, the cells of first plate were used to evaluation of phenotype changes of macrophages by FACS analyses.", [["cells", "ANATOMY", 10, 15], ["macrophages", "ANATOMY", 79, 90], ["cells", "CELL", 10, 15], ["macrophages", "CELL", 79, 90], ["macrophages", "CELL_TYPE", 79, 90], ["the cells of first plate", "TREATMENT", 6, 30], ["evaluation", "TEST", 44, 54], ["phenotype changes of macrophages", "PROBLEM", 58, 90], ["FACS analyses", "TEST", 94, 107]]], ["The other plate was used to co-culture experiments.Cell cultureTo compare of immunomodulatory effects of MEM-D and MEM-ID cells on CD4 T cells with known macrophage phenotypes, co-culture experiments were performed by using PBMCs.", [["Cell", "ANATOMY", 51, 55], ["MEM-ID cells", "ANATOMY", 115, 127], ["CD4 T cells", "ANATOMY", 131, 142], ["macrophage", "ANATOMY", 154, 164], ["PBMCs", "ANATOMY", 224, 229], ["Cell", "CELL", 51, 55], ["MEM-D", "CELL", 105, 110], ["MEM-ID cells", "CELL", 115, 127], ["CD4 T cells", "CELL", 131, 142], ["macrophage", "CELL", 154, 164], ["PBMCs", "CELL", 224, 229], ["MEM-D and MEM-ID cells", "CELL_LINE", 105, 127], ["CD4 T cells", "CELL_TYPE", 131, 142], ["PBMCs", "CELL_TYPE", 224, 229], ["The other plate", "TREATMENT", 0, 15], ["Cell cultureTo", "TEST", 51, 65], ["MEM-D and MEM-ID cells", "TEST", 105, 127], ["CD4 T cells", "TREATMENT", 131, 142], ["known macrophage phenotypes", "PROBLEM", 148, 175], ["co-culture experiments", "TEST", 177, 199], ["plate", "OBSERVATION_MODIFIER", 10, 15], ["macrophage phenotypes", "OBSERVATION", 154, 175]]], ["Before adding the PBMC, transwell cultured MSCs in the MEM-ID group were removed.", [["PBMC", "ANATOMY", 18, 22], ["MSCs", "ANATOMY", 43, 47], ["MEM", "CHEMICAL", 55, 58], ["PBMC", "CELL", 18, 22], ["MSCs", "CELL", 43, 47], ["PBMC", "CELL_TYPE", 18, 22], ["transwell cultured MSCs", "CELL_LINE", 24, 47], ["the PBMC", "TREATMENT", 14, 22], ["transwell cultured MSCs", "TREATMENT", 24, 47], ["the MEM-ID group", "TREATMENT", 51, 67]]], ["PBMCs of each donor were activated by 50 ng/ml IL-2 and 37.5 \u03bcL Dynabeads Human T-Activator CD3/CD28 (Thermo Scientific, USA).", [["PBMCs", "ANATOMY", 0, 5], ["PBMCs", "CELL", 0, 5], ["IL-2", "GENE_OR_GENE_PRODUCT", 47, 51], ["Human", "ORGANISM", 74, 79], ["CD3", "GENE_OR_GENE_PRODUCT", 92, 95], ["CD28", "GENE_OR_GENE_PRODUCT", 96, 100], ["PBMCs", "CELL_TYPE", 0, 5], ["IL", "PROTEIN", 47, 49], ["CD3", "PROTEIN", 92, 95], ["CD28", "PROTEIN", 96, 100], ["Human", "SPECIES", 74, 79], ["PBMCs of each donor", "TREATMENT", 0, 19], ["IL", "TEST", 47, 49]]], ["Than 1\u00d7 10 5 (Mastri et al., 2014) activated PBMCs were added in all different macrophage phenotypes.", [["PBMCs", "ANATOMY", 45, 50], ["macrophage", "ANATOMY", 79, 89], ["PBMCs", "CELL", 45, 50], ["macrophage", "CELL", 79, 89], ["activated PBMCs", "CELL_TYPE", 35, 50], ["activated PBMCs", "TREATMENT", 35, 50], ["macrophage phenotypes", "OBSERVATION", 79, 100]]], ["In different 6 well plate, same amount of activated PBMCs were co-cultured with AD-MSCs only and cultured only as activated control.", [["PBMCs", "ANATOMY", 52, 57], ["AD-MSCs", "ANATOMY", 80, 87], ["PBMCs", "CELL", 52, 57], ["AD-MSCs", "CELL", 80, 87], ["PBMCs", "CELL_TYPE", 52, 57], ["MSCs", "CELL_TYPE", 83, 87], ["activated PBMCs", "TREATMENT", 42, 57], ["AD-MSCs", "TREATMENT", 80, 87], ["well plate", "OBSERVATION_MODIFIER", 15, 25]]], ["To evaluation unstimulated control group, 1\u00d7 10 5 (Mastri et al., 2014) unstimulated PBMCs were cultured in different well.", [["PBMCs", "ANATOMY", 85, 90], ["PBMCs", "CELL", 85, 90], ["PBMCs", "CELL_TYPE", 85, 90], ["evaluation", "TEST", 3, 13], ["unstimulated PBMCs", "TEST", 72, 90]]], ["All cells cultured at 37\u00b0C and %5 CO2 incubator for 3 days.FACS analysesAmbarus et al. have systematically validated the specific markers that change in response to macrophage polarization (Ambarus et al., 2012) .", [["cells", "ANATOMY", 4, 9], ["macrophage", "ANATOMY", 165, 175], ["CO2", "CHEMICAL", 34, 37], ["cells", "CELL", 4, 9], ["macrophage", "CELL", 165, 175], ["All cells", "TEST", 0, 9], ["the specific markers", "TEST", 117, 137], ["macrophage polarization", "TREATMENT", 165, 188], ["macrophage polarization", "OBSERVATION", 165, 188]]], ["They have showed that CD80 and CD64 expressions of macrophages increased with IFN-g stimulation.", [["macrophages", "ANATOMY", 51, 62], ["CD80", "GENE_OR_GENE_PRODUCT", 22, 26], ["CD64", "GENE_OR_GENE_PRODUCT", 31, 35], ["macrophages", "CELL", 51, 62], ["IFN-g", "GENE_OR_GENE_PRODUCT", 78, 83], ["CD80", "PROTEIN", 22, 26], ["CD64", "PROTEIN", 31, 35], ["macrophages", "CELL_TYPE", 51, 62], ["IFN", "PROTEIN", 78, 81], ["CD80", "TEST", 22, 26], ["CD64 expressions", "TEST", 31, 47], ["macrophages", "PROBLEM", 51, 62], ["IFN-g stimulation", "TREATMENT", 78, 95], ["macrophages", "OBSERVATION_MODIFIER", 51, 62], ["increased", "OBSERVATION_MODIFIER", 63, 72]]], ["They have demonstrated that CD14 expression of IL-4-stimulated macrophages decreased, but that CD200R expressions were specifically increased.", [["macrophages", "ANATOMY", 63, 74], ["CD14", "GENE_OR_GENE_PRODUCT", 28, 32], ["IL-4", "GENE_OR_GENE_PRODUCT", 47, 51], ["macrophages", "CELL", 63, 74], ["CD200R", "GENE_OR_GENE_PRODUCT", 95, 101], ["CD14", "PROTEIN", 28, 32], ["IL-4", "PROTEIN", 47, 51], ["macrophages", "CELL_TYPE", 63, 74], ["CD200R", "PROTEIN", 95, 101], ["IL", "TEST", 47, 49], ["stimulated macrophages", "PROBLEM", 52, 74], ["increased", "OBSERVATION_MODIFIER", 132, 141]]], ["Finally, they have reported a specific increase in CD163 in IL-10-stimulated macrophages.", [["macrophages", "ANATOMY", 77, 88], ["CD163", "GENE_OR_GENE_PRODUCT", 51, 56], ["IL-10", "GENE_OR_GENE_PRODUCT", 60, 65], ["macrophages", "CELL", 77, 88], ["CD163", "PROTEIN", 51, 56], ["IL-10-stimulated macrophages", "CELL_LINE", 60, 88], ["CD163 in IL", "TEST", 51, 62], ["increase", "OBSERVATION_MODIFIER", 39, 47]]], ["In our study, we performed FACS analyses by using CD14 FITC, CD64 PE, CD80 PE-Cy5, CD163 PerCP.Cy5.5 and CD200R PE (Biolegend, USA) antibody staining to evaluation of phenotypic changes of macrophage cells.", [["macrophage cells", "ANATOMY", 189, 205], ["FITC", "CHEMICAL", 55, 59], ["CD14 FITC", "GENE_OR_GENE_PRODUCT", 50, 59], ["CD64 PE", "GENE_OR_GENE_PRODUCT", 61, 68], ["CD80", "GENE_OR_GENE_PRODUCT", 70, 74], ["CD163", "GENE_OR_GENE_PRODUCT", 83, 88], ["macrophage cells", "CELL", 189, 205], ["CD14 FITC", "PROTEIN", 50, 59], ["CD64 PE", "PROTEIN", 61, 68], ["CD80", "PROTEIN", 70, 74], ["CD163 PerCP", "PROTEIN", 83, 94], ["Biolegend, USA) antibody", "PROTEIN", 116, 140], ["macrophage cells", "CELL_TYPE", 189, 205], ["our study", "TEST", 3, 12], ["FACS analyses", "TEST", 27, 40], ["CD14 FITC", "TEST", 50, 59], ["CD64 PE", "TEST", 61, 68], ["CD80 PE", "TEST", 70, 77], ["Cy", "TEST", 95, 97], ["CD200R PE", "TEST", 105, 114], ["antibody staining", "TEST", 132, 149], ["evaluation", "TEST", 153, 163], ["phenotypic changes of macrophage cells", "PROBLEM", 167, 205], ["CD64", "ANATOMY", 61, 65], ["PE", "OBSERVATION", 66, 68], ["CD80", "ANATOMY", 70, 74], ["PE", "OBSERVATION", 75, 77], ["PE", "OBSERVATION", 112, 114], ["macrophage cells", "OBSERVATION", 189, 205]]], ["To evaluation of changes of CD4 T cells CD4 FITC, IFN-g PE, IL-4 PE, IL-17a PE (Diaclone, France) and FoxP3 (Biolegend, USA) antibody staining were performed.", [["CD4 T cells", "ANATOMY", 28, 39], ["FITC", "CHEMICAL", 44, 48], ["CD4 T", "GENE_OR_GENE_PRODUCT", 28, 33], ["CD4 FITC", "GENE_OR_GENE_PRODUCT", 40, 48], ["IFN-g PE", "GENE_OR_GENE_PRODUCT", 50, 58], ["IL-4 PE", "SIMPLE_CHEMICAL", 60, 67], ["IL-17a PE", "SIMPLE_CHEMICAL", 69, 78], ["Diaclone", "SIMPLE_CHEMICAL", 80, 88], ["FoxP3", "GENE_OR_GENE_PRODUCT", 102, 107], ["Biolegend", "GENE_OR_GENE_PRODUCT", 109, 118], ["USA", "GENE_OR_GENE_PRODUCT", 120, 123], ["CD4 T cells", "CELL_TYPE", 28, 39], ["CD4 FITC", "PROTEIN", 40, 48], ["IFN", "PROTEIN", 50, 53], ["IL", "PROTEIN", 69, 71], ["FoxP3", "PROTEIN", 102, 107], ["Biolegend, USA) antibody", "PROTEIN", 109, 133], ["evaluation", "TEST", 3, 13], ["CD4 T cells", "TEST", 28, 39], ["CD4", "TEST", 40, 43], ["FITC", "TEST", 44, 48], ["IFN", "TEST", 50, 53], ["PE", "PROBLEM", 56, 58], ["IL", "TEST", 60, 62], ["PE", "PROBLEM", 65, 67], ["IL", "TEST", 69, 71], ["PE", "PROBLEM", 76, 78], ["Diaclone", "TEST", 80, 88], ["FoxP3 (Biolegend, USA) antibody staining", "TEST", 102, 142], ["PE", "OBSERVATION", 56, 58], ["PE", "OBSERVATION", 65, 67]]], ["All measurements were performed with BD Accuri C5 flow cytometry device (BD Biosicience, USA) and all analyses were performed by using FlowJo v10 software (Becton, Dickinson & Company, USA).Luminex analysesTo evaluation of effects of different macrophage phenotypes on inflammatory cytokines IL-1b, IL-4, IL-10, IL-12p70, IL-17a and IFN-g levels were measured by using Luminex Kit (Thermo Fisher Scientific, USA).", [["macrophage", "ANATOMY", 244, 254], ["macrophage", "CELL", 244, 254], ["IL-1b", "GENE_OR_GENE_PRODUCT", 292, 297], ["IL-4", "GENE_OR_GENE_PRODUCT", 299, 303], ["IL-10", "GENE_OR_GENE_PRODUCT", 305, 310], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 312, 320], ["IL-17a", "GENE_OR_GENE_PRODUCT", 322, 328], ["IFN-g", "GENE_OR_GENE_PRODUCT", 333, 338], ["inflammatory cytokines", "PROTEIN", 269, 291], ["IL", "PROTEIN", 292, 294], ["IFN", "PROTEIN", 333, 336], ["All measurements", "TEST", 0, 16], ["all analyses", "TEST", 98, 110], ["Luminex analyses", "TEST", 190, 206], ["evaluation", "TEST", 209, 219], ["different macrophage phenotypes", "PROBLEM", 234, 265], ["inflammatory cytokines IL", "TEST", 269, 294], ["IL", "TEST", 299, 301], ["IL", "TEST", 305, 307], ["IL", "TEST", 312, 314], ["IL", "TEST", 322, 324], ["IFN-g levels", "TEST", 333, 345], ["macrophage phenotypes", "OBSERVATION", 244, 265], ["inflammatory", "OBSERVATION_MODIFIER", 269, 281]]], ["All measurements were performed with LUMINEX 200 \u2122 device (Merck Millipore, USA) that calibrated xPonent 3.1 compatible Calibration Kit (EMD Millipore Cat. # 40-275) and Verification Kit (EMD Millipore Cat. # 40-276).", [["All measurements", "TEST", 0, 16], ["LUMINEX", "TEST", 37, 44]]], ["Obtained signal densities were evaluated with xPotent 3.1 software (Merck Millipore, USA).", [["signal densities", "PROBLEM", 9, 25], ["xPotent", "TEST", 46, 53], ["signal densities", "OBSERVATION", 9, 25]]], ["Median Fluorescence Intensity (MFI) data of each sample were calculated by 5parameter logistic spline curve-fitting method and cytokine concentrations were determined.Cell proliferation and apoptosis assaysTo observe the effect of different macrophage phenotypes on proliferation, we performed WST-1 (Roche, Germany) analysis.", [["sample", "ANATOMY", 49, 55], ["Cell", "ANATOMY", 167, 171], ["macrophage", "ANATOMY", 241, 251], ["Cell", "CELL", 167, 171], ["macrophage", "CELL", 241, 251], ["cytokine", "PROTEIN", 127, 135], ["each sample", "TEST", 44, 55], ["logistic spline curve", "TEST", 86, 107], ["fitting method", "TREATMENT", 108, 122], ["cytokine concentrations", "TREATMENT", 127, 150], ["Cell proliferation", "PROBLEM", 167, 185], ["apoptosis assays", "PROBLEM", 190, 206], ["different macrophage phenotypes", "PROBLEM", 231, 262], ["WST", "TEST", 294, 297], ["apoptosis assays", "OBSERVATION", 190, 206], ["macrophage phenotypes", "OBSERVATION", 241, 262]]], ["1 \u00d7 10 4 cells of each macrophage phenotype and AD-MSCs were seeded a 96 well plate and cultured for 4 h to adhesion of plate surface.", [["cells", "ANATOMY", 9, 14], ["macrophage", "ANATOMY", 23, 33], ["AD-MSCs", "ANATOMY", 48, 55], ["plate surface", "ANATOMY", 120, 133], ["cells", "CELL", 9, 14], ["macrophage", "CELL", 23, 33], ["AD-MSCs", "CELL", 48, 55], ["MSCs", "CELL_TYPE", 51, 55], ["each macrophage phenotype", "PROBLEM", 18, 43], ["AD-MSCs", "TREATMENT", 48, 55], ["macrophage phenotype", "OBSERVATION", 23, 43], ["plate", "ANATOMY_MODIFIER", 120, 125], ["surface", "ANATOMY_MODIFIER", 126, 133]]], ["Than 4 \u00d7 10 5 (Dazzi and Krampera, 2011) activated PBMCs were added on these cells.", [["PBMCs", "ANATOMY", 51, 56], ["cells", "ANATOMY", 77, 82], ["PBMCs", "CELL", 51, 56], ["cells", "CELL", 77, 82], ["PBMCs", "CELL_TYPE", 51, 56], ["Krampera", "TREATMENT", 25, 33], ["activated PBMCs", "TREATMENT", 41, 56]]], ["As control, 4 \u00d7 10 5 (Dazzi and Krampera, 2011) activated and unstimulated PBMCs only were seeded different wells.", [["PBMCs", "ANATOMY", 75, 80], ["PBMCs", "CELL", 75, 80], ["unstimulated PBMCs", "CELL_TYPE", 62, 80], ["Krampera", "TREATMENT", 32, 40], ["unstimulated PBMCs", "TREATMENT", 62, 80]]], ["All cells cultured at 37\u00b0C and %5 CO2 incubator for 24 h.", [["cells", "ANATOMY", 4, 9], ["CO2", "CHEMICAL", 34, 37], ["cells", "CELL", 4, 9], ["All cells cultured", "TEST", 0, 18]]], ["After the culture period, 20 \u03bcL WST-1 solution was added to each well and cultured for 2 h.", [["WST-1", "CHEMICAL", 32, 37], ["the culture period", "TEST", 6, 24], ["20 \u03bcL WST", "TREATMENT", 26, 35]]], ["Absorbance changes were measured at a wavelength of 480 nm with the multi-plate reader Versamax (Sunnyvale, CA, USA).", [["Absorbance changes", "PROBLEM", 0, 18], ["the multi-plate reader Versamax", "TREATMENT", 64, 95]]], ["The CD69 surface expressions, which is activation marker of lymphocytes, were analyzed by flow-cytometry to observe activation status of pre-co-culture T cells.", [["surface", "ANATOMY", 9, 16], ["lymphocytes", "ANATOMY", 60, 71], ["pre-co-culture T cells", "ANATOMY", 137, 159], ["CD69", "GENE_OR_GENE_PRODUCT", 4, 8], ["lymphocytes", "CELL", 60, 71], ["pre-co-culture T cells", "CELL", 137, 159], ["CD69", "PROTEIN", 4, 8], ["lymphocytes", "CELL_TYPE", 60, 71], ["pre-co-culture T cells", "CELL_TYPE", 137, 159], ["The CD69 surface expressions", "TEST", 0, 28], ["flow-cytometry", "TEST", 90, 104], ["pre-co-culture T cells", "PROBLEM", 137, 159]]], ["For this, pre-activated and activated T cells were stained with CD4 FITC and CD69 PE labeled antibodies and analyzed on BD Accuri C5 device.", [["T cells", "ANATOMY", 38, 45], ["FITC", "CHEMICAL", 68, 72], ["T cells", "CELL", 38, 45], ["CD4 FITC", "GENE_OR_GENE_PRODUCT", 64, 72], ["CD69", "GENE_OR_GENE_PRODUCT", 77, 81], ["pre-activated and activated T cells", "CELL_TYPE", 10, 45], ["CD4 FITC", "PROTEIN", 64, 72], ["CD69 PE labeled antibodies", "PROTEIN", 77, 103], ["activated T cells", "TEST", 28, 45], ["CD4 FITC", "TEST", 64, 72], ["CD69 PE labeled antibodies", "TEST", 77, 103], ["BD Accuri C5 device", "TREATMENT", 120, 139]]], ["To assess the apoptosis status of the cells, Caspase-3 levels from the media supernatants which collected after co-culture were analyzed using the ELISA kit (MyBioSource, USA).StatisticData obtained from all experiments were evaluated as mean \u00b1 SD and were analyzed by using SPSS v23 (IBM, USA).", [["cells", "ANATOMY", 38, 43], ["supernatants", "ANATOMY", 77, 89], ["cells", "CELL", 38, 43], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 45, 54], ["Caspase-3", "PROTEIN", 45, 54], ["Caspase", "TEST", 45, 52], ["the media supernatants", "TEST", 67, 89], ["co-culture", "TEST", 112, 122], ["StatisticData", "TEST", 176, 189]]], ["To finding statistical differences of all groups, the One-Way ANOVA test was used, and according to Levene statistic results the Tukey HSD or Dunnett T3 posthoc test results were used.", [["the One-Way ANOVA test", "TEST", 50, 72], ["Dunnett T3 posthoc test", "TEST", 142, 165]]], ["To performing graphical charts of statistical results, the Prism v.7 software (GraphPad, USA) were used.Macrophage culture and phenotype analysesTo observe the effects of macrophage and MSC interactions on phenotype, we generated unstimulated (US), M1, M2a and M2c macrophages cells via specific cytokine stimulations, and then compared the phenotypes of each cell type.", [["Macrophage", "ANATOMY", 104, 114], ["macrophage", "ANATOMY", 171, 181], ["MSC", "ANATOMY", 186, 189], ["M1", "ANATOMY", 249, 251], ["M2a", "ANATOMY", 253, 256], ["M2c macrophages cells", "ANATOMY", 261, 282], ["cell", "ANATOMY", 360, 364], ["Macrophage", "CELL", 104, 114], ["macrophage", "CELL", 171, 181], ["MSC", "CELL", 186, 189], ["US", "CELL", 244, 246], ["M1", "CELL", 249, 251], ["M2a", "CELL", 253, 256], ["M2c macrophages cells", "CELL", 261, 282], ["cell type", "CELL", 360, 369], ["unstimulated (US), M1, M2a and M2c macrophages cells", "CELL_LINE", 230, 282], ["cytokine", "PROTEIN", 296, 304], ["Macrophage culture", "TEST", 104, 122], ["phenotype analyses", "TEST", 127, 145], ["macrophage", "PROBLEM", 171, 181], ["MSC interactions", "PROBLEM", 186, 202], ["specific cytokine stimulations", "TEST", 287, 317], ["macrophage", "OBSERVATION", 171, 181], ["cell type", "OBSERVATION", 360, 369]]], ["In microscopic examinations, we observed that M1 and M2c macrophages were predominantly spindleshaped, whereas M2a, MEM-D and MEM-ID macrophages were round cells with dendritic extensions.", [["M1", "ANATOMY", 46, 48], ["M2c macrophages", "ANATOMY", 53, 68], ["M2a", "ANATOMY", 111, 114], ["MEM-ID macrophages", "ANATOMY", 126, 144], ["round cells", "ANATOMY", 150, 161], ["dendritic", "ANATOMY", 167, 176], ["M1", "CELL", 46, 48], ["M2c macrophages", "CELL", 53, 68], ["MEM-D", "CELL", 116, 121], ["MEM-ID macrophages", "CELL", 126, 144], ["cells", "CELL", 156, 161], ["M1 and M2c macrophages", "CELL_LINE", 46, 68], ["M2a, MEM-D and MEM-ID macrophages", "CELL_LINE", 111, 144], ["microscopic examinations", "TEST", 3, 27], ["M2c macrophages", "TEST", 53, 68], ["M2a", "TEST", 111, 114], ["MEM", "TEST", 116, 119], ["MEM", "TEST", 126, 129], ["dendritic extensions", "PROBLEM", 167, 187], ["macrophages", "ANATOMY", 133, 144], ["round cells", "OBSERVATION", 150, 161], ["dendritic extensions", "OBSERVATION", 167, 187]]], ["The microscopic images of each macrophage phenotype are shown in Fig. 1 .Macrophage culture and phenotype analysesWe then analyzed the changes in CD14, CD64, CD80, CD163 and CD200R molecules to evaluate the macrophage phenotypes.", [["macrophage", "ANATOMY", 31, 41], ["Macrophage", "ANATOMY", 73, 83], ["macrophage", "ANATOMY", 207, 217], ["macrophage", "CELL", 31, 41], ["Macrophage", "CELL", 73, 83], ["CD14", "GENE_OR_GENE_PRODUCT", 146, 150], ["CD64", "GENE_OR_GENE_PRODUCT", 152, 156], ["CD80", "GENE_OR_GENE_PRODUCT", 158, 162], ["CD163", "GENE_OR_GENE_PRODUCT", 164, 169], ["CD200R", "GENE_OR_GENE_PRODUCT", 174, 180], ["macrophage", "CELL", 207, 217], ["CD14", "PROTEIN", 146, 150], ["CD64", "PROTEIN", 152, 156], ["CD80", "PROTEIN", 158, 162], ["CD163", "PROTEIN", 164, 169], ["CD200R molecules", "PROTEIN", 174, 190], ["The microscopic images", "TEST", 0, 22], ["Macrophage culture", "TEST", 73, 91], ["phenotype analysesWe", "TEST", 96, 116], ["CD14", "TEST", 146, 150], ["CD64", "TEST", 152, 156], ["CD80", "TEST", 158, 162], ["CD163", "TEST", 164, 169], ["CD200R molecules", "TEST", 174, 190], ["the macrophage phenotypes", "PROBLEM", 203, 228], ["macrophage phenotypes", "OBSERVATION", 207, 228]]], ["To minimize the differences due to biological variations and inter-assay biases, we used the fold of geometric median fluorescence intensity (gMFIfold) values obtained from the gMFI values of stimulated (S) and unstimulated (US) macrophages [gMFIfold=(S-gMFI/US-gMFI)-1].", [["macrophages", "ANATOMY", 229, 240], ["macrophages", "CELL", 229, 240], ["stimulated (S) and unstimulated (US) macrophages", "CELL_LINE", 192, 240], ["inter-assay biases", "TEST", 61, 79], ["the gMFI values", "TEST", 173, 188], ["macrophages", "TEST", 229, 240], ["gMFIfold", "TEST", 242, 250], ["S", "TEST", 252, 253], ["gMFI", "TEST", 254, 258], ["US", "TEST", 259, 261]]], ["The histogram plots obtained from FACS analyses are presented in Fig. 2 , and the comparison of the gMFIfold values of the groups is given in Fig. 3 .Macrophage culture and phenotype analysesIn our experiments, the CD14 expression of the M1 and M2a cells was lower than that of the USeM cells, but this was not statistically significant.", [["Macrophage", "ANATOMY", 150, 160], ["M1", "ANATOMY", 238, 240], ["M2a cells", "ANATOMY", 245, 254], ["USeM cells", "ANATOMY", 282, 292], ["Macrophage", "CELL", 150, 160], ["CD14", "GENE_OR_GENE_PRODUCT", 215, 219], ["M1", "CELL", 238, 240], ["M2a cells", "CELL", 245, 254], ["USeM cells", "CELL", 282, 292], ["CD14", "PROTEIN", 215, 219], ["M1 and M2a cells", "CELL_LINE", 238, 254], ["USeM cells", "CELL_LINE", 282, 292], ["The histogram plots", "TEST", 0, 19], ["FACS analyses", "TEST", 34, 47], ["Macrophage culture", "TEST", 150, 168], ["phenotype analyses", "TEST", 173, 191], ["the CD14 expression", "TEST", 211, 230], ["M2a cells", "TEST", 245, 254], ["M1", "ANATOMY", 238, 240], ["M2a cells", "OBSERVATION", 245, 254]]], ["Even if the CD14 expressions of the M2c, MEM-D and MEM-ID groups were higher compared to the M1 and M2a groups, the difference was only significant between the M2a and MEM-ID groups.", [["CD14", "GENE_OR_GENE_PRODUCT", 12, 16], ["MEM-D", "GENE_OR_GENE_PRODUCT", 41, 46], ["MEM-ID", "GENE_OR_GENE_PRODUCT", 51, 57], ["M2a", "CANCER", 100, 103], ["M2a", "CANCER", 160, 163], ["CD14", "PROTEIN", 12, 16], ["the CD14 expressions", "TEST", 8, 28], ["M1", "ANATOMY", 93, 95], ["significant", "OBSERVATION_MODIFIER", 136, 147], ["M2a", "ANATOMY", 160, 163]]], ["The CD64 expression was increased in all groups except M2a cells, and we found that the MEM-ID group had a significantly higher CD64 expression than the M2a group (Fig. 3) .", [["M2a cells", "ANATOMY", 55, 64], ["CD64", "GENE_OR_GENE_PRODUCT", 4, 8], ["M2a cells", "CELL", 55, 64], ["MEM-ID", "GENE_OR_GENE_PRODUCT", 88, 94], ["CD64", "GENE_OR_GENE_PRODUCT", 128, 132], ["M2a", "CANCER", 153, 156], ["CD64", "PROTEIN", 4, 8], ["M2a cells", "CELL_LINE", 55, 64], ["CD64", "PROTEIN", 128, 132], ["The CD64 expression", "TEST", 0, 19], ["the MEM", "TEST", 84, 91], ["CD64 expression", "OBSERVATION", 4, 19], ["increased", "OBSERVATION_MODIFIER", 24, 33], ["M2a cells", "OBSERVATION", 55, 64], ["CD64 expression", "OBSERVATION", 128, 143]]], ["The highest and statistically significant CD80 expression was observed in the MEM-D group, and thePBMC co-cultureTo observe the effects of the MEM cells on CD4 T cells, we performed co-culture experiments.", [["PBMC", "ANATOMY", 98, 102], ["MEM cells", "ANATOMY", 143, 152], ["CD4 T cells", "ANATOMY", 156, 167], ["CD80", "GENE_OR_GENE_PRODUCT", 42, 46], ["MEM-D", "SIMPLE_CHEMICAL", 78, 83], ["PBMC", "CELL", 98, 102], ["MEM cells", "CELL", 143, 152], ["CD4 T cells", "CELL", 156, 167], ["CD80", "PROTEIN", 42, 46], ["PBMC", "CELL_TYPE", 98, 102], ["MEM cells", "CELL_LINE", 143, 152], ["CD4 T cells", "CELL_TYPE", 156, 167], ["thePBMC co-culture", "TEST", 95, 113], ["the MEM cells", "TREATMENT", 139, 152], ["CD4 T cells", "TREATMENT", 156, 167], ["co-culture experiments", "TEST", 182, 204], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["CD80 expression", "OBSERVATION", 42, 57], ["PBMC", "ANATOMY", 98, 102]]], ["Before the co-culture of PBMCs, we validated the activation status of lymphocytes.", [["PBMCs", "ANATOMY", 25, 30], ["lymphocytes", "ANATOMY", 70, 81], ["PBMCs", "CELL", 25, 30], ["lymphocytes", "CELL", 70, 81], ["PBMCs", "CELL_TYPE", 25, 30], ["lymphocytes", "CELL_TYPE", 70, 81], ["PBMCs", "TEST", 25, 30], ["lymphocytes", "PROBLEM", 70, 81]]], ["For this purpose, we labeled unstimulated and activated PBMCs by CD4 FITC and CD69PE antibodies and analyzed them using FACS.", [["PBMCs", "ANATOMY", 56, 61], ["FITC", "CHEMICAL", 69, 73], ["PBMCs", "CELL", 56, 61], ["CD4 FITC", "GENE_OR_GENE_PRODUCT", 65, 73], ["CD69PE antibodies", "GENE_OR_GENE_PRODUCT", 78, 95], ["PBMCs", "CELL_TYPE", 56, 61], ["CD4 FITC", "PROTEIN", 65, 73], ["CD69PE antibodies", "PROTEIN", 78, 95], ["CD4 FITC", "TEST", 65, 73], ["CD69PE antibodies", "TEST", 78, 95], ["FACS", "TEST", 120, 124]]], ["For all donors, we detected a significant increase in CD69 expression in activated PBMCs compared to the unstimulated PBMCs ( Supplementary Fig-1) .", [["PBMCs", "ANATOMY", 83, 88], ["PBMCs", "ANATOMY", 118, 123], ["donors", "ORGANISM", 8, 14], ["CD69", "GENE_OR_GENE_PRODUCT", 54, 58], ["PBMCs", "CELL", 83, 88], ["PBMCs", "CELL", 118, 123], ["CD69", "PROTEIN", 54, 58], ["PBMCs", "CELL_TYPE", 83, 88], ["unstimulated PBMCs", "CELL_TYPE", 105, 123], ["a significant increase in CD69 expression", "PROBLEM", 28, 69], ["activated PBMCs", "TREATMENT", 73, 88], ["the unstimulated PBMCs", "TREATMENT", 101, 123], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["increase", "OBSERVATION_MODIFIER", 42, 50], ["CD69 expression", "OBSERVATION", 54, 69]]], ["During the co-culture experiments, we observed differences in the interactions between cells.", [["cells", "ANATOMY", 87, 92], ["cells", "CELL", 87, 92], ["the co-culture experiments", "TEST", 7, 33]]], ["The T cells marked with CD3/CD28 beads were orange under a light microscope due to the deposition of iron on their surface.", [["T cells", "ANATOMY", 4, 11], ["surface", "ANATOMY", 115, 122], ["iron", "CHEMICAL", 101, 105], ["iron", "CHEMICAL", 101, 105], ["T cells", "CELL", 4, 11], ["CD3", "GENE_OR_GENE_PRODUCT", 24, 27], ["CD28", "GENE_OR_GENE_PRODUCT", 28, 32], ["iron", "SIMPLE_CHEMICAL", 101, 105], ["surface", "CELLULAR_COMPONENT", 115, 122], ["T cells", "CELL_TYPE", 4, 11], ["CD3", "PROTEIN", 24, 27], ["CD28", "PROTEIN", 28, 32], ["The T cells", "TEST", 0, 11], ["CD3/CD28 beads", "TREATMENT", 24, 38], ["a light microscope", "TEST", 57, 75], ["the deposition of iron on their surface", "PROBLEM", 83, 122], ["iron", "OBSERVATION", 101, 105]]], ["In the microscopic examinations, we found that T lymphocytes generated clusters similar to antigen presentation, and these clusters were more prominent in M2a and MEM-D cells (Fig. 4) .PBMC co-cultureThe changes in CD4 T cell subsets were evaluated by a FACS analysis and the dot-plot charts of each T cell subsets are given in Fig. 5 .", [["T lymphocytes", "ANATOMY", 47, 60], ["M2a", "ANATOMY", 155, 158], ["MEM-D cells", "ANATOMY", 163, 174], ["PBMC", "ANATOMY", 185, 189], ["CD4 T cell", "ANATOMY", 215, 225], ["T cell", "ANATOMY", 300, 306], ["T lymphocytes", "CELL", 47, 60], ["antigen", "GENE_OR_GENE_PRODUCT", 91, 98], ["M2a", "CELL", 155, 158], ["MEM-D cells", "CELL", 163, 174], ["PBMC", "CELL", 185, 189], ["CD4 T cell", "CELL", 215, 225], ["T cell", "CELL", 300, 306], ["T lymphocytes", "CELL_TYPE", 47, 60], ["M2a and MEM-D cells", "CELL_LINE", 155, 174], ["PBMC", "CELL_TYPE", 185, 189], ["CD4 T cell subsets", "CELL_TYPE", 215, 233], ["T cell subsets", "CELL_TYPE", 300, 314], ["the microscopic examinations", "TEST", 3, 31], ["T lymphocytes generated clusters", "PROBLEM", 47, 79], ["PBMC co-culture", "TEST", 185, 200], ["The changes in CD4 T cell subsets", "PROBLEM", 200, 233], ["a FACS analysis", "TEST", 252, 267], ["each T cell subsets", "TREATMENT", 295, 314], ["more prominent", "OBSERVATION_MODIFIER", 137, 151], ["CD4 T cell subsets", "OBSERVATION", 215, 233], ["cell subsets", "OBSERVATION", 302, 314]]], ["The cell frequencies (%) are summarized in supplementary Table-1, and the comparison charts between the groups in Fig. 6 .", [["cell", "ANATOMY", 4, 8], ["cell", "CELL", 4, 8], ["The cell frequencies", "TEST", 0, 20]]], ["The Th1 (CD4 + IFNg + ) cell frequencies of all groups, except the M2a and M2c groups, were significantly higher compared to the US-PBMC group.", [["Th1 (CD4 + IFNg + ) cell", "ANATOMY", 4, 28], ["PBMC", "ANATOMY", 132, 136], ["Th1", "GENE_OR_GENE_PRODUCT", 4, 7], ["CD4", "GENE_OR_GENE_PRODUCT", 9, 12], ["PBMC", "CELL", 132, 136], ["CD4", "PROTEIN", 9, 12], ["IFNg", "PROTEIN", 15, 19], ["PBMC", "CELL_TYPE", 132, 136], ["The Th1", "TEST", 0, 7], ["cell frequencies", "TEST", 24, 40]]], ["In addition, the Th1 frequencies of the M1 group was significantly higher than that of the MSC group.", [["MSC", "ANATOMY", 91, 94], ["MSC", "CELL", 91, 94], ["M1", "ANATOMY", 40, 42], ["MSC", "ANATOMY", 91, 94]]], ["The Th2 (CD4 + IL4 + ) cell frequencies of the M2a and A-PBMC groups were significantly higher compared to the remaining groups.", [["Th2 (CD4 + IL4 + ) cell", "ANATOMY", 4, 27], ["M2a", "ANATOMY", 47, 50], ["A-PBMC", "ANATOMY", 55, 61], ["Th2", "GENE_OR_GENE_PRODUCT", 4, 7], ["CD4", "GENE_OR_GENE_PRODUCT", 9, 12], ["IL4", "GENE_OR_GENE_PRODUCT", 15, 18], ["M2a", "CANCER", 47, 50], ["A-PBMC", "CANCER", 55, 61], ["CD4", "PROTEIN", 9, 12], ["IL4", "PROTEIN", 15, 18], ["The Th2", "TEST", 0, 7], ["IL4", "TEST", 15, 18], ["cell frequencies", "TEST", 23, 39], ["the M2a", "TEST", 43, 50], ["A-PBMC groups", "TEST", 55, 68], ["M2a", "ANATOMY", 47, 50], ["significantly", "OBSERVATION_MODIFIER", 74, 87], ["higher", "OBSERVATION_MODIFIER", 88, 94]]], ["This finding confirmed that M2a macrophages were more effective in inducing the Th2 subset, but it also showed that the MEM-D and MEM-ID cells might be as effective as MSCs in suppressing the Th2 cells.", [["M2a macrophages", "ANATOMY", 28, 43], ["MEM-ID cells", "ANATOMY", 130, 142], ["MSCs", "ANATOMY", 168, 172], ["Th2 cells", "ANATOMY", 192, 201], ["M2a macrophages", "CELL", 28, 43], ["MEM-D", "CELL", 120, 125], ["MEM-ID cells", "CELL", 130, 142], ["MSCs", "CELL", 168, 172], ["Th2 cells", "CELL", 192, 201], ["M2a macrophages", "CELL_TYPE", 28, 43], ["Th2 subset", "CELL_LINE", 80, 90], ["MEM-D and MEM-ID cells", "CELL_LINE", 120, 142], ["MSCs", "CELL_TYPE", 168, 172], ["Th2 cells", "CELL_TYPE", 192, 201], ["M2a macrophages", "PROBLEM", 28, 43], ["the MEM", "TEST", 116, 123], ["MEM-ID cells", "PROBLEM", 130, 142], ["MSCs", "PROBLEM", 168, 172], ["M2a macrophages", "OBSERVATION", 28, 43], ["Th2 cells", "OBSERVATION", 192, 201]]], ["The frequencies of the Th17 (CD4 + IL17a + ) cells of all groups, except the M1 group, were significantly lower compared with the A-PBMC group.", [["Th17 (CD4 + IL17a + ) cells", "ANATOMY", 23, 50], ["A-PBMC", "ANATOMY", 130, 136], ["Th17", "GENE_OR_GENE_PRODUCT", 23, 27], ["CD4", "GENE_OR_GENE_PRODUCT", 29, 32], ["IL17", "GENE_OR_GENE_PRODUCT", 35, 39], ["A-PBMC", "CANCER", 130, 136], ["CD4", "PROTEIN", 29, 32], ["IL17", "PROTEIN", 35, 39], ["the Th17", "TEST", 19, 27], ["CD4", "TEST", 29, 32], ["Th17", "ANATOMY", 23, 27], ["M1", "ANATOMY_MODIFIER", 77, 79]]], ["Unlike the other groups, the M2c group had a significantly higher Th17 frequency than the US-PBMC group.", [["PBMC", "ANATOMY", 93, 97], ["M2c", "CANCER", 29, 32], ["US-PBMC", "CELL", 90, 97], ["PBMC", "CELL_TYPE", 93, 97]]], ["Lastly, we detected that the Treg (CD4 + FoxP3 + ) cell frequencies of the MEM-D cells were significantly higher than the other groups.", [["Treg", "ANATOMY", 29, 33], ["CD4 + FoxP3 + ) cell", "ANATOMY", 35, 55], ["MEM-D cells", "ANATOMY", 75, 86], ["Treg", "CELL", 29, 33], ["CD4", "GENE_OR_GENE_PRODUCT", 35, 38], ["FoxP3", "GENE_OR_GENE_PRODUCT", 41, 46], ["MEM-D cells", "CELL", 75, 86], ["CD4", "PROTEIN", 35, 38], ["FoxP3", "PROTEIN", 41, 46], ["MEM-D cells", "CELL_LINE", 75, 86], ["the Treg", "TEST", 25, 33], ["CD4", "TEST", 35, 38], ["FoxP3", "TEST", 41, 46], ["cell frequencies", "TEST", 51, 67], ["the MEM-D cells", "TEST", 71, 86], ["Treg", "ANATOMY", 29, 33], ["higher", "OBSERVATION_MODIFIER", 106, 112]]], ["This finding suggested that the direct interaction of macrophages and MSCs might have led to a more effective increase in Treg cell levels.PBMC co-cultureAfter the evaluation of phenotypic alterations of CD4 T cells, we evaluated the changes in inflammatory cytokines.", [["macrophages", "ANATOMY", 54, 65], ["MSCs", "ANATOMY", 70, 74], ["Treg cell", "ANATOMY", 122, 131], ["PBMC", "ANATOMY", 139, 143], ["CD4 T cells", "ANATOMY", 204, 215], ["macrophages", "CELL", 54, 65], ["MSCs", "CELL", 70, 74], ["Treg cell", "CELL", 122, 131], ["PBMC", "CELL", 139, 143], ["CD4 T cells", "CELL", 204, 215], ["macrophages", "CELL_TYPE", 54, 65], ["MSCs", "CELL_TYPE", 70, 74], ["PBMC", "CELL_TYPE", 139, 143], ["CD4 T cells", "CELL_TYPE", 204, 215], ["inflammatory cytokines", "PROTEIN", 245, 267], ["the direct interaction of macrophages and MSCs", "PROBLEM", 28, 74], ["a more effective increase in Treg cell levels", "PROBLEM", 93, 138], ["PBMC", "TREATMENT", 139, 143], ["the evaluation", "TEST", 160, 174], ["phenotypic alterations", "PROBLEM", 178, 200], ["CD4 T cells", "PROBLEM", 204, 215], ["the changes in inflammatory cytokines", "PROBLEM", 230, 267], ["Treg cell levels", "OBSERVATION", 122, 138], ["inflammatory cytokines", "OBSERVATION", 245, 267]]], ["The comparative charts of all cytokines are provided in Fig. 7 , and the results of all Table- 2.", [["cytokines", "PROTEIN", 30, 39], ["all cytokines", "TREATMENT", 26, 39]]], ["The IFN-g levels of the M1 groups were significantly higher compared to all co-culture groups, except the M2a and A-PBMC groups.", [["IFN-g", "GENE_OR_GENE_PRODUCT", 4, 9], ["IFN", "PROTEIN", 4, 7], ["The IFN-g levels", "TEST", 0, 16]]], ["The IL-4 levels of the US-M and MEM-ID groups were significantly lower than those of the other groups (p < 0.05), except the US-PBMC group.", [["PBMC", "ANATOMY", 128, 132], ["IL-4", "GENE_OR_GENE_PRODUCT", 4, 8], ["PBMC", "CELL", 128, 132], ["IL", "PROTEIN", 4, 6], ["PBMC", "CELL_TYPE", 128, 132], ["the US", "TEST", 19, 25], ["MEM-ID groups", "TEST", 32, 45], ["the US", "TEST", 121, 127]]], ["The IL-10 levels of all groups were significantly higher compared to the US-PBMC group.", [["PBMC", "ANATOMY", 76, 80], ["IL-10", "GENE_OR_GENE_PRODUCT", 4, 9], ["PBMC", "CELL", 76, 80], ["IL", "PROTEIN", 4, 6], ["PBMC", "CELL_TYPE", 76, 80], ["The IL", "TEST", 0, 6], ["the US", "TEST", 69, 75]]], ["In addition, the IL-10 levels of the MEM-D group were significantly lower than all groups, except the MSC group.", [["MSC", "ANATOMY", 102, 105], ["MEM-D", "CHEMICAL", 37, 42], ["IL-10", "GENE_OR_GENE_PRODUCT", 17, 22], ["MEM-D", "SIMPLE_CHEMICAL", 37, 42], ["MSC", "CELL", 102, 105], ["IL", "PROTEIN", 17, 19], ["the IL", "TEST", 13, 19], ["the MEM-D group", "TEST", 33, 48], ["MSC", "ANATOMY", 102, 105]]], ["Similarly, the MEM-ID group had significantly lower IL-10 levels than the US-M, M2a and M2c groups.", [["IL-10", "GENE_OR_GENE_PRODUCT", 52, 57], ["M2a", "CELL", 80, 83], ["M2c", "CANCER", 88, 91], ["IL", "PROTEIN", 52, 54], ["the US", "TEST", 70, 76]]], ["The IL-17a levels of the US-PBMS group were significantly lower than those of the other groups, except the MEM-D group (p < 0.05), and the M2c group had significantly higher IL-17a levels than the US-M, M2a, MEM-D and MEM-ID groups.", [["IL-17a", "GENE_OR_GENE_PRODUCT", 4, 10], ["MEM-D", "SIMPLE_CHEMICAL", 107, 112], ["M2c", "CANCER", 139, 142], ["IL-17a", "GENE_OR_GENE_PRODUCT", 174, 180], ["MEM-D", "SIMPLE_CHEMICAL", 208, 213], ["MEM-ID", "SIMPLE_CHEMICAL", 218, 224], ["IL", "PROTEIN", 4, 6], ["IL", "PROTEIN", 174, 176], ["the US", "TEST", 21, 27], ["PBMS group", "TEST", 28, 38], ["the US", "TEST", 193, 199], ["M2a", "TEST", 203, 206], ["MEM", "TEST", 208, 211], ["MEM", "TEST", 218, 221]]], ["The IL-12p70 levels were similar in all groups, but they were significantly lower in the MEM-ID groups compared to the MSC and A-PBMC groups (p < 0.05).", [["MSC", "ANATOMY", 119, 122], ["PBMC", "ANATOMY", 129, 133], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 4, 12], ["MSC", "CELL", 119, 122], ["A-PBMC", "CELL", 127, 133], ["IL", "PROTEIN", 4, 6], ["MSC", "CELL_TYPE", 119, 122], ["PBMC", "CELL_TYPE", 129, 133], ["The IL-12p70 levels", "TEST", 0, 19], ["the MSC", "TEST", 115, 122], ["significantly", "OBSERVATION_MODIFIER", 62, 75], ["lower", "OBSERVATION_MODIFIER", 76, 81], ["MSC", "ANATOMY", 119, 122]]], ["For IL-1b, surprisingly, the MEM-D and MSC groups had significantly higher levels compared with the remaining co-culture groups (p < 0.05).PBMC co-cultureTo compare the effects of all macrophage phenotypes on lymphocyte proliferation and apoptosis, we performed WST-1 analyses.", [["MSC", "ANATOMY", 39, 42], ["PBMC", "ANATOMY", 139, 143], ["macrophage", "ANATOMY", 184, 194], ["lymphocyte", "ANATOMY", 209, 219], ["IL-1b", "GENE_OR_GENE_PRODUCT", 4, 9], ["MEM-D", "CELL", 29, 34], ["MSC", "CELL", 39, 42], ["PBMC", "CELL", 139, 143], ["macrophage", "CELL", 184, 194], ["lymphocyte", "CELL", 209, 219], ["IL", "PROTEIN", 4, 6], ["PBMC", "CELL_TYPE", 139, 143], ["WST", "PROTEIN", 262, 265], ["the MEM-D and MSC groups", "TEST", 25, 49], ["significantly higher levels", "PROBLEM", 54, 81], ["PBMC co-culture", "TEST", 139, 154], ["all macrophage phenotypes", "PROBLEM", 180, 205], ["lymphocyte proliferation", "PROBLEM", 209, 233], ["apoptosis", "PROBLEM", 238, 247], ["WST", "TEST", 262, 265], ["macrophage phenotypes", "OBSERVATION", 184, 205], ["lymphocyte proliferation", "OBSERVATION", 209, 233]]], ["The comparative charts of all WST-1 and Caspase-3 results are summarized in Fig. 8 and all results are given in supplementary Table- 3.", [["WST-1", "GENE_OR_GENE_PRODUCT", 30, 35], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 40, 49], ["WST", "PROTEIN", 30, 33], ["Caspase", "PROTEIN", 40, 47], ["all WST", "TEST", 26, 33], ["Caspase", "TEST", 40, 47]]], ["The optical densities (ODs) of the activated PBMC groups were significantly higher than those of the co-culture groups, except the M1 group.", [["PBMC", "ANATOMY", 45, 49], ["PBMC", "CELL", 45, 49], ["PBMC", "CELL_TYPE", 45, 49], ["The optical densities (ODs", "PROBLEM", 0, 26], ["the activated PBMC groups", "TREATMENT", 31, 56], ["optical", "OBSERVATION_MODIFIER", 4, 11], ["densities", "OBSERVATION", 12, 21], ["significantly", "OBSERVATION_MODIFIER", 62, 75], ["higher", "OBSERVATION_MODIFIER", 76, 82], ["M1", "ANATOMY", 131, 133]]], ["In the other hand, the ODs of the unstimulated PBMC groups were significantly lower compared to the US-M, M1 and M2a groups.", [["PBMC", "ANATOMY", 47, 51], ["PBMC", "CELL", 47, 51], ["M1", "CELL", 106, 108], ["PBMC", "CELL_TYPE", 47, 51], ["the unstimulated PBMC groups", "TEST", 30, 58], ["the US", "TEST", 96, 102], ["M1", "ANATOMY", 106, 108]]], ["In addition, the ODs of the MSC group were significantly lower than those of the US-M, M1 and M2a groups.", [["MSC", "ANATOMY", 28, 31], ["MSC", "CELL", 28, 31], ["M1", "CELL", 87, 89], ["M2a", "ORGANISM", 94, 97], ["the US", "TEST", 77, 83], ["M1", "ANATOMY", 87, 89]]], ["To evaluate apoptosis, we performed Caspase-3 ELISA analyses.", [["Caspase-3", "GENE_OR_GENE_PRODUCT", 36, 45], ["Caspase", "PROTEIN", 36, 43], ["apoptosis", "PROBLEM", 12, 21], ["Caspase", "TEST", 36, 43], ["ELISA analyses", "TEST", 46, 60]]], ["The Caspase-3 levels of the MSC and US-PBMSC groups were significantly lower than those of the M2a, M2c, MEM-D and A-PBMC groups.ConclusionsIn this study, we evaluated macrophage polarizations by identifying several distinctive markers for M1, M2a and M2c macrophage phenotypes (Fig. 3) .", [["MSC", "ANATOMY", 28, 31], ["US-PBMSC", "ANATOMY", 36, 44], ["M2a", "ANATOMY", 95, 98], ["M2c", "ANATOMY", 100, 103], ["A-PBMC", "ANATOMY", 115, 121], ["macrophage", "ANATOMY", 168, 178], ["M1", "ANATOMY", 240, 242], ["M2a", "ANATOMY", 244, 247], ["M2c macrophage", "ANATOMY", 252, 266], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 4, 13], ["MSC", "CELL", 28, 31], ["US-PBMSC", "CELL", 36, 44], ["M2a", "CELL", 95, 98], ["M2c", "CELL", 100, 103], ["MEM-D", "CELL", 105, 110], ["A-PBMC", "CELL", 115, 121], ["macrophage", "CELL", 168, 178], ["M1", "CELL", 240, 242], ["M2a", "GENE_OR_GENE_PRODUCT", 244, 247], ["M2c macrophage", "CELL", 252, 266], ["Caspase-3", "PROTEIN", 4, 13], ["MSC", "CELL_TYPE", 28, 31], ["The Caspase", "TEST", 0, 11], ["the MSC", "TEST", 24, 31], ["US", "TEST", 36, 38], ["PBMSC groups", "TEST", 39, 51], ["M2c", "TEST", 100, 103], ["this study", "TEST", 143, 153], ["macrophage polarizations", "TEST", 168, 192], ["M2a", "TEST", 244, 247], ["M2c macrophage phenotypes", "PROBLEM", 252, 277], ["MSC", "ANATOMY", 28, 31]]], ["One of the markers evaluated was CD14, which is a specific marker of monocytes with reduced expression during macrophage maturation (Ambarus et al., 2012) .", [["monocytes", "ANATOMY", 69, 78], ["macrophage", "ANATOMY", 110, 120], ["CD14", "GENE_OR_GENE_PRODUCT", 33, 37], ["monocytes", "CELL", 69, 78], ["macrophage", "CELL", 110, 120], ["CD14", "PROTEIN", 33, 37], ["monocytes", "CELL_TYPE", 69, 78], ["the markers", "TEST", 7, 18], ["CD14", "TEST", 33, 37], ["reduced expression during macrophage maturation", "PROBLEM", 84, 131], ["monocytes", "OBSERVATION", 69, 78], ["reduced", "OBSERVATION_MODIFIER", 84, 91], ["expression", "OBSERVATION_MODIFIER", 92, 102], ["macrophage maturation", "OBSERVATION", 110, 131]]], ["It is well known that MSCs are IL-10-producing cells (Ma et al., 2016; Qu et al., 2012) , and it has been shown that their maturation can be prevented by IL-10 (Schwarz et al., 2013; Allavena et al., 1998) .", [["MSCs", "ANATOMY", 22, 26], ["IL-10-producing cells", "ANATOMY", 31, 52], ["MSCs", "CELL", 22, 26], ["IL-10", "GENE_OR_GENE_PRODUCT", 31, 36], ["cells", "CELL", 47, 52], ["IL-10", "GENE_OR_GENE_PRODUCT", 154, 159], ["MSCs", "CELL_TYPE", 22, 26], ["IL", "PROTEIN", 154, 156], ["IL", "TEST", 31, 33]]], ["We observed that the CD14 expressions of the MEM-D and MEM-ID groups showed a similar pattern to the M2c group, suggesting that MSCs can differentiate macrophage cells into the M2c-like phenotype through direct or indirect effects.", [["MSCs", "ANATOMY", 128, 132], ["macrophage cells", "ANATOMY", 151, 167], ["CD14", "GENE_OR_GENE_PRODUCT", 21, 25], ["MEM-D", "GENE_OR_GENE_PRODUCT", 45, 50], ["MEM-ID", "GENE_OR_GENE_PRODUCT", 55, 61], ["M2c", "CANCER", 101, 104], ["MSCs", "CELL", 128, 132], ["macrophage cells", "CELL", 151, 167], ["M2c", "GENE_OR_GENE_PRODUCT", 177, 180], ["CD14", "PROTEIN", 21, 25], ["MSCs", "CELL_TYPE", 128, 132], ["macrophage cells", "CELL_TYPE", 151, 167], ["the CD14 expressions", "TEST", 17, 37], ["the MEM-D and MEM-ID groups", "TEST", 41, 68], ["MSCs", "PROBLEM", 128, 132], ["macrophage cells", "TEST", 151, 167], ["the M2c", "TEST", 173, 180], ["macrophage cells", "OBSERVATION", 151, 167]]], ["CD64 is a member of the Fc\u03b3 family and plays a role in antibodymediated phagocytosis.", [["CD64", "GENE_OR_GENE_PRODUCT", 0, 4], ["Fc\u03b3", "GENE_OR_GENE_PRODUCT", 24, 27], ["CD64", "PROTEIN", 0, 4], ["Fc\u03b3 family", "PROTEIN", 24, 34]]], ["It has been reported that CD64 expression in monocytes and macrophages increases in response to IFN-g and LPS stimulation but decreases with IL-4 stimulation (Hristodorov et al., 2015) .", [["monocytes", "ANATOMY", 45, 54], ["macrophages", "ANATOMY", 59, 70], ["LPS", "CHEMICAL", 106, 109], ["CD64", "GENE_OR_GENE_PRODUCT", 26, 30], ["monocytes", "CELL", 45, 54], ["macrophages", "CELL", 59, 70], ["IFN-g", "GENE_OR_GENE_PRODUCT", 96, 101], ["LPS", "SIMPLE_CHEMICAL", 106, 109], ["IL-4", "GENE_OR_GENE_PRODUCT", 141, 145], ["CD64", "PROTEIN", 26, 30], ["monocytes", "CELL_TYPE", 45, 54], ["macrophages", "CELL_TYPE", 59, 70], ["IFN", "PROTEIN", 96, 99], ["IL", "PROTEIN", 141, 143], ["CD64 expression in monocytes", "PROBLEM", 26, 54], ["macrophages", "PROBLEM", 59, 70], ["IFN", "TREATMENT", 96, 99], ["LPS stimulation", "TREATMENT", 106, 121], ["IL-4 stimulation", "TREATMENT", 141, 157], ["CD64 expression", "OBSERVATION", 26, 41], ["monocytes", "ANATOMY", 45, 54], ["macrophages", "OBSERVATION_MODIFIER", 59, 70], ["increases", "OBSERVATION_MODIFIER", 71, 80], ["decreases", "OBSERVATION_MODIFIER", 126, 135]]], ["In another study, Ji et al. showed that the CD64 expression of macrophages increased by M-CSF and IL-10 stimulation (Ji et al., 2004) .", [["macrophages", "ANATOMY", 63, 74], ["CD64", "GENE_OR_GENE_PRODUCT", 44, 48], ["macrophages", "CELL", 63, 74], ["M-CSF", "GENE_OR_GENE_PRODUCT", 88, 93], ["IL-10", "GENE_OR_GENE_PRODUCT", 98, 103], ["CD64", "PROTEIN", 44, 48], ["macrophages", "CELL_TYPE", 63, 74], ["another study", "TEST", 3, 16], ["macrophages", "PROBLEM", 63, 74], ["CD64", "OBSERVATION", 44, 48]]], ["For CD64, our findings were similar to the literature in that the CD64 expression of macrophages increased in the M1 and M2c group but decreased in the M2a group.", [["macrophages", "ANATOMY", 85, 96], ["M1", "ANATOMY", 114, 116], ["CD64", "GENE_OR_GENE_PRODUCT", 4, 8], ["CD64", "GENE_OR_GENE_PRODUCT", 66, 70], ["macrophages", "CELL", 85, 96], ["M1", "CELL", 114, 116], ["M2c", "CANCER", 121, 124], ["M2a", "CANCER", 152, 155], ["CD64", "PROTEIN", 4, 8], ["CD64", "PROTEIN", 66, 70], ["macrophages", "CELL_TYPE", 85, 96], ["CD64", "TEST", 4, 8], ["macrophages", "PROBLEM", 85, 96], ["macrophages", "OBSERVATION_MODIFIER", 85, 96], ["increased", "OBSERVATION_MODIFIER", 97, 106], ["M1", "ANATOMY", 114, 116], ["decreased", "OBSERVATION_MODIFIER", 135, 144]]], ["Additionally, the CD64 expressions of the MEM-D and MEM-ID macrophages were similar to those of the M1 and M2c macrophages.", [["MEM-ID macrophages", "ANATOMY", 52, 70], ["M1", "ANATOMY", 100, 102], ["M2c macrophages", "ANATOMY", 107, 122], ["CD64", "GENE_OR_GENE_PRODUCT", 18, 22], ["MEM-D", "GENE_OR_GENE_PRODUCT", 42, 47], ["MEM-ID macrophages", "CELL", 52, 70], ["M1", "CELL", 100, 102], ["M2c macrophages", "CELL", 107, 122], ["CD64", "PROTEIN", 18, 22], ["MEM-D and MEM-ID macrophages", "CELL_LINE", 42, 70], ["M1 and M2c macrophages", "CELL_LINE", 100, 122], ["the CD64 expressions", "TEST", 14, 34], ["the MEM-D and MEM-ID macrophages", "TEST", 38, 70], ["macrophages", "ANATOMY", 59, 70], ["M1", "ANATOMY", 100, 102]]], ["As in the case of CD14 expressions, this finding supports the idea MSCs may alter macrophages into the M2c-like phenotype.", [["MSCs", "ANATOMY", 67, 71], ["macrophages", "ANATOMY", 82, 93], ["CD14", "GENE_OR_GENE_PRODUCT", 18, 22], ["MSCs", "CELL", 67, 71], ["macrophages", "CELL", 82, 93], ["M2c", "GENE_OR_GENE_PRODUCT", 103, 106], ["CD14", "PROTEIN", 18, 22], ["MSCs", "CELL_TYPE", 67, 71], ["macrophages", "CELL_TYPE", 82, 93], ["CD14 expressions", "PROBLEM", 18, 34]]], ["CD80 is a molecule involved in the full activation of T cells by interacting with the CD28 co-stimulatory molecule of T cells during antigen presentation (Freeman et al., 1992) .", [["T cells", "ANATOMY", 54, 61], ["T cells", "ANATOMY", 118, 125], ["CD80", "GENE_OR_GENE_PRODUCT", 0, 4], ["T cells", "CELL", 54, 61], ["CD28", "GENE_OR_GENE_PRODUCT", 86, 90], ["T cells", "CELL", 118, 125], ["CD80", "PROTEIN", 0, 4], ["T cells", "CELL_TYPE", 54, 61], ["CD28 co-stimulatory molecule", "PROTEIN", 86, 114], ["T cells", "CELL_TYPE", 118, 125], ["a molecule", "PROBLEM", 8, 18]]], ["Jiang et al. reported that the CD80 expressions of LPS-stimulated macrophages were suppressed by MSCs; however, Spaggiari et al. reported no change (Jiang et al., 2005; Spaggiari et al., 2009) .", [["macrophages", "ANATOMY", 66, 77], ["MSCs", "ANATOMY", 97, 101], ["LPS", "CHEMICAL", 51, 54], ["CD80", "GENE_OR_GENE_PRODUCT", 31, 35], ["LPS", "SIMPLE_CHEMICAL", 51, 54], ["macrophages", "CELL", 66, 77], ["MSCs", "CELL", 97, 101], ["CD80", "PROTEIN", 31, 35], ["macrophages", "CELL_TYPE", 66, 77], ["MSCs", "CELL_TYPE", 97, 101], ["LPS", "TEST", 51, 54], ["stimulated macrophages", "PROBLEM", 55, 77], ["no", "UNCERTAINTY", 138, 140], ["change", "OBSERVATION_MODIFIER", 141, 147]]], ["In our experiments, we observed that the CD80 expressions of the MEM-D group were significantly higher compared to the other groups, except M2c.", [["CD80", "GENE_OR_GENE_PRODUCT", 41, 45], ["MEM-D", "GENE_OR_GENE_PRODUCT", 65, 70], ["CD80", "PROTEIN", 41, 45], ["the CD80 expressions", "TEST", 37, 57], ["the MEM-D group", "TEST", 61, 76]]], ["As shown in Fig. 4 , clusters where T cells interacted, indicating antigen presentation were more common in the MEM-D group than in the other groups.", [["T cells", "ANATOMY", 36, 43], ["T cells", "CELL", 36, 43], ["MEM-D", "SIMPLE_CHEMICAL", 112, 117], ["T cells", "CELL_TYPE", 36, 43], ["Fig", "OBSERVATION", 12, 15]]], ["These observations suggest that the co-stimulatory properties of macrophages could be increased by the presence of MSCs.ConclusionsCD163 is a scavenger receptor, the expression of which is increased by macrophages in response to IL-10 and TGF-b stimulation, but it is antagonized by IFN-g and IL-4 stimulation (Fabriek et al., 2005) .", [["macrophages", "ANATOMY", 65, 76], ["MSCs", "ANATOMY", 115, 119], ["macrophages", "ANATOMY", 202, 213], ["macrophages", "CELL", 65, 76], ["MSCs", "CELL", 115, 119], ["macrophages", "CELL", 202, 213], ["IL-10", "GENE_OR_GENE_PRODUCT", 229, 234], ["TGF-b", "GENE_OR_GENE_PRODUCT", 239, 244], ["IFN-g", "GENE_OR_GENE_PRODUCT", 283, 288], ["IL-4", "GENE_OR_GENE_PRODUCT", 293, 297], ["macrophages", "CELL_TYPE", 65, 76], ["MSCs", "CELL_TYPE", 115, 119], ["scavenger receptor", "PROTEIN", 142, 160], ["macrophages", "CELL_TYPE", 202, 213], ["IFN", "PROTEIN", 283, 286], ["MSCs", "PROBLEM", 115, 119], ["a scavenger receptor", "TREATMENT", 140, 160], ["IL", "TEST", 229, 231], ["TGF-b stimulation", "TREATMENT", 239, 256], ["macrophages", "OBSERVATION", 65, 76], ["increased", "OBSERVATION_MODIFIER", 86, 95], ["increased", "OBSERVATION_MODIFIER", 189, 198], ["macrophages", "OBSERVATION_MODIFIER", 202, 213]]], ["In this respect, CD163 is a sensitive marker for M2c macrophages, and we found that the CD163 expressions of the M2c macrophages significantly increased compared to the other groups.", [["M2c macrophages", "ANATOMY", 49, 64], ["M2c macrophages", "ANATOMY", 113, 128], ["CD163", "GENE_OR_GENE_PRODUCT", 17, 22], ["M2c macrophages", "CELL", 49, 64], ["CD163", "GENE_OR_GENE_PRODUCT", 88, 93], ["M2c macrophages", "CELL", 113, 128], ["CD163", "PROTEIN", 17, 22], ["M2c macrophages", "CELL_TYPE", 49, 64], ["CD163", "PROTEIN", 88, 93], ["M2c macrophages", "CELL_TYPE", 113, 128], ["M2c macrophages", "PROBLEM", 49, 64], ["the CD163 expressions", "TEST", 84, 105], ["the M2c macrophages", "PROBLEM", 109, 128], ["macrophages", "OBSERVATION", 117, 128], ["significantly", "OBSERVATION_MODIFIER", 129, 142], ["increased", "OBSERVATION_MODIFIER", 143, 152]]], ["Based on CD14 and CD64 expressions observed, we assumed that IL-10 produced by MSCs might differentiate macrophages into the M2c-like phenotype.", [["MSCs", "ANATOMY", 79, 83], ["macrophages", "ANATOMY", 104, 115], ["CD14", "GENE_OR_GENE_PRODUCT", 9, 13], ["CD64", "GENE_OR_GENE_PRODUCT", 18, 22], ["IL-10", "GENE_OR_GENE_PRODUCT", 61, 66], ["MSCs", "CELL", 79, 83], ["macrophages", "CELL", 104, 115], ["M2c", "GENE_OR_GENE_PRODUCT", 125, 128], ["CD14", "PROTEIN", 9, 13], ["CD64", "PROTEIN", 18, 22], ["IL-10", "PROTEIN", 61, 66], ["MSCs", "CELL_TYPE", 79, 83], ["macrophages", "CELL_TYPE", 104, 115], ["CD14", "TEST", 9, 13], ["CD64 expressions", "TEST", 18, 34], ["IL", "TEST", 61, 63]]], ["However, the absence of a CD163 increase in the MEM-D and MEM-ID groups did not support this assumption.", [["CD163", "GENE_OR_GENE_PRODUCT", 26, 31], ["MEM-D", "SIMPLE_CHEMICAL", 48, 53], ["CD163", "PROTEIN", 26, 31], ["a CD163 increase", "PROBLEM", 24, 40], ["MEM-ID groups", "TREATMENT", 58, 71]]], ["Finally, we found that CD200R, a specific MSCs (g).", [["MSCs", "ANATOMY", 42, 46], ["CD200R", "GENE_OR_GENE_PRODUCT", 23, 29], ["MSCs", "CELL", 42, 46], ["CD200R", "PROTEIN", 23, 29], ["MSCs", "CELL_TYPE", 42, 46]]], ["The microscopic images of activated PBMCs (h) and unstimulated PBMCs (i).", [["PBMCs", "ANATOMY", 36, 41], ["PBMCs", "ANATOMY", 63, 68], ["PBMCs", "CELL", 36, 41], ["PBMCs", "CELL", 63, 68], ["PBMCs", "CELL_TYPE", 36, 41], ["PBMCs", "CELL_TYPE", 63, 68], ["The microscopic images", "TEST", 0, 22], ["activated PBMCs (h", "TREATMENT", 26, 44]]], ["The activated T cells (orange colored) have accumulated on the surface of macrophage cells, however these accumulations were detected as more dense at M2a and MEM-D co-culture groups compared with the US-M, M1 and M2c co-culture groups. marker for M2a cells, decreased in M1 macrophages and increased in M2a macrophages, which is consistent with the literature.", [["T cells", "ANATOMY", 14, 21], ["surface", "ANATOMY", 63, 70], ["macrophage cells", "ANATOMY", 74, 90], ["M2a", "ANATOMY", 151, 154], ["M1", "ANATOMY", 207, 209], ["M2a cells", "ANATOMY", 248, 257], ["M1 macrophages", "ANATOMY", 272, 286], ["M2a macrophages", "ANATOMY", 304, 319], ["MEM-D", "CHEMICAL", 159, 164], ["T cells", "CELL", 14, 21], ["surface", "CELLULAR_COMPONENT", 63, 70], ["macrophage cells", "CELL", 74, 90], ["MEM-D", "CELL", 159, 164], ["US-M", "CELL", 201, 205], ["M1", "CELL", 207, 209], ["M2c", "CELL", 214, 217], ["M2a cells", "CELL", 248, 257], ["M1 macrophages", "CELL", 272, 286], ["M2a macrophages", "CELL", 304, 319], ["activated T cells", "CELL_TYPE", 4, 21], ["macrophage cells", "CELL_TYPE", 74, 90], ["M2a cells", "CELL_LINE", 248, 257], ["M1 macrophages", "CELL_TYPE", 272, 286], ["M2a macrophages", "CELL_LINE", 304, 319], ["macrophage cells", "PROBLEM", 74, 90], ["these accumulations", "PROBLEM", 100, 119], ["the US", "TEST", 197, 203], ["M2a cells", "PROBLEM", 248, 257], ["decreased in M1 macrophages", "PROBLEM", 259, 286], ["increased in M2a macrophages", "PROBLEM", 291, 319], ["macrophage cells", "OBSERVATION", 74, 90], ["dense", "OBSERVATION_MODIFIER", 142, 147], ["M1", "ANATOMY", 207, 209], ["M2a cells", "OBSERVATION", 248, 257], ["decreased", "OBSERVATION_MODIFIER", 259, 268], ["M1 macrophages", "OBSERVATION", 272, 286], ["increased", "OBSERVATION_MODIFIER", 291, 300], ["M2a macrophages", "OBSERVATION", 304, 319], ["consistent with", "UNCERTAINTY", 330, 345]]], ["We also observed that similar to CD163, the CD200R expressions of the MEM-D and MEM-ID macrophages were not altered compared to US-M.", [["MEM-ID macrophages", "ANATOMY", 80, 98], ["CD163", "GENE_OR_GENE_PRODUCT", 33, 38], ["CD200R", "GENE_OR_GENE_PRODUCT", 44, 50], ["MEM-D", "CELL", 70, 75], ["MEM-ID macrophages", "CELL", 80, 98], ["CD163", "PROTEIN", 33, 38], ["CD200R", "PROTEIN", 44, 50], ["MEM-D and MEM-ID macrophages", "CELL_LINE", 70, 98], ["CD163", "TEST", 33, 38], ["the MEM-D and MEM-ID macrophages", "TEST", 66, 98], ["macrophages", "ANATOMY", 87, 98]]], ["Not only IL-10, IL-4 and TGF-b, but also various immunosuppressive molecules, such as IDO, HGF, and PGE2 are known to be involved in the formation of immunomodulation effects of MSCs (Chen et al., 2011) .", [["MSCs", "ANATOMY", 178, 182], ["PGE2", "CHEMICAL", 100, 104], ["PGE2", "CHEMICAL", 100, 104], ["IL-10", "GENE_OR_GENE_PRODUCT", 9, 14], ["IL-4", "GENE_OR_GENE_PRODUCT", 16, 20], ["TGF-b", "GENE_OR_GENE_PRODUCT", 25, 30], ["IDO", "GENE_OR_GENE_PRODUCT", 86, 89], ["HGF", "GENE_OR_GENE_PRODUCT", 91, 94], ["PGE2", "SIMPLE_CHEMICAL", 100, 104], ["MSCs", "CELL", 178, 182], ["IL-10", "PROTEIN", 9, 14], ["IL-4", "PROTEIN", 16, 20], ["TGF-b", "PROTEIN", 25, 30], ["immunosuppressive molecules", "PROTEIN", 49, 76], ["IDO", "PROTEIN", 86, 89], ["HGF", "PROTEIN", 91, 94], ["MSCs", "CELL_TYPE", 178, 182], ["IL", "TEST", 9, 11], ["IL", "TEST", 16, 18], ["TGF", "TEST", 25, 28], ["various immunosuppressive molecules", "PROBLEM", 41, 76], ["HGF", "PROBLEM", 91, 94], ["PGE2", "PROBLEM", 100, 104], ["immunomodulation effects of MSCs", "PROBLEM", 150, 182], ["immunosuppressive molecules", "OBSERVATION", 49, 76]]], ["Therefore, macrophages cultured with MSCs are likely to be of a different phenotype than known phenotypes, which is also partially supported by our findings.", [["macrophages", "ANATOMY", 11, 22], ["MSCs", "ANATOMY", 37, 41], ["macrophages", "CELL", 11, 22], ["MSCs", "CELL", 37, 41], ["macrophages", "CELL_TYPE", 11, 22], ["MSCs", "CELL_TYPE", 37, 41], ["MSCs", "PROBLEM", 37, 41], ["a different phenotype than known phenotypes", "PROBLEM", 62, 105], ["macrophages", "OBSERVATION", 11, 22], ["likely to be", "UNCERTAINTY", 46, 58]]], ["We used limited and specific markers to evaluate the macrophage phenotypes; therefore, based on limited data, we were not able to make a definitive conclusion concerning the phenotype to which the macrophages cultured with MSCs were closest.ConclusionsIn this study, we focused on the functional comparison of the immunomodulatory effects of MEM-D and MEM-ID cells on CD4 T cells.ConclusionsTh1 cells, with the main cytokines of IFN-g and IL-2, orchestrate the elimination of intracellular pathogens (Boehm et al., 1997) , and they are related to certain organ-specific autoimmune pathologies, such as Type I diabetes (Luckheeram et al., 2012) .", [["macrophage", "ANATOMY", 53, 63], ["macrophages", "ANATOMY", 197, 208], ["MSCs", "ANATOMY", 223, 227], ["MEM-ID cells", "ANATOMY", 352, 364], ["CD4 T cells", "ANATOMY", 368, 379], ["Th1 cells", "ANATOMY", 391, 400], ["intracellular", "ANATOMY", 476, 489], ["organ", "ANATOMY", 555, 560], ["MEM-D", "CHEMICAL", 342, 347], ["autoimmune pathologies", "DISEASE", 570, 592], ["Type I diabetes", "DISEASE", 602, 617], ["macrophage", "CELL", 53, 63], ["macrophages", "CELL", 197, 208], ["MSCs", "CELL", 223, 227], ["MEM-D", "CELL", 342, 347], ["MEM-ID cells", "CELL", 352, 364], ["CD4 T cells", "CELL", 368, 379], ["Th1 cells", "CELL", 391, 400], ["IFN-g", "GENE_OR_GENE_PRODUCT", 429, 434], ["IL-2", "GENE_OR_GENE_PRODUCT", 439, 443], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 476, 489], ["organ", "ORGAN", 555, 560], ["macrophages", "CELL_TYPE", 197, 208], ["MSCs", "CELL_TYPE", 223, 227], ["MEM-D and MEM-ID cells", "CELL_LINE", 342, 364], ["CD4 T cells", "CELL_TYPE", 368, 379], ["Th1 cells", "CELL_TYPE", 391, 400], ["cytokines", "PROTEIN", 416, 425], ["IFN", "PROTEIN", 429, 432], ["IL", "PROTEIN", 439, 441], ["specific markers", "TEST", 20, 36], ["the macrophage phenotypes", "PROBLEM", 49, 74], ["the phenotype", "PROBLEM", 170, 183], ["MSCs", "PROBLEM", 223, 227], ["this study", "TEST", 255, 265], ["MEM", "TEST", 342, 345], ["IFN", "TEST", 429, 432], ["IL", "TEST", 439, 441], ["intracellular pathogens", "PROBLEM", 476, 499], ["specific autoimmune pathologies", "PROBLEM", 561, 592], ["Type I diabetes", "PROBLEM", 602, 617], ["Th1 cells", "OBSERVATION", 391, 400], ["main", "OBSERVATION_MODIFIER", 411, 415], ["cytokines", "OBSERVATION_MODIFIER", 416, 425], ["intracellular", "OBSERVATION_MODIFIER", 476, 489], ["pathogens", "OBSERVATION", 490, 499], ["autoimmune", "OBSERVATION", 570, 580]]], ["In terms of macrophages, M1 macrophages stimulate the differentiation of naive T cells into the Th1 phenotype.", [["macrophages", "ANATOMY", 12, 23], ["M1 macrophages", "ANATOMY", 25, 39], ["T cells", "ANATOMY", 79, 86], ["macrophages", "CELL", 12, 23], ["M1 macrophages", "CELL", 25, 39], ["T cells", "CELL", 79, 86], ["macrophages", "CELL_TYPE", 12, 23], ["M1 macrophages", "CELL_TYPE", 25, 39], ["naive T cells", "CELL_TYPE", 73, 86], ["macrophages", "PROBLEM", 12, 23], ["M1 macrophages", "PROBLEM", 25, 39], ["macrophages", "OBSERVATION", 12, 23], ["M1 macrophages", "OBSERVATION", 25, 39], ["Th1 phenotype", "OBSERVATION", 96, 109]]], ["In contrast, M2 macrophages stimulate Th2 and/or Treg cell differentiation and suppress Th1 differentiation (Martinez and Gordon, 2014; Charles A Janeway et al., 2001; Mills et al., 2000) .", [["M2 macrophages", "ANATOMY", 13, 27], ["Treg cell", "ANATOMY", 49, 58], ["M2 macrophages", "CELL", 13, 27], ["Th2", "CELL", 38, 41], ["Treg cell", "CELL", 49, 58], ["M2 macrophages", "CELL_TYPE", 13, 27], ["Th2", "TEST", 38, 41], ["Treg cell differentiation", "OBSERVATION", 49, 74]]], ["Previous research also reported that MSCs suppressed the Th1 response and stimulated Treg cells (Chen et al., 2011; Luz-Crawford et al., 2013) .", [["MSCs", "ANATOMY", 37, 41], ["Treg cells", "ANATOMY", 85, 95], ["MSCs", "CELL", 37, 41], ["Treg cells", "CELL", 85, 95], ["MSCs", "CELL_TYPE", 37, 41], ["Treg cells", "CELL_TYPE", 85, 95], ["MSCs", "PROBLEM", 37, 41]]], ["According to our findings, the CD4 + IFNg + (Th1) frequencies of all groups were similar, except the US-PBMC group.", [["CD4 + IFNg", "ANATOMY", 31, 41], ["PBMC", "ANATOMY", 104, 108], ["CD4", "GENE_OR_GENE_PRODUCT", 31, 34], ["IFNg", "GENE_OR_GENE_PRODUCT", 37, 41], ["US-PBMC", "CELL", 101, 108], ["CD4", "PROTEIN", 31, 34], ["IFNg", "PROTEIN", 37, 41], ["PBMC", "CELL_TYPE", 104, 108], ["the CD4", "TEST", 27, 34], ["the US", "TEST", 97, 103]]], ["However, there were dramatic and significant decreases in the IFN-g levels of the M2c, MEM-D, MEM-ID and MSC groups.", [["M2c", "ANATOMY", 82, 85], ["MSC", "ANATOMY", 105, 108], ["IFN-g", "GENE_OR_GENE_PRODUCT", 62, 67], ["M2c", "CELL", 82, 85], ["MEM-D", "CELL", 87, 92], ["MEM-ID", "CELL", 94, 100], ["MSC", "CELL", 105, 108], ["IFN", "PROTEIN", 62, 65], ["significant decreases", "PROBLEM", 33, 54], ["the IFN", "TEST", 58, 65], ["MEM", "TEST", 87, 90], ["MEM", "TEST", 94, 97], ["dramatic", "OBSERVATION_MODIFIER", 20, 28], ["significant", "OBSERVATION_MODIFIER", 33, 44], ["decreases", "OBSERVATION_MODIFIER", 45, 54], ["MSC", "ANATOMY", 105, 108]]], ["This finding suggests that the CD4 + IFNg + cell frequencies may not be affected by different macrophage phenotypes, but their functions can be suppressed by M2c, MEM and MSC cells.ConclusionsTh2 cells orchestrate the immune response to extracellular parasites, and they are associated with asthma and allergic disorders.", [["CD4 + IFNg + cell", "ANATOMY", 31, 48], ["macrophage", "ANATOMY", 94, 104], ["MEM", "ANATOMY", 163, 166], ["MSC cells", "ANATOMY", 171, 180], ["Th2 cells", "ANATOMY", 192, 201], ["extracellular", "ANATOMY", 237, 250], ["asthma", "DISEASE", 291, 297], ["allergic disorders", "DISEASE", 302, 320], ["CD4", "GENE_OR_GENE_PRODUCT", 31, 34], ["macrophage", "CELL", 94, 104], ["M2c", "CELL", 158, 161], ["MEM", "CELL", 163, 166], ["MSC cells", "CELL", 171, 180], ["Th2 cells", "CELL", 192, 201], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 237, 250], ["CD4", "PROTEIN", 31, 34], ["IFNg", "PROTEIN", 37, 41], ["M2c, MEM and MSC cells", "CELL_LINE", 158, 180], ["Th2 cells", "CELL_LINE", 192, 201], ["the CD4", "TEST", 27, 34], ["IFNg + cell frequencies", "PROBLEM", 37, 60], ["different macrophage phenotypes", "PROBLEM", 84, 115], ["extracellular parasites", "PROBLEM", 237, 260], ["asthma", "PROBLEM", 291, 297], ["allergic disorders", "PROBLEM", 302, 320], ["IFNg + cell frequencies", "OBSERVATION", 37, 60], ["may not be", "UNCERTAINTY", 61, 71], ["macrophage phenotypes", "OBSERVATION", 94, 115], ["MSC cells", "OBSERVATION", 171, 180], ["Th2 cells", "OBSERVATION", 192, 201], ["extracellular parasites", "OBSERVATION", 237, 260], ["associated with", "UNCERTAINTY", 275, 290], ["asthma", "OBSERVATION", 291, 297], ["allergic disorders", "OBSERVATION", 302, 320]]], ["The main cytokines of Th2 cells are IL-4, IL-5, IL-13, and IL-10 (Deo et al., 2010; Steinke and Borish, 2001) .", [["Th2 cells", "ANATOMY", 22, 31], ["Th2 cells", "CELL", 22, 31], ["IL-4", "GENE_OR_GENE_PRODUCT", 36, 40], ["IL-5", "GENE_OR_GENE_PRODUCT", 42, 46], ["IL-13", "GENE_OR_GENE_PRODUCT", 48, 53], ["IL-10", "GENE_OR_GENE_PRODUCT", 59, 64], ["cytokines", "PROTEIN", 9, 18], ["Th2 cells", "CELL_TYPE", 22, 31], ["IL", "TEST", 36, 38], ["IL", "TEST", 42, 44], ["IL", "TEST", 48, 50], ["main", "OBSERVATION_MODIFIER", 4, 8], ["cytokines", "OBSERVATION", 9, 18], ["Th2 cells", "OBSERVATION", 22, 31]]], ["The presence of a synergistic interaction between the Th2 cells and M2 macrophages has previously been reported (Muraille et al., 2014) .", [["Th2 cells", "ANATOMY", 54, 63], ["M2 macrophages", "ANATOMY", 68, 82], ["Th2 cells", "CELL", 54, 63], ["M2 macrophages", "CELL", 68, 82], ["Th2 cells", "CELL_LINE", 54, 63], ["M2 macrophages", "CELL_TYPE", 68, 82], ["a synergistic interaction", "PROBLEM", 16, 41], ["synergistic", "OBSERVATION_MODIFIER", 18, 29], ["interaction", "OBSERVATION", 30, 41], ["Th2 cells", "OBSERVATION", 54, 63], ["M2 macrophages", "OBSERVATION", 68, 82]]], ["Our data confirmed that IL-4 stimulated macrophages (M2a) could significantly stimulate Th2 frequencies and IL-4 production.", [["macrophages", "ANATOMY", 40, 51], ["IL-4", "GENE_OR_GENE_PRODUCT", 24, 28], ["macrophages", "CELL", 40, 51], ["M2a", "CANCER", 53, 56], ["IL-4", "GENE_OR_GENE_PRODUCT", 108, 112], ["IL-4", "PROTEIN", 24, 28], ["macrophages", "CELL_TYPE", 40, 51], ["Our data", "TEST", 0, 8], ["IL-4 stimulated macrophages", "TREATMENT", 24, 51]]], ["However, although the Th2 frequencies of the groups except M2a were close to each other, the IL-4 levels of the US-M and MEM-ID groups were significantly lower than those of the other groups.", [["M2a", "GENE_OR_GENE_PRODUCT", 59, 62], ["IL-4", "GENE_OR_GENE_PRODUCT", 93, 97], ["IL", "PROTEIN", 93, 95], ["the US", "TEST", 108, 114], ["MEM-ID groups", "TEST", 121, 134]]], ["In the current literature, different results have been reported about MSC and Th2 interactions.", [["MSC", "ANATOMY", 70, 73], ["MSC", "CELL", 70, 73], ["Th2", "GENE_OR_GENE_PRODUCT", 78, 81], ["MSC", "CELL_TYPE", 70, 73]]], ["Mareschi et al. found that amniotic fluid MSCs and placenta MSCs could stimulate the IL-4 expressions of activated PBMCs, but not in bone marrow MSCs (Mareschi et al., 2015) .", [["amniotic fluid MSCs", "ANATOMY", 27, 46], ["placenta MSCs", "ANATOMY", 51, 64], ["PBMCs", "ANATOMY", 115, 120], ["bone marrow MSCs", "ANATOMY", 133, 149], ["amniotic fluid MSCs", "CELL", 27, 46], ["placenta MSCs", "CELL", 51, 64], ["IL-4", "GENE_OR_GENE_PRODUCT", 85, 89], ["PBMCs", "CELL", 115, 120], ["bone marrow MSCs", "CELL", 133, 149], ["amniotic fluid MSCs", "CELL_TYPE", 27, 46], ["placenta MSCs", "CELL_TYPE", 51, 64], ["IL-4", "PROTEIN", 85, 89], ["PBMCs", "CELL_TYPE", 115, 120], ["bone marrow MSCs", "CELL_TYPE", 133, 149], ["amniotic fluid MSCs", "PROBLEM", 27, 46], ["placenta MSCs", "PROBLEM", 51, 64], ["the IL", "TEST", 81, 87], ["activated PBMCs", "PROBLEM", 105, 120], ["amniotic", "OBSERVATION", 27, 35], ["fluid MSCs", "OBSERVATION", 36, 46], ["bone marrow", "ANATOMY", 133, 144]]], ["\u00d6zdemir et al. and Gen\u00e7 et al. showed that dental tissue MSCs could suppress the IL-4 expressions of T cells (\u00d6zdemir et al., 2016; Gen\u00e7 et al., 2018) .", [["tissue MSCs", "ANATOMY", 50, 61], ["T cells", "ANATOMY", 101, 108], ["dental tissue MSCs", "CELL", 43, 61], ["IL-4", "GENE_OR_GENE_PRODUCT", 81, 85], ["T cells", "CELL", 101, 108], ["MSCs", "CELL_TYPE", 57, 61], ["IL-4", "PROTEIN", 81, 85], ["T cells", "CELL_TYPE", 101, 108], ["dental tissue MSCs", "PROBLEM", 43, 61], ["the IL", "TEST", 77, 83], ["dental tissue", "ANATOMY", 43, 56]]], ["In our experiments, we used adipose tissue MSCs and observed that the IL-4 levels significantly increased in the MSC and MEM-D groups compared with the MEM-ID and US-PBMC groups.", [["adipose tissue MSCs", "ANATOMY", 28, 47], ["MSC", "ANATOMY", 113, 116], ["PBMC", "ANATOMY", 166, 170], ["MEM-D", "CHEMICAL", 121, 126], ["adipose tissue MSCs", "CELL", 28, 47], ["IL-4", "GENE_OR_GENE_PRODUCT", 70, 74], ["MSC", "CELL", 113, 116], ["MEM-D", "SIMPLE_CHEMICAL", 121, 126], ["US-PBMC", "CELL", 163, 170], ["adipose tissue MSCs", "CELL_TYPE", 28, 47], ["IL", "PROTEIN", 70, 72], ["PBMC", "CELL_TYPE", 166, 170], ["adipose tissue MSCs", "TREATMENT", 28, 47], ["the IL-4 levels", "TEST", 66, 81], ["the MEM", "TEST", 148, 155], ["increased", "OBSERVATION_MODIFIER", 96, 105], ["MSC", "ANATOMY", 113, 116]]], ["The similarity we observed in US-M and MEM-ID for IL-4 levels may indicate that MSCs may have forced the macrophages to remain in an unstimulated form when there was no direct interaction.ConclusionsTh17 cells have been reported to play a role in the pathogenesis of many autoimmune diseases; e.g., RA, SLE and Crohn's disease (Tabarkiewicz et al., 2015) .", [["MSCs", "ANATOMY", 80, 84], ["macrophages", "ANATOMY", 105, 116], ["ConclusionsTh17 cells", "ANATOMY", 188, 209], ["autoimmune diseases", "DISEASE", 272, 291], ["RA", "DISEASE", 299, 301], ["SLE", "DISEASE", 303, 306], ["Crohn's disease", "DISEASE", 311, 326], ["MEM-ID", "GENE_OR_GENE_PRODUCT", 39, 45], ["IL-4", "GENE_OR_GENE_PRODUCT", 50, 54], ["MSCs", "CELL", 80, 84], ["macrophages", "CELL", 105, 116], ["ConclusionsTh17 cells", "CELL", 188, 209], ["IL", "PROTEIN", 50, 52], ["MSCs", "CELL_TYPE", 80, 84], ["macrophages", "CELL_TYPE", 105, 116], ["ConclusionsTh17 cells", "CELL_LINE", 188, 209], ["IL-4 levels", "TEST", 50, 61], ["MSCs", "PROBLEM", 80, 84], ["many autoimmune diseases", "PROBLEM", 267, 291], ["SLE", "PROBLEM", 303, 306], ["Crohn's disease", "PROBLEM", 311, 326], ["many", "OBSERVATION_MODIFIER", 267, 271], ["autoimmune", "OBSERVATION", 272, 282], ["RA", "ANATOMY", 299, 301], ["SLE", "ANATOMY", 303, 306], ["Crohn", "OBSERVATION", 311, 316]]], ["As opposed to Th1 and Th2 cells that are terminally differentiated, Th17 cells can alter their phenotype in response to signals from the environment.", [["Th2 cells", "ANATOMY", 22, 31], ["Th17 cells", "ANATOMY", 68, 78], ["Th1", "CELL", 14, 17], ["Th2 cells", "CELL", 22, 31], ["Th17 cells", "CELL", 68, 78], ["Th1 and Th2 cells", "CELL_TYPE", 14, 31], ["Th17 cells", "CELL_TYPE", 68, 78], ["Th1 and Th2 cells", "TREATMENT", 14, 31], ["Th17 cells", "PROBLEM", 68, 78], ["Th1", "ANATOMY", 14, 17], ["Th2 cells", "OBSERVATION", 22, 31], ["Th17 cells", "OBSERVATION", 68, 78]]], ["For example, Bofeng et al. reported that IL-10 induced macrophages contributed to the pathogenesis of colitis by increasing Th17 activity (Li et al., 2015a) .", [["macrophages", "ANATOMY", 55, 66], ["colitis", "DISEASE", 102, 109], ["IL-10", "GENE_OR_GENE_PRODUCT", 41, 46], ["macrophages", "CELL", 55, 66], ["colitis", "PATHOLOGICAL_FORMATION", 102, 109], ["IL-10", "PROTEIN", 41, 46], ["macrophages", "CELL_TYPE", 55, 66], ["IL", "TREATMENT", 41, 43], ["macrophages", "PROBLEM", 55, 66], ["colitis", "PROBLEM", 102, 109], ["colitis", "OBSERVATION", 102, 109]]], ["Haribhai et al. showed that TGF-b-producing M2a macrophages differentiated Th17 cells into anti-inflammatory iTreg cells (Haribhai et al., 2016) .", [["M2a macrophages", "ANATOMY", 44, 59], ["Th17 cells", "ANATOMY", 75, 85], ["iTreg cells", "ANATOMY", 109, 120], ["TGF-b-", "GENE_OR_GENE_PRODUCT", 28, 34], ["M2a macrophages", "CELL", 44, 59], ["Th17 cells", "CELL", 75, 85], ["iTreg cells", "CELL", 109, 120], ["TGF-b-producing M2a macrophages", "CELL_LINE", 28, 59], ["Th17 cells", "CELL_TYPE", 75, 85], ["anti-inflammatory iTreg cells", "CELL_TYPE", 91, 120], ["TGF", "TEST", 28, 31], ["M2a macrophages", "OBSERVATION", 44, 59], ["Th17 cells", "OBSERVATION", 75, 85], ["anti-inflammatory iTreg cells", "OBSERVATION", 91, 120]]], ["For MSCs and Th17 interactions, Qu et al. reported that Th17 cells were suppressed by IL-10 secreted by MSCs (Qu et al., 2012) , Rozenberg et al. showed that PGE2 secreted from MSCs increased the Th17 response but suppressed the Th1 response (Rozenberg et al., 2016) , and Ghannam et al. noted that MSCs increased Treg cells by suppressing Th17 cells (Ghannam et al., 2010) .", [["MSCs", "ANATOMY", 4, 8], ["Th17 cells", "ANATOMY", 56, 66], ["MSCs", "ANATOMY", 104, 108], ["MSCs", "ANATOMY", 177, 181], ["MSCs", "ANATOMY", 299, 303], ["Treg cells", "ANATOMY", 314, 324], ["Th17 cells", "ANATOMY", 340, 350], ["PGE2", "CHEMICAL", 158, 162], ["PGE2", "CHEMICAL", 158, 162], ["MSCs", "CELL", 4, 8], ["Th17", "CELL", 13, 17], ["Th17 cells", "CELL", 56, 66], ["IL-10", "GENE_OR_GENE_PRODUCT", 86, 91], ["MSCs", "CELL", 104, 108], ["PGE2", "SIMPLE_CHEMICAL", 158, 162], ["MSCs", "CELL", 177, 181], ["Th17", "CELL", 196, 200], ["MSCs", "CELL", 299, 303], ["Treg cells", "CELL", 314, 324], ["Th17 cells", "CELL", 340, 350], ["MSCs", "CELL_TYPE", 4, 8], ["Th17 cells", "CELL_TYPE", 56, 66], ["IL-10", "PROTEIN", 86, 91], ["MSCs", "CELL_TYPE", 104, 108], ["PGE2", "PROTEIN", 158, 162], ["MSCs", "CELL_TYPE", 177, 181], ["MSCs", "CELL_TYPE", 299, 303], ["Treg cells", "CELL_TYPE", 314, 324], ["Th17 cells", "CELL_TYPE", 340, 350], ["MSCs", "PROBLEM", 4, 8], ["Th17 cells", "PROBLEM", 56, 66], ["PGE2 secreted", "PROBLEM", 158, 171], ["MSCs", "PROBLEM", 177, 181], ["MSCs increased Treg cells", "PROBLEM", 299, 324], ["Th17 cells", "OBSERVATION", 56, 66], ["MSCs", "ANATOMY", 299, 303], ["increased Treg cells", "OBSERVATION", 304, 324]]], ["Our findings revealed that the Th17 frequencies of the A-PBMC group was significantly higher than those of the remaining groups, except M1 and M2c.", [["A-PBMC", "ANATOMY", 55, 61], ["A-PBMC", "CANCER", 55, 61], ["M1", "CELL", 136, 138], ["M2c", "GENE_OR_GENE_PRODUCT", 143, 146], ["Our findings", "TEST", 0, 12], ["higher", "OBSERVATION_MODIFIER", 86, 92], ["M1", "ANATOMY", 136, 138]]], ["The IL-17a levels and Th17 frequencies of the M1 and M2c groups were consistent, but IL-17a remained high in the MSC group (Fig. 7) .", [["M1", "ANATOMY", 46, 48], ["MSC", "ANATOMY", 113, 116], ["IL-17a", "GENE_OR_GENE_PRODUCT", 4, 10], ["M1", "CELL", 46, 48], ["M2c", "CANCER", 53, 56], ["IL-17a", "GENE_OR_GENE_PRODUCT", 85, 91], ["MSC", "CELL", 113, 116], ["IL", "PROTEIN", 4, 6], ["IL", "PROTEIN", 85, 87], ["The IL-17a levels", "TEST", 0, 17], ["Th17 frequencies", "TEST", 22, 38], ["IL", "TEST", 85, 87], ["M1", "ANATOMY", 46, 48]]], ["According to our data, IL-10 induced macrophages may be important for stimulating both Th17 cell frequency and IL-17a production.", [["macrophages", "ANATOMY", 37, 48], ["Th17 cell", "ANATOMY", 87, 96], ["IL-10", "GENE_OR_GENE_PRODUCT", 23, 28], ["macrophages", "CELL", 37, 48], ["Th17 cell", "CELL", 87, 96], ["IL-17a", "GENE_OR_GENE_PRODUCT", 111, 117], ["macrophages", "CELL_TYPE", 37, 48], ["IL", "TREATMENT", 23, 25]]], ["However, even if there is no effect on Th17 frequencies, direct or indirect interaction of macrophages with MSCs may have a negative effect on IL-17a production.ConclusionsTreg cells are important since they are responsible for the suppression of the immune system and tolerance to self-antigens.", [["macrophages", "ANATOMY", 91, 102], ["MSCs", "ANATOMY", 108, 112], ["Treg cells", "ANATOMY", 172, 182], ["immune system", "ANATOMY", 251, 264], ["Th17", "CELL", 39, 43], ["macrophages", "CELL", 91, 102], ["MSCs", "CELL", 108, 112], ["IL-17a", "GENE_OR_GENE_PRODUCT", 143, 149], ["Treg cells", "CELL", 172, 182], ["macrophages", "CELL_TYPE", 91, 102], ["MSCs", "CELL_TYPE", 108, 112], ["Treg cells", "CELL_TYPE", 172, 182], ["effect on Th17 frequencies", "PROBLEM", 29, 55], ["MSCs", "PROBLEM", 108, 112], ["no", "UNCERTAINTY", 26, 28], ["Treg cells", "OBSERVATION", 172, 182]]], ["Activation of FoxP3, a specific transcription factor of these cells, leads to the secretion of suppressive cytokines, such as IL-10 and TGF-b (Li et al., 2015b) .", [["cells", "ANATOMY", 62, 67], ["FoxP3", "GENE_OR_GENE_PRODUCT", 14, 19], ["cells", "CELL", 62, 67], ["IL-10", "GENE_OR_GENE_PRODUCT", 126, 131], ["TGF-b", "GENE_OR_GENE_PRODUCT", 136, 141], ["FoxP3", "PROTEIN", 14, 19], ["transcription factor", "PROTEIN", 32, 52], ["cytokines", "PROTEIN", 107, 116], ["IL", "PROTEIN", 126, 128], ["TGF", "PROTEIN", 136, 139], ["FoxP3", "TREATMENT", 14, 19], ["these cells", "PROBLEM", 56, 67], ["suppressive cytokines", "TREATMENT", 95, 116], ["IL", "TEST", 126, 128]]], ["A co-inhibitor molecule CTLA-4 is highly expressed on Treg cells and interacts with CD80/CD86 molecules, leading to the secretion of IDO from antigen-presenting cells (Oderup et al., 2006) .", [["Treg cells", "ANATOMY", 54, 64], ["cells", "ANATOMY", 161, 166], ["CTLA-4", "GENE_OR_GENE_PRODUCT", 24, 30], ["Treg cells", "CELL", 54, 64], ["CD80", "GENE_OR_GENE_PRODUCT", 84, 88], ["CD86", "GENE_OR_GENE_PRODUCT", 89, 93], ["IDO", "GENE_OR_GENE_PRODUCT", 133, 136], ["antigen", "GENE_OR_GENE_PRODUCT", 142, 149], ["cells", "CELL", 161, 166], ["co-inhibitor molecule", "PROTEIN", 2, 23], ["CTLA-4", "PROTEIN", 24, 30], ["Treg cells", "CELL_TYPE", 54, 64], ["CD80", "PROTEIN", 84, 88], ["CD86 molecules", "PROTEIN", 89, 103], ["IDO", "PROTEIN", 133, 136], ["antigen-presenting cells", "CELL_TYPE", 142, 166], ["A co-inhibitor molecule CTLA", "TEST", 0, 28], ["CD80/CD86 molecules", "TREATMENT", 84, 103], ["Treg cells", "OBSERVATION", 54, 64]]], ["The comparison charts of CD4 + IFNg + , CD4 + IL4 + , CD4 + IL17a + and CD4 + FoxP3 + T cell frequencies according to experiment groups.", [["CD4 + IFNg + , CD4 + IL4 + , CD4 + IL17", "ANATOMY", 25, 64], ["CD4 + FoxP3 + T cell", "ANATOMY", 72, 92], ["CD4", "GENE_OR_GENE_PRODUCT", 25, 28], ["IFNg", "GENE_OR_GENE_PRODUCT", 31, 35], ["CD4", "GENE_OR_GENE_PRODUCT", 40, 43], ["IL4", "GENE_OR_GENE_PRODUCT", 46, 49], ["CD4", "GENE_OR_GENE_PRODUCT", 54, 57], ["IL17", "GENE_OR_GENE_PRODUCT", 60, 64], ["CD4", "GENE_OR_GENE_PRODUCT", 72, 75], ["FoxP3", "GENE_OR_GENE_PRODUCT", 78, 83], ["CD4", "PROTEIN", 25, 28], ["IFNg", "PROTEIN", 31, 35], ["CD4", "PROTEIN", 40, 43], ["IL4", "PROTEIN", 46, 49], ["CD4", "PROTEIN", 54, 57], ["IL17", "PROTEIN", 60, 64], ["CD4", "PROTEIN", 72, 75], ["FoxP3", "PROTEIN", 78, 83], ["CD4", "TEST", 25, 28], ["IFNg", "TEST", 31, 35], ["CD4", "TEST", 40, 43], ["IL4", "TEST", 46, 49], ["CD4", "TEST", 54, 57], ["IL17", "TEST", 60, 64], ["CD4", "TEST", 72, 75], ["T cell frequencies", "TREATMENT", 86, 104]]], ["There are significant differences (p < 0.05) between the \"a\" and the rhombus symbols, \"b\" and the square symbols, \"c\" and the star symbols.", [["significant", "OBSERVATION_MODIFIER", 10, 21], ["differences", "OBSERVATION_MODIFIER", 22, 33]]], ["Schmidt et al. reported that M2 macrophages stabilized the FoxP3 expression of CD4 T cells, and in this way, led to a decrease in IFN-g and IL-17 production (Schmidt et al., 2016) .", [["M2 macrophages", "ANATOMY", 29, 43], ["CD4 T cells", "ANATOMY", 79, 90], ["M2 macrophages", "CELL", 29, 43], ["FoxP3", "GENE_OR_GENE_PRODUCT", 59, 64], ["CD4 T", "GENE_OR_GENE_PRODUCT", 79, 84], ["IFN-g", "GENE_OR_GENE_PRODUCT", 130, 135], ["IL-17", "GENE_OR_GENE_PRODUCT", 140, 145], ["M2 macrophages", "CELL_TYPE", 29, 43], ["FoxP3", "PROTEIN", 59, 64], ["CD4 T cells", "CELL_TYPE", 79, 90], ["IFN", "PROTEIN", 130, 133], ["M2 macrophages", "PROBLEM", 29, 43], ["CD4 T cells", "PROBLEM", 79, 90], ["a decrease in IFN", "PROBLEM", 116, 133], ["M2 macrophages", "OBSERVATION", 29, 43], ["FoxP3 expression", "OBSERVATION", 59, 75], ["CD4 T cells", "OBSERVATION", 79, 90], ["decrease", "OBSERVATION_MODIFIER", 118, 126]]], ["Similar to M2 macrophages, MSCs have a positive effect on the activation of Treg cells.", [["M2 macrophages", "ANATOMY", 11, 25], ["MSCs", "ANATOMY", 27, 31], ["Treg cells", "ANATOMY", 76, 86], ["M2 macrophages", "CELL", 11, 25], ["MSCs", "CELL", 27, 31], ["Treg cells", "CELL", 76, 86], ["M2 macrophages", "CELL_LINE", 11, 25], ["MSCs", "CELL_TYPE", 27, 31], ["Treg cells", "CELL_TYPE", 76, 86], ["MSCs", "PROBLEM", 27, 31], ["a positive effect", "PROBLEM", 37, 54], ["M2 macrophages", "OBSERVATION", 11, 25], ["positive effect", "OBSERVATION_MODIFIER", 39, 54], ["Treg cells", "OBSERVATION", 76, 86]]], ["Gazdic et al. showed that the interaction between MSCs and Treg cells played an important role in improving acute liver injury in mouse models (Gazdic et al., 2018) .", [["MSCs", "ANATOMY", 50, 54], ["Treg cells", "ANATOMY", 59, 69], ["liver", "ANATOMY", 114, 119], ["acute liver injury", "DISEASE", 108, 126], ["MSCs", "CELL", 50, 54], ["Treg cells", "CELL", 59, 69], ["liver", "ORGAN", 114, 119], ["mouse", "ORGANISM", 130, 135], ["MSCs", "CELL_TYPE", 50, 54], ["Treg cells", "CELL_TYPE", 59, 69], ["mouse", "SPECIES", 130, 135], ["mouse", "SPECIES", 130, 135], ["the interaction between MSCs and Treg cells", "PROBLEM", 26, 69], ["improving acute liver injury", "PROBLEM", 98, 126], ["Treg cells", "OBSERVATION", 59, 69], ["improving", "OBSERVATION_MODIFIER", 98, 107], ["acute", "OBSERVATION_MODIFIER", 108, 113], ["liver", "ANATOMY", 114, 119], ["injury", "OBSERVATION", 120, 126]]], ["Ozdemir et al. suggested that dental pulp MSCs increased the Treg cell ratio, probably due to the phenotypic shift of Th17 cells to Treg cells (\u00d6zdemir et al., 2016) .", [["dental pulp MSCs", "ANATOMY", 30, 46], ["Treg cell", "ANATOMY", 61, 70], ["Th17 cells", "ANATOMY", 118, 128], ["Treg cells", "ANATOMY", 132, 142], ["dental pulp MSCs", "CELL", 30, 46], ["Treg cell", "CELL", 61, 70], ["Th17 cells", "CELL", 118, 128], ["Treg cells", "CELL", 132, 142], ["dental pulp MSCs", "CELL_TYPE", 30, 46], ["Th17 cells", "CELL_TYPE", 118, 128], ["Treg cells", "CELL_TYPE", 132, 142], ["dental pulp MSCs", "TEST", 30, 46], ["the Treg cell ratio", "TEST", 57, 76], ["the phenotypic shift", "PROBLEM", 94, 114], ["Th17 cells", "PROBLEM", 118, 128], ["Treg cell", "OBSERVATION", 61, 70], ["Th17 cells", "OBSERVATION", 118, 128]]], ["In our study, the Treg cell frequencies were significantly higher in the MEM-D group than in the other groups.", [["Treg cell", "ANATOMY", 18, 27], ["MEM-D", "CHEMICAL", 73, 78], ["Treg cell", "CELL", 18, 27], ["MEM-D", "SIMPLE_CHEMICAL", 73, 78], ["our study", "TEST", 3, 12], ["the Treg cell frequencies", "TEST", 14, 39], ["Treg cell", "OBSERVATION", 18, 27], ["significantly", "OBSERVATION_MODIFIER", 45, 58], ["higher", "OBSERVATION_MODIFIER", 59, 65]]], ["However, the IL-10 levels of the MEM-D group were significantly lower compared to the other groups, except the MSC group.", [["MSC", "ANATOMY", 111, 114], ["MEM-D", "CHEMICAL", 33, 38], ["IL-10", "GENE_OR_GENE_PRODUCT", 13, 18], ["MEM-D", "SIMPLE_CHEMICAL", 33, 38], ["MSC", "CELL", 111, 114], ["IL", "PROTEIN", 13, 15], ["the IL", "TEST", 9, 15], ["the MEM-D group", "TEST", 29, 44], ["MSC", "ANATOMY", 111, 114]]], ["We reviewed the literature to interpret this finding and found studies showing that over-activated Th1, Th2 and even Th17 cells could produce IL-10 to manage this activation (Maynard and Weaver, 2008; O'Garra and Vieira, 2007; Ye et al., 2007) .", [["Th17 cells", "ANATOMY", 117, 127], ["Th1", "CELL", 99, 102], ["Th2", "CELL", 104, 107], ["Th17 cells", "CELL", 117, 127], ["IL-10", "GENE_OR_GENE_PRODUCT", 142, 147], ["Th2", "CELL_TYPE", 104, 107], ["Th17 cells", "CELL_TYPE", 117, 127], ["IL", "PROTEIN", 142, 144], ["studies", "TEST", 63, 70], ["IL", "TEST", 142, 144]]], ["It has been reported that the Borrelia burgdorferi and Toxoplasma gondii infections lead to an increase in IFNg + IL-10 + cells (O'Garra and Vieira, 2007) .", [["IFNg + IL-10 + cells", "ANATOMY", 107, 127], ["Borrelia burgdorferi", "DISEASE", 30, 50], ["Toxoplasma gondii infections", "DISEASE", 55, 83], ["Borrelia burgdorferi", "ORGANISM", 30, 50], ["Toxoplasma gondii", "ORGANISM", 55, 72], ["IL-10", "GENE_OR_GENE_PRODUCT", 114, 119], ["IFNg", "PROTEIN", 107, 111], ["Borrelia burgdorferi", "SPECIES", 30, 50], ["Toxoplasma gondii", "SPECIES", 55, 72], ["Borrelia burgdorferi", "SPECIES", 30, 50], ["Toxoplasma gondii", "SPECIES", 55, 72], ["the Borrelia burgdorferi", "PROBLEM", 26, 50], ["Toxoplasma gondii infections", "PROBLEM", 55, 83], ["an increase in IFNg + IL", "PROBLEM", 92, 116], ["Borrelia", "OBSERVATION_MODIFIER", 30, 38], ["increase", "OBSERVATION_MODIFIER", 95, 103]]], ["Another interesting study reported that over-activated virus-specific CD8 + T cells could produce IL-10 in coronavirus infection, and these cells were shown to produce higher levels of pro-inflammatory cytokines and cytotoxic proteins than other cells (Maynard and Weaver, 2008) .", [["CD8 + T cells", "ANATOMY", 70, 83], ["cells", "ANATOMY", 140, 145], ["cells", "ANATOMY", 246, 251], ["coronavirus infection", "DISEASE", 107, 128], ["virus", "ORGANISM", 55, 60], ["CD8", "GENE_OR_GENE_PRODUCT", 70, 73], ["IL-10", "GENE_OR_GENE_PRODUCT", 98, 103], ["coronavirus", "ORGANISM", 107, 118], ["cells", "CELL", 140, 145], ["cells", "CELL", 246, 251], ["CD8 + T cells", "CELL_TYPE", 70, 83], ["IL-10", "PROTEIN", 98, 103], ["pro-inflammatory cytokines", "PROTEIN", 185, 211], ["cytotoxic proteins", "PROTEIN", 216, 234], ["Another interesting study", "TEST", 0, 25], ["activated virus", "PROBLEM", 45, 60], ["T cells", "PROBLEM", 76, 83], ["IL", "TEST", 98, 100], ["coronavirus infection", "PROBLEM", 107, 128], ["these cells", "TEST", 134, 145], ["pro-inflammatory cytokines", "PROBLEM", 185, 211], ["cytotoxic proteins than other cells", "PROBLEM", 216, 251], ["coronavirus", "ANATOMY", 107, 118], ["infection", "OBSERVATION", 119, 128], ["pro-inflammatory cytokines", "OBSERVATION", 185, 211]]], ["If we try to interpret our data according to the information in the literature, the direct interaction of MSCs and macrophage cells may increase the frequency of Treg cells even more than the other macrophage phenotypes, and even MSCs themselves.", [["MSCs", "ANATOMY", 106, 110], ["macrophage cells", "ANATOMY", 115, 131], ["Treg cells", "ANATOMY", 162, 172], ["macrophage", "ANATOMY", 198, 208], ["MSCs", "ANATOMY", 230, 234], ["MSCs", "CELL", 106, 110], ["macrophage cells", "CELL", 115, 131], ["Treg cells", "CELL", 162, 172], ["macrophage", "CELL", 198, 208], ["MSCs", "CELL", 230, 234], ["MSCs", "CELL_TYPE", 106, 110], ["macrophage cells", "CELL_TYPE", 115, 131], ["Treg cells", "CELL_TYPE", 162, 172], ["MSCs", "CELL_TYPE", 230, 234], ["MSCs and macrophage cells", "TREATMENT", 106, 131], ["Treg cells", "PROBLEM", 162, 172]]], ["Furthermore, overactivation of T cells may be the cause of elevated IL- Fig. 7 .", [["T cells", "ANATOMY", 31, 38], ["T cells", "CELL", 31, 38], ["IL", "GENE_OR_GENE_PRODUCT", 68, 70], ["T cells", "CELL_TYPE", 31, 38], ["IL", "PROTEIN", 68, 70], ["overactivation of T cells", "PROBLEM", 13, 38], ["elevated IL- Fig", "PROBLEM", 59, 75], ["elevated", "OBSERVATION_MODIFIER", 59, 67], ["IL", "OBSERVATION", 68, 70]]], ["The comparison charts of IFN-g, IL-1b, IL-4, IL-10, IL-12p70 and IL-17a cytokine levels according to experiment groups.", [["IFN-g", "GENE_OR_GENE_PRODUCT", 25, 30], ["IL-1b", "GENE_OR_GENE_PRODUCT", 32, 37], ["IL-4", "GENE_OR_GENE_PRODUCT", 39, 43], ["IL-10", "GENE_OR_GENE_PRODUCT", 45, 50], ["IL-12p70", "GENE_OR_GENE_PRODUCT", 52, 60], ["IL-17a", "GENE_OR_GENE_PRODUCT", 65, 71], ["IFN", "PROTEIN", 25, 28], ["cytokine", "PROTEIN", 72, 80], ["IFN", "TEST", 25, 28], ["IL", "TEST", 32, 34], ["IL", "TEST", 39, 41], ["IL", "TEST", 45, 47], ["IL", "TEST", 52, 54], ["IL", "TREATMENT", 65, 67], ["cytokine levels", "TEST", 72, 87]]], ["There are significant differences (p < 0.05) between the \"a\" and the rhombus symbols, \"b\" and the square symbols, \"c\" and the star symbols, \"d\" and empty square symbols.", [["significant", "OBSERVATION_MODIFIER", 10, 21], ["differences", "OBSERVATION_MODIFIER", 22, 33]]], ["10 in the US-M, M1, M2a and A-PBMC groups.", [["PBMC", "ANATOMY", 30, 34], ["M1", "CELL", 16, 18], ["M2a", "CELL", 20, 23], ["A-PBMC", "CELL", 28, 34], ["M1", "ANATOMY", 16, 18]]], ["As a result, MEM-D, MEM-ID and MSCs may have led to a decrease in IL-10 production due to their potent inhibitory effects on T cell activation.", [["MSCs", "ANATOMY", 31, 35], ["T cell", "ANATOMY", 125, 131], ["MEM-D", "CHEMICAL", 13, 18], ["MEM-D", "CHEMICAL", 13, 18], ["MEM-D", "SIMPLE_CHEMICAL", 13, 18], ["MEM-ID", "CELL", 20, 26], ["MSCs", "CELL", 31, 35], ["IL-10", "GENE_OR_GENE_PRODUCT", 66, 71], ["T cell", "CELL", 125, 131], ["MSCs", "CELL_TYPE", 31, 35], ["IL", "PROTEIN", 66, 68], ["MSCs", "PROBLEM", 31, 35], ["a decrease in IL", "PROBLEM", 52, 68], ["their potent inhibitory effects", "PROBLEM", 90, 121], ["T cell activation", "TREATMENT", 125, 142], ["decrease", "OBSERVATION_MODIFIER", 54, 62]]], ["Netea et al. and Quintin et al. reported that macrophages could develop a memory by being educated against a situation they had previously encountered (Netea, 2013; Quintin et al., 2014) .", [["macrophages", "ANATOMY", 46, 57], ["macrophages", "CELL", 46, 57], ["macrophages", "CELL_TYPE", 46, 57], ["Quintin et al", "TREATMENT", 17, 30], ["macrophages", "PROBLEM", 46, 57], ["macrophages", "OBSERVATION", 46, 57]]], ["Interestingly, we observed that the MEM-ID cells had similar effects on the Th1, Th2, Th17, and Treg cell frequencies as MEM-D cells.", [["MEM-ID cells", "ANATOMY", 36, 48], ["Treg cell", "ANATOMY", 96, 105], ["MEM-D cells", "ANATOMY", 121, 132], ["MEM-ID cells", "CELL", 36, 48], ["Th1", "CELL", 76, 79], ["Th2", "GENE_OR_GENE_PRODUCT", 81, 84], ["Th17", "CELL", 86, 90], ["Treg cell", "CELL", 96, 105], ["MEM-D cells", "CELL", 121, 132], ["MEM-ID cells", "CELL_LINE", 36, 48], ["Th17", "CELL_TYPE", 86, 90], ["MEM-D cells", "CELL_LINE", 121, 132], ["the MEM-ID cells", "TEST", 32, 48], ["the Th1", "TEST", 72, 79], ["Th2", "TEST", 81, 84], ["Th17", "TEST", 86, 90], ["Th1", "ANATOMY", 76, 79], ["Treg cell", "OBSERVATION", 96, 105]]], ["Besides, these effects were similar for the IFN-g, IL-10 and IL-17a levels.", [["IFN-g", "GENE_OR_GENE_PRODUCT", 44, 49], ["IL-10", "GENE_OR_GENE_PRODUCT", 51, 56], ["IL-17a", "GENE_OR_GENE_PRODUCT", 61, 67], ["IFN", "PROTEIN", 44, 47], ["the IFN", "TEST", 40, 47], ["IL", "TEST", 51, 53]]], ["This suggests that macrophage and MSC interactions may cause a kind of memory formation in macrophage cells.", [["macrophage", "ANATOMY", 19, 29], ["MSC", "ANATOMY", 34, 37], ["macrophage cells", "ANATOMY", 91, 107], ["macrophage", "CELL", 19, 29], ["MSC", "CELL", 34, 37], ["macrophage cells", "CELL", 91, 107], ["MSC", "CELL_TYPE", 34, 37], ["macrophage cells", "CELL_TYPE", 91, 107], ["macrophage and MSC interactions", "PROBLEM", 19, 50], ["memory formation in macrophage cells", "PROBLEM", 71, 107], ["macrophage", "OBSERVATION", 19, 29], ["macrophage cells", "OBSERVATION", 91, 107]]], ["In addition, this memory appears to develop in a suppressive direction for all T cell cytokine responses.ConclusionsWe performed a WST-1 analysis to observe the changes in proliferation of T cells as a result of activation.", [["T cell", "ANATOMY", 79, 85], ["T cells", "ANATOMY", 189, 196], ["T cell", "CELL", 79, 85], ["T cells", "CELL", 189, 196], ["cytokine", "PROTEIN", 86, 94], ["WST", "DNA", 131, 134], ["T cells", "CELL_TYPE", 189, 196], ["a WST-1 analysis", "TEST", 129, 145], ["the changes in proliferation of T cells", "PROBLEM", 157, 196]]], ["It is known that M2 macrophages can suppress T cell proliferation via secretion of NO and IDO or surface molecule PD-L2 (Bingisser et al., 1998; Huber et al., 2010; Munn et al., 1999) .", [["M2 macrophages", "ANATOMY", 17, 31], ["T cell", "ANATOMY", 45, 51], ["NO", "CHEMICAL", 83, 85], ["NO", "CHEMICAL", 83, 85], ["M2 macrophages", "CELL", 17, 31], ["T cell", "CELL", 45, 51], ["NO", "GENE_OR_GENE_PRODUCT", 83, 85], ["IDO", "GENE_OR_GENE_PRODUCT", 90, 93], ["PD-L2", "GENE_OR_GENE_PRODUCT", 114, 119], ["M2 macrophages", "CELL_TYPE", 17, 31], ["IDO", "PROTEIN", 90, 93], ["M2 macrophages", "PROBLEM", 17, 31], ["T cell proliferation", "PROBLEM", 45, 65], ["cell proliferation", "OBSERVATION", 47, 65], ["L2", "ANATOMY", 117, 119]]], ["MSCs can also effectively suppress T cell proliferation via cytokines, such as IDO, PGE2, IL-10, and TGF-b (Chen et al., 2011) .", [["MSCs", "ANATOMY", 0, 4], ["T cell", "ANATOMY", 35, 41], ["PGE2", "CHEMICAL", 84, 88], ["MSCs", "CELL", 0, 4], ["T cell", "CELL", 35, 41], ["IDO", "GENE_OR_GENE_PRODUCT", 79, 82], ["PGE2", "GENE_OR_GENE_PRODUCT", 84, 88], ["IL-10", "GENE_OR_GENE_PRODUCT", 90, 95], ["TGF-b", "GENE_OR_GENE_PRODUCT", 101, 106], ["MSCs", "CELL_TYPE", 0, 4], ["cytokines", "PROTEIN", 60, 69], ["IDO", "PROTEIN", 79, 82], ["PGE2", "PROTEIN", 84, 88], ["IL", "PROTEIN", 90, 92], ["TGF", "PROTEIN", 101, 104], ["MSCs", "PROBLEM", 0, 4], ["T cell proliferation via cytokines", "PROBLEM", 35, 69], ["IDO", "TEST", 79, 82], ["PGE2", "TEST", 84, 88], ["IL", "TEST", 90, 92]]], ["According to our findings, consistent with the literature, the proliferation rates of all co-culture groups, except M1 macrophages, were significantly lower than those of the A-PBMC group, and the proliferation rates of the M1 and M2a group were significantly higher compared to the MSC group.", [["M1 macrophages", "ANATOMY", 116, 130], ["A-PBMC", "ANATOMY", 175, 181], ["M1", "ANATOMY", 224, 226], ["MSC", "ANATOMY", 283, 286], ["M1 macrophages", "CELL", 116, 130], ["A-PBMC", "CANCER", 175, 181], ["M1", "CELL", 224, 226], ["M2a", "CANCER", 231, 234], ["MSC", "CELL", 283, 286], ["M1 macrophages", "CELL_LINE", 116, 130], ["all co-culture groups", "TEST", 86, 107], ["the proliferation rates", "TEST", 193, 216], ["consistent with", "UNCERTAINTY", 27, 42], ["significantly", "OBSERVATION_MODIFIER", 137, 150], ["lower", "OBSERVATION_MODIFIER", 151, 156], ["M1", "ANATOMY", 224, 226], ["higher", "OBSERVATION_MODIFIER", 260, 266]]], ["These data suggest that macrophages may not be as effective as MSCs in suppressing T cell proliferation.", [["macrophages", "ANATOMY", 24, 35], ["MSCs", "ANATOMY", 63, 67], ["T cell", "ANATOMY", 83, 89], ["macrophages", "CELL", 24, 35], ["MSCs", "CELL", 63, 67], ["T cell", "CELL", 83, 89], ["macrophages", "CELL_TYPE", 24, 35], ["MSCs", "CELL_TYPE", 63, 67], ["macrophages", "PROBLEM", 24, 35], ["MSCs", "PROBLEM", 63, 67], ["suppressing T cell proliferation", "PROBLEM", 71, 103], ["macrophages", "OBSERVATION", 24, 35], ["may not be", "UNCERTAINTY", 36, 46], ["cell proliferation", "OBSERVATION", 85, 103]]], ["It is also known that macrophages can lead to over-activated T cell apoptosis by secretion of NO and by Fas/FasL mechanism in acute bacterial infections or IFN-g and LPS stimulation (Daigneault et al., 2012; Hortelano et al., 2000) .", [["macrophages", "ANATOMY", 22, 33], ["T cell", "ANATOMY", 61, 67], ["NO", "CHEMICAL", 94, 96], ["bacterial infections", "DISEASE", 132, 152], ["LPS", "CHEMICAL", 166, 169], ["NO", "CHEMICAL", 94, 96], ["macrophages", "CELL", 22, 33], ["T cell", "CELL", 61, 67], ["NO", "GENE_OR_GENE_PRODUCT", 94, 96], ["Fas", "GENE_OR_GENE_PRODUCT", 104, 107], ["FasL", "GENE_OR_GENE_PRODUCT", 108, 112], ["IFN-g", "GENE_OR_GENE_PRODUCT", 156, 161], ["LPS", "SIMPLE_CHEMICAL", 166, 169], ["macrophages", "CELL_TYPE", 22, 33], ["Fas", "PROTEIN", 104, 107], ["FasL", "PROTEIN", 108, 112], ["IFN", "PROTEIN", 156, 159], ["macrophages", "PROBLEM", 22, 33], ["activated T cell apoptosis", "PROBLEM", 51, 77], ["acute bacterial infections", "PROBLEM", 126, 152], ["IFN", "PROBLEM", 156, 159], ["LPS stimulation", "TREATMENT", 166, 181], ["macrophages", "OBSERVATION", 22, 33], ["cell apoptosis", "OBSERVATION", 63, 77], ["acute", "OBSERVATION_MODIFIER", 126, 131], ["bacterial", "OBSERVATION_MODIFIER", 132, 141], ["infections", "OBSERVATION", 142, 152]]], ["However, MSCs do not cause lymphocyte apoptosis while suppressing proliferation (Haddad and Saldanha-Araujo, 2014; Xu et al., 2007) .", [["MSCs", "ANATOMY", 9, 13], ["lymphocyte", "ANATOMY", 27, 37], ["MSCs", "CELL", 9, 13], ["lymphocyte", "CELL", 27, 37], ["MSCs", "CELL_TYPE", 9, 13], ["MSCs", "PROBLEM", 9, 13], ["lymphocyte apoptosis", "PROBLEM", 27, 47], ["not cause", "UNCERTAINTY", 17, 26], ["lymphocyte apoptosis", "OBSERVATION", 27, 47]]], ["We observed that the Caspase-3 levels were significantly higher in M1 macrophages than in the MEM-ID, MSC and US-PBMC groups, confirming that MSCs can successfully suppress T cell proliferation, but does not lead to apoptosis.ConclusionsOverall, our data revealed that MSC and macrophage interactions may lead to the formation of a different phenotype than the known macrophage phenotypes.", [["M1 macrophages", "ANATOMY", 67, 81], ["MEM-ID", "ANATOMY", 94, 100], ["MSC", "ANATOMY", 102, 105], ["US-PBMC", "ANATOMY", 110, 117], ["MSCs", "ANATOMY", 142, 146], ["T cell", "ANATOMY", 173, 179], ["MSC", "ANATOMY", 269, 272], ["macrophage", "ANATOMY", 277, 287], ["macrophage", "ANATOMY", 367, 377], ["Caspase-3", "GENE_OR_GENE_PRODUCT", 21, 30], ["M1 macrophages", "CELL", 67, 81], ["MEM-ID", "CELL", 94, 100], ["MSC", "CELL", 102, 105], ["US-PBMC", "CELL", 110, 117], ["MSCs", "CELL", 142, 146], ["T cell", "CELL", 173, 179], ["MSC", "CELL", 269, 272], ["macrophage", "CELL", 277, 287], ["macrophage", "CELL", 367, 377], ["Caspase-3", "PROTEIN", 21, 30], ["M1 macrophages", "CELL_TYPE", 67, 81], ["MSC", "CELL_TYPE", 102, 105], ["PBMC", "CELL_TYPE", 113, 117], ["MSCs", "CELL_TYPE", 142, 146], ["MSC", "CELL_TYPE", 269, 272], ["the Caspase-3 levels", "TEST", 17, 37], ["MSCs", "PROBLEM", 142, 146], ["T cell proliferation", "PROBLEM", 173, 193], ["apoptosis", "PROBLEM", 216, 225], ["our data", "TEST", 246, 254], ["MSC", "PROBLEM", 269, 272], ["macrophage interactions", "PROBLEM", 277, 300], ["a different phenotype", "PROBLEM", 330, 351], ["the known macrophage phenotypes", "PROBLEM", 357, 388], ["higher", "OBSERVATION_MODIFIER", 57, 63], ["M1 macrophages", "OBSERVATION", 67, 81], ["cell proliferation", "OBSERVATION", 175, 193], ["macrophage", "OBSERVATION", 277, 287], ["macrophage phenotypes", "OBSERVATION", 367, 388]]], ["Although this phenotype was closer to the M2c phenotype, it cannot be considered a M2c cell due to the low expression of CD163, which is the characteristic marker of M2c.", [["M2c cell", "ANATOMY", 83, 91], ["M2c", "CANCER", 42, 45], ["M2c cell", "CELL", 83, 91], ["CD163", "GENE_OR_GENE_PRODUCT", 121, 126], ["M2c", "GENE_OR_GENE_PRODUCT", 166, 169], ["M2c cell", "CELL_LINE", 83, 91], ["CD163", "PROTEIN", 121, 126], ["M2c", "PROTEIN", 166, 169], ["a M2c cell", "PROBLEM", 81, 91], ["the low expression of CD163", "PROBLEM", 99, 126], ["low expression", "OBSERVATION_MODIFIER", 103, 117], ["CD163", "OBSERVATION", 121, 126]]], ["While MEM-D, MEM-ID, and MSCs had similar inhibitory effects on Th2 and Th17 cells, the most significant increase in Treg cell frequencies was seen in MEM-D cells.", [["MSCs", "ANATOMY", 25, 29], ["Th17 cells", "ANATOMY", 72, 82], ["Treg cell", "ANATOMY", 117, 126], ["MEM-D cells", "ANATOMY", 151, 162], ["MEM-D", "CHEMICAL", 6, 11], ["MEM-D", "CHEMICAL", 6, 11], ["MEM-D", "SIMPLE_CHEMICAL", 6, 11], ["MEM-ID", "CELL", 13, 19], ["MSCs", "CELL", 25, 29], ["Th2", "CELL", 64, 67], ["Th17 cells", "CELL", 72, 82], ["Treg cell", "CELL", 117, 126], ["MEM-D cells", "CELL", 151, 162], ["MSCs", "CELL_TYPE", 25, 29], ["Th2 and Th17 cells", "CELL_TYPE", 64, 82], ["MEM-D cells", "CELL_LINE", 151, 162], ["similar inhibitory effects on Th2 and Th17 cells", "PROBLEM", 34, 82], ["Treg cell frequencies", "PROBLEM", 117, 138], ["significant", "OBSERVATION_MODIFIER", 93, 104], ["increase", "OBSERVATION_MODIFIER", 105, 113], ["Treg cell frequencies", "OBSERVATION", 117, 138]]], ["Macrophages can alter their phenotypes and functions according to the stimuli from the environment.", [["Macrophages", "ANATOMY", 0, 11], ["Macrophages", "CELL", 0, 11], ["Macrophages", "CELL_TYPE", 0, 11]]], ["The fact that macrophages educated with MSCs suppressed the production of all the cytokines evaluated even after the removal of MSCs suggests that these cells may be differentiated by MSCs into a suppressive macrophage subgroup.", [["macrophages", "ANATOMY", 14, 25], ["MSCs", "ANATOMY", 40, 44], ["MSCs", "ANATOMY", 128, 132], ["cells", "ANATOMY", 153, 158], ["MSCs", "ANATOMY", 184, 188], ["macrophage", "ANATOMY", 208, 218], ["macrophages", "CELL", 14, 25], ["MSCs", "CELL", 40, 44], ["MSCs", "CELL", 128, 132], ["cells", "CELL", 153, 158], ["MSCs", "CELL", 184, 188], ["macrophage", "CELL", 208, 218], ["macrophages", "CELL_TYPE", 14, 25], ["MSCs", "CELL_TYPE", 40, 44], ["cytokines", "PROTEIN", 82, 91], ["MSCs", "CELL_TYPE", 128, 132], ["MSCs", "CELL_TYPE", 184, 188], ["MSCs", "TREATMENT", 40, 44], ["the removal of MSCs", "TREATMENT", 113, 132], ["these cells", "PROBLEM", 147, 158], ["a suppressive macrophage subgroup", "TREATMENT", 194, 227], ["macrophages", "OBSERVATION", 14, 25]]], ["However, Treg cell activation caused by direct interactions between MSC and macrophage cells may be the most prominent observation of this study.", [["Treg cell", "ANATOMY", 9, 18], ["MSC", "ANATOMY", 68, 71], ["macrophage cells", "ANATOMY", 76, 92], ["Treg cell", "CELL", 9, 18], ["MSC", "CELL", 68, 71], ["macrophage cells", "CELL", 76, 92], ["MSC", "CELL_TYPE", 68, 71], ["macrophage cells", "CELL_TYPE", 76, 92], ["Treg cell activation", "PROBLEM", 9, 29], ["MSC and macrophage cells", "TREATMENT", 68, 92], ["this study", "TEST", 134, 144], ["Treg cell activation", "OBSERVATION", 9, 29], ["macrophage cells", "OBSERVATION", 76, 92], ["most prominent", "OBSERVATION_MODIFIER", 104, 118]]], ["In conclusion, according to our data, interactions of MSCs and macrophages may lead to differentiate macrophage cells into an immunosuppressive phenotype, and these macrophages may suppress T lymphocyte subgroups at least as effectively as MSCs.", [["MSCs", "ANATOMY", 54, 58], ["macrophages", "ANATOMY", 63, 74], ["macrophage cells", "ANATOMY", 101, 117], ["macrophages", "ANATOMY", 165, 176], ["T lymphocyte", "ANATOMY", 190, 202], ["MSCs", "ANATOMY", 240, 244], ["MSCs", "CELL", 54, 58], ["macrophages", "CELL", 63, 74], ["macrophage cells", "CELL", 101, 117], ["macrophages", "CELL", 165, 176], ["T lymphocyte", "CELL", 190, 202], ["MSCs", "CELL", 240, 244], ["MSCs", "CELL_TYPE", 54, 58], ["macrophages", "CELL_TYPE", 63, 74], ["macrophage cells", "CELL_TYPE", 101, 117], ["macrophages", "CELL_TYPE", 165, 176], ["MSCs", "CELL_TYPE", 240, 244], ["MSCs", "TREATMENT", 54, 58], ["macrophages", "TREATMENT", 63, 74], ["macrophage cells", "PROBLEM", 101, 117], ["an immunosuppressive phenotype", "PROBLEM", 123, 153], ["these macrophages", "PROBLEM", 159, 176], ["T lymphocyte subgroups", "PROBLEM", 190, 212], ["macrophage cells", "OBSERVATION", 101, 117], ["immunosuppressive phenotype", "OBSERVATION", 126, 153]]], ["However, considering that we obtained our data from in vitro experiments, our findings should be supported by future in vivo studies.Declaration of interestThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.", [["our data", "TEST", 38, 46], ["vivo studies", "TEST", 120, 132]]], ["The Scientific and Technological Research Council of Turkey (TUBITAK) supported the project for this study, whose reference number is 216 S 761.", [["S 761", "CHEMICAL", 138, 143], ["this study", "TEST", 96, 106]]]], "PMC2582601": [["INTRODUCTIONWith the recent focus on nonprotein coding RNA (ncRNA) genes, interest in detecting novel ncRNAs has rapidly emerged.", [["nonprotein coding RNA", "GENE_OR_GENE_PRODUCT", 37, 58], ["nonprotein coding RNA (ncRNA) genes", "DNA", 37, 72], ["ncRNAs", "DNA", 102, 108]]], ["Since the structure of RNA is evolutionarily more conserved than its sequence, predicting the RNA's; secondary structure is one of the most important steps towards its functional analysis.", [["the RNA's", "PROBLEM", 90, 99], ["secondary structure", "PROBLEM", 101, 120], ["its functional analysis", "TEST", 164, 187], ["RNA", "OBSERVATION", 23, 26], ["more conserved", "OBSERVATION_MODIFIER", 45, 59]]], ["There are two fundamentally different approaches to predicting RNA secondary structures, namely free-energy minimization and probabilistic approaches, which often use phylogenetic information given by a multiple sequence alignment.", [["a multiple sequence alignment", "TEST", 201, 230], ["free", "OBSERVATION_MODIFIER", 96, 100], ["energy minimization", "OBSERVATION", 101, 120]]], ["This duality of approaches represents two different types of RNA structure information, the former relies on the physical properties of single sequences, while the latter uses evolutionary information in the form of compensatory base pair substitutions.INTRODUCTIONThe advantage of energy minimization is that it relies on experimentally determined parameters.", [["compensatory base pair substitutions", "PROBLEM", 216, 252], ["energy minimization", "TREATMENT", 282, 301], ["two", "OBSERVATION_MODIFIER", 38, 41], ["different", "OBSERVATION_MODIFIER", 42, 51], ["types", "OBSERVATION_MODIFIER", 52, 57], ["RNA structure", "OBSERVATION", 61, 74], ["pair substitutions", "OBSERVATION", 234, 252]]], ["On the other hand, it is known that methods such as RNAfold (1) and Mfold (2) achieve an overall sensitivity of about 70% (3).", [["an overall sensitivity", "TEST", 86, 108]]], ["For example, H/ACA snoRNAs usually do not produce the characteristic two-stem when the energy minimization alone is used to determine the structure.", [["H/ACA snoRNAs", "RNA", 13, 26], ["H/ACA snoRNAs", "PROBLEM", 13, 26], ["the energy minimization", "TREATMENT", 83, 106], ["ACA", "ANATOMY", 15, 18], ["snoRNAs", "OBSERVATION", 19, 26], ["stem", "OBSERVATION_MODIFIER", 73, 77]]], ["In general, there are several reasons for the inaccuracy of energy minimization.", [["energy minimization", "TREATMENT", 60, 79]]], ["First, the energy model is incomplete, especially for multi-loop structures.", [["the energy model", "TEST", 7, 23], ["incomplete", "OBSERVATION", 27, 37]]], ["Second, there can be alternative structures with similar free energies.", [["free energies", "OBSERVATION", 57, 70]]], ["And third, true structures are often stabilized by bound molecules.", [["bound molecules", "PROTEIN", 51, 66], ["bound molecules", "OBSERVATION", 51, 66]]], ["The only feasible way to determine the effects of these inaccuracies is to include phylogenetic information by looking for conserved substructures that cannot be accounted for by thermodynamic folding alone.INTRODUCTIONHence, it is desirable to combine this duality of RNA structure information into a single optimization problem.", [["a single optimization problem", "TREATMENT", 300, 329]]], ["This was probably addressed for the first time in 1985 by David Sankoff (7), who introduced an algorithm that solved the problem of simultaneously aligning and folding a set of unaligned RNA sequences.", [["unaligned RNA sequences", "DNA", 177, 200]]], ["Thus, practical implementations of the Sankoff algorithm like FOLDALIGN (9\u201312), Dynalign (13,14), PMcomp (15), LocARNA (16,17) and PARTS (18), published more than 20 years later, introduce different constraints and somewhat arbitrary choices in their scoring schemes to make the approach tractable for realistic input sizes.INTRODUCTIONProbabilistic approaches to the problem of simultaneously aligning and folding a set of RNA sequences, e.g. Stemloc (19) and Consan (20), are usually based on stochastic context-free grammars (SCFG).", [["RNA sequences", "DNA", 424, 437], ["LocARNA", "TREATMENT", 111, 118], ["somewhat arbitrary choices", "TREATMENT", 215, 241], ["INTRODUCTIONProbabilistic approaches", "TREATMENT", 324, 360], ["RNA sequences", "TEST", 424, 437], ["Stemloc", "TEST", 444, 451]]], ["Unlike the aforementioned Sankoff-like methods where the energy is explicitly reflected in the scoring scheme, these approaches rely purely on statistical learning methods to determine their parameters.", [["statistical learning methods", "TREATMENT", 143, 171]]], ["A mixed approach is employed by CMfinder (21) that implicitly combines energy contributions with an SCFG.", [["SCFG", "PROTEIN", 100, 104], ["an SCFG", "TREATMENT", 97, 104]]], ["As a seed CMfinder uses energetically folded structures from which a covariance model (SCFG) is constructed in successive rounds of optimization.", [["seed CMfinder", "DNA", 5, 18], ["energetically folded structures", "PROBLEM", 24, 55], ["a covariance model (SCFG)", "TREATMENT", 67, 92]]], ["There are no sequence-dependent energy contributions, but an energy term that depends on the topology of the consensus structure.INTRODUCTIONThe main disadvantage of the Sankoff-like approaches is their high-computational cost.", [["no", "UNCERTAINTY", 10, 12], ["dependent", "OBSERVATION_MODIFIER", 22, 31], ["energy contributions", "OBSERVATION", 32, 52], ["main", "OBSERVATION_MODIFIER", 145, 149], ["disadvantage", "OBSERVATION_MODIFIER", 150, 162], ["high", "OBSERVATION_MODIFIER", 203, 207]]], ["For this reason, a class of methods was developed that saves computational resources by predicting the optimal structure from given RNA alignments, which are usually produced by multiple sequence alignment methods.", [["RNA alignments", "TEST", 132, 146], ["RNA alignments", "OBSERVATION", 132, 146]]], ["This approach has proven useful in genomic screens for ncRNAs (23,24), despite their limitations in finding RNA structures in more divergent sequences (25).", [["ncRNAs", "DNA", 55, 61], ["RNA structures", "RNA", 108, 122], ["genomic screens", "TEST", 35, 50], ["ncRNAs", "TEST", 55, 61]]], ["It has been shown that the quality of the predictions breaks down in cases where sequence identity is <60% (26).", [["sequence identity", "TEST", 81, 98]]], ["On the other hand, these methods can also be applied to improve the consensus structure prediction in Sankoff-like approaches.", [["Sankoff", "SIMPLE_CHEMICAL", 102, 109], ["these methods", "TREATMENT", 19, 32]]], ["The reason is simply that the Sankoff-like approaches usually apply a progressive strategy by combining pairwise alignments to build the final multiple alignment.", [["the Sankoff-like approaches", "PROBLEM", 26, 53], ["a progressive strategy", "TREATMENT", 68, 90], ["combining pairwise alignments", "PROBLEM", 94, 123], ["progressive", "OBSERVATION_MODIFIER", 70, 81], ["multiple", "OBSERVATION_MODIFIER", 143, 151], ["alignment", "OBSERVATION_MODIFIER", 152, 161]]], ["Thus, consensus structure prediction can be improved when considering the complete phylogenetic information.INTRODUCTIONIn this article, we extend Pfold (27) to simultaneously use evolutionary and energetic information while searching for the common structure in a set of prealigned sequences.", [["prealigned sequences", "DNA", 272, 292]]], ["The probabilistic approach underlying Pfold combines an explicit evolutionary model of the RNA sequences with a probabilistic model of the secondary structures.", [["Pfold", "DNA", 38, 43], ["RNA sequences", "DNA", 91, 104], ["the RNA sequences", "TEST", 87, 104]]], ["When trying to extend this approach to incorporate thermodynamic folding, the first idea was to develop a combined probabilistic model for evolution and folding, using the partition function approach of McCaskill (28) as a probabilistic model for thermodynamic folding.INTRODUCTIONThere are two main problems for a combined probabilistic model.", [["this approach", "TREATMENT", 22, 35], ["thermodynamic folding", "TREATMENT", 51, 72], ["thermodynamic folding", "OBSERVATION", 247, 268], ["main", "OBSERVATION_MODIFIER", 295, 299]]], ["First, there is no simple way to weight the different information sources in such a combined model.", [["no", "UNCERTAINTY", 16, 18], ["simple", "OBSERVATION_MODIFIER", 19, 25]]], ["And second, the structure prediction would be based on a maximum likelihood or maximum a posteriori (MAP) approach.", [["maximum a posteriori (MAP) approach", "TREATMENT", 79, 114]]], ["Basically, the implicit assumption of a maximum likelihood or MAP approach is that the structure with the highest probability is also the structure where the ensemble of close neighbors has the highest probability mass, which is often not the case.", [["MAP approach", "TREATMENT", 62, 74], ["the highest probability mass", "PROBLEM", 190, 218], ["mass", "OBSERVATION", 214, 218]]], ["Hence, Carvalho and Lawrence proposed different new classes of estimators, which included estimators already used in sequence alignment and RNA secondary structure prediction.", [["secondary structure", "OBSERVATION", 144, 163]]], ["(30) and successfully applied to sequence alignment in ProbCons (31) and to RNA structure prediction in CONTRAfold (3).", [["sequence alignment in ProbCons", "TEST", 33, 63]]], ["A partition function version of the Sankoff algorithm (which is related to MEA scoring) was introduced in ref.", [["the Sankoff algorithm", "TEST", 32, 53]]], ["Another example is Pfold itself, since the current implementation does not use the maximum likelihood approach originally introduced in ref.", [["Pfold", "SIMPLE_CHEMICAL", 19, 24], ["the maximum likelihood approach", "TREATMENT", 79, 110], ["Pfold", "OBSERVATION", 19, 24]]], ["(33), but is based on reliability scores (27), which can be interpreted as a variant of MEA scoring.INTRODUCTIONHence, our approach is based on a combined MEA score.", [["reliability scores", "TEST", 22, 40]]], ["The combined score is based on both base pair and single-strand probabilities as calculated by RNAfold and the reliabilities of base pairs and single-stranded positions as extracted from Pfold.", [["single-strand probabilities", "PROBLEM", 50, 77], ["base pairs", "TREATMENT", 128, 138], ["single-stranded positions", "TREATMENT", 143, 168]]], ["The latter is due to the fact that the algorithm searches for a structure that shares as many base pairs as possible with all alternative structures.", [["the algorithm searches", "TEST", 35, 57], ["many base pairs", "PROBLEM", 89, 104]]], ["We implemented this Probabilistic Evolutionary and Thermodynamic folding algorithm (PETfold) for multiple RNA sequence alignments.INTRODUCTIONRecently, several methods for finding the common structure in a set of sequences that are either unaligned or aligned have been published (34\u201337).", [["Thermodynamic folding algorithm", "TEST", 51, 82], ["multiple RNA sequence alignments", "TEST", 97, 129]]], ["Essentially, they all carry out a global alignment or predict a common structure on a set of globally aligned sequences.", [["global", "OBSERVATION_MODIFIER", 34, 40], ["alignment", "OBSERVATION", 41, 50], ["common", "OBSERVATION_MODIFIER", 64, 70]]], ["RNAalifold (38) basically applies energy minimization to a complete alignment.", [["energy minimization", "TREATMENT", 34, 53]]], ["In addition, it introduces an evolutionarily motivated score to measure sequence covariation for base pairs.", [["base pairs", "PROBLEM", 97, 107]]], ["Since it is widely used and applies a thermodynamic-based scoring scheme, it was chosen as a benchmark method in addition to Pfold.The Pfold model ::: MATERIALS AND METHODSWe now recall the Pfold (33) model.", [["Pfold", "PROTEIN", 125, 130], ["a benchmark method", "TREATMENT", 91, 109]]], ["In the following, a secondary structure \u03c3 is a set of base pairs that do not cross.", [["\u03c3", "PROTEIN", 40, 41], ["a set of base pairs", "PROBLEM", 45, 64]]], ["Let A be a multiple alignment of the sequences s1 \u2026 sn.", [["Let A", "GENE_OR_GENE_PRODUCT", 0, 5], ["s1", "DNA", 47, 49], ["sn", "DNA", 52, 54]]], ["Furthermore, let T be a given evolutionary tree and M be a prior model for the secondary structures.", [["let T", "GENE_OR_GENE_PRODUCT", 13, 18]]], ["Thus the model provides a probability distribution on the structures, given the data (i.e. the alignment A) and the background information (i.e. the secondary structure background model M and the tree T):1Since Pr [A|T,M] is independent from the structure \u03c3, we need to optimize only Pr [A|T,\u03c3,M] P[\u03c3 |T,M].The Pfold model ::: MATERIALS AND METHODSHere, P[\u03c3|T,M] is the prior distribution over all secondary structures.", [["Pr [A|T,\u03c3,M] P", "CHEMICAL", 284, 298], ["Pr", "TEST", 284, 286], ["A|", "TEST", 288, 290], ["T", "TEST", 290, 291]]]], "f7c1723300049130372dcad75381a222c4cc2a83": [["This study attempts to explore how the lockdown/containment measures taken by the government during the COVID-19 pandemic have threatened educated Muslim women's negotiated identity regarding wifehood and motherhood in urban Pakistan and how they struggle to reposition to reconstruct it.", [["women", "ORGANISM", 154, 159], ["women", "SPECIES", 154, 159], ["This study", "TEST", 0, 10], ["the lockdown/containment measures", "TREATMENT", 35, 68]]], ["Through semi-structured interviews, making an in-depth comparative study of three differently situated cases (Muslim women), this study argues that the abnormal situation that has ensued from the pandemic has reinforced the vulnerability of women's nascent negotiated identity by landing them in a space where they are supposed by the normative structures to step back to carrying out their traditional responsibilities as 'good' wife and mother during the crisis.", [["women", "ORGANISM", 117, 122], ["women", "ORGANISM", 241, 246], ["women", "SPECIES", 117, 122], ["women", "SPECIES", 241, 246], ["an in-depth comparative study", "TEST", 43, 72], ["this study", "TEST", 125, 135], ["the abnormal situation", "PROBLEM", 148, 170]]], ["It has found that the pandemic has similarity in its impacts for the women in their familial lives, despite their being variously situated and resistive, due to the general religio-culturally defined patriarchal social behaviour of the place (Pakistan) toward women and lack of action on the part of the state for implementing its laws of women's empowerment.K E Y W O R D SCOVID-19, identity, motherhood, Muslim women, Pakistan, wifehood| INTRODUCTIONThe world has scrambled to deal with the multidimensional impacts of the cataclysmic COVID-19 pandemic which first erupted in Wuhan, China in December 2019 and spread across the world within weeks (at the time of writing in the last week of March 2020 the virus has claimed about 30,000 lives and has infected hundreds of thousands of people across the globe; the virus is still spreading and casualties multiplying with no medicine to cure it so far).| INTRODUCTIONThough statistics reported in the media have shown men in greater number as victims of the pandemic, the effects of the virus cannot be taken as limited to just physical illness or mortality.", [["K", "CHEMICAL", 359, 360], ["illness", "DISEASE", 1088, 1095], ["K", "CHEMICAL", 359, 360], ["women", "ORGANISM", 69, 74], ["women", "ORGANISM", 260, 265], ["women", "ORGANISM", 339, 344], ["women", "ORGANISM", 413, 418], ["people", "ORGANISM", 787, 793], ["men", "ORGANISM", 969, 972], ["women", "SPECIES", 69, 74], ["women", "SPECIES", 260, 265], ["women", "SPECIES", 339, 344], ["women", "SPECIES", 413, 418], ["people", "SPECIES", 787, 793], ["men", "SPECIES", 969, 972], ["K", "SPECIES", 359, 360], ["the cataclysmic COVID", "TEST", 521, 542], ["the virus", "PROBLEM", 812, 821], ["medicine", "TREATMENT", 876, 884], ["the virus", "PROBLEM", 1034, 1043], ["pandemic", "OBSERVATION", 22, 30], ["globe", "ANATOMY", 805, 810]]], ["There is a need to study the outbreak with reference to its impact on women in terms of increased aggravation of unpaid labour, domestic and sexual violence, reproductive health, issues of pregnancy and maternity, and economic burden.", [["domestic and sexual violence", "DISEASE", 128, 156], ["women", "ORGANISM", 70, 75], ["women", "SPECIES", 70, 75], ["increased aggravation of unpaid labour", "PROBLEM", 88, 126], ["pregnancy and maternity", "PROBLEM", 189, 212], ["economic burden", "PROBLEM", 218, 233], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["aggravation", "OBSERVATION", 98, 109]]], ["There is hardly any published academic research on the impact of COVID-19 on women regarding how it has worsened gender issues.", [["women", "ORGANISM", 77, 82], ["women", "SPECIES", 77, 82], ["COVID", "TREATMENT", 65, 70]]], ["Pandemics like COVID-19 can have severe and long-term gender impacts for women, especially in religio-culturally inspired patriarchal societies like Pakistan.", [["COVID-19", "CHEMICAL", 15, 23], ["women", "ORGANISM", 73, 78], ["women", "SPECIES", 73, 78], ["Pandemics", "PROBLEM", 0, 9]]], ["Informed by the little feminist research focused on the impacts of the Zika and Ebola epidemics (the diseases that struck South and North America and Africa during [2013] [2014] [2015] [2016] , this study, from the feminist perspective, attempts to explore the impact of the COVID-19 pandemic on Muslim women in Pakistan.| INTRODUCTIONEbola in Africa resulted in long-term destructive consequences for women by affecting their life chances as many of them had to drop out of school; teenage-pregnancy rates increased, domestic and sexual violence grew, women's health deteriorated and the rate of women dying due to obstetric complications rose (Farmer, 2014; Lewis, 2020; Marindo, 2017) .", [["Zika", "DISEASE", 71, 75], ["Ebola epidemics", "DISEASE", 80, 95], ["domestic and sexual violence", "DISEASE", 518, 546], ["Ebola", "ORGANISM", 80, 85], ["women", "ORGANISM", 303, 308], ["women", "ORGANISM", 402, 407], ["women", "ORGANISM", 553, 558], ["women", "ORGANISM", 597, 602], ["women", "SPECIES", 303, 308], ["women", "SPECIES", 402, 407], ["women", "SPECIES", 553, 558], ["women", "SPECIES", 597, 602], ["this study", "TEST", 194, 204], ["the COVID", "TREATMENT", 271, 280], ["long-term destructive consequences", "PROBLEM", 363, 397], ["pregnancy rates", "PROBLEM", 491, 506], ["obstetric complications", "PROBLEM", 616, 639], ["long-term destructive", "OBSERVATION_MODIFIER", 363, 384]]], ["Zika epidemics, in Latin America, were exacerbated due to the lack of reproductive rights of women in that patriarchal society which had deep structural economic inequalities for its women (Velez & Diniz, 2016) .| INTRODUCTIONTo contain the spread of the highly contagious COVID-19 virus, Pakistan's federal and provincial governments closed down all schools, colleges and universities across the country from 11 March 2020 to 31 May 2020.", [["women", "ORGANISM", 93, 98], ["women", "ORGANISM", 183, 188], ["COVID-19 virus", "ORGANISM", 273, 287], ["women", "SPECIES", 93, 98], ["women", "SPECIES", 183, 188], ["COVID-19 virus", "SPECIES", 273, 287], ["Zika epidemics", "PROBLEM", 0, 14]]], ["All types of international, national, inter-city and intra-city travel were banned; shopping malls, businesses and all types of public gatherings were prohibited; along with other law enforcement agencies, the army was deployed to force people to stay at home.| INTRODUCTIONThe lockdown period was extended to 7 April 2020, which could further be increased in view of the spread of the virus.| INTRODUCTIONMuslim women in Pakistan have long struggled to negotiate their gender identity in the religiously inspired patriarchal sociocultural structures of the postcolonial globalized nation state that came into existence (in 1947) in the name of Islam (details in the following section).", [["people", "ORGANISM", 237, 243], ["women", "ORGANISM", 413, 418], ["people", "SPECIES", 237, 243], ["women", "SPECIES", 413, 418], ["the virus", "PROBLEM", 382, 391], ["increased", "OBSERVATION_MODIFIER", 347, 356]]], ["This study attempts to explore how the lockdown/containment measures taken by the government during the COVID-19 pandemic have threatened educated Muslim women's negotiated identity regarding wifehood and motherhood in urban Pakistan and how they struggle to reposition to reconstruct it.", [["women", "ORGANISM", 154, 159], ["women", "SPECIES", 154, 159], ["This study", "TEST", 0, 10], ["the lockdown/containment measures", "TREATMENT", 35, 68]]], ["Through semi-structured interviews, making an in-depth comparative study of three differently situated cases (Muslim women), this study argues that the abnormal situation resulting from the pandemic has reinforced the vulnerability of the women's nascent negotiated identity by landing them in a space where they are supposed by the normative structures to step back to carrying out their traditional responsibilities as 'good' wife and mother during the crisis.| INTRODUCTIONIt has been found that the pandemic has similarity in its impacts for the women in their familial lives, despite their being variously situated and resistive, due to the general religio-culturally defined patriarchal social behaviour of the place (Pakistan) toward women and lack of will and action on the part of the state for implementing its laws of women's empowerment.", [["women", "ORGANISM", 117, 122], ["women", "ORGANISM", 239, 244], ["women", "ORGANISM", 550, 555], ["women", "ORGANISM", 741, 746], ["women", "ORGANISM", 829, 834], ["women", "SPECIES", 117, 122], ["women", "SPECIES", 239, 244], ["women", "SPECIES", 550, 555], ["women", "SPECIES", 741, 746], ["women", "SPECIES", 829, 834], ["an in-depth comparative study", "TEST", 43, 72], ["this study", "TEST", 125, 135], ["the abnormal situation", "PROBLEM", 148, 170]]], ["The pandemic for the women has resulted in the form of increased burden of unrecognized unpaid domestic labour and domestic violence which, as a result, has caused them mental stress and apprehension regarding the loss of the identity that they had long negotiated their religio-traditional structures to achieve.", [["domestic violence", "DISEASE", 115, 132], ["women", "ORGANISM", 21, 26], ["women", "SPECIES", 21, 26], ["them mental stress", "PROBLEM", 164, 182], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["burden", "OBSERVATION_MODIFIER", 65, 71]]], ["Within the framework of the case study methodology, the data from the interviews is properly coded and categorized for their thematic analysis.", [["their thematic analysis", "TEST", 119, 142]]], ["Though gender-defining intersectional factors like social status, class, education, economic independence, locality, interpretation of religion and physical beauty usually intervene to influence a woman's empowerment in the family, this study finds that, in addition to the influence of these factors, the general dominant social behaviour toward women and the lack of will and action/infrastructure on the part of the government to ensure women's empowerment are major factors which even worsen their condition during a crisis like COVID-19.| POSITIONING GENDER OF MUSLIM WOMEN IN PAKISTANMuslim women in Pakistan have never been able to get rid of being viewed as symbols of the religiously rooted national and postcolonial culture in which they have to embody and enact the modest and pious Muslim lady as a daughter, sister, mother and wife.", [["woman", "ORGANISM", 197, 202], ["women", "ORGANISM", 347, 352], ["women", "ORGANISM", 440, 445], ["women", "ORGANISM", 597, 602], ["woman", "SPECIES", 197, 202], ["women", "SPECIES", 347, 352], ["women", "SPECIES", 440, 445], ["women", "SPECIES", 597, 602], ["this study", "TEST", 232, 242], ["COVID", "TEST", 533, 538], ["postcolonial culture", "TEST", 713, 733]]], ["Social, political, cultural, religious and economic structures of Pakistan see its women as caregivers at home and have deep gender disparities.", [["women", "ORGANISM", 83, 88], ["women", "SPECIES", 83, 88]]], ["However, cultural and economic globalization and increasing geographic and non-geographic physical and intellectual mobility of women can also be felt through its effects on changing lifestyles and social spaces (Safdar & Ghani, 2018) .| POSITIONING GENDER OF MUSLIM WOMEN IN PAKISTANThough a number of factors like class, region, locality, ethnicity, social status, age and historical specificity have intersected to define and position gender of Muslim women in Pakistan, the intervention of religion and state discourses has always had, throughout the country's history, a major influence on the construction of the perceptions and expectations associated with gender (Jafar, 2005; Jamal, 2006; Julia, 2013; Mumtaz & Shaheed, 1987; Shaheed, 2010; Yasmin, Naseem & Sohail, 2019; Yasmin, Naseem & Raza, 2018; Zia, 2018) .| POSITIONING GENDER OF MUSLIM WOMEN IN PAKISTANReligious and state discourses, though varied across various government configurations (democratic and dictatorial), have been key to forming general social behaviour and the state's policy toward determining female spaces.", [["women", "ORGANISM", 128, 133], ["women", "ORGANISM", 455, 460], ["women", "SPECIES", 128, 133], ["women", "SPECIES", 455, 460], ["cultural", "TEST", 9, 17], ["economic globalization", "TEST", 22, 44], ["increasing geographic and non-geographic physical and intellectual mobility of women", "PROBLEM", 49, 133], ["economic", "OBSERVATION_MODIFIER", 22, 30], ["globalization", "OBSERVATION_MODIFIER", 31, 44], ["increasing", "OBSERVATION_MODIFIER", 49, 59], ["geographic", "OBSERVATION_MODIFIER", 60, 70]]], ["The moderate social space women gained through their active participation in the struggle for independence of the nation during the 1940s reduced after independence in 1947 and then was drastically curtailed in the name of Islam by the dictatorship of General Zial-ul-Haq in the 1980s (Saigol, 2016; Suleri, 1992) .", [["women", "ORGANISM", 26, 31], ["women", "SPECIES", 26, 31], ["moderate", "OBSERVATION_MODIFIER", 4, 12], ["social space", "OBSERVATION", 13, 25]]], ["The state promulgated such legislations (including Zina and Hodood ordinances) and initiated such public discourses (people could act as vigilantes to judge and police the character of women) that have continued to victimize women.", [["people", "ORGANISM", 117, 123], ["women", "ORGANISM", 185, 190], ["women", "ORGANISM", 225, 230], ["people", "SPECIES", 117, 123], ["women", "SPECIES", 185, 190], ["women", "SPECIES", 225, 230], ["Zina and Hodood ordinances", "TREATMENT", 51, 77]]], ["Women Action Forum (WAF), led by upper-class women following the politics of secular feminism, protested against the regime of Zia for its women-biased public discourse and policies, and demanded equality of women.", [["Women", "ORGANISM", 0, 5], ["women", "ORGANISM", 45, 50], ["women", "ORGANISM", 139, 144], ["women", "ORGANISM", 208, 213], ["Women", "SPECIES", 0, 5], ["women", "SPECIES", 45, 50], ["women", "SPECIES", 139, 144], ["women", "SPECIES", 208, 213], ["secular feminism", "PROBLEM", 77, 93], ["Zia", "TREATMENT", 127, 130]]], ["WAF, though struggled hard for the democratic rights of women and other suppressed communities, failed to attract common women largely due to the dominant religiously inspired social behaviour toward women.", [["WAF", "DISEASE", 0, 3], ["women", "ORGANISM", 56, 61], ["women", "ORGANISM", 121, 126], ["women", "ORGANISM", 200, 205], ["women", "SPECIES", 56, 61], ["women", "SPECIES", 121, 126], ["women", "SPECIES", 200, 205], ["WAF", "PROBLEM", 0, 3]]], ["Its problems in forwarding its agenda multiplied in the aftermath of 9/11, when it became usual in Pakistan to label secular feminist struggles with the stigma of westernization of the society.", [["Its problems", "PROBLEM", 0, 12]]], ["Feminism, having been ambivalently interpreted by the majority of people in the country, has been in retreat; instead, a third space enabling women to negotiate the oppressive indigenous religio-cultural patriarchal structures and western notions of women's equality has increasingly opened for women to negotiate their space (Akhtar, 2014; Mansoor, 2014; Safdar & Ghani, 2018; Zubair & Zubair, 2017) .", [["people", "ORGANISM", 66, 72], ["women", "ORGANISM", 142, 147], ["women", "ORGANISM", 250, 255], ["women", "ORGANISM", 295, 300], ["people", "SPECIES", 66, 72], ["women", "SPECIES", 142, 147], ["women", "SPECIES", 250, 255], ["women", "SPECIES", 295, 300]]], ["As a reaction to secular perceptions of gender, religion-based struggle for women's rights has been advocated by academics as the alternative indigenous agency that does not necessarily mean to subvert patriarchy in the sense that secular feminism means (Iqtidar, 2011; Mahmood, 2005; Syed, 2010) .| POSITIONING GENDER OF MUSLIM WOMEN IN PAKISTANThe pre-and post-Zia era state policies exploited relatively moderate versions of religious interpretations to forward their political and economic agendas.", [["women", "ORGANISM", 76, 81], ["women", "SPECIES", 76, 81], ["moderate", "OBSERVATION_MODIFIER", 407, 415]]], ["General Pervez Musharraf's regime (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) included religious political parties in the coalition government and advocated cultural enlightenment and women's rights.", [["women", "ORGANISM", 210, 215], ["women", "SPECIES", 210, 215], ["General Pervez Musharraf's regime", "TREATMENT", 0, 33]]], ["Successive governments after Musharraf have also introduced several women-friendly legal measures.", [["women", "ORGANISM", 68, 73], ["women", "SPECIES", 68, 73]]], ["However, the recently reignited discursive conflict between secular and religious viewpoints about Muslim women's gender roles and rights in Pakistan by the Marvi Sarmad (a Pakistani feminist activist) and Khalil ur Rehaman (a playwright) episode (DAWN, 2020a (DAWN, , 2020b has revealed that the majority of people in Pakistan view gender of Muslim women through the perspectives of their religion and local culture rather than secularism.| POSITIONING GENDER OF MUSLIM WOMEN IN PAKISTANwomen's visibility and mobility have been growing across the country, and as a result, their intellectual mobility as well in the form of an increasing sense of reasoning and critical thinking.", [["women", "ORGANISM", 106, 111], ["people", "ORGANISM", 309, 315], ["women", "ORGANISM", 350, 355], ["women", "SPECIES", 106, 111], ["people", "SPECIES", 309, 315], ["women", "SPECIES", 350, 355], ["local culture", "TEST", 403, 416]]], ["However, they mostly seek their agency from interpretations of religion, especially in the case of middle-class women (Khurshid, 2015) .", [["women", "ORGANISM", 112, 117], ["women", "SPECIES", 112, 117]]], ["The state, in the last two decades, has also passed a number of pro-women legislations to punish the perpetrators of honour killings, domestic violence and sexual harassment, and to empower women in matters related to divorce and marriage (DAWN, 2016; Mirza, 2011) .", [["domestic violence and sexual harassment", "DISEASE", 134, 173], ["women", "ORGANISM", 190, 195], ["women", "SPECIES", 190, 195]]], ["However, what is missing is the will, readiness, proper training and consistency in action on the part of the state institutions to implement these laws (DAWN, 2020a (DAWN, , 2020b .", [["proper training", "TREATMENT", 49, 64]]], ["It has resulted in scattered, disorganized and haphazard growth in social behaviours towards gender in the contemporary Pakistan which is globalized and also always mindful of the reason of its being (that is, religion).| RESEARCH SETTINGThe COVID-19 pandemic and the asymmetric condition of gender in hardcore patriarchal societies like Pakistan form the background of this study.", [["scattered, disorganized and haphazard growth", "PROBLEM", 19, 63], ["pandemic", "PROBLEM", 251, 259], ["the asymmetric condition", "PROBLEM", 264, 288], ["this study", "TEST", 370, 380], ["scattered", "OBSERVATION_MODIFIER", 19, 28], ["disorganized", "OBSERVATION_MODIFIER", 30, 42], ["haphazard", "OBSERVATION_MODIFIER", 47, 56], ["growth", "OBSERVATION_MODIFIER", 57, 63], ["social behaviours", "OBSERVATION", 67, 84], ["asymmetric", "OBSERVATION_MODIFIER", 268, 278]]], ["The study conducts purposive sampling to explore the impact of the pandemic on the familial life of those Pakistani Muslim (single parent and double parent) women who are highly educated, comparatively less educated (grade 10-12), economically independent/dependent and located in urban areas in Pakistan.", [["women", "ORGANISM", 157, 162], ["women", "SPECIES", 157, 162], ["The study", "TEST", 0, 9]]], ["It is generally assumed that educated and economically independent women located in urban areas exercise comparatively greater agency than uneducated and economically dependent women who are located in rural/remote areas.", [["women", "ORGANISM", 67, 72], ["women", "ORGANISM", 177, 182], ["women", "SPECIES", 67, 72], ["women", "SPECIES", 177, 182]]], ["This is why this study attempts to explore the experience of the educated and economically independent (and dependent as well) women who are located in urban areas to understand how the women have to struggle to maintain their relatively better position regarding their rights/agency in the times of pandemics like COVID-19.", [["women", "ORGANISM", 127, 132], ["women", "ORGANISM", 186, 191], ["women", "SPECIES", 127, 132], ["women", "SPECIES", 186, 191], ["this study", "TEST", 12, 22]]], ["All the three cases selected for this study are from Sialkot.", [["this study", "TEST", 33, 43]]], ["Case study methodology, as explained in Hood (2009) , provides a useful entry point to explore the experiences of the women through their personal narratives; narratives constitute and can help understand one's identity (Neitz, 2004; Wuthnow, 2011) .", [["women", "ORGANISM", 118, 123], ["women", "SPECIES", 118, 123]]], ["Since the authors are also married and going through similar experiences as the cases are in their familial life during the containment measures, self-reflexivity as a method, which is often employed by feminist research (Alldred, 1998; Birch, 1998; Parr, 1998; Zubair, 2005; Zubair & Zubair, 2017) , is also used to feel a connection with the research participants and to research with rather than on them.", [["participants", "SPECIES", 353, 365], ["the containment measures", "TREATMENT", 120, 144]]], ["As typical with Linguistics and Discourse Studies, language is constitutive and expressive of one's identity; this study therefore attempts to investigate and capture the lived experiences of the Muslim women through their talks.| RESEARCH SETTINGThe following prompt was used to initiate the semi-structured individual interviews which lasted over an hour each and also included informal irrelevant exchanges of ideas and gossip:| RESEARCH SETTINGHow are you doing during these lockdown/containment measures by the government?| RESEARCH SETTINGSince the interviews were recorded, the relevant material was later noted down and transcribed for the study.| RESEARCH SETTINGTwo of the cases (both of them women and coded as Nisa and Rida) and the authors have been serving as colleagues in the same university in Sialkot for several years, and have visited each other's families many times.", [["women", "ORGANISM", 203, 208], ["women", "ORGANISM", 703, 708], ["women", "SPECIES", 203, 208], ["women", "SPECIES", 703, 708], ["Discourse Studies", "TEST", 32, 49], ["this study", "TEST", 110, 120], ["the study", "TEST", 644, 653]]], ["Therefore, the authors position themselves with respect to the two participants as colleagues and friends who have a deep understanding of each other's familial situations and can share their experiences confiding in each other.", [["participants", "SPECIES", 67, 79]]], ["The third case (also a woman coded as Nayab) for this study is a relative of ours with whom also we can position ourselves in a situation where there is mutual confidence and trust and deep knowledge of each other's familial experiences.", [["woman", "SPECIES", 23, 28], ["this study", "TEST", 49, 59]]], ["Though the authors' positionalities with the participants are such that they have mutual confidence, trust and deep knowledge of each other's familial and personal lives, the first author, being a male, may have to be more reflective and empathetic to understand the women participants' sensibilities.", [["women", "ORGANISM", 267, 272], ["participants", "SPECIES", 45, 57], ["women", "SPECIES", 267, 272], ["participants", "SPECIES", 273, 285]]], ["However, this sexual opposition of the author enables him to be more interested and curious to explore the experiences of the women.", [["women", "ORGANISM", 126, 131], ["women", "SPECIES", 126, 131]]], ["The second author, being a woman, can better feel with the women participants and helps the first author to feel the same by explaining to him the situations of the participants.| RidaRida is a single parent, parenting her five-year-old daughter after her divorce two years ago.", [["RidaRida", "CHEMICAL", 180, 188], ["woman", "ORGANISM", 27, 32], ["women", "ORGANISM", 59, 64], ["woman", "SPECIES", 27, 32], ["women", "SPECIES", 59, 64], ["participants", "SPECIES", 65, 77], ["participants", "SPECIES", 165, 177]]], ["Her family environment is not that strict in religious matters like dress and rituals, etc. She wears cultural (Shalwar Qameez) and modern dress also (like pants and loose shirts).", [["cultural (Shalwar Qameez", "TREATMENT", 102, 126], ["modern dress", "TREATMENT", 132, 144]]], ["However, she wears a scarf which is a symbol of modesty and piety in Pakistan.", [["a scarf", "PROBLEM", 19, 26], ["scarf", "OBSERVATION", 21, 26]]], ["Her father's retirement pension also adds a considerable amount to her monthly budget.", [["Her father's retirement pension", "TREATMENT", 0, 31]]], ["As culturally and religiously expected, she personally takes care of most of the services of her parents and daughter even when the servant is also available.| NisaNisa is a double parent having three sons and no daughter.", [["NisaNisa", "CHEMICAL", 160, 168]]], ["With the purpose of avoiding obscenity and irreligiousness, they do not even have a television at home.", [["obscenity", "PROBLEM", 29, 38], ["irreligiousness", "PROBLEM", 43, 58]]], ["Though she is allowed to travel alone to the university campus, which is only a mile away from her home, she first used to wear a full head-to-toe veil (abaya), however, latter, for a few years she has negotiated her veil and now wears a complete head scarf instead of the head-to-toe veil.| NisaThe authors have never seen her wearing pants and shirts; she dresses according to religious and cultural norms.", [["head", "ANATOMY", 135, 139], ["abaya", "ANATOMY", 153, 158], ["head", "ANATOMY", 247, 251], ["head", "ANATOMY", 273, 277], ["Nisa", "CHEMICAL", 292, 296], ["Nisa", "CHEMICAL", 292, 296], ["head", "ORGANISM_SUBDIVISION", 135, 139], ["abaya", "ORGANISM_SUBDIVISION", 153, 158], ["head", "ORGANISM_SUBDIVISION", 247, 251], ["head", "ORGANISM_SUBDIVISION", 273, 277], ["Nisa", "SPECIES", 292, 296], ["a complete head scarf", "PROBLEM", 236, 257], ["toe", "ANATOMY", 143, 146], ["head", "ANATOMY", 247, 251], ["scarf", "OBSERVATION", 252, 257], ["head", "ANATOMY", 273, 277], ["toe", "ANATOMY", 281, 284], ["veil", "ANATOMY_MODIFIER", 285, 289]]], ["During the COVID-19 pandemic, she has had to spend all of her time at home with her family.| NayabThe third case coded as Nayab is a woman in her thirties with two children (a five-year-old daughter and a two-yearold son).", [["Nayab", "CHEMICAL", 93, 98], ["woman", "ORGANISM", 133, 138], ["children", "ORGANISM", 164, 172], ["woman", "SPECIES", 133, 138], ["children", "SPECIES", 164, 172], ["Nayab", "SPECIES", 93, 98]]], ["She is comparatively less educated (she has ten years of schooling) than the other two cases in this study and is not financially independent.", [["this study", "TEST", 96, 106]]], ["She does all the household chores herself, however, during the last few weeks of her pregnancy and the initial weeks after giving birth to her two children, she hired a female servant for the household chores.", [["children", "ORGANISM", 147, 155], ["children", "SPECIES", 147, 155]]], ["During the COVID-19 pandemic, her husband spends most of his time at home doing his professional work online through Internet and mobile phone services.| NayabTo study the experiences of the participants, the authors have come from the position of moderate, educated Pakistani Muslims who believe in the progressively negotiated identity of Muslim women that resists universalist as well as indigenous traditional oppressions.| NayabIn the following sections, major themes that were identified through regressive and recursive readings of the transcripts are analysed.", [["sections", "ANATOMY", 450, 458], ["Nayab", "CHEMICAL", 154, 159], ["women", "ORGANISM", 348, 353], ["participants", "SPECIES", 191, 203], ["women", "SPECIES", 348, 353], ["Nayab", "SPECIES", 154, 159], ["regressive", "OBSERVATION_MODIFIER", 502, 512]]], ["Our analysis is informed by the feminist assumption that the non-traditional agency of women, like the one that comes from their mobility and economic independence, in patriarchal societies, easily falls vulnerable to curtailment during moments of national crisis, and they are mostly supposed to step back to their conventional gender roles.| COMPROMISED IDENTITY AND MENTAL STRESSOne of the major themes that transpired from the data is the compromised identity and frequent mental stress that all the three cases under study have experienced in their respective familial environments during the lockdown period.", [["women", "ORGANISM", 87, 92], ["women", "SPECIES", 87, 92], ["Our analysis", "TEST", 0, 12], ["frequent mental stress", "PROBLEM", 468, 490]]], ["Doing jobs, Nisa and Rida had become accustomed to such an environment which they considered was professional and in which they used to think and act professionally as useful and empowered persons of the society.| COMPROMISED IDENTITY AND MENTAL STRESSBut the lockdown shut them in homes rendering them traditional mothers and caregivers while facing harsh behaviours of their male life-partners which added to the mental stress they were already suffering from because of the widespread fear of the pandemic.", [["mothers", "ORGANISM", 315, 322], ["the pandemic", "PROBLEM", 496, 508]]], ["Nisa says: It is signified by the above excerpt that though Nisa has multiple coexisting positions and identities as an educated, economically independent, professional Muslim married woman, what ultimately dominates her, during these times of national calamity, is her identity as a 'good' wife and mother; the rest have to be compromised and even suppressed, at least for the time being.", [["Nisa", "CHEMICAL", 60, 64], ["calamity", "DISEASE", 253, 261], ["woman", "ORGANISM", 184, 189], ["woman", "SPECIES", 184, 189]]], ["Though the educated, professional and economically empowered positionalities and identities enable her to discern the patriarchal suppression and negotiate the religioculturally defined 'pari likhi' (educated) wife and mother makes her behave patiently and modestly, corresponding with the findings of Khurshid (2015) about educated Muslim women in an ethnographic study in Pakistan.", [["women", "ORGANISM", 340, 345], ["women", "SPECIES", 340, 345]]], ["Being an educated Muslim woman in Pakistan implies a privileged social position entitled to claiming power in decision-making in familial matters, but these educated women feel greater social pressure to abide by the Islamic morality and struggle within rather than without the institutions of family, culture and religion (Khurshid, 2015) .", [["women", "ORGANISM", 166, 171], ["woman", "SPECIES", 25, 30], ["women", "SPECIES", 166, 171], ["culture", "TEST", 302, 309]]], ["Zubair and Zubair (2017) argue through personal narratives of their research participants (Muslim women educated in English literature in Pakistan) that multiple positionalities and identities, like the one seen in Nisa, enable women to negotiate in the third space by being resistive to the local religioculturally defined patriarchal structures and the western concepts of women's autonomy.", [["women", "ORGANISM", 98, 103], ["women", "ORGANISM", 228, 233], ["women", "ORGANISM", 375, 380], ["participants", "SPECIES", 77, 89], ["women", "SPECIES", 98, 103], ["women", "SPECIES", 228, 233], ["women", "SPECIES", 375, 380], ["resistive", "OBSERVATION", 275, 284]]], ["However, the situation wherein Nisa is operating is unusual which has triggered reinforcement of traditional norms in familial environments which expect her to conform rather than to resist or negotiate.", [["Nisa", "CHEMICAL", 31, 35]]], ["People have turned more religious, intended to please God to forgive them and end His wrath that has struck them in the form of the pandemic; this general behaviour of the society also makes its imprint on familial environments.", [["People", "ORGANISM", 0, 6], ["People", "SPECIES", 0, 6]]], ["Fighting against and suppressing her identity as an empowered and intellectually mobile woman while embodying like a good wife and mother has created unusual psychological pressure for her.| COMPROMISED IDENTITY AND MENTAL STRESSSimilarly, Rida says: Rida, though a single parent who divorced her husband years ago and has only one daughter and parents to take care of, has started feeling like the traditional woman who is just supposed to stay at home and look after familial domestic matters.", [["woman", "ORGANISM", 88, 93], ["woman", "ORGANISM", 411, 416], ["woman", "SPECIES", 88, 93], ["woman", "SPECIES", 411, 416]]], ["She feels that the identity that she had negotiated for herself as an independent professional woman has come under threat through the containment/lockdown measures.Nisa says:I feel as if this disease is the new super authoritarian man that has been fast rendering me powerless and reduced to femininity.", [["woman", "ORGANISM", 95, 100], ["man", "ORGANISM", 232, 235], ["woman", "SPECIES", 95, 100], ["man", "SPECIES", 232, 235], ["lockdown measures", "TREATMENT", 147, 164], ["this disease", "PROBLEM", 188, 200]]], ["I do try to find some time to read books, and to answer the queries of my students who keep sending me messages through WhatsApp about their studies.", [["their studies", "TEST", 135, 148]]], ["However, you really have to grapple to find some time for such things.Nisa says:Nisa personifies COVID-19 as the super authoritarian man that has continuously been rendering her deprived of her power to negotiate the traditional patriarchal norms and assert herself.", [["man", "ORGANISM", 133, 136], ["man", "SPECIES", 133, 136]]], ["She has to continuously remind herself to situate her thinking, feelings and actions within the sociocultural structures of her family which are hyper-conservative.", [["hyper-conservative", "PROBLEM", 145, 163]]], ["Though cultural fluidity giving rise to women's mobility and less conservative social spaces in the contemporary globalized Pakistan cannot be denied, its effects are still restricted mostly to the private lives of people rather than seen generally in the society (Safdar & Ghani, 2018) .", [["women", "ORGANISM", 40, 45], ["people", "ORGANISM", 215, 221], ["women", "SPECIES", 40, 45], ["people", "SPECIES", 215, 221], ["cultural fluidity", "PROBLEM", 7, 24], ["women's mobility", "PROBLEM", 40, 56]]], ["Despite shifts in their identity due to their multiple social positions, women in Pakistan have to embody traditional gender perceptions while in public spaces.", [["women", "ORGANISM", 73, 78], ["women", "SPECIES", 73, 78]]], ["The identity of these women is precarious and vulnerable to challenges due to their being in multiple social positions, locations and roles that are contradictory.", [["women", "ORGANISM", 22, 27], ["women", "SPECIES", 22, 27]]], ["As Mouffe (1993) notes:Nisa says:The identity of such a multiple and contradictory subject is therefore always contingent and precarious, temporarily fixed at the intersection of those positions and dependent on specific forms of identification.", [["a multiple and contradictory subject", "PROBLEM", 54, 90]]], ["It is therefore impossible to speak of the social agent as if we were dealing with a unified, homogeneous entity.", [["homogeneous", "OBSERVATION_MODIFIER", 94, 105], ["entity", "OBSERVATION", 106, 112]]], ["77) Zubair and Zubair (2017) call it frontstage and backstage identities when educated Muslim women in Pakistan have to behave and act differently in their public and private lives and/or while in different social spaces.", [["women", "ORGANISM", 94, 99], ["women", "SPECIES", 94, 99]]], ["But being at frontstage and backstage is not devoid of mental stress, at least in the cases of Nisa and Rida who, after having learnt to think critically and negotiate their identity, have to step back and dormant their faculties of reasoning and negotiating just to conform to the traditional and dogmatic normative structures.Nisa says:Nayab's situation, however, is pretty different from Nisa and Rida.", [["mental stress", "PROBLEM", 55, 68], ["Nayab's situation", "PROBLEM", 338, 355]]], ["Being an average educated housewife with a husband who is more interested and involved in his professional matters than those of home, she is happy performing her household responsibilities regarding looking after and feeding her two children, and cooking, washing and cleansing.", [["children", "ORGANISM", 234, 242], ["children", "SPECIES", 234, 242], ["cleansing", "TREATMENT", 269, 278]]], ["This negotiated position comes under threat when her husband has to stay at home all the time due to the lockdown/containment measures of the government.", [["the lockdown/containment measures", "TREATMENT", 101, 134]]], ["Before the COVID-19 pandemic, Nayab used to use her ability and skills of taking care of her home, husband and children as her agency to negotiate and resist the domineering influence and superiority of her husband's education and provision of financial resources.", [["Nayab", "CHEMICAL", 30, 35], ["children", "ORGANISM", 111, 119], ["children", "SPECIES", 111, 119], ["Nayab", "TREATMENT", 30, 35]]], ["However, the newly emerged situation in which they have to live together inside the home for weeks has made her husband even question her very ability that had enabled her to negotiate her identity.Nisa says:All the three women, though situated differently and having different positionalities and identities, have similarity in the perceived threats to the identity that they had taken years to develop; and these perceived threats are a cause of their mental stress.", [["women", "ORGANISM", 222, 227], ["women", "SPECIES", 222, 227], ["their mental stress", "PROBLEM", 448, 467]]], ["Her silence is not a helpless or unthoughtful surrender but a strategy to pull herself off the conflict and prove through her behaviour and action that she is more in control of her temperament, behaviour and treatment to others.", [["treatment", "TREATMENT", 209, 218]]], ["However, she does feel the pain her husband's growing misbehaviour has caused her.", [["pain", "DISEASE", 27, 31], ["misbehaviour", "DISEASE", 54, 66], ["the pain", "PROBLEM", 23, 31]]], ["Though I feel upset but I mind my own business even more carefully.I don't indulge in conflicts with him, I keep silence and leave him raging; this is how I don't let thingsThe use of silence by Nayab to silence her raging husband is strategic, agentive and resistive.", [["Nayab", "GENE_OR_GENE_PRODUCT", 195, 200], ["Nayab", "PROTEIN", 195, 200], ["resistive", "OBSERVATION", 258, 267]]], ["It is in correspondence with the findings of Bartkowski and Read (2003) about wifely submission of Christian female participants; it is also resonant of the findings of Zubair and Zubair (2017) regarding agentive silence of Muslim women to their husbands in the patriarchal religio-cultural society of Pakistan.", [["women", "ORGANISM", 231, 236], ["participants", "SPECIES", 116, 128], ["women", "SPECIES", 231, 236]]], ["It enables them to resist against the patriarchal structures that have pushed to narrow their gender space.", [["patriarchal", "ANATOMY_MODIFIER", 38, 49], ["narrow", "OBSERVATION_MODIFIER", 81, 87]]], ["Further, Nisa being the mother of three sons (giving birth to a son in a patriarchal society empowers the mother by enhancing her respect and value in her family and society) possesses another point of leverage.", [["Nisa", "CHEMICAL", 9, 13]]], ["On the one hand, her religio-culturally fundamentalist family environment curtails many of her human rights; on the other hand, she, being very knowledgeable in Islamic teachings about Muslim women's rights, embeds her agency in religion.", [["human", "ORGANISM", 95, 100], ["women", "ORGANISM", 192, 197], ["human", "SPECIES", 95, 100], ["women", "SPECIES", 192, 197], ["human", "SPECIES", 95, 100]]], ["She resists her husband's oppressive manoeuvres through silence as well as discourse that are supported by her stance in religion.", [["She", "ORGANISM", 0, 3]]], ["Her agency is neither of the type that Mahmood's (2005) women exercise through their piety, nor is it of the type of Islamic feminism which reinterprets Quranic text from a feminine perspective (Barlas, 2013) .I don't indulge in conflicts with him, I keep silence and leave him raging; this is how I don't let thingsRida's comparatively less conservative environment than that of Nisa and her having no husband to domineer her also enables her to easily create a space for herself.", [["women", "ORGANISM", 56, 61], ["women", "SPECIES", 56, 61]]], ["However, being a divorced middle-aged woman she also has to be careful regarding her modesty and piety in society as she is more likely to be seen by others to be having an illicit relationship.", [["woman", "ORGANISM", 38, 43], ["woman", "SPECIES", 38, 43]]], ["Nayab's domestic environment is also not conservative; also, she is not in a socially disadvantageous position regarding the sex of her children as she has given birth to a daughter and a son.", [["children", "ORGANISM", 136, 144], ["children", "SPECIES", 136, 144]]], ["The identity of each of these three women is contingent on the conjuncture of a number of intersecting factors defining their gender.", [["women", "ORGANISM", 36, 41], ["women", "SPECIES", 36, 41]]], ["Nisa supposes men, the state and the dominant social behaviour toward women as being in connivance with each other in the form of a nexus to ensure enforcement of patriarchal power structures.", [["Nisa", "CHEMICAL", 0, 4], ["men", "ORGANISM", 14, 17], ["women", "ORGANISM", 70, 75], ["men", "SPECIES", 14, 17], ["women", "SPECIES", 70, 75]]], ["Though by her religious and cultural orientation she does not consider it appropriate for a Muslim woman in Pakistan to complain to state institutions against her own husband for minor abuse or torture, she highlights the need for the availability of and ease of access to such state institutions whom a woman can conveniently approach for justice if she feels she is being seriously tormented by her husband or in-laws.", [["woman", "ORGANISM", 99, 104], ["woman", "ORGANISM", 304, 309], ["woman", "SPECIES", 99, 104], ["woman", "SPECIES", 304, 309]]], ["Despite being highly educated and being in professional jobs, both Nisa and Rida do not know the existence of any state institution or even a helpline in their city that is especially available to rescue a woman if she is under threat of any kind.", [["woman", "ORGANISM", 206, 211], ["woman", "SPECIES", 206, 211]]], ["It corresponds with the observations of DAWN (2020a DAWN ( , 2020b that the state has introduced several legislations over the previous two decades to protect women's rights.", [["women", "ORGANISM", 159, 164], ["women", "SPECIES", 159, 164]]], ["However, due to the lack of proper planning and allocation of resources for the implementation of these legislations, the condition of women has not changed much; even a dominant majority of women is unaware of these laws.", [["women", "ORGANISM", 135, 140], ["women", "ORGANISM", 191, 196], ["women", "SPECIES", 135, 140], ["women", "SPECIES", 191, 196], ["these legislations", "TREATMENT", 98, 116]]], ["It seems the patriarchal core of the nature of the state institutions has not changed; consistent implementation, training of state institutions and change in social behaviours are still things a long way off.", [["change in social behaviours", "PROBLEM", 149, 176]]], ["The Pakistani state being actively involved in defining and shaping the gender of its Muslim women became glaringly obvious during General Zia's regime, whose impact can still be felt in its various forms including extremist religious ideologies regarding Muslim women's identity in public spaces (Jamal, 2006 (Jamal, , 2009 Rouse, 2004; Saigol, 2016; Suleri, 1992; Zia, 2018) .", [["women", "ORGANISM", 93, 98], ["women", "ORGANISM", 263, 268], ["women", "SPECIES", 93, 98], ["women", "SPECIES", 263, 268], ["General Zia's regime", "TREATMENT", 131, 151]]], ["In the last few decades, the state has passed several such legislations (perhaps under the pressure of its western donors that want to see gender equality) that are pro-women, but lack of coherence in their implementation indicates the level of seriousness on the part of the state.", [["donors", "ORGANISM", 115, 121]]], ["Even in normal situations in the country, the appropriated and reconstructed identity of educated, working, mobile Muslim women remains vulnerable to the patriarchy's whims; abnormal situations like COVID-19 just add to its vulnerability in which women find no option other than to succumb and/or reposition themselves depending on their own specific situations.", [["women", "ORGANISM", 122, 127], ["women", "ORGANISM", 247, 252], ["women", "SPECIES", 122, 127], ["women", "SPECIES", 247, 252], ["abnormal situations", "PROBLEM", 174, 193], ["COVID", "TEST", 199, 204], ["normal", "OBSERVATION", 8, 14]]], ["In a society where there does not exist in normal conditions the generally accepted social practice to approach the state for matters like domestic violence, women perhaps cannot even imagine doing so during the pandemic-like national crisis which traditionally demands them to be more 'cooperative' to their men.Nayab says:It is good that there should be some institution to complain; at least we are also human beings.", [["domestic violence", "DISEASE", 139, 156], ["women", "ORGANISM", 158, 163], ["men", "ORGANISM", 309, 312], ["human", "ORGANISM", 407, 412], ["women", "SPECIES", 158, 163], ["men", "SPECIES", 309, 312], ["human", "SPECIES", 407, 412], ["human", "SPECIES", 407, 412], ["good", "OBSERVATION_MODIFIER", 330, 334]]], ["I've heard about some women who were even killed by their husbands and in-laws.Nayab says:When asked if she would complain against her husband, she says:Nayab says:No, not at all.", [["women", "ORGANISM", 22, 27], ["women", "SPECIES", 22, 27]]], ["It is not fair.", [["not", "UNCERTAINTY", 6, 9], ["fair", "OBSERVATION", 10, 14]]], ["These are hard times on us.", [["hard times", "OBSERVATION_MODIFIER", 10, 20]]], ["Doing so will be highly unfair.Nayab says:Though Nayab is aware of her rights as a human being and is worried about the mental torture given to her by her husband's growingly oppressive and insulting behaviour, she does not think it appropriate to complain about it to the state because doing so is socially unacceptable.", [["human", "ORGANISM", 83, 88], ["human", "SPECIES", 83, 88], ["human", "SPECIES", 83, 88]]], ["Like most other states, the Pakistani state has also played a major role in shaping the social behaviour of its people; in Pakistan, patriarchal interpretations of religion and culture have greatly inspired the state's policies focused to regulate social behaviours.", [["people", "ORGANISM", 112, 118], ["people", "SPECIES", 112, 118], ["culture", "TEST", 177, 184]]], ["Nayab's predicament can be described as a typical example of many of those Muslim women in her situation who are conscious of their oppression but are unarmed and revert back (by the overtly/covertly state-supported social behaviours) to their traditional strategies of resistance that are silence and psychological agency, rather than 'rhetorical agency' which is seen on the part of Nisa and Rida to re-construct new subject positions for them (Sinha, 1999, p.", [["women", "ORGANISM", 82, 87], ["women", "SPECIES", 82, 87], ["Nayab's predicament", "TREATMENT", 0, 19]]], ["208) .| CONCLUSIONThis study reveals that the chances of vulnerability of the negotiated identity and social space of middle-class educated Muslim women in urban Pakistan get heightened in situations like COVID-19 mainly due to the religiously inspired dominant patriarchal social behaviours and the state's inability to practically empower its women during normal conditions.", [["women", "ORGANISM", 147, 152], ["women", "ORGANISM", 345, 350], ["women", "SPECIES", 147, 152], ["women", "SPECIES", 345, 350], ["CONCLUSIONThis study", "TEST", 8, 28], ["COVID", "TEST", 205, 210]]], ["Though neither the abnormal pandemic conditions are to stay as permanent, nor the women in these situations, what gets exposed is the nascence of their negotiated identities and social spaces which are contingent on the intersectional social structures and conditions.", [["women", "ORGANISM", 82, 87], ["women", "SPECIES", 82, 87], ["the abnormal pandemic conditions", "PROBLEM", 15, 47], ["abnormal", "OBSERVATION_MODIFIER", 19, 27], ["pandemic", "OBSERVATION", 28, 36]]], ["The psychological scars of Nayab and Nisa due to their husbands' oppressive and even insulting behaviour may get stored in their unconscious and not be healed for a long time, and can also leave a long-lasting impression on their children's psyche and behaviour as well.", [["children", "ORGANISM", 230, 238], ["children", "SPECIES", 230, 238], ["healed", "OBSERVATION", 152, 158]]], ["Given the dominant general social behaviour towards the state's treatment of gender, what is considered of paramount importance by all the three women, during the abnormal pandemic circumstances, is to conform to the normative structures while innovating new forms of re-positioning and re-negotiating their identity in their respective contexts.", [["women", "ORGANISM", 145, 150], ["women", "SPECIES", 145, 150], ["the abnormal pandemic circumstances", "PROBLEM", 159, 194], ["re-positioning", "TREATMENT", 268, 282], ["dominant", "OBSERVATION_MODIFIER", 10, 18]]], ["Gendered social behaviour, the state's policies and women's identity are interlinked.", [["women", "ORGANISM", 52, 57], ["women", "SPECIES", 52, 57]]], ["The study also reveals that awareness, education, mobility, religiosity and economic self-dependence intersect (variously according to their contextual setups) to re-enable the women to re-negotiate their traditional gender identity as wife and mother, re-position and reconstruct their subjectivities even during the stressful times.", [["women", "ORGANISM", 177, 182], ["women", "SPECIES", 177, 182], ["The study", "TEST", 0, 9]]], ["They take care of their families and perform their wifely and motherly duties as well as innovate ways to re-position themselves to seek agency.| CONCLUSIONThis study indicates that if educated urban women feel the social pressure to step back to their traditional patriarchal roles while bearing domestic violence as well, the situation of those living in remote/rural areas or less empowered women could be much worse.", [["domestic violence", "DISEASE", 297, 314], ["women", "ORGANISM", 200, 205], ["women", "ORGANISM", 394, 399], ["women", "SPECIES", 200, 205], ["women", "SPECIES", 394, 399], ["CONCLUSIONThis study", "TEST", 146, 166]]], ["The nexus of religiously inspired patriarchal social behaviour and the state's callousness regarding implementation of its laws renders women suppressed.| CONCLUSIONGiven the religiously disguised violent reaction of the local patriarchal elements to feminist voices in Pakistan, the authors, throughout this study have felt the normative pressure not to speak about the issues related to the women participants' sexuality which are cultural taboos.", [["women", "ORGANISM", 136, 141], ["women", "ORGANISM", 393, 398], ["women", "SPECIES", 136, 141], ["women", "SPECIES", 393, 398], ["participants", "SPECIES", 399, 411], ["violent reaction", "PROBLEM", 197, 213], ["this study", "TEST", 304, 314]]], ["The findings and conclusion of this study enable the first author, whose gendered perspective repeatedly intervened to demand closer insights and empathy in order to feel and understand the participants' situations, to get insight into the underlying religio-culturally disguised patriarchal oppressions of which he himself, consciously or unconsciously, at least partly, had been a part.", [["participants", "SPECIES", 190, 202], ["this study", "TEST", 31, 41]]], ["However, the author has progressively been moderate, advocated and voiced for the rights of Muslim women in Pakistan.DECLARATION OF CONFLICTING INTERESTSThe authors declared no potential conflicts of interests with respect to the authorship and/or publication of this article.Muhammad Safdarhttps://orcid.org/0000-0002-3927-3781Muhammad SafdarMusarat Yasmin https://orcid.org/0000-0002-0571-7575", [["women", "ORGANISM", 99, 104], ["women", "SPECIES", 99, 104], ["SafdarMusarat", "TREATMENT", 337, 350], ["moderate", "OBSERVATION_MODIFIER", 43, 51]]]], "a8b801f23efa409e89226176fec4c0517e330717": [["Conclusions:The results of this study show that microarray technology is a useful approach in screening for, and generation of molecular biomarkers in endangered, non-model organisms, identifying specific genes that can be directly linked with sublethal toxicological endpoints; such as changes in expression levels of neuromuscular genes resulting in measurable swimming impairments.", [["neuromuscular", "ANATOMY", 319, 332], ["swimming impairments", "DISEASE", 363, 383], ["neuromuscular genes", "DNA", 319, 338], ["this study", "TEST", 27, 37], ["microarray technology", "TEST", 48, 69], ["screening", "TEST", 94, 103], ["molecular biomarkers", "TEST", 127, 147], ["non-model organisms", "PROBLEM", 163, 182], ["sublethal toxicological endpoints", "PROBLEM", 244, 277], ["changes in expression levels of neuromuscular genes", "PROBLEM", 287, 338], ["measurable swimming impairments", "PROBLEM", 352, 383]]], ["The developed microarrays were successfully applied on larval fish exposed to esfenvalerate, a known contaminant of the Sacramento-San Joaquin estuary, and has permitted the identification of specific biomarkers which could provide insight into the factors contributing to delta smelt population decline.BackgroundThe delta smelt (Hypomesus transpacificus) is a pelagic fish species endemic to the Sacramento-San Joaquin estuary, whose abundance has dramatically declined since the 1980s, and more precipitously in recent years [1] [2] [3] [4] .", [["esfenvalerate", "CHEMICAL", 78, 91], ["esfenvalerate", "CHEMICAL", 78, 91], ["fish", "ORGANISM", 62, 66], ["esfenvalerate", "SIMPLE_CHEMICAL", 78, 91], ["delta smelt", "ORGANISM", 318, 329], ["Hypomesus transpacificus", "ORGANISM", 331, 355], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 528, 543], ["Hypomesus transpacificus", "SPECIES", 331, 355], ["delta smelt", "SPECIES", 318, 329], ["Hypomesus transpacificus", "SPECIES", 331, 355], ["microarrays", "TREATMENT", 14, 25], ["specific biomarkers", "TEST", 192, 211], ["delta smelt population decline", "PROBLEM", 273, 303], ["The delta smelt (Hypomesus transpacificus", "PROBLEM", 314, 355], ["delta smelt", "OBSERVATION", 318, 329]]], ["It was listed as endangered in 2009, under both the Federal Endangered Species Act (ESA) and California Endangered Species Act (CESA).", [["Endangered Species", "OBSERVATION", 60, 78]]], ["Considerable efforts are presently being made to understand the causes of this recent population decline [4, 5] , especially because several other pelagic species have shown similar population trends.", [["this recent population decline", "PROBLEM", 74, 104], ["several other pelagic species", "PROBLEM", 133, 162]]], ["Delta habitats have been compromised by a number of complex factors, both known and unknown, potentially affecting aquatic species throughout the Sacramento-San Joaquin watersheds and estuary [4] .", [["Delta", "GENE_OR_GENE_PRODUCT", 0, 5], ["complex factors", "PROTEIN", 52, 67], ["Delta habitats", "PROBLEM", 0, 14], ["complex factors", "PROBLEM", 52, 67], ["aquatic species", "PROBLEM", 115, 130]]], ["Pollution, in the form of chemicals contained in runoff from agricultural and urban areas, and old mining sites, treated wastewater effluent, along with the effects of water exports, invasive species and habitat destruction are amongst potential causes for the population decline of several pelagic species [5] .BackgroundIdentifying the sublethal impacts of environmental stressors and their mechanistic effects on resident individuals and populations is a major challenge in ecotoxicology.", [["Pollution", "TREATMENT", 0, 9], ["old mining sites", "PROBLEM", 95, 111], ["water exports", "TREATMENT", 168, 181], ["invasive species", "PROBLEM", 183, 199], ["habitat destruction", "PROBLEM", 204, 223], ["the population decline", "PROBLEM", 257, 279], ["several pelagic species", "PROBLEM", 283, 306], ["chemicals", "OBSERVATION", 26, 35], ["runoff", "OBSERVATION_MODIFIER", 49, 55], ["agricultural", "OBSERVATION_MODIFIER", 61, 73], ["urban", "OBSERVATION_MODIFIER", 78, 83], ["areas", "OBSERVATION_MODIFIER", 84, 89], ["wastewater effluent", "OBSERVATION", 121, 140], ["invasive", "OBSERVATION_MODIFIER", 183, 191], ["several", "OBSERVATION_MODIFIER", 283, 290], ["pelagic species", "OBSERVATION", 291, 306]]], ["Contaminants may not only affect organism survival, but can compromise ecological fitness of individual species via sublethal physiological, behavioral or immunological effects (e.g. [6] [7] [8] [9] [10] ), consequently altering food web and ecosystem dynamics.", [["[6] [7] [8] [9] [10]", "CHEMICAL", 183, 203], ["[6] [7] [8] [9] [10]", "SIMPLE_CHEMICAL", 183, 203], ["individual species", "PROBLEM", 93, 111], ["may not only", "UNCERTAINTY", 13, 25]]], ["However, such physiological endpoints are often difficult to determine in field studies, because they either require behavioral observation and measurements, or because affected individuals will not survive in the wild.", [["such physiological endpoints", "PROBLEM", 9, 37], ["field studies", "TEST", 74, 87], ["behavioral observation", "TEST", 117, 139], ["affected individuals", "PROBLEM", 169, 189]]], ["Similarly, widely used ecotoxicological tools such as standard toxicity tests [11, 12] cannot easily be adapted to resident species of concern, and, conversely, it is problematic to extrapolate test results obtained with surrogate species to resident species of concern [13] .", [["toxicity", "DISEASE", 63, 71], ["standard toxicity tests", "TEST", 54, 77], ["widely", "OBSERVATION_MODIFIER", 11, 17]]], ["Recent comparative studies have demonstrated a need for identifying effects directly in the species of concern, as traditional model organisms may differ in sensitivity and physiological response to environmental contaminants and other stressors [14, 15] .BackgroundCarefully selected molecular biomarkers can provide species-specific and sensitive, mechanistic information on the overall health of an organism, as toxic responses are often preceded by alterations in gene expression [16, 17] .", [["Recent comparative studies", "TEST", 0, 26], ["traditional model organisms", "PROBLEM", 115, 142], ["an organism", "PROBLEM", 399, 410]]], ["The predictive value of microarrays as screening tools, as well as our understanding of these responses and their application in the field of ecotoxicology is rapidly growing.", [["screening tools", "TEST", 39, 54]]], ["This technology can be applied in vertebrates and invertebrates, plants, algae, cell lines and unicellular organisms [20] .", [["algae", "ANATOMY", 73, 78], ["cell lines", "ANATOMY", 80, 90], ["algae", "CELL", 73, 78], ["cell lines", "CELL", 80, 90], ["algae, cell lines", "CELL_LINE", 73, 90], ["This technology", "TREATMENT", 0, 15], ["unicellular organisms", "PROBLEM", 95, 116], ["cell lines", "OBSERVATION", 80, 90]]], ["In addition, links are being established between specific molecular biomarkers identified by microarray technology, and higher-level life history parameters, such as metabolism, growth and reproduction [16, 18, 21, 22] .", [["microarray technology", "TEST", 93, 114]]], ["Gene expression studies carried out over short-term exposures have allowed for the prediction of chronic stressor effects, such as reduced fecundity and embryonic arrest, somatic growth, and population dynamics [16, 18, 21, 23] .", [["embryonic", "ANATOMY", 153, 162], ["embryonic arrest", "DISEASE", 153, 169], ["embryonic", "DEVELOPING_ANATOMICAL_STRUCTURE", 153, 162], ["Gene expression studies", "TEST", 0, 23], ["chronic stressor effects", "PROBLEM", 97, 121], ["reduced fecundity", "PROBLEM", 131, 148], ["embryonic arrest", "PROBLEM", 153, 169], ["somatic growth", "PROBLEM", 171, 185], ["embryonic arrest", "OBSERVATION", 153, 169], ["growth", "OBSERVATION_MODIFIER", 179, 185]]], ["Thus, specific gene responses in studied organisms would not only be indicative of health status, but when used in conservation studies, could highlight potential causes for population decline.", [["conservation studies", "TEST", 115, 135], ["population decline", "PROBLEM", 174, 192]]], ["However, few biomarkers are currently understood well enough to provide conclusive evidence of contaminant impacts on aquatic species in field monitoring, and extrapolating effects seen at the biomarker level to individual or population-level toxicity continues to be a challenge.", [["toxicity", "DISEASE", 243, 251], ["contaminant impacts", "PROBLEM", 95, 114], ["field monitoring", "TEST", 137, 153], ["level toxicity", "PROBLEM", 237, 251], ["contaminant", "OBSERVATION", 95, 106], ["aquatic species", "OBSERVATION", 118, 133]]], ["For molecular biomarkers to be used as successful monitoring tools of individual, population and ecosystem damage, strong links need to continue to be established between gene expression and health status.BackgroundTo better understand the sublethal effects of contaminants upon H. transpacificus, and to identify biomarkers for future field investigations, we have constructed a microarray with 8,448 Expressed Sequence Tags (ESTs).", [["H. transpacificus", "ORGANISM", 279, 296], ["8,448 Expressed Sequence Tags", "DNA", 396, 425], ["H. transpacificus", "SPECIES", 279, 296], ["H. transpacificus", "SPECIES", 279, 296], ["molecular biomarkers", "TEST", 4, 24], ["ecosystem damage", "PROBLEM", 97, 113], ["future field investigations", "TEST", 329, 356], ["a microarray", "TEST", 378, 390]]], ["No genomic information was available on any database at the time this project began, other than a few mitochondrial sequences used in taxonomic studies [24] .", [["mitochondrial", "ANATOMY", 102, 115], ["mitochondrial", "CELLULAR_COMPONENT", 102, 115], ["mitochondrial sequences", "DNA", 102, 125], ["a few mitochondrial sequences", "PROBLEM", 96, 125], ["taxonomic studies", "TEST", 134, 151]]], ["We describe here, the construction and first application of this tool to identify genes in the delta smelt, specifically responding to exposure to esfenvalerate, a pyrethroid insecticide, and present gene expression quantitation of selected biomarkers, utilizing these to explain observed swimming abnormalities.", [["esfenvalerate", "CHEMICAL", 147, 160], ["pyrethroid", "CHEMICAL", 164, 174], ["esfenvalerate", "CHEMICAL", 147, 160], ["pyrethroid", "CHEMICAL", 164, 174], ["esfenvalerate", "SIMPLE_CHEMICAL", 147, 160], ["delta smelt", "DNA", 95, 106], ["a pyrethroid insecticide", "TREATMENT", 162, 186], ["selected biomarkers", "TEST", 232, 251], ["swimming abnormalities", "PROBLEM", 289, 311]]], ["We used esfenvalerate in our study because biochemical responses and adverse effects on the whole organisms are relatively well understood [25] and therefore would aid interpretation of results in this \"proof of principle\" test.", [["esfenvalerate", "TREATMENT", 8, 21], ["our study", "TEST", 25, 34], ["biochemical responses", "PROBLEM", 43, 64], ["adverse effects", "PROBLEM", 69, 84], ["the whole organisms", "PROBLEM", 88, 107]]], ["Esfenvalerate [(S)-a-cyano-3-phenoxybenzyl-(S)-2-(-4-chlorophenyl)-3-methylbutyrate] is a synthetic pyrethroid insecticide, widely used in agriculture, with a high risk to aquatic organisms [26] .", [["Esfenvalerate", "CHEMICAL", 0, 13], ["(S)-a-cyano-3-phenoxybenzyl-(S)-2-(-4-chlorophenyl)-3-methylbutyrate", "CHEMICAL", 15, 83], ["Esfenvalerate", "CHEMICAL", 0, 13], ["(S)-a-cyano-3-phenoxybenzyl-(S)-2-(-4-chlorophenyl)-3-methylbutyrate", "CHEMICAL", 15, 83], ["pyrethroid", "CHEMICAL", 100, 110], ["Esfenvalerate", "SIMPLE_CHEMICAL", 0, 13], ["(S)-a-cyano-3-phenoxybenzyl-(S)-2-(-4-chlorophenyl)-3-methylbutyrate", "SIMPLE_CHEMICAL", 15, 83], ["Esfenvalerate", "TEST", 0, 13], ["a-cyano", "TEST", 19, 26], ["chlorophenyl)", "TREATMENT", 53, 66], ["methylbutyrate", "TREATMENT", 69, 83], ["a synthetic pyrethroid insecticide", "TREATMENT", 88, 122]]], ["It causes neurological damage by blocking sodium and potassium channels, resulting in repetitive neurological discharge [25] .", [["neurological", "ANATOMY", 10, 22], ["neurological", "ANATOMY", 97, 109], ["neurological damage", "DISEASE", 10, 29], ["sodium", "CHEMICAL", 42, 48], ["potassium", "CHEMICAL", 53, 62], ["sodium", "CHEMICAL", 42, 48], ["potassium", "CHEMICAL", 53, 62], ["sodium", "SIMPLE_CHEMICAL", 42, 48], ["potassium", "SIMPLE_CHEMICAL", 53, 62], ["neurological damage", "PROBLEM", 10, 29], ["blocking sodium and potassium channels", "PROBLEM", 33, 71], ["repetitive neurological discharge", "PROBLEM", 86, 119]]], ["In addition, pyrethroid insecticides are highly soluble in myelin sheaths of nerves, causing demyelination, resulting in conduction deficiencies through nerve lesions [27] , directly affecting swimming ability, and impinging on foraging and migration.", [["myelin sheaths", "ANATOMY", 59, 73], ["nerves", "ANATOMY", 77, 83], ["nerve lesions", "ANATOMY", 153, 166], ["pyrethroid", "CHEMICAL", 13, 23], ["demyelination", "DISEASE", 93, 106], ["pyrethroid", "CHEMICAL", 13, 23], ["pyrethroid insecticides", "SIMPLE_CHEMICAL", 13, 36], ["myelin sheaths", "CELLULAR_COMPONENT", 59, 73], ["nerves", "MULTI-TISSUE_STRUCTURE", 77, 83], ["pyrethroid insecticides", "TREATMENT", 13, 36], ["highly soluble in myelin sheaths of nerves", "PROBLEM", 41, 83], ["demyelination", "PROBLEM", 93, 106], ["conduction deficiencies through nerve lesions", "PROBLEM", 121, 166], ["nerves", "ANATOMY", 77, 83], ["causing", "UNCERTAINTY", 85, 92], ["demyelination", "OBSERVATION", 93, 106], ["conduction deficiencies", "OBSERVATION", 121, 144], ["nerve", "ANATOMY", 153, 158], ["lesions", "OBSERVATION", 159, 166], ["migration", "OBSERVATION_MODIFIER", 241, 250]]], ["Fish are highly sensitive to this insecticide, with for example effects on bluegill behavior at measured concentrations as low as 0.025 \u03bcg/L -1 [28] .", [["this insecticide", "TREATMENT", 29, 45], ["bluegill behavior", "PROBLEM", 75, 92]]], ["Pyrethroids have also been reported to affect growth, induce immune responses, reduce hepatic glycogen levels and delay spawning [9, 29] .BackgroundThe main focus of this study was not the development of the microarray, rather the identification of molecular biomarkers specific to the delta smelt and stressors found in the San Joaquin-Sacramento delta.", [["hepatic", "ANATOMY", 86, 93], ["Pyrethroids", "CHEMICAL", 0, 11], ["glycogen", "CHEMICAL", 94, 102], ["Pyrethroids", "CHEMICAL", 0, 11], ["Pyrethroids", "SIMPLE_CHEMICAL", 0, 11], ["hepatic", "ORGAN", 86, 93], ["glycogen", "SIMPLE_CHEMICAL", 94, 102], ["Sacramento delta", "ORGANISM", 337, 353], ["Pyrethroids", "TREATMENT", 0, 11], ["hepatic glycogen levels", "TEST", 86, 109], ["this study", "TEST", 166, 176], ["the microarray", "TEST", 204, 218], ["molecular biomarkers", "TEST", 249, 269], ["the delta smelt", "PROBLEM", 282, 297], ["hepatic", "ANATOMY", 86, 93], ["glycogen levels", "OBSERVATION", 94, 109], ["main", "OBSERVATION_MODIFIER", 152, 156]]], ["We present here results from annotated genes identified through microarray analyses and specifically quantitative PCR analyses of selected molecular biomarkers.Results and DiscussionEffects of esfenvalerate exposure: mortality and swimming behavior Fish larvae are known to be highly sensitive to esfenvalerate, with effects on swimming performance and enhanced susceptibility to predation resulting from concentrations as low as 0.0625 \u03bcg/L -1 [10] .", [["esfenvalerate", "CHEMICAL", 193, 206], ["esfenvalerate", "CHEMICAL", 297, 310], ["esfenvalerate", "CHEMICAL", 193, 206], ["esfenvalerate", "CHEMICAL", 297, 310], ["esfenvalerate", "SIMPLE_CHEMICAL", 193, 206], ["esfenvalerate", "SIMPLE_CHEMICAL", 297, 310], ["microarray analyses", "TEST", 64, 83], ["quantitative PCR analyses", "TEST", 101, 126], ["selected molecular biomarkers", "TEST", 130, 159], ["swimming performance", "TEST", 328, 348]]], ["Behavior alterations are construed as being consequential to the reported neurological mode of action of this pesticide, further affecting foraging, migration and reproduction [30] .", [["neurological", "ANATOMY", 74, 86], ["this pesticide", "PROBLEM", 105, 119]]], ["Toxicity of pyrethroids in the Sacramento-San Joaquin estuary is likely alleviated by the presence of particles and organic matter, and to date concentrations of esfenvalerate detected in the water column were low, however, concentrations in winter storm runoff from agricultural lands have been reported up to 0.093 \u03bcg.L -1 [31] , influencing our decision to investigate dose response exposures to both high and environmentally relevant concentrations in confirmatory studies.Results and DiscussionIn terms of mortality, 10-d old delta smelt were only slightly more sensitive in this study (LC 50,24 h = 0.19 \u03bcg.L -1 ) than 52-d old (LC 50,24 h = 0.24 \u03bcg.L -1 ), however swimming performance of the younger larvae was affected at a concentration approximating one third of that observed affecting older fish (figure 1).", [["Toxicity", "DISEASE", 0, 8], ["pyrethroids", "CHEMICAL", 12, 23], ["esfenvalerate", "CHEMICAL", 162, 175], ["pyrethroids", "CHEMICAL", 12, 23], ["esfenvalerate", "CHEMICAL", 162, 175], ["esfenvalerate", "SIMPLE_CHEMICAL", 162, 175], ["fish", "ORGANISM_SUBDIVISION", 804, 808], ["pyrethroids", "TREATMENT", 12, 23], ["esfenvalerate", "PROBLEM", 162, 175], ["confirmatory studies", "TEST", 456, 476], ["old delta smelt", "TEST", 527, 542], ["this study", "TEST", 580, 590], ["LC", "TEST", 592, 594], ["\u03bcg.L", "TEST", 610, 614], ["LC", "TEST", 635, 637], ["\u03bcg.L", "TEST", 653, 657], ["organic matter", "OBSERVATION", 116, 130]]], ["Swimming abnormality in 10-d old larvae, intensified with increasing esfenvalerate concentration at 4 h, escalating significantly after 24 h exposure (figure 1a).", [["esfenvalerate", "CHEMICAL", 69, 82], ["esfenvalerate", "CHEMICAL", 69, 82], ["esfenvalerate", "SIMPLE_CHEMICAL", 69, 82], ["Swimming abnormality", "PROBLEM", 0, 20], ["increasing esfenvalerate concentration", "PROBLEM", 58, 96]]], ["This swimming abnormality was also concentration dependent in 52-d old fish, however swimming effects resulting from different time point measurements differed only at the highest exposure concentration of 0.250 \u03bcg.L -1 (figure 1b), where effects on motion increased from 22.5% anomaly at 4 h to 45% at 24 h.", [["anomaly", "DISEASE", 278, 285], ["fish", "ORGANISM", 71, 75], ["This swimming abnormality", "PROBLEM", 0, 25], ["concentration dependent", "PROBLEM", 35, 58], ["swimming effects", "PROBLEM", 85, 101]]], ["Behavioral abnormalities, reduced food intake and growth, as well as increased susceptibility to predation were reported in fathead minnow larvae exposed to esfenvalerate for 4 h to concentrations above 0.455 \u03bcg.L -1 [10] .", [["Behavioral abnormalities", "DISEASE", 0, 24], ["esfenvalerate", "CHEMICAL", 157, 170], ["esfenvalerate", "CHEMICAL", 157, 170], ["esfenvalerate", "SIMPLE_CHEMICAL", 157, 170], ["fathead minnow", "SPECIES", 124, 138], ["Behavioral abnormalities", "PROBLEM", 0, 24], ["reduced food intake", "PROBLEM", 26, 45], ["increased susceptibility to predation", "PROBLEM", 69, 106], ["reduced", "OBSERVATION_MODIFIER", 26, 33], ["food intake", "OBSERVATION", 34, 45]]], ["Significant swimming impairments were determined in this study at 0.250 \u03bcg.L -1 , thus delta smelt are highly sensitive to sublethal esfenvalerate exposure.", [["swimming impairments", "DISEASE", 12, 32], ["esfenvalerate", "CHEMICAL", 133, 146], ["esfenvalerate", "CHEMICAL", 133, 146], ["esfenvalerate", "SIMPLE_CHEMICAL", 133, 146], ["Significant swimming impairments", "PROBLEM", 0, 32], ["this study", "TEST", 52, 62], ["delta smelt", "PROBLEM", 87, 98], ["sublethal esfenvalerate exposure", "PROBLEM", 123, 155]]], ["Furthermore, bioaccumulation in rainbow trout have resulted in concentrations 400 times higher than background ambient levels http://extoxnet.orst.edu.Microarray application and q-PCRThrough the application of the delta smelt microarrays, and combined analytical methods, we have identified 288 ESTs, from which a number of genes of interest could be used to measure the effect of esfenvalerate and potentially other pyrethroid insecticides; further investigating their use as biomarkers in this species.", [["esfenvalerate", "CHEMICAL", 381, 394], ["esfenvalerate", "CHEMICAL", 381, 394], ["pyrethroid", "CHEMICAL", 417, 427], ["rainbow", "ORGANISM", 32, 39], ["trout", "ORGANISM", 40, 45], ["esfenvalerate", "SIMPLE_CHEMICAL", 381, 394], ["rainbow trout", "SPECIES", 32, 45], ["rainbow trout", "SPECIES", 32, 45], ["the delta smelt microarrays", "TEST", 210, 237], ["esfenvalerate", "TREATMENT", 381, 394], ["other pyrethroid insecticides", "TREATMENT", 411, 440]]], ["Of the sequenced ESTs that responded significantly, 118 genes were successfully annotated; 170 matched unnamed or hypothetical proteins, or did not match the described annotation selection criteria; i.e. BLASTx searches resulted in expect-values greater than 1 \u00d7 10 -5 and scores below 50.", [["the sequenced ESTs", "TEST", 3, 21], ["hypothetical proteins", "PROBLEM", 114, 135], ["BLASTx searches", "TEST", 204, 219]]], ["Based on gene ontology; molecular function, biological processes and cellular components, 94 unique genes were functionally classified (figure 2 and table 1) and described below.", [["cellular", "ANATOMY", 69, 77], ["cellular", "CELL", 69, 77], ["cellular components", "TEST", 69, 88]]], ["Based on the proportions of ESTs responding to successfully annotated unique genes (33%), it is estimated that of the 8,448 ESTs printed on the microarray, there could be above 2,500 unique genes identified in the delta smelt.", [["8,448 ESTs", "DNA", 118, 128], ["delta smelt", "DNA", 214, 225], ["the microarray", "TEST", 140, 154], ["delta smelt", "OBSERVATION", 214, 225]]], ["These numbers however represent responses to a single contaminant, and should not be construed as final as there will have an intrinsic bias exerted upon them, however, the proportion of repeated sequences in the analyses was very low, with a maximum of nine repetitions for CHK1 checkpoint homologue and not more than one or two duplication for a few others.", [["CHK1", "GENE_OR_GENE_PRODUCT", 275, 279], ["CHK1 checkpoint homologue", "PROTEIN", 275, 300], ["an intrinsic bias", "PROBLEM", 123, 140], ["repeated sequences", "TEST", 187, 205], ["the analyses", "TEST", 209, 221], ["CHK1 checkpoint homologue", "TREATMENT", 275, 300]]], ["It is also important to note that the microarray was manufactured with incomplete genome data, thus information presented in figure 2 represents proportions of a limited number of available genes.Microarray application and q-PCRDifferences between methods used allow for greater mining of possible biomarkers.", [["the microarray", "TEST", 34, 48], ["Microarray application", "TREATMENT", 196, 218], ["q-PCRDifferences between methods", "TREATMENT", 223, 255], ["biomarkers", "TEST", 298, 308]]], ["The method by Loguinov et al [32] identified a single differentially expressed gene at 0.125 \u03bcg/L -1 esfenvalerate (with no significant homol-ogy).", [["esfenvalerate", "CHEMICAL", 101, 114], ["esfenvalerate", "SIMPLE_CHEMICAL", 101, 114]]], ["The addition of LIMMA GUI analysis, also identifying this single gene, generated a broader list of genes for biomarker selection.Microarray application and q-PCRA large percentage of uniquely annotated genes, responding to esfenvalerate exposure; 49%, were classified as involved in various biological processes.", [["esfenvalerate", "CHEMICAL", 223, 236], ["esfenvalerate", "CHEMICAL", 223, 236], ["LIMMA GUI analysis", "TEST", 16, 34], ["biomarker selection", "TREATMENT", 109, 128], ["Microarray application", "TEST", 129, 151]]], ["These included genes encoding for ribosomal proteins, t-RNA synthases, telomerases, uncoupling proteins and genes involved in chromosome maintenance.", [["ribosomal", "ANATOMY", 34, 43], ["chromosome", "ANATOMY", 126, 136], ["ribosomal", "CELLULAR_COMPONENT", 34, 43], ["telomerases", "GENE_OR_GENE_PRODUCT", 71, 82], ["chromosome", "CELLULAR_COMPONENT", 126, 136], ["ribosomal proteins", "PROTEIN", 34, 52], ["t-RNA synthases", "PROTEIN", 54, 69], ["telomerases", "PROTEIN", 71, 82], ["uncoupling proteins", "PROTEIN", 84, 103], ["ribosomal proteins", "TREATMENT", 34, 52], ["t-RNA synthases", "TREATMENT", 54, 69], ["telomerases", "TREATMENT", 71, 82], ["uncoupling proteins", "PROBLEM", 84, 103], ["chromosome maintenance", "TREATMENT", 126, 148]]], ["Of greater interest was the identification of genes involved in neuromuscular activity; representing 19% of identified sequences, a further 12% eliciting immune responses, along with 6% related to oxidative stress, respiration and iron storage and 5% relevant to apoptosis.", [["neuromuscular", "ANATOMY", 64, 77], ["iron", "CHEMICAL", 231, 235], ["iron", "CHEMICAL", 231, 235], ["neuromuscular", "ANATOMICAL_SYSTEM", 64, 77], ["iron", "SIMPLE_CHEMICAL", 231, 235], ["oxidative stress", "PROBLEM", 197, 213], ["iron storage", "TREATMENT", 231, 243], ["greater", "OBSERVATION_MODIFIER", 3, 10], ["neuromuscular", "ANATOMY", 64, 77]]], ["Digestion appears to have also been affected, along with growth and development, repre- Genes selected for quantitative PCR analyses are shown in bold. * indicates genes responding at 0.0625 \u03bcg.L -1 esfenvalerate and ** indicates gene responding to both 0.0625 and 0.125 \u03bcg.L 1 esfenvalerate.", [["L -1 esfenvalerate", "CHEMICAL", 194, 212], ["esfenvalerate", "CHEMICAL", 278, 291], ["L -1 esfenvalerate", "GENE_OR_GENE_PRODUCT", 194, 212], ["Digestion", "PROBLEM", 0, 9], ["quantitative PCR analyses", "TEST", 107, 132], ["esfenvalerate", "OBSERVATION", 278, 291]]], ["Remaining genes responded only at 0.125 \u03bcg.L 1 esfenvalerate exposure.", [["esfenvalerate", "CHEMICAL", 47, 60], ["esfenvalerate", "CHEMICAL", 47, 60], ["esfenvalerate exposure", "OBSERVATION", 47, 69]]], ["Information represents proportions of a limited number of available genes on the applied microarray. sented by genes coding for pancreatic enzymes, a zona pellucida protein; inferred to be choriogenin, and a growth hormone.Swimming behavior and mortalityA selected group of genes, highlighted in bold in the gene list in table 1, were validated using q-PCR and further investigated for use as molecular biomarkers.", [["pancreatic", "ANATOMY", 128, 138], ["pancreatic enzymes", "GENE_OR_GENE_PRODUCT", 128, 146], ["zona pellucida", "GENE_OR_GENE_PRODUCT", 150, 164], ["choriogenin", "GENE_OR_GENE_PRODUCT", 189, 200], ["pancreatic enzymes", "PROTEIN", 128, 146], ["zona pellucida protein", "PROTEIN", 150, 172], ["choriogenin", "PROTEIN", 189, 200], ["pancreatic enzymes", "TEST", 128, 146], ["a zona pellucida protein", "TEST", 148, 172], ["choriogenin", "PROBLEM", 189, 200], ["a growth hormone", "PROBLEM", 206, 222], ["q-PCR", "TEST", 351, 356], ["molecular biomarkers", "TEST", 393, 413], ["pancreatic", "ANATOMY", 128, 138]]], ["These results are described below, in conjunction with differentially expressed genes identified through microarray application.Specific effects of esfenvalerate exposure on gene expressionPyrethroid insecticides are known sodium and potassium channel modulators [25] , with axon demyelinating effects [27] .", [["axon", "ANATOMY", 275, 279], ["esfenvalerate", "CHEMICAL", 148, 161], ["sodium", "CHEMICAL", 223, 229], ["potassium", "CHEMICAL", 234, 243], ["esfenvalerate", "CHEMICAL", 148, 161], ["Pyrethroid", "CHEMICAL", 189, 199], ["sodium", "CHEMICAL", 223, 229], ["potassium", "CHEMICAL", 234, 243], ["esfenvalerate", "SIMPLE_CHEMICAL", 148, 161], ["Pyrethroid insecticides", "SIMPLE_CHEMICAL", 189, 212], ["sodium", "SIMPLE_CHEMICAL", 223, 229], ["potassium", "SIMPLE_CHEMICAL", 234, 243], ["microarray application", "TREATMENT", 105, 127], ["esfenvalerate exposure", "PROBLEM", 148, 170], ["gene expressionPyrethroid insecticides", "TREATMENT", 174, 212], ["sodium and potassium channel modulators", "TREATMENT", 223, 262], ["axon demyelinating effects", "PROBLEM", 275, 301]]], ["This the proof-of-principle microarray assessment of esfenvalerate exposure of 52-d old delta smelt, was suc-cessfully used to screen for, and further understand its mode of action, identifying neuromuscular responses, that were confirmed as highly significant through qPCR, corroborating known effects of this pesticide, but also pointing at other significant effects upon growth and development, digestion and the immune system.", [["neuromuscular", "ANATOMY", 194, 207], ["immune system", "ANATOMY", 416, 429], ["esfenvalerate", "CHEMICAL", 53, 66], ["principle microarray assessment", "TEST", 18, 49], ["esfenvalerate exposure", "PROBLEM", 53, 75], ["old delta smelt", "PROBLEM", 84, 99], ["qPCR", "TEST", 269, 273], ["this pesticide", "TREATMENT", 306, 320], ["digestion and the immune system", "PROBLEM", 398, 429]]], ["Gene expression assessed by qPCR on 10-d old delta smelt that verified these genomic responses are presented below.", [["Gene expression", "PROBLEM", 0, 15], ["qPCR", "TEST", 28, 32]]], ["Correlations in expression between q-PCR investigated genes are shown in table 2 and fold changes in gene expression are summarized in figure 3 and table 3.i.", [["q-PCR", "TEST", 35, 40], ["fold changes in gene expression", "PROBLEM", 85, 116]]], ["Neuromuscular responsesParvalbumin expression in 10 d old larvae was induced 1.8-fold (t-test, p = 0.008) at 0.0313 \u03bcg.L -1 esfenvalerate, reducing in expression at higher concentrations.", [["Neuromuscular", "ANATOMY", 0, 13], ["L -1 esfenvalerate", "CHEMICAL", 119, 137], ["L -1 esfenvalerate", "CHEMICAL", 119, 137], ["Parvalbumin", "GENE_OR_GENE_PRODUCT", 23, 34], ["larvae", "ORGANISM", 58, 64], ["L -1 esfenvalerate", "SIMPLE_CHEMICAL", 119, 137], ["Parvalbumin", "PROTEIN", 23, 34], ["Neuromuscular responses", "TEST", 0, 23], ["Parvalbumin expression", "TREATMENT", 23, 45], ["esfenvalerate", "OBSERVATION", 124, 137], ["higher concentrations", "OBSERVATION", 165, 186]]], ["Localized in fast-contracting muscles, some endocrine tissues, in the Redox and iron binding 6% Various cellular processes 49%i.", [["muscles", "ANATOMY", 30, 37], ["endocrine tissues", "ANATOMY", 44, 61], ["cellular", "ANATOMY", 104, 112], ["iron", "CHEMICAL", 80, 84], ["iron", "CHEMICAL", 80, 84], ["muscles", "ORGAN", 30, 37], ["endocrine tissues", "TISSUE", 44, 61], ["iron", "SIMPLE_CHEMICAL", 80, 84], ["cellular", "CELL", 104, 112], ["some endocrine tissues", "PROBLEM", 39, 61], ["iron binding", "TEST", 80, 92], ["Various cellular processes", "TEST", 96, 122], ["fast", "OBSERVATION_MODIFIER", 13, 17], ["contracting muscles", "ANATOMY", 18, 37], ["endocrine tissues", "OBSERVATION", 44, 61]]], ["Neuromuscular responsesDigestion 5%i.", [["Neuromuscular", "ANATOMY", 0, 13], ["Neuromuscular responsesDigestion", "TEST", 0, 32]]], ["Neuromuscular responsesApoptosis 5%i.", [["Neuromuscular", "ANATOMY", 0, 13], ["Neuromuscular responsesApoptosis", "PROBLEM", 0, 32]]], ["Neuromuscular responsesGrowth and development 2%Neuromuscular 19%Detoxification 1% Immune response 12%Neuromuscular 19%Osmotic stress 1%Neuromuscular 19%nervous system in GABAergic interneurons and in the brain [33] , parvalbumin removes calcium from myofibrils, protecting neurons from hyper-excitability and facilitating muscle relaxation [34] .", [["Neuromuscular", "ANATOMY", 0, 13], ["Neuromuscular", "ANATOMY", 136, 149], ["nervous system", "ANATOMY", 153, 167], ["GABAergic interneurons", "ANATOMY", 171, 193], ["brain", "ANATOMY", 205, 210], ["myofibrils", "ANATOMY", 251, 261], ["neurons", "ANATOMY", 274, 281], ["muscle", "ANATOMY", 323, 329], ["calcium", "CHEMICAL", 238, 245], ["calcium", "CHEMICAL", 238, 245], ["nervous system", "ANATOMICAL_SYSTEM", 153, 167], ["GABAergic interneurons", "CELL", 171, 193], ["brain", "ORGAN", 205, 210], ["parvalbumin", "GENE_OR_GENE_PRODUCT", 218, 229], ["calcium", "SIMPLE_CHEMICAL", 238, 245], ["myofibrils", "CELLULAR_COMPONENT", 251, 261], ["neurons", "CELL", 274, 281], ["muscle", "ORGAN", 323, 329], ["parvalbumin", "PROTEIN", 218, 229], ["Neuromuscular responsesGrowth", "TEST", 0, 29], ["development", "TEST", 34, 45], ["Neuromuscular", "TEST", 48, 61], ["Detoxification", "TEST", 65, 79], ["Immune response", "TEST", 83, 98], ["Neuromuscular", "TEST", 102, 115], ["Osmotic stress", "TEST", 119, 133], ["Neuromuscular 19%nervous system", "PROBLEM", 136, 167], ["GABAergic interneurons", "TEST", 171, 193], ["calcium", "TEST", 238, 245], ["myofibrils", "PROBLEM", 251, 261], ["GABAergic interneurons", "OBSERVATION", 171, 193], ["brain", "ANATOMY", 205, 210], ["muscle", "ANATOMY", 323, 329]]], ["Accumulation of calcium in muscular tissue contributes to muscle degradation, muscular dystrophy and muscle fiber necrosis [35] .", [["muscular tissue", "ANATOMY", 27, 42], ["muscle", "ANATOMY", 58, 64], ["muscular", "ANATOMY", 78, 86], ["muscle fiber", "ANATOMY", 101, 113], ["calcium", "CHEMICAL", 16, 23], ["muscle degradation", "DISEASE", 58, 76], ["muscular dystrophy", "DISEASE", 78, 96], ["muscle fiber necrosis", "DISEASE", 101, 122], ["calcium", "CHEMICAL", 16, 23], ["calcium", "SIMPLE_CHEMICAL", 16, 23], ["muscular tissue", "TISSUE", 27, 42], ["muscle", "ORGAN", 58, 64], ["calcium in muscular tissue", "PROBLEM", 16, 42], ["muscle degradation", "PROBLEM", 58, 76], ["muscular dystrophy", "PROBLEM", 78, 96], ["muscle fiber necrosis", "PROBLEM", 101, 122], ["calcium", "OBSERVATION", 16, 23], ["muscular tissue", "ANATOMY", 27, 42], ["muscle", "ANATOMY", 58, 64], ["degradation", "OBSERVATION", 65, 76], ["muscular dystrophy", "OBSERVATION", 78, 96], ["muscle", "ANATOMY", 101, 107], ["fiber necrosis", "OBSERVATION", 108, 122]]], ["Estrogen is required for parvalbumin expression, thus estrogen receptor-\u03b2 co-expresses with parvalbumin [36] .", [["estrogen", "CHEMICAL", 54, 62], ["Estrogen", "CHEMICAL", 0, 8], ["estrogen", "CHEMICAL", 54, 62], ["Estrogen", "GENE_OR_GENE_PRODUCT", 0, 8], ["parvalbumin", "GENE_OR_GENE_PRODUCT", 25, 36], ["estrogen receptor-\u03b2", "GENE_OR_GENE_PRODUCT", 54, 73], ["parvalbumin", "GENE_OR_GENE_PRODUCT", 92, 103], ["parvalbumin", "PROTEIN", 25, 36], ["estrogen receptor", "PROTEIN", 54, 71], ["\u03b2", "PROTEIN", 72, 73], ["Estrogen", "TREATMENT", 0, 8], ["parvalbumin expression", "TREATMENT", 25, 47], ["estrogen receptor", "TREATMENT", 54, 71]]], ["Estrogen is also required in brain development and has a protective neurological role, by regulating the activity of GABAergic systems within the hippocampus, basal forebrain and hypothalamus [37] .", [["brain", "ANATOMY", 29, 34], ["neurological", "ANATOMY", 68, 80], ["hippocampus", "ANATOMY", 146, 157], ["basal forebrain", "ANATOMY", 159, 174], ["hypothalamus", "ANATOMY", 179, 191], ["Estrogen", "CHEMICAL", 0, 8], ["Estrogen", "GENE_OR_GENE_PRODUCT", 0, 8], ["brain", "ORGAN", 29, 34], ["hippocampus", "MULTI-TISSUE_STRUCTURE", 146, 157], ["basal forebrain", "CELLULAR_COMPONENT", 159, 174], ["Estrogen", "TREATMENT", 0, 8], ["hippocampus", "ANATOMY", 146, 157], ["basal forebrain", "ANATOMY", 159, 174], ["hypothalamus", "ANATOMY", 179, 191]]], ["Differential expression of parvalbumin on exposure to esfenvalerate may be resultant of estrogenic effects.", [["esfenvalerate", "CHEMICAL", 54, 67], ["esfenvalerate", "CHEMICAL", 54, 67], ["parvalbumin", "GENE_OR_GENE_PRODUCT", 27, 38], ["esfenvalerate", "SIMPLE_CHEMICAL", 54, 67], ["parvalbumin", "PROTEIN", 27, 38], ["estrogenic effects", "PROBLEM", 88, 106], ["estrogenic effects", "OBSERVATION", 88, 106]]], ["Pyrethroid pesticides have steroid receptor-binding activity [38] linked with endocrine disruption [39] , thus exposure is likely to affect the population dynamics of wildlife not only through neuromuscular impairments, but also by affecting reproductive output [29, 40] .", [["endocrine", "ANATOMY", 78, 87], ["neuromuscular", "ANATOMY", 193, 206], ["Pyrethroid", "CHEMICAL", 0, 10], ["steroid", "CHEMICAL", 27, 34], ["neuromuscular impairments", "DISEASE", 193, 218], ["Pyrethroid", "CHEMICAL", 0, 10], ["steroid", "CHEMICAL", 27, 34], ["Pyrethroid", "SIMPLE_CHEMICAL", 0, 10], ["steroid", "SIMPLE_CHEMICAL", 27, 34], ["endocrine", "ANATOMICAL_SYSTEM", 78, 87], ["neuromuscular", "ANATOMICAL_SYSTEM", 193, 206], ["steroid receptor", "PROTEIN", 27, 43], ["Pyrethroid pesticides", "TREATMENT", 0, 21], ["steroid receptor", "TREATMENT", 27, 43], ["endocrine disruption", "PROBLEM", 78, 98], ["neuromuscular impairments", "PROBLEM", 193, 218], ["reproductive output", "TEST", 242, 261]]], ["Parvalbumin, could therefore, be a good indicator of possible endocrine-disruption as well as neuromuscular impairments.", [["endocrine", "ANATOMY", 62, 71], ["neuromuscular", "ANATOMY", 94, 107], ["Parvalbumin", "CHEMICAL", 0, 11], ["neuromuscular impairments", "DISEASE", 94, 119], ["Parvalbumin", "GENE_OR_GENE_PRODUCT", 0, 11], ["endocrine", "ANATOMICAL_SYSTEM", 62, 71], ["neuromuscular", "MULTI-TISSUE_STRUCTURE", 94, 107], ["Parvalbumin", "TREATMENT", 0, 11], ["endocrine-disruption", "PROBLEM", 62, 82], ["neuromuscular impairments", "PROBLEM", 94, 119], ["disruption", "OBSERVATION", 72, 82]]], ["Interestingly, expression of aspartoacylase (ASPA) in exposed 10-d old delta smelt larvae was significantly affected at all concentrations, downregulating with increasing esfenvalerate concentration in a dose response manner, and correlating significantly with swimming anomaly at 24 h (r = 0.913, p = 0.029).", [["esfenvalerate", "CHEMICAL", 171, 184], ["swimming anomaly", "DISEASE", 261, 277], ["esfenvalerate", "CHEMICAL", 171, 184], ["aspartoacylase", "GENE_OR_GENE_PRODUCT", 29, 43], ["ASPA", "GENE_OR_GENE_PRODUCT", 45, 49], ["delta smelt", "ORGANISM", 71, 82], ["esfenvalerate", "SIMPLE_CHEMICAL", 171, 184], ["aspartoacylase", "PROTEIN", 29, 43], ["ASPA", "PROTEIN", 45, 49], ["aspartoacylase (ASPA)", "PROBLEM", 29, 50], ["old delta smelt larvae", "PROBLEM", 67, 89], ["increasing esfenvalerate concentration", "TREATMENT", 160, 198], ["swimming anomaly", "PROBLEM", 261, 277]]], ["Aspartoacylase catalyzes hydrolysis of N-acetyl-L-aspartate (NAA) to aspartate and acetate in the vertebrate brain [41] .", [["brain", "ANATOMY", 109, 114], ["Aspartoacylase", "CHEMICAL", 0, 14], ["N-acetyl-L-aspartate", "CHEMICAL", 39, 59], ["NAA", "CHEMICAL", 61, 64], ["aspartate", "CHEMICAL", 69, 78], ["acetate", "CHEMICAL", 83, 90], ["N-acetyl-L-aspartate", "CHEMICAL", 39, 59], ["NAA", "CHEMICAL", 61, 64], ["aspartate", "CHEMICAL", 69, 78], ["acetate", "CHEMICAL", 83, 90], ["Aspartoacylase", "SIMPLE_CHEMICAL", 0, 14], ["N-acetyl-L-aspartate", "SIMPLE_CHEMICAL", 39, 59], ["NAA", "SIMPLE_CHEMICAL", 61, 64], ["aspartate", "SIMPLE_CHEMICAL", 69, 78], ["acetate", "SIMPLE_CHEMICAL", 83, 90], ["brain", "ORGAN", 109, 114], ["N-acetyl", "TEST", 39, 47], ["L-aspartate (NAA)", "TREATMENT", 48, 65], ["aspartate and acetate", "TREATMENT", 69, 90], ["brain", "ANATOMY", 109, 114]]], ["Variations in NAA measured in urine, blood and brain, have been used as diagnosis of nervous system diseases such as Alzheimer's and multiple sclerosis [42, 43] .", [["urine", "ANATOMY", 30, 35], ["blood", "ANATOMY", 37, 42], ["brain", "ANATOMY", 47, 52], ["nervous system", "ANATOMY", 85, 99], ["NAA", "CHEMICAL", 14, 17], ["nervous system diseases", "DISEASE", 85, 108], ["Alzheimer's and multiple sclerosis", "DISEASE", 117, 151], ["NAA", "CHEMICAL", 14, 17], ["NAA", "SIMPLE_CHEMICAL", 14, 17], ["urine", "ORGANISM_SUBSTANCE", 30, 35], ["blood", "ORGANISM_SUBSTANCE", 37, 42], ["brain", "ORGAN", 47, 52], ["nervous", "ANATOMICAL_SYSTEM", 85, 92], ["system", "ANATOMICAL_SYSTEM", 93, 99], ["Variations in NAA measured in urine, blood and brain", "PROBLEM", 0, 52], ["nervous system diseases", "PROBLEM", 85, 108], ["Alzheimer's", "PROBLEM", 117, 128], ["multiple sclerosis", "PROBLEM", 133, 151], ["blood", "ANATOMY", 37, 42], ["brain", "ANATOMY", 47, 52], ["nervous system", "ANATOMY", 85, 99], ["multiple", "OBSERVATION_MODIFIER", 133, 141], ["sclerosis", "OBSERVATION", 142, 151]]], ["Measurements of NAA, along with ADP levels determined by creatine kinase activity, are used to evaluate the energetic state of the brain, a positive linear correlation existing between NAA and ADP synthesis [44] .", [["brain", "ANATOMY", 131, 136], ["NAA", "CHEMICAL", 16, 19], ["ADP", "CHEMICAL", 32, 35], ["creatine", "CHEMICAL", 57, 65], ["NAA", "CHEMICAL", 185, 188], ["ADP", "CHEMICAL", 193, 196], ["NAA", "CHEMICAL", 16, 19], ["ADP", "CHEMICAL", 32, 35], ["creatine", "CHEMICAL", 57, 65], ["NAA", "CHEMICAL", 185, 188], ["ADP", "CHEMICAL", 193, 196], ["NAA", "SIMPLE_CHEMICAL", 16, 19], ["ADP", "SIMPLE_CHEMICAL", 32, 35], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 57, 72], ["brain", "ORGAN", 131, 136], ["NAA", "SIMPLE_CHEMICAL", 185, 188], ["ADP", "SIMPLE_CHEMICAL", 193, 196], ["creatine kinase", "PROTEIN", 57, 72], ["NAA", "TEST", 16, 19], ["ADP levels", "TEST", 32, 42], ["creatine kinase activity", "TEST", 57, 81], ["NAA and ADP synthesis", "TEST", 185, 206], ["brain", "ANATOMY", 131, 136]]], ["Deficiency in ASPA activity leads to degeneration of the myelin; an ensheathment that isolates and controls axonal activity, it is associated with schizophrenia [45] , and is the established cause of leukodystrophy in Canavan's disease [43] .", [["myelin", "ANATOMY", 57, 63], ["axonal", "ANATOMY", 108, 114], ["schizophrenia", "DISEASE", 147, 160], ["leukodystrophy", "DISEASE", 200, 214], ["Canavan's disease", "DISEASE", 218, 235], ["ASPA", "GENE_OR_GENE_PRODUCT", 14, 18], ["myelin", "CELLULAR_COMPONENT", 57, 63], ["Canavan's disease", "CANCER", 218, 235], ["ASPA", "PROTEIN", 14, 18], ["Deficiency in ASPA activity", "PROBLEM", 0, 27], ["degeneration of the myelin", "PROBLEM", 37, 63], ["schizophrenia", "PROBLEM", 147, 160], ["leukodystrophy in Canavan's disease", "PROBLEM", 200, 235], ["myelin", "ANATOMY", 57, 63], ["axonal activity", "OBSERVATION", 108, 123], ["leukodystrophy", "OBSERVATION", 200, 214]]], ["Abnormal myelination is known to result from acyltransferase deficiency [46] .", [["acyltransferase", "GENE_OR_GENE_PRODUCT", 45, 60], ["acyltransferase", "PROTEIN", 45, 60], ["Abnormal myelination", "PROBLEM", 0, 20], ["acyltransferase deficiency", "PROBLEM", 45, 71], ["myelination", "OBSERVATION", 9, 20]]], ["Ependymin, a myelin associated glycoprotein related to memory formation and involved in neuronal regeneration [47] , was also negatively affected by esfenvalerate.", [["neuronal", "ANATOMY", 88, 96], ["Ependymin", "CHEMICAL", 0, 9], ["esfenvalerate", "CHEMICAL", 149, 162], ["esfenvalerate", "CHEMICAL", 149, 162], ["Ependymin", "GENE_OR_GENE_PRODUCT", 0, 9], ["myelin associated glycoprotein", "GENE_OR_GENE_PRODUCT", 13, 43], ["neuronal", "CELL", 88, 96], ["esfenvalerate", "SIMPLE_CHEMICAL", 149, 162], ["Ependymin", "PROTEIN", 0, 9], ["myelin associated glycoprotein", "PROTEIN", 13, 43], ["Ependymin", "PROBLEM", 0, 9], ["a myelin associated glycoprotein", "PROBLEM", 11, 43], ["memory formation", "PROBLEM", 55, 71]]], ["Myelin has been postulated as a probable modulator of ASPA activity [48] further affecting this critical pathway of neurological function.", [["neurological", "ANATOMY", 116, 128], ["Myelin", "GENE_OR_GENE_PRODUCT", 0, 6], ["ASPA", "GENE_OR_GENE_PRODUCT", 54, 58], ["ASPA", "PROTEIN", 54, 58], ["Myelin", "PROBLEM", 0, 6], ["ASPA activity", "PROBLEM", 54, 67]]], ["ASPA protein activity is a strong biomarker of brain damage and neurological impairment investigation, used regularly in human and veterinary disease diagnostics [49] .Neuromuscular 19%Creatine kinase was significantly up-regulated at 0.0313 \u03bcg.L -1 esfenvalerate (t-test, p < 0.05).", [["brain", "ANATOMY", 47, 52], ["neurological", "ANATOMY", 64, 76], ["Neuromuscular", "ANATOMY", 168, 181], ["brain damage", "DISEASE", 47, 59], ["neurological impairment", "DISEASE", 64, 87], ["Creatine", "CHEMICAL", 185, 193], ["L -1 esfenvalerate", "CHEMICAL", 245, 263], ["Creatine", "CHEMICAL", 185, 193], ["ASPA", "GENE_OR_GENE_PRODUCT", 0, 4], ["brain", "ORGAN", 47, 52], ["human", "ORGANISM", 121, 126], ["Creatine kinase", "GENE_OR_GENE_PRODUCT", 185, 200], ["L -1 esfenvalerate", "SIMPLE_CHEMICAL", 245, 263], ["ASPA", "PROTEIN", 0, 4], ["Creatine kinase", "PROTEIN", 185, 200], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["ASPA protein activity", "TEST", 0, 21], ["brain damage", "PROBLEM", 47, 59], ["neurological impairment investigation", "PROBLEM", 64, 101], ["Neuromuscular", "TEST", 168, 181], ["Creatine kinase", "TEST", 185, 200], ["L", "TEST", 245, 246], ["protein activity", "OBSERVATION", 5, 21], ["brain", "ANATOMY", 47, 52], ["damage", "OBSERVATION", 53, 59]]], ["Creatine kinase protein is used not only as a diagnosis of brain energetic value as mentioned above, but also of diseases like cardiac infarction and skeletal muscle necrosis [50] .", [["brain", "ANATOMY", 59, 64], ["cardiac", "ANATOMY", 127, 134], ["skeletal muscle", "ANATOMY", 150, 165], ["Creatine", "CHEMICAL", 0, 8], ["cardiac infarction", "DISEASE", 127, 145], ["skeletal muscle necrosis", "DISEASE", 150, 174], ["Creatine", "CHEMICAL", 0, 8], ["Creatine kinase", "GENE_OR_GENE_PRODUCT", 0, 15], ["brain", "ORGAN", 59, 64], ["cardiac", "ORGAN", 127, 134], ["skeletal muscle", "TISSUE", 150, 165], ["Creatine kinase protein", "PROTEIN", 0, 23], ["Creatine kinase protein", "TEST", 0, 23], ["brain energetic value", "PROBLEM", 59, 80], ["diseases", "PROBLEM", 113, 121], ["cardiac infarction", "PROBLEM", 127, 145], ["skeletal muscle necrosis", "PROBLEM", 150, 174], ["brain", "ANATOMY", 59, 64], ["energetic value", "OBSERVATION", 65, 80], ["diseases", "OBSERVATION", 113, 121], ["cardiac", "ANATOMY", 127, 134], ["infarction", "OBSERVATION", 135, 145], ["skeletal muscle", "ANATOMY", 150, 165], ["necrosis", "OBSERVATION", 166, 174]]], ["In muscle, creatine kinase is specifically bound to sarcoendoplasmic reticulum, and regulates calcium uptake and ATP/ADP ratios [51] , thus is directly involved in muscle contraction.Neuromuscular 19%Of interest here, are the pathway links and correlating responses (r = 0.98) between parvalbumin; facilitating muscle relaxation by binding calcium, and creatine kinase, which regulates calcium uptake.", [["muscle", "ANATOMY", 3, 9], ["sarcoendoplasmic reticulum", "ANATOMY", 52, 78], ["muscle", "ANATOMY", 164, 170], ["Neuromuscular", "ANATOMY", 183, 196], ["muscle", "ANATOMY", 311, 317], ["creatine", "CHEMICAL", 11, 19], ["calcium", "CHEMICAL", 94, 101], ["ATP", "CHEMICAL", 113, 116], ["ADP", "CHEMICAL", 117, 120], ["calcium", "CHEMICAL", 340, 347], ["creatine", "CHEMICAL", 353, 361], ["calcium", "CHEMICAL", 386, 393], ["creatine", "CHEMICAL", 11, 19], ["calcium", "CHEMICAL", 94, 101], ["ATP", "CHEMICAL", 113, 116], ["ADP", "CHEMICAL", 117, 120], ["calcium", "CHEMICAL", 340, 347], ["creatine", "CHEMICAL", 353, 361], ["calcium", "CHEMICAL", 386, 393], ["muscle", "ORGAN", 3, 9], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 11, 26], ["sarcoendoplasmic reticulum", "CELLULAR_COMPONENT", 52, 78], ["calcium", "SIMPLE_CHEMICAL", 94, 101], ["ATP", "SIMPLE_CHEMICAL", 113, 116], ["ADP", "SIMPLE_CHEMICAL", 117, 120], ["muscle", "ORGAN", 164, 170], ["parvalbumin", "GENE_OR_GENE_PRODUCT", 285, 296], ["muscle", "ORGAN", 311, 317], ["calcium", "SIMPLE_CHEMICAL", 340, 347], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 353, 368], ["calcium", "SIMPLE_CHEMICAL", 386, 393], ["creatine kinase", "PROTEIN", 11, 26], ["parvalbumin", "PROTEIN", 285, 296], ["creatine kinase", "PROTEIN", 353, 368], ["creatine kinase", "TEST", 11, 26], ["calcium uptake", "TEST", 94, 108], ["ATP/ADP ratios", "TEST", 113, 127], ["parvalbumin", "TREATMENT", 285, 296], ["binding calcium", "TEST", 332, 347], ["creatine kinase", "TEST", 353, 368], ["calcium uptake", "PROBLEM", 386, 400], ["muscle", "ANATOMY", 3, 9], ["muscle", "ANATOMY", 164, 170], ["contraction", "OBSERVATION", 171, 182], ["muscle", "ANATOMY", 311, 317]]], ["These two param- eters on their own indicate muscular activity impairments, creating strong links with observed larval swimming behavior.Molecular biomarkers responsesTitin expression also correlated significantly with parvalbumin (r = 0.95) and creatine kinase (r = 0.92), though not statistically significant in q-PCR assessments of 10-d old smelt larvae.", [["muscular", "ANATOMY", 45, 53], ["muscular activity impairments", "DISEASE", 45, 74], ["creatine", "CHEMICAL", 246, 254], ["creatine", "CHEMICAL", 246, 254], ["muscular", "ORGANISM_SUBDIVISION", 45, 53], ["Titin", "GENE_OR_GENE_PRODUCT", 167, 172], ["parvalbumin", "GENE_OR_GENE_PRODUCT", 219, 230], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 246, 261], ["smelt", "ORGANISM", 344, 349], ["Titin", "PROTEIN", 167, 172], ["parvalbumin", "PROTEIN", 219, 230], ["creatine kinase", "PROTEIN", 246, 261], ["muscular activity impairments", "PROBLEM", 45, 74], ["Molecular biomarkers responses", "TEST", 137, 167], ["parvalbumin", "TEST", 219, 230], ["creatine kinase", "TEST", 246, 261], ["q-PCR assessments", "TEST", 314, 331], ["old smelt larvae", "PROBLEM", 340, 356], ["muscular", "ANATOMY", 45, 53], ["activity", "OBSERVATION", 54, 62], ["significant", "OBSERVATION_MODIFIER", 299, 310], ["smelt larvae", "OBSERVATION", 344, 356]]], ["Titin is an important protein also involved in muscle contraction, responsible for muscle elasticity and is the molecular scaffold for thick actin filament formation, forming a connection between filaments and the muscle Z-line [52] .", [["muscle", "ANATOMY", 47, 53], ["muscle", "ANATOMY", 83, 89], ["filament", "ANATOMY", 147, 155], ["filaments", "ANATOMY", 196, 205], ["muscle Z-line", "ANATOMY", 214, 227], ["Titin", "GENE_OR_GENE_PRODUCT", 0, 5], ["muscle", "ORGAN", 47, 53], ["muscle", "ORGAN", 83, 89], ["actin", "GENE_OR_GENE_PRODUCT", 141, 146], ["filament", "CELLULAR_COMPONENT", 147, 155], ["filaments", "CELLULAR_COMPONENT", 196, 205], ["muscle", "ORGAN", 214, 220], ["Titin", "PROTEIN", 0, 5], ["actin", "PROTEIN", 141, 146], ["muscle elasticity", "PROBLEM", 83, 100], ["thick actin filament formation", "PROBLEM", 135, 165], ["the muscle Z-line", "TREATMENT", 210, 227], ["muscle", "ANATOMY", 47, 53], ["muscle", "ANATOMY", 214, 220]]], ["Myozenin, another protein involved in muscle contraction, was significantly influenced by esfenvalerate exposure (t-test, p < 0.05) in 10-d old larvae.", [["muscle", "ANATOMY", 38, 44], ["Myozenin", "CHEMICAL", 0, 8], ["esfenvalerate", "CHEMICAL", 90, 103], ["Myozenin", "CHEMICAL", 0, 8], ["esfenvalerate", "CHEMICAL", 90, 103], ["Myozenin", "GENE_OR_GENE_PRODUCT", 0, 8], ["muscle", "ORGAN", 38, 44], ["esfenvalerate", "SIMPLE_CHEMICAL", 90, 103], ["larvae", "ORGANISM", 144, 150], ["Myozenin", "TREATMENT", 0, 8], ["muscle contraction", "PROBLEM", 38, 56], ["t-test", "TEST", 114, 120], ["p", "TEST", 122, 123], ["muscle", "ANATOMY", 38, 44]]], ["Co-regulating with Titin (r = 0.90), myozenin is a Z-line, \u03b1-actininand \u03b3-filamin-binding protein expressed predominantly in skeletal muscle, and has been suggested as a biomarker for muscular dystrophy and other neuromuscular disorders [53] .Molecular biomarkers responsesii Immune responses In this study we have identified a significant alteration in expression of several genes involved in immune responses, most of them with links to neurological damage. \u03b2-microglobulin, a small protein normally found on the surface of many cells, including lymphocytes, is known to be involved in cell protection [54] . \u03b2microglobulin is almost exclusively catabolized in the kidney and its excretion is an indication of long term nephrotoxicity [55] .", [["skeletal muscle", "ANATOMY", 125, 140], ["muscular", "ANATOMY", 184, 192], ["neuromuscular", "ANATOMY", 213, 226], ["neurological", "ANATOMY", 439, 451], ["surface", "ANATOMY", 515, 522], ["cells", "ANATOMY", 531, 536], ["lymphocytes", "ANATOMY", 548, 559], ["cell", "ANATOMY", 588, 592], ["kidney", "ANATOMY", 667, 673], ["myozenin", "CHEMICAL", 37, 45], ["muscular dystrophy", "DISEASE", 184, 202], ["neuromuscular disorders", "DISEASE", 213, 236], ["neurological damage", "DISEASE", 439, 458], ["\u03b2-microglobulin", "CHEMICAL", 460, 475], ["\u03b2microglobulin", "CHEMICAL", 611, 625], ["nephrotoxicity", "DISEASE", 722, 736], ["myozenin", "CHEMICAL", 37, 45], ["Titin", "SIMPLE_CHEMICAL", 19, 24], ["myozenin", "GENE_OR_GENE_PRODUCT", 37, 45], ["\u03b1-actininand \u03b3-filamin-binding protein", "GENE_OR_GENE_PRODUCT", 59, 97], ["skeletal muscle", "TISSUE", 125, 140], ["muscular", "ORGAN", 184, 192], ["\u03b2-microglobulin", "GENE_OR_GENE_PRODUCT", 460, 475], ["surface", "CELLULAR_COMPONENT", 515, 522], ["cells", "CELL", 531, 536], ["lymphocytes", "CELL", 548, 559], ["cell", "CELL", 588, 592], ["\u03b2microglobulin", "GENE_OR_GENE_PRODUCT", 611, 625], ["kidney", "ORGAN", 667, 673], ["myozenin", "PROTEIN", 37, 45], ["\u03b1-actininand \u03b3-filamin-binding protein", "PROTEIN", 59, 97], ["\u03b2-microglobulin", "PROTEIN", 460, 475], ["lymphocytes", "CELL_TYPE", 548, 559], ["\u03b2microglobulin", "PROTEIN", 611, 625], ["Titin", "TEST", 19, 24], ["myozenin", "TREATMENT", 37, 45], ["a Z-line", "TREATMENT", 49, 57], ["\u03b1-actininand \u03b3-filamin", "TREATMENT", 59, 81], ["binding protein", "PROBLEM", 82, 97], ["muscular dystrophy", "PROBLEM", 184, 202], ["other neuromuscular disorders", "PROBLEM", 207, 236], ["Molecular biomarkers", "TEST", 243, 263], ["this study", "TEST", 296, 306], ["a significant alteration", "PROBLEM", 326, 350], ["neurological damage", "PROBLEM", 439, 458], ["\u03b2-microglobulin", "TEST", 460, 475], ["a small protein", "PROBLEM", 477, 492], ["many cells", "PROBLEM", 526, 536], ["lymphocytes", "PROBLEM", 548, 559], ["\u03b2microglobulin", "TREATMENT", 611, 625], ["long term nephrotoxicity", "PROBLEM", 712, 736], ["skeletal muscle", "ANATOMY", 125, 140], ["significant", "OBSERVATION_MODIFIER", 328, 339], ["alteration", "OBSERVATION", 340, 350], ["small", "OBSERVATION_MODIFIER", 479, 484], ["protein", "OBSERVATION", 485, 492], ["many cells", "OBSERVATION", 526, 536], ["known to be", "UNCERTAINTY", 564, 575], ["almost", "OBSERVATION_MODIFIER", 629, 635], ["exclusively", "OBSERVATION_MODIFIER", 636, 647], ["catabolized", "OBSERVATION_MODIFIER", 648, 659], ["kidney", "ANATOMY", 667, 673], ["long term", "OBSERVATION_MODIFIER", 712, 721], ["nephrotoxicity", "OBSERVATION", 722, 736]]], ["High concentrations of \u03b2-microglobulin are reported to inhibit generation of functional dendritic cells [56] , thus an increased amount in the blood or urine may be a sign of neural degeneration and of certain diseases, including some types of cancer, such as multiple myeloma or lymphoma. \u03b2-microglobulin levels are also reported to rise following viral infection and its reduced expression can compromise the immune system [57] .", [["dendritic cells", "ANATOMY", 88, 103], ["blood", "ANATOMY", 143, 148], ["urine", "ANATOMY", 152, 157], ["neural", "ANATOMY", 175, 181], ["cancer", "ANATOMY", 244, 250], ["myeloma", "ANATOMY", 269, 276], ["lymphoma", "ANATOMY", 280, 288], ["\u03b2-microglobulin", "CHEMICAL", 23, 38], ["neural degeneration", "DISEASE", 175, 194], ["cancer", "DISEASE", 244, 250], ["multiple myeloma or lymphoma", "DISEASE", 260, 288], ["\u03b2-microglobulin", "CHEMICAL", 290, 305], ["viral infection", "DISEASE", 349, 364], ["\u03b2-microglobulin", "CHEMICAL", 23, 38], ["\u03b2-microglobulin", "GENE_OR_GENE_PRODUCT", 23, 38], ["dendritic cells", "CELL", 88, 103], ["blood", "ORGANISM_SUBSTANCE", 143, 148], ["urine", "ORGANISM_SUBSTANCE", 152, 157], ["neural", "TISSUE", 175, 181], ["cancer", "CANCER", 244, 250], ["myeloma", "CANCER", 269, 276], ["lymphoma", "CANCER", 280, 288], ["\u03b2-microglobulin", "GENE_OR_GENE_PRODUCT", 290, 305], ["\u03b2-microglobulin", "PROTEIN", 23, 38], ["dendritic cells", "CELL_TYPE", 88, 103], ["\u03b2-microglobulin", "PROTEIN", 290, 305], ["High concentrations of \u03b2-microglobulin", "PROBLEM", 0, 38], ["functional dendritic cells", "PROBLEM", 77, 103], ["an increased amount in the blood or urine", "PROBLEM", 116, 157], ["neural degeneration", "PROBLEM", 175, 194], ["certain diseases", "PROBLEM", 202, 218], ["cancer", "PROBLEM", 244, 250], ["multiple myeloma", "PROBLEM", 260, 276], ["lymphoma", "PROBLEM", 280, 288], ["\u03b2-microglobulin levels", "TEST", 290, 312], ["viral infection", "PROBLEM", 349, 364], ["dendritic cells", "OBSERVATION", 88, 103], ["increased", "OBSERVATION_MODIFIER", 119, 128], ["amount", "OBSERVATION_MODIFIER", 129, 135], ["may be a sign of", "UNCERTAINTY", 158, 174], ["neural degeneration", "OBSERVATION", 175, 194], ["certain diseases", "OBSERVATION", 202, 218], ["cancer", "OBSERVATION", 244, 250], ["multiple", "OBSERVATION_MODIFIER", 260, 268], ["myeloma", "OBSERVATION", 269, 276], ["lymphoma", "OBSERVATION", 280, 288], ["viral", "OBSERVATION_MODIFIER", 349, 354], ["infection", "OBSERVATION", 355, 364]]], ["Interestingly, exposure to esfenvalerate resulted in a significant increase of pathogen susceptibility in chinook salmon [9] . \u03b2-microglobulin assessment with q-PCR did not show any significance in expression in 10 d old larvae (t-test, p = 0.131), however, an overall increase was observed at low concentrations of esfenvalerate, correlating significantly with expression of other genes investigated, further discussed below.Molecular biomarkers responsesMultiple sclerosis is caused by an immunological attack on myelin [58] , decreasing NAA and resulting in neurological instability.", [["myelin", "ANATOMY", 515, 521], ["neurological", "ANATOMY", 561, 573], ["esfenvalerate", "CHEMICAL", 27, 40], ["esfenvalerate", "CHEMICAL", 316, 329], ["responsesMultiple sclerosis", "DISEASE", 447, 474], ["NAA", "CHEMICAL", 540, 543], ["neurological instability", "DISEASE", 561, 585], ["esfenvalerate", "CHEMICAL", 27, 40], ["esfenvalerate", "CHEMICAL", 316, 329], ["NAA", "CHEMICAL", 540, 543], ["esfenvalerate", "SIMPLE_CHEMICAL", 27, 40], ["\u03b2-microglobulin", "SIMPLE_CHEMICAL", 127, 142], ["esfenvalerate", "SIMPLE_CHEMICAL", 316, 329], ["NAA", "SIMPLE_CHEMICAL", 540, 543], ["chinook salmon", "SPECIES", 106, 120], ["chinook salmon", "SPECIES", 106, 120], ["a significant increase of pathogen susceptibility in chinook salmon", "PROBLEM", 53, 120], ["\u03b2-microglobulin assessment", "TEST", 127, 153], ["q-PCR", "TEST", 159, 164], ["t-test", "TEST", 229, 235], ["p", "TEST", 237, 238], ["low concentrations of esfenvalerate", "PROBLEM", 294, 329], ["Molecular biomarkers responsesMultiple sclerosis", "PROBLEM", 426, 474], ["an immunological attack on myelin", "PROBLEM", 488, 521], ["decreasing NAA", "PROBLEM", 529, 543], ["neurological instability", "PROBLEM", 561, 585], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["increase", "OBSERVATION_MODIFIER", 67, 75], ["pathogen susceptibility", "OBSERVATION", 79, 102], ["overall", "OBSERVATION_MODIFIER", 261, 268], ["increase", "OBSERVATION", 269, 277], ["low concentrations", "OBSERVATION_MODIFIER", 294, 312], ["sclerosis", "OBSERVATION", 465, 474], ["neurological instability", "OBSERVATION", 561, 585]]], ["Furthermore, oxidative stress is inductive of apoptosis of myelin-reactive T cells [59] .", [["myelin-reactive T cells", "ANATOMY", 59, 82], ["myelin", "GENE_OR_GENE_PRODUCT", 59, 65], ["T cells", "CELL", 75, 82], ["myelin-reactive T cells", "CELL_TYPE", 59, 82], ["oxidative stress", "PROBLEM", 13, 29], ["apoptosis of myelin", "PROBLEM", 46, 65], ["reactive T cells", "PROBLEM", 66, 82], ["reactive", "OBSERVATION_MODIFIER", 66, 74]]], ["A putative T cell receptor gene was identified through microarray screening, probably reacting to pyrethroid exposure, acting upon the myelin sheath and causing further neurological damage and cell death.Molecular biomarkers responsesiii Apoptotic responses Caspases (cysteine-aspartic acid protease) belong to a family of cysteine proteases that cleave other proteins, such as the precursor forms of the inflammatory cytokines interleukin 1-\u03b2 and interleukin 18, into active mature peptides and are also involved in programmed cell death; or apoptosis [60] .", [["T cell", "ANATOMY", 11, 17], ["myelin sheath", "ANATOMY", 135, 148], ["neurological", "ANATOMY", 169, 181], ["cell", "ANATOMY", 193, 197], ["cell", "ANATOMY", 528, 532], ["pyrethroid", "CHEMICAL", 98, 108], ["neurological damage", "DISEASE", 169, 188], ["death", "DISEASE", 198, 203], ["cysteine-aspartic acid", "CHEMICAL", 268, 290], ["death", "DISEASE", 533, 538], ["pyrethroid", "CHEMICAL", 98, 108], ["cysteine", "CHEMICAL", 268, 276], ["aspartic acid", "CHEMICAL", 277, 290], ["cysteine", "CHEMICAL", 323, 331], ["T cell receptor", "GENE_OR_GENE_PRODUCT", 11, 26], ["pyrethroid", "SIMPLE_CHEMICAL", 98, 108], ["myelin sheath", "CELLULAR_COMPONENT", 135, 148], ["cell", "CELL", 193, 197], ["Caspases", "GENE_OR_GENE_PRODUCT", 258, 266], ["cysteine-aspartic acid protease", "GENE_OR_GENE_PRODUCT", 268, 299], ["cysteine", "AMINO_ACID", 323, 331], ["interleukin 1-\u03b2", "GENE_OR_GENE_PRODUCT", 428, 443], ["interleukin 18", "GENE_OR_GENE_PRODUCT", 448, 462], ["cell", "CELL", 528, 532], ["putative T cell receptor gene", "DNA", 2, 31], ["Caspases", "PROTEIN", 258, 266], ["cysteine-aspartic acid protease", "PROTEIN", 268, 299], ["cysteine proteases", "PROTEIN", 323, 341], ["inflammatory cytokines", "PROTEIN", 405, 427], ["interleukin 1", "PROTEIN", 428, 441], ["\u03b2", "PROTEIN", 442, 443], ["interleukin 18", "PROTEIN", 448, 462], ["A putative T cell receptor gene", "TREATMENT", 0, 31], ["microarray screening", "TEST", 55, 75], ["pyrethroid exposure", "PROBLEM", 98, 117], ["the myelin sheath", "TREATMENT", 131, 148], ["further neurological damage", "PROBLEM", 161, 188], ["cell death", "PROBLEM", 193, 203], ["Molecular biomarkers", "TEST", 204, 224], ["Caspases (cysteine-aspartic acid protease)", "TREATMENT", 258, 300], ["cysteine proteases", "TREATMENT", 323, 341], ["other proteins", "PROBLEM", 354, 368], ["the inflammatory cytokines interleukin", "TEST", 401, 439], ["programmed cell death", "PROBLEM", 517, 538], ["apoptosis", "PROBLEM", 543, 552], ["cell death", "OBSERVATION", 193, 203], ["inflammatory", "OBSERVATION_MODIFIER", 405, 417], ["cell death", "OBSERVATION", 528, 538]]], ["Enzymatic activity requires an aspartic acid residue, and plays a critical role in the regulation of proinflammatory cytokines [61] that are associated with septic shock and autoimmune syndromes [62] .", [["aspartic acid", "CHEMICAL", 31, 44], ["septic shock", "DISEASE", 157, 169], ["autoimmune syndromes", "DISEASE", 174, 194], ["aspartic acid", "CHEMICAL", 31, 44], ["aspartic acid", "AMINO_ACID", 31, 44], ["proinflammatory cytokines", "PROTEIN", 101, 126], ["an aspartic acid residue", "PROBLEM", 28, 52], ["proinflammatory cytokines", "PROBLEM", 101, 126], ["septic shock", "PROBLEM", 157, 169], ["autoimmune syndromes", "PROBLEM", 174, 194], ["associated with", "UNCERTAINTY", 141, 156], ["septic shock", "OBSERVATION", 157, 169]]], ["Upregulation of proinflammatory cytokines were reported in viral infected salmon, which further increased in expression following esfenvalerate exposure [63] .", [["esfenvalerate", "CHEMICAL", 130, 143], ["esfenvalerate", "CHEMICAL", 130, 143], ["salmon", "ORGANISM", 74, 80], ["esfenvalerate", "SIMPLE_CHEMICAL", 130, 143], ["proinflammatory cytokines", "PROTEIN", 16, 41], ["salmon", "SPECIES", 74, 80], ["Upregulation of proinflammatory cytokines", "PROBLEM", 0, 41], ["viral infected salmon", "PROBLEM", 59, 80], ["proinflammatory cytokines", "OBSERVATION", 16, 41], ["viral", "OBSERVATION_MODIFIER", 59, 64], ["infected salmon", "OBSERVATION", 65, 80], ["increased", "OBSERVATION_MODIFIER", 96, 105]]], ["Caspases contribute to the pathogenesis of neurodegenerative disorders such as ischemia, Krabbes and Huntington's diseases, Alzheimer's, and other leukodystrophic diseases resulting in neural degeneration [64, 65] .", [["neural", "ANATOMY", 185, 191], ["neurodegenerative disorders", "DISEASE", 43, 70], ["ischemia", "DISEASE", 79, 87], ["Krabbes", "DISEASE", 89, 96], ["Huntington's diseases", "DISEASE", 101, 122], ["Alzheimer's", "DISEASE", 124, 135], ["leukodystrophic diseases", "DISEASE", 147, 171], ["neural degeneration", "DISEASE", 185, 204], ["Caspases", "GENE_OR_GENE_PRODUCT", 0, 8], ["neural", "ANATOMICAL_SYSTEM", 185, 191], ["Caspases", "PROTEIN", 0, 8], ["Caspases", "TREATMENT", 0, 8], ["neurodegenerative disorders", "PROBLEM", 43, 70], ["ischemia", "PROBLEM", 79, 87], ["Krabbes", "PROBLEM", 89, 96], ["Huntington's diseases", "PROBLEM", 101, 122], ["Alzheimer's", "PROBLEM", 124, 135], ["other leukodystrophic diseases", "PROBLEM", 141, 171], ["neural degeneration", "PROBLEM", 185, 204], ["neurodegenerative", "OBSERVATION_MODIFIER", 43, 60], ["disorders", "OBSERVATION", 61, 70], ["ischemia", "OBSERVATION", 79, 87], ["leukodystrophic diseases", "OBSERVATION", 147, 171], ["neural degeneration", "OBSERVATION", 185, 204]]], ["Moreover, caspase inhibitors have been suggested as therapeutic treatments for neurodegenerative diseases [66] .", [["neurodegenerative diseases", "DISEASE", 79, 105], ["caspase", "GENE_OR_GENE_PRODUCT", 10, 17], ["caspase inhibitors", "TREATMENT", 10, 28], ["therapeutic treatments", "TREATMENT", 52, 74], ["neurodegenerative diseases", "PROBLEM", 79, 105]]], ["Low concentrations of esfenvalerate; 0.0313 \u03bcg.L -1 , significantly induced caspase-3 expression 2-fold (t-test, p = 0.002) in 10-d old delta smelt.", [["esfenvalerate", "CHEMICAL", 22, 35], ["esfenvalerate", "CHEMICAL", 22, 35], ["esfenvalerate", "SIMPLE_CHEMICAL", 22, 35], ["L -1", "GENE_OR_GENE_PRODUCT", 47, 51], ["caspase-3", "GENE_OR_GENE_PRODUCT", 76, 85], ["caspase-3", "PROTEIN", 76, 85], ["Low concentrations of esfenvalerate", "PROBLEM", 0, 35], ["caspase", "TEST", 76, 83], ["t-test", "TEST", 105, 111], ["p", "TEST", 113, 114], ["old delta smelt", "PROBLEM", 132, 147], ["caspase", "OBSERVATION", 76, 83]]], ["As caspases are activated by aspartic acid, induction may be suggestive of increases in substrate residues, along with inflammatory cytokines, probable effects upon the immune system, and subsequent neurodegeneration.", [["immune system", "ANATOMY", 169, 182], ["aspartic acid", "CHEMICAL", 29, 42], ["neurodegeneration", "DISEASE", 199, 216], ["aspartic acid", "CHEMICAL", 29, 42], ["caspases", "GENE_OR_GENE_PRODUCT", 3, 11], ["aspartic acid", "SIMPLE_CHEMICAL", 29, 42], ["caspases", "PROTEIN", 3, 11], ["inflammatory cytokines", "PROTEIN", 119, 141], ["aspartic acid", "TEST", 29, 42], ["increases in substrate residues", "PROBLEM", 75, 106], ["inflammatory cytokines", "PROBLEM", 119, 141], ["effects upon the immune system", "PROBLEM", 152, 182], ["subsequent neurodegeneration", "PROBLEM", 188, 216], ["may be suggestive of", "UNCERTAINTY", 54, 74], ["increases", "OBSERVATION_MODIFIER", 75, 84], ["substrate residues", "OBSERVATION", 88, 106], ["inflammatory", "OBSERVATION_MODIFIER", 119, 131], ["probable", "UNCERTAINTY", 143, 151], ["neurodegeneration", "OBSERVATION", 199, 216]]], ["Furthermore, a decrease in ASPA expression could be suggestive of reduced breakdown of NNA to aspartate and acetate, required as substrate for caspase activity, and synthesis of proteins required in repair mechanisms.iv.", [["aspartate", "CHEMICAL", 94, 103], ["acetate", "CHEMICAL", 108, 115], ["NNA", "CHEMICAL", 87, 90], ["aspartate", "CHEMICAL", 94, 103], ["acetate", "CHEMICAL", 108, 115], ["ASPA", "GENE_OR_GENE_PRODUCT", 27, 31], ["NNA", "SIMPLE_CHEMICAL", 87, 90], ["aspartate", "SIMPLE_CHEMICAL", 94, 103], ["acetate", "SIMPLE_CHEMICAL", 108, 115], ["caspase", "GENE_OR_GENE_PRODUCT", 143, 150], ["ASPA", "PROTEIN", 27, 31], ["NNA", "PROTEIN", 87, 90], ["caspase", "PROTEIN", 143, 150], ["a decrease in ASPA expression", "PROBLEM", 13, 42], ["reduced breakdown of NNA", "PROBLEM", 66, 90], ["aspartate and acetate", "TREATMENT", 94, 115], ["caspase activity", "TREATMENT", 143, 159], ["synthesis of proteins", "TREATMENT", 165, 186], ["repair mechanisms.iv", "TREATMENT", 199, 219], ["decrease", "OBSERVATION_MODIFIER", 15, 23], ["could be suggestive of", "UNCERTAINTY", 43, 65], ["reduced", "OBSERVATION_MODIFIER", 66, 73], ["breakdown", "OBSERVATION", 74, 83]]], ["Redox and metal ion bindingUpregulation of hemopexin was confirmed by quantitative PCR in 10-d old delta smelt exposed to 0.0313 \u03bcg.L -1 esfenvalerate.", [["L -1 esfenvalerate", "CHEMICAL", 132, 150], ["hemopexin", "GENE_OR_GENE_PRODUCT", 43, 52], ["L -1 esfenvalerate", "SIMPLE_CHEMICAL", 132, 150], ["hemopexin", "PROTEIN", 43, 52], ["Redox and metal ion bindingUpregulation of hemopexin", "TREATMENT", 0, 52], ["quantitative PCR", "TEST", 70, 86], ["esfenvalerate", "OBSERVATION", 137, 150]]], ["Hemopexin-like protein, a gene sequence displaying vast similarities to warm-temperature-acclimation-related-65 protein (WAP65) on BLAST homologies with Japanese medaka (Oryzias latipes), was identified as significantly upregulated through microarray screening.", [["Hemopexin", "CHEMICAL", 0, 9], ["Hemopexin", "GENE_OR_GENE_PRODUCT", 0, 9], ["WAP65", "GENE_OR_GENE_PRODUCT", 121, 126], ["medaka", "ORGANISM_SUBDIVISION", 162, 168], ["Oryzias latipes", "ORGANISM", 170, 185], ["Hemopexin", "PROTEIN", 0, 9], ["65 protein", "PROTEIN", 109, 119], ["WAP65", "PROTEIN", 121, 126], ["Oryzias latipes", "SPECIES", 170, 185], ["Japanese medaka", "SPECIES", 153, 168], ["Oryzias latipes", "SPECIES", 170, 185], ["Hemopexin", "TEST", 0, 9], ["a gene sequence", "TEST", 24, 39], ["temperature", "TEST", 77, 88], ["acclimation", "TEST", 89, 100], ["BLAST homologies", "TEST", 131, 147], ["Japanese medaka", "PROBLEM", 153, 168], ["microarray screening", "TEST", 240, 260]]], ["Hemopexin is synthesized by Schwann cells following nerve injury [67] , accumulation has been reported in the peripheral nervous system following axonal lesions, and is specifically regulated during repair, returning to normal levels on axonal regeneration [68] .", [["Schwann cells", "ANATOMY", 28, 41], ["nerve", "ANATOMY", 52, 57], ["peripheral nervous system", "ANATOMY", 110, 135], ["axonal lesions", "ANATOMY", 146, 160], ["axonal", "ANATOMY", 237, 243], ["Hemopexin", "CHEMICAL", 0, 9], ["nerve injury", "DISEASE", 52, 64], ["Hemopexin", "CHEMICAL", 0, 9], ["Hemopexin", "GENE_OR_GENE_PRODUCT", 0, 9], ["Schwann cells", "CELL", 28, 41], ["nerve", "TISSUE", 52, 57], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 110, 135], ["axonal lesions", "PATHOLOGICAL_FORMATION", 146, 160], ["Hemopexin", "PROTEIN", 0, 9], ["Schwann cells", "CELL_TYPE", 28, 41], ["Hemopexin", "PROBLEM", 0, 9], ["nerve injury", "PROBLEM", 52, 64], ["accumulation", "PROBLEM", 72, 84], ["axonal lesions", "PROBLEM", 146, 160], ["repair", "TREATMENT", 199, 205], ["Schwann cells", "OBSERVATION", 28, 41], ["nerve", "ANATOMY", 52, 57], ["peripheral", "ANATOMY_MODIFIER", 110, 120], ["nervous system", "ANATOMY", 121, 135], ["axonal", "OBSERVATION_MODIFIER", 146, 152], ["lesions", "OBSERVATION", 153, 160], ["repair", "OBSERVATION", 199, 205], ["axonal regeneration", "OBSERVATION", 237, 256]]], ["Wallerian degeneration occurs after axonal injury and is critical for repair, it is characterized by axonal and myelin degeneration [69] , is accompanied by macrophage invasion and subsequent synthesis of hemopexin [67] .", [["axonal", "ANATOMY", 36, 42], ["axonal", "ANATOMY", 101, 107], ["myelin", "ANATOMY", 112, 118], ["macrophage", "ANATOMY", 157, 167], ["Wallerian degeneration", "DISEASE", 0, 22], ["axonal injury", "DISEASE", 36, 49], ["axonal", "CELLULAR_COMPONENT", 101, 107], ["myelin", "CELLULAR_COMPONENT", 112, 118], ["macrophage", "CELL", 157, 167], ["hemopexin", "GENE_OR_GENE_PRODUCT", 205, 214], ["hemopexin", "PROTEIN", 205, 214], ["Wallerian degeneration", "PROBLEM", 0, 22], ["axonal injury", "PROBLEM", 36, 49], ["repair", "TREATMENT", 70, 76], ["axonal and myelin degeneration", "PROBLEM", 101, 131], ["macrophage invasion", "PROBLEM", 157, 176], ["subsequent synthesis of hemopexin", "TREATMENT", 181, 214], ["degeneration", "OBSERVATION", 10, 22], ["axonal injury", "OBSERVATION", 36, 49], ["repair", "OBSERVATION", 70, 76], ["axonal", "OBSERVATION_MODIFIER", 101, 107], ["myelin degeneration", "OBSERVATION", 112, 131], ["macrophage invasion", "OBSERVATION", 157, 176]]], ["Hemopexin appears to play a significant role in neural regeneration, but may be resultant of oxidative stress mediated T cell activity on myelin sheaths (described above, under immune responses).", [["neural", "ANATOMY", 48, 54], ["T cell", "ANATOMY", 119, 125], ["myelin sheaths", "ANATOMY", 138, 152], ["Hemopexin", "CHEMICAL", 0, 9], ["Hemopexin", "GENE_OR_GENE_PRODUCT", 0, 9], ["neural", "TISSUE", 48, 54], ["T cell", "CELL", 119, 125], ["myelin sheaths", "CELLULAR_COMPONENT", 138, 152], ["Hemopexin", "PROTEIN", 0, 9], ["Hemopexin", "PROBLEM", 0, 9], ["neural regeneration", "PROBLEM", 48, 67], ["oxidative stress mediated T cell activity", "PROBLEM", 93, 134], ["myelin sheaths", "TREATMENT", 138, 152], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["neural regeneration", "OBSERVATION", 48, 67], ["cell activity", "OBSERVATION", 121, 134]]], ["Though upregulation follows nerve injury and there are strong connections with apoptosis, we classify hemopexin under oxidative stress as it has a high affinity with heme and reportedly plays a strong role in both heme transport and preventing heme-catalyzed oxidative damage [70] .", [["nerve", "ANATOMY", 28, 33], ["nerve injury", "DISEASE", 28, 40], ["heme", "CHEMICAL", 166, 170], ["heme", "CHEMICAL", 214, 218], ["heme", "CHEMICAL", 244, 248], ["nerve", "MULTI-TISSUE_STRUCTURE", 28, 33], ["hemopexin", "GENE_OR_GENE_PRODUCT", 102, 111], ["heme", "SIMPLE_CHEMICAL", 166, 170], ["heme", "SIMPLE_CHEMICAL", 214, 218], ["heme", "SIMPLE_CHEMICAL", 244, 248], ["hemopexin", "PROTEIN", 102, 111], ["heme", "PROTEIN", 166, 170], ["nerve injury", "PROBLEM", 28, 40], ["apoptosis", "PROBLEM", 79, 88], ["hemopexin under oxidative stress", "TREATMENT", 102, 134], ["both heme transport", "TREATMENT", 209, 228], ["heme-catalyzed oxidative damage", "TREATMENT", 244, 275], ["nerve", "ANATOMY", 28, 33], ["injury", "OBSERVATION", 34, 40]]], ["Moreover, pyrethroids have been shown to generate free radicals and induce oxidative stress [71] .iv.", [["pyrethroids", "CHEMICAL", 10, 21], ["pyrethroids", "CHEMICAL", 10, 21], ["pyrethroids", "SIMPLE_CHEMICAL", 10, 21], ["pyrethroids", "TREATMENT", 10, 21]]], ["Redox and metal ion bindingHeme is known to respond to nerve injury, and has been suggested to play a role in neurodegenerative disorders [72] , and hemopexin-mediated heme transport was reported to significantly decrease levels of transferrin receptor mRNA in HeLa cells [70] .", [["nerve", "ANATOMY", 55, 60], ["HeLa cells", "ANATOMY", 261, 271], ["nerve injury", "DISEASE", 55, 67], ["neurodegenerative disorders", "DISEASE", 110, 137], ["nerve", "TISSUE", 55, 60], ["hemopexin", "GENE_OR_GENE_PRODUCT", 149, 158], ["heme", "SIMPLE_CHEMICAL", 168, 172], ["transferrin receptor", "GENE_OR_GENE_PRODUCT", 232, 252], ["HeLa cells", "CELL", 261, 271], ["Heme", "PROTEIN", 27, 31], ["hemopexin", "PROTEIN", 149, 158], ["transferrin receptor mRNA", "RNA", 232, 257], ["HeLa cells", "CELL_LINE", 261, 271], ["nerve injury", "PROBLEM", 55, 67], ["neurodegenerative disorders", "PROBLEM", 110, 137], ["hemopexin", "TEST", 149, 158], ["transferrin receptor mRNA", "TREATMENT", 232, 257], ["HeLa cells", "TEST", 261, 271], ["nerve", "ANATOMY", 55, 60], ["injury", "OBSERVATION", 61, 67]]], ["Transferrin was also identified by microarray screening as significantly upregulated by esfenvalerate exposure.", [["esfenvalerate", "CHEMICAL", 88, 101], ["esfenvalerate", "CHEMICAL", 88, 101], ["Transferrin", "GENE_OR_GENE_PRODUCT", 0, 11], ["esfenvalerate", "SIMPLE_CHEMICAL", 88, 101], ["Transferrin", "PROTEIN", 0, 11], ["microarray screening", "TEST", 35, 55]]], ["The primary role of transferrin is the delivery of iron across the blood brain barrier, and its expression in brain is not only related to myelin production, but may be a permissive agent in the process of myelination [73] .", [["blood brain barrier", "ANATOMY", 67, 86], ["brain", "ANATOMY", 110, 115], ["myelin", "ANATOMY", 139, 145], ["iron", "CHEMICAL", 51, 55], ["iron", "CHEMICAL", 51, 55], ["transferrin", "GENE_OR_GENE_PRODUCT", 20, 31], ["iron", "SIMPLE_CHEMICAL", 51, 55], ["blood brain barrier", "TISSUE", 67, 86], ["brain", "ORGAN", 110, 115], ["myelin", "GENE_OR_GENE_PRODUCT", 139, 145], ["transferrin", "PROTEIN", 20, 31], ["iron", "TREATMENT", 51, 55], ["the blood brain barrier", "TREATMENT", 63, 86], ["myelin production", "PROBLEM", 139, 156], ["a permissive agent", "TREATMENT", 169, 187], ["blood brain", "ANATOMY", 67, 78], ["brain", "ANATOMY", 110, 115]]], ["Furthermore, hemopexin and transferrin reportedly act by similar receptor-mediated mechanisms [74] .v.", [["hemopexin", "GENE_OR_GENE_PRODUCT", 13, 22], ["transferrin", "GENE_OR_GENE_PRODUCT", 27, 38], ["hemopexin", "PROTEIN", 13, 22], ["transferrin", "PROTEIN", 27, 38], ["hemopexin and transferrin", "TEST", 13, 38]]], ["Growth and developmentMicroarray analyses identified a gene with high homology to egg envelope glycoproteins within the zona pellucida (ZPA) referred to as choriogenins, in fish [75] .", [["zona pellucida", "ANATOMY", 120, 134], ["egg envelope glycoproteins", "GENE_OR_GENE_PRODUCT", 82, 108], ["zona pellucida", "ORGANISM", 120, 134], ["ZPA", "GENE_OR_GENE_PRODUCT", 136, 139], ["choriogenins", "GENE_OR_GENE_PRODUCT", 156, 168], ["egg envelope glycoproteins", "PROTEIN", 82, 108], ["Microarray analyses", "TEST", 22, 41], ["high homology to egg envelope glycoproteins", "TREATMENT", 65, 108]]], ["This was significantly expressed in 52-d old larvae, however, no statistical differences in expression of ZPA were measured with qPCR in 10-d old larvae exposed to esfenvalerate.", [["esfenvalerate", "CHEMICAL", 164, 177], ["esfenvalerate", "CHEMICAL", 164, 177], ["larvae", "ORGANISM", 45, 51], ["ZPA", "GENE_OR_GENE_PRODUCT", 106, 109], ["larvae", "ORGANISM", 146, 152], ["esfenvalerate", "SIMPLE_CHEMICAL", 164, 177], ["ZPA", "PROTEIN", 106, 109], ["ZPA", "TEST", 106, 109], ["qPCR", "TEST", 129, 133]]], ["Choriogenin is reportedly more sensitive to endocrine disrupting chemicals (EDCs) than estrogen receptors and vitellogenin [76] .", [["endocrine", "ANATOMY", 44, 53], ["Choriogenin", "CHEMICAL", 0, 11], ["estrogen", "CHEMICAL", 87, 95], ["Choriogenin", "CHEMICAL", 0, 11], ["estrogen", "CHEMICAL", 87, 95], ["Choriogenin", "SIMPLE_CHEMICAL", 0, 11], ["endocrine disrupting chemicals", "SIMPLE_CHEMICAL", 44, 74], ["estrogen receptors", "GENE_OR_GENE_PRODUCT", 87, 105], ["vitellogenin [76]", "GENE_OR_GENE_PRODUCT", 110, 127], ["estrogen receptors", "PROTEIN", 87, 105], ["estrogen receptors", "TEST", 87, 105], ["vitellogenin", "TEST", 110, 122]]], ["Composed primarily of glycoproteins with various functions during fertilization and development, choriogenin has been suggested as a biomarker of exposure to endocrine disrupting chemicals, as it is induced in late stage embryos, larvae and adult male fish exposed to estrogens [76, 77] .", [["endocrine", "ANATOMY", 158, 167], ["embryos", "ANATOMY", 221, 228], ["choriogenin", "CHEMICAL", 97, 108], ["estrogens", "CHEMICAL", 268, 277], ["estrogens", "CHEMICAL", 268, 277], ["choriogenin", "GENE_OR_GENE_PRODUCT", 97, 108], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 221, 228], ["larvae", "DEVELOPING_ANATOMICAL_STRUCTURE", 230, 236], ["fish", "ORGANISM", 252, 256], ["estrogens", "SIMPLE_CHEMICAL", 268, 277], ["glycoproteins", "PROTEIN", 22, 35], ["choriogenin", "PROTEIN", 97, 108], ["glycoproteins", "TREATMENT", 22, 35], ["fertilization", "TREATMENT", 66, 79], ["stage embryos", "OBSERVATION", 215, 228]]], ["Choriogenin is synthesized in liver of adult females, in response to estrogen, transported in blood and incorporated into the fish egg envelope; chorion or zona pellucida (ZPA), an extracellular matrix that surrounds the oocyte and early embryo [78] .", [["liver", "ANATOMY", 30, 35], ["blood", "ANATOMY", 94, 99], ["chorion", "ANATOMY", 145, 152], ["zona pellucida", "ANATOMY", 156, 170], ["ZPA", "ANATOMY", 172, 175], ["extracellular matrix", "ANATOMY", 181, 201], ["oocyte", "ANATOMY", 221, 227], ["embryo", "ANATOMY", 238, 244], ["Choriogenin", "CHEMICAL", 0, 11], ["estrogen", "CHEMICAL", 69, 77], ["Choriogenin", "CHEMICAL", 0, 11], ["estrogen", "CHEMICAL", 69, 77], ["Choriogenin", "GENE_OR_GENE_PRODUCT", 0, 11], ["liver", "ORGAN", 30, 35], ["estrogen", "SIMPLE_CHEMICAL", 69, 77], ["blood", "ORGANISM_SUBSTANCE", 94, 99], ["fish", "ORGANISM", 126, 130], ["egg", "ORGANISM_SUBSTANCE", 131, 134], ["chorion", "TISSUE", 145, 152], ["zona pellucida", "GENE_OR_GENE_PRODUCT", 156, 170], ["ZPA", "GENE_OR_GENE_PRODUCT", 172, 175], ["extracellular matrix", "CELLULAR_COMPONENT", 181, 201], ["oocyte", "CELLULAR_COMPONENT", 221, 227], ["embryo", "DEVELOPING_ANATOMICAL_STRUCTURE", 238, 244], ["Choriogenin", "PROTEIN", 0, 11], ["zona pellucida (ZPA)", "TREATMENT", 156, 176], ["an extracellular matrix", "TREATMENT", 178, 201], ["liver", "ANATOMY", 30, 35], ["adult", "OBSERVATION_MODIFIER", 39, 44], ["females", "OBSERVATION", 45, 52]]], ["Expression was notably elevated at low pyrethroid concentration, and it responded in a similar fashion to creatine kinase (r = 0.93), though no significant links were identified between these two biomarkers.vi.", [["pyrethroid", "CHEMICAL", 39, 49], ["creatine", "CHEMICAL", 106, 114], ["pyrethroid", "CHEMICAL", 39, 49], ["creatine", "CHEMICAL", 106, 114], ["pyrethroid", "SIMPLE_CHEMICAL", 39, 49], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 106, 121], ["creatine kinase", "PROTEIN", 106, 121], ["elevated at low pyrethroid concentration", "PROBLEM", 23, 63], ["creatine kinase", "TEST", 106, 121], ["these two biomarkers", "TEST", 186, 206], ["elevated", "OBSERVATION_MODIFIER", 23, 31]]], ["DetoxificationPregnane \u00d7 receptor (PXR), involved in the detection of toxic substances and a key regulator of xenobiotic metabolism, was identified through microarray assessments, as downregulated in 52-d old larvae.", [["DetoxificationPregnane \u00d7 receptor", "GENE_OR_GENE_PRODUCT", 0, 33], ["PXR", "GENE_OR_GENE_PRODUCT", 35, 38], ["larvae", "ORGANISM", 209, 215], ["DetoxificationPregnane \u00d7 receptor", "PROTEIN", 0, 33], ["PXR", "PROTEIN", 35, 38], ["toxic substances", "PROBLEM", 70, 86], ["microarray assessments", "TEST", 156, 178]]], ["PXR is a steroid receptor and transcriptional regulator of detoxification mechanisms such as cytochrome oxidases, and phase II conjugating enzymes such as glutathione-S-tranferases [79, 80] .", [["steroid", "CHEMICAL", 9, 16], ["glutathione-S-tranferases", "CHEMICAL", 155, 180], ["steroid", "CHEMICAL", 9, 16], ["glutathione", "CHEMICAL", 155, 166], ["S", "CHEMICAL", 167, 168], ["PXR", "GENE_OR_GENE_PRODUCT", 0, 3], ["steroid receptor", "GENE_OR_GENE_PRODUCT", 9, 25], ["cytochrome oxidases", "GENE_OR_GENE_PRODUCT", 93, 112], ["glutathione-S-tranferases", "SIMPLE_CHEMICAL", 155, 180], ["PXR", "PROTEIN", 0, 3], ["steroid receptor", "PROTEIN", 9, 25], ["transcriptional regulator", "PROTEIN", 30, 55], ["cytochrome oxidases", "PROTEIN", 93, 112], ["phase II conjugating enzymes", "PROTEIN", 118, 146], ["glutathione-S-tranferases", "PROTEIN", 155, 180], ["a steroid receptor", "TREATMENT", 7, 25], ["detoxification mechanisms", "TREATMENT", 59, 84], ["cytochrome oxidases", "TEST", 93, 112], ["phase II conjugating enzymes", "TEST", 118, 146], ["glutathione", "TEST", 155, 166]]], ["Downregulation of PXR expression has been linked with growth inhibition and cell death in rats and human cell lines following exposure to medroxyprogesterone and estradiol, known PXR ligands [80] , further supporting identified apoptotic responses, steroid receptor-binding and endocrine disruption activity of esfenvalerate [38, 39] .", [["cell", "ANATOMY", 76, 80], ["cell lines", "ANATOMY", 105, 115], ["endocrine", "ANATOMY", 278, 287], ["death", "DISEASE", 81, 86], ["medroxyprogesterone", "CHEMICAL", 138, 157], ["estradiol", "CHEMICAL", 162, 171], ["steroid", "CHEMICAL", 249, 256], ["esfenvalerate", "CHEMICAL", 311, 324], ["medroxyprogesterone", "CHEMICAL", 138, 157], ["estradiol", "CHEMICAL", 162, 171], ["steroid", "CHEMICAL", 249, 256], ["esfenvalerate", "CHEMICAL", 311, 324], ["PXR", "GENE_OR_GENE_PRODUCT", 18, 21], ["cell", "CELL", 76, 80], ["rats", "ORGANISM", 90, 94], ["human", "ORGANISM", 99, 104], ["cell lines", "CELL", 105, 115], ["medroxyprogesterone", "SIMPLE_CHEMICAL", 138, 157], ["estradiol", "SIMPLE_CHEMICAL", 162, 171], ["PXR", "GENE_OR_GENE_PRODUCT", 179, 182], ["steroid receptor", "GENE_OR_GENE_PRODUCT", 249, 265], ["esfenvalerate", "SIMPLE_CHEMICAL", 311, 324], ["PXR", "PROTEIN", 18, 21], ["human cell lines", "CELL_LINE", 99, 115], ["PXR", "PROTEIN", 179, 182], ["steroid receptor", "PROTEIN", 249, 265], ["rats", "SPECIES", 90, 94], ["human", "SPECIES", 99, 104], ["human", "SPECIES", 99, 104], ["Downregulation of PXR expression", "PROBLEM", 0, 32], ["growth inhibition", "PROBLEM", 54, 71], ["cell death in rats", "PROBLEM", 76, 94], ["human cell lines", "TREATMENT", 99, 115], ["medroxyprogesterone", "TREATMENT", 138, 157], ["estradiol", "TREATMENT", 162, 171], ["PXR ligands", "TEST", 179, 190], ["apoptotic responses", "PROBLEM", 228, 247], ["steroid receptor-binding", "TREATMENT", 249, 273], ["endocrine disruption activity of esfenvalerate", "PROBLEM", 278, 324], ["PXR", "ANATOMY", 18, 21], ["cell death", "OBSERVATION", 76, 86], ["human cell lines", "OBSERVATION", 99, 115]]], ["PXR expression was not significantly different in q-PCR assessments of 10-d old larvae exposed to esfenvalerate, however, overall expression declined in a dose response manner, correlating with ASPA (r = 0.880; p = 0.049), making it a notable candidate of xenobiotic detection for future biomarker investigations in the delta smelt.vi.", [["esfenvalerate", "CHEMICAL", 98, 111], ["esfenvalerate", "CHEMICAL", 98, 111], ["PXR", "GENE_OR_GENE_PRODUCT", 0, 3], ["larvae", "ORGANISM", 80, 86], ["esfenvalerate", "SIMPLE_CHEMICAL", 98, 111], ["PXR", "PROTEIN", 0, 3], ["q-PCR assessments", "TEST", 50, 67], ["ASPA", "TEST", 194, 198], ["xenobiotic detection", "TEST", 256, 276], ["future biomarker investigations", "TEST", 281, 312], ["not", "UNCERTAINTY", 19, 22], ["significantly different", "OBSERVATION_MODIFIER", 23, 46]]], ["Detoxificationvii Osmotic Stress A hyperosmotic glycine rich protein was identified with the microarrays as significantly downregulated by exposure to 0.0625 \u03bcg.L -1 esfenvalerate in 52-d old larvae.", [["glycine", "CHEMICAL", 48, 55], ["L -1 esfenvalerate", "CHEMICAL", 161, 179], ["glycine", "CHEMICAL", 48, 55], ["glycine", "AMINO_ACID", 48, 55], ["L -1 esfenvalerate", "SIMPLE_CHEMICAL", 161, 179], ["larvae", "ORGANISM", 192, 198], ["Osmotic Stress", "PROBLEM", 18, 32], ["A hyperosmotic glycine rich protein", "TREATMENT", 33, 68], ["the microarrays", "TREATMENT", 89, 104]]], ["Osmoregulation is physiologically controlled by chemical messages from the endocrine system, along with cell signalling and nerve transmission [81] .", [["endocrine system", "ANATOMY", 75, 91], ["cell", "ANATOMY", 104, 108], ["nerve", "ANATOMY", 124, 129], ["Osmoregulation", "DISEASE", 0, 14], ["endocrine system", "ANATOMICAL_SYSTEM", 75, 91], ["cell", "CELL", 104, 108], ["nerve transmission", "TEST", 124, 142], ["nerve", "ANATOMY", 124, 129]]], ["Pyrethroids have been suggested to induce osmotic imbalances in common carp larvae [82] which are linked to effects on ATPase activity responsible for maintaining the Sodium transmembrane electrochemical gradient [83] .", [["Pyrethroids", "CHEMICAL", 0, 11], ["Sodium", "CHEMICAL", 167, 173], ["Pyrethroids", "CHEMICAL", 0, 11], ["Sodium", "CHEMICAL", 167, 173], ["Pyrethroids", "SIMPLE_CHEMICAL", 0, 11], ["carp", "ORGANISM", 71, 75], ["ATPase", "GENE_OR_GENE_PRODUCT", 119, 125], ["Sodium", "SIMPLE_CHEMICAL", 167, 173], ["ATPase", "PROTEIN", 119, 125], ["carp", "SPECIES", 71, 75], ["common carp", "SPECIES", 64, 75], ["Pyrethroids", "TREATMENT", 0, 11], ["osmotic imbalances", "PROBLEM", 42, 60], ["ATPase activity", "TEST", 119, 134], ["the Sodium transmembrane electrochemical gradient", "TEST", 163, 212]]], ["Larval fish are under direct exposure to osmotic stress as their endocrine system is not fully developed [84] .", [["endocrine system", "ANATOMY", 65, 81], ["endocrine", "ANATOMICAL_SYSTEM", 65, 74], ["system", "ANATOMICAL_SYSTEM", 75, 81], ["osmotic stress", "PROBLEM", 41, 55]]], ["Parvalbumin and choriogenin expression have indicated possible effects on the endocrine system, thus expression of this hyperosmotic glycine rich protein may be directly caused by conditions affecting endocrine regulation.viii DigestionChitinase was identified through microarray analysis as being downregulated by esfenvalerate exposure.", [["endocrine system", "ANATOMY", 78, 94], ["endocrine", "ANATOMY", 201, 210], ["glycine", "CHEMICAL", 133, 140], ["esfenvalerate", "CHEMICAL", 315, 328], ["glycine", "CHEMICAL", 133, 140], ["esfenvalerate", "CHEMICAL", 315, 328], ["Parvalbumin", "GENE_OR_GENE_PRODUCT", 0, 11], ["choriogenin", "GENE_OR_GENE_PRODUCT", 16, 27], ["endocrine system", "ANATOMICAL_SYSTEM", 78, 94], ["endocrine", "ANATOMICAL_SYSTEM", 201, 210], ["esfenvalerate", "SIMPLE_CHEMICAL", 315, 328], ["choriogenin", "PROTEIN", 16, 27], ["hyperosmotic glycine rich protein", "PROTEIN", 120, 153], ["Parvalbumin", "TREATMENT", 0, 11], ["choriogenin expression", "TREATMENT", 16, 38], ["effects on the endocrine system", "PROBLEM", 63, 94], ["this hyperosmotic glycine rich protein", "TREATMENT", 115, 153], ["microarray analysis", "TEST", 269, 288]]], ["Chitinase is the principal enzyme involved in digesting chitin, a major component of insect and crustacean exoskeleton [85] .", [["chitin", "CHEMICAL", 56, 62], ["Chitinase", "GENE_OR_GENE_PRODUCT", 0, 9], ["chitin", "GENE_OR_GENE_PRODUCT", 56, 62], ["Chitinase", "PROTEIN", 0, 9], ["digesting chitin", "TREATMENT", 46, 62]]], ["Not only chitinase but, other digestive enzymes; apolipoproteins, pancreatic enzymes, carboxypeptidase precursors and chemotrypsinogen, were also significantly upregulated following exposure in 52-d old larvae.", [["pancreatic", "ANATOMY", 66, 76], ["chitinase", "GENE_OR_GENE_PRODUCT", 9, 18], ["apolipoproteins", "GENE_OR_GENE_PRODUCT", 49, 64], ["pancreatic enzymes", "GENE_OR_GENE_PRODUCT", 66, 84], ["carboxypeptidase", "GENE_OR_GENE_PRODUCT", 86, 102], ["chemotrypsinogen", "GENE_OR_GENE_PRODUCT", 118, 134], ["larvae", "ORGANISM", 203, 209], ["chitinase", "PROTEIN", 9, 18], ["digestive enzymes", "PROTEIN", 30, 47], ["apolipoproteins", "PROTEIN", 49, 64], ["pancreatic enzymes", "PROTEIN", 66, 84], ["carboxypeptidase precursors", "PROTEIN", 86, 113], ["chemotrypsinogen", "PROTEIN", 118, 134], ["other digestive enzymes", "TEST", 24, 47], ["apolipoproteins", "TEST", 49, 64], ["pancreatic enzymes", "TEST", 66, 84], ["carboxypeptidase precursors", "TEST", 86, 113], ["chemotrypsinogen", "TREATMENT", 118, 134], ["pancreatic", "ANATOMY", 66, 76]]], ["Effects on digestion alone will undoubtedly have significant effects on growth, which when combined with hypothesized feeding reduction resulting from impaired swimming would lead to significant malnutrition.", [["impaired swimming", "DISEASE", 151, 168], ["malnutrition", "DISEASE", 195, 207], ["digestion", "TREATMENT", 11, 20], ["hypothesized feeding reduction", "TREATMENT", 105, 135], ["impaired swimming", "PROBLEM", 151, 168], ["significant malnutrition", "PROBLEM", 183, 207], ["significant", "OBSERVATION_MODIFIER", 183, 194], ["malnutrition", "OBSERVATION", 195, 207]]], ["Contaminants affect a whole ecosystem, at all levels, and dramatic reductions in copepods, cladoceran and amphipod populations; organisms predated upon by the delta smelt, have been reported in the Sacramento delta [86] .", [["amphipod populations", "PROBLEM", 106, 126], ["organisms", "PROBLEM", 128, 137], ["dramatic", "OBSERVATION_MODIFIER", 58, 66], ["reductions", "OBSERVATION_MODIFIER", 67, 77]]], ["Scarcity in food and reduced ingestion ability, besides digestion will significantly affect population dynamics of any specie.ConclusionsMicroarray technology was used as an initial screening of probable genes responding to esfenvalerate exposure therefore no multiple testing correction was applied.", [["esfenvalerate", "CHEMICAL", 224, 237], ["esfenvalerate", "CHEMICAL", 224, 237], ["esfenvalerate", "SIMPLE_CHEMICAL", 224, 237], ["Scarcity in food", "PROBLEM", 0, 16], ["reduced ingestion ability", "PROBLEM", 21, 46], ["any specie", "PROBLEM", 115, 125], ["Microarray technology", "TEST", 137, 158], ["an initial screening", "TEST", 171, 191], ["esfenvalerate exposure", "TREATMENT", 224, 246], ["multiple testing correction", "TREATMENT", 260, 287], ["reduced", "OBSERVATION_MODIFIER", 21, 28]]], ["Due to the measured behavioral responses, the classification approach contains a certain bias towards understanding neuromuscular effects.", [["neuromuscular", "ANATOMY", 116, 129], ["neuromuscular", "ANATOMICAL_SYSTEM", 116, 129]]], ["It is interesting that qPCR measurements have identified a greater response at the lower concentrations, implying homeostatic alterations, at environmentally relevant concentrations.", [["qPCR measurements", "TEST", 23, 40], ["homeostatic alterations", "PROBLEM", 114, 137], ["greater", "OBSERVATION_MODIFIER", 59, 66], ["response", "OBSERVATION_MODIFIER", 67, 75], ["lower concentrations", "OBSERVATION_MODIFIER", 83, 103], ["homeostatic alterations", "OBSERVATION", 114, 137]]], ["Hemopexin for example is known to be involved in axon repair, and the myelin sheath surrounding the axon needs to be degraded for this repair to be processed, hypothesizing therefore that ASPA downregulation is resultant of neurological damage.", [["axon", "ANATOMY", 49, 53], ["myelin sheath", "ANATOMY", 70, 83], ["axon", "ANATOMY", 100, 104], ["neurological", "ANATOMY", 224, 236], ["Hemopexin", "CHEMICAL", 0, 9], ["neurological damage", "DISEASE", 224, 243], ["Hemopexin", "GENE_OR_GENE_PRODUCT", 0, 9], ["axon", "MULTI-TISSUE_STRUCTURE", 49, 53], ["myelin sheath", "CELLULAR_COMPONENT", 70, 83], ["axon", "CELLULAR_COMPONENT", 100, 104], ["ASPA", "GENE_OR_GENE_PRODUCT", 188, 192], ["Hemopexin", "PROTEIN", 0, 9], ["ASPA", "PROTEIN", 188, 192], ["Hemopexin", "TREATMENT", 0, 9], ["axon repair", "TREATMENT", 49, 60], ["the myelin sheath", "TREATMENT", 66, 83], ["this repair", "TREATMENT", 130, 141], ["ASPA downregulation", "PROBLEM", 188, 207], ["neurological damage", "PROBLEM", 224, 243], ["axon repair", "OBSERVATION", 49, 60]]], ["The subsequent decrease of hemopexin expression at higher exposure concentrations, and further decrease in ASPA, may be indicative of repair impairments.ConclusionsWhat becomes apparent from this study is that exposure to sublethal concentrations of esfenvalerate results in neurological damage and a series of compensatory molecular responses that attempt to repair nerve damage.", [["neurological", "ANATOMY", 275, 287], ["nerve", "ANATOMY", 367, 372], ["esfenvalerate", "CHEMICAL", 250, 263], ["neurological damage", "DISEASE", 275, 294], ["nerve damage", "DISEASE", 367, 379], ["esfenvalerate", "CHEMICAL", 250, 263], ["hemopexin", "GENE_OR_GENE_PRODUCT", 27, 36], ["ASPA", "GENE_OR_GENE_PRODUCT", 107, 111], ["esfenvalerate", "SIMPLE_CHEMICAL", 250, 263], ["nerve", "TISSUE", 367, 372], ["hemopexin", "PROTEIN", 27, 36], ["ASPA", "PROTEIN", 107, 111], ["hemopexin expression", "PROBLEM", 27, 47], ["higher exposure concentrations", "PROBLEM", 51, 81], ["further decrease in ASPA", "PROBLEM", 87, 111], ["repair impairments", "PROBLEM", 134, 152], ["this study", "TEST", 191, 201], ["sublethal concentrations of esfenvalerate", "PROBLEM", 222, 263], ["neurological damage", "PROBLEM", 275, 294], ["compensatory molecular responses", "PROBLEM", 311, 343], ["repair nerve damage", "PROBLEM", 360, 379], ["decrease", "OBSERVATION_MODIFIER", 15, 23], ["hemopexin expression", "OBSERVATION", 27, 47], ["decrease", "OBSERVATION_MODIFIER", 95, 103], ["may be indicative of", "UNCERTAINTY", 113, 133], ["repair", "OBSERVATION", 134, 140], ["neurological damage", "OBSERVATION", 275, 294], ["nerve", "ANATOMY", 367, 372], ["damage", "OBSERVATION", 373, 379]]], ["We would hypothesize that induction of transcription of the genes encoding ASPA, hemopexin, parvalbumin and creatine kinase are part of a pathway of damage triggered repair mechanisms, responding to esfenvalerate insult.", [["creatine", "CHEMICAL", 108, 116], ["esfenvalerate", "CHEMICAL", 199, 212], ["creatine", "CHEMICAL", 108, 116], ["esfenvalerate", "CHEMICAL", 199, 212], ["ASPA", "GENE_OR_GENE_PRODUCT", 75, 79], ["hemopexin", "GENE_OR_GENE_PRODUCT", 81, 90], ["parvalbumin", "GENE_OR_GENE_PRODUCT", 92, 103], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 108, 123], ["esfenvalerate", "SIMPLE_CHEMICAL", 199, 212], ["ASPA", "PROTEIN", 75, 79], ["hemopexin", "PROTEIN", 81, 90], ["parvalbumin", "PROTEIN", 92, 103], ["creatine kinase", "PROTEIN", 108, 123], ["hemopexin", "TREATMENT", 81, 90], ["parvalbumin and creatine kinase", "TREATMENT", 92, 123], ["damage", "PROBLEM", 149, 155], ["repair mechanisms", "TREATMENT", 166, 183], ["esfenvalerate insult", "PROBLEM", 199, 219]]], ["Reduction in expression of ASPA indicates that myelin sheaths may be degraded, resulting in a number of detrimental effects on the lesion sites, and similarly, muscular structure and function is being compromised as measured by alterations in titin and myozenin expression.", [["myelin sheaths", "ANATOMY", 47, 61], ["lesion sites", "ANATOMY", 131, 143], ["muscular structure", "ANATOMY", 160, 178], ["ASPA", "GENE_OR_GENE_PRODUCT", 27, 31], ["myelin sheaths", "CELLULAR_COMPONENT", 47, 61], ["lesion sites", "MULTI-TISSUE_STRUCTURE", 131, 143], ["titin", "GENE_OR_GENE_PRODUCT", 243, 248], ["myozenin", "GENE_OR_GENE_PRODUCT", 253, 261], ["ASPA", "PROTEIN", 27, 31], ["titin", "PROTEIN", 243, 248], ["myozenin", "PROTEIN", 253, 261], ["ASPA", "PROBLEM", 27, 31], ["myelin sheaths", "TREATMENT", 47, 61], ["detrimental effects on the lesion sites", "PROBLEM", 104, 143], ["titin and myozenin expression", "TREATMENT", 243, 272], ["lesion", "OBSERVATION", 131, 137], ["muscular structure", "OBSERVATION", 160, 178]]], ["The expression of \u03b2-microglobulins could be a compensatory reaction to toxic damage, protecting cells from infections in a susceptible immune system caused by exposure to esfenvalerate.", [["cells", "ANATOMY", 96, 101], ["immune system", "ANATOMY", 135, 148], ["toxic damage", "DISEASE", 71, 83], ["infections", "DISEASE", 107, 117], ["esfenvalerate", "CHEMICAL", 171, 184], ["esfenvalerate", "CHEMICAL", 171, 184], ["\u03b2-microglobulins", "GENE_OR_GENE_PRODUCT", 18, 34], ["cells", "CELL", 96, 101], ["esfenvalerate", "SIMPLE_CHEMICAL", 171, 184], ["\u03b2-microglobulins", "PROTEIN", 18, 34], ["\u03b2-microglobulins", "PROBLEM", 18, 34], ["a compensatory reaction", "PROBLEM", 44, 67], ["toxic damage", "PROBLEM", 71, 83], ["protecting cells", "PROBLEM", 85, 101], ["infections", "PROBLEM", 107, 117], ["a susceptible immune system", "PROBLEM", 121, 148], ["compensatory reaction", "OBSERVATION", 46, 67], ["toxic", "OBSERVATION_MODIFIER", 71, 76], ["damage", "OBSERVATION", 77, 83], ["infections", "OBSERVATION", 107, 117]]], ["Previous studies, carried out in esfenvalerate exposed chinook salmon have reported a compromised immunity and significantly higher susceptibility to infection [9, 63] .", [["infection", "DISEASE", 150, 159], ["chinook salmon", "ORGANISM", 55, 69], ["chinook salmon", "SPECIES", 55, 69], ["chinook salmon", "SPECIES", 55, 69], ["Previous studies", "TEST", 0, 16], ["a compromised immunity", "PROBLEM", 84, 106], ["significantly higher susceptibility to infection", "PROBLEM", 111, 159], ["infection", "OBSERVATION", 150, 159]]], ["Furthermore, polluted waters not only contain mixtures of contaminants, but also harbor multiple pathogens that will further affect health parameters.ConclusionsBehavioral endpoints, such as swimming behavior, are amongst the most sensitive and ecologically relevant parameters to assess sublethal toxicity of neurotoxic chemicals [29] .", [["toxicity", "DISEASE", 298, 306], ["neurotoxic", "DISEASE", 310, 320], ["harbor multiple pathogens", "PROBLEM", 81, 106], ["Behavioral endpoints", "TEST", 161, 181], ["sublethal toxicity of neurotoxic chemicals", "PROBLEM", 288, 330], ["contaminants", "OBSERVATION", 58, 70], ["multiple", "OBSERVATION_MODIFIER", 88, 96], ["pathogens", "OBSERVATION", 97, 106]]], ["The high susceptibility of delta smelt to esfenvalerate, mediated neurological damage resulting in impaired swimming ability, also raises questions on the likely effects upon their chemosensory system; olfactory system, important in sensing reproductive pheromones, mediating reproduction.", [["neurological", "ANATOMY", 66, 78], ["chemosensory system", "ANATOMY", 181, 200], ["olfactory system", "ANATOMY", 202, 218], ["esfenvalerate", "CHEMICAL", 42, 55], ["neurological damage", "DISEASE", 66, 85], ["delta smelt", "ORGANISM", 27, 38], ["olfactory system", "ANATOMICAL_SYSTEM", 202, 218], ["The high susceptibility of delta smelt", "PROBLEM", 0, 38], ["mediated neurological damage", "PROBLEM", 57, 85], ["impaired swimming ability", "PROBLEM", 99, 124], ["high susceptibility", "OBSERVATION_MODIFIER", 4, 23]]], ["Neu-rological damage affecting the olfactory nerves, the brain and or entire nervous system, could lead to further impairments in reproductive success following exposure to pyrethroids.", [["olfactory nerves", "ANATOMY", 35, 51], ["brain", "ANATOMY", 57, 62], ["nervous system", "ANATOMY", 77, 91], ["pyrethroids", "CHEMICAL", 173, 184], ["pyrethroids", "CHEMICAL", 173, 184], ["olfactory nerves", "MULTI-TISSUE_STRUCTURE", 35, 51], ["brain", "ORGAN", 57, 62], ["nervous system", "ANATOMICAL_SYSTEM", 77, 91], ["Neu-rological damage", "PROBLEM", 0, 20], ["further impairments", "PROBLEM", 107, 126], ["pyrethroids", "TREATMENT", 173, 184], ["damage", "OBSERVATION", 14, 20], ["olfactory nerves", "ANATOMY", 35, 51], ["brain", "ANATOMY", 57, 62], ["nervous system", "ANATOMY", 77, 91]]], ["Damage to the olfactory system has been used as a sublethal toxicological endpoint in fish, in studies investigating behavior following pesticide exposures [88] .", [["olfactory system", "ANATOMY", 14, 30], ["olfactory system", "ANATOMICAL_SYSTEM", 14, 30], ["fish", "ORGANISM", 86, 90], ["Damage to the olfactory system", "PROBLEM", 0, 30]]], ["Pyrethroids are known to affect the olfactory system [89] .", [["olfactory system", "ANATOMY", 36, 52], ["Pyrethroids", "CHEMICAL", 0, 11], ["Pyrethroids", "CHEMICAL", 0, 11], ["Pyrethroids", "SIMPLE_CHEMICAL", 0, 11], ["Pyrethroids", "TREATMENT", 0, 11]]], ["A chemosensory gene, ictacalcin, responding to esfenvalerate exposure was also differentially expressed on the microarray.", [["ictacalcin", "CHEMICAL", 21, 31], ["esfenvalerate", "CHEMICAL", 47, 60], ["esfenvalerate", "CHEMICAL", 47, 60], ["ictacalcin", "GENE_OR_GENE_PRODUCT", 21, 31], ["esfenvalerate", "SIMPLE_CHEMICAL", 47, 60], ["chemosensory gene", "DNA", 2, 19], ["ictacalcin", "DNA", 21, 31], ["ictacalcin", "TREATMENT", 21, 31]]], ["Ictacalcin is a gene originally identified in catfish (Ictalurus punctatus), involved in chemosensory tissues, and highly expressed in barbell, olfactory mucosa and gill [90] .", [["chemosensory tissues", "ANATOMY", 89, 109], ["barbell", "ANATOMY", 135, 142], ["olfactory mucosa", "ANATOMY", 144, 160], ["gill", "ANATOMY", 165, 169], ["Ictacalcin", "CHEMICAL", 0, 10], ["Ictacalcin", "CHEMICAL", 0, 10], ["Ictacalcin", "GENE_OR_GENE_PRODUCT", 0, 10], ["catfish (", "ORGANISM", 46, 55], ["Ictalurus punctatus", "ORGANISM", 55, 74], ["chemosensory tissues", "TISSUE", 89, 109], ["barbell", "TISSUE", 135, 142], ["olfactory mucosa", "MULTI-TISSUE_STRUCTURE", 144, 160], ["gill", "ORGAN", 165, 169], ["Ictacalcin", "DNA", 0, 10], ["catfish", "SPECIES", 46, 53], ["Ictalurus punctatus", "SPECIES", 55, 74], ["Ictalurus punctatus", "SPECIES", 55, 74], ["Ictacalcin", "TREATMENT", 0, 10], ["chemosensory tissues", "ANATOMY", 89, 109], ["olfactory mucosa", "ANATOMY", 144, 160]]], ["Differential expression of this gene may indicate that further behavioral parameters, not investigated in this study, such as recognition, alarm response, feeding, imprinting and homing, gamete release and synchronization, contaminant avoidance [88] , and other behavioral parameters that are governed by chemosensory system, could be compromised.", [["gamete", "ANATOMY", 187, 193], ["chemosensory system", "ANATOMY", 305, 324], ["further behavioral parameters", "TEST", 55, 84], ["this study", "TEST", 106, 116], ["homing, gamete release", "TREATMENT", 179, 201], ["other behavioral parameters", "TEST", 256, 283], ["compromised", "OBSERVATION", 335, 346]]], ["We could speculate that outside laboratory conditions, neuromuscular and chemosensory impairments would probably result in higher ecological parameters being affected through inability to swim against water currents, making them more susceptible to predation and reducing their ability to obtain food.", [["neuromuscular", "ANATOMY", 55, 68], ["neuromuscular and chemosensory impairments", "DISEASE", 55, 97], ["neuromuscular and chemosensory impairments", "PROBLEM", 55, 97]]], ["Furthermore, effects on chemosensory parameters would lead to migratory, reproductive, predator and contaminant avoidance impairments.ConclusionsInhibition of repair mechanisms, leading to neuromuscular damage and eventual death, was behaviorally observed throughout exposure, as impairment in swimming ability.", [["neuromuscular", "ANATOMY", 189, 202], ["avoidance impairments", "DISEASE", 112, 133], ["neuromuscular damage", "DISEASE", 189, 209], ["death", "DISEASE", 223, 228], ["chemosensory parameters", "TEST", 24, 47], ["contaminant avoidance impairments", "PROBLEM", 100, 133], ["repair mechanisms", "TREATMENT", 159, 176], ["neuromuscular damage", "PROBLEM", 189, 209], ["eventual death", "PROBLEM", 214, 228], ["migratory", "OBSERVATION_MODIFIER", 62, 71], ["repair", "OBSERVATION", 159, 165]]], ["The ability to use molecular biomarkers of neuromuscular effect further strengthens links between mechanistic effects with parameters of ecological relevance.", [["neuromuscular", "ANATOMY", 43, 56], ["neuromuscular", "ANATOMICAL_SYSTEM", 43, 56], ["molecular biomarkers", "TEST", 19, 39]]], ["Our study supports the use of gene expression as a productive way of understanding modes of actions of individual chemicals in endangered species.", [["Our study", "TEST", 0, 9], ["gene expression", "PROBLEM", 30, 45], ["endangered species", "OBSERVATION", 127, 145]]], ["Furthermore, this screening and interrogative approach permits the identification and development of biomarkers for species of concern in which prior information is limited and allows for investigations into problems specific to the organism in question; assessing possible causes of detrimental effects and resulting influences on individual performance and hypothesizing effects upon population dynamics.", [["this screening", "TEST", 13, 27], ["interrogative approach", "TEST", 32, 54], ["the identification", "TEST", 63, 81], ["biomarkers", "TEST", 101, 111], ["species", "PROBLEM", 116, 123], ["detrimental effects", "PROBLEM", 284, 303]]], ["A suite of biomarkers developed in this manner, though additions and subtractions are required from the presented list, could be used to aid monitor impacts of stressors upon organisms within a specific environment and could be an essential tool in determining causative factors of population decline in the delta smelt and other threatened species.", [["delta smelt", "SPECIES", 308, 319], ["A suite of biomarkers", "TEST", 0, 21], ["subtractions", "TREATMENT", 69, 81], ["stressors upon organisms", "PROBLEM", 160, 184], ["population decline", "PROBLEM", 282, 300], ["the delta smelt", "PROBLEM", 304, 319], ["other threatened species", "PROBLEM", 324, 348], ["delta smelt", "OBSERVATION_MODIFIER", 308, 319], ["threatened species", "OBSERVATION", 330, 348]]], ["The selected biomarkers clearly need to be further investigated and validated against other known contaminants, and suitability in field applications.Microarray constructionWe constructed a delta smelt microarray using 8448 PCR amplified fragments from a normalized cDNA library.", [["fragments", "ANATOMY", 238, 247], ["8448 PCR amplified fragments", "DNA", 219, 247], ["cDNA library", "DNA", 266, 278], ["other known contaminants", "PROBLEM", 86, 110], ["a delta smelt microarray", "TEST", 188, 212], ["PCR amplified fragments", "PROBLEM", 224, 247], ["a normalized cDNA library", "PROBLEM", 253, 278], ["contaminants", "OBSERVATION", 98, 110]]], ["A cDNA library was created using expressed sequence tags (ESTs) ligated into p-BS plasmid vectors and cloned into chemically competent Escherichia coli cells (BioS&T Inc, Montreal, Quebec, Canada).", [["cells", "ANATOMY", 152, 157], ["Escherichia coli cells", "CELL", 135, 157], ["BioS&T Inc", "CELL", 159, 169], ["cDNA library", "DNA", 2, 14], ["expressed sequence tags", "DNA", 33, 56], ["ESTs", "DNA", 58, 62], ["p-BS plasmid vectors", "DNA", 77, 97], ["Escherichia coli cells", "CELL_LINE", 135, 157], ["Escherichia coli", "SPECIES", 135, 151], ["Escherichia coli", "SPECIES", 135, 151], ["A cDNA library", "TEST", 0, 14], ["p-BS plasmid vectors", "TREATMENT", 77, 97], ["Escherichia coli cells", "PROBLEM", 135, 157], ["Escherichia coli cells", "OBSERVATION", 135, 157]]], ["RNA for library construction was obtained from a number of larval, juvenile and adult delta smelt, ranging from unexposed, control conditions, to fish from exposures to high temperature (25\u00b0C), and sublethal concentrations of copper, esfenvalerate, and a six field water samples from throughout the Sacramento-San Joaquin estuary.", [["copper", "CHEMICAL", 226, 232], ["esfenvalerate", "CHEMICAL", 234, 247], ["copper", "CHEMICAL", 226, 232], ["esfenvalerate", "CHEMICAL", 234, 247], ["copper", "SIMPLE_CHEMICAL", 226, 232], ["esfenvalerate", "SIMPLE_CHEMICAL", 234, 247], ["library construction", "TREATMENT", 8, 28], ["adult delta smelt", "PROBLEM", 80, 97], ["high temperature", "PROBLEM", 169, 185], ["esfenvalerate", "TREATMENT", 234, 247], ["a six field water samples", "TREATMENT", 253, 278], ["delta smelt", "OBSERVATION", 86, 97], ["high temperature", "OBSERVATION_MODIFIER", 169, 185]]], ["Products were PCR amplified from 1 \u03bcl bacterial suspension, and visualized on agarose gels.RNA isolation, cDNA synthesis and fluorescence labelingRNA was extracted from whole, individual organisms using a standard phenol:chloroform protocol with Trizol Reagent (Invitrogen).", [["phenol", "CHEMICAL", 214, 220], ["phenol", "CHEMICAL", 214, 220], ["chloroform", "CHEMICAL", 221, 231], ["agarose", "SIMPLE_CHEMICAL", 78, 85], ["phenol", "SIMPLE_CHEMICAL", 214, 220], ["PCR", "TEST", 14, 17], ["1 \u03bcl bacterial suspension", "TREATMENT", 33, 58], ["agarose gels", "TREATMENT", 78, 90], ["RNA isolation", "TREATMENT", 91, 104], ["cDNA synthesis", "TREATMENT", 106, 120], ["fluorescence labelingRNA", "PROBLEM", 125, 149], ["a standard phenol:chloroform protocol", "TREATMENT", 203, 240], ["Trizol Reagent (Invitrogen)", "TREATMENT", 246, 273]]], ["Fifteen micrograms of total RNA were used for cDNA synthesis, spiked with control RNA (CAB, RCA, RBCL and LTP4 (SpotReport, Stratagene) and labeled with Alexa fluor dyes, using SuperScript\u2122 Plus Indirect cDNA labeling System (Invitrogen).", [["Alexa fluor dyes", "SIMPLE_CHEMICAL", 153, 169], ["total RNA", "RNA", 22, 31], ["CAB", "PROTEIN", 87, 90], ["RCA", "DNA", 92, 95], ["RBCL", "DNA", 97, 101], ["LTP4", "DNA", 106, 110], ["SpotReport", "DNA", 112, 122], ["Stratagene", "DNA", 124, 134], ["total RNA", "TREATMENT", 22, 31], ["cDNA synthesis", "TREATMENT", 46, 60], ["control RNA", "TREATMENT", 74, 85], ["RBCL", "TEST", 97, 101], ["LTP4", "TEST", 106, 110], ["Alexa fluor dyes", "TREATMENT", 153, 169], ["SuperScript", "TREATMENT", 177, 188], ["RCA", "ANATOMY", 92, 95]]], ["Each experimental sample and control was combined with a reference pool cDNA prior to hybridization using an automated Tecan HS4800 hybridization station.", [["sample", "ANATOMY", 18, 24], ["reference pool cDNA", "DNA", 57, 76], ["a reference pool cDNA", "TREATMENT", 55, 76], ["hybridization", "TREATMENT", 86, 99]]], ["Slides were scanned using a GenePix 4000B scanner (Axon Instruments).RNA isolation, cDNA synthesis and fluorescence labelingMicroarray images and data from esfenvalerate exposed delta smelt can be accessed at http://www.vet med.ucdavis.edu/apc/WernerLab/ subpagpelagic_organism_decline.html; POD archive data.Microarray AnalysesNormalization and analytical methods are described in Loguinov et. al. [32] and Smyth [92] .", [["a GenePix 4000B scanner (Axon Instruments", "TREATMENT", 26, 67], ["RNA isolation", "TEST", 69, 82], ["cDNA synthesis", "TEST", 84, 98], ["fluorescence labelingMicroarray images", "TEST", 103, 141], ["Microarray AnalysesNormalization", "TEST", 309, 341], ["analytical methods", "TEST", 346, 364]]], ["In brief, print tip normalization was carried out within slides and sequential single slide data analysis was carried out as an alternative to between-slide normalization.", [["print tip normalization", "TEST", 10, 33], ["sequential single slide data analysis", "TEST", 68, 105], ["tip", "OBSERVATION_MODIFIER", 16, 19]]], ["An \u03b1-outliergenerating model was used to identify differentially expressed genes by applying the following decision rule for multiple-slide data analysis: a given gene was selected as a candidate if it was detected as significantly up-or downregulated in 4 of 4 replicates (raw p-value = 0.0625 using exact binomial test and considering outcomes as Bernoulli trials).", [["exact binomial test", "TEST", 301, 320], ["Bernoulli trials", "TREATMENT", 349, 365]]], ["This method however, detected only one significant differentially expressed candidate gene at the highest exposure concentration (0.125 \u03bcg/L -1 ), (with no significant annotation identity -see results and discussion).", [["candidate gene", "DNA", 76, 90]]], ["As a result, a second analytical method was applied to increase the number of probable genes for consideration in biomarker development.", [["a second analytical method", "TREATMENT", 13, 39]]], ["Thus we further analyzed the data using LIMMA GUI (Linear model for microarray analysis graphical user interface)Microarray Analyses[92], written in the R-programming language available through Bioconductor http://www.Bioconductor.org.", [["LIMMA GUI", "DNA", 40, 49], ["microarray analysis", "TEST", 68, 87], ["Microarray Analyses", "TEST", 113, 132]]], ["Data was normalized within arrays using print-tip Lowess and between arrays applying aquantile normalization methods [92] .", [["print-tip Lowess", "TREATMENT", 40, 56]]], ["A linear model fit was computed using the duplicates on the arrays and the least-squares method, no multiple assessment methods were applied to eliminate false positives as our aim was to increase the number of genes available for biomarker assessment, and qualify these through quantitative PCR.Sequencing and AnnotationSequencing was carried out at the CA&ES Genomic Facility, UC Davis.", [["A linear model fit", "PROBLEM", 0, 18], ["multiple assessment methods", "TEST", 100, 127], ["false positives", "PROBLEM", 154, 169], ["biomarker assessment", "TEST", 231, 251], ["quantitative PCR", "TEST", 279, 295], ["Sequencing", "TEST", 296, 306], ["linear", "OBSERVATION_MODIFIER", 2, 8]]], ["Basic Local Alignment Search Tool; translated nucleotide (BLASTx) searches were performed on specific fragments that responded significantly to the exposure treatments.", [["fragments", "ANATOMY", 102, 111], ["nucleotide", "CHEMICAL", 46, 56], ["BLASTx", "DNA", 58, 64], ["nucleotide (BLASTx) searches", "TREATMENT", 46, 74], ["specific fragments", "PROBLEM", 93, 111], ["the exposure treatments", "TREATMENT", 144, 167], ["Local Alignment", "OBSERVATION", 6, 21]]], ["Only genes that were differentially expressed following esfenvalerate exposure were sequenced.", [["esfenvalerate", "CHEMICAL", 56, 69], ["esfenvalerate", "CHEMICAL", 56, 69], ["esfenvalerate", "SIMPLE_CHEMICAL", 56, 69], ["esfenvalerate exposure", "PROBLEM", 56, 78]]], ["Sequences were annotated according to homologies to protein database searches using translated nucleotide sequences and direct nucleotide queries http:/ /blast.ncbi.nlm.nih.gov/Blast.cgi.", [["nucleotide", "CHEMICAL", 127, 137], ["nucleotide", "CHEMICAL", 95, 105], ["nucleotide", "CHEMICAL", 127, 137], ["translated nucleotide sequences", "DNA", 84, 115], ["translated nucleotide sequences", "TEST", 84, 115], ["direct nucleotide queries", "TEST", 120, 145]]], ["Specific genes of interest were selected for further investigation using quantitative PCR.Biomarker developmentGenes were selected according to level of expression significance, knowledge base from literature, and functional classification.", [["further investigation", "TEST", 45, 66], ["quantitative PCR", "TEST", 73, 89], ["Biomarker development", "TEST", 90, 111]]], ["Primer and probes for qPCR analyses were designed using Roche Universal Probe Library Assay Design Center https://www.roche-applied-science.com.", [["qPCR analyses", "TEST", 22, 35]]], ["Designed primers were obtained from Eurofins MWG Operon http://www.eurofinsdna.com, and TaqMan probes were supplied by Roche.", [["TaqMan probes", "DNA", 88, 101], ["Designed primers", "TEST", 0, 16], ["TaqMan probes", "TREATMENT", 88, 101]]], ["Sequences for all genes assessed by qPCR analyses have been submitted to genbank http://www.ncbi.nlm.nih.gov.", [["qPCR analyses", "TEST", 36, 49]]], ["Primers and probes, and genbank accession numbers, for investigated biomarkers are detailed in table 4.", [["investigated biomarkers", "TEST", 55, 78]]], ["Myozenin and creatine kinase, though not resulting from the current study, were genes identified in investigations carried out during microarray development, and added to the selected biomarkers due to our interest in neuromuscular activity.Quantitative PCRA total of 1.5 \u03bcg RNA was cDNA synthesized using random primers, and diluted to a total of 50 \u03bcl with nuclease free water to generate sufficient template for qPCR analysis.", [["neuromuscular", "ANATOMY", 218, 231], ["Myozenin", "CHEMICAL", 0, 8], ["creatine", "CHEMICAL", 13, 21], ["Myozenin", "CHEMICAL", 0, 8], ["creatine", "CHEMICAL", 13, 21], ["Myozenin", "GENE_OR_GENE_PRODUCT", 0, 8], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 13, 28], ["neuromuscular", "ANATOMICAL_SYSTEM", 218, 231], ["Myozenin", "PROTEIN", 0, 8], ["creatine kinase", "PROTEIN", 13, 28], ["1.5 \u03bcg RNA", "RNA", 268, 278], ["nuclease", "PROTEIN", 359, 367], ["Myozenin and creatine kinase", "TEST", 0, 28], ["the current study", "TEST", 56, 73], ["the selected biomarkers", "TEST", 171, 194], ["Quantitative PCRA total", "TEST", 241, 264], ["random primers", "TREATMENT", 306, 320], ["nuclease free water", "TREATMENT", 359, 378], ["qPCR analysis", "TEST", 415, 428]]], ["TaqMan Universal PCR Mastermix (Applied Biosystems) was used in q-PCR amplifications in a reaction containing 10mMTris-HCl (pH 8.3), 50 mM KCl, 5 mM MgCl2, 2.5 mM deoxynucleotide triphosphates, 0.625 U AmpliTaq Gold DNA polymerase per reaction, 0.25 U AmpErase UNG per reaction and 5 \u03bcL of cDNA sample in a final volume of 12 \u03bcL.", [["sample", "ANATOMY", 295, 301], ["10mMTris-HCl", "CHEMICAL", 110, 122], ["KCl", "CHEMICAL", 139, 142], ["MgCl2", "CHEMICAL", 149, 154], ["deoxynucleotide triphosphates", "CHEMICAL", 163, 192], ["10mMTris-HCl", "CHEMICAL", 110, 122], ["KCl", "CHEMICAL", 139, 142], ["MgCl2", "CHEMICAL", 149, 154], ["deoxynucleotide triphosphates", "CHEMICAL", 163, 192], ["10mMTris-HCl", "SIMPLE_CHEMICAL", 110, 122], ["MgCl2", "SIMPLE_CHEMICAL", 149, 154], ["deoxynucleotide triphosphates", "SIMPLE_CHEMICAL", 163, 192], ["DNA", "CELLULAR_COMPONENT", 216, 219], ["TaqMan", "TEST", 0, 6], ["Universal PCR Mastermix (Applied Biosystems", "TREATMENT", 7, 50], ["pH", "TEST", 124, 126], ["50 mM KCl", "TREATMENT", 133, 142], ["5 mM MgCl2", "TREATMENT", 144, 154], ["2.5 mM deoxynucleotide triphosphates", "TREATMENT", 156, 192], ["cDNA sample", "TEST", 290, 301], ["a final volume", "TEST", 305, 319]]], ["The samples were placed in 384 well plates and cDNA was amplified in an automated fluorometer (ABI PRISM 7900 Sequence Detection System, Applied Biosystems).", [["samples", "ANATOMY", 4, 11], ["cDNA", "DNA", 47, 51], ["The samples", "TEST", 0, 11], ["an automated fluorometer", "TEST", 69, 93]]], ["Amplification conditions were 2 min at 50\u00b0C, 10 min at 95\u00b0C, 40 cycles of 15 s at 95\u00b0C and 60 s at 60\u00b0C. Fluorescence of samples was measured every 7 s and signals were considered positive if fluorescence intensity exceeded 10 times the standard deviation of the baseline fluorescence (threshold cycle, CT).", [["samples", "ANATOMY", 121, 128], ["Fluorescence of samples", "TEST", 105, 128], ["fluorescence intensity", "TEST", 192, 214], ["the baseline fluorescence", "TEST", 259, 284], ["CT", "TEST", 303, 305]]], ["SDS 2.2.1 software (Applied Biosystems) was used to quantify transcription.Quantitative PCRQuantitative PCR data was analyzed using the relative quantification 2(-Delta Delta CT) method ()([93].", [["SDS", "TEST", 0, 3], ["software (Applied Biosystems)", "TREATMENT", 10, 39], ["Quantitative PCRQuantitative PCR data", "TEST", 75, 112], ["the relative quantification", "TEST", 132, 159]]], ["In the absence of house keeping genes, expression was calculated relative to the mean of controls in respective exposures.", [["house keeping genes", "DNA", 18, 37]]], ["Surviving larvae from each replicate of the 10-d old exposed delta smelt were used for q-PCR analyses.", [["Surviving larvae", "PROBLEM", 0, 16], ["old exposed delta smelt", "PROBLEM", 49, 72], ["q-PCR analyses", "TEST", 87, 101]]], ["Oneway ANOVA was used to assess differences in gene expression through out the exposure concentrations, and data were further assessed using Student's T-test at individual concentrations in respect to solvent controls.AbbreviationsEST: expressed sequence tag; q-PCR: real-time quantitative polymerase chain reaction; ASPA: aspartoacylase; ESA: endangered species act; CESA: California endangered spe-cies act; LIMMA GUI: linear model for microarray analysis, graphical user interface; BLAST: basic local alignment search tool; GABA: gamma-aminobutyric acid; NAA: Nacetyl-L-aspartate; ADP: adenosine diphosphate; WAP65: warm-temperature-acclimation-related-65 protein; EDC: endocrine disrupting chemical; ZPA: zona pellucida; PXR: pregnane \u00d7 receptor; p-BS: p-Bluescript; IPTG: isopropyl \u03b2-galactosidase; LB: Luria Bertani; FCCL: Fish Conservation and Culture Laboratory; UNG: Uracil N-glycosylase; CT: cycle threshold.", [["endocrine", "ANATOMY", 673, 682], ["GABA", "CHEMICAL", 527, 531], ["gamma-aminobutyric acid", "CHEMICAL", 533, 556], ["NAA", "CHEMICAL", 558, 561], ["Nacetyl-L-aspartate", "CHEMICAL", 563, 582], ["ADP", "CHEMICAL", 584, 587], ["adenosine", "CHEMICAL", 589, 598], ["WAP65", "CHEMICAL", 612, 617], ["GABA", "CHEMICAL", 527, 531], ["gamma-aminobutyric acid", "CHEMICAL", 533, 556], ["NAA", "CHEMICAL", 558, 561], ["Nacetyl-L-aspartate", "CHEMICAL", 563, 582], ["ADP", "CHEMICAL", 584, 587], ["adenosine diphosphate", "CHEMICAL", 589, 610], ["IPTG", "CHEMICAL", 771, 775], ["isopropyl \u03b2-galactosidase", "CHEMICAL", 777, 802], ["ESA", "SIMPLE_CHEMICAL", 339, 342], ["GABA", "SIMPLE_CHEMICAL", 527, 531], ["gamma-aminobutyric acid", "SIMPLE_CHEMICAL", 533, 556], ["NAA", "SIMPLE_CHEMICAL", 558, 561], ["Nacetyl-L-aspartate", "SIMPLE_CHEMICAL", 563, 582], ["ADP", "SIMPLE_CHEMICAL", 584, 587], ["adenosine diphosphate", "SIMPLE_CHEMICAL", 589, 610], ["WAP65", "SIMPLE_CHEMICAL", 612, 617], ["EDC", "SIMPLE_CHEMICAL", 668, 671], ["ZPA", "SIMPLE_CHEMICAL", 704, 707], ["PXR", "GENE_OR_GENE_PRODUCT", 725, 728], ["pregnane \u00d7 receptor", "GENE_OR_GENE_PRODUCT", 730, 749], ["p-Bluescript", "SIMPLE_CHEMICAL", 757, 769], ["IPTG", "SIMPLE_CHEMICAL", 771, 775], ["isopropyl \u03b2-galactosidase", "SIMPLE_CHEMICAL", 777, 802], ["ASPA: aspartoacylase", "PROTEIN", 317, 337], ["ESA", "PROTEIN", 339, 342], ["PXR", "PROTEIN", 725, 728], ["UNG", "PROTEIN", 871, 874], ["Uracil N-glycosylase", "PROTEIN", 876, 896], ["CT", "PROTEIN", 898, 900], ["Student's T-test", "TEST", 141, 157], ["sequence tag", "TEST", 246, 258], ["q-PCR", "TEST", 260, 265], ["quantitative polymerase chain reaction", "PROBLEM", 277, 315], ["microarray analysis", "TEST", 438, 457], ["gamma-aminobutyric acid", "TEST", 533, 556], ["NAA", "TEST", 558, 561], ["Nacetyl", "TEST", 563, 570], ["adenosine diphosphate", "TREATMENT", 589, 610], ["temperature", "TEST", 624, 635], ["isopropyl \u03b2-galactosidase", "TREATMENT", 777, 802], ["Uracil", "TEST", 876, 882], ["CT", "TEST", 898, 900]]]], "0825a7b4df2562051386a726f10e5ce14560a69e": [["IntroductionBelonging to the Mononegavirales order, Paramyxoviridae family and Avulavirus genus, Newcastle disease virus (NDV) is an enveloped virus containing linear, non-segmented single-stranded RNA (Lamb et al., 2005) .", [["Newcastle disease", "DISEASE", 97, 114], ["Avulavirus genus", "ORGANISM", 79, 95], ["Newcastle disease virus", "ORGANISM", 97, 120], ["NDV", "ORGANISM", 122, 125], ["Newcastle disease virus", "SPECIES", 97, 120], ["NDV", "SPECIES", 122, 125], ["Newcastle disease virus", "SPECIES", 97, 120], ["NDV", "SPECIES", 122, 125], ["Newcastle disease virus (NDV", "PROBLEM", 97, 125], ["an enveloped virus", "PROBLEM", 130, 148], ["enveloped", "OBSERVATION_MODIFIER", 133, 142], ["virus", "OBSERVATION", 143, 148], ["linear", "OBSERVATION_MODIFIER", 160, 166], ["stranded RNA", "OBSERVATION_MODIFIER", 189, 201]]], ["NDV strains are classified into one of three major pathotypes: velogenic, mesogenic and lentogenic (Beard and Hanson, 1984) .", [["NDV", "ORGANISM", 0, 3], ["NDV", "SPECIES", 0, 3], ["NDV", "SPECIES", 0, 3], ["NDV strains", "PROBLEM", 0, 11], ["velogenic", "PROBLEM", 63, 72], ["velogenic", "OBSERVATION", 63, 72], ["mesogenic", "OBSERVATION_MODIFIER", 74, 83], ["lentogenic", "OBSERVATION_MODIFIER", 88, 98]]], ["Highly virulent velogenic strains cause acute infections with high mortality, mesogenic (intermediately virulent) strains cause respiratory disease in young chickens and decreased egg production, whereas lentogenic (avirulent) strains cause mild respiratory infection or give no symptoms in poultry (Seal et al., 1995) .", [["respiratory", "ANATOMY", 128, 139], ["egg", "ANATOMY", 180, 183], ["respiratory", "ANATOMY", 246, 257], ["infections", "DISEASE", 46, 56], ["respiratory disease", "DISEASE", 128, 147], ["respiratory infection", "DISEASE", 246, 267], ["velogenic strains", "ORGANISM", 16, 33], ["chickens", "ORGANISM", 157, 165], ["egg", "ORGANISM_SUBSTANCE", 180, 183], ["chickens", "SPECIES", 157, 165], ["chickens", "SPECIES", 157, 165], ["Highly virulent velogenic strains", "PROBLEM", 0, 33], ["acute infections", "PROBLEM", 40, 56], ["high mortality", "PROBLEM", 62, 76], ["mesogenic (intermediately virulent) strains", "PROBLEM", 78, 121], ["respiratory disease", "PROBLEM", 128, 147], ["young chickens", "PROBLEM", 151, 165], ["decreased egg production", "PROBLEM", 170, 194], ["lentogenic (avirulent) strains", "PROBLEM", 204, 234], ["mild respiratory infection", "PROBLEM", 241, 267], ["symptoms", "PROBLEM", 279, 287], ["virulent", "OBSERVATION_MODIFIER", 7, 15], ["velogenic strains", "OBSERVATION", 16, 33], ["acute", "OBSERVATION_MODIFIER", 40, 45], ["infections", "OBSERVATION", 46, 56], ["high mortality", "OBSERVATION_MODIFIER", 62, 76], ["mesogenic", "OBSERVATION_MODIFIER", 78, 87], ["respiratory disease", "OBSERVATION", 128, 147], ["young chickens", "OBSERVATION", 151, 165], ["decreased", "OBSERVATION_MODIFIER", 170, 179], ["egg production", "OBSERVATION", 180, 194], ["mild", "OBSERVATION_MODIFIER", 241, 245], ["respiratory", "ANATOMY", 246, 257], ["infection", "OBSERVATION", 258, 267]]], ["Studies conducted by Rott and Klenk (1988) revealed the key role of a small amino acid motif at the cleavage site of the F0 protein of NDV in the molecular determination of the pathotype.", [["amino acid", "CHEMICAL", 76, 86], ["amino acid", "CHEMICAL", 76, 86], ["amino acid", "AMINO_ACID", 76, 86], ["NDV", "ORGANISM", 135, 138], ["small amino acid motif", "PROTEIN", 70, 92], ["cleavage site", "PROTEIN", 100, 113], ["F0 protein", "PROTEIN", 121, 131], ["NDV", "SPECIES", 135, 138], ["Studies", "TEST", 0, 7], ["a small amino acid motif", "TREATMENT", 68, 92], ["NDV", "PROBLEM", 135, 138], ["NDV", "OBSERVATION", 135, 138], ["pathotype", "OBSERVATION", 177, 186]]], ["The presence of two pairs of basic amino acids at positions 112, 113, 115 and 116 and phenyloalanine at position 117, at fusion protein cleavage site, makes this site susceptible to cleavage by common subtilisin-like protease and easier spread throughout the host.", [["amino acids", "CHEMICAL", 35, 46], ["112, 113, 115 and 116", "CHEMICAL", 60, 81], ["phenyloalanine", "CHEMICAL", 86, 100], ["amino acids", "CHEMICAL", 35, 46], ["phenyloalanine", "CHEMICAL", 86, 100], ["amino acids", "AMINO_ACID", 35, 46], ["phenyloalanine", "AMINO_ACID", 86, 100], ["subtilisin-like protease", "GENE_OR_GENE_PRODUCT", 201, 225], ["position 117", "PROTEIN", 104, 116], ["fusion protein cleavage site", "PROTEIN", 121, 149], ["common subtilisin-like protease", "PROTEIN", 194, 225], ["basic amino acids", "TEST", 29, 46], ["phenyloalanine", "TEST", 86, 100], ["fusion protein cleavage site", "TREATMENT", 121, 149], ["this site", "PROBLEM", 157, 166], ["common subtilisin-like protease", "PROBLEM", 194, 225], ["amino acids", "OBSERVATION", 35, 46]]], ["The sequence (C-112 R/K-R-Q-K/R-R-F 117 -N) is observed in highly virulent strains.", [["strains", "ANATOMY", 75, 82], ["The sequence", "TEST", 0, 12], ["C", "TEST", 14, 15], ["K", "TEST", 22, 23], ["highly virulent strains", "PROBLEM", 59, 82], ["virulent strains", "OBSERVATION", 66, 82]]], ["In the low virulence strains, there are only two basic Abbreviations: AIV, avian influenza virus; APMV, avian paramyxovirus; CSFV, classical swine fever virus; EID, egg infective dose; ICPI, intercerebral pathogenicity index; NDV, Newcastle disease virus; PCR, polymerase chain reaction.Introduction* Corresponding author.", [["avian influenza virus", "DISEASE", 75, 96], ["avian paramyxovirus", "DISEASE", 104, 123], ["swine fever", "DISEASE", 141, 152], ["Newcastle disease", "DISEASE", 231, 248], ["AIV", "ORGANISM", 70, 73], ["avian influenza virus", "ORGANISM", 75, 96], ["APMV", "ORGANISM", 98, 102], ["avian paramyxovirus", "ORGANISM", 104, 123], ["CSFV", "ORGANISM", 125, 129], ["classical swine fever virus", "ORGANISM", 131, 158], ["NDV", "ORGANISM", 226, 229], ["Newcastle disease virus", "ORGANISM", 231, 254], ["avian influenza virus", "SPECIES", 75, 96], ["avian paramyxovirus", "SPECIES", 104, 123], ["CSFV", "SPECIES", 125, 129], ["swine fever virus", "SPECIES", 141, 158], ["NDV", "SPECIES", 226, 229], ["avian influenza virus", "SPECIES", 75, 96], ["APMV", "SPECIES", 98, 102], ["CSFV", "SPECIES", 125, 129], ["swine fever virus", "SPECIES", 141, 158], ["NDV", "SPECIES", 226, 229], ["Newcastle disease virus", "SPECIES", 231, 254], ["the low virulence strains", "PROBLEM", 3, 28], ["AIV", "PROBLEM", 70, 73], ["avian influenza virus", "PROBLEM", 75, 96], ["APMV", "TREATMENT", 98, 102], ["avian paramyxovirus", "PROBLEM", 104, 123], ["CSFV", "PROBLEM", 125, 129], ["classical swine fever virus", "PROBLEM", 131, 158], ["ICPI", "PROBLEM", 185, 189], ["intercerebral pathogenicity index", "PROBLEM", 191, 224], ["NDV", "PROBLEM", 226, 229], ["Newcastle disease virus", "PROBLEM", 231, 254], ["PCR", "TEST", 256, 259], ["polymerase chain reaction", "PROBLEM", 261, 286], ["low virulence", "OBSERVATION_MODIFIER", 7, 20], ["influenza virus", "OBSERVATION", 81, 96]]], ["Tel.: +48 58 5236336; fax: +48 58 3057312.IntroductionE-mail address: dawid.nidzworski@biotech.ug.gda.pl (D. Nidzworski). amino acids at position 113 and 116, along with leucine at position 117 (C-112 G/E-K/R-Q-G/E-R-L 117 -N).", [["+48 58 5236336", "CHEMICAL", 6, 20], ["amino acids", "CHEMICAL", 122, 133], ["leucine", "CHEMICAL", 170, 177], ["+48 58 5236336", "CHEMICAL", 6, 20], ["amino acids", "CHEMICAL", 122, 133], ["leucine", "CHEMICAL", 170, 177], ["amino acids", "AMINO_ACID", 122, 133], ["leucine", "AMINO_ACID", 170, 177], ["K", "PROTEIN", 205, 206], ["R-Q", "PROTEIN", 207, 210], ["E", "PROTEIN", 213, 214], ["amino acids", "TEST", 122, 133], ["leucine", "TEST", 170, 177], ["C", "TEST", 195, 196], ["G/E", "TEST", 201, 204], ["K", "TEST", 205, 206]]], ["This motif is recognized only by trypsin-like proteases, which are present mainly in the respiratory tract (Collins et al., 1996; Nagai et al., 1976) .", [["respiratory tract", "ANATOMY", 89, 106], ["trypsin", "GENE_OR_GENE_PRODUCT", 33, 40], ["respiratory tract", "ORGANISM_SUBDIVISION", 89, 106], ["trypsin-like proteases", "PROTEIN", 33, 55], ["trypsin-like proteases", "PROBLEM", 33, 55], ["respiratory tract", "ANATOMY", 89, 106]]], ["Because of the role of the cleavage site in pathogenicity, the F gene is the major target for differentiation of Newcastle disease virus.", [["Newcastle disease", "DISEASE", 113, 130], ["F", "GENE_OR_GENE_PRODUCT", 63, 64], ["Newcastle disease virus", "ORGANISM", 113, 136], ["F gene", "DNA", 63, 69], ["Newcastle disease virus", "SPECIES", 113, 136], ["the cleavage site", "PROBLEM", 23, 40], ["Newcastle disease virus", "PROBLEM", 113, 136], ["Newcastle disease", "OBSERVATION", 113, 130]]], ["The variability in the virulence of NDV causes diagnostic difficulties because only viral infections with an ICPI of 0.7 or greater are notifiable (OIE, 2009) .", [["NDV", "DISEASE", 36, 39], ["viral infections", "DISEASE", 84, 100], ["NDV", "ORGANISM", 36, 39], ["NDV", "SPECIES", 36, 39], ["NDV", "PROBLEM", 36, 39], ["diagnostic difficulties", "PROBLEM", 47, 70], ["viral infections", "PROBLEM", 84, 100], ["an ICPI", "TEST", 106, 113], ["variability", "OBSERVATION_MODIFIER", 4, 15], ["viral", "OBSERVATION_MODIFIER", 84, 89], ["infections", "OBSERVATION", 90, 100]]], ["Therefore, detection of the virus only is not a sufficient for notification and should be followed by methods that evaluate the pathogenicity of isolates.IntroductionThe sensitivity and short time analysis of real-time PCR are its two most important advantages (Higuchi et al., 1992) .", [["the virus", "PROBLEM", 24, 33], ["the pathogenicity of isolates", "PROBLEM", 124, 153], ["The sensitivity", "TEST", 166, 181], ["short time analysis", "TEST", 186, 205], ["real-time PCR", "TEST", 209, 222], ["virus", "OBSERVATION", 28, 33]]], ["Several methods for the detection and differentiation of NDV have been previously described.", [["NDV", "ORGANISM", 57, 60], ["NDV", "SPECIES", 57, 60], ["the detection", "TEST", 20, 33], ["NDV", "PROBLEM", 57, 60], ["NDV", "OBSERVATION", 57, 60]]], ["Most assays are based on the detection of the fusion gene (Pham et al., 2005) or the matrix and fusion genes (Wise et al., 2004; Steyer et al., 2010) .", [["matrix", "ANATOMY", 85, 91], ["matrix", "CELLULAR_COMPONENT", 85, 91], ["fusion gene", "DNA", 46, 57], ["matrix and fusion genes", "DNA", 85, 108], ["the matrix and fusion genes", "TREATMENT", 81, 108]]], ["However, other regions are also used for general detection and differentiation (Fuller et al., 2010; Tan et al., 2009 ).", [["general detection", "TEST", 41, 58]]], ["The first SYBR Green I assay for the detection of NDV was described by Tan et al. (2004) , but this assay could not be used for differentiation of pathotypes of the virus.", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 10, 22], ["NDV", "ORGANISM", 50, 53], ["NDV", "SPECIES", 50, 53], ["NDV", "PROBLEM", 50, 53], ["this assay", "TEST", 95, 105], ["pathotypes", "PROBLEM", 147, 157], ["the virus", "PROBLEM", 161, 170]]], ["Pham et al. (2005) described a SYBR Green I real-time PCR melting curve analysis assay for differentiation, although the differences in the Tm values between the three genotypes were not very significant and could cause false characterization of the virus.", [["a SYBR", "TEST", 29, 35], ["PCR melting curve analysis assay", "TEST", 54, 86], ["the Tm values", "TEST", 136, 149], ["the virus", "PROBLEM", 246, 255]]], ["Many real-time PCR assays for NDV detection and differentiation using different TaqMan probes were developed but degenerated primers were not used very often.", [["NDV", "ORGANISM", 30, 33], ["TaqMan probes", "DNA", 80, 93], ["NDV", "SPECIES", 30, 33], ["Many real-time PCR assays", "TEST", 0, 25], ["NDV detection", "TEST", 30, 43], ["different TaqMan probes", "TREATMENT", 70, 93], ["degenerated primers", "PROBLEM", 113, 132]]], ["Also, false negative results were reported (Cattoli et al., 2009; Wise et al., 2004) .", [["false negative", "OBSERVATION", 6, 20]]], ["In some cases, to differentiate between pathotypes of NDV, it was necessary to use two or three pairs of primers and several different TaqMan probes in one reaction were necessary (Wise et al., 2004; Farkas et al., 2009) .IntroductionDegenerated primers have been proven to be a good tool for the detection of the highly variable Newcastle disease virus (Farkas et al., 2009; Li et al., 2009; Steyer et al., 2010) .", [["Newcastle disease", "DISEASE", 330, 347], ["NDV", "ORGANISM", 54, 57], ["Newcastle disease virus", "ORGANISM", 330, 353], ["TaqMan probes", "DNA", 135, 148], ["NDV", "SPECIES", 54, 57], ["Newcastle disease virus", "SPECIES", 330, 353], ["NDV", "PROBLEM", 54, 57], ["primers", "TREATMENT", 105, 112], ["several different TaqMan probes", "TREATMENT", 117, 148], ["Degenerated primers", "PROBLEM", 234, 253], ["the detection", "TEST", 293, 306], ["the highly variable Newcastle disease virus", "PROBLEM", 310, 353], ["NDV", "OBSERVATION", 54, 57]]], ["In this study, a one tube diagnostic method is described for the detection and differentiation of Newcastle disease virus using degenerated primers.Virus strains and RNA extractionThe NDV strains that were analyzed in this study are listed in Table 1 .", [["Newcastle disease", "DISEASE", 98, 115], ["tube", "TISSUE", 21, 25], ["Newcastle disease virus", "ORGANISM", 98, 121], ["Virus", "ORGANISM", 148, 153], ["NDV", "ORGANISM", 184, 187], ["Newcastle disease virus", "SPECIES", 98, 121], ["NDV", "SPECIES", 184, 187], ["this study", "TEST", 3, 13], ["a one tube diagnostic method", "TREATMENT", 15, 43], ["the detection", "TEST", 61, 74], ["Newcastle disease virus", "PROBLEM", 98, 121], ["degenerated primers", "PROBLEM", 128, 147], ["Virus strains", "PROBLEM", 148, 161], ["RNA extraction", "TREATMENT", 166, 180], ["The NDV strains", "PROBLEM", 180, 195], ["this study", "TEST", 218, 228], ["RNA extraction", "OBSERVATION", 166, 180]]], ["All of the strains were derived from the collection of the National Veterinary Research Institute (Pulawy, Poland) and were classified into three major pathotypes based on the intracerebral pathogenicity index (ICPI) and comparison with reference strains.", [["intracerebral", "ANATOMY", 176, 189], ["intracerebral", "IMMATERIAL_ANATOMICAL_ENTITY", 176, 189], ["the strains", "PROBLEM", 7, 18], ["the intracerebral pathogenicity index", "TEST", 172, 209]]], ["Avian influenza virus (AIV) subtype H5N2, Coronavirus (165/08 5-8), rotavirus (G036/10 1-5), Gumboro virus (131/92), and classical swine fever virus (CSVF) Cellpest strain were from the National Veterinary Research Institute (Pulawy, Poland).", [["Avian influenza virus (AIV) subtype H5N2", "DISEASE", 0, 40], ["rotavirus", "DISEASE", 68, 77], ["G036/10 1-5", "CHEMICAL", 79, 90], ["swine fever", "DISEASE", 131, 142], ["Avian influenza virus", "ORGANISM", 0, 21], ["AIV) subtype H5N2", "ORGANISM", 23, 40], ["Coronavirus", "ORGANISM", 42, 53], ["rotavirus", "ORGANISM", 68, 77], ["G036/10 1-5", "ORGANISM", 79, 90], ["Gumboro virus", "ORGANISM", 93, 106], ["classical swine fever virus", "ORGANISM", 121, 148], ["Avian influenza virus", "SPECIES", 0, 21], ["H5N2", "SPECIES", 36, 40], ["rotavirus", "SPECIES", 68, 77], ["Gumboro virus", "SPECIES", 93, 106], ["swine fever virus", "SPECIES", 131, 148], ["Avian influenza virus", "SPECIES", 0, 21], ["AIV", "SPECIES", 23, 26], ["Gumboro virus", "SPECIES", 93, 106], ["classical swine fever virus", "SPECIES", 121, 148], ["CSVF", "SPECIES", 150, 154], ["Avian influenza virus (AIV) subtype H5N2", "PROBLEM", 0, 40], ["Coronavirus", "TEST", 42, 53], ["rotavirus (G036/10", "TEST", 68, 86], ["Gumboro virus", "PROBLEM", 93, 106], ["classical swine fever virus (CSVF) Cellpest strain", "PROBLEM", 121, 171], ["influenza virus", "OBSERVATION", 6, 21]]], ["APMV strains were bought from x-OvO Limited (Dunfermline, United Kingdom).", [["APMV", "SPECIES", 0, 4], ["APMV strains", "PROBLEM", 0, 12]]], ["Reovirus (Reo S1133) and Infectious Bronchitis virus (IB K+ 4/91) were vaccine components of Nobilis REO 1133 and Nobilis IB 4-91 (Intervet/Schering-Plough Animal Health, Holland).Virus strains and RNA extractionRNA was extracted from allantoic fluid of SPF embryonated eggs (Lohman, Germany), and inoculated with NDV strains in accordance with the OIE Diagnostic Manual (OIE, 2009) using an RNeasy Mini Kit (Qiagen, Valencia, CA, USA) protocol.", [["allantoic fluid", "ANATOMY", 235, 250], ["eggs", "ANATOMY", 270, 274], ["Infectious Bronchitis virus", "DISEASE", 25, 52], ["K", "CHEMICAL", 57, 58], ["Nobilis REO 1133", "CHEMICAL", 93, 109], ["Nobilis IB 4-91", "CHEMICAL", 114, 129], ["Reo S1133", "ORGANISM", 10, 19], ["Infectious Bronchitis virus", "ORGANISM", 25, 52], ["Nobilis REO 1133", "CELL", 93, 109], ["Virus", "ORGANISM", 180, 185], ["allantoic fluid", "ORGANISM_SUBSTANCE", 235, 250], ["NDV", "ORGANISM", 314, 317], ["Infectious Bronchitis virus", "SPECIES", 25, 52], ["Infectious Bronchitis virus (IB K+ 4/91", "SPECIES", 25, 64], ["Nobilis REO 1133", "SPECIES", 93, 109], ["Nobilis IB 4-91", "SPECIES", 114, 129], ["SPF", "SPECIES", 254, 257], ["NDV", "SPECIES", 314, 317], ["Reovirus", "TEST", 0, 8], ["Infectious Bronchitis virus", "PROBLEM", 25, 52], ["IB K", "TEST", 54, 58], ["Nobilis REO", "TEST", 93, 104], ["Nobilis IB", "TEST", 114, 124], ["Virus strains", "PROBLEM", 180, 193], ["RNA extractionRNA", "PROBLEM", 198, 215], ["allantoic fluid", "TEST", 235, 250], ["SPF embryonated eggs", "TREATMENT", 254, 274], ["NDV strains", "PROBLEM", 314, 325], ["an RNeasy Mini Kit", "TREATMENT", 389, 407], ["CA, USA) protocol", "TREATMENT", 427, 444], ["Infectious", "OBSERVATION_MODIFIER", 25, 35], ["Bronchitis", "OBSERVATION", 36, 46], ["Nobilis", "ANATOMY", 93, 100], ["allantoic", "OBSERVATION_MODIFIER", 235, 244], ["fluid", "OBSERVATION_MODIFIER", 245, 250]]], ["Additionally, RNA from oral and cloacal swabs and homogenized tissues was isolated using the same kit.Primer designA set of degenerated primers based on the F0 gene of NDV was used in this study:Primer designNDV-F (position 4826-4842) 5 -CTT GGT GAY TCY ATC CG-3 NDV R (position 4901-4917) 5 -ACA CYG CCD ATA ATG GC-3Primer designwhere Y = C or T; D = A or G or T. The amplified cDNA fragment was 92 base pairs (bp) long and contained the region encoding the F cleavage site.cDNA synthesis and real-time PCRSynthesis of the first strand of cDNA was carried out according to the procedure described for the Transcriptor High Fidelity cDNA Synthesis Kit (Roche Diagnostics, Mannheim, Germany).", [["oral", "ANATOMY", 23, 27], ["cloacal swabs", "ANATOMY", 32, 45], ["tissues", "ANATOMY", 62, 69], ["oral", "ORGANISM_SUBDIVISION", 23, 27], ["cloacal swabs", "ORGANISM_SUBSTANCE", 32, 45], ["tissues", "TISSUE", 62, 69], ["NDV", "ORGANISM", 168, 171], ["Y = C", "GENE_OR_GENE_PRODUCT", 336, 341], ["D = A", "GENE_OR_GENE_PRODUCT", 348, 353], ["G", "GENE_OR_GENE_PRODUCT", 357, 358], ["F0 gene", "DNA", 157, 164], ["Primer designNDV-F (position 4826-4842) 5 -CTT GGT GAY TCY ATC CG-3 NDV R", "DNA", 195, 268], ["position 4901-4917) 5 -ACA CYG CCD ATA ATG GC-3Primer", "DNA", 270, 323], ["amplified cDNA fragment", "DNA", 369, 392], ["92 base pairs", "DNA", 397, 410], ["F cleavage site", "DNA", 459, 474], ["cDNA", "DNA", 540, 544], ["NDV", "SPECIES", 168, 171], ["RNA", "TEST", 14, 17], ["oral and cloacal swabs", "TEST", 23, 45], ["homogenized tissues", "PROBLEM", 50, 69], ["degenerated primers", "PROBLEM", 124, 143], ["NDV", "PROBLEM", 168, 171], ["this study", "TEST", 184, 194], ["CTT GGT GAY", "TEST", 238, 249], ["TCY", "TEST", 250, 253], ["ATC", "TEST", 254, 257], ["CG", "TEST", 258, 260], ["ACA", "TEST", 293, 296], ["ATG", "TEST", 309, 312], ["GC", "TEST", 313, 315], ["3Primer", "TEST", 316, 323], ["The amplified cDNA fragment", "PROBLEM", 365, 392], ["base pairs", "TEST", 400, 410], ["bp", "TEST", 412, 414], ["the first strand of cDNA", "TREATMENT", 520, 544], ["the procedure", "TREATMENT", 574, 587], ["degenerated", "OBSERVATION", 124, 135]]], ["The reaction mixture contained: viral RNA, random hexamer primers and water that was incubated for 10 min at 65 \u2022 C. Subsequently, the reaction buffer, RNase inhibitor, dNTPs, DTT, and reverse transcriptase were added.", [["dNTPs", "CHEMICAL", 169, 174], ["DTT", "CHEMICAL", 176, 179], ["dNTPs", "CHEMICAL", 169, 174], ["DTT", "CHEMICAL", 176, 179], ["RNase", "GENE_OR_GENE_PRODUCT", 152, 157], ["dNTPs", "SIMPLE_CHEMICAL", 169, 174], ["DTT", "SIMPLE_CHEMICAL", 176, 179], ["viral RNA", "RNA", 32, 41], ["RNase", "PROTEIN", 152, 157], ["reverse transcriptase", "PROTEIN", 185, 206], ["The reaction mixture", "PROBLEM", 0, 20], ["viral RNA", "PROBLEM", 32, 41], ["random hexamer primers", "TREATMENT", 43, 65], ["the reaction buffer", "TREATMENT", 131, 150], ["RNase inhibitor", "TREATMENT", 152, 167], ["dNTPs", "TREATMENT", 169, 174], ["DTT", "TREATMENT", 176, 179], ["reverse transcriptase", "TREATMENT", 185, 206], ["viral RNA", "OBSERVATION", 32, 41]]], ["The final mixture contained: 1\u00d7 reaction buffer [250 mM Tris-HCl, 150 mM KCl, 40 mM MgCl 2 ; pH 8.5], 20 U of RNase inhibitor [in: 20 mM Hepes-KOH, 50 mM KCl, 8 mM DTT, 50% glycerol; pH 7.6], 60 M of random hexamer primers, Table 1 Melting-curve analysis of viral strains.", [["Tris-HCl", "CHEMICAL", 56, 64], ["KCl", "CHEMICAL", 73, 76], ["KCl", "CHEMICAL", 154, 157], ["glycerol", "CHEMICAL", 173, 181], ["Tris-HCl", "CHEMICAL", 56, 64], ["KCl", "CHEMICAL", 73, 76], ["MgCl 2", "CHEMICAL", 84, 90], ["Hepes-KOH", "CHEMICAL", 137, 146], ["KCl", "CHEMICAL", 154, 157], ["DTT", "CHEMICAL", 164, 167], ["glycerol", "CHEMICAL", 173, 181], ["Tris-HCl", "SIMPLE_CHEMICAL", 56, 64], ["RNase", "GENE_OR_GENE_PRODUCT", 110, 115], ["glycerol", "SIMPLE_CHEMICAL", 173, 181], ["Tris", "TEST", 56, 60], ["HCl", "TEST", 61, 64], ["KCl", "TEST", 73, 76], ["MgCl", "TEST", 84, 88], ["pH", "TEST", 93, 95], ["RNase inhibitor", "TREATMENT", 110, 125], ["Hepes", "TEST", 137, 142], ["KOH", "TEST", 143, 146], ["KCl", "TEST", 154, 157], ["DTT", "TEST", 164, 167], ["glycerol", "TEST", 173, 181], ["pH", "TEST", 183, 185], ["random hexamer primers", "TREATMENT", 200, 222], ["Table 1 Melting", "TEST", 224, 239], ["curve analysis", "TEST", 240, 254], ["viral strains", "PROBLEM", 258, 271], ["viral strains", "OBSERVATION", 258, 271]]], ["Lineages by Aldous et al. (2003) .cDNA synthesis and real-time PCRAPMV -9 NA ---28cDNA synthesis and real-time PCRCoronavirus 165 1 mM of each dNTPs, 5 mM of DTT, and 10 U of reverse transcriptase (in: 200 mM potassium phosphate, 2 mM DTT, 0.2% Triton X-100, 50% glycerol, pH 7.2).", [["PCRAPMV -9 NA", "CHEMICAL", 63, 76], ["dNTPs", "CHEMICAL", 143, 148], ["DTT", "CHEMICAL", 158, 161], ["potassium phosphate", "CHEMICAL", 209, 228], ["Triton X-100", "CHEMICAL", 245, 257], ["glycerol", "CHEMICAL", 263, 271], ["dNTPs", "CHEMICAL", 143, 148], ["DTT", "CHEMICAL", 158, 161], ["potassium phosphate", "CHEMICAL", 209, 228], ["DTT", "CHEMICAL", 235, 238], ["Triton X-100", "CHEMICAL", 245, 257], ["glycerol", "CHEMICAL", 263, 271], ["DTT", "SIMPLE_CHEMICAL", 158, 161], ["potassium phosphate", "SIMPLE_CHEMICAL", 209, 228], ["DTT", "SIMPLE_CHEMICAL", 235, 238], ["Triton X-100", "SIMPLE_CHEMICAL", 245, 257], ["glycerol", "SIMPLE_CHEMICAL", 263, 271], ["reverse transcriptase", "PROTEIN", 175, 196], ["synthesis", "TEST", 39, 48], ["PCRAPMV", "TEST", 63, 70], ["NA ---28cDNA synthesis", "TEST", 74, 96], ["PCRCoronavirus", "TEST", 111, 125], ["dNTPs", "TEST", 143, 148], ["DTT", "TEST", 158, 161], ["reverse transcriptase", "TREATMENT", 175, 196], ["mM potassium phosphate", "TREATMENT", 206, 228], ["DTT", "TEST", 235, 238], ["pH", "TEST", 273, 275]]], ["SYBR Green I real-time PCR was performed using a LightCycler 2.0 TM (Roche Diagnostics, Mannheim, Germany).", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 0, 12], ["PCR", "TEST", 23, 26], ["a LightCycler", "TEST", 47, 60]]], ["10 l of the final mixture contained 9 l of reaction mixture: 1\u00d7 LC DNA Master SYBR Green I (Roche Diagnostics, Mannheim, Germany), MgCl 2 (4 mM), 0.2 M of each primer, and 1 l of cDNA.", [["cDNA", "DNA", 179, 183]]], ["A negative control lacking cDNA was also prepared.", [["cDNA", "DNA", 27, 31], ["negative", "OBSERVATION", 2, 10]]], ["The samples were initially denatured at 95 \u2022 C for 10 min, followed by 50 cycles of the following: 95 \u2022 C (denaturation) for 10 s, 48 \u2022 C (annealing) for 10 s, and 72 \u2022 C (extension) for 11 s.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11]]], ["To confirm the specificity of the amplified product, a melting curve analysis step was included.", [["a melting curve analysis step", "TEST", 53, 82]]], ["The internal temperature of the LightCycler was increased rapidly to 95 \u2022 C, then decreased at 0.1 \u2022 C/s to 70 \u2022 C, and then the sample was incubated for 15 s.", [["sample", "ANATOMY", 129, 135], ["the LightCycler", "TEST", 28, 43], ["the sample", "TEST", 125, 135], ["internal", "OBSERVATION_MODIFIER", 4, 12]]], ["The fluorescence at 530 nm was measured continuously.", [["The fluorescence", "TEST", 0, 16]]], ["The melting peaks were generated using LightCycler software by plotting the first negative derivative of the fluorescence over the temperature versus the temperature (\u2212dF/dT).Detection limit, cloning, sequencing and specificity of the assayThe detection limit was determined using the target copy number and virus titer (50% egg infective dose -EID 50 ) as reference units. (i) A fragment (320 bp) of the F gene of the LaSota strain was cloned into pGEM-T easy vector (Promega, Madison, WI, USA).", [["F", "GENE_OR_GENE_PRODUCT", 405, 406], ["LaSota", "GENE_OR_GENE_PRODUCT", 419, 425], ["pGEM-T", "GENE_OR_GENE_PRODUCT", 449, 455], ["F gene", "DNA", 405, 411], ["The melting peaks", "PROBLEM", 0, 17], ["LightCycler software", "TEST", 39, 59], ["the temperature", "TEST", 127, 142], ["the temperature", "TEST", 150, 165], ["the assay", "TEST", 231, 240], ["virus titer", "TREATMENT", 308, 319], ["A fragment", "PROBLEM", 378, 388], ["bp", "TEST", 394, 396], ["the LaSota strain", "TREATMENT", 415, 432], ["fragment", "OBSERVATION", 380, 388]]], ["Plasmid DNA was extracted from the bacteria by using a Plasmid mini Kit (A&A Biotechnology, Gdansk, Poland).", [["Plasmid", "ANATOMY", 0, 7], ["Plasmid DNA", "CELLULAR_COMPONENT", 0, 11], ["Plasmid DNA", "DNA", 0, 11], ["Plasmid DNA", "PROBLEM", 0, 11], ["the bacteria", "PROBLEM", 31, 43], ["DNA", "OBSERVATION", 8, 11], ["bacteria", "OBSERVATION_MODIFIER", 35, 43]]], ["The concentration of the plasmid DNA was determined spectrophotometrically.", [["plasmid", "ANATOMY", 25, 32], ["DNA", "CELLULAR_COMPONENT", 33, 36], ["plasmid DNA", "DNA", 25, 36], ["the plasmid DNA", "TREATMENT", 21, 36], ["concentration", "OBSERVATION_MODIFIER", 4, 17], ["plasmid DNA", "OBSERVATION", 25, 36]]], ["The DNA copy number was calculated using the formula described by Ke et al. (2006) .", [["DNA", "CELLULAR_COMPONENT", 4, 7]]], ["The plasmid was serially 10-fold diluted to serve as a standard for determining the sensitivity of the real-time PCR assay. (ii) Serial 10-fold dilutions of the known EID 50 stock solution of lentogenic (LaSota) and velogenic (Italy/2736/00) strains were prepared using sterile dH 2 0.", [["plasmid", "ANATOMY", 4, 11], ["plasmid", "DNA", 4, 11], ["The plasmid", "TREATMENT", 0, 11], ["Serial 10-fold dilutions", "TREATMENT", 129, 153], ["lentogenic (LaSota)", "TREATMENT", 192, 211], ["velogenic", "PROBLEM", 216, 225], ["strains", "PROBLEM", 242, 249]]], ["RNA was extracted and transcribed as described above. cDNA was added to the reaction mixture as a template.Detection limit, cloning, sequencing and specificity of the assayThe SYBR Green I melting peaks analysis assay was compared with the method described by Mia Kim et al. (2008) .Detection limit, cloning, sequencing and specificity of the assayThe sequencing was carried out by Genomed Ltd.", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 176, 188], ["RNA", "RNA", 0, 3], ["cDNA", "DNA", 54, 58], ["the reaction mixture", "TREATMENT", 72, 92], ["the assay", "TEST", 163, 172], ["analysis assay", "TEST", 203, 217], ["the assay", "TEST", 339, 348], ["The sequencing", "TEST", 348, 362]]], ["(Warsaw, Poland) using a Roche GS FLX/Titanium sequencer.", [["FLX", "CHEMICAL", 34, 37], ["a Roche GS FLX/Titanium sequencer", "TREATMENT", 23, 56]]], ["MultAlin software (Corpet, 1988) was used to align the sequences to check for homology with reference NDV sequences.Detection limit, cloning, sequencing and specificity of the assayThe specificity of the SYBR Green I real-time PCR assay was investigated using the RNA extracted from NDV strains and 14 other avian viruses shown in Table 1 .Phylogenetic analysisPhylogenetic analysis of members of 6 lineages of Newcastle disease virus (Aldous et al., 2003) was performed utilizing the neighbor-joining method (Saitou and Nei, 1987) in MEGA 4 software.", [["Newcastle disease", "DISEASE", 411, 428], ["NDV", "ORGANISM", 102, 105], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 204, 216], ["NDV", "ORGANISM", 283, 286], ["Newcastle disease virus", "ORGANISM", 411, 434], ["reference NDV sequences", "DNA", 92, 115], ["NDV", "SPECIES", 102, 105], ["NDV", "SPECIES", 283, 286], ["Newcastle disease virus", "SPECIES", 411, 434], ["reference NDV sequences", "TEST", 92, 115], ["the assay", "TEST", 172, 181], ["the SYBR", "TEST", 200, 208], ["PCR assay", "TEST", 227, 236], ["the RNA", "TREATMENT", 260, 267], ["NDV strains", "TREATMENT", 283, 294], ["Phylogenetic analysis", "TEST", 340, 361], ["Phylogenetic analysis", "TEST", 361, 382], ["Newcastle disease virus", "PROBLEM", 411, 434], ["Newcastle disease", "OBSERVATION", 411, 428]]], ["Strains of NDV were derived from GenBank or from the Polish strains sequenced previously.Detection and differentiation of NDV strains by melting peak analysisThe representatives of 4 lineages of NDV strains were tested.", [["NDV", "ORGANISM", 11, 14], ["NDV", "ORGANISM", 122, 125], ["NDV", "ORGANISM", 195, 198], ["NDV", "SPECIES", 11, 14], ["NDV", "SPECIES", 195, 198], ["NDV", "SPECIES", 11, 14], ["NDV", "SPECIES", 122, 125], ["NDV", "SPECIES", 195, 198], ["Strains of NDV", "PROBLEM", 0, 14], ["Detection", "TEST", 89, 98], ["NDV strains", "PROBLEM", 122, 133], ["melting peak analysis", "TEST", 137, 158], ["NDV strains", "PROBLEM", 195, 206], ["NDV", "OBSERVATION", 11, 14], ["NDV strains", "OBSERVATION", 195, 206]]], ["Using the SYBR Green I real-time PCR melting peak analysis, it was possible to detect and differentiate virulent and avirulent strains of Newcastle disease virus.", [["Newcastle disease virus", "DISEASE", 138, 161], ["Newcastle disease virus", "ORGANISM", 138, 161], ["Newcastle disease virus", "SPECIES", 138, 161], ["PCR melting peak analysis", "TEST", 33, 58], ["virulent", "PROBLEM", 104, 112], ["Newcastle disease virus", "PROBLEM", 138, 161], ["Newcastle disease", "OBSERVATION", 138, 155]]], ["Eighteen NDV strains (including ten lentogenic, two mesogenic and six velogenic isolates) were analyzed.", [["strains", "ANATOMY", 13, 20], ["NDV", "ORGANISM", 9, 12], ["NDV", "SPECIES", 9, 12], ["NDV", "SPECIES", 9, 12], ["Eighteen NDV strains", "PROBLEM", 0, 20], ["six velogenic isolates", "TREATMENT", 66, 88]]], ["Melting curve analysis revealed that all 18 strains were divided into two distinct groups (Fig. 1) .", [["Melting curve analysis", "TEST", 0, 22], ["all 18 strains", "PROBLEM", 37, 51]]], ["T m values for lentogenic (avirulent) strains were estimated to be between 80.00 and 83.80 \u2022 C, and the T m values for mesogenic and velogenic (virulent) strains were higher than 83.80 \u2022 C ( Table 1 ).", [["T m", "GENE_OR_GENE_PRODUCT", 0, 3], ["T m", "GENE_OR_GENE_PRODUCT", 104, 107], ["T m values", "TEST", 0, 10], ["lentogenic (avirulent) strains", "PROBLEM", 15, 45], ["the T m values", "TEST", 100, 114], ["mesogenic and velogenic (virulent) strains", "PROBLEM", 119, 161]]], ["The boundary line was calculated as the medium between the highest T m value for avirulent strains and the lowest for virulent strains.", [["T m", "GENE_OR_GENE_PRODUCT", 67, 70], ["The boundary line", "TREATMENT", 0, 17], ["avirulent strains", "PROBLEM", 81, 98], ["virulent strains", "PROBLEM", 118, 134], ["boundary line", "OBSERVATION", 4, 17]]], ["The phylogenetic relationship of the NDV strains used in this study is depicted in Fig. 2.Specificity of real-time PCR assay and detection limitThe specificity of this real-time PCR assay was investigated by analysing 18 NDV strains and 14 samples of other viruses (Table 1) .", [["samples", "ANATOMY", 240, 247], ["NDV", "ORGANISM", 37, 40], ["NDV", "ORGANISM", 221, 224], ["NDV", "SPECIES", 37, 40], ["NDV", "SPECIES", 37, 40], ["NDV", "SPECIES", 221, 224], ["the NDV strains", "PROBLEM", 33, 48], ["this study", "TEST", 57, 67], ["PCR assay", "TEST", 115, 124], ["this real-time PCR assay", "TEST", 163, 187], ["18 NDV strains", "PROBLEM", 218, 232], ["NDV strains", "OBSERVATION", 37, 48]]], ["No amplification products were detected when templates originating from these fourteen unrelated viruses were used, while all templates from NDV strains gave distinctive products.Specificity of real-time PCR assay and detection limitThe detection limit of this assay was assessed by analysing the serial dilutions of a plasmid carrying s 320 bp fragment of the F gene of NDV and the serial dilutions of the known stock of NDV.", [["plasmid", "ANATOMY", 319, 326], ["NDV", "ORGANISM", 141, 144], ["F", "GENE_OR_GENE_PRODUCT", 361, 362], ["NDV", "ORGANISM", 371, 374], ["NDV", "ORGANISM", 422, 425], ["plasmid", "DNA", 319, 326], ["320 bp fragment", "DNA", 338, 353], ["F gene", "DNA", 361, 367], ["NDV", "SPECIES", 141, 144], ["NDV", "SPECIES", 371, 374], ["NDV", "SPECIES", 422, 425], ["amplification products", "TREATMENT", 3, 25], ["these fourteen unrelated viruses", "PROBLEM", 72, 104], ["NDV strains", "PROBLEM", 141, 152], ["distinctive products", "TREATMENT", 158, 178], ["PCR assay", "TEST", 204, 213], ["this assay", "TEST", 256, 266], ["a plasmid carrying s 320 bp fragment", "TREATMENT", 317, 353], ["NDV", "TREATMENT", 371, 374], ["the serial dilutions", "TREATMENT", 379, 399], ["NDV", "PROBLEM", 422, 425], ["viruses", "OBSERVATION", 97, 104], ["NDV", "OBSERVATION", 371, 374], ["NDV", "OBSERVATION", 422, 425]]], ["In the real-time PCR assay, the detection limits were 2 \u00d7 10 2 copies of DNA plasmid per reaction or 10 2 EID 50 concentration range for the velogenic strain (Italy/2736/00) and 10 3 EID 50 for the lentogenic strain (LaSota).", [["DNA", "CELLULAR_COMPONENT", 73, 76], ["DNA plasmid", "DNA", 73, 84], ["DNA plasmid", "TREATMENT", 73, 84], ["the velogenic strain", "PROBLEM", 137, 157], ["the lentogenic strain", "PROBLEM", 194, 215]]], ["Any results with a Ct value higher than 45 were treated as unconvincing and were rejected.", [["a Ct value", "TEST", 17, 27]]], ["The new assay was compared with the method described previously by Mia Kim et al. (2008) -both gave similar results (Table 2A) in oral and cloacal swabs.", [["oral", "ANATOMY", 130, 134], ["cloacal swabs", "ANATOMY", 139, 152], ["oral", "ORGANISM_SUBDIVISION", 130, 134], ["cloacal swabs", "ORGANISM_SUBSTANCE", 139, 152], ["The new assay", "TEST", 0, 13], ["oral and cloacal swabs", "TREATMENT", 130, 152], ["new", "OBSERVATION_MODIFIER", 4, 7]]], ["The difference in Ct values resulted from the use of different methods in the assays (TaqMan and SYBR Green I, respectively).", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 97, 109], ["Ct values", "TEST", 18, 27], ["different methods", "TREATMENT", 53, 70], ["the assays", "TEST", 74, 84], ["difference", "OBSERVATION_MODIFIER", 4, 14]]], ["The new assay detected NDV in three tissue samples while the one described previously detected NDV only in one sample (Table 2B) .Ulster2CQueensland V4/66 (Aldous et al., 2003) .", [["tissue samples", "ANATOMY", 36, 50], ["NDV", "ORGANISM", 23, 26], ["tissue samples", "CANCER", 36, 50], ["NDV", "ORGANISM", 95, 98], ["NDV", "SPECIES", 23, 26], ["NDV", "SPECIES", 95, 98], ["The new assay", "TEST", 0, 13], ["NDV", "PROBLEM", 23, 26], ["NDV", "PROBLEM", 95, 98], ["new", "OBSERVATION_MODIFIER", 4, 7], ["NDV", "OBSERVATION", 23, 26], ["three tissue", "OBSERVATION_MODIFIER", 30, 42], ["NDV", "OBSERVATION", 95, 98]]], ["The Phylogenetic tree was generated using the neighbor-joining method (Saitou and Nei, 1987) .", [["Phylogenetic tree", "OBSERVATION", 4, 21]]], ["Ulster 2C (Table 1) ; Queensland V4/66 (M24693); Roakin (AY289000); Beaudette C/45 (M24697); B1/47 (M24695); 117/90 (Table 1) ; 18/91 (Table 1) ; 111/90 (Table 1) ; 299/92 (Table 1) ; 548/04 (Table 1) ; 549/04 (Table 1) ; 89/90 (Table 1) ; Radom (Table 1) ; BSDCK72176 (AY135752); POK/70 (Y19014); BBGCK68168 (AY175669); BHKPI89165 (AY175672); Herts/33 (M24702); TEXAS (M33855); Mukteswar (AY175676); Miyadera/51 (M24701); Australia/32 (M21881); AR5 (Table 1) ; AR8 (Table 1) ; AR3 (Table 1) ; AR2 (Table 1) ; AR7 (Table 1) ; AR4 (Table 1) ; Italy (Table 1) ; GB1168/84 (AF109885); CH1/95 (AF001132); Kuwait (AF001109); Lebanon/70 (AF139160); Warwick/66 (U52457); BSACK95121 (AY175694); BBECK97037 (AY135741); QGB506/97 (AF109887); Fi1001/96 (AF091623); QGB445/97 (AF109886); CZ3898/96 (AF109883); TW156/99 (AF234031); HFRDK77188 (AY135758).Table 2A comparison of the sensitivity of SYBR Green I real-time PCR melting peaks analysis assay (SYBR MPA) with the previously published system by Mia Kim et al. (2008) .", [["BBGCK68168", "CHEMICAL", 298, 308], ["BHKPI89165", "CHEMICAL", 321, 331], ["BSACK95121", "CHEMICAL", 664, 674], ["BBECK97037", "CHEMICAL", 687, 697], ["Fi1001/96", "CHEMICAL", 732, 741], ["QGB445/97", "CHEMICAL", 754, 763], ["AF109886", "CHEMICAL", 765, 773], ["CZ3898/96", "CHEMICAL", 776, 785], ["AF109883", "CHEMICAL", 787, 795], ["TW156/99", "CHEMICAL", 798, 806], ["HFRDK77188", "CHEMICAL", 819, 829], ["AY135758", "CHEMICAL", 831, 839], ["BBGCK68168", "CHEMICAL", 298, 308], ["BHKPI89165", "CHEMICAL", 321, 331], ["CZ3898/96", "CHEMICAL", 776, 785], ["AF109883", "CHEMICAL", 787, 795], ["TW156/99", "CHEMICAL", 798, 806], ["AF234031", "CHEMICAL", 808, 816], ["HFRDK77188", "CHEMICAL", 819, 829], ["AY135758", "CHEMICAL", 831, 839], ["HFRDK77188", "SIMPLE_CHEMICAL", 819, 829], ["AY135758", "DNA", 831, 839], ["Ulster", "TEST", 0, 6], ["B1", "TEST", 93, 95], ["BHKPI89165", "TEST", 321, 331], ["Herts", "TEST", 344, 349], ["Mukteswar", "TEST", 379, 388], ["Miyadera/", "TEST", 401, 410], ["Australia/", "TEST", 423, 433], ["CZ3898/96", "TEST", 776, 785], ["the sensitivity", "TEST", 864, 879], ["PCR melting", "TEST", 906, 917], ["analysis assay", "TEST", 924, 938]]], ["(A) Three chickens were infected with a lentogenic strain (LaSota) with a dose of 10 7,5 EID50 of the virus.", [["chickens", "ORGANISM", 10, 18], ["chickens", "SPECIES", 10, 18], ["chickens", "SPECIES", 10, 18], ["a lentogenic strain (LaSota)", "TREATMENT", 38, 66], ["the virus", "PROBLEM", 98, 107]]], ["Oral (O) and cloacal (C) swabs were collected 3 and 5 days post infection (dpi).", [["Oral", "ANATOMY", 0, 4], ["cloacal", "ANATOMY", 13, 20], ["swabs", "ANATOMY", 25, 30], ["infection", "DISEASE", 64, 73], ["Oral (O)", "TREATMENT", 0, 8], ["cloacal (C) swabs", "TREATMENT", 13, 30], ["infection", "PROBLEM", 64, 73], ["infection", "OBSERVATION", 64, 73]]], ["(B) One chicken was killed 5 days post infection, and tissues were prepared.", [["tissues", "ANATOMY", 54, 61], ["infection", "DISEASE", 39, 48], ["chicken", "ORGANISM", 8, 15], ["tissues", "TISSUE", 54, 61], ["chicken", "SPECIES", 8, 15], ["chicken", "SPECIES", 8, 15], ["infection", "PROBLEM", 39, 48], ["infection", "OBSERVATION", 39, 48]]], ["RNA was extracted as described above from a homogenate of tissues.DiscussionIn this study, a method for the rapid detection and differentiation of Newcastle disease virus by SYBR Green I melting-curve analysis was described.", [["homogenate", "ANATOMY", 44, 54], ["tissues", "ANATOMY", 58, 65], ["Newcastle disease", "DISEASE", 147, 164], ["tissues", "TISSUE", 58, 65], ["Newcastle disease virus", "ORGANISM", 147, 170], ["SYBR Green I", "GENE_OR_GENE_PRODUCT", 174, 186], ["RNA", "RNA", 0, 3], ["Newcastle disease virus", "SPECIES", 147, 170], ["this study", "TEST", 79, 89], ["the rapid detection", "TEST", 104, 123], ["Newcastle disease virus", "PROBLEM", 147, 170], ["curve analysis", "TEST", 195, 209], ["tissues", "ANATOMY", 58, 65]]], ["F gene-specific, degenerated primers were used in the assay.", [["F", "GENE_OR_GENE_PRODUCT", 0, 1], ["F gene", "DNA", 0, 6], ["degenerated primers", "PROBLEM", 17, 36]]], ["The use of degenerated primers made it possible to avoid the previously reported difficulties in the design of primers (Aldous and Alexander, 2001 ) and, additionally, it allowed for the use of only one set of primers for the differentiation of virulent and avirulent strains of Newcastle disease virus.", [["Newcastle disease virus", "DISEASE", 279, 302], ["Newcastle disease virus", "ORGANISM", 279, 302], ["Newcastle disease virus", "SPECIES", 279, 302], ["degenerated primers", "PROBLEM", 11, 30], ["primers", "TREATMENT", 210, 217], ["virulent", "PROBLEM", 245, 253], ["Newcastle disease virus", "PROBLEM", 279, 302], ["Newcastle disease", "OBSERVATION", 279, 296]]], ["This is the first assay based on SYBR Green I that uses degenerated primers to detect virulent and avirulent strains of NDV in one tube reaction with high resolution.", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 33, 45], ["NDV", "ORGANISM", 120, 123], ["tube", "TISSUE", 131, 135], ["SYBR Green I", "PROTEIN", 33, 45], ["NDV", "SPECIES", 120, 123], ["degenerated primers", "PROBLEM", 56, 75], ["virulent and avirulent strains of NDV", "PROBLEM", 86, 123], ["one tube reaction", "PROBLEM", 127, 144], ["high resolution", "OBSERVATION_MODIFIER", 150, 165]]], ["The correlations between virulent (ICPI > 0.7) and non-virulent (ICPI < 0.7) strains and melting temperature values are shown in Table 1 .", [["ICPI", "TEST", 35, 39], ["ICPI", "TEST", 65, 69], ["strains", "PROBLEM", 77, 84], ["melting temperature values", "TEST", 89, 115], ["virulent", "OBSERVATION_MODIFIER", 25, 33]]], ["The distinction between lentogenic and mesogenic (3.26 \u2022 C) or lentogenic and velogenic (5.15 \u2022 C) NDV strains was more simple than previously described by Pham et al. (2005) , which yielded values of 1.22 \u2022 C and 2.15 \u2022 C, respectively.", [["NDV", "ORGANISM", 99, 102], ["NDV", "SPECIES", 99, 102], ["lentogenic", "TEST", 24, 34], ["mesogenic", "TEST", 39, 48], ["lentogenic", "TEST", 63, 73], ["velogenic", "TEST", 78, 87], ["C) NDV strains", "PROBLEM", 96, 110], ["values", "TEST", 191, 197], ["C", "TEST", 208, 209], ["mesogenic", "OBSERVATION_MODIFIER", 39, 48], ["velogenic", "OBSERVATION_MODIFIER", 78, 87]]], ["Additionally, such a high difference in melting temperature values makes it possible to calculate a safe boundary line (83.80 \u2022 C) for differentiation of NDV strains.", [["NDV", "ORGANISM", 154, 157], ["NDV", "SPECIES", 154, 157], ["a high difference in melting temperature values", "PROBLEM", 19, 66], ["a safe boundary line", "TREATMENT", 98, 118], ["NDV strains", "PROBLEM", 154, 165]]], ["This in turn allows for a straightforward method to monitor and classify virulent and avirulent strains of NDV in agreement with European Union directive (CEC, 1992) , which calls for the full control of isolates with an intercerebral pathogenicity index (ICPI) greater than 0.7.DiscussionThe sensitivity of the method described in this report is similar to the method described by Mia Kim et al. (2008) and Wise et al. (2004) and by Pham et al. (2005) .", [["NDV", "DISEASE", 107, 110], ["NDV", "ORGANISM", 107, 110], ["NDV", "SPECIES", 107, 110], ["NDV", "SPECIES", 107, 110], ["a straightforward method", "TREATMENT", 24, 48], ["virulent", "PROBLEM", 73, 81], ["an intercerebral pathogenicity index", "TEST", 218, 254], ["ICPI", "TEST", 256, 260]]], ["Differences in Ct values are cause by differences across methods.", [["Ct values", "TEST", 15, 24]]], ["In real-time PCR using the TaqMan method (Mia Kim et al., 2008) , probes are released and degraded during each cycle and fluorescence increases cumulatively during the reaction.", [["the TaqMan method", "TEST", 23, 40], ["the reaction", "PROBLEM", 164, 176]]], ["When the SYBR Green I method is used fluorescence increases proportionally.", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 9, 21]]], ["That explains why higher Ct values were obtained while using this method.", [["higher Ct values", "TEST", 18, 34], ["this method", "TREATMENT", 61, 72]]], ["The advantages of using this SYBR Green I method are that its operation costs are lower in comparison to either methods using TaqMan, and it is possible to perform the reaction in a single tube.", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 29, 41], ["tube", "TISSUE", 189, 193], ["this SYBR Green I method", "TREATMENT", 24, 48], ["its operation costs", "TREATMENT", 58, 77], ["TaqMan", "TEST", 126, 132], ["the reaction", "PROBLEM", 164, 176], ["a single tube", "TREATMENT", 180, 193], ["lower", "OBSERVATION_MODIFIER", 82, 87], ["tube", "OBSERVATION", 189, 193]]], ["The previous methods employed two or three pairs of primers (Wise et al., 2004) , and their products for lentogenic and velogenic strains (Farkas et al., 2009) , in some cases, were different in length, which excludes the possibility of using the real-time PCR SYBR Green I assay.", [["SYBR Green I", "GENE_OR_GENE_PRODUCT", 261, 273], ["lentogenic and velogenic strains", "PROBLEM", 105, 137], ["different", "OBSERVATION_MODIFIER", 182, 191]]]]}